-DOCSTART- (8701013)

Famotidine	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

Famotidine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
histamine	ADJ	O	O
H2-receptor	NOUN	O	O
antagonist	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
inpatient	ADJ	O	O
settings	NOUN	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
stress	NOUN	O	O
ulcers	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
showing	VERB	O	O
increasing	VERB	O	O
popularity	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
low	ADJ	O	O
cost	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
all	DET	O	O
of	ADP	O	O
the	DET	O	O
currently	ADV	O	O
available	ADJ	O	O
H2-receptor	NOUN	O	O
antagonists	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
the	DET	O	O
propensity	NOUN	O	O
to	PART	O	O
cause	VERB	O	O
delirium	NOUN	O	I-Entity
,	PUNCT	O	O
only	ADV	O	O
two	NUM	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
famotidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
report	VERB	O	O
on	ADP	O	O
six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
famotidine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
delirium	NOUN	O	I-Entity
in	ADP	O	O
hospitalized	VERB	O	O
patients	NOUN	O	O
who	NOUN	O	O
cleared	VERB	O	O
completely	ADV	O	O
upon	ADP	O	O
removal	NOUN	O	O
of	ADP	O	O
famotidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
famotidine	NOUN	O	I-Entity
are	VERB	O	O
reviewed	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
its	ADJ	O	O
metabolism	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
population	NOUN	O	O
seen	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
implications	NOUN	O	O
of	ADP	O	O
using	VERB	O	O
famotidine	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
persons	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (439781)

Indomethacin	PROPN	O	I-Entity
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
volume	NOUN	O	O
depleted	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
indomethacin	NOUN	O	I-Entity
(	PUNCT	O	O
IDM	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
volume	NOUN	O	O
depleted	VERB	O	O
rats	NOUN	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
activity	NOUN	O	O
(	PUNCT	O	O
PRA	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
fell	VERB	O	O
significantly	ADV	O	O
within	ADP	O	O
four	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
sodium	NOUN	O	I-Entity
repleted	VERB	O	O
animals	NOUN	O	O
indomethacin	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
although	ADP	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	I-Entity
by	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
may	VERB	O	O
diminish	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
maintaining	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
stimulated	VERB	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
volume	NOUN	O	O
depletion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (22836123)

Late	ADV	O	O
-	PUNCT	O	O
onset	NOUN	O	O
scleroderma	NOUN	O	B-Entity
renal	ADJ	O	I-Entity
crisis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
prednisolone	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Scleroderma	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
crisis	NOUN	O	I-Entity
(	PUNCT	O	O
SRC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
SSc	PROPN	O	I-Entity
)	PUNCT	O	O
but	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
severe	ADJ	O	O
enough	ADV	O	O
to	PART	O	O
require	VERB	O	O
temporary	ADJ	O	O
or	CCONJ	O	O
permanent	ADJ	O	O
renal	ADJ	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Moderate	PROPN	O	O
to	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
corticosteroid	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
recognized	VERB	O	O
as	ADP	O	O
a	DET	O	O
major	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
SRC	PROPN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
have	VERB	O	O
been	VERB	O	O
reports	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
precipitated	VERB	O	O
by	ADP	O	O
cyclosporine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SSc	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
article	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
SRC	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
corticosteroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
work	NOUN	O	O
is	VERB	O	O
to	PART	O	O
call	VERB	O	O
attention	NOUN	O	O
to	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
use	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SSc	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (23433219)

The	DET	O	O
risk	NOUN	O	O
and	CCONJ	O	O
associated	ADJ	O	O
factors	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
psychosis	NOUN	O	I-Entity
in	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
Malaysia	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
lifetime	NOUN	O	O
and	CCONJ	O	O
current	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
methamphetamine	NOUN	O	I-Entity
dependence	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
between	ADP	O	O
psychiatric	ADJ	O	O
co	PROPN	O	O
-	PUNCT	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
based	VERB	O	O
on	ADP	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
were	VERB	O	O
interviewed	VERB	O	O
using	VERB	O	O
the	DET	O	O
Mini	PROPN	O	O
International	PROPN	O	O
Neuropsychiatric	PROPN	O	O
Interview	PROPN	O	O
(	PUNCT	O	O
M.I.N.I.	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
Axis	PROPN	O	O
I	PRON	O	O
psychiatric	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
292	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
47.9%	NUM	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
had	VERB	O	O
a	DET	O	O
past	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
and	CCONJ	O	O
13.0%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
having	VERB	O	O
current	ADJ	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Co	PROPN	O	O
-	PUNCT	O	O
morbid	ADJ	O	O
major	ADJ	O	O
depressive	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OR=7.18	PROPN	O	O
,	PUNCT	O	O
95	NUM	O	O
CI=2.612	NOUN	O	O
-	PUNCT	O	O
19.708	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OR=13.807	PROPN	O	O
,	PUNCT	O	O
95	NUM	O	O
CI=5.194	NOUN	O	O
-	PUNCT	O	O
36.706	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
antisocial	ADJ	O	B-Entity
personality	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OR=12.619	PROPN	O	O
,	PUNCT	O	O
95	NUM	O	O
CI=6.702	NOUN	O	O
-	PUNCT	O	O
23.759	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O

heavy	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
uses	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
lifetime	NOUN	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
after	ADP	O	O
adjusted	VERB	O	O
for	ADP	O	O
other	ADJ	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Major	ADJ	O	B-Entity
depressive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OR=2.870	PROPN	O	O
,	PUNCT	O	O
CI=1.154	PROPN	O	O
-	PUNCT	O	O
7.142	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
antisocial	ADJ	O	B-Entity
personality	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OR=3.299	PROPN	O	O
,	PUNCT	O	O
95	NUM	O	O
CI=1.375	NOUN	O	O
-	PUNCT	O	O
7.914	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
the	DET	O	O
only	ADJ	O	O
factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
current	ADJ	O	O
psychosis	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
was	VERB	O	O
a	DET	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
psychosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
methamphetamine	NOUN	O	I-Entity
dependence	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
co	NOUN	O	O
-	PUNCT	O	O
morbid	ADJ	O	O
affective	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
antisocial	ADJ	O	B-Entity
personality	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
heavy	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
dependence	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
screened	VERB	O	O
for	ADP	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (23535177)

motor	NOUN	O	O
cortical	ADJ	O	O
plasticity	NOUN	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O

clues	NOUN	O	O
from	ADP	O	O
dyskinetic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
plasticity	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
motor	NOUN	O	O
cortex	NOUN	O	O
(	PUNCT	O	O
M1	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
LIDs	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
severely	ADV	O	O
impaired	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
the	DET	O	O
deficient	ADJ	O	O
sensorimotor	NOUN	O	O
M1	PROPN	O	O
plasticity	NOUN	O	O
in	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
LIDs	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
reinstated	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
session	NOUN	O	O
of	ADP	O	O
real	ADJ	O	O
inhibitory	NOUN	O	O
cerebellar	ADJ	O	O
stimulation	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
sham	ADJ	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
inhibitory	NOUN	O	O
cerebellar	ADJ	O	O
stimulation	NOUN	O	O
on	ADP	O	O
LIDs	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
.	PUNCT	O	O

To	PART	O	O
explore	VERB	O	O
whether	ADP	O	O
this	DET	O	O
benefit	NOUN	O	O
is	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
the	DET	O	O
restoration	NOUN	O	O
of	ADP	O	O
sensorimotor	NOUN	O	O
plasticity	NOUN	O	O
of	ADP	O	O
M1	PROPN	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
study	NOUN	O	O
looking	VERB	O	O
at	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
LIDs	NOUN	O	I-Entity
and	CCONJ	O	O
PAS	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
plasticity	NOUN	O	O
after	ADP	O	O
10	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
either	DET	O	O
bilateral	ADJ	O	O
,	PUNCT	O	O
real	ADJ	O	O
inhibitory	NOUN	O	O
cerebellar	ADJ	O	O
stimulation	NOUN	O	O
or	CCONJ	O	O
sham	ADJ	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
alterations	NOUN	O	O
in	ADP	O	O
cerebellar	ADJ	O	O
sensory	ADJ	O	O
processing	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
occurring	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
abnormal	ADJ	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
signals	NOUN	O	O
reaching	VERB	O	O
it	PRON	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
element	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
the	DET	O	O
maladaptive	ADJ	O	O
sensorimotor	NOUN	O	O
plasticity	NOUN	O	O
of	ADP	O	O
M1	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
emergence	NOUN	O	O
of	ADP	O	O
abnormal	ADJ	O	B-Entity
involuntary	ADJ	O	I-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (23666265)

The	DET	O	O
function	NOUN	O	O
of	ADP	O	O
P2X3	PROPN	O	O
receptor	NOUN	O	O
and	CCONJ	O	O
NK1	PROPN	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
on	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
P2X3	PROPN	O	O
and	CCONJ	O	O
NK1	PROPN	O	O
receptors	NOUN	O	O
antagonists	NOUN	O	O
on	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYP)-induced	VERB	O	I-Entity
cystitis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

injected	VERB	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
rats	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
i.p	ADJ	O	O
.	PUNCT	O	O

injected	VERB	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
with	ADP	O	O
subsequently	ADV	O	O
perfusion	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
with	ADP	O	O
P2X3	PROPN	O	O
and	CCONJ	O	O
NK1	PROPN	O	O
receptors	NOUN	O	O
'	PART	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
Suramin	PROPN	O	I-Entity
and	CCONJ	O	O
GR	PROPN	O	B-Entity
82334	NUM	O	I-Entity
.	PUNCT	O	O

Spontaneous	ADJ	O	O
pain	NOUN	O	I-Entity
behaviors	NOUN	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
CYP	PROPN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Cyclophosphamide	NOUN	O	I-Entity
treatment	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
spontaneous	ADJ	O	O
pain	NOUN	O	I-Entity
behaviors	NOUN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
changes	NOUN	O	O
evident	ADJ	O	O
in	ADP	O	O
model	NOUN	O	O
and	CCONJ	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
rats	NOUN	O	O
'	PART	O	O
bladder	NOUN	O	O
included	VERB	O	O
edema	NOUN	O	I-Entity
,	PUNCT	O	O
vasodilation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
P2X3	PROPN	O	O
and	CCONJ	O	O
NK1	PROPN	O	O
receptors	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
urothelium	NOUN	O	O
and/or	CCONJ	O	O
suburothelium	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23846525)

Acute	PROPN	O	O
hepatitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
clopidogrel	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
recognition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
responsible	ADJ	O	O
drug	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
difficult	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Reports	NOUN	O	O
about	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
clopidogrel	NOUN	O	I-Entity
are	VERB	O	O
increasing	VERB	O	O
in	ADP	O	O
the	DET	O	O
last	ADJ	O	O
few	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
increased	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
believe	VERB	O	O
that	ADP	O	O
physicians	NOUN	O	O
should	VERB	O	O
carefully	ADV	O	O
consider	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
when	ADV	O	O
clopidogrel	NOUN	O	I-Entity
is	VERB	O	O
prescribed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (23864035)

Bortezomib	PROPN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
as	ADP	O	O
salvage	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O

refractory	ADJ	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
:	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Bortezomib	PROPN	O	I-Entity

(	PUNCT	O	O
bort)-dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
dex	NOUN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
(	PUNCT	O	O
R	PROPN	O	O
/	SYM	O	O
R	PROPN	O	O
)	PUNCT	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
(	PUNCT	O	O
MM	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
bort	NOUN	O	I-Entity
(	PUNCT	O	O
1.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
11	NUM	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dex	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
and	CCONJ	O	O
the	DET	O	O
day	NOUN	O	O
after	ADP	O	O
bort	NOUN	O	I-Entity
)	PUNCT	O	O
as	ADP	O	O
salvage	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
85	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
R	PROPN	O	O
/	SYM	O	O
R	PROPN	O	O
MM	PROPN	O	I-Entity
after	ADP	O	O
prior	ADV	O	O
autologous	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
or	CCONJ	O	O
conventional	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Eighty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
immunomodulatory	ADJ	O	O
drugs	NOUN	O	O
included	VERB	O	O
in	ADP	O	O
some	DET	O	O
line	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
before	ADP	O	O
bort	NOUN	O	I-Entity
-	PUNCT	O	O
dex	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
bort	NOUN	O	I-Entity
-	PUNCT	O	O
dex	NOUN	O	I-Entity
cycles	NOUN	O	O
was	VERB	O	O
6	NUM	O	O
,	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
relevant	ADJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
was	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
occurred	VERB	O	O
in	ADP	O	O
78	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
grade	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
38	NUM	O	O
%	NOUN	O	O
;	PUNCT	O	O
grade	NOUN	O	O
III	PROPN	O	O
,	PUNCT	O	O
21	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
led	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
discontinuation	NOUN	O	O
in	ADP	O	O
6	NUM	O	O
%	NOUN	O	O
.	PUNCT	O	O

Prolonged	VERB	O	O
PFS	PROPN	O	O
and	CCONJ	O	O
OS	PROPN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
achieving	VERB	O	O
CR	PROPN	O	O
and	CCONJ	O	O
receiving	VERB	O	O
bort	NOUN	O	I-Entity
-	PUNCT	O	O
dex	NOUN	O	I-Entity
a	DET	O	O
single	ADJ	O	O
line	NOUN	O	O
of	ADP	O	O
prior	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Bort	PROPN	O	I-Entity
-	PUNCT	O	O
dex	PROPN	O	I-Entity
was	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
salvage	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
MM	PROPN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
for	ADP	O	O
those	DET	O	O
in	ADP	O	O
first	ADJ	O	O
relapse	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23871786)

Pubertal	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
Bisphenol	PROPN	O	B-Entity
A	PROPN	O	I-Entity
increases	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
decreases	VERB	O	O
acetylcholinesterase	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
male	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
negative	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Bisphenol	PROPN	O	B-Entity
A	PROPN	O	I-Entity
(	PUNCT	O	O
BPA	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
neurodevelopment	NOUN	O	O
and	CCONJ	O	O
behaviors	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
well	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

Acetylcholinesterase	NOUN	O	O
(	PUNCT	O	O
AChE	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
regulatory	ADJ	O	O
enzyme	NOUN	O	O
which	ADJ	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
behavioral	ADJ	O	O
phenotypes	NOUN	O	O
and	CCONJ	O	O
AChE	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
male	ADJ	O	O
mice	NOUN	O	O
following	VERB	O	O
BPA	PROPN	O	I-Entity
exposure	NOUN	O	O
during	ADP	O	O
puberty	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
postnatal	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
PND	PROPN	O	O
)	PUNCT	O	O
35	NUM	O	O
,	PUNCT	O	O
male	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
BPA	PROPN	O	I-Entity
/	SYM	O	O
kg	INTJ	O	O
diet	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
from	ADP	O	O
our	ADJ	O	O
behavioral	ADJ	O	O
phenotyping	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
BPA	PROPN	O	I-Entity
.	PUNCT	O	O

AChE	DET	O	O
activity	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
BPA	PROPN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
prefrontal	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
hypothalamus	NOUN	O	O
and	CCONJ	O	O
cerebellum	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
pubertal	ADJ	O	O
BPA	PROPN	O	I-Entity
exposure	NOUN	O	O
increased	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
decreased	ADJ	O	O
AChE	PROPN	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
male	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
cholinergic	NOUN	O	O
signaling	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
PBE	PROPN	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23872883)

Biochemical	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Solidago	PROPN	O	O
virgaurea	NOUN	O	O
extract	VERB	O	O
on	ADP	O	O
experimental	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiovascular	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
(	PUNCT	O	O
CVDs	NOUN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
the	DET	O	O
major	ADJ	O	O
health	NOUN	O	O
problem	NOUN	O	O
of	ADP	O	O
advanced	VERB	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
developing	VERB	O	O
countries	NOUN	O	O
of	ADP	O	O
the	DET	O	O
world	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Solidago	PROPN	O	O
virgaurea	NOUN	O	O
extract	VERB	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
)	PUNCT	O	O
into	ADP	O	O
rats	NOUN	O	O
twice	ADV	O	O
at	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
,	PUNCT	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
,	PUNCT	O	O
alanine	NOUN	O	I-Entity
transaminase	NOUN	O	O
,	PUNCT	O	O
aspartate	ADJ	O	I-Entity
transaminase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
angiotensin	VERB	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
activities	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
,	PUNCT	O	O
triglycerides	NOUN	O	I-Entity
,	PUNCT	O	O
free	ADJ	O	O
serum	NOUN	O	O
fatty	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
cardiac	ADJ	O	O
tissue	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
(	PUNCT	O	O
MDA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
glutathione	NOUN	O	I-Entity
and	CCONJ	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
tissue	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
S.	PROPN	O	O
virgaurea	NOUN	O	O
extract	VERB	O	O
for	ADP	O	O
5	NUM	O	O
weeks	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
250	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
followed	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
injection	NOUN	O	O
significantly	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
observed	ADJ	O	O
alterations	NOUN	O	O
.	PUNCT	O	O

Captopril	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
given	VERB	O	O
orally	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
cardioprotective	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
S.	PROPN	O	O
virgaurea	NOUN	O	O
extract	NOUN	O	O
exerts	VERB	O	O
its	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
by	ADP	O	O
decreasing	VERB	O	O
MDA	PROPN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
increasing	VERB	O	O
the	DET	O	O
antioxidant	NOUN	O	O
status	NOUN	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23892921)

"	PUNCT	O	O
Real	ADJ	O	O
-	PUNCT	O	O
world	NOUN	O	O
"	PUNCT	O	O
data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
lenalidomide	NOUN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
multiple	NOUN	O	B-Entity
myeloma	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Greek	PROPN	O	O
Myeloma	PROPN	O	I-Entity
Study	PROPN	O	O
Group	PROPN	O	O
.	PUNCT	O	O

Lenalidomide	PROPN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
RD	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
(	PUNCT	O	O
RRMM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
is	VERB	O	O
limited	VERB	O	O
published	VERB	O	O
data	NOUN	O	O
on	ADP	O	O
its	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
real	ADJ	O	O
world	NOUN	O	O
"	PUNCT	O	O
(	PUNCT	O	O
RW	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
International	PROPN	O	O
Society	PROPN	O	O
of	ADP	O	O
Pharmacoeconomics	PROPN	O	O
and	CCONJ	O	O
Outcomes	PROPN	O	O
Research	PROPN	O	O
definition	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
212	NUM	O	O
RRMM	PROPN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
RD	PROPN	O	I-Entity
in	ADP	O	O
RW	PROPN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
time	NOUN	O	O
to	PART	O	O
CR	VERB	O	O
when	ADV	O	O
RD	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
as	ADP	O	O
2nd	NOUN	O	O
or	CCONJ	O	O
>	X	O	O
2(nd)-line	NUM	O	O
treatment	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
11	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Quality	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
was	VERB	O	O
independent	ADJ	O	O
of	ADP	O	O
previous	ADJ	O	O
lines	NOUN	O	O
of	ADP	O	O
therapies	NOUN	O	O
or	CCONJ	O	O
previous	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
thalidomide	NOUN	O	I-Entity
or	CCONJ	O	O
bortezomib	NOUN	O	I-Entity
.	PUNCT	O	O

Median	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
was	VERB	O	O
34.4	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
was	VERB	O	O
higher	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
RD	PROPN	O	I-Entity
until	ADP	O	O
progression	NOUN	O	O
(	PUNCT	O	O
not	ADV	O	O
reached	VERB	O	O
versus	ADP	O	O
19	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
68.9	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
myelosuppression	NOUN	O	I-Entity
in	ADP	O	O
49.4	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12.7	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
needed	VERB	O	O
hospitalization	NOUN	O	O
.	PUNCT	O	O

Peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
2.5	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
deep	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
5.7	NUM	O	O
%	NOUN	O	O
.	PUNCT	O	O

Performance	NOUN	O	O
status	NOUN	O	O
(	PUNCT	O	O
PS	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
initial	ADJ	O	O
lenalidomide	NOUN	O	I-Entity
dose	NOUN	O	O
predicted	VERB	O	O
for	ADP	O	O
treatment	NOUN	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
study	NOUN	O	O
confirms	VERB	O	O
that	ADP	O	O
RD	PROPN	O	I-Entity
is	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
in	ADP	O	O
RRMM	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
RW	PROPN	O	O
;	PUNCT	O	O
it	PRON	O	O
produces	VERB	O	O
durable	ADJ	O	O
responses	NOUN	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
continue	VERB	O	O
on	ADP	O	O
treatment	NOUN	O	O
till	ADP	O	O
progression	NOUN	O	O
and	CCONJ	O	O
improves	VERB	O	O
humoral	ADJ	O	O
immunity	NOUN	O	O
even	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23949582)

The	DET	O	O
cytogenetic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
,	PUNCT	O	O
mesna	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
combination	NOUN	O	O
on	ADP	O	O
peripheral	ADJ	O	O
rabbit	NOUN	O	O
lymphocytes	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
/	SYM	O	O
in	ADP	O	O
vitro	NOUN	O	O
cytogenetic	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Ifosfamide	PROPN	O	I-Entity
(	PUNCT	O	O
IFO	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
alkylating	VERB	O	O
nitrogen	NOUN	O	I-Entity
mustard	NOUN	O	O
,	PUNCT	O	O
administrated	VERB	O	O
as	ADP	O	O
an	DET	O	O
antineoplasmic	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
intense	ADJ	O	O
urotoxic	ADJ	O	O
action	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
IFO	PROPN	O	I-Entity
raises	VERB	O	O
the	DET	O	O
requirement	NOUN	O	O
for	ADP	O	O
the	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
2-sulfanylethanesulfonate	NUM	O	I-Entity
(	PUNCT	O	O
Mesna	PROPN	O	I-Entity
)	PUNCT	O	O
aiming	VERB	O	O
to	PART	O	O
avoid	VERB	O	O
or	CCONJ	O	O
minimize	VERB	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

IFO	PROPN	O	I-Entity
and	CCONJ	O	O
Mesna	PROPN	O	I-Entity
were	VERB	O	O
administrated	VERB	O	O
separately	ADV	O	O
on	ADP	O	O
rabbit	NOUN	O	O
's	PART	O	O
lymphocytes	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
later	ADV	O	O
developed	VERB	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

Mesna	PROPN	O	I-Entity
's	PART	O	O
action	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
IFO	PROPN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
SCEs	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
SCEs	PROPN	O	O
recordings	NOUN	O	O
obtained	VERB	O	O
when	ADV	O	O
IFO	PROPN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
alone	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
this	DET	O	O
,	PUNCT	O	O
when	ADV	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
Mesna	PROPN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
alone	ADV	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
PRI	PROPN	O	O
were	VERB	O	O
noted	VERB	O	O
,	PUNCT	O	O
than	ADP	O	O
with	ADP	O	O
IFO	PROPN	O	I-Entity
acting	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
concentration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
lymphocytes	NOUN	O	O
.	PUNCT	O	O

Mesna	PROPN	O	I-Entity
significantly	ADV	O	O
reduces	VERB	O	O
IFO	PROPN	O	I-Entity
's	PART	O	O
genotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
when	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
it	PRON	O	O
acts	VERB	O	O
in	ADP	O	O
an	DET	O	O
inhibitory	ADJ	O	O
fashion	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cytostatic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (23952588)

Risk	NOUN	O	O
factors	NOUN	O	O
and	CCONJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
among	ADP	O	O
multiethnic	ADJ	O	O
Malaysians	PROPN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
pulsatile	NOUN	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
leads	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
and	CCONJ	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
and	CCONJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
among	ADP	O	O
multiethnic	ADJ	O	O
Malaysian	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
study	NOUN	O	O
involving	VERB	O	O
95	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
on	ADP	O	O
uninterrupted	ADJ	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
predictors	NOUN	O	O
of	ADP	O	O
dyskinesia	NOUN	O	I-Entity
were	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
multivariate	NOUN	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Dyskinesia	PROPN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
44%	NUM	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
42	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
median	ADJ	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Eighty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
dyskinesia	NOUN	O	I-Entity
had	VERB	O	O
clinical	ADJ	O	O
fluctuations	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
dyskinesia	NOUN	O	I-Entity
had	VERB	O	O
lower	ADJ	O	O
onset	NOUN	O	O
age	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
longer	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
higher	ADJ	O	O
total	ADJ	O	O
daily	ADJ	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
higher	ADJ	O	O
total	ADJ	O	O
UPDRS	PROPN	O	O
scores	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
three	NUM	O	O
significant	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
dyskinesia	NOUN	O	I-Entity
were	VERB	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
onset	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	O
daily	ADJ	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patients	NOUN	O	O
was	VERB	O	O
44%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
significant	ADJ	O	O
predictors	NOUN	O	O
were	VERB	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
daily	ADJ	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
onset	NOUN	O	O
age	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24040781)

An	DET	O	O
unexpected	ADJ	O	O
diagnosis	NOUN	O	O
in	ADP	O	O
a	DET	O	O
renal	NOUN	O	O
-	PUNCT	O	O
transplant	NOUN	O	O
patient	NOUN	O	O
with	ADP	O	O
proteinuria	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
everolimus	NOUN	O	I-Entity
:	PUNCT	O	O
AL	PROPN	O	I-Entity
amyloidosis	NOUN	O	I-Entity
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
expected	VERB	O	O
complication	NOUN	O	O
in	ADP	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
mammalian	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
rapamycin	ADJ	O	I-Entity
inhibitors	NOUN	O	O
(	PUNCT	O	O
mTOR	PROPN	O	O
-	PUNCT	O	O
i	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
suspicion	NOUN	O	O
should	VERB	O	O
always	ADV	O	O
be	VERB	O	O
supported	VERB	O	O
by	ADP	O	O
histological	ADJ	O	O
evidence	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
potential	ADJ	O	O
alternate	ADJ	O	O
diagnoses	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
acute	ADJ	O	O
or	CCONJ	O	O
chronic	ADJ	O	O
rejection	NOUN	O	O
,	PUNCT	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
and	CCONJ	O	O
tubular	NOUN	O	O
atrophy	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
recurrent	ADJ	O	O
or	CCONJ	O	O
de	X	O	O
novo	X	O	O
glomerulopathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
case	NOUN	O	O
we	PRON	O	O
report	VERB	O	O
the	DET	O	O
unexpected	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
amyloidosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
renal	NOUN	O	O
-	PUNCT	O	O
transplant	NOUN	O	O
patient	NOUN	O	O
with	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
transplant	NOUN	O	O
monoclonal	ADJ	O	O
gammapathy	NOUN	O	O
of	ADP	O	O
undetermined	ADJ	O	O
significance	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
conversion	NOUN	O	O
from	ADP	O	O
tacrolimus	NOUN	O	I-Entity
to	ADP	O	O
everolimus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24067251)

An	DET	O	O
investigation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
persons	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
tenofovir	NOUN	O	B-Entity
disoproxil	NOUN	O	I-Entity
fumarate	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
examination	NOUN	O	O
of	ADP	O	O
a	DET	O	O
large	ADJ	O	O
population	NOUN	O	O
database	NOUN	O	O
(	PUNCT	O	O
MHRA	PROPN	O	O
database	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
tenofovir	NOUN	O	I-Entity
to	PART	O	O
cause	VERB	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
syndromes	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
established	VERB	O	O
from	ADP	O	O
mechanistic	ADJ	O	O
and	CCONJ	O	O
randomised	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
undertook	VERB	O	O
a	DET	O	O
descriptive	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
Yellow	PROPN	O	O
Card	PROPN	O	O
records	NOUN	O	O
of	ADP	O	O
407	NUM	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
persons	NOUN	O	O
taking	VERB	O	O
tenofovir	NOUN	O	B-Entity
disoproxil	NOUN	O	I-Entity
fumarate	NOUN	O	I-Entity
(	PUNCT	O	O
TDF	PROPN	O	I-Entity
)	PUNCT	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
regimen	NOUN	O	O
and	CCONJ	O	O
submitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
Medicines	PROPN	O	O
and	CCONJ	O	O
Healthcare	PROPN	O	O
Products	PROPN	O	O
Regulatory	PROPN	O	O
Agency	PROPN	O	O
(	PUNCT	O	O
MHRA	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
suspected	VERB	O	O
kidney	NOUN	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Reports	NOUN	O	O
that	ADJ	O	O
satisfy	VERB	O	O
defined	VERB	O	O
criteria	NOUN	O	O
were	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
kidney	NOUN	O	B-Entity
tubular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
Fanconi	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
407	NUM	O	O
Yellow	PROPN	O	O
Card	PROPN	O	O
records	NOUN	O	O
analysed	VERB	O	O
,	PUNCT	O	O
106	NUM	O	O
satisfied	ADJ	O	O
criteria	NOUN	O	O
for	ADP	O	O
TDF	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
kidney	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
of	ADP	O	O
which	ADJ	O	O
53	NUM	O	O
(	PUNCT	O	O
50%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-Entity
tubular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
35	NUM	O	O
(	PUNCT	O	O
33%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
18	NUM	O	O
(	PUNCT	O	O
17%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
Fanconi	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
TDF	PROPN	O	I-Entity
exposure	NOUN	O	O
was	VERB	O	O
316	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
interquartile	ADJ	O	O
range	NOUN	O	O
120	NUM	O	O
-	SYM	O	O
740	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
hospitalisation	NOUN	O	O
for	ADP	O	O
TDF	PROPN	O	I-Entity
kidney	NOUN	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
was	VERB	O	O
high	ADJ	O	O
,	PUNCT	O	O
particularly	ADV	O	O
amongst	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
features	NOUN	O	O
of	ADP	O	O
Fanconi	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Cessation	NOUN	O	O
of	ADP	O	O
TDF	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
complete	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
up	ADP	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
this	DET	O	O
report	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24068571)

Incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
is	VERB	O	O
high	ADJ	O	O
even	ADV	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
without	ADP	O	O
known	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
recognized	VERB	O	O
complication	NOUN	O	O
in	ADP	O	O
populations	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
without	ADP	O	O
known	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
ICU	PROPN	O	O
for	ADP	O	O
postoperative	ADJ	O	O
monitoring	NOUN	O	O
after	ADP	O	O
elective	ADJ	O	O
major	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Exclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
any	DET	O	O
preexisting	VERB	O	O
predisposing	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
delirium	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
potentially	ADV	O	O
confounding	VERB	O	O
neurological	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
daily	ADV	O	O
using	VERB	O	O
the	DET	O	O
confusion	NOUN	O	I-Entity
assessment	NOUN	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
ICU	PROPN	O	O
scale	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Early	ADV	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
incidence	NOUN	O	O
risk	NOUN	O	O
factors	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
assessed	VERB	O	O
through	ADP	O	O
three	NUM	O	O
different	ADJ	O	O
multiple	ADJ	O	O
regression	NOUN	O	O
models	NOUN	O	O
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
the	DET	O	O
confusion	NOUN	O	O
assessment	NOUN	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
ICU	PROPN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
28	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
early	ADJ	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
thiopentone	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
eight	NUM	O	O
-	PUNCT	O	O
fold	NOUN	O	O
-	PUNCT	O	O
higher	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
delirium	NOUN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
propofol	NOUN	O	I-Entity
(	PUNCT	O	O
57.1%	NUM	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
early	ADV	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
very	ADV	O	O
common	ADJ	O	O
complication	NOUN	O	O
after	ADP	O	O
major	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
without	ADP	O	O
known	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Thiopentone	PROPN	O	I-Entity
was	VERB	O	O
independently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
its	ADJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24072398)

A	DET	O	O
single	ADJ	O	O
neurotoxic	NOUN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
induces	VERB	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
depressive	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behaviour	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
METH	PROPN	O	I-Entity
)	PUNCT	O	O
triggers	VERB	O	O
a	DET	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
monoaminergic	ADJ	O	O
system	NOUN	O	O
and	CCONJ	O	O
METH	PROPN	O	I-Entity
abuse	NOUN	O	O
leads	VERB	O	O
to	ADP	O	O
negative	ADJ	O	O
emotional	ADJ	O	O
states	NOUN	O	O
including	VERB	O	O
depressive	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
during	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
currently	ADV	O	O
unknown	ADJ	O	O
if	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
toxic	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
also	ADV	O	O
causes	VERB	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
depressive	ADJ	O	I-Entity
phenotype	NOUN	O	O
and	CCONJ	O	O
persistent	ADJ	O	O
monoaminergic	ADJ	O	O
deficits	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
now	ADV	O	O
assessed	VERB	O	O
the	DET	O	O
depressive	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behaviour	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
at	ADP	O	O
early	ADV	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
periods	NOUN	O	O
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
high	ADJ	O	O
METH	PROPN	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METH	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
the	DET	O	O
motor	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
procedural	ADJ	O	O
memory	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
as	ADP	O	O
assessed	VERB	O	O
by	ADP	O	O
swimming	VERB	O	O
speed	NOUN	O	O
and	CCONJ	O	O
escape	VERB	O	O
latency	NOUN	O	O
to	PART	O	O
find	VERB	O	O
the	DET	O	O
platform	NOUN	O	O
in	ADP	O	O
a	DET	O	O
cued	VERB	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
water	NOUN	O	O
maze	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
METH	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
immobility	NOUN	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tail	NOUN	O	O
suspension	NOUN	O	O
test	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
49	NUM	O	O
days	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
depressive	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
METH	PROPN	O	I-Entity
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
a	DET	O	O
marked	VERB	O	O
depletion	NOUN	O	O
of	ADP	O	O
frontostriatal	ADJ	O	O
dopaminergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
neurotransmission	NOUN	O	O
,	PUNCT	O	O
indicated	VERB	O	O
by	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
DOPAC	PROPN	O	I-Entity
and	CCONJ	O	O
HVA	PROPN	O	I-Entity
,	PUNCT	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
and	CCONJ	O	O
serotonin	NOUN	O	I-Entity
,	PUNCT	O	O
observed	VERB	O	O
at	ADP	O	O
both	DET	O	O
3	NUM	O	O
and	CCONJ	O	O
49	NUM	O	O
days	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
parallel	NOUN	O	O
,	PUNCT	O	O
another	DET	O	O
neurochemical	ADJ	O	O
feature	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
--	PUNCT	O	O
astroglial	ADJ	O	O
dysfunction	NOUN	O	O
--	PUNCT	O	O
was	VERB	O	O
unaffected	VERB	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
striatal	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
astrocytic	ADJ	O	O
protein	NOUN	O	O
marker	NOUN	O	O
,	PUNCT	O	O
glial	ADJ	O	O
fibrillary	ADJ	O	O
acidic	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
only	ADV	O	O
transiently	ADV	O	O
increased	VERB	O	O
at	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
that	ADJ	O	O
a	DET	O	O
single	ADJ	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
induces	VERB	O	O
long	ADV	O	O
-	PUNCT	O	O
lasting	VERB	O	O
depressive	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behaviour	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
frontostriatal	ADJ	O	O
dopaminergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
homoeostasis	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24088636)

Linezolid	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
linezolid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
on	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
tuberculous	ADJ	O	O
drugs	NOUN	O	O
including	VERB	O	O
linezolid	NOUN	O	I-Entity
and	CCONJ	O	O
ethambutol	NOUN	O	I-Entity
for	ADP	O	O
extensively	ADV	O	B-Entity
drug	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
resistant	ADJ	O	I-Entity
tuberculosis	NOUN	O	I-Entity
(	PUNCT	O	O
XDR	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
TB	PROPN	O	I-Entity
)	PUNCT	O	O
presented	VERB	O	O
to	ADP	O	O
us	PRON	O	O
with	ADP	O	O
painless	ADJ	O	O
progressive	ADJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Color	ADJ	O	O
vision	NOUN	O	O
was	VERB	O	O
defective	ADJ	O	O
and	CCONJ	O	O
fundus	ADJ	O	O
examination	NOUN	O	O
revealed	VERB	O	O
optic	NOUN	O	B-Entity
disc	NOUN	O	I-Entity
edema	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Ethambutol	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxic	ADJ	O	B-Entity
optic	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
and	CCONJ	O	O
tablet	NOUN	O	O
ethambutol	NOUN	O	I-Entity
was	VERB	O	O
withdrawn	VERB	O	O
.	PUNCT	O	O

Deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
occurred	VERB	O	O
despite	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
.	PUNCT	O	O

Discontinuation	NOUN	O	O
of	ADP	O	O
linezolid	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
marked	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
vision	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
report	NOUN	O	O
emphasizes	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
monitoring	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
linezolid	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24091473)

Resuscitation	NOUN	O	O
with	ADP	O	O
lipid	NOUN	O	O
,	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
in	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
newborn	ADJ	O	O
piglets	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
dosing	NOUN	O	O
regimens	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
emulsion	NOUN	O	O
,	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
are	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
determined	VERB	O	O
in	ADP	O	O
neonates	NOUN	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
LAST	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Newborn	ADJ	O	O
piglets	NOUN	O	O
received	VERB	O	O
levobupivacaine	NOUN	O	I-Entity
until	ADP	O	O
cardiovascular	NOUN	O	B-Entity
collapse	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Standard	ADJ	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
and	CCONJ	O	O
electrocardiogram	NOUN	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
QRS	PROPN	O	O
prolongation	NOUN	O	O
.	PUNCT	O	O

Piglets	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
(	PUNCT	O	O
saline	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Intralipid	PROPN	O	O
(	PUNCT	O	O
)	PUNCT	O	O
alone	ADV	O	O
,	PUNCT	O	O
epinephrine	ADV	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
Intralipd	PROPN	O	O
plus	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
ECG	PROPN	O	O
abnormalities	NOUN	O	O
was	VERB	O	O
zero	NUM	O	O
in	ADP	O	O
the	DET	O	O
Intralipid	PROPN	O	O
only	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
14	NUM	O	O
and	CCONJ	O	O
17	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
epinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
plus	CCONJ	O	O
lipid	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Lipid	PROPN	O	O
emulsion	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
alone	ADJ	O	O
were	VERB	O	O
equally	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
achieving	VERB	O	O
a	DET	O	O
return	NOUN	O	O
to	ADP	O	O
spontaneous	ADJ	O	O
circulation	NOUN	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
of	ADP	O	O
LAST	PROPN	O	O
.	PUNCT	O	O

Epinephrine	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
lipid	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
number	NOUN	O	O
of	ADP	O	O
ECG	PROPN	O	O
abnormalities	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
lipid	ADJ	O	O
emulsion	NOUN	O	O
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (24100055)

Incidence	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
and	CCONJ	O	O
postoperative	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
platelet	NOUN	O	O
count	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
graft	NOUN	O	O
recipients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
retrospective	ADJ	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Thrombocytopenia	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
disorder	NOUN	O	O
caused	VERB	O	O
mainly	ADV	O	O
by	ADP	O	O
portal	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
low	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
thrombopoetin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endotoxemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
immune	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
few	ADJ	O	O
literature	NOUN	O	O
citations	NOUN	O	O
reporting	VERB	O	O
contradictory	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
perioperative	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
and	CCONJ	O	O
determine	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
HIT	PROPN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
retrospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
medical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
205	NUM	O	O
consecutive	ADJ	O	O
adult	NOUN	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
full	ADJ	O	O
-	PUNCT	O	O
size	NOUN	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
between	ADP	O	O
January	PROPN	O	O
2006	NUM	O	O
and	CCONJ	O	O
December	PROPN	O	O
2010	NUM	O	O
due	ADP	O	O
to	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
malignant	ADJ	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Preoperative	ADJ	O	O
platelet	NOUN	O	O
count	NOUN	O	O
,	PUNCT	O	O
postoperative	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
platelets	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
155	NUM	O	O
(	PUNCT	O	O
75.6%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
205	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
thrombocytopenia	VERB	O	I-Entity
before	ADP	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
Model	PROPN	O	O
of	ADP	O	O
End	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Stage	PROPN	O	I-Entity
Liver	PROPN	O	I-Entity
Disease	PROPN	O	I-Entity
score	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	B-Entity
cirrhosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
platelet	NOUN	O	O
count	NOUN	O	O
exceeded	VERB	O	O
100,000/uL	NUM	O	O
in	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
193	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
medium	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
d.	NOUN	O	O
Regarding	VERB	O	O
HIT	PROPN	O	B-Entity
II	PROPN	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
four	NUM	O	O
(	PUNCT	O	O
1.95%	NUM	O	O
)	PUNCT	O	O

patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
background	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
about	ADV	O	O
1.95%	NUM	O	O
,	PUNCT	O	O
rare	ADJ	O	O
.	PUNCT	O	O

For	ADP	O	O
further	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	B-Entity
type	NOUN	O	I-Entity
II	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
heparin	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
prophylactic	ADJ	O	O
anticoagulation	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
molecular	ADJ	O	O
-	PUNCT	O	O
weight	NOUN	O	O
heparin	NOUN	O	I-Entity
after	ADP	O	O
normalization	NOUN	O	O
of	ADP	O	O
platelet	NOUN	O	O
count	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24100257)

Takotsubo	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
or	CCONJ	O	O
apical	ADJ	O	B-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
)	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
Zolmitriptan	PROPN	O	I-Entity
.	PUNCT	O	O

Takotsubo	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
TS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
also	ADV	O	O
known	VERB	O	O
as	ADP	O	O
broken	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
left	ADV	O	O
ventricle	ADJ	O	O
apical	ADJ	O	O
ballooning	NOUN	O	O
with	ADP	O	O
elevated	ADJ	O	O
cardiac	ADJ	O	O
biomarkers	NOUN	O	O
and	CCONJ	O	O
electrocardiographic	ADJ	O	O
changes	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
coronary	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
ie	X	O	O
,	PUNCT	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
elevation	NOUN	O	O
,	PUNCT	O	O
T	PROPN	O	O
wave	NOUN	O	O
inversions	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pathologic	ADJ	O	O
Q	NOUN	O	O
waves	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
medical	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
mitral	ADJ	O	B-Entity
valve	NOUN	O	I-Entity
prolapse	NOUN	O	I-Entity
and	CCONJ	O	O
migraines	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
substernal	ADJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
electrocardiogram	NOUN	O	O
demonstrated	VERB	O	O
1/2	NUM	O	O
mm	PROPN	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
elevation	NOUN	O	O
in	ADP	O	O
leads	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
III	PROPN	O	O
,	PUNCT	O	O
aVF	PROPN	O	O
,	PUNCT	O	O
V5	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
V6	PROPN	O	O
and	CCONJ	O	O
positive	ADJ	O	O
troponin	NOUN	O	O
I.	PROPN	O	O
Emergent	ADJ	O	O
coronary	ADJ	O	O
angiogram	NOUN	O	O
revealed	VERB	O	O
normal	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
with	ADP	O	O
moderately	ADV	O	O
reduced	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
with	ADP	O	O
wall	NOUN	O	O
motion	NOUN	O	O
abnormalities	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
TS	PROPN	O	I-Entity
.	PUNCT	O	O

Detailed	VERB	O	O
history	NOUN	O	O
obtained	VERB	O	O
retrospectively	ADV	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
took	VERB	O	O
zolmitriptan	NOUN	O	I-Entity
sparingly	ADV	O	O
only	ADV	O	O
when	ADV	O	O
she	PRON	O	O
had	VERB	O	O
migraines	NOUN	O	I-Entity
.	PUNCT	O	O

But	CCONJ	O	O
before	ADP	O	O
this	DET	O	O
event	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
was	VERB	O	O
taking	VERB	O	O
zolmitriptan	NOUN	O	I-Entity
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
times	NOUN	O	O
daily	ADV	O	O
for	ADP	O	O
several	ADJ	O	O
days	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
migraine	ADJ	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
any	DET	O	O
recent	ADJ	O	O
stress	NOUN	O	O
or	CCONJ	O	O
status	NOUN	O	B-Entity
migrainosus	NOUN	O	I-Entity
.	PUNCT	O	O

Extensive	ADJ	O	O
literature	NOUN	O	O
search	NOUN	O	O
revealed	VERB	O	O
multiple	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
vasospasm	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
zolmitriptan	VERB	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
TS	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24114426)

Depression	NOUN	O	I-Entity
,	PUNCT	O	O
impulsiveness	NOUN	O	I-Entity
,	PUNCT	O	O
sleep	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
memory	NOUN	O	O
in	ADP	O	O
past	ADJ	O	O
and	CCONJ	O	O
present	ADJ	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
of	ADP	O	O
3,4-methylenedioxymethamphetamine	NUM	O	I-Entity
(	PUNCT	O	O
MDMA	NOUN	O	I-Entity
,	PUNCT	O	O
ecstasy	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

RATIONALE	NOUN	O	O
:	PUNCT	O	O
Ecstasy	PROPN	O	I-Entity
(	PUNCT	O	O
3,4-methylenedioxymethamphetamine	NUM	O	I-Entity
,	PUNCT	O	O
MDMA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
worldwide	ADJ	O	O
recreational	ADJ	O	O
drug	NOUN	O	O
of	ADP	O	O
abuse	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
largest	ADJ	O	O
to	ADP	O	O
date	NOUN	O	O
in	ADP	O	O
sample	NOUN	O	O
size	NOUN	O	O
and	CCONJ	O	O
5HT	NUM	O	O
-	PUNCT	O	O
related	VERB	O	O
behaviors	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
to	PART	O	O
compare	VERB	O	O
present	ADJ	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
with	ADP	O	O
past	ADJ	O	O
users	NOUN	O	O
after	ADP	O	O
an	DET	O	O
abstinence	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
first	ADJ	O	O
to	PART	O	O
include	VERB	O	O
robust	ADJ	O	O
controls	NOUN	O	O
for	ADP	O	O
other	ADJ	O	O
recreational	ADJ	O	O
substances	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
997	NUM	O	O
participants	NOUN	O	O
(	PUNCT	O	O
52	NUM	O	O
%	NOUN	O	O
male	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
recruited	VERB	O	O
to	ADP	O	O
four	NUM	O	O
control	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
drug	NOUN	O	O
(	PUNCT	O	O
ND	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
alcohol	NOUN	O	I-Entity
/	PUNCT	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
AN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
cannabis	X	O	I-Entity
/	SYM	O	O
alcohol	NOUN	O	I-Entity
/	SYM	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
CAN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
ecstasy	NOUN	O	I-Entity
polydrug	NOUN	O	O
(	PUNCT	O	O
PD	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
ecstasy	NOUN	O	I-Entity
polydrug	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
present	ADJ	O	O
(	PUNCT	O	O
MDMA	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
past	ADJ	O	O
users	NOUN	O	O
(	PUNCT	O	O
EX	PROPN	O	O
-	PUNCT	O	O
MDMA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
completed	VERB	O	O
a	DET	O	O
drug	NOUN	O	O
history	NOUN	O	O
questionnaire	NOUN	O	O
,	PUNCT	O	O
Beck	PROPN	O	O
Depression	PROPN	O	I-Entity
Inventory	PROPN	O	O
,	PUNCT	O	O
Barratt	PROPN	O	O
Impulsiveness	PROPN	O	I-Entity
Scale	PROPN	O	O
,	PUNCT	O	O
Pittsburgh	PROPN	O	O
Sleep	PROPN	O	O
Quality	PROPN	O	O
Index	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Wechsler	PROPN	O	O
Memory	PROPN	O	O
Scale	PROPN	O	O
-	PUNCT	O	O
Revised	PROPN	O	O
which	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
total	NOUN	O	O
,	PUNCT	O	O
provided	VERB	O	O
13	NUM	O	O
psychometric	ADJ	O	O
measures	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
CAN	PROPN	O	I-Entity
and	CCONJ	O	O
PD	PROPN	O	O
groups	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
record	VERB	O	O
greater	ADJ	O	O
deficits	NOUN	O	O
than	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
drug	NOUN	O	O
controls	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MDMA	PROPN	O	I-Entity
and	CCONJ	O	O
EX	PROPN	O	O
-	PUNCT	O	O
MDMA	PROPN	O	I-Entity
groups	NOUN	O	O
recorded	VERB	O	O
greater	ADJ	O	O
deficits	NOUN	O	O
than	ADP	O	O
all	ADJ	O	O
the	DET	O	O
control	NOUN	O	O
groups	NOUN	O	O
on	ADP	O	O
ten	NUM	O	O
of	ADP	O	O
the	DET	O	O
13	NUM	O	O
psychometric	ADJ	O	O
measures	NOUN	O	O
.	PUNCT	O	O

Strikingly	ADV	O	O
,	PUNCT	O	O
despite	ADP	O	O
prolonged	VERB	O	O
abstinence	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
,	PUNCT	O	O
4.98	NUM	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
-	SYM	O	O
9	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
past	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
showed	VERB	O	O
few	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
present	ADJ	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
past	NOUN	O	O
users	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
change	NOUN	O	O
for	ADP	O	O
ten	NUM	O	O
measures	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
impairment	NOUN	O	O
for	ADP	O	O
two	NUM	O	O
measures	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
improvement	NOUN	O	O
on	ADP	O	O
just	ADV	O	O
one	NUM	O	O
measure	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
this	DET	O	O
record	NOUN	O	O
of	ADP	O	O
impaired	ADJ	O	B-Entity
memory	NOUN	O	I-Entity
and	CCONJ	O	O
clinically	ADV	O	O
significant	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
,	PUNCT	O	O
impulsiveness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
prognosis	NOUN	O	O
for	ADP	O	O
the	DET	O	O
current	ADJ	O	O
generation	NOUN	O	O
of	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
cause	NOUN	O	O
for	ADP	O	O
concern	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24126708)

Association	NOUN	O	O
of	ADP	O	O
common	ADJ	O	O
genetic	ADJ	O	O
variants	NOUN	O	O
of	ADP	O	O
HOMER1	PROPN	O	O
gene	NOUN	O	O
with	ADP	O	O
levodopa	ADV	O	I-Entity
adverse	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
effective	ADJ	O	O
symptomatic	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
chronic	ADJ	O	O
use	NOUN	O	O
could	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
chronic	ADJ	O	O
adverse	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
,	PUNCT	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
.	PUNCT	O	O

HOMER1	NOUN	O	O
is	VERB	O	O
a	DET	O	O
protein	NOUN	O	O
with	ADP	O	O
pivotal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
glutamate	NOUN	O	I-Entity
transmission	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
complications	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigates	VERB	O	O
whether	ADP	O	O
polymorphisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
HOMER1	PROPN	O	O
gene	NOUN	O	O
promoter	NOUN	O	O
region	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
205	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
rs4704559	NOUN	O	O
G	PROPN	O	O
allele	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
dyskinesia	NOUN	O	I-Entity
(	PUNCT	O	O
prevalence	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
PR)=0.615	PROPN	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	PROPN	O	O
)	PUNCT	O	O
0.426	NUM	O	O
-	SYM	O	O
0.887	NUM	O	O
,	PUNCT	O	O
P=0.009	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
(	PUNCT	O	O
PR=0.515	PROPN	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.295	NUM	O	O
-	SYM	O	O
0.899	NUM	O	O
,	PUNCT	O	O
P=0.020	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
HOMER1	PROPN	O	O
rs4704559	NOUN	O	O
G	PROPN	O	O
allele	NOUN	O	O
has	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
levodopa	ADV	O	I-Entity
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24132704)

Crocin	PROPN	O	I-Entity
improves	VERB	O	O
lipid	ADJ	O	O
dysregulation	NOUN	O	O
in	ADP	O	O
subacute	NOUN	O	O
diazinon	NOUN	O	I-Entity
exposure	NOUN	O	O
through	ADP	O	O
ERK1/2	PROPN	O	O
pathway	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
liver	NOUN	O	O
.	PUNCT	O	O

Diazinon	PROPN	O	I-Entity
Yis	PROPN	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
broadly	ADV	O	O
used	VERB	O	O
organophosphorus	NOUN	O	I-Entity
insecticides	NOUN	O	O
in	ADP	O	O
agriculture	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
diazinon	NOUN	O	I-Entity
may	VERB	O	O
interfere	VERB	O	O
with	ADP	O	O
lipid	ADJ	O	O
metabolism	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
hypolipidemic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
crocin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
established	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
ERK	PROPN	O	O
and	CCONJ	O	O
LDLr	PROPN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
subacute	VERB	O	O
diazinon	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
ameliorating	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
crocin	NOUN	O	I-Entity
on	ADP	O	O
diazinon	NOUN	O	I-Entity
induced	VERB	O	O
disturbed	VERB	O	O
cholesterol	NOUN	O	I-Entity
homeostasis	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

24	NUM	O	O
Rats	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
and	CCONJ	O	O
received	VERB	O	O
following	VERB	O	O
treatments	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
Corn	PROPN	O	O
oil	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diazinon	NOUN	O	I-Entity
(	PUNCT	O	O
15mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
orally	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
crocin	NOUN	O	I-Entity
(	PUNCT	O	O
12.5	NUM	O	O
and	CCONJ	O	O
25mg	PROPN	O	O
/	SYM	O	O

kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
intraperitoneally	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
diazinon	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
cholesterol	NOUN	O	I-Entity
,	PUNCT	O	O
triglyceride	NOUN	O	I-Entity
and	CCONJ	O	O
LDL	PROPN	O	O
in	ADP	O	O
blood	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
data	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
subacute	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
diazinon	VERB	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
concentrations	NOUN	O	O
of	ADP	O	O
cholesterol	NOUN	O	I-Entity
,	PUNCT	O	O
triglyceride	NOUN	O	I-Entity
and	CCONJ	O	O
LDL	PROPN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
diazinon	NOUN	O	I-Entity
decreased	VERB	O	O
ERK1/2	PROPN	O	O
protein	NOUN	O	O
phosphorylation	NOUN	O	O
and	CCONJ	O	O
LDLr	NOUN	O	O
transcript	NOUN	O	O
.	PUNCT	O	O

Crocin	PROPN	O	I-Entity
reduced	VERB	O	O
inhibition	NOUN	O	O
of	ADP	O	O
ERK	PROPN	O	O
activation	NOUN	O	O
and	CCONJ	O	O
diazinon	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperlipemia	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
LDLr	NOUN	O	O
transcript	NOUN	O	O
.	PUNCT	O	O

Crocin	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
protective	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
diazinon	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperlipemia	NOUN	O	I-Entity
through	ADP	O	O
modulating	NOUN	O	O
of	ADP	O	O
ERK	PROPN	O	O
pathway	NOUN	O	O
and	CCONJ	O	O
increase	NOUN	O	O
of	ADP	O	O
LDLr	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24158386)

GEM	NOUN	O	I-Entity
-	PUNCT	O	O
P	NOUN	O	O
chemotherapy	NOUN	O	O
is	VERB	O	O
active	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
relapsed	VERB	O	O
Hodgkin	PROPN	O	B-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

Hodgkin	PROPN	O	B-Entity
lymphoma	NOUN	O	I-Entity
(	PUNCT	O	O
HL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
relatively	ADV	O	O
chemosensitive	ADJ	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

Regimens	NOUN	O	O
commonly	ADV	O	O
used	VERB	O	O
often	ADV	O	O
require	VERB	O	O
inpatient	ADJ	O	O
administration	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
difficult	ADJ	O	O
to	PART	O	O
deliver	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Gemcitabine	PROPN	O	I-Entity
and	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
have	VERB	O	O
activity	NOUN	O	O
in	ADP	O	O
HL	PROPN	O	I-Entity
,	PUNCT	O	O
non	ADV	O	O
-	PUNCT	O	O
overlapping	VERB	O	O
toxicity	NOUN	O	I-Entity
with	ADP	O	O
first	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
chemotherapeutics	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
delivered	VERB	O	O
in	ADP	O	O
an	DET	O	O
outpatient	NOUN	O	O
setting	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
retrospective	ADJ	O	O
single	ADJ	O	O
-	PUNCT	O	O
centre	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsed	VERB	O	O
or	CCONJ	O	O
refractory	ADJ	O	O
HL	PROPN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
gemcitabine	SYM	O	I-Entity
1,000	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
D)1	PROPN	O	O
,	PUNCT	O	O
D8	PROPN	O	O
and	CCONJ	O	O
D15	PROPN	O	O
;	PUNCT	O	O
methylprednisolone	NOUN	O	I-Entity
1,000	NUM	O	O
mg	NUM	O	O
D1	NUM	O	O
-	PUNCT	O	O
5	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
cisplatin	VERB	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
D15	NOUN	O	O
,	PUNCT	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Demographic	ADJ	O	O
,	PUNCT	O	O
survival	NOUN	O	O
,	PUNCT	O	O
response	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
data	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
twenty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
were	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
total	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
3	NUM	O	O
cycles	NOUN	O	O
;	PUNCT	O	O
range	VERB	O	O
1	NUM	O	O
-	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

patients	NOUN	O	O
received	VERB	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
as	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
11/41	NUM	O	O
(	PUNCT	O	O
27	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
ORR	PROPN	O	O
)	PUNCT	O	O
to	ADP	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
in	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
cohort	NOUN	O	O
was	VERB	O	O
80	NUM	O	O
%	NOUN	O	O
(	PUNCT	O	O
complete	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
CR	PROPN	O	O
)	PUNCT	O	O
37	NUM	O	O
%	NOUN	O	O
,	PUNCT	O	O
partial	ADJ	O	O
response	NOUN	O	O
44	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
14/15	NUM	O	O
CR	PROPN	O	O
confirmed	VERB	O	O
as	ADP	O	O
a	DET	O	O
metabolic	NOUN	O	O
CR	NOUN	O	O
on	ADP	O	O
PET	PROPN	O	O
and	CCONJ	O	O
ORR	PROPN	O	O
of	ADP	O	O
85	NUM	O	O
%	NOUN	O	O
in	ADP	O	O
the	DET	O	O
20	NUM	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

3/4	NUM	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
haematological	ADJ	O	O
:	PUNCT	O	O
neutropenia	ADJ	O	I-Entity
54	NUM	O	O
%	NOUN	O	O
and	CCONJ	O	O
thrombocytopenia	ADV	O	I-Entity
51	NUM	O	O
%	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
from	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
GEM	NOUN	O	I-Entity
-	PUNCT	O	O
P	NOUN	O	O
was	VERB	O	O
4.5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
,	PUNCT	O	O
5-year	NUM	O	O
progression	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
survival	NOUN	O	O
was	VERB	O	O
46	NUM	O	O
%	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
30	NUM	O	O
-	SYM	O	O
62	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5-year	NUM	O	O
overall	ADJ	O	O
survival	NOUN	O	O
was	VERB	O	O
59	NUM	O	O
%	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	NOUN	O	O
CI	PROPN	O	O
,	PUNCT	O	O
43	NUM	O	O
-	SYM	O	O
74	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

GEM	NOUN	O	I-Entity
-	PUNCT	O	O
P	NOUN	O	O
is	VERB	O	O
a	DET	O	O
salvage	NOUN	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
relatively	ADV	O	O
high	ADJ	O	O
response	NOUN	O	O
rates	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
successful	ADJ	O	O
transplantation	NOUN	O	O
in	ADP	O	O
appropriate	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
relapsed	VERB	O	O
or	CCONJ	O	O
refractory	ADJ	O	O
HL	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24190587)

Basal	ADJ	O	O
functioning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypothalamic	NOUN	O	O
-	PUNCT	O	O
pituitary	NOUN	O	O
-	PUNCT	O	O
adrenal	ADJ	O	O
(	PUNCT	O	O
HPA	PROPN	O	O
)	PUNCT	O	O
axis	NOUN	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
distress	NOUN	O	O
in	ADP	O	O
recreational	ADJ	O	O
ecstasy	NOUN	O	I-Entity
polydrug	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

RATIONALE	NOUN	O	O
:	PUNCT	O	O
Ecstasy	PROPN	O	I-Entity
(	PUNCT	O	O
MDMA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
psychostimulant	ADJ	O	O
drug	NOUN	O	O
which	ADJ	O	O
is	VERB	O	O
increasingly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
psychobiological	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
use	NOUN	O	O
on	ADP	O	O
psychological	ADJ	O	O
distress	NOUN	O	O
and	CCONJ	O	O
basal	NOUN	O	O
functioning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HPA	PROPN	O	O
axis	NOUN	O	O
through	ADP	O	O
assessing	VERB	O	O
the	DET	O	O
secretion	NOUN	O	O
of	ADP	O	O
cortisol	NOUN	O	I-Entity
across	ADP	O	O
the	DET	O	O
diurnal	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
participants	NOUN	O	O
(	PUNCT	O	O
21	NUM	O	O
nonusers	NOUN	O	O
,	PUNCT	O	O
29	NUM	O	O
light	ADJ	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
heavy	ADJ	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
)	PUNCT	O	O
completed	VERB	O	O
a	DET	O	O
substance	NOUN	O	O
use	NOUN	O	O
inventory	NOUN	O	O
and	CCONJ	O	O
measures	NOUN	O	O
of	ADP	O	O
psychological	ADJ	O	O
distress	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
two	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
of	ADP	O	O
cortisol	NOUN	O	I-Entity
sampling	NOUN	O	O
(	PUNCT	O	O
on	ADP	O	O
awakening	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
post	NOUN	O	O
awakening	NOUN	O	O
,	PUNCT	O	O
between	ADP	O	O
1400	NUM	O	O
and	CCONJ	O	O
1600	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
pre	VERB	O	O
bedtime	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
user	NOUN	O	O
groups	NOUN	O	O
exhibited	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
depression	NOUN	O	I-Entity
than	ADP	O	O
nonusers	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
all	DET	O	O
participants	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
typical	ADJ	O	O
cortisol	NOUN	O	I-Entity
profile	NOUN	O	O
,	PUNCT	O	O
though	ADP	O	O
light	NOUN	O	O
users	NOUN	O	O
had	VERB	O	O
significantly	ADV	O	O
elevated	VERB	O	O
levels	NOUN	O	O
pre	ADP	O	O
-	PUNCT	O	O
bed	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
heavy	ADJ	O	O
users	NOUN	O	O
demonstrated	VERB	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
upon	ADP	O	O
awakening	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
demonstrated	VERB	O	O
elevated	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
bed	NOUN	O	O
levels	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
.	PUNCT	O	O

Significant	NOUN	O	O
between	ADP	O	O
group	NOUN	O	O
differences	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
afternoon	NOUN	O	O
cortisol	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
overall	ADJ	O	O
cortisol	NOUN	O	I-Entity
secretion	NOUN	O	O
across	ADP	O	O
the	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increases	NOUN	O	O
in	ADP	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
depression	NOUN	O	I-Entity
are	VERB	O	O
in	ADP	O	O
line	NOUN	O	O
with	ADP	O	O
previous	ADJ	O	O
observations	NOUN	O	O
in	ADP	O	O
recreational	ADJ	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

Dysregulated	VERB	O	O
diurnal	ADJ	O	O
cortisol	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
indicative	ADJ	O	O
of	ADP	O	O
inappropriate	ADJ	O	O
anticipation	NOUN	O	O
of	ADP	O	O
forthcoming	ADJ	O	O
demands	NOUN	O	O
and	CCONJ	O	O
hypersecretion	NOUN	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
the	DET	O	O
increased	VERB	O	O
psychological	ADJ	O	O
and	CCONJ	O	O
physical	ADJ	O	O
morbidity	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
heavy	ADJ	O	O
recreational	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
ecstasy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24209900)

Ifosfamide	ADV	O	I-Entity
related	VERB	O	O
encephalopathy	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
a	DET	O	O
timely	ADJ	O	O
EEG	PROPN	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

Ifosfamide	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
alkylating	VERB	O	O
agent	NOUN	O	O
useful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
cancers	NOUN	O	I-Entity
including	VERB	O	O
sarcomas	NOUN	O	I-Entity
,	PUNCT	O	O
lymphoma	NOUN	O	I-Entity
,	PUNCT	O	O
gynecologic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
testicular	ADJ	O	I-Entity
cancers	NOUN	O	I-Entity
.	PUNCT	O	O

Encephalopathy	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
10	NUM	O	O
-	PUNCT	O	O
40%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
IV	PROPN	O	O
ifosfamide	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
highlight	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
electroencephalogram	NOUN	O	O
(	PUNCT	O	O
EEG	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
ifosfamide	ADV	O	I-Entity
related	VERB	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Retrospective	ADJ	O	O
chart	NOUN	O	O
review	NOUN	O	O
including	VERB	O	O
clinical	ADJ	O	O
data	NOUN	O	O
and	CCONJ	O	O
EEG	PROPN	O	O
recordings	NOUN	O	O
was	VERB	O	O
done	VERB	O	O
on	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
admitted	VERB	O	O
to	ADP	O	O
MD	PROPN	O	O
Anderson	PROPN	O	O
Cancer	PROPN	O	I-Entity
Center	PROPN	O	O
between	ADP	O	O
years	NOUN	O	O
2009	NUM	O	O
and	CCONJ	O	O
2012	NUM	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
ifosfamide	ADV	O	I-Entity
related	VERB	O	O
acute	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
five	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
encephalopathy	NOUN	O	I-Entity
soon	ADV	O	O
after	ADP	O	O
(	PUNCT	O	O
within	ADP	O	O
12	NUM	O	O
h-2	NOUN	O	O
days	NOUN	O	O
)	PUNCT	O	O
receiving	VERB	O	O
ifosfamide	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
generalized	ADJ	O	O
convulsions	NOUN	O	I-Entity
while	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
continuous	ADJ	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
convulsive	ADJ	O	I-Entity
status	NOUN	O	I-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
NCSE	PROPN	O	I-Entity
)	PUNCT	O	O
that	ADJ	O	O
required	VERB	O	O
ICU	PROPN	O	O
admission	NOUN	O	O
and	CCONJ	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Severity	NOUN	O	O
of	ADP	O	O
ifosfamide	ADV	O	I-Entity
related	VERB	O	O
encephalopathy	ADJ	O	I-Entity
correlates	NOUN	O	O
with	ADP	O	O
EEG	PROPN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
a	DET	O	O
timely	ADJ	O	O
EEG	PROPN	O	O
evaluation	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
ifosfamide	NOUN	O	I-Entity
who	NOUN	O	O
develop	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24220752)

Incidence	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
hospitalised	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
and	CCONJ	O	O
possible	ADJ	O	O
factors	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
contrast	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CIN	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
hospitalised	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
the	DET	O	O
day	NOUN	O	O
before	ADP	O	O
contrast	NOUN	O	I-Entity
-	PUNCT	O	O
enhanced	VERB	O	O
computed	VERB	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
CT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
serially	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

CIN	PROPN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
Cr	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
dl	VERB	O	O
or	CCONJ	O	O
more	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
Cr	PROPN	O	I-Entity
to	ADP	O	O
25	NUM	O	O
%	NOUN	O	O
over	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

CIN	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
bevacizumab	NOUN	O	I-Entity
/	SYM	O	O
irinotecan	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.021	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.044	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CIN	PROPN	O	O
developed	VERB	O	O
4.5-times	NUM	O	O
more	ADJ	O	O
frequently	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
undergone	VERB	O	O
recent	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
bevacizumab	NOUN	O	I-Entity
/	SYM	O	O
irinotecan	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
additional	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
CIN	PROPN	O	O
development	NOUN	O	O
.	PUNCT	O	O

Contrast	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CIN	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
concern	NOUN	O	O
for	ADP	O	O
oncological	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
CT	PROPN	O	O
.	PUNCT	O	O
.	PUNCT	O	O

Hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
bevacizumab	NOUN	O	I-Entity
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
additional	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24234943)

Syndrome	PROPN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
secretion	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
desvenlafaxine	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
diuretic	NOUN	O	I-Entity
hormone	NOUN	O	I-Entity
(	PUNCT	O	O
SIADH	PROPN	O	I-Entity
)	PUNCT	O	O
secretion	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
desvenlafaxine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
57-year	ADJ	O	O
old	ADJ	O	O
female	NOUN	O	O
with	ADP	O	O
hyponatraemia	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
medications	NOUN	O	O
included	VERB	O	O
desvenlafaxine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
included	VERB	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
confusion	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
sodium	NOUN	O	I-Entity
at	ADP	O	O
this	DET	O	O
time	NOUN	O	O
was	VERB	O	O
120	NUM	O	O
mmol	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
osmolality	NOUN	O	O
was	VERB	O	O
263	NUM	O	O
mosmol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
urine	NOUN	O	O
osmolality	NOUN	O	O

410	NUM	O	O
mosmol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
sodium	NOUN	O	I-Entity
63	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
SIADH	PROPN	O	I-Entity
.	PUNCT	O	O

Desvenlafaxine	PROPN	O	I-Entity
was	VERB	O	O
ceased	VERB	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
restriction	NOUN	O	O
implemented	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
the	DET	O	O
sodium	NOUN	O	I-Entity
increased	VERB	O	O
to	ADP	O	O
128	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
restriction	NOUN	O	O
was	VERB	O	O
relaxed	ADJ	O	O
.	PUNCT	O	O

During	ADP	O	O
her	ADJ	O	O
further	ADJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
inpatient	ADJ	O	O
admission	NOUN	O	O
the	DET	O	O
serum	NOUN	O	O
sodium	NOUN	O	I-Entity
ranged	VERB	O	O
from	ADP	O	O
134	NUM	O	O
to	ADP	O	O
137	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
mirtazapine	NOUN	O	I-Entity
.	PUNCT	O	O

SIADH	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
widely	ADV	O	O
reported	VERB	O	O
with	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
antidepressants	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
desvenlafaxine	NOUN	O	I-Entity
might	VERB	O	O
cause	VERB	O	O
clinically	ADV	O	O
significant	ADJ	O	O
hyponatremia	NOUN	O	I-Entity
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
antidepressants	NOUN	O	O
to	PART	O	O
cause	VERB	O	O
hyponatremia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
take	VERB	O	O
appropriate	ADJ	O	O
corrective	ADJ	O	O
action	NOUN	O	O
where	ADV	O	O
necessary	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (24275640)

Oxidative	ADJ	O	O
stress	NOUN	O	O
on	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
single	ADJ	O	O
and	CCONJ	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX)-induced	VERB	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
remains	VERB	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

Wistar	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
66	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
DOX	PROPN	O	I-Entity
injections	NOUN	O	O
intraperitoneally	ADV	O	O
and	CCONJ	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
2	NUM	O	O
experimental	ADJ	O	O
protocols	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
rats	NOUN	O	O
were	VERB	O	O
killed	VERB	O	O
before	ADV	O	O
(	PUNCT	O	O
-24	PUNCT	O	O
h	INTJ	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
8)	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
acute	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
rats	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
58	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
4	NUM	O	O
injections	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
killed	VERB	O	O
before	ADP	O	O
the	DET	O	O
first	ADJ	O	O
injection	NOUN	O	O
(	PUNCT	O	O
M0	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
week	NOUN	O	O
after	ADP	O	O
each	DET	O	O
injection	NOUN	O	O
(	PUNCT	O	O
M1	PROPN	O	O
,	PUNCT	O	O
M2	PROPN	O	O
,	PUNCT	O	O
M3	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
M4	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
chronological	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
cardiac	ADJ	O	B-Entity
disarrangement	NOUN	O	I-Entity
,	PUNCT	O	O
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
DNA	PROPN	O	O
damage	NOUN	O	O
(	PUNCT	O	O
strand	NOUN	O	O
breaks	NOUN	O	O
(	PUNCT	O	O
SBs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
oxidized	VERB	O	O
pyrimidines	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	O
TAP	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
chronological	ADJ	O	O
study	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
on	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
R	NOUN	O	O
=	SYM	O	O
-0.99	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.011	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
necrosis	NOUN	O	I-Entity
(	PUNCT	O	O
R	NOUN	O	O
=	SYM	O	O
1.00	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
TAP	PROPN	O	O
(	PUNCT	O	O

DNA	PROPN	O	O
SBs	PROPN	O	O
damage	NOUN	O	O
was	VERB	O	O
negatively	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
TAP	PROPN	O	O
(	PUNCT	O	O
R	NOUN	O	O
=	SYM	O	O
-0.98	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.018	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
necrosis	NOUN	O	I-Entity

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
only	ADV	O	O
.	PUNCT	O	O

Increased	VERB	O	O
resistance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
is	VERB	O	O
plausible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
different	ADJ	O	O
mechanisms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
acute	ADJ	O	O
toxicity	NOUN	O	I-Entity
versus	ADP	O	O
chronic	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24283660)

Tacrolimus	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
seizure	NOUN	O	I-Entity
after	ADP	O	O
pediatric	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
-	PUNCT	O	O
center	NOUN	O	O
experience	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
identify	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
new	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
pediatric	ADJ	O	O
LT	PROPN	O	O
and	CCONJ	O	O
to	PART	O	O
assess	VERB	O	O
their	ADJ	O	O
clinical	ADJ	O	O
implications	NOUN	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
seizures	NOUN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
non	NOUN	O	O
-	PUNCT	O	O
seizures	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
four	NUM	O	O
children	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
14.8%	NUM	O	O
.	PUNCT	O	O

All	DET	O	O
exhibited	VERB	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
two	NUM	O	O
wk	NOUN	O	O
after	ADP	O	O
LT	PROPN	O	O
.	PUNCT	O	O

Univariate	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
pediatric	ADJ	O	O
LT	PROPN	O	O
included	VERB	O	O
gender	NOUN	O	O
,	PUNCT	O	O
pediatric	ADJ	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
score	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
Child	PROPN	O	O
-	PUNCT	O	O
Pugh	PROPN	O	O
score	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
total	NOUN	O	O
bilirubin	NOUN	O	I-Entity
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
trough	NOUN	O	O
TAC	PROPN	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
trough	NOUN	O	O
TAC	PROPN	O	I-Entity
level	NOUN	O	O
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
children	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
seizures	NOUN	O	I-Entity
survived	VERB	O	O
with	ADP	O	O
good	ADJ	O	O
graft	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
remained	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
without	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
epileptic	ADJ	O	I-Entity
drugs	NOUN	O	O
over	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
33.7	NUM	O	O
+	SYM	O	O
14.6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
trough	NOUN	O	O
TAC	PROPN	O	I-Entity
level	NOUN	O	O
was	VERB	O	O
the	DET	O	O
predominant	ADJ	O	O
factor	NOUN	O	O
that	ADJ	O	O
contributed	VERB	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
period	NOUN	O	O
after	ADP	O	O
pediatric	ADJ	O	O
LT	PROPN	O	O
.	PUNCT	O	O

High	ADJ	O	O
PELD	PROPN	O	O
and	CCONJ	O	O
Child	PROPN	O	O
-	PUNCT	O	O
Pugh	PROPN	O	O
scores	NOUN	O	O
before	ADP	O	O
LT	PROPN	O	O
and	CCONJ	O	O
high	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	NOUN	O	O
serum	NOUN	O	O
Tbil	PROPN	O	O
may	VERB	O	O
be	VERB	O	O
contributory	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
TAC	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24284476)

The	DET	O	O
flavonoid	ADJ	O	I-Entity
apigenin	NOUN	O	I-Entity
delays	NOUN	O	O
forgetting	VERB	O	O
of	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
conditioning	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
experiments	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
flavonoid	ADJ	O	I-Entity
apigenin	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
intraperitoneally	ADV	O	O
(	PUNCT	O	O
i.p	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
1	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
acquisition	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
retention	NOUN	O	O
performance	NOUN	O	O
and	CCONJ	O	O
forgetting	NOUN	O	O
of	ADP	O	O
a	DET	O	O
step	NOUN	O	O
-	PUNCT	O	O
through	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
young	ADJ	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
saline-	NOUN	O	O
and	CCONJ	O	O
apigenin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
24	NUM	O	O
h	PROPN	O	O
retention	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
apigenin	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
the	DET	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
1mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
saline-	NOUN	O	O
and	CCONJ	O	O
apigenin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
step	VERB	O	O
through	PART	O	O
into	ADP	O	O
the	DET	O	O
dark	ADJ	O	O
compartment	NOUN	O	O
during	ADP	O	O
the	DET	O	O
cut	NOUN	O	O
-	PUNCT	O	O
off	ADJ	O	O
time	NOUN	O	O
(	PUNCT	O	O
540	NUM	O	O
s	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
retested	VERB	O	O
weekly	ADV	O	O
for	ADP	O	O
up	ADV	O	O
to	PART	O	O
eight	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
saline	NOUN	O	O
treated	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
significant	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
response	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
complete	ADJ	O	O
memory	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
five	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
acquisition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
60%	NUM	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
apigenin	NOUN	O	I-Entity
still	ADV	O	O
did	VERB	O	O
not	ADV	O	O
step	VERB	O	O
through	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
1	PUNCT	O	O
)	PUNCT	O	O
apigenin	NOUN	O	I-Entity
delays	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
forgetting	NOUN	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
modulate	VERB	O	O
the	DET	O	O
24	NUM	O	O
h	PROPN	O	O
retention	NOUN	O	O
of	ADP	O	O
fear	NOUN	O	O
memory	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
obtained	VERB	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
apigenin	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
conditioning	NOUN	O	O
is	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
mechanisms	NOUN	O	O
that	ADJ	O	O
do	VERB	O	O
not	ADV	O	O
implicate	VERB	O	O
its	ADJ	O	O
action	NOUN	O	O
on	ADP	O	O
the	DET	O	O
muscarinic	ADJ	O	O
cholinergic	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24309294)

Cholecystokinin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
octapeptide	NOUN	O	I-Entity
restored	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hippocampal	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
potentiation	NOUN	O	O
impairment	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Cholecystokinin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
octapeptide	NOUN	O	I-Entity
(	PUNCT	O	O
CCK-8	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
a	DET	O	O
typical	ADJ	O	O
brain	NOUN	O	O
-	PUNCT	O	O
gut	NOUN	O	O
peptide	NOUN	O	O
,	PUNCT	O	O
exerts	VERB	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
biological	ADJ	O	O
activities	NOUN	O	O
on	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
previously	ADV	O	O
reported	VERB	O	O
that	ADP	O	O
CCK-8	PROPN	O	I-Entity
significantly	ADV	O	O
alleviated	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
and	CCONJ	O	O
reversed	VERB	O	O
spine	NOUN	O	O
density	NOUN	O	O
decreases	VERB	O	O
in	ADP	O	O
the	DET	O	O
CA1	PROPN	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
CCK-8	PROPN	O	I-Entity
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
potentiation	NOUN	O	O
(	PUNCT	O	O
LTP	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
perforant	ADJ	O	O
path	NOUN	O	O
(	PUNCT	O	O
LPP)-granule	PROPN	O	O
cell	NOUN	O	O
synapse	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
(	PUNCT	O	O
DG	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
acute	ADJ	O	O
saline	NOUN	O	O
or	CCONJ	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
morphine	NOUN	O	I-Entity

treatment	NOUN	O	O
significantly	ADV	O	O
attenuated	ADJ	O	O
hippocampal	ADJ	O	O
LTP	PROPN	O	O
and	CCONJ	O	O
CCK-8	PROPN	O	I-Entity
(	PUNCT	O	O
1ug	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O
restored	VERB	O	O
the	DET	O	O
amplitude	NOUN	O	O
of	ADP	O	O
PS	PROPN	O	O
that	ADJ	O	O
was	VERB	O	O
attenuated	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
microinjection	NOUN	O	O
of	ADP	O	O
CCK-8	PROPN	O	I-Entity
(	PUNCT	O	O
0.1	PUNCT	O	O
and	CCONJ	O	O
1ug	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O
also	ADV	O	O
significantly	ADV	O	O
augmented	VERB	O	O
hippocampal	ADJ	O	O
LTP	PROPN	O	O
in	ADP	O	O
saline	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
(	PUNCT	O	O
1ml	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pre	PROPN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
CCK2	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
L-365,260	PROPN	O	O
(	PUNCT	O	O
10ug	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
)	PUNCT	O	O
reversed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
CCK-8	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
CCK1	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
L-364,718	PROPN	O	O
(	PUNCT	O	O
10ug	NOUN	O	O
,	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
CCK-8	PROPN	O	I-Entity
attenuates	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
on	ADP	O	O
hippocampal	ADJ	O	O
LTP	PROPN	O	O
through	ADP	O	O
CCK2	PROPN	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
suggest	VERB	O	O
an	DET	O	O
ameliorative	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
CCK-8	PROPN	O	I-Entity
on	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24333387)

Glial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
synaptic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
key	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
Streptozotocin	PROPN	O	I-Entity
(	PUNCT	O	O
ICV	PROPN	O	O
)	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
glial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
synaptic	ADJ	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
ICV	PROPN	O	O
Streptozotocin	PROPN	O	I-Entity
(	PUNCT	O	O
STZ	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impaired	VERB	O	I-Entity
rats	NOUN	O	O
was	VERB	O	O
explored	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
experiment	NOUN	O	O
set	VERB	O	O
up	PART	O	O
1	NUM	O	O
:	PUNCT	O	O
Memory	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
Morris	PROPN	O	O
water	NOUN	O	O
maze	NOUN	O	O
test	NOUN	O	O
on	ADP	O	O
14	NUM	O	O
-	SYM	O	O
16	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
STZ	PROPN	O	I-Entity
(	PUNCT	O	O
ICV	PROPN	O	O
;	PUNCT	O	O
3mg	PROPN	O	O
/	PUNCT	O	O
Kg	PROPN	O	O
)	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

STZ	PROPN	O	I-Entity
causes	VERB	O	O
increased	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
GFAP	PROPN	O	O
,	PUNCT	O	O
CD11b	PROPN	O	O
and	CCONJ	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
a	DET	O	O
indicating	VERB	O	O
glial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
neuroinflammation	NOUN	O	I-Entity
.	PUNCT	O	O

STZ	PROPN	O	I-Entity
also	ADV	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
ROS	PROPN	O	O
,	PUNCT	O	O
nitrite	NOUN	O	I-Entity
,	PUNCT	O	O
Ca(2	PROPN	O	I-Entity
+	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
reduced	VERB	O	O
the	DET	O	O
mitochondrial	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
synaptosomal	ADJ	O	O
preparation	NOUN	O	O
illustrating	VERB	O	O
free	ADJ	O	O
radical	ADJ	O	O
generation	NOUN	O	O
and	CCONJ	O	O
excitotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Increased	ADJ	O	O
expression	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
Caspase-3	PROPN	O	O
was	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
STZ	PROPN	O	I-Entity
treated	VERB	O	O
rat	NOUN	O	O
which	ADJ	O	O
specify	VERB	O	O
apoptotic	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
in	ADP	O	O
hippocampus	NOUN	O	O
and	CCONJ	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

STZ	NOUN	O	I-Entity
treatment	NOUN	O	O
showed	VERB	O	O
decrease	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
post	NOUN	O	O
synaptic	ADJ	O	O
markers	NOUN	O	O
CaMKIIa	PROPN	O	O
and	CCONJ	O	O
PSD-95	PROPN	O	O
,	PUNCT	O	O
while	ADP	O	O
,	PUNCT	O	O
expression	NOUN	O	O
of	ADP	O	O
pre	NOUN	O	O
synaptic	ADJ	O	O
markers	NOUN	O	O
(	PUNCT	O	O
synaptophysin	NOUN	O	O
and	CCONJ	O	O
SNAP-25	PROPN	O	O
)	PUNCT	O	O
remains	VERB	O	O
unaltered	ADJ	O	O
indicating	VERB	O	O
selective	ADJ	O	O
post	NOUN	O	O
synaptic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Oral	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
Memantine	PROPN	O	I-Entity
(	PUNCT	O	O
10mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Ibuprofen	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
13	NUM	O	O
days	NOUN	O	O
attenuated	VERB	O	O

STZ	PROPN	O	I-Entity
induced	VERB	O	O
glial	ADJ	O	O
activation	NOUN	O	O
,	PUNCT	O	O
apoptotic	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
synaptic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
brain	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
experiment	NOUN	O	O
set	VERB	O	O
up	PART	O	O
2	NUM	O	O
:	PUNCT	O	O
where	ADV	O	O
memory	NOUN	O	O
function	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
i.e.	X	O	O
7	NUM	O	O
-	SYM	O	O
9	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
STZ	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
level	NOUN	O	O
of	ADP	O	O
GFAP	PROPN	O	O
,	PUNCT	O	O
CD11b	PROPN	O	O
,	PUNCT	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
a	DET	O	O
,	PUNCT	O	O
ROS	PROPN	O	O
and	CCONJ	O	O
nitrite	ADJ	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
increased	VERB	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
apoptotic	ADJ	O	O
marker	NOUN	O	O
,	PUNCT	O	O
synaptic	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
Ca(2	PROPN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
levels	NOUN	O	O
remained	VERB	O	O
unaffected	ADJ	O	O
.	PUNCT	O	O

Collective	ADJ	O	O
data	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
neuroinflammatory	ADJ	O	I-Entity
process	NOUN	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
occurs	VERB	O	O
earlier	ADV	O	O
to	ADP	O	O
apoptosis	NOUN	O	O
and	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
memory	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Present	ADJ	O	O
study	NOUN	O	O
clearly	ADV	O	O
suggests	VERB	O	O
that	ADP	O	O
glial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
synaptic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
are	VERB	O	O
the	DET	O	O
key	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
STZ	PROPN	O	I-Entity
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
neuronal	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24341598)

Comparison	NOUN	O	O
of	ADP	O	O
effects	NOUN	O	O
of	ADP	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
with	ADP	O	O
diltiazem	NOUN	O	I-Entity
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Contrast	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CIN	PROPN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
increases	VERB	O	O
the	DET	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
and	CCONJ	O	O
compare	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
with	ADP	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
preventing	VERB	O	O
CIN	PROPN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
study	NOUN	O	O
included	VERB	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
30	NUM	O	O
-	SYM	O	O
60	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
iodinated	ADJ	O	O
contrast	NOUN	O	I-Entity
agent	NOUN	O	O
for	ADP	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
PCAG	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
all	DET	O	O
with	ADP	O	O
creatinine	NOUN	O	I-Entity
values	NOUN	O	O
between	ADP	O	O
1.1	NUM	O	O
and	CCONJ	O	O
3.1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL.	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
and	CCONJ	O	O
each	DET	O	O
group	NOUN	O	O
had	VERB	O	O
20	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
a	DET	O	O
solution	NOUN	O	O
that	ADP	O	O
of	ADP	O	O
5%	NUM	O	O
dextrose	NOUN	O	I-Entity
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
contrast	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
diltiazem	NOUN	O	I-Entity
the	DET	O	O
day	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
first	ADV	O	O
2	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
contrast	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
'	PART	O	O
plasma	NOUN	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
(	PUNCT	O	O
BUN	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
and	CCONJ	O	O
seventh	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
contrast	NOUN	O	I-Entity
material	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
basal	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
all	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	VERB	O	O
>	NUM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ARF	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
contrast	NOUN	O	I-Entity
material	NOUN	O	O
was	VERB	O	O
injected	VERB	O	O
(	PUNCT	O	O
26.6%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
ARF	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
five	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
six	NUM	O	O
(	PUNCT	O	O
30%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
five	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
,	PUNCT	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
and	CCONJ	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
with	ADP	O	O
diltiazem	NOUN	O	I-Entity
application	NOUN	O	O
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
CIN	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (24345882)

Neurocognitive	ADJ	O	O
and	CCONJ	O	O
neuroradiologic	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
late	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
treated	VERB	O	O
on	ADP	O	O
Pediatric	PROPN	O	O
Oncology	PROPN	O	O
Group	PROPN	O	O
(	PUNCT	O	O
POG	PROPN	O	O
)	PUNCT	O	O
P9605	PROPN	O	O
(	PUNCT	O	O
standard	ADJ	O	O
risk	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
P9201	PROPN	O	O
(	PUNCT	O	O
lesser	ADJ	O	O
risk	NOUN	O	O
)	PUNCT	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
protocols	NOUN	O	O
(	PUNCT	O	O
ACCL0131	PROPN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
methotrexate	NOUN	O	I-Entity
consequence	NOUN	O	O
?	PUNCT	O	O

Concerns	NOUN	O	O
about	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
MTX	PROPN	O	I-Entity
)	PUNCT	O	O

neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
1990s	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
modifications	NOUN	O	O
in	ADP	O	O
intrathecal	ADJ	O	O
(	PUNCT	O	O
IT	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
leucovorin	NOUN	O	O
rescue	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
MTX	PROPN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
neurocognitive	ADJ	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
neuroradiologic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
leukoencephalopathy	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
intense	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS)-directed	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
P9605	PROPN	O	O
)	PUNCT	O	O
versus	ADP	O	O
those	DET	O	O
receiving	VERB	O	O
fewer	ADJ	O	O
CNS	PROPN	O	O
-	PUNCT	O	O
directed	VERB	O	O
treatment	NOUN	O	O
days	NOUN	O	O
during	ADP	O	O
intensive	ADJ	O	O
consolidation	NOUN	O	O
(	PUNCT	O	O
P9201	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
66	NUM	O	O
children	NOUN	O	O
from	ADP	O	O
16	NUM	O	O
Pediatric	PROPN	O	O
Oncology	PROPN	O	O
Group	PROPN	O	O
institutions	NOUN	O	O
with	ADP	O	O
"	PUNCT	O	O
standard	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
"	PUNCT	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
,	PUNCT	O	O
1.00	NUM	O	O
to	PART	O	O
9.99	NUM	O	O
years	NOUN	O	O
at	ADP	O	O
diagnosis	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
CNS	PROPN	O	O
leukemia	NOUN	O	I-Entity
at	ADP	O	O
diagnosis	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
on	ADP	O	O
ACCL0131	PROPN	O	O
:	PUNCT	O	O
28	NUM	O	O
from	ADP	O	O
P9201	PROPN	O	O
and	CCONJ	O	O
38	NUM	O	O
from	ADP	O	O
P9605	PROPN	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
more	ADJ	O	O
P9605	ADJ	O	O
patients	NOUN	O	O
developed	VERB	O	O
leukoencephalopathy	ADJ	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
P9201	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
68%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
49%-83%	NUM	O	O
vs.	X	O	O
22%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
5%-44%	NUM	O	O
;	PUNCT	O	O
P=0.001	PUNCT	O	O
)	PUNCT	O	O
identified	VERB	O	O
as	ADP	O	O
late	ADV	O	O
as	ADP	O	O
7.7	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
on	ADP	O	O
both	DET	O	O
studies	NOUN	O	O
had	VERB	O	O
significant	ADJ	O	O
attention	NOUN	O	B-Entity
problems	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
P9605	PROPN	O	O
children	NOUN	O	O
scored	VERB	O	O
below	ADP	O	O
average	ADJ	O	O
on	ADP	O	O
more	ADJ	O	O
neurocognitive	ADJ	O	O
measures	NOUN	O	O
than	ADP	O	O
those	DET	O	O
treated	VERB	O	O
on	ADP	O	O
P9201	PROPN	O	O
(	PUNCT	O	O
82%	NUM	O	O
,	PUNCT	O	O
14/17	NUM	O	O
measures	NOUN	O	O
vs.	ADP	O	O
24%	NUM	O	O
,	PUNCT	O	O
4/17	NUM	O	O
measures	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
supports	VERB	O	O
ongoing	ADJ	O	O
concerns	NOUN	O	O
about	ADP	O	O
intensive	ADJ	O	O
MTX	PROPN	O	I-Entity
exposure	NOUN	O	O
as	ADP	O	O
a	DET	O	O
major	ADJ	O	O
contributor	NOUN	O	O
to	PART	O	O
CNS	PROPN	O	O
late	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24434397)

Tranexamic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
overdosage	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
in	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
lady	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
stage	NOUN	O	O
4	NUM	O	O
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	O
tubulointerstial	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
center	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
anemia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
menorrhagia	NOUN	O	I-Entity
and	CCONJ	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

Tranexamic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
TNA	PROPN	O	I-Entity
)	PUNCT	O	O

1	NUM	O	O
g	NOUN	O	O
8-hourly	ADV	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
her	PRON	O	O
to	PART	O	O
control	VERB	O	O
bleeding	VERB	O	I-Entity
per	ADP	O	O
vaginum	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
sixth	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
TNA	PROPN	O	I-Entity
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
an	DET	O	O
episode	NOUN	O	O
of	ADP	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
clonic	ADJ	O	I-Entity
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

TNA	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

Investigations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
biochemical	ADJ	O	O
or	CCONJ	O	O
structural	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	B-Entity
system	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
that	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
provoked	VERB	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
had	VERB	O	O
no	DET	O	O
further	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
convulsion	NOUN	O	I-Entity
till	ADP	O	O
dis	NOUN	O	O
-	PUNCT	O	O
charge	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
two	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
precipitating	VERB	O	O
cause	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
was	VERB	O	O
believed	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
overdose	NOUN	O	I-Entity
of	ADP	O	O
TNA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24438483)

Pre	PROPN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
using	VERB	O	O
different	ADJ	O	O
lipid	ADJ	O	O
formulations	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

Pre	PROPN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
lipid	NOUN	O	O
emulsions	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
increase	VERB	O	O
lethal	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
lipid	ADJ	O	O
content	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
may	VERB	O	O
alleviate	VERB	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
intralipid	NOUN	O	O
or	CCONJ	O	O
medialipid	ADJ	O	O
emulsions	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
anaesthetised	VERB	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
were	VERB	O	O
given	VERB	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
intralipid	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
P	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
medialipid	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
C	PROPN	O	O
)	PUNCT	O	O
over	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

bupivacaine	NOUN	O	I-Entity
0.5%	NUM	O	O
was	VERB	O	O
infused	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
recorded	VERB	O	O
time	NOUN	O	O
to	PART	O	O
first	ADV	O	O
dysrhythmia	NOUN	O	I-Entity
occurrence	NOUN	O	O
,	PUNCT	O	O
respective	ADJ	O	O
times	NOUN	O	O
to	ADP	O	O
25%	NUM	O	O
and	CCONJ	O	O
50%	NUM	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
mean	VERB	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	PART	O	O
asystole	VERB	O	I-Entity
and	CCONJ	O	O
total	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
consumption	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
following	VERB	O	O
asystole	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
to	PART	O	O
first	ADV	O	O
dysrhythmia	NOUN	O	I-Entity
occurrence	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
25%	NUM	O	O
and	CCONJ	O	O
50%	NUM	O	O
reductions	NOUN	O	O
in	ADP	O	O
HR	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	ADP	O	O
asystole	NOUN	O	I-Entity
were	VERB	O	O
longer	ADV	O	O
in	ADP	O	O
Group	PROPN	O	O
P	NOUN	O	O
than	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
dose	NOUN	O	O
given	VERB	O	O
at	ADP	O	O
those	DET	O	O
time	NOUN	O	O
points	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
P.	PROPN	O	O
Plasma	PROPN	O	O
bupivacaine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
P	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
Group	PROPN	O	O
C.	PROPN	O	O
Bupivacaine	PROPN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
P	PROPN	O	O
and	CCONJ	O	O
Group	PROPN	O	O
L	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
Group	PROPN	O	O
C.	PROPN	O	O
CONCLUSION	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
intralipid	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
medialipid	NOUN	O	O
or	CCONJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
delayed	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
reduced	VERB	O	O
plasma	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
explore	VERB	O	O
tissue	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
medialipid	NOUN	O	O
and	CCONJ	O	O
adapt	VERB	O	O
these	DET	O	O
results	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24451297)

Drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Induced	PROPN	O	I-Entity
Acute	PROPN	O	I-Entity
Liver	PROPN	O	I-Entity
Injury	PROPN	O	I-Entity

Within	ADP	O	O
12	NUM	O	O
Hours	NOUN	O	O
After	ADP	O	O
Fluvastatin	PROPN	O	I-Entity
Therapy	PROPN	O	O
.	PUNCT	O	O

Although	ADP	O	O
statins	NOUN	O	I-Entity
are	VERB	O	O
generally	ADV	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
recent	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
liver	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
their	ADJ	O	O
use	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
52-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Chinese	ADJ	O	O
man	NOUN	O	O
reported	VERB	O	O
with	ADP	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
appeared	VERB	O	O
12	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
beginning	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
fluvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

Patient	PROPN	O	O
presented	VERB	O	O
with	ADP	O	O
complaints	NOUN	O	O
of	ADP	O	O
increasing	VERB	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
anorexia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
upper	ADJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
laboratory	NOUN	O	O
values	NOUN	O	O
showed	VERB	O	O
elevated	ADJ	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
and	CCONJ	O	O
transaminases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
liver	NOUN	O	O
biochemistries	NOUN	O	O
eventually	ADV	O	O
normalized	VERB	O	O
within	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
stopping	VERB	O	O
the	DET	O	O
fluvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
prescribing	VERB	O	O
statins	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
taken	VERB	O	O
into	ADP	O	O
account	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24459006)

Fluconazole	PROPN	O	I-Entity
associated	VERB	O	O
agranulocytosis	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

CASE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
associated	VERB	O	O
agranulocytosis	NOUN	O	I-Entity
with	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
recovery	NOUN	O	O
upon	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
began	VERB	O	O
to	PART	O	O
have	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
white	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
platelets	NOUN	O	O
within	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
and	CCONJ	O	O
began	VERB	O	O
to	PART	O	O
recover	VERB	O	O
with	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
of	ADP	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
highlights	VERB	O	O
that	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
blood	NOUN	O	B-Entity
dyscrasias	NOUN	O	I-Entity
can	VERB	O	O
occur	VERB	O	O
unexpectedly	ADV	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
drug	NOUN	O	O
thought	NOUN	O	O
to	PART	O	O
be	VERB	O	O
"	PUNCT	O	O
safe	ADJ	O	O
"	PUNCT	O	O
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
Naranjo	PROPN	O	O
's	PART	O	O
algorithm	NOUN	O	O
the	DET	O	O
likelihood	NOUN	O	O
that	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
's	PART	O	O
agranulocytosis	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
occurred	VERB	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
fluconazole	NOUN	O	I-Entity
is	VERB	O	O
probable	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
points	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
the	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
abatement	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
that	ADJ	O	O
rapidly	ADV	O	O
reversed	VERB	O	O
immediately	ADV	O	O
following	VERB	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24464946)

Two	NUM	O	O
-	PUNCT	O	O
dimensional	ADJ	O	O
speckle	NOUN	O	O
tracking	VERB	O	O
echocardiography	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
sensitive	ADJ	O	O
cardiac	ADJ	O	O
troponin	NOUN	O	O
T	NOUN	O	O
in	ADP	O	O
early	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
prediction	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
during	ADP	O	O
epirubicine	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
alterations	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
strain	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
sensitive	ADJ	O	O
cardiac	ADJ	O	O
troponin	NOUN	O	O
T	PROPN	O	O
(	PUNCT	O	O
cTnT	PROPN	O	O
)	PUNCT	O	O
could	VERB	O	O
predict	VERB	O	O
future	ADJ	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
epirubicin	ADJ	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
lymphoma	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
epirubicin	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Cardiotoxicity	PROPN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
LVEF	PROPN	O	O
of	ADP	O	O
>	X	O	O

5%	NUM	O	O
to	PART	O	O
<	VERB	O	O
55%	NUM	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
or	CCONJ	O	O
an	DET	O	O
asymptomatic	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
LVEF	PROPN	O	O
of	ADP	O	O
>	X	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Fourteen	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
18.67%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

AUC	PROPN	O	O
=	SYM	O	O
0.757	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
the	DET	O	O
third	ADJ	O	O
cycle	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
predicted	VERB	O	O
later	ADV	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
GLS	PROPN	O	O
remained	VERB	O	O
the	DET	O	O
only	ADJ	O	O
independent	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.000	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

GLS	PROPN	O	O
combined	VERB	O	O
with	ADP	O	O
cTnT	PROPN	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
reliable	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
invasive	ADJ	O	O
method	NOUN	O	O
to	PART	O	O
predict	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24535067)

Prevention	PROPN	O	O
of	ADP	O	O
etomidate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myoclonus	NOUN	O	I-Entity
:	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
superior	ADJ	O	O
:	PUNCT	O	O

Fentanyl	PROPN	O	I-Entity
,	PUNCT	O	O
midazolam	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
?	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
retrospective	NOUN	O	O
comparative	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
,	PUNCT	O	O
midazolam	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
midazolam	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
etomidate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myoclonus	NOUN	O	I-Entity
.	PUNCT	O	O

Depending	VERB	O	O
on	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
that	ADJ	O	O
would	VERB	O	O
be	VERB	O	O
given	VERB	O	O
before	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
etomidate	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
separated	VERB	O	O
into	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
no	DET	O	O
pretreatment	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
NP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	I-Entity
1	NUM	O	O
ug.kg-1	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
F	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
midazolam	NOUN	O	I-Entity
0.03	NUM	O	O
mg.kg-1	PROPN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
M	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
midazolam	NOUN	O	I-Entity
0.015	NUM	O	O
mg.kg-1	NOUN	O	O
+	CCONJ	O	O
fentanyl	NOUN	O	I-Entity

Patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
the	DET	O	O
same	ADJ	O	O
anesthetic	NOUN	O	O
procedure	NOUN	O	O
were	VERB	O	O
selected	VERB	O	O
:	PUNCT	O	O
2	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
intravenous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pretreatment	NOUN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
anesthesia	NOUN	O	O
is	VERB	O	O
induced	VERB	O	O
with	ADP	O	O
0.3	NUM	O	O
mg.kg-1	NUM	O	O
etomidate	NOUN	O	I-Entity
injected	VERB	O	O
intravenously	ADV	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
-	SYM	O	O
30	NUM	O	O
seconds	NOUN	O	O
.	PUNCT	O	O

Myoclonic	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
are	VERB	O	O
evaluated	VERB	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
observed	VERB	O	O
and	CCONJ	O	O
graded	VERB	O	O
according	VERB	O	O
to	ADP	O	O
clinical	ADJ	O	O
severity	NOUN	O	O
during	ADP	O	O
the	DET	O	O
2	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
etomidate	ADJ	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
etomidate	NOUN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Study	NOUN	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
myoclonus	NOUN	O	I-Entity
incidence	NOUN	O	O
was	VERB	O	O
85%	NUM	O	O
,	PUNCT	O	O
40%	NUM	O	O
,	PUNCT	O	O
70%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
25%	NUM	O	O
in	ADP	O	O
Group	PROPN	O	O
NP	PROPN	O	O
,	PUNCT	O	O
Group	PROPN	O	O
F	PROPN	O	O
,	PUNCT	O	O
Group	PROPN	O	O
M	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Group	PROPN	O	O
FM	PROPN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
F	PROPN	O	O
and	CCONJ	O	O
Group	PROPN	O	O
FM	PROPN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
fentanyl	NOUN	O	I-Entity
or	CCONJ	O	O
combination	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
midazolam	NOUN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
etomidate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myoclonus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24554916)

Cholestatic	ADJ	O	I-Entity
presentation	NOUN	O	O
of	ADP	O	O
yellow	ADJ	O	O
phosphorus	NOUN	O	I-Entity
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O

Yellow	PROPN	O	O
phosphorus	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
component	NOUN	O	O
of	ADP	O	O
certain	ADJ	O	O
pesticide	NOUN	O	O
pastes	NOUN	O	O
and	CCONJ	O	O
fireworks	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
well	ADV	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Poisoning	VERB	O	I-Entity
with	ADP	O	O
yellow	ADJ	O	O
phosphorus	NOUN	O	I-Entity
classically	ADV	O	O
manifests	VERB	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
which	ADJ	O	O
may	VERB	O	O
need	VERB	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
yellow	ADJ	O	O
phosphorus	NOUN	O	I-Entity
poisoning	NOUN	O	I-Entity
in	ADP	O	O
which	ADJ	O	O
a	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
florid	ADJ	O	O
clinical	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
cholestasis	NOUN	O	I-Entity
highlighting	VERB	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
cholestasis	NOUN	O	I-Entity
can	VERB	O	O
rarely	ADV	O	O
be	VERB	O	O
a	DET	O	O
presenting	VERB	O	O
feature	NOUN	O	O
of	ADP	O	O
yellow	ADJ	O	O
phosphorus	NOUN	O	I-Entity
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24571687)

Vasovagal	PROPN	O	B-Entity
syncope	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
bradycardia	NOUN	O	I-Entity
following	VERB	O	O
intranasal	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
for	ADP	O	O
pediatric	ADJ	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
syncope	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
11-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
intranasal	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
for	ADP	O	O
sedation	NOUN	O	O
for	ADP	O	O
a	DET	O	O
voiding	VERB	O	O
cystourethrogram	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
abnormality	NOUN	O	O
found	VERB	O	O
was	VERB	O	O
persistent	ADJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
she	PRON	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
telemetric	ADJ	O	O
observation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
bradycardia	NOUN	O	I-Entity
lasted	VERB	O	O
~2	PROPN	O	O
h	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
further	ADJ	O	O
cardiac	ADJ	O	O
workup	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
underlying	VERB	O	O
abnormality	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24582773)

Paradoxical	ADJ	O	O
severe	ADJ	O	O
agitation	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
add	VERB	O	O
-	PUNCT	O	O
on	PART	O	O
high	ADJ	O	O
-	PUNCT	O	O
doses	NOUN	O	O
quetiapine	NOUN	O	I-Entity
in	ADP	O	O
schizo	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
affective	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
35-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
suffering	NOUN	O	O
from	ADP	O	O
schizo	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
affective	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
since	ADP	O	O
the	DET	O	O
age	NOUN	O	O
of	ADP	O	O
19	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
treated	VERB	O	O
by	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
first	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
antipsychotics	NOUN	O	O
,	PUNCT	O	O
zuclopenthixol	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O
1200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
serum	NOUN	O	O
lithium=0.85	NOUN	O	I-Entity
mEq	PROPN	O	O
/	SYM	O	O
l	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
associated	ADJ	O	O
personality	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
particularly	ADV	O	O
no	DET	O	O
antisocial	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
substance	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
48	NUM	O	O
h	NOUN	O	O
following	VERB	O	O
the	DET	O	O
gradual	ADJ	O	O
introduction	NOUN	O	O
of	ADP	O	O
quetiapine	NOUN	O	I-Entity
(	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
severe	ADJ	O	O
agitation	NOUN	O	I-Entity
without	ADP	O	O
an	DET	O	O
environmental	ADJ	O	O
explanation	NOUN	O	O
,	PUNCT	O	O
contrasting	VERB	O	O
with	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
aggressiveness	NOUN	O	I-Entity
or	CCONJ	O	O
personality	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
diagnoses	NOUN	O	O
of	ADP	O	O
manic	ADJ	O	I-Entity
shift	NOUN	O	O
and	CCONJ	O	O
akathisia	NOUN	O	I-Entity
were	VERB	O	O
dismissed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
withdrawal	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
gradual	ADJ	O	O
reintroduction	NOUN	O	O
of	ADP	O	O
quetiapine	ADJ	O	I-Entity
2	NUM	O	O
weeks	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
which	ADJ	O	O
led	VERB	O	O
to	ADP	O	O
another	DET	O	O
severe	ADJ	O	O
agitation	NOUN	O	I-Entity
,	PUNCT	O	O
enabled	VERB	O	O
us	PRON	O	O
to	PART	O	O
attribute	VERB	O	O
the	DET	O	O
agitation	NOUN	O	I-Entity
specifically	ADV	O	O
to	ADP	O	O
quetiapine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24587916)

Antioxidant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
bovine	ADJ	O	O
lactoferrin	NOUN	O	O
on	ADP	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Dexamethasone-	PROPN	O	I-Entity
(	PUNCT	O	O
Dex-	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
enhanced	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Lactoferrin	PROPN	O	O
(	PUNCT	O	O
LF	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
iron	NOUN	O	I-Entity
-	PUNCT	O	O
binding	VERB	O	O
glycoprotein	NOUN	O	O
with	ADP	O	O
antihypertensive	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
LF	PROPN	O	O
on	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
hypertension	NOUN	O	I-Entity
upon	ADP	O	O
Dex	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
Dex	PROPN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
u	NOUN	O	O

In	ADP	O	O
a	DET	O	O
prevention	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
rats	NOUN	O	O
received	VERB	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
LF	PROPN	O	O
treatment	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
Dex	PROPN	O	I-Entity
and	CCONJ	O	O
continued	VERB	O	O
during	ADP	O	O
the	DET	O	O
test	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
hydrogen	NOUN	O	B-Entity
peroxide	NOUN	O	I-Entity
(	PUNCT	O	O
H2O2	PROPN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
ferric	NOUN	O	O
reducing	VERB	O	O
antioxidant	ADJ	O	O
power	NOUN	O	O
(	PUNCT	O	O
FRAP	PROPN	O	O
)	PUNCT	O	O
value	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
SBP	PROPN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
H2O2	PROPN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
thymus	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
weights	NOUN	O	O
.	PUNCT	O	O

LF	PROPN	O	O
lowered	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dose	NOUN	O	O
dependently	ADV	O	O
prevented	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	PUNCT	O	O
)	PUNCT	O	O
Dex	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

LF	PROPN	O	O
prevented	VERB	O	O
body	NOUN	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
elevated	ADJ	O	O
plasma	NOUN	O	O
H2O2	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
FRAP	PROPN	O	O
values	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
LF	PROPN	O	O
strongly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
production	NOUN	O	O
of	ADP	O	O
ROS	PROPN	O	O
and	CCONJ	O	O
improved	VERB	O	O
antioxidant	ADJ	O	O
capacity	NOUN	O	O
in	ADP	O	O
Dex	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
as	ADP	O	O
another	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
antihypertensive	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
LF	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (24588023)

The	DET	O	O
association	NOUN	O	O
between	ADP	O	O
tranexamic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
and	CCONJ	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
after	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
multivariate	NOUN	O	O
analysis	NOUN	O	O
in	ADP	O	O
11	NUM	O	O
529	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
contemporary	ADJ	O	O
data	NOUN	O	O
regarding	VERB	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
undertook	VERB	O	O
a	DET	O	O
retrospective	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
prospectively	ADV	O	O
collected	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
11	NUM	O	O
529	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
from	ADP	O	O
January	PROPN	O	O
2004	NUM	O	O
to	ADP	O	O
December	PROPN	O	O
2010	NUM	O	O
.	PUNCT	O	O

A	DET	O	O
convulsive	ADJ	O	I-Entity
seizure	NOUN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
disturbed	ADJ	O	O
brain	NOUN	O	O
function	NOUN	O	O
characterised	VERB	O	O
by	ADP	O	O
abnormal	ADJ	O	B-Entity
involuntary	ADJ	O	I-Entity
motor	NOUN	O	I-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O

Multivariate	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
identify	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
(	PUNCT	O	O
0.9%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
developed	VERB	O	O
postoperative	ADJ	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Generalised	VERB	O	B-Entity
and	CCONJ	O	I-Entity
focal	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
were	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
68	NUM	O	O
and	CCONJ	O	O
32	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

)	PUNCT	O	O
time	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
when	ADV	O	O
the	DET	O	O
seizure	NOUN	O	I-Entity
occurred	VERB	O	O
was	VERB	O	O
7	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
-	SYM	O	O
12	NUM	O	O
[	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
216	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O

Independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
seizures	NOUN	O	I-Entity
included	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
female	ADJ	O	O
sex	NOUN	O	O
,	PUNCT	O	O
redo	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
calcification	NOUN	O	O
of	ADP	O	O
ascending	VERB	O	O
aorta	NOUN	O	O
,	PUNCT	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
deep	ADJ	O	O
hypothermic	ADJ	O	I-Entity
circulatory	ADJ	O	O
arrest	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
aortic	ADJ	O	O
cross	NOUN	O	O
-	PUNCT	O	O
clamp	NOUN	O	O
and	CCONJ	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
multivariate	NOUN	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
independent	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
14.3	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O

Patients	NOUN	O	O
with	ADP	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
had	VERB	O	O
2.5	NUM	O	O
times	NOUN	O	O
higher	ADJ	O	O
in	ADP	O	O
-	PUNCT	O	O
hospital	NOUN	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
and	CCONJ	O	O
twice	ADJ	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	O
hospital	NOUN	O	O
stay	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

h	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
26	NUM	O	O
(	PUNCT	O	O
22	NUM	O	O
-	SYM	O	O
69	NUM	O	O
[	PUNCT	O	O
14	NUM	O	O
-	SYM	O	O
1080	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O

h	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
seizures	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
serious	ADJ	O	O
postoperative	ADJ	O	B-Entity
complication	NOUN	O	I-Entity
after	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
only	ADJ	O	O
modifiable	ADJ	O	O
factor	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
administration	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
doses	NOUN	O	O
exceeding	VERB	O	O
80	NUM	O	O
mg.kg(-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
should	VERB	O	O
be	VERB	O	O
weighed	VERB	O	O
against	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24595967)

Dysfunctional	ADJ	O	B-Entity
overnight	ADJ	O	I-Entity
memory	NOUN	O	I-Entity
consolidation	NOUN	O	O
in	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
have	VERB	O	O
marked	VERB	O	O
and	CCONJ	O	O
persistent	ADJ	O	O
neurocognitive	ADJ	O	O
and	CCONJ	O	O
sleep	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
related	VERB	O	I-Entity
impairments	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
extend	VERB	O	O
past	ADJ	O	O
research	NOUN	O	O
by	ADP	O	O
examining	VERB	O	O
overnight	ADV	O	O
memory	NOUN	O	O
consolidation	NOUN	O	O
among	ADP	O	O
regular	ADJ	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
n=12	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
drug	NOUN	O	O
naive	ADJ	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n=26	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ecstasy	PROPN	O	I-Entity
users	NOUN	O	O
demonstrated	VERB	O	O
impaired	ADJ	O	B-Entity
overnight	ADV	O	I-Entity
memory	NOUN	O	I-Entity
consolidation	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
finding	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
more	ADV	O	O
pronounced	ADJ	O	O
following	VERB	O	O
associative	ADJ	O	O
interference	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
demonstrated	VERB	O	O
impairments	NOUN	O	O
on	ADP	O	O
tasks	NOUN	O	O
recruiting	VERB	O	O
frontostriatal	ADJ	O	O
and	CCONJ	O	O
hippocampal	ADJ	O	O
neural	ADJ	O	O
circuitry	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
domains	NOUN	O	O
of	ADP	O	O
proactive	ADJ	O	O
interference	NOUN	O	O
memory	NOUN	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
memory	NOUN	O	O
,	PUNCT	O	O
encoding	NOUN	O	O
,	PUNCT	O	O
working	VERB	O	O
memory	NOUN	O	O
and	CCONJ	O	O
complex	ADJ	O	O
planning	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
fronto	NOUN	O	O
-	PUNCT	O	O
temporal	ADJ	O	O
circuitry	NOUN	O	O
may	VERB	O	O
underlie	VERB	O	O
overnight	ADJ	O	O
consolidation	NOUN	O	O
memory	NOUN	O	B-Entity
impairments	NOUN	O	I-Entity
in	ADP	O	O
regular	ADJ	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24614773)

Normoammonemic	PROPN	O	O
encephalopathy	NOUN	O	I-Entity
:	PUNCT	O	O
solely	ADV	O	O
valproate	VERB	O	I-Entity
induced	VERB	O	O
or	CCONJ	O	O
multiple	ADJ	O	O
mechanisms	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
77-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
subacute	ADJ	O	O
onset	NOUN	O	O
progressive	ADJ	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
aggression	NOUN	O	I-Entity
,	PUNCT	O	O
auditory	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
and	CCONJ	O	O
delusions	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
preceding	ADJ	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
admissions	NOUN	O	O
with	ADP	O	O
transient	ADJ	O	O
unilateral	ADJ	O	O
hemiparesis	NOUN	O	I-Entity
with	ADP	O	O
facial	ADJ	O	O
droop	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
had	VERB	O	O
been	VERB	O	O
started	VERB	O	O
on	ADP	O	O
valproate	NOUN	O	I-Entity
for	ADP	O	O
presumed	VERB	O	O
hemiplegic	ADJ	O	B-Entity
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

Valproate	PROPN	O	I-Entity
was	VERB	O	O
withdrawn	VERB	O	O
soon	ADV	O	O
after	ADP	O	O
admission	NOUN	O	O
and	CCONJ	O	O
her	ADJ	O	O
cognitive	ADJ	O	O
abilities	NOUN	O	O
have	VERB	O	O
gradually	ADV	O	O
improved	VERB	O	O
over	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Valproate	PROPN	O	I-Entity
levels	NOUN	O	O
taken	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
withdrawal	NOUN	O	O
were	VERB	O	O
subtherapeutic	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
normoammonaemic	ADJ	O	O
.	PUNCT	O	O

EEG	PROPN	O	O
undertaken	VERB	O	O
during	ADP	O	O
inpatient	ADJ	O	O
stay	NOUN	O	O
showed	VERB	O	O
changes	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
titre	NOUN	O	O

N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
antibodies	NOUN	O	O
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
aetiologies	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
and	CCONJ	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
encephalitis	NOUN	O	I-Entity
present	VERB	O	O
a	DET	O	O
diagnostic	ADJ	O	O
dilemma	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24618873)

Cerebellar	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
oculomotor	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
rapid	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
.	PUNCT	O	O

Pethidine	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
opioid	NOUN	O	O
that	ADJ	O	O
gains	VERB	O	O
its	ADJ	O	O
popularity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
effective	ADJ	O	O
pain	NOUN	O	I-Entity
control	NOUN	O	O
through	ADP	O	O
acting	VERB	O	O
on	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
-	PUNCT	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
rapid	ADJ	O	O
pain	NOUN	O	I-Entity
relief	NOUN	O	O
sometimes	ADV	O	O
brings	VERB	O	O
about	ADV	O	O
unfavourable	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
that	ADJ	O	O
largely	ADV	O	O
limit	VERB	O	O
its	ADJ	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
.	PUNCT	O	O

Common	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
include	VERB	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
renal	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
liver	NOUN	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
those	DET	O	O
who	NOUN	O	O
need	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
pain	NOUN	O	I-Entity
control	NOUN	O	O
,	PUNCT	O	O
pethidine	NOUN	O	I-Entity
may	VERB	O	O
cause	VERB	O	O
excitatory	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
effects	NOUN	O	O
through	ADP	O	O
its	ADJ	O	O
neurotoxic	NOUN	O	I-Entity
metabolite	NOUN	O	O
,	PUNCT	O	O
norpethidine	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
irritability	NOUN	O	I-Entity
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
though	ADP	O	O
not	ADV	O	O
clinically	ADV	O	O
apparent	ADJ	O	O
,	PUNCT	O	O
pethidine	NOUN	O	I-Entity
potentially	ADV	O	O
causes	VERB	O	O
inhibitory	ADJ	O	O
impacts	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CNS	PROPN	O	O
and	CCONJ	O	O
impairs	ADP	O	O
normal	ADJ	O	O
cerebellar	NOUN	O	O
and	CCONJ	O	O
oculomotor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
highlight	VERB	O	O
opioid	NOUN	O	O
's	PART	O	O
inhibitory	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cerebellar	ADJ	O	O
structure	NOUN	O	O
that	ADJ	O	O
causes	VERB	O	O
dysmetria	NOUN	O	I-Entity
,	PUNCT	O	O
dysarthria	NOUN	O	I-Entity
,	PUNCT	O	O
reduced	VERB	O	O
smooth	ADJ	O	O
pursuit	NOUN	O	O
gain	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
saccadic	ADJ	O	O
velocity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24641119)

Baboon	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ketoconazole	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
27-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
a	DET	O	O
maculopapular	ADJ	O	B-Entity
eruption	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
flexural	ADJ	O	O
areas	NOUN	O	O
and	CCONJ	O	O
buttocks	NOUN	O	O
after	ADP	O	O
using	VERB	O	O
oral	ADJ	O	O
ketoconazole	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
baboon	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
based	VERB	O	O
on	ADP	O	O
his	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
included	VERB	O	O
prior	ADJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
topical	ADJ	O	O
ketoconazole	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
histopathological	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Baboon	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
drug-	NOUN	O	O
or	CCONJ	O	O
contact	NOUN	O	O
allergen	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
maculopapular	ADJ	O	B-Entity
eruption	NOUN	O	I-Entity
that	ADJ	O	O
typically	ADV	O	O
involves	VERB	O	O
the	DET	O	O
flexural	ADJ	O	O
and	CCONJ	O	O
gluteal	ADJ	O	O
areas	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
the	DET	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
ketoconazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
baboon	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
English	ADJ	O	O
literature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24653743)

A	DET	O	O
Case	NOUN	O	O
of	ADP	O	O
Sudden	PROPN	O	B-Entity
Cardiac	PROPN	O	I-Entity
Death	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
Pilsicainide	PROPN	O	I-Entity
-	PUNCT	O	O
Induced	PROPN	O	O
Torsades	PROPN	O	B-Entity
de	PROPN	O	I-Entity
Pointes	PROPN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
84-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
received	VERB	O	O
oral	ADJ	O	O
pilsicainide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
pure	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
with	ADP	O	O
slow	ADJ	O	O
recovery	NOUN	O	O
kinetics	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
convert	VERB	O	O
his	ADJ	O	O
paroxysmal	ADJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
sudden	ADJ	O	B-Entity
cardiac	ADJ	O	I-Entity
death	NOUN	O	I-Entity
two	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
Holter	PROPN	O	O
electrocardiogram	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
worn	VERB	O	O
by	ADP	O	O
chance	NOUN	O	O
,	PUNCT	O	O
revealed	VERB	O	O
torsade	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
with	ADP	O	O
gradually	ADV	O	O
prolonged	VERB	O	O
QT	PROPN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
highly	ADV	O	O
impaired	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
pilsicainide	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
pilsicainide	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
high	ADJ	O	O
,	PUNCT	O	O
which	ADJ	O	O
can	VERB	O	O
produce	VERB	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
octogenarian	ADJ	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
class	NOUN	O	O
IC	PROPN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
pilsicainide	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
to	PART	O	O
terminate	VERB	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
careful	ADJ	O	O
consideration	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
taken	VERB	O	O
before	ADP	O	O
giving	VERB	O	O
these	DET	O	O
drugs	NOUN	O	O
to	ADP	O	O
octogenarians	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24658375)

All	DET	O	B-Entity
-	PUNCT	O	I-Entity
trans	NOUN	O	I-Entity
retinoic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
inflammatory	ADJ	O	O
myositis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	B-Entity
-	PUNCT	O	I-Entity
trans	NOUN	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
ATRA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
component	NOUN	O	O
of	ADP	O	O
standard	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
APL	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
potentially	ADV	O	O
serious	ADJ	O	O
but	CCONJ	O	O
treatable	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
involving	VERB	O	O
numerous	ADJ	O	O
organ	NOUN	O	O
systems	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
rare	ADJ	O	O
skeletal	ADJ	O	O
muscle	NOUN	O	O
involvement	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
a	DET	O	O
handful	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
ATRA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myositis	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
none	NOUN	O	O
in	ADP	O	O
the	DET	O	O
radiology	NOUN	O	O
literature	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
such	ADJ	O	O
a	DET	O	O
case	NOUN	O	O
in	ADP	O	O
a	DET	O	O
15-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
with	ADP	O	O
APL	PROPN	O	I-Entity
,	PUNCT	O	O
where	ADV	O	O
recognition	NOUN	O	O
of	ADP	O	O
imaging	VERB	O	O
findings	NOUN	O	O
played	VERB	O	O
a	DET	O	O
crucial	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
making	VERB	O	O
the	DET	O	O
diagnosis	NOUN	O	O
and	CCONJ	O	O
facilitated	VERB	O	O
prompt	NOUN	O	O
,	PUNCT	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24659727)

Tolerability	NOUN	O	O
of	ADP	O	O
lomustine	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
describes	VERB	O	O
toxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
lomustine	NOUN	O	I-Entity
(	PUNCT	O	O
CCNU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CTX	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

CCNU	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
per	ADP	O	O
os	NOUN	O	O
(	PUNCT	O	O
PO	PROPN	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
targeted	VERB	O	O
dosage	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
mg	NOUN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
CTX	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
PO	PROPN	O	O
at	ADP	O	O
a	DET	O	O
targeted	VERB	O	O
dosage	NOUN	O	O
of	ADP	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
divided	VERB	O	O
over	ADP	O	O
days	NOUN	O	O
0	NUM	O	O
through	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
dogs	NOUN	O	O
received	VERB	O	O
prophylactic	ADJ	O	O
antibiotics	NOUN	O	O
.	PUNCT	O	O

Neutropenia	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
principal	ADJ	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
overall	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
CCNU	PROPN	O	I-Entity
/	SYM	O	O
CTX	PROPN	O	I-Entity
was	VERB	O	O
30%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
-	PUNCT	O	O
43%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
19.7	NUM	O	O
kg	NOUN	O	O
+	SYM	O	O
13.4	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
dogs	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
develop	VERB	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
31.7	NUM	O	O
kg	NOUN	O	O
+	SYM	O	O
12.4	NUM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
dog	NOUN	O	O
(	PUNCT	O	O
3%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
hematologic	ADJ	O	O
changes	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
dogs	NOUN	O	O
had	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
or	CCONJ	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
findings	NOUN	O	O
reported	VERB	O	O
herein	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
mg	NOUN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
CCNU	PROPN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
CTX	PROPN	O	I-Entity
(	PUNCT	O	O
divided	VERB	O	O
over	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O

4	NUM	O	O
wk	NOUN	O	O
is	VERB	O	O
tolerable	ADJ	O	O
in	ADP	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
bearing	VERB	O	O
dogs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24664478)

Nelarabine	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
with	ADP	O	O
concurrent	ADJ	O	O
intrathecal	ADJ	O	O
chemotherapy	NOUN	O	O
:	PUNCT	O	O

Severe	ADJ	O	O
nelarabine	ADJ	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
concurrent	ADJ	O	O
intrathecal	ADJ	O	O

A	DET	O	O
37-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
T	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
lymphoblastic	ADJ	O	I-Entity
lymphoma	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
for	ADP	O	O
relapsed	VERB	O	O
disease	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
developed	VERB	O	O
relapsed	VERB	O	O
disease	NOUN	O	O
10	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
with	ADP	O	O
leukemic	ADJ	O	I-Entity
involvement	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
was	VERB	O	O
re	ADP	O	O
-	PUNCT	O	O
induced	VERB	O	O
with	ADP	O	O
nelarabine	NOUN	O	I-Entity
1500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
with	ADP	O	O
1	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
IT	PROPN	O	O
cytarabine	VERB	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
on	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
as	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
prophylaxis	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
was	VERB	O	O
on	ADP	O	O
continuous	ADJ	O	O
renal	ADJ	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
sequelae	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	B-Entity
lysis	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
TLS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

She	PRON	O	O
received	VERB	O	O
a	DET	O	O
second	ADJ	O	O
cycle	NOUN	O	O
of	ADP	O	O
nelarabine	NOUN	O	I-Entity
without	ADP	O	O
additional	ADJ	O	O
IT	NOUN	O	O
prophylaxis	NOUN	O	O
one	NUM	O	O
month	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Predominantly	ADV	O	O
sensory	ADJ	O	O
,	PUNCT	O	O
though	ADP	O	O
also	ADV	O	O
motor	NOUN	O	O
and	CCONJ	O	O
autonomic	NOUN	O	O
,	PUNCT	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
started	VERB	O	O
in	ADP	O	O
her	ADJ	O	O
feet	NOUN	O	O
,	PUNCT	O	O
ascended	VERB	O	O
proximally	ADV	O	O
to	ADP	O	O
the	DET	O	O
mid	ADJ	O	O
-	PUNCT	O	O
thoracic	NOUN	O	O
region	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
eventually	ADV	O	O
included	VERB	O	O
her	PRON	O	O
distal	ADJ	O	O
upper	ADJ	O	O
extremities	NOUN	O	O
.	PUNCT	O	O

Nelarabine	PROPN	O	I-Entity
was	VERB	O	O
felt	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Her	ADJ	O	O
neuropathy	NOUN	O	I-Entity
stabilized	VERB	O	O
and	CCONJ	O	O
showed	VERB	O	O
slight	ADJ	O	O
improvement	NOUN	O	O
and	CCONJ	O	O
ultimately	ADV	O	O
received	VERB	O	O
an	DET	O	O
unrelated	ADJ	O	O
,	PUNCT	O	O
reduced	VERB	O	O
-	PUNCT	O	O
intensity	NOUN	O	O
allogeneic	NOUN	O	O
transplant	NOUN	O	O
while	NOUN	O	O
in	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
relapsed	VERB	O	O
disease	NOUN	O	O
10	NUM	O	O
weeks	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
published	VERB	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
nelarabine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
concurrent	ADJ	O	O
IT	NOUN	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24665854)

Valproate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperammonemic	NOUN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
renal	NOUN	O	O
transplanted	VERB	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Neurological	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
after	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
constitute	VERB	O	O
an	DET	O	O
important	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Valproate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperammonemic	NOUN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
uncommon	ADJ	O	O
but	CCONJ	O	O
serious	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
15-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
on	ADP	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
valproate	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
epilepsy	NOUN	O	I-Entity
and	CCONJ	O	O
revealed	VERB	O	O
impaired	ADJ	O	B-Entity
consciousness	NOUN	O	I-Entity
with	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
12	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
withdraw	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
,	PUNCT	O	O
patients	NOUN	O	O
'	PART	O	O
symptoms	NOUN	O	O
resolved	VERB	O	O
within	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
Clinicians	NOUN	O	O
should	VERB	O	O
increase	VERB	O	O
their	ADJ	O	O
awareness	NOUN	O	O
for	ADP	O	O
potential	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
transplanted	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24671324)

Necrotising	VERB	O	B-Entity
fasciitis	NOUN	O	I-Entity
after	ADP	O	O
bortezomib	NOUN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimen	NOUN	O	O
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
patient	NOUN	O	O
of	ADP	O	O
Waldenstrom	PROPN	O	B-Entity
macroglobulinaemia	NOUN	O	I-Entity
.	PUNCT	O	O

Bortezomib	PROPN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimens	NOUN	O	O
are	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
generally	ADV	O	O
tolerable	ADJ	O	O
with	ADP	O	O
few	ADJ	O	O
severe	ADJ	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
B	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
malignancies	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
76-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
Waldenstrom	PROPN	O	B-Entity
macroglobulinaemia	NOUN	O	I-Entity
who	NOUN	O	O
suffered	VERB	O	O
necrotising	VERB	O	B-Entity
fasciitis	NOUN	O	I-Entity
without	ADP	O	O
neutropenia	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
bortezomib	NOUN	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dexamethasone	NOUN	O	I-Entity
and	CCONJ	O	O
rituximab	NOUN	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
should	VERB	O	O
recognise	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
bortezomib	NOUN	O	I-Entity
plus	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dexamethasone	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
we	PRON	O	O
believe	VERB	O	O
this	DET	O	O
case	NOUN	O	O
warrants	VERB	O	O
further	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24675088)

An	DET	O	O
integrated	ADJ	O	O
characterization	NOUN	O	O
of	ADP	O	O
serological	ADJ	O	O
,	PUNCT	O	O
pathological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Many	ADJ	O	O
efficacious	ADJ	O	O
cancer	NOUN	O	I-Entity
treatments	NOUN	O	O
cause	VERB	O	O
significant	ADJ	O	O
cardiac	ADJ	O	O
morbidity	NOUN	O	O
,	PUNCT	O	O
yet	CCONJ	O	O
biomarkers	NOUN	O	O
or	CCONJ	O	O
functional	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
damage	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
would	VERB	O	O
allow	VERB	O	O
monitoring	NOUN	O	O
and	CCONJ	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
lacking	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
utilized	VERB	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX)-induced	VERB	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
applying	VERB	O	O
multiple	ADJ	O	O
approaches	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
cardiac	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
MRI	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	PART	O	O
provide	VERB	O	O
the	DET	O	O
most	ADV	O	O
comprehensive	ADJ	O	O
characterization	NOUN	O	O
to	ADP	O	O
date	NOUN	O	O
of	ADP	O	O
the	DET	O	O
timecourse	NOUN	O	O
of	ADP	O	O
serological	ADJ	O	O
,	PUNCT	O	O
pathological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	O
events	NOUN	O	O
underlying	VERB	O	O
this	DET	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Hannover	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
dosed	VERB	O	O
with	ADP	O	O
1.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
DOX	PROPN	O	I-Entity
weekly	ADJ	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
4	NUM	O	O
week	NOUN	O	O
off	ADV	O	O
-	PUNCT	O	O
dosing	VERB	O	O
"	PUNCT	O	O
recovery	NOUN	O	O
"	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

Electron	PROPN	O	O
microscopy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
revealed	VERB	O	O
subcellular	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
and	CCONJ	O	O
marked	VERB	O	O
mitochondrial	ADJ	O	O
changes	NOUN	O	O
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
progressive	ADJ	O	O
cardiomyocyte	NOUN	O	B-Entity
degeneration	NOUN	O	I-Entity
,	PUNCT	O	O
hypertrophy	PROPN	O	I-Entity
/	SYM	O	O
cytomegaly	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
extensive	ADJ	O	O
vacuolation	NOUN	O	O
after	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Extensive	ADJ	O	O
replacement	NOUN	O	O
fibrosis	NOUN	O	I-Entity
(	PUNCT	O	O
quantified	VERB	O	O
by	ADP	O	O
Sirius	PROPN	O	O
red	ADJ	O	O
staining	NOUN	O	O
)	PUNCT	O	O
developed	VERB	O	O
during	ADP	O	O
the	DET	O	O
off	ADV	O	O
-	PUNCT	O	O
dosing	VERB	O	O
period	NOUN	O	O
.	PUNCT	O	O

Functional	ADJ	O	O
indices	NOUN	O	O
assessed	VERB	O	O
by	ADP	O	O
cardiac	ADJ	O	O
MRI	NOUN	O	O
(	PUNCT	O	O
including	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
(	PUNCT	O	O
LVEF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
E	PROPN	O	O
/	SYM	O	O
A	PROPN	O	O
ratio	NOUN	O	O
)	PUNCT	O	O
declined	VERB	O	O
progressively	ADV	O	O
,	PUNCT	O	O
reaching	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
after	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
and	CCONJ	O	O
culminating	VERB	O	O
in	ADP	O	O
"	PUNCT	O	O
clinical	ADJ	O	O
"	PUNCT	O	O
LV	PROPN	O	B-Entity
dysfunction	NOUN	O	I-Entity
by	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Troponin	PROPN	O	O
I	PRON	O	O
levels	VERB	O	O
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
delayed	VERB	O	O
and	CCONJ	O	O
peak	NOUN	O	O
gadolinium	NOUN	O	I-Entity
contrast	NOUN	O	O
enhancement	NOUN	O	O
,	PUNCT	O	O
histopathological	ADJ	O	O
grading	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
diastolic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
subcellular	ADJ	O	O
cardiomyocyte	NOUN	O	B-Entity
degeneration	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
earliest	ADJ	O	O
marker	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
progressive	ADJ	O	O
functional	ADJ	O	O
decline	NOUN	O	O
and	CCONJ	O	O
histopathological	ADJ	O	O
manifestations	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
indices	NOUN	O	O
predated	VERB	O	O
"	PUNCT	O	O
clinical	ADJ	O	O
"	PUNCT	O	O
LV	PROPN	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
thus	ADV	O	O
warrant	VERB	O	O
further	ADJ	O	O
evaluation	NOUN	O	O
as	ADP	O	O
predictive	ADJ	O	O
biomarkers	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24684312)

Intradermal	ADJ	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
injections	NOUN	O	O
:	PUNCT	O	O
intra-	NOUN	O	O
and	CCONJ	O	O
interindividual	ADJ	O	O
variability	NOUN	O	O
of	ADP	O	O
provoked	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity
.	PUNCT	O	O

Intradermal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
are	VERB	O	O
attractive	ADJ	O	O
to	PART	O	O
use	VERB	O	O
in	ADP	O	O
human	ADJ	O	O
experimental	ADJ	O	O
pain	NOUN	O	I-Entity
models	NOUN	O	O
because	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	ADJ	O	I-Entity
mimic	NOUN	O	O
isolated	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
pain	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
volunteers	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
24	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
range	VERB	O	O
18	NUM	O	O
-	SYM	O	O
38	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
intradermal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
volar	ADJ	O	O
forearm	NOUN	O	O
.	PUNCT	O	O

Magnitudes	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	O
pinprick	NOUN	O	O
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
brush	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
allodynia	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
using	VERB	O	O
von	PROPN	O	O
Frey	PROPN	O	O
filaments	VERB	O	O
(	PUNCT	O	O
gauges	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
brush	NOUN	O	O
strokes	NOUN	O	O
.	PUNCT	O	O

Areas	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity
were	VERB	O	O
quantified	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
injection	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
15	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
and	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
pinprick	NOUN	O	O
hyperalgesia	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
as	ADP	O	O
a	DET	O	O
marked	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	PROPN	O	O
)	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
von	PROPN	O	O
Frey	PROPN	O	O
gauges	VERB	O	O
60	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
g	NOUN	O	O

<	X	O	O
0.001	PUNCT	O	O
)	PUNCT	O	O
after	ADP	O	O
glutamate	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
capsaicin	NOUN	O	I-Entity
,	PUNCT	O	O
secondary	ADJ	O	O
pinprick	NOUN	O	O
hyperalgesia	NOUN	O	I-Entity
was	VERB	O	O
detected	VERB	O	O
with	ADP	O	O
all	DET	O	O
von	PROPN	O	O
Frey	PROPN	O	O
gauges	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Glutamate	PROPN	O	I-Entity
evoked	VERB	O	O
reproducible	ADJ	O	O
VAS	PROPN	O	O
response	NOUN	O	O
to	ADP	O	O
all	DET	O	O
von	PROPN	O	O
Frey	PROPN	O	O
gauges	VERB	O	O
(	PUNCT	O	O
ICC	PROPN	O	O
>	PROPN	O	O
0.60	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
brush	NOUN	O	O
strokes	NOUN	O	O
(	PUNCT	O	O
ICC	PROPN	O	O
>	PROPN	O	O
0.83	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
injection	NOUN	O	O
was	VERB	O	O
reproducible	ADJ	O	O
for	ADP	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
(	PUNCT	O	O
ICC	PROPN	O	O
>	PROPN	O	O
0.70	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity

Intra	PROPN	O	O
-	PUNCT	O	O
individual	ADJ	O	O
variability	NOUN	O	O
was	VERB	O	O
generally	ADV	O	O
lower	ADJ	O	O
for	ADP	O	O
the	DET	O	O
VAS	PROPN	O	O
response	NOUN	O	O
to	ADP	O	O
von	PROPN	O	O
Frey	PROPN	O	O
and	CCONJ	O	O
brush	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
areas	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
yield	NOUN	O	O
reproducible	ADJ	O	O
hyperalgesic	NOUN	O	I-Entity
and	CCONJ	O	O
allodynic	ADJ	O	I-Entity
responses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
present	ADJ	O	O
model	NOUN	O	O
is	VERB	O	O
well	ADV	O	O
suited	ADJ	O	O
for	ADP	O	O
basic	ADJ	O	O
research	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
for	ADP	O	O
assessing	VERB	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
phenomena	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24691439)

Ocular	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
ER	PROPN	O	O
stress	NOUN	O	O
reduction	NOUN	O	O
rescues	VERB	O	O
glaucoma	NOUN	O	I-Entity
in	ADP	O	O
murine	NOUN	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
induces	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
untreated	ADJ	O	O
,	PUNCT	O	O
these	DET	O	O
patients	NOUN	O	O
can	VERB	O	O
develop	VERB	O	O
a	DET	O	O
secondary	ADJ	O	O
glaucoma	NOUN	O	I-Entity
that	ADJ	O	O
resembles	VERB	O	O
primary	ADJ	O	B-Entity
open	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
angle	NOUN	O	I-Entity
glaucoma	NOUN	O	I-Entity
(	PUNCT	O	O
POAG	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
underlying	VERB	O	O
pathology	NOUN	O	O
of	ADP	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
glaucoma	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
fully	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
due	ADJ	O	O
in	ADP	O	O
part	NOUN	O	O
to	ADP	O	O
lack	NOUN	O	O
of	ADP	O	O
an	DET	O	O
appropriate	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
developed	VERB	O	O
a	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
glaucoma	NOUN	O	I-Entity
that	ADJ	O	O
exhibits	VERB	O	O
glaucoma	NOUN	O	I-Entity
features	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
WT	PROPN	O	O
mice	NOUN	O	O
with	ADP	O	O
topical	ADJ	O	O
ocular	ADJ	O	O
0.1%	NUM	O	O
dexamethasone	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
elevation	NOUN	O	O
of	ADP	O	O
intraocular	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
IOP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
functional	ADJ	O	O
and	CCONJ	O	O
structural	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
retinal	ADJ	O	B-Entity
ganglion	NOUN	O	I-Entity
cells	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
axonal	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
,	PUNCT	O	O
resembling	VERB	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
glaucoma	NOUN	O	I-Entity
in	ADP	O	O
human	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
ER	PROPN	O	O
stress	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trabecular	ADJ	O	O
meshwork	NOUN	O	O
(	PUNCT	O	O
TM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
to	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
treatment	NOUN	O	O
reduced	VERB	O	O
elevated	ADJ	O	O
IOP	PROPN	O	O
and	CCONJ	O	O
ER	PROPN	O	O
stress	NOUN	O	O
in	ADP	O	O
this	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
induced	VERB	O	O
the	DET	O	O
transcriptional	ADJ	O	O
factor	NOUN	O	O
CHOP	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
marker	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
ER	PROPN	O	O
stress	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
segment	NOUN	O	O
tissues	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Chop	PROPN	O	O
deletion	NOUN	O	O
reduced	VERB	O	O
ER	PROPN	O	O
stress	NOUN	O	O
in	ADP	O	O
these	DET	O	O
tissues	NOUN	O	O
and	CCONJ	O	O
prevented	VERB	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
reduction	NOUN	O	O
of	ADP	O	O
ER	PROPN	O	O
stress	NOUN	O	O
in	ADP	O	O
the	DET	O	O
TM	PROPN	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
4-phenylbutyrate	NUM	O	I-Entity
prevented	VERB	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
WT	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
ER	PROPN	O	O
stress	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
glucocorticoid	VERB	O	O
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
reducing	VERB	O	O
ER	PROPN	O	O
stress	NOUN	O	O
has	VERB	O	O
potential	ADJ	O	O
as	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
strategy	NOUN	O	O
for	ADP	O	O
treating	VERB	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24709919)

Effects	NOUN	O	O
of	ADP	O	O
ginsenosides	NOUN	O	I-Entity
on	ADP	O	O
opioid	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Opioid	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
(	PUNCT	O	O
OIH	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
nociceptive	ADJ	O	O
sensitization	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
cessation	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
opioid	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

OIH	PROPN	O	I-Entity
can	VERB	O	O
limit	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
opioid	ADJ	O	O
analgesics	NOUN	O	O
and	CCONJ	O	O
complicate	VERB	O	O
withdrawal	NOUN	O	O
from	ADP	O	O
opioid	ADJ	O	B-Entity
addiction	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Re	PROPN	O	B-Entity
,	PUNCT	O	I-Entity
Rg1	PROPN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
Rb1	PROPN	O	I-Entity
ginsenosides	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
bioactive	ADJ	O	O
components	NOUN	O	O
of	ADP	O	O
ginseng	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
OIH	PROPN	O	I-Entity
.	PUNCT	O	O

OIH	PROPN	O	I-Entity
was	VERB	O	O
achieved	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
after	ADP	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
for	ADP	O	O
7	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
three	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
withdrawal	NOUN	O	O
(	PUNCT	O	O
days	NOUN	O	O
8	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
these	DET	O	O
mice	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
Re	ADP	O	I-Entity
,	PUNCT	O	O
Rg1	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
Rb1	PROPN	O	I-Entity
intragastrically	ADV	O	O
two	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
test	NOUN	O	O
day	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mice	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
the	DET	O	O
thermal	ADJ	O	O
sensitivity	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
acetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
writhing	VERB	O	O
test	NOUN	O	O
.	PUNCT	O	O

Re	ADP	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
inhibited	VERB	O	O
OIH	PROPN	O	I-Entity
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
thermal	ADJ	O	O
sensitivity	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
acetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
writhing	VERB	O	O
test	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
Rg1	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
Rb1	PROPN	O	I-Entity
ginsenosides	NOUN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
OIH	PROPN	O	I-Entity
in	ADP	O	O
either	DET	O	O
test	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
Rg1	PROPN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
tendency	NOUN	O	O
to	PART	O	O
aggravate	VERB	O	O
OIH	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
acetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
writhing	VERB	O	O
test	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
ginsenoside	NOUN	O	B-Entity
Re	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
Rg1	NUM	O	I-Entity
or	CCONJ	O	O
Rb1	PROPN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
contribute	VERB	O	O
toward	ADP	O	O
reversal	NOUN	O	O
of	ADP	O	O
OIH	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24717468)

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hemodynamic	ADJ	O	O
disturbances	NOUN	O	O
between	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
and	CCONJ	O	O
propofol	NOUN	O	I-Entity
for	ADP	O	O
sedation	NOUN	O	O
in	ADP	O	O
neurocritical	ADJ	O	O
care	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Dexmedetomidine	PROPN	O	I-Entity
and	CCONJ	O	O
propofol	NOUN	O	I-Entity
are	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
sedatives	NOUN	O	O
in	ADP	O	O
neurocritical	ADJ	O	O
care	NOUN	O	O
as	ADP	O	O
they	PRON	O	O
allow	VERB	O	O
for	ADP	O	O
frequent	ADJ	O	O
neurologic	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hemodynamic	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
neurocritical	ADJ	O	O
care	NOUN	O	O
patients	NOUN	O	O
receiving	VERB	O	O
dexmedetomidine	NOUN	O	I-Entity
and	CCONJ	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
:	PUNCT	O	O
Continuous	ADJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
or	CCONJ	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
342	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
105	NUM	O	O
dexmedetomidine	NOUN	O	I-Entity
and	CCONJ	O	O
237	NUM	O	O
propofol	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
190	NUM	O	O
matched	VERB	O	O
(	PUNCT	O	O
95	NUM	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
propensity	NOUN	O	O
score	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
composite	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
<	X	O	O
60	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
(	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
<	SYM	O	O
50	NUM	O	O
beats	NOUN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
sedative	NOUN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
analyzed	VERB	O	O
separately	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
or	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
unmatched	ADJ	O	O
or	CCONJ	O	O
matched	ADJ	O	O
cohorts	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
occur	VERB	O	O
at	ADP	O	O
similar	ADJ	O	O
prevalence	NOUN	O	O
in	ADP	O	O
neurocritical	ADJ	O	O
care	NOUN	O	O
patients	NOUN	O	O
who	NOUN	O	O
receive	VERB	O	O
dexmedetomidine	NOUN	O	I-Entity
or	CCONJ	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

Providers	NOUN	O	O
should	VERB	O	O
similarly	ADV	O	O
consider	VERB	O	O
the	DET	O	O
likelihood	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
or	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
before	ADP	O	O
starting	VERB	O	O
either	CCONJ	O	O
sedative	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24727461)

Hydroxytyrosol	PROPN	O	I-Entity
ameliorates	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Oxidative	ADJ	O	O
stress	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
processes	NOUN	O	O
including	VERB	O	O
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
aging	VERB	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
potentiate	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Doxorubicin	ADJ	O	I-Entity
causes	VERB	O	O
significant	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
marked	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Herein	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigate	VERB	O	O
whether	ADP	O	O
doxorubicin	ADV	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chronic	ADJ	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
ameliorated	VERB	O	O
with	ADP	O	O
the	DET	O	O
antioxidant	NOUN	O	O
hydroxytyrosol	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
rats	NOUN	O	O
bearing	VERB	O	O
breast	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
induced	VERB	O	O
chemically	ADV	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
hydroxytyrosol	NOUN	O	I-Entity
(	PUNCT	O	O
0.5mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
5days	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
1mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
plus	CCONJ	O	O
hydroxytyrosol	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiac	PROPN	O	B-Entity
disturbances	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
cellular	ADJ	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	O
level	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
electron	ADJ	O	O
transport	NOUN	O	O
chain	NOUN	O	O
complexes	NOUN	O	O
I	PRON	O	O
-	PUNCT	O	O
IV	PROPN	O	O
and	CCONJ	O	O
apoptosis	NOUN	O	O
-	PUNCT	O	O
inducing	VERB	O	O
factor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
markers	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

Hydroxytyrosol	PROPN	O	I-Entity
improved	VERB	O	O
the	DET	O	O
cardiac	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
enhanced	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
by	ADP	O	O
significantly	ADV	O	O
reducing	VERB	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
altered	VERB	O	O
mitochondria	NOUN	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
hydroxytyrosol	PRON	O	I-Entity
improve	VERB	O	O
the	DET	O	O
mitochondrial	ADJ	O	O
electron	NOUN	O	O
transport	NOUN	O	O
chain	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
hydroxytyrosol	NOUN	O	I-Entity
protect	NOUN	O	O
rat	ADJ	O	O
heart	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
provoked	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
decreasing	VERB	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	O
alterations	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24729111)

Amiodarone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myxoedema	NOUN	O	B-Entity
coma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
62-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
hypothermia	NOUN	O	I-Entity
and	CCONJ	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
3	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

0.3	NUM	O	O
-	SYM	O	O
5	NUM	O	O
uIU	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
free	ADJ	O	O
thyroxine	NOUN	O	I-Entity
(	PUNCT	O	O
FT4	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
<	X	O	O
0.2	NUM	O	O
ng	INTJ	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
nl	PROPN	O	O
.	PUNCT	O	O

He	PRON	O	O
received	VERB	O	O
intravenous	ADJ	O	O
fluids	NOUN	O	O
,	PUNCT	O	O
vasopressor	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
stress	NOUN	O	O
dose	NOUN	O	O
steroids	NOUN	O	I-Entity
;	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
intubated	VERB	O	O
and	CCONJ	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
received	VERB	O	O
500	NUM	O	O
ug	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
levothyroxine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
18	NUM	O	O
h	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
150	NUM	O	O
ug	ADJ	O	O
intravenous	ADJ	O	O
daily	ADJ	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
on	ADP	O	O
levothyroxine	NOUN	O	I-Entity
175	NUM	O	O
(	PUNCT	O	O
g	NOUN	O	O
POorally	ADV	O	O
daily	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
24	NUM	O	O
hour	NOUN	O	O
excretion	NOUN	O	O
of	ADP	O	O
iodine	NOUN	O	I-Entity
was	VERB	O	O
3657	NUM	O	O
(	PUNCT	O	O
mcg	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
756	NUM	O	O
(	PUNCT	O	O
mcg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myxoedema	NOUN	O	B-Entity
coma	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
report	NOUN	O	O
patient	NOUN	O	O
death	NOUN	O	O
despite	ADP	O	O
supportive	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
thyroid	ADJ	O	O
hormone	NOUN	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
represents	VERB	O	O
the	DET	O	O
most	ADV	O	O
thoroughly	ADV	O	O
investigated	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myxoedema	NOUN	O	B-Entity
coma	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
significant	ADJ	O	O
for	ADP	O	O
subclinical	ADJ	O	O
thyroid	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24733133)

Use	NOUN	O	O
of	ADP	O	O
argatroban	ADJ	O	I-Entity
and	CCONJ	O	O
catheter	NOUN	O	O
-	PUNCT	O	O
directed	VERB	O	O
thrombolysis	NOUN	O	I-Entity
with	ADP	O	O
alteplase	NOUN	O	O
in	ADP	O	O
an	DET	O	O
oncology	NOUN	O	O
patient	NOUN	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
of	ADP	O	O
an	DET	O	O
oncology	NOUN	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
HITT	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
argatroban	ADJ	O	I-Entity
plus	CCONJ	O	O
catheter	NOUN	O	O
-	PUNCT	O	O
directed	VERB	O	O
thrombolysis	NOUN	O	I-Entity
(	PUNCT	O	O
CDT	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
alteplase	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
63-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	O
amyloidosis	NOUN	O	I-Entity
undergoing	VERB	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
collection	NOUN	O	O
for	ADP	O	O
an	DET	O	O
autologous	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplant	NOUN	O	O
developed	VERB	O	O
extensive	ADJ	O	O
bilateral	ADJ	O	O
upper	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
extremity	NOUN	O	I-Entity
deep	ADJ	O	I-Entity
venous	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
DVT	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	B-Entity
embolism	NOUN	O	I-Entity
secondary	NOUN	O	O
to	ADP	O	O
heparin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

infusion	NOUN	O	O
of	ADP	O	O
argatroban	NOUN	O	I-Entity
was	VERB	O	O
initiated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
managed	VERB	O	O
on	ADP	O	O
the	DET	O	O
general	ADJ	O	O
medical	ADJ	O	O
floor	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
transferred	VERB	O	O
to	ADP	O	O
the	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
with	ADP	O	O
cardiopulmonary	ADJ	O	O
compromise	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
superior	ADJ	O	B-Entity
vena	NOUN	O	I-Entity
cava	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
SVC	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
percutaneous	ADJ	O	O
mechanical	ADJ	O	O
thrombectomy	NOUN	O	O
and	CCONJ	O	O
CDT	PROPN	O	O
with	ADP	O	O
alteplase	NOUN	O	O
were	VERB	O	O
attempted	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
procedure	NOUN	O	O
was	VERB	O	O
aborted	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
epistaxis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
epistaxis	NOUN	O	I-Entity
resolved	VERB	O	O
the	DET	O	O
next	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
restarted	VERB	O	O
on	ADP	O	O
argatroban	NOUN	O	I-Entity
.	PUNCT	O	O

Postthrombectomy	PROPN	O	O
continuous	ADJ	O	O
CDT	PROPN	O	O
with	ADP	O	O
alteplase	NOUN	O	O
was	VERB	O	O
commenced	VERB	O	O
while	ADP	O	O
argatroban	NOUN	O	I-Entity
was	VERB	O	O
withheld	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
complete	ADJ	O	O
patency	NOUN	O	O
of	ADP	O	O
the	DET	O	O
SVC	PROPN	O	O
and	CCONJ	O	O
central	ADJ	O	O
veins	NOUN	O	O
was	VERB	O	O
achieved	VERB	O	O
after	ADP	O	O
three	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Alteplase	PROPN	O	O
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
reinitiated	VERB	O	O
on	ADP	O	O
argatroban	NOUN	O	I-Entity
;	PUNCT	O	O
ultimately	ADV	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
transitioned	VERB	O	O
to	ADP	O	O
warfarin	VERB	O	I-Entity
for	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
anticoagulation	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
recovered	VERB	O	O
,	PUNCT	O	O
he	PRON	O	O
experienced	VERB	O	O
permanent	ADJ	O	O
vision	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
63-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	O
amyloidosis	NOUN	O	I-Entity
and	CCONJ	O	O
SVC	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
HITT	PROPN	O	I-Entity
was	VERB	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
argatroban	ADJ	O	I-Entity
and	CCONJ	O	O
CDT	PROPN	O	O
with	ADP	O	O
alteplase	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24739405)

Effects	NOUN	O	O
of	ADP	O	O
dehydroepiandrosterone	NOUN	O	I-Entity
in	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
schizophrenia	NOUN	O	I-Entity
models	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
examine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
dehydroepiandrosterone	NOUN	O	I-Entity
(	PUNCT	O	O
DHEA	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
Swiss	ADJ	O	O
albino	ADJ	O	O
female	ADJ	O	O
mice	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
35	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
DHEA	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
DHEA	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
intraperitoneally	ADV	O	O
(	PUNCT	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Amphetamine	PROPN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
hyper	ADJ	O	I-Entity
locomotion	NOUN	O	O
,	PUNCT	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O

subcutaneously	ADV	O	O
[	PUNCT	O	O
sc	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
induced	VERB	O	O
climbing	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
sc	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
tests	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
as	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

Statistical	ADJ	O	O
analysis	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
using	VERB	O	O
Kruskal	PROPN	O	O
-	PUNCT	O	O
Wallis	PROPN	O	O
test	NOUN	O	O
for	ADP	O	O
hyper	ADJ	O	I-Entity
locomotion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
-	PUNCT	O	O
way	NOUN	O	O
ANOVA	PROPN	O	O
for	ADP	O	O
climbing	VERB	O	O
and	CCONJ	O	O
catalepsy	ADJ	O	I-Entity
tests	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotion	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
all	DET	O	O
movements	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
DHEA	PROPN	O	I-Entity
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
p<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
p<0.01	PROPN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
decreased	VERB	O	O
all	DET	O	O
movements	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotion	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
test	NOUN	O	O
(	PUNCT	O	O
p<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
climbing	NOUN	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
climbing	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
p>0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
that	ADP	O	O
DHEA	PROPN	O	I-Entity
reduced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
catalepsy	NOUN	O	I-Entity
at	ADP	O	O
both	DET	O	O
doses	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
it	PRON	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
climbing	VERB	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
DHEA	PROPN	O	I-Entity
displays	VERB	O	O
typical	ADJ	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24742750)

Availability	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
induced	VERB	O	O
pluripotent	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
cardiomyocytes	NOUN	O	O
in	ADP	O	O
assessment	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
potential	NOUN	O	O
for	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O

Field	NOUN	O	O
potential	ADJ	O	O
duration	NOUN	O	O
(	PUNCT	O	O
FPD	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
human	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
pluripotent	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
cardiomyocytes	NOUN	O	O
(	PUNCT	O	O
hiPS	PROPN	O	O
-	PUNCT	O	O
CMs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
can	VERB	O	O
express	VERB	O	O
QT	PROPN	O	O
interval	NOUN	O	O
in	ADP	O	O
an	DET	O	O
electrocardiogram	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
tool	NOUN	O	O
to	PART	O	O
predict	VERB	O	O
K(+	PROPN	O	I-Entity
)	PUNCT	O	O
channel	NOUN	O	O
and	CCONJ	O	O
Ca(2	PROPN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
channel	NOUN	O	O
blocker	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
report	NOUN	O	O
showing	VERB	O	O
that	ADP	O	O
this	DET	O	O
technique	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
predict	VERB	O	O
multichannel	NOUN	O	O
blocker	NOUN	O	O
potential	NOUN	O	O
for	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
show	VERB	O	O
that	ADP	O	O
FPD	PROPN	O	O
from	ADP	O	O
MEA	PROPN	O	O
(	PUNCT	O	O
Multielectrode	PROPN	O	O
array	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
hiPS	PROPN	O	O
-	PUNCT	O	O
CMs	PROPN	O	O
can	VERB	O	O
detect	VERB	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
multichannel	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

IKr	NOUN	O	O
and	CCONJ	O	O
IKs	ADJ	O	O
blockers	NOUN	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
prolonged	VERB	O	O
corrected	VERB	O	O
FPD	PROPN	O	O
(	PUNCT	O	O
FPDc	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	SYM	O	O
)	PUNCT	O	O
channel	NOUN	O	O
blockers	NOUN	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
shortened	VERB	O	O
FPDc	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
multichannel	NOUN	O	O
blockers	NOUN	O	O
Amiodarone	PROPN	O	I-Entity
,	PUNCT	O	O
Paroxetine	PROPN	O	I-Entity
,	PUNCT	O	O
Terfenadine	PROPN	O	I-Entity
and	CCONJ	O	O
Citalopram	PROPN	O	I-Entity
prolonged	VERB	O	O
FPDc	NOUN	O	O
in	ADP	O	O
a	DET	O	O
concentration	NOUN	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
IKr	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
Terfenadine	PROPN	O	I-Entity
and	CCONJ	O	O
Citalopram	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
reported	VERB	O	O
to	PART	O	O
cause	VERB	O	O
Torsade	PROPN	O	B-Entity
de	PROPN	O	I-Entity
Pointes	PROPN	O	I-Entity
(	PUNCT	O	O
TdP	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
,	PUNCT	O	O
produced	VERB	O	O
early	ADJ	O	O
afterdepolarization	NOUN	O	O
(	PUNCT	O	O
EAD	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
also	ADV	O	O
shows	VERB	O	O
that	ADP	O	O
this	DET	O	O
assay	NOUN	O	O
can	VERB	O	O
help	VERB	O	O
detect	VERB	O	O
EAD	PROPN	O	O
for	ADP	O	O
drugs	NOUN	O	O
with	ADP	O	O
TdP	PROPN	O	I-Entity
potential	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24753331)

Dermal	ADJ	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
N	PROPN	O	O
-	PUNCT	O	O
phenylimide	NOUN	O	O
herbicides	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
S-53482	NOUN	O	I-Entity
and	CCONJ	O	O
S-23121	PROPN	O	I-Entity
are	VERB	O	O
N	PROPN	O	O
-	PUNCT	O	O
phenylimide	NOUN	O	O
herbicides	NOUN	O	O
and	CCONJ	O	O
produced	VERB	O	O
embryolethality	NOUN	O	I-Entity
,	PUNCT	O	O
teratogenicity	NOUN	O	I-Entity
(	PUNCT	O	O
mainly	ADV	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defects	NOUN	O	I-Entity
and	CCONJ	O	O
wavy	ADJ	O	O
ribs	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
growth	NOUN	O	B-Entity
retardation	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
in	ADP	O	O
conventional	ADJ	O	O
oral	ADJ	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
studies	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
objective	NOUN	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
the	DET	O	O
compounds	NOUN	O	O
induce	VERB	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
via	ADP	O	O
the	DET	O	O
dermal	ADJ	O	O
route	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
more	ADV	O	O
relevant	ADJ	O	O
to	ADP	O	O
occupational	ADJ	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
hence	ADV	O	O
better	ADJ	O	O
addressing	VERB	O	O
human	ADJ	O	O
health	NOUN	O	O
risks	NOUN	O	O
.	PUNCT	O	O

S-53482	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
dermally	ADV	O	O
to	ADP	O	O
rats	NOUN	O	O
at	ADP	O	O
30	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
during	ADP	O	O
organogenesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
S-23121	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
200	NUM	O	O
,	PUNCT	O	O
400	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
maximum	ADJ	O	O
applicable	ADJ	O	O
dose	NOUN	O	O
level	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Dermal	ADJ	O	O
exposure	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
to	ADP	O	O
S-53482	PROPN	O	I-Entity
at	ADP	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
produced	VERB	O	O
patterns	NOUN	O	O
of	ADP	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
resulting	VERB	O	O
from	ADP	O	O
oral	ADJ	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	I-Entity
included	VERB	O	O
embryolethality	NOUN	O	I-Entity
,	PUNCT	O	O
teratogenicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
growth	NOUN	O	B-Entity
retardation	NOUN	O	I-Entity
.	PUNCT	O	O

Dermal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
S-23121	PROPN	O	I-Entity
at	ADP	O	O
800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
embryonic	ADJ	O	B-Entity
death	NOUN	O	I-Entity
and	CCONJ	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defect	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
retarded	ADJ	O	O
fetal	ADJ	O	O
growth	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
as	ADP	O	O
it	PRON	O	O
was	VERB	O	O
following	VERB	O	O
oral	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
S-23121	PROPN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
results	NOUN	O	O
,	PUNCT	O	O
S-53482	PROPN	O	I-Entity
and	CCONJ	O	O
S-23121	PROPN	O	I-Entity
were	VERB	O	O
teratogenic	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
dermally	ADV	O	O
to	ADP	O	O
pregnant	ADJ	O	O
rats	NOUN	O	O
as	ADP	O	O
were	VERB	O	O
the	DET	O	O
compounds	NOUN	O	O
administered	VERB	O	O
orally	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (24778426)

Rates	NOUN	O	O
of	ADP	O	O
Renal	PROPN	O	B-Entity
Toxicity	PROPN	O	I-Entity
in	ADP	O	O
Cancer	PROPN	O	I-Entity
Patients	PROPN	O	O

Receiving	VERB	O	O
Cisplatin	PROPN	O	I-Entity

With	ADP	O	O
and	CCONJ	O	O
Without	ADP	O	O
Mannitol	PROPN	O	I-Entity
.	PUNCT	O	O

Cisplatin	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
antineoplastic	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
many	ADJ	O	O
strategies	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
this	DET	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
nephroprotectant	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
hydration	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
single	ADJ	O	O
-	PUNCT	O	O
agent	NOUN	O	O
cisplatin	NOUN	O	I-Entity
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
mannitol	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
single	ADJ	O	O
-	PUNCT	O	O
center	NOUN	O	O
retrospective	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
a	DET	O	O
quasi	ADJ	O	O
experiment	NOUN	O	O
created	VERB	O	O
by	ADP	O	O
the	DET	O	O
national	ADJ	O	O
mannitol	NOUN	O	I-Entity
shortage	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
on	ADP	O	O
adult	NOUN	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
single	ADJ	O	O
-	PUNCT	O	O
agent	NOUN	O	O
cisplatin	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
outpatient	NOUN	O	O
from	ADP	O	O
January	PROPN	O	O
2011	NUM	O	O
to	ADP	O	O
September	PROPN	O	O
2012	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
AKI	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
143	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
single	ADJ	O	O
-	PUNCT	O	O
agent	NOUN	O	O
cisplatin	NOUN	O	I-Entity
;	PUNCT	O	O
97.2%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
had	VERB	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
as	ADP	O	O
their	ADJ	O	O
primary	ADJ	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
mannitol	NOUN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
develop	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
OR	NOUN	O	O
]	PUNCT	O	O
=	SYM	O	O
2.646	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
=	SYM	O	O
1.008	NUM	O	O
,	PUNCT	O	O
6.944	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.048	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
the	DET	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
dosing	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
also	ADV	O	O
had	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
likelihood	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
OR	CCONJ	O	O
=	SYM	O	O
11.494	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
=	SYM	O	O
4.149	NUM	O	O
,	PUNCT	O	O
32.258	NUM	O	O
;	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
When	ADV	O	O
limited	VERB	O	O
quantities	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
are	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
it	PRON	O	O
should	VERB	O	O
preferentially	ADV	O	O
be	VERB	O	O
given	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
particularly	ADV	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
analysis	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
those	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
the	DET	O	O
dosing	NOUN	O	O
schedule	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
those	DET	O	O
with	ADP	O	O
hypertension	NOUN	O	I-Entity
are	VERB	O	O
at	ADP	O	O
the	DET	O	O
greatest	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
would	VERB	O	O
benefit	VERB	O	O
from	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24802403)

Metformin	PROPN	O	I-Entity
protects	VERB	O	O
against	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
learning	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
impairments	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
pentylenetetrazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
kindling	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
and	CCONJ	O	O
severe	ADJ	O	O
comorbidity	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
greatly	ADV	O	O
diminishes	VERB	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
current	ADJ	O	O
therapeutic	ADJ	O	O
interventions	NOUN	O	O
for	ADP	O	O
epilepsy	NOUN	O	I-Entity
can	VERB	O	O
also	ADV	O	O
cause	VERB	O	O
untoward	ADJ	O	O
cognitive	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
an	DET	O	O
urgent	ADJ	O	O
need	NOUN	O	O
for	ADP	O	O
new	ADJ	O	O
kinds	NOUN	O	O
of	ADP	O	O
agents	NOUN	O	O
targeting	VERB	O	O
both	DET	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
cognition	NOUN	O	B-Entity
deficits	NOUN	O	I-Entity
.	PUNCT	O	O

Oxidative	ADJ	O	O
stress	NOUN	O	O
is	VERB	O	O
considered	VERB	O	O
to	PART	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
epileptogenesis	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
antioxidants	NOUN	O	O
have	VERB	O	O
a	DET	O	O
putative	ADJ	O	O
antiepileptic	ADJ	O	O
potential	NOUN	O	O
.	PUNCT	O	O

Metformin	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
antidiabetic	ADJ	O	O
oral	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
antioxidant	VERB	O	O
properties	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
ameliorative	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
on	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
brain	NOUN	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
markers	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
pentylenetetrazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
kindling	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Male	NOUN	O	O
C57BL/6	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
with	ADP	O	O
subconvulsive	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
37	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
for	ADP	O	O
14	NUM	O	O
injections	NOUN	O	O
.	PUNCT	O	O

Metformin	PROPN	O	I-Entity
was	VERB	O	O
injected	VERB	O	O
intraperitoneally	ADV	O	O
in	ADP	O	O
dose	NOUN	O	O
of	ADP	O	O
200mg	PROPN	O	O
/	SYM	O	O

kg	ADV	O	O
along	ADP	O	O
with	ADP	O	O
alternate	ADJ	O	O
-	PUNCT	O	O
day	NOUN	O	O
PTZ	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
metformin	NOUN	O	I-Entity
suppressed	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
kindling	NOUN	O	O
,	PUNCT	O	O
ameliorated	VERB	O	O
the	DET	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
brain	NOUN	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
concluded	VERB	O	O
that	ADP	O	O
metformin	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
a	DET	O	O
protective	ADJ	O	O
medicine	NOUN	O	O
against	ADP	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24812279)

P53	NOUN	O	O
inhibition	NOUN	O	O
exacerbates	VERB	O	O
late	ADJ	O	O
-	PUNCT	O	O
stage	NOUN	O	O
anthracycline	NOUN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

AIMS	PROPN	O	O
:	PUNCT	O	O
Doxorubicin	PROPN	O	I-Entity
(	PUNCT	O	O
DOX	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
cancer	NOUN	O	I-Entity
therapeutic	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
both	CCONJ	O	O
acute	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
-	PUNCT	O	O
stage	NOUN	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Children	NOUN	O	O
are	VERB	O	O
particularly	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
p53	NOUN	O	O
inhibition	NOUN	O	O
on	ADP	O	O
acute	ADJ	O	O
vs.	NOUN	O	O
late	ADV	O	O
-	PUNCT	O	O
stage	NOUN	O	O
DOX	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
a	DET	O	O
juvenile	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

littermates	NOUN	O	O
received	VERB	O	O
weekly	ADJ	O	O
DOX	PROPN	O	I-Entity
injections	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
week	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
DOX	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
acute	ADJ	O	O
stage	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
CB7	PROPN	O	O
mice	NOUN	O	O
exhibited	VERB	O	O
improved	ADJ	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
cardiomyocyte	NOUN	O	O
apoptosis	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
NON	PROPN	O	O
-	PUNCT	O	O
TXG	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
by	ADP	O	O
13	NUM	O	O
weeks	NOUN	O	O
following	VERB	O	O
the	DET	O	O
last	ADJ	O	O
DOX	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
late	ADJ	O	O
stage	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
CB7	PROPN	O	O
exhibited	VERB	O	O
a	DET	O	O
progressive	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
cardiomyocyte	NOUN	O	O
apoptosis	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
NON	NOUN	O	O
-	PUNCT	O	O
TXG	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

p53	NOUN	O	O
inhibition	NOUN	O	O
blocked	VERB	O	O
transient	ADJ	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
STAT3	PROPN	O	O
activation	NOUN	O	O
in	ADP	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
CB7	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
enhanced	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DNA	PROPN	O	O
repair	NOUN	O	O
proteins	NOUN	O	O
Ku70	PROPN	O	O
and	CCONJ	O	O
Ku80	PROPN	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
with	ADP	O	O
cardiomyocyte	NOUN	O	O
-	PUNCT	O	O
restricted	VERB	O	O
deletion	NOUN	O	O
of	ADP	O	O
STAT3	PROPN	O	O
exhibited	VERB	O	O
worse	ADJ	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
cardiomyocyte	NOUN	O	O
apoptosis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
greater	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
Ku70	PROPN	O	O
and	CCONJ	O	O
Ku80	PROPN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
DOX	PROPN	O	I-Entity
treatment	NOUN	O	O
during	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
stage	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
animals	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
These	DET	O	O
data	NOUN	O	O
support	VERB	O	O
a	DET	O	O
model	NOUN	O	O
wherein	ADP	O	O
a	DET	O	O
p53-dependent	ADJ	O	O
cardioprotective	ADJ	O	O
pathway	NOUN	O	O
,	PUNCT	O	O
mediated	VERB	O	O
via	ADP	O	O
STAT3	PROPN	O	O
activation	NOUN	O	O
,	PUNCT	O	O
mitigates	VERB	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	O
stress	NOUN	O	O
during	ADP	O	O
drug	NOUN	O	O
delivery	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
an	DET	O	O
explanation	NOUN	O	O
as	ADP	O	O
to	ADP	O	O
how	ADV	O	O
p53	ADJ	O	O
inhibition	NOUN	O	O
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
cardioprotection	NOUN	O	O
during	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
paradoxically	ADV	O	O
,	PUNCT	O	O
enhanced	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
long	ADV	O	O
after	ADP	O	O
the	DET	O	O
cessation	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24816962)

Metronidazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
uncommon	ADJ	O	O
scenario	NOUN	O	O
.	PUNCT	O	O

Metronidazole	PROPN	O	I-Entity
can	VERB	O	O
produce	VERB	O	O
neurological	ADJ	O	O
complications	NOUN	O	O
although	ADP	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
common	ADJ	O	O
scenario	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
where	ADV	O	O
a	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
encephalopathy	ADJ	O	I-Entity
following	VERB	O	O
prolonged	ADJ	O	O
metronidazole	NOUN	O	I-Entity
intake	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
made	VERB	O	O
by	ADP	O	O
the	DET	O	O
MRI	PROPN	O	O
findings	NOUN	O	O
and	CCONJ	O	O
supported	VERB	O	O
clinically	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (24840785)

Aconitine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Ca2	PROPN	O	I-Entity
+	CCONJ	O	O
overload	NOUN	O	O
causes	VERB	O	O
arrhythmia	NOUN	O	I-Entity
and	CCONJ	O	O
triggers	VERB	O	O
apoptosis	NOUN	O	O
through	ADP	O	O
p38	NOUN	O	O
MAPK	PROPN	O	O
signaling	VERB	O	O
pathway	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Aconitine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
bioactive	ADJ	O	O
diterpenoid	NOUN	O	O
alkaloid	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
content	NOUN	O	O
derived	VERB	O	O
from	ADP	O	O
herbal	ADJ	O	O
aconitum	NOUN	O	O
plants	NOUN	O	O
.	PUNCT	O	O

Emerging	VERB	O	O
evidence	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
voltage	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
Na(+	PROPN	O	I-Entity
)	PUNCT	O	O
channels	NOUN	O	O
have	VERB	O	O
pivotal	ADJ	O	O
roles	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
aconitine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
reports	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
aconitine	NOUN	O	I-Entity
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
explored	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
pathological	ADJ	O	O
Ca(2	NOUN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
signaling	VERB	O	O
in	ADP	O	O
aconitine	NOUN	O	I-Entity
poisoning	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	SYM	O	O
)	PUNCT	O	O
overload	NOUN	O	O
lead	NOUN	O	O
to	ADP	O	O
accelerated	VERB	O	O
beating	VERB	O	O
rhythm	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
rat	NOUN	O	O
ventricular	ADJ	O	O
myocytes	NOUN	O	O
and	CCONJ	O	O
caused	VERB	O	O
arrhythmia	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
freely	ADV	O	O
moving	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
aconitine	NOUN	O	I-Entity
on	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
cytotoxicity	NOUN	O	I-Entity
assay	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
rat	NOUN	O	O
ventricular	NOUN	O	O
myocytes	NOUN	O	O
(	PUNCT	O	O
NRVMs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
measured	VERB	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
culture	NOUN	O	O
medium	NOUN	O	O
of	ADP	O	O
NRVMs	PROPN	O	O
and	CCONJ	O	O
activities	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cardiac	ADJ	O	O
enzymes	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
reduced	VERB	O	O
NRVMs	PROPN	O	O
viability	NOUN	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
.	PUNCT	O	O

transferase	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
dUTP	NOUN	O	I-Entity
-	PUNCT	O	O
biotin	NOUN	O	I-Entity
nick	NOUN	O	O
end	NOUN	O	O
labeling	VERB	O	O
assay	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
stimulated	VERB	O	O
apoptosis	NOUN	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
expression	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	PROPN	O	O
)	PUNCT	O	O

handling	VERB	O	O
proteins	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
promoted	VERB	O	O
Ca(2	PROPN	O	I-Entity
+	SYM	O	O
)	PUNCT	O	O
overload	NOUN	O	O
through	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
regulation	NOUN	O	O
of	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	PROPN	O	O
)	PUNCT	O	O
handling	VERB	O	O
proteins	NOUN	O	O
.	PUNCT	O	O

Hence	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
significantly	ADV	O	O
aggravates	VERB	O	O
Ca(2	NUM	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
overload	NOUN	O	O
and	CCONJ	O	O
causes	VERB	O	O
arrhythmia	NOUN	O	I-Entity
and	CCONJ	O	O
finally	ADV	O	O
promotes	VERB	O	O
apoptotic	ADJ	O	O
development	NOUN	O	O
via	ADP	O	O
phosphorylation	NOUN	O	O
of	ADP	O	O
P38	PROPN	O	O
mitogen	NOUN	O	O
-	PUNCT	O	O
activated	VERB	O	O
protein	NOUN	O	O
kinase	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24842192)

Chronic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	I-Entity
suppresses	VERB	O	O
toll	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
receptor	NOUN	O	O
4	NUM	O	O
signaling	VERB	O	O
and	CCONJ	O	O
attenuates	NOUN	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
following	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	I-Entity
has	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
by	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
responses	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
AMP	PROPN	O	I-Entity
-	PUNCT	O	O
activated	VERB	O	O
protein	NOUN	O	O
kinase	NOUN	O	O
(	PUNCT	O	O
AMPK	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	I-Entity
on	ADP	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
toll	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
receptor	NOUN	O	O
4	NUM	O	O
(	PUNCT	O	O
TLR4	PROPN	O	O
)	PUNCT	O	O
activities	NOUN	O	O
following	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
relation	NOUN	O	O
with	ADP	O	O
AMPK	PROPN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	NUM	O	O
of	ADP	O	O
5	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n=6	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
normal	ADJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
groups	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
isoproterenol	ADV	O	I-Entity
after	ADP	O	O
chronic	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
25	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
100mg	PROPN	O	O
/	SYM	O	O

kg	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Isoproterenol	PROPN	O	I-Entity
(	PUNCT	O	O
100mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
subcutaneously	ADV	O	O
on	ADP	O	O
the	DET	O	O
13th	NOUN	O	O
and	CCONJ	O	O
14th	ADJ	O	O
days	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Isoproterenol	NOUN	O	I-Entity
alone	ADV	O	O
decreased	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
systolic	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
contractility	NOUN	O	O
indexed	VERB	O	O
as	ADP	O	O
LVdp	PROPN	O	O
/	SYM	O	O
dtmax	NOUN	O	O
and	CCONJ	O	O
LVdp	PROPN	O	O
/	SYM	O	O
dtmin	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
left	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
25	NUM	O	O
and	CCONJ	O	O
50mg	PROPN	O	O
/	SYM	O	O

kg	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
.	PUNCT	O	O

Metfromin	PROPN	O	O
markedly	ADV	O	O
lowered	VERB	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
elevation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
TLR4	PROPN	O	O
mRNA	PROPN	O	O
,	PUNCT	O	O
myeloid	ADJ	O	O
differentiation	NOUN	O	O
protein	NOUN	O	O
88	NUM	O	O
(	PUNCT	O	O
MyD88	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
a	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
interleukin	VERB	O	O
6	NUM	O	O
(	PUNCT	O	O
IL-6	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

kg	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
,	PUNCT	O	O
slightly	ADV	O	O
by	ADP	O	O
50mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
100mg	PROPN	O	O

Chronic	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	I-Entity
reduces	VERB	O	O
post	NOUN	O	O
-	PUNCT	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
cardiac	ADJ	O	O
dysfunction	NOUN	O	O
and	CCONJ	O	O
suppresses	VERB	O	O
inflammatory	ADJ	O	O
responses	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
through	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
TLR4	PROPN	O	O
activities	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24881749)

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
tetrabenazine	NOUN	O	I-Entity
and	CCONJ	O	O
tiapride	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
Japanese	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
Huntington	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
terminal	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
herein	ADV	O	O
describe	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
an	DET	O	O
81-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Japanese	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
that	ADJ	O	O
occurred	VERB	O	O
36	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
tiapride	NOUN	O	I-Entity
(	PUNCT	O	O
75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tetrabenazine	NOUN	O	I-Entity
(	PUNCT	O	O
12.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
Huntington	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
tiapride	NOUN	O	I-Entity
or	CCONJ	O	O
tetrabenazine	NOUN	O	I-Entity
alone	ADV	O	O
without	ADP	O	O
any	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
before	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
also	ADV	O	O
had	VERB	O	O
advanced	VERB	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
when	ADV	O	O
the	DET	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O

To	ADP	O	O
the	DET	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
tetrabenazine	NOUN	O	I-Entity
and	CCONJ	O	O
tiapride	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Tetrabenazine	PRON	O	I-Entity
should	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
very	ADV	O	O
carefully	ADV	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
neuroleptic	ADJ	O	B-Entity
drugs	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
worsening	VERB	O	O
general	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24894748)

A	DET	O	O
metoprolol	NOUN	O	I-Entity
-	PUNCT	O	O
terbinafine	NOUN	O	I-Entity
combination	NOUN	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
report	VERB	O	O
a	DET	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
terbinafine	ADJ	O	I-Entity
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
63	NUM	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
man	NOUN	O	O
on	ADP	O	O
metoprolol	NOUN	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
stable	ADJ	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
prescribed	VERB	O	O
a	DET	O	O
90-day	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
terbinafine	NOUN	O	I-Entity
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
onychomycosis	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
49th	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
terbinafine	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
brought	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
room	NOUN	O	O
for	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
his	ADJ	O	O
global	ADJ	O	O
health	NOUN	O	O
status	NOUN	O	O
,	PUNCT	O	O
confusion	NOUN	O	I-Entity
and	CCONJ	O	O
falls	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
electrocardiogram	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
37	NUM	O	O
beats	NOUN	O	O
/	SYM	O	O
min	VERB	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
score	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
on	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reaction	NOUN	O	I-Entity
probability	NOUN	O	O
scale	NOUN	O	O
indicates	VERB	O	O
a	DET	O	O
probable	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
between	ADP	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
terbinafine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
ameliorated	VERB	O	O
first	ADV	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
subsequently	ADV	O	O
changed	VERB	O	O
to	ADP	O	O
bisoprolol	VERB	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
remained	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

By	ADP	O	O
inhibiting	VERB	O	O
the	DET	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
2D6	NUM	O	O
,	PUNCT	O	O
terbinafine	NOUN	O	I-Entity
had	VERB	O	O
decreased	VERB	O	O
metoprolol	NOUN	O	I-Entity
's	PART	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
in	ADP	O	O
metoprolol	NOUN	O	I-Entity
accumulation	NOUN	O	O
which	ADJ	O	O
has	VERB	O	O
resulted	VERB	O	O
in	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24897009)

Optochiasmatic	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
ethambutol	NOUN	O	I-Entity
overtreatment	NOUN	O	O
.	PUNCT	O	O

Ethambutol	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
more	ADV	O	O
rarely	ADV	O	O
,	PUNCT	O	O
axonal	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
characterize	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
neurophysiological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neuroimaging	VERB	O	O
findings	NOUN	O	O
in	ADP	O	O
a	DET	O	O
72-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
paresthesias	NOUN	O	I-Entity
after	ADP	O	O
11	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
supratherapeutic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
demonstrates	VERB	O	O
the	DET	O	O
selective	ADJ	O	O
vulnerability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
visual	ADJ	O	O
pathways	NOUN	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
nerves	NOUN	O	O
to	ADP	O	O
ethambutol	VERB	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24902786)

Testosterone	NOUN	O	I-Entity
ameliorates	VERB	O	O
streptozotocin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
testosterone	NOUN	O	I-Entity
on	ADP	O	O
streptozotocin	NOUN	O	I-Entity
(	PUNCT	O	O
STZ)-induced	VERB	O	I-Entity
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Adult	NOUN	O	O
male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
intracerebroventricularly	ADV	O	O
(	PUNCT	O	O
icv	NOUN	O	O
)	PUNCT	O	O
infused	VERB	O	O
with	ADP	O	O
STZ	PROPN	O	I-Entity
(	PUNCT	O	O
750	NUM	O	O
ug	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
d	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
d	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
STZ	PROPN	O	I-Entity
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg.kg(-1).d(-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sc	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
androgen	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
flutamide	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg.kg(-1).d(-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
estrogen	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
tamoxifen	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg.kg(-1).d(-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
aromatase	NOUN	O	O
inhibitor	NOUN	O	O
letrozole	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg.kg(-1).d(-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ip	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
for	ADP	O	O
6	NUM	O	O
d	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
STZ	PROPN	O	I-Entity
.	PUNCT	O	O

STZ	PROPN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
castration	NOUN	O	O
markedly	ADV	O	O
decreased	VERB	O	O
both	DET	O	O
STL1	PROPN	O	O
(	PUNCT	O	O
the	DET	O	O
short	ADJ	O	O
memory	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
STL2	PROPN	O	O
(	PUNCT	O	O
the	DET	O	O
long	ADJ	O	O
memory	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
replacement	NOUN	O	O
almost	ADV	O	O
restored	VERB	O	O
the	DET	O	O
STL1	PROPN	O	O
and	CCONJ	O	O
STL2	PROPN	O	O
in	ADP	O	O
castrated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
prolonged	VERB	O	O
the	DET	O	O
STL1	PROPN	O	O
and	CCONJ	O	O
STL2	PROPN	O	O
in	ADP	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
flutamide	NOUN	O	I-Entity
,	PUNCT	O	O
letrozole	NOUN	O	I-Entity
or	CCONJ	O	O
tamoxifen	NOUN	O	I-Entity
significantly	ADV	O	O
impaired	VERB	O	B-Entity
the	DET	O	I-Entity
memory	NOUN	O	I-Entity
in	ADP	O	O
intact	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
testosterone	NOUN	O	I-Entity
replacement	NOUN	O	O
in	ADP	O	O
improving	VERB	O	O
STZ-	PROPN	O	I-Entity
and	CCONJ	O	O
castration	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Testosterone	PROPN	O	I-Entity
administration	NOUN	O	O
ameliorates	VERB	O	O
STZ-	PROPN	O	I-Entity
and	CCONJ	O	O
castration	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24911645)

Behavioral	PROPN	O	O
and	CCONJ	O	O
neurochemical	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
garcinielliptone	NOUN	O	B-Entity
FC	PROPN	O	I-Entity
in	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Garcinielliptone	PROPN	O	B-Entity
FC	PROPN	O	I-Entity
(	PUNCT	O	O
GFC	PROPN	O	I-Entity
)	PUNCT	O	O
isolated	ADJ	O	O
from	ADP	O	O
hexanic	ADJ	O	O
fraction	NOUN	O	O
seed	NOUN	O	O
extract	NOUN	O	O
of	ADP	O	O
species	NOUN	O	O
Platonia	PROPN	O	O
insignis	VERB	O	O
Mart	PROPN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
folk	NOUN	O	O
medicine	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
skin	NOUN	O	B-Entity
diseases	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
humans	NOUN	O	O
and	CCONJ	O	O
animals	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
seed	NOUN	O	O
decoction	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
diarrheas	NOUN	O	I-Entity
and	CCONJ	O	O
inflammatory	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
research	NOUN	O	O
on	ADP	O	O
GFC	PROPN	O	I-Entity
effects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
of	ADP	O	O
rodents	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
GFC	PROPN	O	I-Entity
effects	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
or	CCONJ	O	O
75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
on	ADP	O	O
seizure	NOUN	O	I-Entity
parameters	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
their	ADJ	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
r	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
glutamine	NOUN	O	I-Entity
,	PUNCT	O	O
aspartate	NOUN	O	I-Entity
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
)	PUNCT	O	O
levels	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
on	ADP	O	O
acetylcholinesterase	NOUN	O	O
(	PUNCT	O	O
AChE	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
hippocampus	ADV	O	O
after	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

GFC	PROPN	O	I-Entity
produced	VERB	O	O
an	DET	O	O
increased	VERB	O	O
latency	NOUN	O	O
to	ADP	O	O
first	ADJ	O	O
seizure	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
doses	NOUN	O	O
25mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
20.12	NUM	O	O
+	SYM	O	O
2.20	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
50mg	PROPN	O	O
/	PUNCT	O	O
kg	NOUN	O	O
(	PUNCT	O	O
20.95	NUM	O	O
+	SYM	O	O
2.21	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
23.43	NUM	O	O
+	SYM	O	O
1.99	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
seized	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
GABA	PROPN	O	I-Entity
content	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
hippocampus	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
GFC75	PROPN	O	O
plus	CCONJ	O	O
P400	PROPN	O	O
showed	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
46.90%	NUM	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
seized	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
aspartate	NOUN	O	I-Entity
,	PUNCT	O	O
glutamine	NOUN	O	I-Entity
and	CCONJ	O	O
glutamate	NOUN	O	I-Entity
levels	NOUN	O	O
detected	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
5.21%	NUM	O	O
,	PUNCT	O	O
13.55%	NUM	O	O
and	CCONJ	O	O
21.80%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
in	ADP	O	O
mice	NOUN	O	O
hippocampus	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
GFC75	PROPN	O	O
plus	CCONJ	O	O
P400	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
seized	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
GFC	PROPN	O	I-Entity
can	VERB	O	O
exert	VERB	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
reduce	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
installation	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
demonstrated	VERB	O	O
by	ADP	O	O
increase	NOUN	O	O
in	ADP	O	O
latency	NOUN	O	O
to	ADP	O	O
first	ADJ	O	O
seizure	NOUN	O	I-Entity
and	CCONJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
GFC	PROPN	O	I-Entity
may	VERB	O	O
influence	VERB	O	O
in	ADP	O	O
epileptogenesis	NOUN	O	O
and	CCONJ	O	O
promote	VERB	O	O
anticonvulsant	ADJ	O	O
actions	NOUN	O	O
in	ADP	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
by	ADP	O	O
modulating	VERB	O	O
the	DET	O	O
GABA	PROPN	O	I-Entity
and	CCONJ	O	O
glutamate	ADJ	O	I-Entity
contents	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
AChE	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
seized	VERB	O	O
mice	NOUN	O	O
hippocampus	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24923469)

Standard	ADJ	O	O
operating	NOUN	O	O
procedures	NOUN	O	O
for	ADP	O	O
antibiotic	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
interventional	ADJ	O	O
,	PUNCT	O	O
observational	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
AKI	PROPN	O	I-Entity
)	PUNCT	O	O
occurs	VERB	O	O
in	ADP	O	O
7%	NUM	O	O
of	ADP	O	O
hospitalized	VERB	O	O
and	CCONJ	O	O
66%	NUM	O	O
of	ADP	O	O
Intensive	PROPN	O	O
Care	PROPN	O	O
Unit	PROPN	O	O
(	PUNCT	O	O
ICU	PROPN	O	O
)	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
,	PUNCT	O	O
whether	ADP	O	O
there	ADV	O	O
is	VERB	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
adherence	NOUN	O	O
to	ADP	O	O
guidelines	NOUN	O	O
(	PUNCT	O	O
standard	ADJ	O	O
operating	NOUN	O	O
procedures	NOUN	O	O
(	PUNCT	O	O
SOP	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
potentially	ADV	O	O
nephrotoxic	ADJ	O	I-Entity
antibiotics	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
AKI	PROPN	O	I-Entity
.	PUNCT	O	O

163	NUM	O	O
of	ADP	O	O
these	DET	O	O
had	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
vancomycin	NOUN	O	I-Entity
,	PUNCT	O	O
gentamicin	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
tobramycin	NOUN	O	I-Entity
;	PUNCT	O	O
were	VERB	O	O
>	ADJ	O	O
18	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
treated	VERB	O	O
in	ADP	O	O
the	DET	O	O
ICU	PROPN	O	O
for	ADP	O	O
>	SYM	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

AKI	PROPN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
according	VERB	O	O
to	ADP	O	O
RIFLE	PROPN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

Development	NOUN	O	O
of	ADP	O	O
AKI	PROPN	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
with	ADP	O	O
exact	ADJ	O	O
Chi2-test	PROPN	O	O
and	CCONJ	O	O
multivariate	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
(	PUNCT	O	O
two	NUM	O	O
-	PUNCT	O	O
sided	ADJ	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

AKI	PROPN	O	I-Entity
occurred	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
often	ADV	O	O
in	ADP	O	O
LAG	PROPN	O	O
with	ADP	O	O
36%	NUM	O	O
versus	ADP	O	O
21%	NUM	O	O
in	ADP	O	O
HAG	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.035	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Basic	ADJ	O	O
characteristics	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
,	PUNCT	O	O
except	ADP	O	O
an	DET	O	O
increased	VERB	O	O
rate	NOUN	O	O
of	ADP	O	O
soft	ADJ	O	O
tissue	NOUN	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
LAG	PROPN	O	O
.	PUNCT	O	O

Multivariate	PROPN	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
an	DET	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
2.5-fold	NUM	O	O
for	ADP	O	O
LAG	NOUN	O	O
to	PART	O	O
develop	VERB	O	O
AKI	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
HAG	NOUN	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
1.195	NUM	O	O
to	ADP	O	O
5.124	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.039	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Low	ADJ	O	O
adherence	NOUN	O	O
to	PART	O	O
SOPs	VERB	O	O
for	ADP	O	O
potentially	ADV	O	O
nephrotoxic	ADJ	O	I-Entity
antibiotics	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
AKI	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24927617)

Rhabdomyolysis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
hepatitis	NOUN	O	B-Entity
C	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
infected	VERB	O	I-Entity
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
telaprevir	NOUN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
46-year	ADJ	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
a	DET	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	B-Entity
C	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
received	VERB	O	O
triple	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
ribavirin	NOUN	O	I-Entity
,	PUNCT	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
telaprevir	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
simvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
starting	VERB	O	O
the	DET	O	O
antiviral	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
because	ADP	O	O
he	PRON	O	O
developed	VERB	O	O
rhabdomyolysis	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
admission	NOUN	O	O
simvastatin	NOUN	O	I-Entity
and	CCONJ	O	O
all	DET	O	O
antiviral	ADJ	O	O
drugs	NOUN	O	O
were	VERB	O	O
discontinued	VERB	O	O
because	ADP	O	O
toxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
was	VERB	O	O
suspected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
peaked	VERB	O	O
at	ADP	O	O
62,246	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
hospitalization	NOUN	O	O
,	PUNCT	O	O
creatine	ADJ	O	I-Entity
kinase	NOUN	O	O
level	NOUN	O	O
had	VERB	O	O
returned	VERB	O	O
to	ADP	O	O
230	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
discharged	VERB	O	O
.	PUNCT	O	O

Telaprevir	PROPN	O	I-Entity
was	VERB	O	O
considered	VERB	O	O
the	DET	O	O
probable	ADJ	O	O
causative	NOUN	O	O
agent	NOUN	O	O
of	ADP	O	O
an	DET	O	O
interaction	NOUN	O	O
with	ADP	O	O
simvastatin	NOUN	O	I-Entity
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Drug	NOUN	O	O
Interaction	PROPN	O	O
Probability	PROPN	O	O
Scale	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
interaction	NOUN	O	O
is	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
CYP3A4-mediated	PROPN	O	O
simvastatin	ADJ	O	I-Entity
clearance	NOUN	O	O
.	PUNCT	O	O

Simvastatin	ADJ	O	I-Entity
plasma	NOUN	O	O
concentration	NOUN	O	O
increased	VERB	O	O
30	NUM	O	O
times	NOUN	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
statin	NOUN	O	I-Entity
induced	VERB	O	O
muscle	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
statin	NOUN	O	I-Entity
in	ADP	O	O
blood	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
this	DET	O	O
case	NOUN	O	O
we	PRON	O	O
illustrate	VERB	O	O
that	DET	O	O
telaprevir	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
statins	NOUN	O	I-Entity
are	VERB	O	O
susceptible	ADJ	O	O
to	ADP	O	O
clinical	ADJ	O	O
relevant	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24928523)

Combination	NOUN	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
,	PUNCT	O	O
thalidomide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
VTD	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
after	ADP	O	O
autologous	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
symptomatic	ADJ	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
in	ADP	O	O
Japanese	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Consolidation	PROPN	O	O
therapy	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
(	PUNCT	O	O
MM	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
widely	ADV	O	O
adopted	VERB	O	O
to	PART	O	O
improve	VERB	O	O
treatment	NOUN	O	O
response	NOUN	O	O
following	VERB	O	O
autologous	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
retrospectively	ADV	O	O
analyzed	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
regimen	NOUN	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
,	PUNCT	O	O
thalidomide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
VTD	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
24	NUM	O	O
Japanese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
MM	PROPN	O	I-Entity
.	PUNCT	O	O

VTD	PROPN	O	O
consisted	VERB	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
1.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
22	NUM	O	O
of	ADP	O	O
a	DET	O	O
35-day	NOUN	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
daily	ADJ	O	O
oral	ADJ	O	O
thalidomide	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

Grade	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
were	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
four	NUM	O	O
and	CCONJ	O	O
three	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
17	NUM	O	O
and	CCONJ	O	O
13	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
drug	NOUN	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
cytopenia	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
required	VERB	O	O
in	ADP	O	O
any	DET	O	O
case	NOUN	O	O
.	PUNCT	O	O

Peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
common	ADJ	O	O
(	PUNCT	O	O
63	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
severe	ADJ	O	O
grade	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (24971338)

Conversion	NOUN	O	O
to	ADP	O	O
sirolimus	NOUN	O	I-Entity
ameliorates	VERB	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
focus	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	O
,	PUNCT	O	O
urine	NOUN	O	O
,	PUNCT	O	O
gene	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
protein	NOUN	O	O
renal	ADJ	O	O
expression	NOUN	O	O
biomarkers	NOUN	O	O
.	PUNCT	O	O

Protocols	PROPN	O	O
of	ADP	O	O
conversion	NOUN	O	O
from	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	PROPN	O	I-Entity
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
sirolimus	VERB	O	I-Entity
(	PUNCT	O	O
SRL	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
immunotherapy	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
CsA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
these	DET	O	O
protocols	NOUN	O	O
remain	VERB	O	O
nuclear	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
molecular	ADJ	O	O
pathways	NOUN	O	O
and	CCONJ	O	O
putative	ADJ	O	O
biomarkers	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
SRL	PROPN	O	I-Entity
conversion	NOUN	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
animal	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
during	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
CsA	PROPN	O	I-Entity
,	PUNCT	O	O
SRL	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
conversion	NOUN	O	O
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
SRL	PROPN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
were	VERB	O	O
analyzed	VERB	O	O
in	ADP	O	O
hematoxylin	NOUN	O	I-Entity
and	CCONJ	O	O
eosin	NOUN	O	I-Entity
,	PUNCT	O	O
periodic	ADJ	O	O
acid	NOUN	O	O
-	PUNCT	O	O
Schiff	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Masson	PROPN	O	O
's	PART	O	O
trichrome	NOUN	O	O
stains	NOUN	O	O
.	PUNCT	O	O

SRL	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
presented	VERB	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
NGAL	PROPN	O	O
(	PUNCT	O	O
serum	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
)	PUNCT	O	O
as	ADP	O	O
the	DET	O	O
best	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Short	ADJ	O	O
CsA	PROPN	O	I-Entity
treatment	NOUN	O	O
presented	VERB	O	O
slight	ADJ	O	O
or	CCONJ	O	O
even	ADV	O	O
absent	ADJ	O	O
kidney	NOUN	O	B-Entity
lesions	NOUN	O	I-Entity
and	CCONJ	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
b	PROPN	O	O
,	PUNCT	O	O
NF-	PROPN	O	O
kb	NOUN	O	O
,	PUNCT	O	O
mTOR	PROPN	O	O
,	PUNCT	O	O
PCNA	PROPN	O	O
,	PUNCT	O	O
TP53	PROPN	O	O
,	PUNCT	O	O
KIM-1	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CTGF	PROPN	O	O
as	ADP	O	O
relevant	ADJ	O	O
gene	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Prolonged	VERB	O	O
CsA	NOUN	O	I-Entity
exposure	NOUN	O	O
aggravated	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
clear	ADJ	O	O
changes	NOUN	O	O
on	ADP	O	O
the	DET	O	O
traditional	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
serums	NOUN	O	O
TGF-	PROPN	O	O
b	PROPN	O	O
and	CCONJ	O	O
IL-7	PROPN	O	O
,	PUNCT	O	O
TBARs	PROPN	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
kidney	NOUN	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
b	PROPN	O	O
and	CCONJ	O	O
mTOR	PROPN	O	O
.	PUNCT	O	O

Conversion	PROPN	O	O
to	ADP	O	O
SRL	PROPN	O	I-Entity
prevented	VERB	O	O
CsA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
evolution	NOUN	O	O
(	PUNCT	O	O
absent	ADJ	O	O
/	SYM	O	O
mild	ADJ	O	O
grade	NOUN	O	O
lesions	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
NGAL	PROPN	O	O
(	PUNCT	O	O
serum	NOUN	O	O
versus	ADP	O	O
urine	NOUN	O	O
)	PUNCT	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
feasible	ADJ	O	O
biomarker	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
replacement	NOUN	O	O
to	ADP	O	O
SRL	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24975837)

cisplatin	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Cisplatin	PROPN	O	I-Entity
treatment	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
adopted	VERB	O	O
in	ADP	O	O
some	DET	O	O
chemotherapies	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
drug	NOUN	O	O
can	VERB	O	O
induce	VERB	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
due	ADP	O	O
its	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
negatively	ADV	O	O
affect	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
augment	VERB	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
urea	NOUN	O	I-Entity
,	PUNCT	O	O
increase	VERB	O	O
the	DET	O	O
acute	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
score	NOUN	O	O
and	CCONJ	O	O
up	ADV	O	O
-	PUNCT	O	O
regulate	VERB	O	O
cytokines	NOUN	O	O
(	PUNCT	O	O
e.g.	ADV	O	O
,	PUNCT	O	O
IL-1b	PROPN	O	O
and	CCONJ	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
a	DET	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
inflammation	NOUN	O	I-Entity
process	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
cytokine	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
deletion	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
status	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
examine	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
in	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
challenged	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
WT	PROPN	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
after	ADP	O	O
cisplatin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

B2	NOUN	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
deficient	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
than	ADP	O	O
the	DET	O	O
WT	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
shown	VERB	O	O
by	ADP	O	O
reduced	ADJ	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
better	ADJ	O	O
preservation	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
down	ADP	O	O
regulation	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
cytokines	NOUN	O	O
and	CCONJ	O	O
less	ADV	O	O
acute	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
effectively	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
blood	NOUN	O	O
urea	NOUN	O	I-Entity
after	ADP	O	O
cisplatin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
by	ADP	O	O
mediating	VERB	O	O
the	DET	O	O
necrotic	ADJ	O	I-Entity
process	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
cytokines	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
resulting	VERB	O	O
in	ADP	O	O
declined	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
highlight	VERB	O	O
the	DET	O	O
kinin	NOUN	O	O
B2	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
amelioration	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cisplatin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (24999722)

Safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
intravitreal	NOUN	O	O
implant	NOUN	O	O
(	PUNCT	O	O
0.59	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
birdshot	NOUN	O	B-Entity
retinochoroidopathy	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
outcomes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
intravitreal	NOUN	O	O
implant	NOUN	O	O
(	PUNCT	O	O
0.59	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
birdshot	NOUN	O	B-Entity
retinochoroidopathy	VERB	O	I-Entity
whose	ADJ	O	O
disease	NOUN	O	O
is	VERB	O	O
refractory	ADJ	O	O
or	CCONJ	O	O
intolerant	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
immunomodulatory	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
retrospective	ADJ	O	O
case	NOUN	O	O
series	NOUN	O	O
involving	VERB	O	O
11	NUM	O	O
birdshot	NOUN	O	B-Entity
retinochoroidopathy	ADJ	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eleven	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
underwent	VERB	O	O
surgery	NOUN	O	O
for	ADP	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
implant	NOUN	O	O
(	PUNCT	O	O
0.59	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	PROPN	O	O
outcomes	NOUN	O	O
of	ADP	O	O
interest	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
implant	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
beyond	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Disease	NOUN	O	O
activity	NOUN	O	O
markers	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	O
inflammation	NOUN	O	I-Entity
,	PUNCT	O	O
evidence	NOUN	O	O
of	ADP	O	O
retinal	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
,	PUNCT	O	O
Swedish	ADJ	O	O
interactive	ADJ	O	O
threshold	NOUN	O	O
algorithm	NOUN	O	O
-	PUNCT	O	O
short	ADJ	O	O
wavelength	NOUN	O	O
automated	VERB	O	O
perimetry	NOUN	O	O
Humphrey	PROPN	O	O
visual	ADJ	O	O
field	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
electroretinographic	ADJ	O	O
parameters	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
optical	ADJ	O	O
coherence	NOUN	O	O
tomography	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
occurrence	NOUN	O	O
of	ADP	O	O
cataract	NOUN	O	I-Entity
and	CCONJ	O	O
raised	VERB	O	B-Entity
intraocular	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
were	VERB	O	O
collected	VERB	O	O
in	ADP	O	O
all	DET	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Intraocular	ADJ	O	O
inflammation	NOUN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
54.5	NUM	O	O
,	PUNCT	O	O
9.9	NUM	O	O
,	PUNCT	O	O
11.1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
beyond	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
the	DET	O	O
implant	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Active	ADJ	O	O
vasculitis	NOUN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
36.3%	NUM	O	O
patients	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
0%	NUM	O	O
at	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

More	ADJ	O	O
than	ADP	O	O
20%	NUM	O	O
(	PUNCT	O	O
47.61	NUM	O	O
-	PUNCT	O	O
67.2%	NUM	O	O
)	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
central	ADJ	O	O
retinal	ADJ	O	O
thickness	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
cystoid	NOUN	O	B-Entity
macular	ADJ	O	I-Entity
edema	NOUN	O	I-Entity
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
years	NOUN	O	O
postimplant	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
included	VERB	O	O
increased	ADJ	O	B-Entity
intraocular	ADJ	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	O
54.5%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cataract	ADJ	O	I-Entity
formation	NOUN	O	O
(	PUNCT	O	O
100%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
implant	NOUN	O	O
(	PUNCT	O	O
0.59	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
helps	VERB	O	O
to	PART	O	O
control	VERB	O	O
inflammation	NOUN	O	I-Entity
in	ADP	O	O
otherwise	ADV	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
refractory	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
birdshot	NOUN	O	B-Entity
retinochoroidopathy	ADJ	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
cataract	NOUN	O	I-Entity
and	CCONJ	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
requiring	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25006369)

Optimal	ADJ	O	O
precurarizing	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
to	PART	O	O
decrease	VERB	O	O
fasciculation	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
following	VERB	O	O
succinylcholine	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Succinylcholine	PROPN	O	I-Entity
commonly	ADV	O	O
produces	VERB	O	O
frequent	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
identified	VERB	O	O
the	DET	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
succinylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fasciculation	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
and	CCONJ	O	O
evaluated	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
speed	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
succinylcholine	NOUN	O	I-Entity
.	PUNCT	O	O

/	SYM	O	O
kg	ADV	O	O
rocuronium	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
precurarizing	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
succinylcholine	ADV	O	I-Entity

1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
the	DET	O	O
precurarization	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
assessed	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
fasciculations	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
myalgia	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
visible	ADJ	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
with	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
precurarizing	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Those	DET	O	O
of	ADP	O	O
myalgia	NOUN	O	I-Entity
tend	VERB	O	O
to	PART	O	O
decrease	VERB	O	O
according	VERB	O	O
to	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
precurarizing	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significance	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.072	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
onset	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
longer	ADV	O	O
with	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
precurarizing	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
rocuronium	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Precurarization	NOUN	O	O
with	ADP	O	O
0.04	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
rocuronium	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
considering	VERB	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
fasciculation	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
with	ADP	O	O
acceptable	ADJ	O	O
onset	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
precurarization	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25006961)

Absence	NOUN	O	O
of	ADP	O	O
PKC	PROPN	O	O
-	PUNCT	O	O
alpha	ADJ	O	O
attenuates	NOUN	O	O
lithium	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
effective	ADJ	O	O
antipsychotic	NOUN	O	O
,	PUNCT	O	O
induces	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	VERB	O	I-Entity
(	PUNCT	O	O
NDI	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
40%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
decreased	ADJ	O	O
capacity	NOUN	O	O
to	PART	O	O
concentrate	VERB	O	O
urine	NOUN	O	O
is	VERB	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
acutely	ADV	O	O
disrupting	VERB	O	O
the	DET	O	O
cAMP	PROPN	O	I-Entity
pathway	NOUN	O	O
and	CCONJ	O	O
chronically	ADV	O	O
reducing	VERB	O	O
urea	NOUN	O	I-Entity
transporter	NOUN	O	O
(	PUNCT	O	O
UT	PROPN	O	O
-	PUNCT	O	O
A1	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
water	NOUN	O	O
channel	NOUN	O	O
(	PUNCT	O	O
AQP2	PROPN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
inner	ADJ	O	O
medulla	NOUN	O	O
.	PUNCT	O	O

Targeting	VERB	O	O
an	DET	O	O
alternative	NOUN	O	O
signaling	VERB	O	O
pathway	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
PKC	PROPN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
signaling	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
.	PUNCT	O	O

)	PUNCT	O	O
controls	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
for	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
or	CCONJ	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
WT	PROPN	O	O
mice	NOUN	O	O
had	VERB	O	O
19-fold	NUM	O	O
increased	VERB	O	O
urine	NOUN	O	O
output	NOUN	O	O
whereas	ADP	O	O
treated	VERB	O	O
PKCa	NOUN	O	O
KO	PROPN	O	O
animals	NOUN	O	O
had	VERB	O	O
a	DET	O	O
4-fold	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
output	NOUN	O	O
.	PUNCT	O	O

AQP2	PUNCT	O	O
and	CCONJ	O	O
UT	PROPN	O	O
-	PUNCT	O	O
A1	PROPN	O	O
expression	NOUN	O	O
was	VERB	O	O
lowered	VERB	O	O
in	ADP	O	O
6	NUM	O	O
week	NOUN	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
WT	PROPN	O	O
animals	NOUN	O	O
whereas	ADP	O	O
in	ADP	O	O
treated	VERB	O	O
PKCa	NOUN	O	O
KO	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
AQP2	PROPN	O	O
was	VERB	O	O
only	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
2-fold	NUM	O	O
and	CCONJ	O	O
UT	PROPN	O	O
-	PUNCT	O	O
A1	PROPN	O	O
expression	NOUN	O	O
was	VERB	O	O
unaffected	ADJ	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
and	CCONJ	O	O
calcium	NOUN	O	I-Entity
were	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
fed	VERB	O	O
WT	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
fed	VERB	O	O
PKCa	NOUN	O	O
KO	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
ablation	NOUN	O	O
of	ADP	O	O
PKCa	NOUN	O	O
preserves	VERB	O	O
AQP2	PROPN	O	O
and	CCONJ	O	O
UT	PROPN	O	O
-	PUNCT	O	O
A1	PROPN	O	O
protein	NOUN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
localization	NOUN	O	O
in	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
NDI	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
prevents	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
severe	ADJ	O	O
polyuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25031906)

Is	VERB	O	O
Dysguesia	NOUN	O	I-Entity
Going	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
Rare	PROPN	O	O
or	CCONJ	O	O
a	DET	O	O
Common	PROPN	O	O
Side	PROPN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
Amlodipine	PROPN	O	I-Entity
?	PUNCT	O	O

A	DET	O	O
very	ADV	O	O
rare	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
amlodipine	NOUN	O	I-Entity
is	VERB	O	O
dysguesia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
about	ADP	O	O
a	DET	O	O
female	ADJ	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
on	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
amlodipine	NOUN	O	I-Entity
developed	VERB	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
taste	NOUN	O	I-Entity
sensation	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
amlodipine	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
dysguesia	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
presentation	NOUN	O	O
and	CCONJ	O	O
review	VERB	O	O
the	DET	O	O
relevant	ADJ	O	O
literature	NOUN	O	O
on	ADP	O	O
amlodipine	NOUN	O	I-Entity
and	CCONJ	O	O
dysguesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (25041770)

Rhabdomyolysis	NOUN	O	I-Entity
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
simvastatin	NOUN	O	I-Entity
and	CCONJ	O	O
dosage	NOUN	O	O
increment	NOUN	O	O
in	ADP	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

Clarithromycin	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
documented	VERB	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
3A4	PROPN	O	O
(	PUNCT	O	O
CYP3A4	PROPN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
to	PART	O	O
cause	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
interaction	NOUN	O	O
with	ADP	O	O
simvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
particular	ADJ	O	O
case	NOUN	O	O
is	VERB	O	O
of	ADP	O	O
interest	NOUN	O	O
as	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
only	ADV	O	O
occurred	VERB	O	O
after	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
raised	VERB	O	O
cardiac	ADJ	O	O
biomarkers	NOUN	O	O
without	ADP	O	O
any	DET	O	O
obvious	ADJ	O	O
cardiac	ADJ	O	O
issues	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
phenomenon	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
rhabdomyolysis	VERB	O	I-Entity
previously	ADV	O	O
.	PUNCT	O	O

To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
has	VERB	O	O
been	VERB	O	O
no	DET	O	O
reported	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
structure	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
muscle	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
need	VERB	O	O
to	PART	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
prescribing	VERB	O	O
concomitant	ADJ	O	O
medications	NOUN	O	O
that	ADJ	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
myopathy	NOUN	O	I-Entity
or	CCONJ	O	O
inhibit	VERB	O	O
the	DET	O	O
CYP3A4	PROPN	O	O
enzyme	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
case	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
troponin	NOUN	O	O
elevation	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
statin	NOUN	O	I-Entity
induced	VERB	O	O
rhabdomyolysis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
warrant	VERB	O	O
further	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25054547)

Val204Asp	PUNCT	O	O
)	PUNCT	O	O
causes	VERB	O	O
loss	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
and	CCONJ	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
with	ADP	O	O
suxamethonium	NOUN	O	I-Entity
.	PUNCT	O	O

Butyrylcholinesterase	PROPN	O	B-Entity
deficiency	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
relaxants	NOUN	O	O
(	PUNCT	O	O
suxamethonium	NOUN	O	I-Entity
or	CCONJ	O	O
mivacurium	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
mutations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BCHE	PROPN	O	O
gene	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
prolonged	ADJ	O	O
neuromuscular	ADJ	O	O
block	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
the	DET	O	O
discovery	NOUN	O	O
of	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
BCHE	PROPN	O	O
variant	NOUN	O	O
(	PUNCT	O	O
c.695T	ADJ	O	O
>	PROPN	O	O
A	PROPN	O	O
,	PUNCT	O	O
p	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
patient	ADJ	O	O
plasma	NOUN	O	O
butyrylcholinesterase	NOUN	O	O
with	ADP	O	O
butyrylthiocholine	NOUN	O	I-Entity
(	PUNCT	O	O
BTC	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
benzoylcholine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
values	NOUN	O	O
of	ADP	O	O
dibucaine	NOUN	O	I-Entity
and	CCONJ	O	O
fluoride	NOUN	O	I-Entity
numbers	NOUN	O	O
fit	VERB	O	O
with	ADP	O	O
heterozygous	ADJ	O	O
atypical	ADJ	O	O
silent	ADJ	O	O
genotype	NOUN	O	O
.	PUNCT	O	O

BChE	PROPN	O	O
displays	VERB	O	O
a	DET	O	O
pure	ADJ	O	O
Michaelian	ADJ	O	O
behavior	NOUN	O	O
with	ADP	O	O
BTC	PROPN	O	I-Entity
as	ADP	O	O
the	DET	O	O
substrate	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
catalytic	ADJ	O	O
parameters	NOUN	O	O
Km	PROPN	O	O
=	SYM	O	O
265	NUM	O	O
uM	NOUN	O	O
for	ADP	O	O
BTC	PROPN	O	I-Entity
,	PUNCT	O	O
two	NUM	O	O
times	NOUN	O	O
higher	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
atypical	ADJ	O	O
enzyme	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
low	ADJ	O	O
Vmax	PROPN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
against	ADP	O	O
suxamethonium	NOUN	O	I-Entity
.	PUNCT	O	O

Val204Asp	NOUN	O	O
is	VERB	O	O
disruption	NOUN	O	O
of	ADP	O	O
hydrogen	NOUN	O	I-Entity
bonding	NOUN	O	O
between	ADP	O	O
Gln223	PROPN	O	O
and	CCONJ	O	O
Glu441	PROPN	O	O
,	PUNCT	O	O
leading	VERB	O	O
Ser198	PROPN	O	O
and	CCONJ	O	O
His438	PROPN	O	O
to	PART	O	O
move	VERB	O	O
away	ADV	O	O
from	ADP	O	O
each	DET	O	O
other	ADJ	O	O
with	ADP	O	O
subsequent	ADJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
catalytic	ADJ	O	O
triad	NOUN	O	O
functionality	NOUN	O	O
regardless	ADV	O	O
of	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
substrate	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25071004)

Delayed	VERB	O	O
anemia	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
injectable	ADJ	O	O
artesunate	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Democratic	PROPN	O	O
Republic	PROPN	O	O
of	ADP	O	O
the	DET	O	O
Congo	PROPN	O	O
:	PUNCT	O	O
a	DET	O	O
manageable	ADJ	O	O
issue	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
of	ADP	O	O
delayed	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
injectable	ADJ	O	O
artesunate	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
current	ADJ	O	O
World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
(	PUNCT	O	O
WHO)-recommended	VERB	O	O
first	ADV	O	O
-	PUNCT	O	O
line	NOUN	O	O
drug	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
malaria	NOUN	O	I-Entity
.	PUNCT	O	O

>	X	O	O
5	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
followed	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
injectable	ADJ	O	O
artesunate	NOUN	O	I-Entity
for	ADP	O	O
severe	ADJ	O	O
malaria	NOUN	O	I-Entity
in	ADP	O	O
hospitals	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
centers	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Democratic	PROPN	O	O
Republic	PROPN	O	O
of	ADP	O	O
the	DET	O	O
Congo	PROPN	O	O
.	PUNCT	O	O

All	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
delayed	VERB	O	O
anemia	NOUN	O	I-Entity
were	VERB	O	O
clinically	ADV	O	O
manageable	ADJ	O	O
and	CCONJ	O	O
resolved	VERB	O	O
within	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25080425)

Regulation	NOUN	O	O
of	ADP	O	O
signal	NOUN	O	O
transducer	NOUN	O	O
and	CCONJ	O	O
activator	NOUN	O	O
of	ADP	O	O
transcription	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
apoptotic	ADJ	O	O
pathways	NOUN	O	O
by	ADP	O	O
betaine	NOUN	O	I-Entity
attenuates	NOUN	O	O
isoproterenol	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
cardioprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
betaine	NOUN	O	I-Entity
on	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
induced	VERB	O	O
experimentally	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
focusing	VERB	O	O
on	ADP	O	O
regulation	NOUN	O	O
of	ADP	O	O
signal	NOUN	O	O
transducer	NOUN	O	O
and	CCONJ	O	O
activator	NOUN	O	O
of	ADP	O	O
transcription	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
STAT3	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
apoptotic	ADJ	O	O
pathways	NOUN	O	O
as	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
mechanism	NOUN	O	O
underlying	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
betaine	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
orally	ADV	O	O
for	ADP	O	O
40	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
myocardial	ADJ	O	B-Entity
ischemic	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
85	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
for	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
betaine	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
marker	NOUN	O	O
enzyme	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
and	CCONJ	O	O
prevented	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	B-Entity
remodeling	NOUN	O	I-Entity
.	PUNCT	O	O

Western	ADJ	O	O
blot	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
phosphorylation	NOUN	O	O
of	ADP	O	O
STAT3	PROPN	O	O
was	VERB	O	O
maintained	VERB	O	O
or	CCONJ	O	O
further	ADV	O	O
enhanced	VERB	O	O
by	ADP	O	O
betaine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
myocardium	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
betaine	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
ventricular	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
Bcl-2	PROPN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
Bax	PROPN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
causing	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
Bcl-2/Bax	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
betaine	NOUN	O	I-Entity
on	ADP	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
further	ADV	O	O
confirmed	VERB	O	O
by	ADP	O	O
histopathological	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
betaine	NOUN	O	I-Entity
pretreatment	NOUN	O	O
attenuated	ADJ	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
via	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
STAT3	PROPN	O	O
and	CCONJ	O	O
apoptotic	ADJ	O	O
pathways	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25084821)

Quetiapine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neutropenia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
bipolar	ADJ	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Quetiapine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
dibenzothiazepine	NOUN	O	O
derivative	ADJ	O	O
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
clozapine	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
causing	VERB	O	O
blood	NOUN	O	B-Entity
dyscrasias	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
neutropenia	ADJ	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
some	DET	O	O
case	NOUN	O	O
reports	VERB	O	O
about	ADP	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
quetiapine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
are	VERB	O	O
seldom	ADV	O	O
discussed	VERB	O	O
and	CCONJ	O	O
identified	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
that	ADJ	O	O
developed	VERB	O	O
neutropenia	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
here	ADV	O	O
.	PUNCT	O	O

CASE	NOUN	O	O
REPORT	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
62-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Taiwanese	ADJ	O	O
widow	NOUN	O	O
with	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
at	ADP	O	O
age	NOUN	O	O
60	NUM	O	O
.	PUNCT	O	O

She	PRON	O	O
developed	VERB	O	O
leucopenia	NOUN	O	I-Entity
after	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
quetiapine	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
her	ADJ	O	O
white	ADJ	O	O
blood	NOUN	O	O
cell	NOUN	O	O
count	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Although	ADP	O	O
neutropenia	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
common	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
quetiapine	NOUN	O	I-Entity
,	PUNCT	O	O
physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
cautious	ADJ	O	O
about	ADP	O	O
its	ADJ	O	O
presentation	NOUN	O	O
and	CCONJ	O	O
associated	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
concomitant	ADJ	O	O
fever	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
diagnostic	ADJ	O	O
marker	NOUN	O	O
for	ADP	O	O
adverse	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
quetiapine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (25096313)

Lateral	ADJ	O	O
antebrachial	ADJ	O	O
cutaneous	ADJ	O	O
neuropathy	NOUN	O	I-Entity
after	ADP	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
at	ADP	O	O
lateral	ADJ	O	O
epicondyle	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
lateral	ADJ	O	O
antebrachial	ADJ	O	O
cutaneous	ADJ	O	O
neuropathy	NOUN	O	I-Entity
(	PUNCT	O	O
LACNP	PROPN	O	O
)	PUNCT	O	O
that	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
a	DET	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
epicondyle	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
lateral	ADJ	O	B-Entity
epicondylitis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
decreased	ADJ	O	O
sensation	NOUN	O	O
and	CCONJ	O	O
paresthesia	NOUN	O	I-Entity
over	ADP	O	O
her	ADJ	O	O
right	ADJ	O	O
lateral	ADJ	O	O
forearm	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
paresthesia	NOUN	O	I-Entity
had	VERB	O	O
occurred	VERB	O	O
after	ADP	O	O
a	DET	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
lateral	ADJ	O	O
epicondyle	NOUN	O	O
3	NUM	O	O
months	NOUN	O	O
before	ADV	O	O
.	PUNCT	O	O

Her	ADJ	O	O
sensation	NOUN	O	O
of	ADP	O	O
light	ADJ	O	O
touch	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
diminished	VERB	O	O
over	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
forearm	NOUN	O	O
and	CCONJ	O	O
wrist	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
LACNP	PROPN	O	O
that	ADJ	O	O
developed	VERB	O	O
after	ADP	O	O
a	DET	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
lateral	ADJ	O	B-Entity
epicondylitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (25119790)

Curcumin	NOUN	O	I-Entity
prevents	VERB	O	O
maleate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
relation	NOUN	O	O
to	ADP	O	O
hemodynamic	ADJ	O	O
alterations	NOUN	O	O
,	PUNCT	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
complex	NOUN	O	O
I.	NOUN	O	O
The	DET	O	O
potential	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dietary	ADJ	O	O
antioxidant	NOUN	O	O
curcumin	NOUN	O	I-Entity
(	PUNCT	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
Kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
against	ADP	O	O
the	DET	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maleate	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Tubular	ADJ	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
maleate	NOUN	O	I-Entity
(	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Maleate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
included	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
glucose	NOUN	O	I-Entity
,	PUNCT	O	O
sodium	NOUN	O	I-Entity
,	PUNCT	O	O
neutrophil	ADJ	O	O
gelatinase	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
lipocalin	NOUN	O	O
(	PUNCT	O	O
NGAL	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
N	PROPN	O	O
-	PUNCT	O	O
acetyl	PROPN	O	O
b	NOUN	O	O
-	PUNCT	O	O
D	NOUN	O	O
-	PUNCT	O	O
glucosaminidase	NOUN	O	O
(	PUNCT	O	O
NAG	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
upregulation	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
molecule	NOUN	O	O
(	PUNCT	O	O
KIM)-1	PROPN	O	O
,	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
and	CCONJ	O	O
claudin-2	ADJ	O	O
expression	NOUN	O	O
besides	ADP	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
cells	NOUN	O	O
on	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
Oxidative	ADJ	O	O
stress	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
the	DET	O	O
oxidation	NOUN	O	O
of	ADP	O	O
lipids	NOUN	O	O
and	CCONJ	O	O
proteins	NOUN	O	O
and	CCONJ	O	O
diminution	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
Nrf2	PROPN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Maleate	PROPN	O	I-Entity
induced	VERB	O	O
cell	NOUN	O	O
damage	NOUN	O	O
and	CCONJ	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
(	PUNCT	O	O
ROS	PROPN	O	O
)	PUNCT	O	O
production	NOUN	O	O
in	ADP	O	O
LLC	PROPN	O	O
-	PUNCT	O	O
PK1	PROPN	O	O
cells	NOUN	O	O
in	ADP	O	O
culture	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
maleate	ADJ	O	I-Entity
treatment	NOUN	O	O
reduced	VERB	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
in	ADP	O	O
ADP	PROPN	O	I-Entity
-	PUNCT	O	O
stimulated	VERB	O	O
mitochondria	NOUN	O	O
and	CCONJ	O	O
diminished	VERB	O	O
respiratory	ADJ	O	O
control	NOUN	O	O
index	NOUN	O	O
when	ADV	O	O
using	VERB	O	O
malate	NOUN	O	I-Entity
/	SYM	O	O
glutamate	NOUN	O	I-Entity
as	ADP	O	O
substrate	NOUN	O	O
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
above	ADJ	O	O
-	PUNCT	O	O
described	VERB	O	O
alterations	NOUN	O	O
were	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
curcumin	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
curcumin	NOUN	O	I-Entity
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
attenuate	VERB	O	O
in	ADP	O	O
vivo	NOUN	O	O
maleate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
cell	NOUN	O	O
damage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
protection	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
to	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
preservation	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
complex	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
in	ADP	O	O
vitro	ADJ	O	O
protection	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
to	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
ROS	PROPN	O	O
production	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25907210)

Incidence	PROPN	O	O
of	ADP	O	O
solid	ADJ	O	O
tumours	NOUN	O	I-Entity
among	ADP	O	O
pesticide	NOUN	O	O
applicators	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
organophosphate	ADJ	O	I-Entity
insecticide	NOUN	O	O
diazinon	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Agricultural	PROPN	O	O
Health	PROPN	O	O
Study	PROPN	O	O
:	PUNCT	O	O
an	DET	O	O
updated	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Diazinon	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
organophosphate	NOUN	O	I-Entity
insecticide	NOUN	O	O
with	ADP	O	O
genotoxic	NOUN	O	O
properties	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
previously	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Agricultural	PROPN	O	O
Health	PROPN	O	O
Study	PROPN	O	O
(	PUNCT	O	O
AHS	PROPN	O	O
)	PUNCT	O	O
cohort	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
few	ADJ	O	O
other	ADJ	O	O
epidemiological	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
examined	VERB	O	O
diazinon	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cancer	NOUN	O	I-Entity
risk	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
updated	VERB	O	O
diazinon	ADJ	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
cancer	NOUN	O	I-Entity
incidence	NOUN	O	O
information	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
solid	ADJ	O	O
tumour	ADJ	O	I-Entity
risk	NOUN	O	O
in	ADP	O	O
the	DET	O	O
AHS	PROPN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
pesticide	NOUN	O	O
applicators	NOUN	O	O
in	ADP	O	O
Iowa	PROPN	O	O
and	CCONJ	O	O
North	PROPN	O	O
Carolina	PROPN	O	O
reported	VERB	O	O
lifetime	NOUN	O	O
diazinon	NOUN	O	I-Entity
use	NOUN	O	O
at	ADP	O	O
enrolment	NOUN	O	O
(	PUNCT	O	O
1993	NUM	O	O
-	SYM	O	O
1997	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
(	PUNCT	O	O
1998	NUM	O	O
-	SYM	O	O
2005	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
cancer	NOUN	O	I-Entity
incidence	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
through	ADP	O	O
2010(North	NUM	O	O
Carolina)/2011(Iowa	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
applicators	NOUN	O	O
with	ADP	O	O
usage	NOUN	O	O
information	NOUN	O	O
sufficient	ADJ	O	O
to	PART	O	O
evaluate	VERB	O	O
exposure	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
patterns	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
used	VERB	O	O
Poisson	PROPN	O	O
regression	NOUN	O	O
to	PART	O	O
estimate	VERB	O	O
adjusted	VERB	O	O
rate	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
RRs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
95%	NUM	O	O
CI	NOUN	O	O
for	ADP	O	O
cancer	NOUN	O	I-Entity
sites	NOUN	O	O
with	ADP	O	O
>	SYM	O	O
10	NUM	O	O
exposed	VERB	O	O
cases	NOUN	O	O
for	ADP	O	O
both	DET	O	O
lifetime	NOUN	O	O
(	PUNCT	O	O
LT	PROPN	O	O
)	PUNCT	O	O
exposure	NOUN	O	O
days	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
(	PUNCT	O	O
IW	PROPN	O	O
)	PUNCT	O	O
lifetime	NOUN	O	O
exposure	NOUN	O	O
days	NOUN	O	O
(	PUNCT	O	O
accounting	VERB	O	O
for	ADP	O	O
factors	NOUN	O	O
impacting	VERB	O	O
exposure	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
elevated	ADJ	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
risks	NOUN	O	O
(	PUNCT	O	O
N=283	PROPN	O	O
)	PUNCT	O	O
among	ADP	O	O
applicators	NOUN	O	O
with	ADP	O	O
the	DET	O	O
greatest	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
LT	PROPN	O	O
(	PUNCT	O	O
RR=1.60	PROPN	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.11	NUM	O	O
to	ADP	O	O
2.31	NUM	O	O
;	PUNCT	O	O
Ptrend=0.02	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
IW	PROPN	O	O
days	NOUN	O	O
of	ADP	O	O
diazinon	NOUN	O	I-Entity
use	NOUN	O	O
(	PUNCT	O	O
RR=1.41	PROPN	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.98	NUM	O	O
to	ADP	O	O
2.04	NUM	O	O
;	PUNCT	O	O
Ptrend=0.08	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Kidney	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
N=94	PROPN	O	O
)	PUNCT	O	O

risks	NOUN	O	O
were	VERB	O	O
non	ADV	O	O
-	PUNCT	O	O
significantly	ADV	O	O
elevated	ADJ	O	O
(	PUNCT	O	O
RRLT	PROPN	O	O
days=1.77	PROPN	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.90	NUM	O	O
to	ADP	O	O
3.51	NUM	O	O
;	PUNCT	O	O
Ptrend=0.09	PROPN	O	O
;	PUNCT	O	O
RRIW	PROPN	O	O
days	NOUN	O	O
1.37	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.64	NUM	O	O
to	ADP	O	O
2.92	NUM	O	O
;	PUNCT	O	O
Ptrend=0.50	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADP	O	O
were	VERB	O	O
risks	NOUN	O	O
for	ADP	O	O
aggressive	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
N=656	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
updated	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
diazinon	NOUN	O	I-Entity
provides	VERB	O	O
additional	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
an	DET	O	O
association	NOUN	O	O
with	ADP	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
risk	NOUN	O	O
.	PUNCT	O	O

Newly	ADV	O	O
identified	VERB	O	O
links	NOUN	O	O
to	ADP	O	O
kidney	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
associations	NOUN	O	O
with	ADP	O	O
aggressive	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
require	VERB	O	O
further	ADJ	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25951420)

Associations	NOUN	O	O
of	ADP	O	O
Ozone	NOUN	O	I-Entity
and	CCONJ	O	O
PM2.5	ADJ	O	O
Concentrations	NOUN	O	O
With	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Among	PROPN	O	O
Participants	PROPN	O	O
in	ADP	O	O
the	DET	O	O
Agricultural	PROPN	O	O
Health	PROPN	O	O
Study	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
describes	VERB	O	O
associations	NOUN	O	O
of	ADP	O	O
ozone	NOUN	O	I-Entity
and	CCONJ	O	O
fine	ADJ	O	O
particulate	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
observed	VERB	O	O
among	ADP	O	O
farmers	NOUN	O	O
in	ADP	O	O
North	PROPN	O	O
Carolina	PROPN	O	O
and	CCONJ	O	O
Iowa	PROPN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
used	VERB	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
associations	NOUN	O	O
of	ADP	O	O
these	DET	O	O
pollutants	NOUN	O	O
with	ADP	O	O
self	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
,	PUNCT	O	O
doctor	NOUN	O	O
-	PUNCT	O	O
diagnosed	VERB	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
positive	ADJ	O	O
associations	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
ozone	NOUN	O	I-Entity
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
=	SYM	O	O
1.39	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.98	NUM	O	O
to	ADP	O	O
1.98	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fine	ADJ	O	O
particulate	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
=	SYM	O	O
1.34	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.93	NUM	O	O
to	ADP	O	O
1.93	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
North	PROPN	O	O
Carolina	PROPN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
Iowa	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
plausibility	NOUN	O	O
of	ADP	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ambient	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
these	DET	O	O
pollutants	NOUN	O	O
on	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
risk	NOUN	O	O
is	VERB	O	O
supported	VERB	O	O
by	ADP	O	O
experimental	ADJ	O	O
data	NOUN	O	O
demonstrating	VERB	O	O
damage	NOUN	O	O
to	ADP	O	O
dopaminergic	ADJ	O	O
neurons	NOUN	O	O
at	ADP	O	O
relevant	ADJ	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (25986755)

Low	ADJ	O	O
functional	ADJ	O	O
programming	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
AT2R	PROPN	O	O
mediates	VERB	O	O
the	DET	O	O
developmental	ADJ	O	O
origin	NOUN	O	O
of	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
prenatal	ADJ	O	O
caffeine	NOUN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

UNASSIGNED	PROPN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
previous	ADJ	O	O
study	NOUN	O	O
has	VERB	O	O
indicated	VERB	O	O
that	ADP	O	O
prenatal	ADJ	O	O
caffeine	NOUN	O	I-Entity
exposure	NOUN	O	O
(	PUNCT	O	O
PCE	PROPN	O	O
)	PUNCT	O	O
could	VERB	O	O
induce	VERB	O	O
intrauterine	ADJ	O	B-Entity
growth	NOUN	O	I-Entity
retardation	NOUN	O	I-Entity
(	PUNCT	O	O
IUGR	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
offspring	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
research	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
IUGR	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
whether	ADP	O	O
PCE	PROPN	O	O
could	VERB	O	O
induce	VERB	O	O
glomerulosclerosis	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
underlying	ADJ	O	O
mechanisms	NOUN	O	O
remain	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
induction	NOUN	O	O
to	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
by	ADP	O	O
PCE	PROPN	O	O
and	CCONJ	O	O
its	ADJ	O	O
intrauterine	ADJ	O	O
programming	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
IUGR	PROPN	O	I-Entity
was	VERB	O	O
established	VERB	O	O
by	ADP	O	O
PCE	PROPN	O	O
,	PUNCT	O	O
male	ADJ	O	O
fetuses	NOUN	O	O
and	CCONJ	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
at	ADP	O	O
the	DET	O	O
age	NOUN	O	O
of	ADP	O	O
postnatal	ADJ	O	O
week	NOUN	O	O
24	NUM	O	O
were	VERB	O	O
euthanized	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
kidneys	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PCE	PROPN	O	O
group	NOUN	O	O
exhibited	VERB	O	O
glomerulosclerosis	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
interstitial	ADJ	O	B-Entity
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
accompanied	VERB	O	O
by	ADP	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
urine	NOUN	O	O
protein	NOUN	O	O
.	PUNCT	O	O

Renal	PROPN	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
type	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
AT2R	PROPN	O	O
)	PUNCT	O	O
gene	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
PCE	PROPN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
type	NOUN	O	O
1a	NOUN	O	O
(	PUNCT	O	O
AT1aR)/AT2R	ADJ	O	O
expression	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
AT2R	PROPN	O	O
gene	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
expressions	NOUN	O	O
in	ADP	O	O
fetal	ADJ	O	O
kidneys	NOUN	O	O
were	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
PCE	PROPN	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
repression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
gene	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
glial	ADJ	O	O
-	PUNCT	O	O
cell	NOUN	O	O
-	PUNCT	O	O
line	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
neurotrophic	ADJ	O	O
factor	NOUN	O	O
(	PUNCT	O	O
GDNF)/tyrosine	PROPN	O	I-Entity
kinase	NOUN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
c	NOUN	O	O
-	PUNCT	O	O
Ret	PROPN	O	O
)	PUNCT	O	O
signaling	VERB	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
PCE	PROPN	O	O
could	VERB	O	O
induce	VERB	O	O
dysplasia	NOUN	O	B-Entity
of	ADP	O	I-Entity
fetal	ADJ	O	I-Entity
kidneys	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
of	ADP	O	O
adult	NOUN	O	O
offspring	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
low	ADJ	O	O
functional	ADJ	O	O
programming	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
AT2R	PROPN	O	O
might	VERB	O	O
mediate	VERB	O	O
the	DET	O	O
developmental	ADJ	O	O
origin	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
glomerulosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (26002693)

1,3-Butadiene	NUM	O	I-Entity
,	PUNCT	O	O
CML	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
t(9:22	NOUN	O	O
)	PUNCT	O	O

Epidemiological	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
1,3-butadiene	NUM	O	I-Entity
have	VERB	O	O
suggest	ADJ	O	O
that	ADP	O	O
exposures	NOUN	O	O
to	ADP	O	O
humans	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
myeloid	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
CML	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

CML	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
documented	VERB	O	O
association	NOUN	O	O
with	ADP	O	O
ionizing	VERB	O	O
radiation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
reports	NOUN	O	O
of	ADP	O	O
associations	NOUN	O	O
with	ADP	O	O
chemical	ADJ	O	O
exposures	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
questioned	VERB	O	O
.	PUNCT	O	O

Ionizing	VERB	O	O
radiation	NOUN	O	O
is	VERB	O	O
capable	ADJ	O	O
of	ADP	O	O
inducing	VERB	O	O
the	DET	O	O
requisite	ADJ	O	O
CML	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
t(9:22	NOUN	O	O
)	PUNCT	O	O

translocation	NOUN	O	O
(	PUNCT	O	O
Philadelphia	PROPN	O	B-Entity
chromosome	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
appropriate	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O

We	PRON	O	O
have	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
1,3-butadiene	NUM	O	I-Entity
metabolites	NOUN	O	O
be	VERB	O	O
so	ADV	O	O
tested	VERB	O	O
as	ADP	O	O
a	DET	O	O
reality	NOUN	O	O
check	NOUN	O	O
on	ADP	O	O
the	DET	O	O
epidemiological	ADJ	O	O
reports	NOUN	O	O
.	PUNCT	O	O

Conditions	NOUN	O	O
that	ADJ	O	O
will	VERB	O	O
be	VERB	O	O
required	VERB	O	O
for	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
1,3-butadiene	NUM	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (26033014)

Cancer	NOUN	O	I-Entity
incidence	NOUN	O	O
and	CCONJ	O	O
metolachlor	NOUN	O	I-Entity
use	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Agricultural	PROPN	O	O
Health	PROPN	O	O
Study	PROPN	O	O
:	PUNCT	O	O

Metolachlor	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
herbicide	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
a	DET	O	O
Group	PROPN	O	O
C	PROPN	O	O
carcinogen	NOUN	O	O
by	ADP	O	O
the	DET	O	O
U.S.	PROPN	O	O
Environmental	PROPN	O	O
Protection	PROPN	O	O
Agency	PROPN	O	O
based	VERB	O	O
on	ADP	O	O
increased	VERB	O	O
liver	NOUN	O	B-Entity
neoplasms	NOUN	O	I-Entity
in	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Epidemiologic	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
health	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
metolachlor	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
cancer	NOUN	O	I-Entity
incidence	NOUN	O	O
through	ADP	O	O
2010/2011	NUM	O	O
(	PUNCT	O	O
NC	PROPN	O	O
/	SYM	O	O
IA	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
49,616	NUM	O	O
applicators	NOUN	O	O
,	PUNCT	O	O
53%	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
reported	VERB	O	O
ever	ADV	O	O
using	VERB	O	O
metolachlor	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
Poisson	PROPN	O	O
regression	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
relations	NOUN	O	O
between	ADP	O	O
two	NUM	O	O
metrics	NOUN	O	O
of	ADP	O	O
metolachlor	NOUN	O	I-Entity
use	NOUN	O	O
(	PUNCT	O	O
lifetime	NOUN	O	O
days	NOUN	O	O
,	PUNCT	O	O
intensity	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
lifetime	NOUN	O	O
days	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cancer	NOUN	O	I-Entity
incidence	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
saw	VERB	O	O
no	DET	O	O
association	NOUN	O	O
between	ADP	O	O
metolachlor	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
all	DET	O	O
cancers	NOUN	O	I-Entity
combined	VERB	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
5,701	NUM	O	O
with	ADP	O	O
a	DET	O	O
5-year	NUM	O	O
lag	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
most	ADJ	O	O
site	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
cancers	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
liver	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
analyses	NOUN	O	O
restricted	VERB	O	O
to	ADP	O	O
exposed	VERB	O	O
workers	NOUN	O	O
,	PUNCT	O	O
elevations	NOUN	O	O
observed	VERB	O	O
at	ADP	O	O
higher	ADJ	O	O
categories	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
trends	NOUN	O	O
for	ADP	O	O
both	DET	O	O
lifetime	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
lifetime	NOUN	O	O
days	NOUN	O	O
of	ADP	O	O
metolachor	NOUN	O	I-Entity
use	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
and	CCONJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
with	ADP	O	O
an	DET	O	O
unexposed	ADJ	O	O
reference	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
similar	ADJ	O	O
pattern	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
follicular	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
lymphoma	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
other	ADJ	O	O
lymphoma	NOUN	O	I-Entity
subtypes	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
earlier	ADJ	O	O
suggestion	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
risk	NOUN	O	O
at	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
metolachlor	NOUN	O	I-Entity
use	NOUN	O	O
in	ADP	O	O
this	DET	O	O
cohort	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
confirmed	VERB	O	O
in	ADP	O	O
this	DET	O	O
update	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
suggestion	NOUN	O	O
of	ADP	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
metolachlor	NOUN	O	I-Entity
and	CCONJ	O	O
liver	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
among	ADP	O	O
pesticide	NOUN	O	O
applicators	NOUN	O	O
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
finding	NOUN	O	O
and	CCONJ	O	O
echoes	VERB	O	O
observation	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
liver	NOUN	O	B-Entity
neoplasms	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
animal	NOUN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
findings	NOUN	O	O
for	ADP	O	O
both	DET	O	O
liver	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
follicular	ADJ	O	O
cell	NOUN	O	O
lymphoma	NOUN	O	I-Entity
warrant	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
to	PART	O	O
better	ADV	O	O
differentiate	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
metolachlor	NOUN	O	I-Entity
use	NOUN	O	O
from	ADP	O	O
other	ADJ	O	O
factors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (26115410)

Mechanisms	NOUN	O	O
Underlying	VERB	O	O
Latent	PROPN	O	O
Disease	PROPN	O	O
Risk	PROPN	O	O
Associated	PROPN	O	O
with	ADP	O	O
Early	PROPN	O	O
-	PUNCT	O	O
Life	PROPN	O	O
Arsenic	PROPN	O	I-Entity

Millions	NOUN	O	O
of	ADP	O	O
individuals	NOUN	O	O
worldwide	ADV	O	O
,	PUNCT	O	O
particularly	ADV	O	O
those	DET	O	O
living	VERB	O	O
in	ADP	O	O
rural	ADJ	O	O
and	CCONJ	O	O
developing	VERB	O	O
areas	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
harmful	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
inorganic	ADJ	O	B-Entity
arsenic	NOUN	O	I-Entity
(	PUNCT	O	O
iAs	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
their	ADJ	O	O
drinking	NOUN	O	O
water	NOUN	O	O
.	PUNCT	O	O

Inorganic	ADJ	O	B-Entity
As	ADP	O	I-Entity
exposure	NOUN	O	O
during	ADP	O	O
key	ADJ	O	O
developmental	ADJ	O	O
periods	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
health	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
those	DET	O	O
that	ADJ	O	O
are	VERB	O	O
evident	ADJ	O	O
in	ADP	O	O
adulthood	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
considerable	ADJ	O	O
interest	NOUN	O	O
in	ADP	O	O
identifying	VERB	O	O
the	DET	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
that	ADJ	O	O
relate	VERB	O	O
early	ADV	O	O
-	PUNCT	O	O
life	NOUN	O	O
iAs	PROPN	O	I-Entity
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
these	DET	O	O
latent	ADJ	O	O
diseases	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
relationship	NOUN	O	O
to	ADP	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
summarizes	VERB	O	O
research	NOUN	O	O
on	ADP	O	O
the	DET	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
that	ADJ	O	O
underlie	VERB	O	O
the	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	I-Entity
development	NOUN	O	O
in	ADP	O	O
adulthood	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
early	ADJ	O	O
-	PUNCT	O	O
life	NOUN	O	O
iAs	PROPN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Epigenetic	ADJ	O	O
reprogramming	NOUN	O	O
that	ADJ	O	O
imparts	VERB	O	O
functional	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
gene	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	I-Entity
stem	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
immunomodulation	NOUN	O	O
are	VERB	O	O
plausible	ADJ	O	O
underlying	ADJ	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
early	ADV	O	O
-	PUNCT	O	O
life	NOUN	O	O
iAs	NOUN	O	I-Entity
exposure	NOUN	O	O
elicits	VERB	O	O
latent	ADJ	O	O
carcinogenic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Evidence	NOUN	O	O
is	VERB	O	O
mounting	VERB	O	O
that	DET	O	O
relates	VERB	O	O
early	ADJ	O	O
-	PUNCT	O	O
life	NOUN	O	O
iAs	PROPN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
cancer	NOUN	O	I-Entity
development	NOUN	O	O
later	ADV	O	O
in	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (44072)

On	ADP	O	O
the	DET	O	O
antiarrhythmic	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
N	NOUN	O	O
-	PUNCT	O	O
substituted	VERB	O	O
piperazine	NOUN	O	I-Entity
derivative	NOUN	O	O
of	ADP	O	O
trans-2-amino-3-hydroxy-1	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
2	NUM	O	I-Entity
,	PUNCT	O	I-Entity
3	NUM	O	I-Entity
,	PUNCT	O	I-Entity
4-tetrahydroanaphthalene	NUM	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
antiarrhythmic	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
compound	NOUN	O	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	NUM	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
referred	VERB	O	O
to	ADP	O	O
as	ADV	O	O
P11	PROPN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
studied	VERB	O	O
on	ADP	O	O
anaesthesized	VERB	O	O
cats	NOUN	O	O
and	CCONJ	O	O
Wistar	PROPN	O	O
albino	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
on	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
anaesthesized	VERB	O	O
rabbits	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
types	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
arrhythmia	NOUN	O	I-Entity
are	VERB	O	O
used	VERB	O	O
--	PUNCT	O	O
with	ADP	O	O
BaCl2	PROPN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
chloroform	NOUN	O	I-Entity
-	PUNCT	O	O
adrenaline	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
strophantine	NOUN	O	B-Entity
G	PROPN	O	I-Entity
and	CCONJ	O	O
with	ADP	O	O
aconitine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
compound	NOUN	O	O
P11	PROPN	O	I-Entity
is	VERB	O	O
introduced	VERB	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
0.25	NUM	O	O
and	CCONJ	O	O
0.50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
intravenously	ADV	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
orally	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
compound	NOUN	O	O
manifests	VERB	O	O
antiarrhythmic	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
all	DET	O	O
models	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
arrhythmia	NOUN	O	I-Entity
used	VERB	O	O
,	PUNCT	O	O
causing	VERB	O	O
greatest	ADJ	O	O
inhibition	NOUN	O	O
on	ADP	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
chloroform	NOUN	O	I-Entity
-	PUNCT	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
in	ADP	O	O
90	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
BaCl2	PROPN	O	I-Entity
(	PUNCT	O	O
in	ADP	O	O
84	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (753803)

Experimental	ADJ	O	O
progressive	ADJ	O	O
muscular	ADJ	O	B-Entity
dystrophy	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
anabolizing	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
are	VERB	O	O
still	ADV	O	O
a	DET	O	O
long	ADJ	O	O
way	NOUN	O	O
from	ADP	O	O
discovering	VERB	O	O
an	DET	O	O
unequivocal	ADJ	O	O
pathogenetic	ADJ	O	O
interpretation	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
muscular	ADJ	O	B-Entity
dystrophy	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Myopathy	PROPN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
lack	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
and	CCONJ	O	O
myopathy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
certain	ADJ	O	O
viruses	NOUN	O	O
have	VERB	O	O
much	ADJ	O	O
in	ADP	O	O
common	ADJ	O	O
anatomically	ADV	O	O
and	CCONJ	O	O
pathologically	ADV	O	O
with	ADP	O	O
the	DET	O	O
human	ADJ	O	O
form	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
induced	VERB	O	O
myodystrophy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
by	ADP	O	O
giving	VERB	O	O
it	PRON	O	O
a	DET	O	O
diet	NOUN	O	O
lacking	VERB	O	O
in	ADP	O	O
vitamin	NOUN	O	B-Entity
E.	NOUN	O	I-Entity
The	DET	O	O
pharmacological	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
degenerative	ADJ	O	O
changes	NOUN	O	O
brought	VERB	O	O
about	ADV	O	O
by	ADP	O	O
its	ADJ	O	O
deficiency	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
the	DET	O	O
muscles	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
illustrated	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
thus	ADV	O	O
confirmed	VERB	O	O
that	ADP	O	O
the	DET	O	O
histological	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
myopathic	ADJ	O	I-Entity
rat	NOUN	O	O
muscle	NOUN	O	O
induced	VERB	O	O
experimentally	ADV	O	O
are	VERB	O	O
extraordinarily	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
human	ADJ	O	O
myopathy	NOUN	O	I-Entity
as	ADP	O	O
confirmed	VERB	O	O
during	ADP	O	O
biopsies	NOUN	O	O
performed	VERB	O	O
at	ADP	O	O
the	DET	O	O
Orthopaedic	PROPN	O	O
Traumatological	PROPN	O	O
Centre	PROPN	O	O
,	PUNCT	O	O
Florence	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
encouraging	ADJ	O	O
results	NOUN	O	O
obtained	VERB	O	O
in	ADP	O	O
various	ADJ	O	O
authoratative	ADJ	O	O
departments	NOUN	O	O
in	ADP	O	O
myopathic	ADJ	O	I-Entity
patients	NOUN	O	O
by	ADP	O	O
using	VERB	O	O
anabolizing	VERB	O	O
steroids	NOUN	O	I-Entity
have	VERB	O	O
encouraged	VERB	O	O
the	DET	O	O
authors	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
anabolizing	VERB	O	O
agent	NOUN	O	O
(	PUNCT	O	O
Dianabol	PROPN	O	I-Entity
,	PUNCT	O	O
CIBA	PROPN	O	I-Entity
)	PUNCT	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
rendered	VERB	O	O
myopathic	ADJ	O	I-Entity
by	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
deficient	NOUN	O	O
in	ADP	O	O
vitamin	NOUN	O	B-Entity
E.	PROPN	O	I-Entity

In	ADP	O	O
this	DET	O	O
way	NOUN	O	O
they	PRON	O	O
obtained	VERB	O	O
appreciable	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
increased	VERB	O	O
from	ADP	O	O
50	NUM	O	O
to	ADP	O	O
70	NUM	O	O
g	NOUN	O	O
after	ADP	O	O
forty	NOUN	O	O
days	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
of	ADP	O	O
anabolizing	VERB	O	O
agent	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
most	ADJ	O	O
of	ADP	O	O
all	DET	O	O
they	PRON	O	O
found	VERB	O	O
histological	ADJ	O	O
changes	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
"	PUNCT	O	O
regenerative	ADJ	O	O
"	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
muscle	NOUN	O	O
tissue	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
however	ADV	O	O
maintained	VERB	O	O
its	ADJ	O	O
myopathic	ADJ	O	I-Entity
characteristics	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
animals	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
not	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
anabolizing	VERB	O	O
agent	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
conclude	VERB	O	O
by	ADP	O	O
affirming	VERB	O	O
the	DET	O	O
undoubted	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anabolizing	NOUN	O	O
steroids	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
myopathic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
they	PRON	O	O
have	VERB	O	O
reservations	NOUN	O	O
as	ADP	O	O
to	ADP	O	O
the	DET	O	O
transfer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
results	NOUN	O	O
into	ADP	O	O
the	DET	O	O
human	ADJ	O	O
field	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
high	ADJ	O	O
dosage	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
carried	VERB	O	O
out	PART	O	O
continuously	ADV	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
on	ADP	O	O
virility	NOUN	O	O
;	PUNCT	O	O
because	ADP	O	O
the	DET	O	O
tissue	NOUN	O	O
injury	NOUN	O	O
too	ADV	O	O
often	ADV	O	O
occurs	VERB	O	O
at	ADP	O	O
an	DET	O	O
irreversible	ADJ	O	O
stage	NOUN	O	O
vis	X	O	O
-	PUNCT	O	O
a	X	O	O
-	PUNCT	O	O
vis	X	O	O
the	DET	O	O
"	PUNCT	O	O
regeneration	NOUN	O	O
"	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
muscle	NOUN	O	O
tissue	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
finally	ADV	O	O
because	ADP	O	O
the	DET	O	O
dystrophic	ADJ	O	O
injurious	ADJ	O	O
agent	NOUN	O	O
is	VERB	O	O
certainly	ADV	O	O
not	ADV	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
but	CCONJ	O	O
something	NOUN	O	O
as	ADP	O	O
yet	ADV	O	O
unknown	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (920167)

Fetal	ADJ	O	O
risks	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
warfarin	NOUN	O	I-Entity
therapy	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
mothers	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	O
valve	NOUN	O	O
prosthesis	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
a	DET	O	O
caesarean	ADJ	O	O
section	NOUN	O	O
was	VERB	O	O
done	VERB	O	O
one	NUM	O	O
week	NOUN	O	O
after	ADP	O	O
replacement	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
with	ADP	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
baby	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
pulmonary	ADJ	O	I-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
baby	NOUN	O	O
showed	VERB	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
embryopathy	NOUN	O	I-Entity
with	ADP	O	O
nasal	ADJ	O	B-Entity
hypoplasia	NOUN	O	I-Entity
and	CCONJ	O	O
stippled	VERB	O	B-Entity
epiphyses	NOUN	O	I-Entity
(	PUNCT	O	O
chondrodysplasia	NOUN	O	B-Entity
punctata	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Nasal	PROPN	O	B-Entity
hypoplasia	NOUN	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
stippled	VERB	O	B-Entity
epiphyses	NOUN	O	I-Entity
has	VERB	O	O
now	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
11	NUM	O	O
infants	NOUN	O	O
born	VERB	O	O
to	ADP	O	O
mothers	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trimester	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
causal	ADJ	O	O
association	NOUN	O	O
is	VERB	O	O
probable	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (1451544)

Isradipine	ADJ	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
general	ADJ	O	O
practice	NOUN	O	O
in	ADP	O	O
Hong	PROPN	O	O
Kong	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
6-week	NOUN	O	O
open	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
isradipine	ADJ	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
general	ADJ	O	O
practice	NOUN	O	O
in	ADP	O	O
Hong	PROPN	O	O
Kong	PROPN	O	O
.	PUNCT	O	O

303	NUM	O	O
Chinese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	PART	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	I-Entity
entered	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
were	VERB	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
,	PUNCT	O	O
palpitation	NOUN	O	I-Entity
and	CCONJ	O	O
flushing	NOUN	O	I-Entity
and	CCONJ	O	O
these	DET	O	O
were	VERB	O	O
not	ADV	O	O
more	ADV	O	O
frequent	ADJ	O	O
than	ADP	O	O
reported	VERB	O	O
in	ADP	O	O
other	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
isradipine	NOUN	O	I-Entity
or	CCONJ	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
reductions	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
standing	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
postural	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2782734)

Tachyphylaxis	PROPN	O	O
to	ADP	O	O
systemic	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
to	PART	O	O
airway	VERB	O	O
responses	NOUN	O	O
during	ADP	O	O
prolonged	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	I-Entity
in	ADP	O	O
asthmatics	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	I-Entity
produce	VERB	O	O
substantial	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
airway	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
asthma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
systemic	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
responses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
tachyphylaxis	NOUN	O	O
occurs	VERB	O	O
during	ADP	O	O
prolonged	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	I-Entity
.	PUNCT	O	O

Twelve	NUM	O	O
asthmatic	ADJ	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
FEV1	PROPN	O	O
,	PUNCT	O	O
81	NUM	O	O

were	VERB	O	O
given	VERB	O	O
a	DET	O	O
14-day	NUM	O	O
treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	I-Entity
(	PUNCT	O	O
HDS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4,000	NUM	O	O
micrograms	NOUN	O	O
daily	ADV	O	O
,	PUNCT	O	O
low	ADJ	O	O
dose	NOUN	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	I-Entity
(	PUNCT	O	O
LDS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
800	NUM	O	O
micrograms	NOUN	O	O
daily	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
PI	PROPN	O	O
)	PUNCT	O	O
by	ADP	O	O
metered	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
inhaler	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
crossover	ADJ	O	O
design	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
14-day	NUM	O	O
run	NOUN	O	O
-	PUNCT	O	O
in	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
washout	NOUN	O	O
periods	NOUN	O	O
,	PUNCT	O	O
inhaled	VERB	O	O
beta	NOUN	O	O
-	PUNCT	O	O
agonists	NOUN	O	O
were	VERB	O	O
withheld	VERB	O	O
and	CCONJ	O	O
ipratropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
was	VERB	O	O
substituted	VERB	O	O
for	ADP	O	O
rescue	NOUN	O	O
purposes	NOUN	O	O
.	PUNCT	O	O

chronotropic	NOUN	O	O
(	PUNCT	O	O
HR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
metabolic	NOUN	O	O
(	PUNCT	O	O
K	PROPN	O	I-Entity
,	PUNCT	O	O
Glu	PROPN	O	I-Entity
)	PUNCT	O	O
responses	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
each	DET	O	O
step	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
100	NUM	O	O
to	ADP	O	O
4,000	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DRC	NOUN	O	O
for	ADP	O	O
HR	PROPN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
K	PROPN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Glu	PROPN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.005	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
attenuated	ADJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
HDS	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
PI	PROPN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
also	ADV	O	O
differences	NOUN	O	O
between	ADP	O	O
HDS	PROPN	O	O
and	CCONJ	O	O
LDS	PROPN	O	O
for	ADP	O	O
HR	PROPN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Glu	PROPN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
responses	NOUN	O	O
.	PUNCT	O	O

Frequency	PROPN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
subjective	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
reduced	VERB	O	O
after	ADP	O	O
HDS	PROPN	O	O
:	PUNCT	O	O
tremor	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
palpitations	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001).(ABSTRACT	NUM	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (2983630)

Increased	VERB	O	O
anxiogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
panic	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
behavioral	ADJ	O	O
ratings	NOUN	O	O
,	PUNCT	O	O
somatic	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
3-methoxy-4-hydroxyphenethyleneglycol	NUM	O	I-Entity
(	PUNCT	O	O
MHPG	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cortisol	NOUN	O	I-Entity
were	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
17	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
21	NUM	O	O
patients	NOUN	O	O
meeting	VERB	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
III	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
agoraphobia	NOUN	O	I-Entity
with	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
or	CCONJ	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Caffeine	NOUN	O	I-Entity
produced	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
subject	NOUN	O	O
-	PUNCT	O	O
rated	VERB	O	O
anxiety	NOUN	O	I-Entity
,	PUNCT	O	O
nervousness	NOUN	O	O
,	PUNCT	O	O
fear	NOUN	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
palpitations	NOUN	O	I-Entity
,	PUNCT	O	O
restlessness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
tremors	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
symptoms	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
plasma	NOUN	O	O
caffeine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Seventy	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
reported	VERB	O	O
that	ADP	O	O
the	DET	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
experienced	VERB	O	O
during	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
.	PUNCT	O	O

Caffeine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
plasma	NOUN	O	O
MHPG	PROPN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
or	CCONJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Caffeine	NOUN	O	I-Entity
increased	VERB	O	O
plasma	NOUN	O	O
cortisol	NOUN	O	I-Entity
levels	NOUN	O	O
equally	ADV	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
healthy	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
caffeine	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
some	DET	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
patients	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
abnormalities	NOUN	O	B-Entity
in	ADP	O	I-Entity
neuronal	ADJ	O	I-Entity
systems	NOUN	O	I-Entity
involving	VERB	O	O
adenosine	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
anxiety	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
may	VERB	O	O
benefit	VERB	O	O
by	ADP	O	O
avoiding	VERB	O	O
caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
foods	NOUN	O	O
and	CCONJ	O	O
beverages	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3711722)

intestinal	ADJ	O	O
polypeptide	NOUN	O	O
:	PUNCT	O	O
decrease	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Myocardial	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
VIP	NOUN	O	O
were	VERB	O	O
assayed	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
canine	ADJ	O	O
models	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
,	PUNCT	O	O
cobalt	NOUN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
dogs	NOUN	O	O
;	PUNCT	O	O
VIP	NOUN	O	O
(	PUNCT	O	O
by	ADP	O	O
radioimmunoassay	NOUN	O	O
)	PUNCT	O	O
decreased	VERB	O	O
from	ADP	O	O
35	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
dogs	NOUN	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
VIP	PROPN	O	O
decreased	VERB	O	O
from	ADP	O	O
31	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
VIP	PROPN	O	O
content	NOUN	O	O
of	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
muscle	NOUN	O	O
of	ADP	O	O
resected	VERB	O	O
failing	VERB	O	O
hearts	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
heart	NOUN	O	O
transplant	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
papillary	ADJ	O	O
muscles	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
five	NUM	O	O
with	ADP	O	O
rheumatic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
nine	NUM	O	O
with	ADP	O	O
myxomatous	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
)	PUNCT	O	O
receiving	VERB	O	O
mitral	ADJ	O	O
valve	NOUN	O	O
prostheses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lowest	ADJ	O	O
myocardial	ADJ	O	O
VIP	PROPN	O	O
concentration	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
hearts	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
transplant	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
receiving	VERB	O	O
mitral	ADJ	O	O
prostheses	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
6.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
hearts	NOUN	O	O
without	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
average	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
of	ADP	O	O
this	DET	O	O
group	NOUN	O	O
62%	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

7.9	NUM	O	O
pg	INTJ	O	O
/	SYM	O	O
mg	INTJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
was	VERB	O	O
greater	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
hearts	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
hearts	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
transplant	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	O
catecholamines	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
determined	VERB	O	O
in	ADP	O	O
14	NUM	O	O
subjects	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
weak	ADJ	O	O
correlation	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.57	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
tissue	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
VIP	PROPN	O	O
and	CCONJ	O	O
norepinephrine	NOUN	O	I-Entity
was	VERB	O	O
noted.(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (6728873)

Interstrain	PROPN	O	O
variation	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
toxic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
caffeine	NOUN	O	I-Entity
among	ADP	O	O
inbred	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
toxic	ADJ	O	O
dosage	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
males	NOUN	O	O
from	ADP	O	O
seven	NUM	O	O
inbred	ADJ	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
(	PUNCT	O	O
A	PROPN	O	O
/	SYM	O	O
J	PROPN	O	O
,	PUNCT	O	O
BALB	PROPN	O	O
/	SYM	O	O
cJ	PROPN	O	O
,	PUNCT	O	O
CBA	PROPN	O	O
/	SYM	O	O
J	PROPN	O	O
,	PUNCT	O	O
C3H	PROPN	O	O
/	SYM	O	O
HeJ	PROPN	O	O
,	PUNCT	O	O
C57BL/6J	PROPN	O	O
,	PUNCT	O	O
DBA/2J	PROPN	O	O
,	PUNCT	O	O
SWR	PROPN	O	O
/	SYM	O	O
J	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

C57BL/6J	PROPN	O	O
,	PUNCT	O	O
chosen	VERB	O	O
as	ADP	O	O
a	DET	O	O
"	PUNCT	O	O
prototypic	NOUN	O	O
"	PUNCT	O	O
mouse	NOUN	O	O
strain	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	VERB	O	O
behavioral	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
a	DET	O	O
broad	ADJ	O	O
range	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
doses	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
phenotypic	ADJ	O	O
characteristics	NOUN	O	O
--	PUNCT	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
righting	VERB	O	O
ability	NOUN	O	O
,	PUNCT	O	O
clonic	ADJ	O	B-Entity
seizure	NOUN	O	I-Entity
induction	NOUN	O	O
,	PUNCT	O	O
stress	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
lethality	NOUN	O	O
,	PUNCT	O	O
death	NOUN	O	O
without	ADP	O	O
external	ADJ	O	O
stress	NOUN	O	O
--	PUNCT	O	O
were	VERB	O	O
scored	VERB	O	O
at	ADP	O	O
various	ADJ	O	O
caffeine	NOUN	O	I-Entity
doses	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
naive	ADJ	O	O
animals	NOUN	O	O
under	ADP	O	O
empirically	ADV	O	O
optimized	VERB	O	O
,	PUNCT	O	O
rigidly	ADV	O	O
constant	ADJ	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
12	NUM	O	O
for	ADP	O	O
each	DET	O	O
point	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
single	ADJ	O	O
IP	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
volume	NOUN	O	O
/	PUNCT	O	O
g	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
physiological	ADJ	O	O
saline	ADJ	O	O
carrier	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
125	NUM	O	O
-	SYM	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
same	ADJ	O	O
animals	NOUN	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
clonic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
was	VERB	O	O
scored	VERB	O	O
as	ADP	O	O
to	ADP	O	O
time	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
for	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
these	DET	O	O
proceeded	VERB	O	O
to	PART	O	O
tonic	VERB	O	B-Entity
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
death	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
surviving	VERB	O	O
for	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
were	VERB	O	O
immediately	ADV	O	O
stressed	VERB	O	O
by	ADP	O	O
a	DET	O	O
swim	NOUN	O	O
test	NOUN	O	O
in	ADP	O	O
25	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
water	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	O
-	PUNCT	O	O
producing	VERB	O	O
tonic	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
were	VERB	O	O
scored	VERB	O	O
for	ADP	O	O
2	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
other	ADJ	O	O
animals	NOUN	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
15	NUM	O	O
or	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
caffeine	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
any	DET	O	O
single	ADJ	O	O
behavioral	ADJ	O	O
criterion	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	DET	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
marked	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
toxic	ADJ	O	O
caffeine	NOUN	O	I-Entity
doses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
strains	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
behavioral	ADJ	O	O
toxicity	NOUN	O	I-Entity
testing	NOUN	O	O
of	ADP	O	O
alkylxanthines	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
mouse	NOUN	O	O
strain	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
misleading	ADJ	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
toxic	ADJ	O	O
responses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
this	DET	O	O
class	NOUN	O	O
of	ADP	O	O
compounds	NOUN	O	O
are	VERB	O	O
genetically	ADV	O	O
influenced	VERB	O	O
in	ADP	O	O
mammals	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7248895)

Invasive	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
following	VERB	O	O
cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
nonmalignant	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
right	ADJ	O	O
hydroureteronephrosis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
ureterovesical	ADJ	O	O
junction	NOUN	O	O
obstruction	NOUN	O	O
had	VERB	O	O
gross	ADJ	O	O
hematuria	NOUN	O	I-Entity
after	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
five	NUM	O	O
years	NOUN	O	O
wtih	ADV	O	O
cyclophosphamide	NOUN	O	I-Entity
for	ADP	O	O
cerebral	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
right	ADJ	O	O
nephroureterectomy	NOUN	O	O
was	VERB	O	O
required	VERB	O	O
for	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
bleeding	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pathology	NOUN	O	O
specimen	NOUN	O	O
contained	VERB	O	O
clinically	ADV	O	O
occult	NOUN	O	O
invasive	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
to	PART	O	O
cause	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
urine	NOUN	O	O
cytologic	ADJ	O	O
abnormalities	NOUN	O	O
indistinguishable	ADJ	O	O
from	ADP	O	O
high	ADJ	O	O
grade	NOUN	O	O
carcinoma	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
known	VERB	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
less	ADV	O	O
widely	ADV	O	O
appreciated	VERB	O	O
that	ADP	O	O
it	PRON	O	O
is	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
urinary	ADJ	O	I-Entity
tract	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
carcinomas	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
urinary	ADJ	O	I-Entity
bladder	NOUN	O	I-Entity
and	CCONJ	O	O
one	NUM	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
prostate	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
the	DET	O	O
third	ADJ	O	O
urinary	ADJ	O	B-Entity
tract	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
nonmalignant	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
with	ADP	O	O
preexisting	VERB	O	O
hydroureteronephrosis	NOUN	O	I-Entity
suggests	VERB	O	O
that	ADP	O	O
stasis	NOUN	O	O
prolonged	VERB	O	O
and	CCONJ	O	O
intensified	VERB	O	O
exposure	NOUN	O	O
of	ADP	O	O
upper	ADJ	O	O
urinary	ADJ	O	O
tract	NOUN	O	O
epithelium	NOUN	O	O
to	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
candidates	NOUN	O	O
for	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
cyclophosphamide	NOUN	O	I-Entity
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
routinely	ADV	O	O
evaluated	VERB	O	O
for	ADP	O	O
obstructive	ADJ	O	B-Entity
uropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9578276)

Ascending	VERB	O	O
dose	NOUN	O	O
tolerance	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
intramuscular	NOUN	O	O
carbetocin	NOUN	O	I-Entity
administered	VERB	O	O
after	ADP	O	O
normal	ADJ	O	O
vaginal	ADJ	O	O
birth	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
maximum	NOUN	O	O
tolerated	VERB	O	O
dose	NOUN	O	O
(	PUNCT	O	O
MTD	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
carbetocin	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
synthetic	ADJ	O	O
analogue	NOUN	O	O
of	ADP	O	O
oxytocin	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
when	ADV	O	O
administered	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
vaginal	ADJ	O	O
delivery	NOUN	O	O
at	ADP	O	O
term	NOUN	O	O
.	PUNCT	O	O

Carbetocin	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
as	ADP	O	O
an	DET	O	O
intramuscular	ADJ	O	O
injection	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
birth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infant	NOUN	O	O
in	ADP	O	O
45	NUM	O	O
healthy	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
singleton	NOUN	O	O
pregnancies	NOUN	O	O
who	NOUN	O	O
delivered	VERB	O	O
vaginally	ADV	O	O
at	ADP	O	O
term	NOUN	O	O
.	PUNCT	O	O

Dosage	NOUN	O	O
groups	NOUN	O	O
of	ADP	O	O
15	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
75	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
125	NUM	O	O
,	PUNCT	O	O
150	NUM	O	O
,	PUNCT	O	O
175	NUM	O	O
or	CCONJ	O	O
200	NUM	O	O
microg	NOUN	O	O
carbetocin	NOUN	O	I-Entity
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
blocks	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
women	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
continual	ADJ	O	O
reassessment	NOUN	O	O
method	NOUN	O	O
(	PUNCT	O	O
CRM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Recorded	VERB	O	O
were	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
:	PUNCT	O	O
hyper-	X	O	B-Entity
or	CCONJ	O	I-Entity
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
three	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
severe	ADJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
(	PUNCT	O	O
0	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
(	PUNCT	O	O
0	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
retained	VERB	O	B-Entity
placenta	NOUN	O	I-Entity
(	PUNCT	O	O
four	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
seven	NUM	O	O
women	NOUN	O	O
:	PUNCT	O	O
six	NUM	O	O
cases	NOUN	O	O
with	ADP	O	O
blood	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
1000	NUM	O	O
ml	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
manual	NOUN	O	O
placenta	NOUN	O	O
removal	NOUN	O	O
,	PUNCT	O	O
five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
additional	ADJ	O	O
oxytocics	NOUN	O	O
administration	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
transfusion	NOUN	O	O
.	PUNCT	O	O

Maximum	ADJ	O	O
blood	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
was	VERB	O	O
greatest	ADJ	O	O
at	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
and	CCONJ	O	O
lower	ADJ	O	O
dose	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lowest	ADJ	O	O
in	ADP	O	O
the	DET	O	O
70	NUM	O	O
-	SYM	O	O
125	NUM	O	O
microg	NOUN	O	O
dose	NOUN	O	O
range	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
out	ADP	O	O
of	ADP	O	O
six	NUM	O	O
cases	NOUN	O	O
with	ADP	O	O
blood	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
1000	NUM	O	O
ml	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
200	NUM	O	O
microg	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
MTD	PROPN	O	O
was	VERB	O	O
calculated	VERB	O	O
to	PART	O	O
be	VERB	O	O
at	ADP	O	O
200	NUM	O	O
microg	NOUN	O	O
carbetocin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11423811)

A	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
dobutamine	ADJ	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
evaluation	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Chest	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
poses	VERB	O	O
a	DET	O	O
diagnostic	ADJ	O	O
dilemma	NOUN	O	O
.	PUNCT	O	O

Dobutamine	PROPN	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
(	PUNCT	O	O
DSE	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
available	ADJ	O	O
and	CCONJ	O	O
sensitive	ADJ	O	O
test	NOUN	O	O
for	ADP	O	O
evaluating	VERB	O	O
cardiac	ADJ	O	O
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
theoretical	ADJ	O	O
concern	NOUN	O	O
regarding	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
dobutamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
DSE	PROPN	O	O
in	ADP	O	O
emergency	NOUN	O	O
department	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
DSE	PROPN	O	O
if	ADP	O	O
they	PRON	O	O
had	VERB	O	O
used	VERB	O	O
cocaine	NOUN	O	I-Entity
within	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
preceding	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
ECG	PROPN	O	O
and	CCONJ	O	O
tropinin	NOUN	O	O
I	PRON	O	O
level	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
exhibiting	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
continuing	VERB	O	O
cocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
were	VERB	O	O
excluded	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
inadequate	ADJ	O	O
resting	VERB	O	O
images	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
DSE	PROPN	O	O
was	VERB	O	O
terminated	VERB	O	O
because	ADP	O	O
of	ADP	O	O
inferior	ADJ	O	O
hypokinesis	NOUN	O	I-Entity
,	PUNCT	O	O
another	DET	O	O
DSE	PROPN	O	O
was	VERB	O	O
terminated	VERB	O	O
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
atrial	ADJ	O	O
conduction	NOUN	O	O
deficit	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
patient	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
reach	VERB	O	O
the	DET	O	O
target	NOUN	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
experienced	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
exaggerated	ADJ	O	O
adrenergic	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
of	ADP	O	O
greater	ADJ	O	O
than	ADP	O	O
200	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
or	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
tachydysrhythmias	NOUN	O	I-Entity
(	PUNCT	O	O
excluding	VERB	O	O
sinus	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Further	ADV	O	O
suggesting	VERB	O	O
lack	NOUN	O	O
of	ADP	O	O
exaggerated	ADJ	O	O
adrenergic	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
13	NUM	O	O
(	PUNCT	O	O
65%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
required	VERB	O	O
supplemental	ADJ	O	O
atropine	NOUN	O	I-Entity
to	PART	O	O
reach	VERB	O	O
their	ADJ	O	O
target	NOUN	O	O
heart	NOUN	O	O
rates	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
exaggerated	ADJ	O	O
adrenergic	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
when	ADV	O	O
dobutamine	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12678199)

Amiodarone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
torsade	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
during	ADP	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
unusual	ADJ	O	O
presentation	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
(	PUNCT	O	O
within	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
development	NOUN	O	O
of	ADP	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
TdP	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Consistent	ADJ	O	O
with	ADP	O	O
other	ADJ	O	O
reports	NOUN	O	O
this	DET	O	O
case	NOUN	O	O
of	ADP	O	O
TdP	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
multiple	ADJ	O	O
exacerbating	VERB	O	O
factors	NOUN	O	O
including	VERB	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
digoxin	VERB	O	I-Entity
excess	ADJ	O	O
.	PUNCT	O	O

Transient	ADJ	O	O
prolongation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
QT	PROPN	O	O
during	ADP	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
prompted	VERB	O	O
the	DET	O	O
episode	NOUN	O	O
of	ADP	O	O
TdP.	PROPN	O	I-Entity
It	PRON	O	O
is	VERB	O	O
well	ADV	O	O
known	VERB	O	O
that	ADP	O	O
bradycardia	NOUN	O	I-Entity
exacerbates	VERB	O	O
acquired	VERB	O	O
TdP.	PROPN	O	I-Entity

The	DET	O	O
authors	NOUN	O	O
speculate	VERB	O	O
that	ADP	O	O
the	DET	O	O
increased	VERB	O	O
vagal	ADJ	O	O
tone	NOUN	O	O
during	ADP	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
vagal	NOUN	O	O
maneuver	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
proarrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
second	ADJ	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
TdP	PROPN	O	I-Entity
despite	ADP	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
hypomagnesemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15696449)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
melphalan	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
systemic	ADJ	O	I-Entity
amyloidosis	NOUN	O	I-Entity
during	ADP	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
systemic	ADJ	O	I-Entity
amyloidosis	NOUN	O	I-Entity
(	PUNCT	O	O
AL	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
a	DET	O	O
poor	ADJ	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
melphalan	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplant	NOUN	O	O
(	PUNCT	O	O
PBSCT	PROPN	O	O
)	PUNCT	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
most	ADV	O	O
promising	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
treatment	NOUN	O	O
mortality	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
high	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
have	VERB	O	O
noted	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
immediately	ADV	O	O
after	ADP	O	O
melphalan	NOUN	O	I-Entity
conditioning	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Consecutive	ADJ	O	O
AL	PROPN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
PBSCT	PROPN	O	O
were	VERB	O	O
studied	VERB	O	O
retrospectively	ADV	O	O
.	PUNCT	O	O

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
(	PUNCT	O	O
ARI	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
melphalan	NOUN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
by	ADP	O	O
a	DET	O	O
minimum	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
44	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
level	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
greater	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
baseline	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
conditioning	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
80	NUM	O	O
patients	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
ARI	PROPN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
18.8%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
melphalan	NOUN	O	I-Entity
.	PUNCT	O	O

Univariate	ADJ	O	O
analysis	NOUN	O	O
identified	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
hypoalbuminemia	NOUN	O	I-Entity
,	PUNCT	O	O
heavy	ADJ	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
diuretic	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
urine	ADJ	O	O
sediment	NOUN	O	O
score	NOUN	O	O
(	PUNCT	O	O
>	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
as	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
ARI	PROPN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
melphalan	NOUN	O	I-Entity
underwent	VERB	O	O
dialysis	NOUN	O	O
more	ADV	O	O
often	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.007	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
had	VERB	O	O
a	DET	O	O
worse	ADJ	O	O
1-year	ADJ	O	O
survival	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
timing	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
strongly	ADV	O	O
suggests	VERB	O	O
melphalan	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
causative	NOUN	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Ongoing	VERB	O	O
tubular	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
prerequisite	NOUN	O	O
for	ADP	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
by	ADP	O	O
melphalan	NOUN	O	I-Entity
as	ADP	O	O
evidenced	VERB	O	O
by	ADP	O	O
the	DET	O	O
active	ADJ	O	O
urinary	ADJ	O	O
sediment	NOUN	O	O
.	PUNCT	O	O

Development	PROPN	O	O
of	ADP	O	O
ARI	PROPN	O	I-Entity
adversely	ADV	O	O
affected	VERB	O	O
the	DET	O	O
outcome	NOUN	O	O
after	ADP	O	O
PBSCT	PROPN	O	O
.	PUNCT	O	O

Effective	ADJ	O	O
preventive	ADJ	O	O
measures	NOUN	O	O
may	VERB	O	O
help	VERB	O	O
decrease	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
mortality	NOUN	O	O
of	ADP	O	O
PBSCT	PROPN	O	O
in	ADP	O	O
AL	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17554526)

Impaired	ADJ	O	B-Entity
fear	NOUN	O	I-Entity
recognition	NOUN	O	I-Entity
in	ADP	O	O
regular	ADJ	O	O
recreational	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
conduct	VERB	O	O
the	DET	O	O
first	ADJ	O	O
investigation	NOUN	O	O
of	ADP	O	O
facial	ADJ	O	O
expression	NOUN	O	O
recognition	NOUN	O	O
performance	NOUN	O	O
in	ADP	O	O
recreational	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
Three	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
comprised	VERB	O	O
of	ADP	O	O
21	NUM	O	O
cocaine	NOUN	O	I-Entity
naive	ADJ	O	O
participants	NOUN	O	O
(	PUNCT	O	O
CN	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
30	NUM	O	O
occasional	ADJ	O	O
cocaine	NOUN	O	I-Entity
(	PUNCT	O	O
OC	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
48	NUM	O	O
regular	ADJ	O	O
recreational	ADJ	O	O
cocaine	NOUN	O	I-Entity
(	PUNCT	O	O
RC	PROPN	O	O
)	PUNCT	O	O
users	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
group	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
psychopathology	NOUN	O	O
or	CCONJ	O	O
"	PUNCT	O	O
eyes	NOUN	O	O
task	NOUN	O	O
"	PUNCT	O	O
performance	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
RC	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
otherwise	ADV	O	O
had	VERB	O	O
similar	ADJ	O	O
illicit	ADJ	O	O
substance	NOUN	O	O
use	NOUN	O	O
histories	NOUN	O	O
to	ADP	O	O
the	DET	O	O
OC	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
exhibited	VERB	O	O
impaired	ADJ	O	B-Entity
fear	NOUN	O	I-Entity
recognition	NOUN	O	I-Entity
accuracy	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
OC	PROPN	O	O
and	CCONJ	O	O
CN	PROPN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
selective	ADJ	O	O
deficit	NOUN	O	B-Entity
in	ADP	O	I-Entity
fear	NOUN	O	I-Entity
recognition	NOUN	O	I-Entity
accuracy	NOUN	O	O
manifested	VERB	O	O
by	ADP	O	O
the	DET	O	O
RC	PROPN	O	O
group	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
explained	VERB	O	O
by	ADP	O	O
the	DET	O	O
subacute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
ecstasy	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
recent	ADJ	O	O
and	CCONJ	O	O
less	ADV	O	O
recent	ADJ	O	O
users	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
within	ADP	O	O
this	DET	O	O
group	NOUN	O	O
were	VERB	O	O
similarly	ADV	O	O
impaired	VERB	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
parallels	NOUN	O	O
between	ADP	O	O
RC	PROPN	O	O
users	NOUN	O	O
and	CCONJ	O	O
psychopaths	NOUN	O	I-Entity
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
impaired	ADJ	O	B-Entity
fear	NOUN	O	I-Entity
recognition	NOUN	O	I-Entity
,	PUNCT	O	O
amygdala	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
etiology	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17721298)

Corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
aerosolized	ADJ	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
4	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
ulcers	NOUN	O	I-Entity
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Review	NOUN	O	O
of	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
seen	VERB	O	O
at	ADP	O	O
our	ADJ	O	O
institution	NOUN	O	O
from	ADP	O	O
July	PROPN	O	O
2006	NUM	O	O
to	ADP	O	O
December	PROPN	O	O
2006	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
were	VERB	O	O
cultured	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
intensive	ADJ	O	O
topical	ADJ	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
comprehensive	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
medical	ADJ	O	O
and	CCONJ	O	O
substance	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
consultations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
infections	NOUN	O	I-Entity
responded	VERB	O	O
to	ADP	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
needed	VERB	O	O
a	DET	O	O
lateral	ADJ	O	O
tarsorrhaphy	NOUN	O	O
for	ADP	O	O
persistent	ADJ	O	O
epithelial	ADJ	O	B-Entity
defects	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Aerosolized	VERB	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
provides	VERB	O	O
additional	ADJ	O	O
challenges	NOUN	O	O
for	ADP	O	O
management	NOUN	O	O
.	PUNCT	O	O

Not	ADV	O	O
only	ADV	O	O
treatment	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
infections	NOUN	O	I-Entity
but	CCONJ	O	O
also	ADV	O	O
the	DET	O	O
overall	ADJ	O	O
poor	ADJ	O	O
health	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
noncompliance	NOUN	O	O
need	VERB	O	O
to	PART	O	O
be	VERB	O	O
addressed	VERB	O	O
.	PUNCT	O	O

Comprehensive	ADJ	O	O
care	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
the	DET	O	O
opportunity	NOUN	O	O
to	PART	O	O
discontinue	VERB	O	O
their	ADJ	O	O
substance	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
,	PUNCT	O	O
improve	VERB	O	O
their	ADJ	O	O
overall	ADJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prevent	VERB	O	O
future	ADJ	O	O
corneal	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18341442)

Levetiracetam	PROPN	O	I-Entity
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
phenobarbital	ADJ	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
cats	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
idiopathic	ADJ	O	B-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
pharmacokinetics	NOUN	O	O
,	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
levetiracetam	NOUN	O	I-Entity
administered	VERB	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
phenobarbital	ADJ	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
cats	NOUN	O	O
with	ADP	O	O
poorly	ADV	O	O
controlled	VERB	O	O
suspected	VERB	O	O
idiopathic	ADJ	O	B-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

ANIMALS	NOUN	O	O
:	PUNCT	O	O
12	NUM	O	O
cats	NOUN	O	O
suspected	VERB	O	O
to	PART	O	O
have	VERB	O	O
idiopathic	ADJ	O	B-Entity
epilepsy	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
poorly	ADV	O	O
controlled	VERB	O	O
with	ADP	O	O
phenobarbital	NOUN	O	I-Entity
or	CCONJ	O	O
that	DET	O	O
had	VERB	O	O
unacceptable	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
when	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
phenobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

Cats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
levetiracetam	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
[	PUNCT	O	O
9.1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
lb	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
PO	PROPN	O	O
,	PUNCT	O	O
q	PROPN	O	O
8	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
levetiracetam	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
maximum	ADJ	O	O
and	CCONJ	O	O
minimum	ADJ	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
elimination	NOUN	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
were	VERB	O	O
calculated	VERB	O	O
.	PUNCT	O	O

Seizure	PROPN	O	I-Entity
frequencies	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
levetiracetam	NOUN	O	I-Entity
treatment	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Median	ADJ	O	O
maximum	ADJ	O	O
serum	NOUN	O	O
levetiracetam	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
25.5	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
median	ADJ	O	O
minimum	ADJ	O	O
serum	NOUN	O	O
levetiracetam	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
8.3	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
median	ADJ	O	O
elimination	NOUN	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
was	VERB	O	O
2.9	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
levetiracetam	NOUN	O	I-Entity
(	PUNCT	O	O
2.1	NUM	O	O
seizures	NOUN	O	I-Entity
/	SYM	O	O
mo	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
median	ADJ	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
levetiracetam	NOUN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
0.42	PUNCT	O	O
seizures	NOUN	O	I-Entity
/	SYM	O	O
mo	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
7	NUM	O	O
of	ADP	O	O
10	NUM	O	O
cats	NOUN	O	O
were	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
having	VERB	O	O
responded	VERB	O	O
to	ADP	O	O
levetiracetam	VERB	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
ie	X	O	O
,	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or=50%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
cats	NOUN	O	O
had	VERB	O	O
transient	ADJ	O	O
lethargy	NOUN	O	I-Entity
and	CCONJ	O	O
inappetence	NOUN	O	I-Entity
.	PUNCT	O	O

Results	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
levetiracetam	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
in	ADP	O	O
cats	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
phenobarbital	ADJ	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
cats	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19681452)

Bilateral	ADJ	O	O
haemorrhagic	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
globus	NOUN	O	I-Entity
pallidus	NOUN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
alcohol	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
both	DET	O	O
ischemic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
haemorrhagic	ADJ	O	I-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
31-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
bilateral	ADJ	O	O
ischemia	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
globus	NOUN	O	I-Entity
pallidus	NOUN	O	I-Entity
after	ADP	O	O
excessive	ADJ	O	O
alcohol	NOUN	O	I-Entity
and	CCONJ	O	O
intranasal	NOUN	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
globus	NOUN	O	B-Entity
pallidus	NOUN	O	I-Entity
infarctions	NOUN	O	I-Entity
are	VERB	O	O
most	ADV	O	O
often	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
heroin	NOUN	O	I-Entity
.	PUNCT	O	O

Bilateral	ADJ	O	O
basal	NOUN	O	B-Entity
ganglia	NOUN	O	I-Entity
infarcts	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
concurrent	ADJ	O	O
heroin	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
never	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
transient	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
or	CCONJ	O	O
respiratory	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
and/or	CCONJ	O	O
ethanol	NOUN	O	I-Entity
use	NOUN	O	O
were	VERB	O	O
the	DET	O	O
most	ADV	O	O
likely	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
hypoperfusion	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20009434)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methotrexate	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
ileostomy	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
HD	PROPN	O	O
-	PUNCT	O	O
MTX	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
Burkitt	PROPN	O	B-Entity
lymphoma	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
can	VERB	O	O
cause	VERB	O	O
hepatic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
when	ADV	O	O
its	ADJ	O	O
clearance	NOUN	O	O
is	VERB	O	O
delayed	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
HD	PROPN	O	O
-	PUNCT	O	O
MTX	PROPN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
ileostomy	NOUN	O	O
,	PUNCT	O	O
The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
a	DET	O	O
3-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
a	DET	O	O
living	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
congenital	ADJ	O	O
biliary	ADJ	O	B-Entity
atresia	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
day	NOUN	O	O
833	NUM	O	O
after	ADP	O	O
the	DET	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
PTLD	PROPN	O	I-Entity
(	PUNCT	O	O
post	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
transplantation	NOUN	O	I-Entity
lymphoproliferative	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
Burkitt	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
type	NOUN	O	I-Entity
malignant	NOUN	O	I-Entity
lymphoma	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
HD	PROPN	O	O
-	PUNCT	O	O
MTX	PROPN	O	I-Entity
therapy	NOUN	O	O
caused	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
that	ADJ	O	O
required	VERB	O	O
continuous	ADJ	O	O
hemodialysis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
supposed	VERB	O	O
that	ADP	O	O
intravascular	ADJ	O	O
hypovolemia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
substantial	ADJ	O	O
drainage	NOUN	O	O
from	ADP	O	O
the	DET	O	O
ileostoma	NOUN	O	O
caused	VERB	O	O
acute	ADJ	O	B-Entity
prerenal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
recovery	NOUN	O	O
of	ADP	O	O
his	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
could	VERB	O	O
safely	ADV	O	O
treat	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
HD	PROPN	O	O
-	PUNCT	O	O
MTX	PROPN	O	I-Entity
therapy	NOUN	O	O
by	ADP	O	O
controlling	VERB	O	O
drainage	NOUN	O	O
from	ADP	O	O
ileostoma	NOUN	O	O
with	ADP	O	O
total	ADJ	O	O
parenteral	ADJ	O	O
nutrition	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20431083)

Antithrombotic	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
cerebral	ADJ	O	B-Entity
microbleeds	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
systematic	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
published	VERB	O	O
and	CCONJ	O	O
unpublished	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	PROPN	O	O
AND	CCONJ	O	O
PURPOSE	PROPN	O	O
:	PUNCT	O	O
Cerebral	ADJ	O	B-Entity
microbleeds	NOUN	O	I-Entity
(	PUNCT	O	O
MB	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
potential	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
ICH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
unclear	ADJ	O	O
if	ADP	O	O
they	PRON	O	O
are	VERB	O	O
a	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
using	VERB	O	O
antithrombotic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Insights	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
gained	VERB	O	O
by	ADP	O	O
pooling	VERB	O	O
data	NOUN	O	O
on	ADP	O	O
MB	PROPN	O	I-Entity
frequency	NOUN	O	O
stratified	VERB	O	O
by	ADP	O	O
antithrombotic	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
cohorts	NOUN	O	O
with	ADP	O	O
ICH	PROPN	O	I-Entity
and	CCONJ	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
IS)/transient	PROPN	O	B-Entity
ischemic	ADJ	O	I-Entity
attack	NOUN	O	I-Entity
(	PUNCT	O	O
TIA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
systematic	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
published	VERB	O	O
and	CCONJ	O	O
unpublished	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
cohorts	NOUN	O	O
with	ADP	O	O
stroke	NOUN	O	I-Entity
or	CCONJ	O	O
TIA	PROPN	O	I-Entity
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
MB	PROPN	O	I-Entity
in	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
antithrombotic	ADJ	O	O
users	NOUN	O	O
vs	ADP	O	O
nonantithrombotic	ADJ	O	O
users	NOUN	O	O
with	ADP	O	O
ICH	PROPN	O	I-Entity
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
antithrombotic	ADJ	O	O
users	NOUN	O	O
vs	ADP	O	O
nonusers	NOUN	O	O
with	ADP	O	O
IS	PROPN	O	I-Entity
/	SYM	O	O
TIA	PROPN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
ICH	PROPN	O	I-Entity
vs	ADP	O	O
ischemic	ADJ	O	I-Entity
events	NOUN	O	O
stratified	VERB	O	O
by	ADP	O	O
antithrombotic	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
analyzed	VERB	O	O
published	VERB	O	O
and	CCONJ	O	O
unpublished	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
data	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ICH	PROPN	O	I-Entity
in	ADP	O	O
antithrombotic	ADJ	O	O
users	NOUN	O	O
with	ADP	O	O
MB	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
pooled	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
1460	NUM	O	O
ICH	PROPN	O	I-Entity
and	CCONJ	O	O
3817	NUM	O	O
IS	PROPN	O	I-Entity
/	SYM	O	O
TIA	PROPN	O	I-Entity
,	PUNCT	O	O
MB	PROPN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
in	ADP	O	O
ICH	PROPN	O	I-Entity
vs	PROPN	O	O

IS	PROPN	O	I-Entity
/	SYM	O	O
TIA	PROPN	O	I-Entity
in	ADP	O	O
all	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
excess	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
2.8	NUM	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
2.3	NUM	O	O
-	SYM	O	O
3.5	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
nonantithrombotic	ADJ	O	O
users	NOUN	O	O
to	ADP	O	O
5.7	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
3.4	NUM	O	O
-	SYM	O	O
9.7	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
antiplatelet	NOUN	O	O
users	NOUN	O	O
and	CCONJ	O	O
8.0	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
3.5	NUM	O	O
-	SYM	O	O
17.8	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
warfarin	NOUN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
difference=0.01	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
also	ADV	O	O
an	DET	O	O
excess	NOUN	O	O
of	ADP	O	O
MB	PROPN	O	I-Entity
in	ADP	O	O
warfarin	NOUN	O	I-Entity
users	NOUN	O	O
vs	ADP	O	O
nonusers	NOUN	O	O
with	ADP	O	O
ICH	PROPN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
,	PUNCT	O	O
2.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.6	NUM	O	O
-	PUNCT	O	O
4.4	NUM	O	O
;	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
none	NOUN	O	O
in	ADP	O	O
warfarin	NOUN	O	I-Entity
users	NOUN	O	O
with	ADP	O	O
IS	PROPN	O	I-Entity
/	SYM	O	O
TIA	PROPN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
0.9	NUM	O	O
-	SYM	O	O
1.7	NUM	O	O
;	PUNCT	O	O
P=0.33	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
difference=0.01	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
smaller	ADJ	O	O
excess	NOUN	O	O
of	ADP	O	O
MB	PROPN	O	I-Entity
in	ADP	O	O
antiplatelet	NOUN	O	O
users	NOUN	O	O
vs	ADP	O	O
nonusers	NOUN	O	O
with	ADP	O	O
ICH	PROPN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
,	PUNCT	O	O
1.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
2.3	NUM	O	O
;	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
findings	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
antiplatelet	NOUN	O	O
users	NOUN	O	O
with	ADP	O	O
IS	PROPN	O	I-Entity
/	SYM	O	O
TIA	PROPN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
,	PUNCT	O	O
1.4	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
1.2	NUM	O	O
-	SYM	O	O
1.7	NUM	O	O
;	PUNCT	O	O
P<0.001	PROPN	O	O
;	PUNCT	O	O
P	NOUN	O	O
difference=0.25	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
pooled	VERB	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
data	NOUN	O	O
for	ADP	O	O
768	NUM	O	O
antithrombotic	ADJ	O	O
users	NOUN	O	O
,	PUNCT	O	O
presence	NOUN	O	O
of	ADP	O	O
MB	PROPN	O	I-Entity
at	ADP	O	O
baseline	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
substantially	ADV	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
ICH	PROPN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
,	PUNCT	O	O
12.1	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
3.4	NUM	O	O
-	SYM	O	O
42.5	NUM	O	O
;	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
excess	NOUN	O	O
of	ADP	O	O
MB	PROPN	O	I-Entity
in	ADP	O	O
warfarin	NOUN	O	I-Entity
users	NOUN	O	O
with	ADP	O	O
ICH	PROPN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
groups	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
MB	PROPN	O	I-Entity
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
ICH	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20595935)

Verapamil	ADJ	O	I-Entity
stimulation	NOUN	O	O
test	NOUN	O	O
in	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
:	PUNCT	O	O
loss	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
anatomic	ADJ	O	O
or	CCONJ	O	O
functional	ADJ	O	O
stalk	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
stimulation	NOUN	O	O
test	NOUN	O	O
was	VERB	O	O
previously	ADV	O	O
investigated	VERB	O	O
as	ADP	O	O
a	DET	O	O
tool	NOUN	O	O
for	ADP	O	O
differential	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
conflicting	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

Macroprolactinemia	PROPN	O	I-Entity
was	VERB	O	O
never	ADV	O	O
considered	VERB	O	O
in	ADP	O	O
those	DET	O	O
previous	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
aimed	VERB	O	O
to	ADP	O	O
re	VERB	O	O
-	PUNCT	O	O
investigate	VERB	O	O
the	DET	O	O
diagnostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
all	DET	O	O
screened	VERB	O	O
for	ADP	O	O
macroprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

Prolactin	PROPN	O	O
responses	NOUN	O	O
to	ADP	O	O
verapamil	VERB	O	I-Entity
in	ADP	O	O
65	NUM	O	O
female	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
:	PUNCT	O	O
29.9	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

8.1	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
were	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
descriptive	ADJ	O	O
,	PUNCT	O	O
matched	VERB	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Verapamil	PROPN	O	I-Entity
80	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
responsiveness	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
peak	NOUN	O	O
percent	NOUN	O	O
change	NOUN	O	O
in	ADP	O	O
basal	NOUN	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
PRL	PROPN	O	O
levels	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
N.	PROPN	O	O
8	NUM	O	O
,	PUNCT	O	O
PRL	NOUN	O	O
:	PUNCT	O	O
183%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
macroprolactinoma	NOUN	O	I-Entity
(	PUNCT	O	O
N.	PROPN	O	O
8	NUM	O	O
,	PUNCT	O	O
PRL	NOUN	O	O
:	PUNCT	O	O
7%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
microprolactinoma	NOUN	O	I-Entity
(	PUNCT	O	O
N.	PROPN	O	O
19	NUM	O	O
,	PUNCT	O	O
PRL	PROPN	O	O
:	PUNCT	O	O
21%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
macroprolactinemia	NOUN	O	I-Entity

but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
pseudoprolactinoma	NOUN	O	I-Entity
(	PUNCT	O	O
N.	PROPN	O	O
8	NUM	O	O
,	PUNCT	O	O
PRL	NOUN	O	O
:	PUNCT	O	O
0.8%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
(	PUNCT	O	O
N.	PROPN	O	O
7	NUM	O	O
,	PUNCT	O	O

ROC	PROPN	O	O
curve	NOUN	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
unresponsiveness	NOUN	O	O
to	ADP	O	O
verapamil	ADV	O	I-Entity
defined	VERB	O	O
as	ADP	O	O
PRL	PROPN	O	O

<	X	O	O
0.001	NUM	O	O
,	PUNCT	O	O
CI	PROPN	O	O
:	PUNCT	O	O
0.768	NUM	O	O
-	PUNCT	O	O
0.942	NUM	O	O
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
pseudoprolactinoma	NOUN	O	I-Entity
or	CCONJ	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Verapamil	PROPN	O	I-Entity
responsiveness	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
reliable	ADJ	O	O
finding	NOUN	O	O
for	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
verapamil	ADJ	O	I-Entity
unresponsiveness	NOUN	O	O
discriminates	NOUN	O	O
stalk	VERB	O	O
effect	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
anatomically	ADV	O	O
or	CCONJ	O	O
functionally	ADV	O	O
inhibited	VERB	O	O
dopaminergic	ADJ	O	O
tonus	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
other	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
with	ADP	O	O
varying	VERB	O	O
degrees	NOUN	O	O
of	ADP	O	O
responsiveness	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (35781)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
naphazoline	NOUN	O	I-Entity
and	CCONJ	O	O
xylometazoline	NOUN	O	I-Entity
on	ADP	O	O
analgesia	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
codeine	NOUN	O	I-Entity
,	PUNCT	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
pentazocine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
cataleptic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
codine	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
biochemical	ADJ	O	O
assays	NOUN	O	O
on	ADP	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
analgesics	NOUN	O	O
on	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
turnover	NOUN	O	O
of	ADP	O	O
noradrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
NA	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
performed	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
found	VERB	O	O
that	ADP	O	O
three	NUM	O	O
drugs	NOUN	O	O
stimulating	VERB	O	O
central	ADJ	O	O
NA	PROPN	O	I-Entity
receptors	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
affect	VERB	O	O
the	DET	O	O
analgesic	NOUN	O	O
ED50	PROPN	O	O
of	ADP	O	O
all	DET	O	O
antinociceptive	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
they	PRON	O	O
enhanced	VERB	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
.	PUNCT	O	O

Codeine	ADJ	O	I-Entity
catalepsy	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
by	ADP	O	O
naphazoline	NOUN	O	I-Entity
and	CCONJ	O	O
xylometazoline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
brain	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
changed	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
of	ADP	O	O
codeine	NOUN	O	I-Entity
(	PUNCT	O	O
45	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
slightly	ADV	O	O
enhanced	VERB	O	O
it	PRON	O	O
.	PUNCT	O	O

Pentazocine	PROPN	O	I-Entity
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
brain	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
turnover	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
altered	VERB	O	O
by	ADP	O	O
analgesics	NOUN	O	O
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
(	PUNCT	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
following	VERB	O	O
which	ADJ	O	O
the	DET	O	O
disappearance	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
from	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
was	VERB	O	O
diminished	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
in	ADP	O	O
rats	NOUN	O	O
the	DET	O	O
brain	NOUN	O	O
NA	PROPN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
less	ADV	O	O
important	ADJ	O	O
function	NOUN	O	O
than	ADP	O	O
the	DET	O	O
other	ADJ	O	O
monoamines	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
behavioural	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
potent	ADJ	O	O
analgesics	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (48835)

Modification	NOUN	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
of	ADP	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
induced	VERB	O	O
hypoglycaemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
hypoglycaemia	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockade	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
fourteen	NUM	O	O
healthy	ADJ	O	O
men	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
received	VERB	O	O
insulin	NOUN	O	O
alone	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
eight	NUM	O	O
,	PUNCT	O	O
including	VERB	O	O
two	NUM	O	O
of	ADP	O	O
the	DET	O	O
original	ADJ	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
only	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
insulin	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
group	NOUN	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
hypoglycaemia	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
-	PUNCT	O	O
rate	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
propranolol	NOUN	O	I-Entity
-	PUNCT	O	O
insulin	NOUN	O	O
group	NOUN	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
-	PUNCT	O	O
rate	NOUN	O	O
in	ADP	O	O
most	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
diastolic	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

/	PUNCT	O	O
T	NOUN	O	O
changes	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
group	NOUN	O	O
but	CCONJ	O	O
in	ADP	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
propranolol	NOUN	O	I-Entity
-	PUNCT	O	O
insulin	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Hypertension	NOUN	O	I-Entity
in	ADP	O	O
diabetics	NOUN	O	I-Entity
prone	ADJ	O	O
to	ADP	O	O
hypoglycaemia	VERB	O	I-Entity
attacks	NOUN	O	O
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
because	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
a	DET	O	O
sharp	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (89511)

Prevention	PROPN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
climacteric	ADJ	O	O
women	NOUN	O	O
receiving	VERB	O	O
oestrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
are	VERB	O	O
described	VERB	O	O
in	ADP	O	O
74	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
endometrial	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
among	ADP	O	O
850	NUM	O	O
climacteric	ADJ	O	O
women	NOUN	O	O
receiving	VERB	O	O
oestrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Cystic	ADJ	O	O
hyperplasia	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
unopposed	ADJ	O	O
oestrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
without	ADP	O	O
progestagen	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
norethisterone	NOUN	O	I-Entity
daily	ADV	O	O
caused	VERB	O	O
reversion	NOUN	O	O
to	ADP	O	O
normal	ADJ	O	O
in	ADP	O	O
all	DET	O	O
57	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cystic	NOUN	O	O
hyperplasia	NOUN	O	I-Entity
and	CCONJ	O	O
6	NUM	O	O
of	ADP	O	O
the	DET	O	O
8	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
hyperplasia	NOUN	O	I-Entity
.	PUNCT	O	O

4	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
referred	VERB	O	O
from	ADP	O	O
elsewhere	ADV	O	O
demonstrated	VERB	O	O
the	DET	O	O
problems	NOUN	O	O
of	ADP	O	O
inappropriate	ADJ	O	O
and	CCONJ	O	O
unsupervised	ADJ	O	O
unopposed	ADJ	O	O
oestrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
difficulty	NOUN	O	O
in	ADP	O	O
distinguishing	VERB	O	O
severe	ADJ	O	O
hyperplasia	NOUN	O	I-Entity
from	ADP	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

Cyclical	ADJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
oestrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
with	ADP	O	O
7	NUM	O	O
-	PUNCT	O	O
-13	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
progestagen	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
hyperplasia	NOUN	O	I-Entity
or	CCONJ	O	O
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (146391)

Pure	ADJ	O	B-Entity
red	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
aplasia	NOUN	O	I-Entity
,	PUNCT	O	O
toxic	ADJ	O	B-Entity
dermatitis	NOUN	O	I-Entity
and	CCONJ	O	O
lymphadenopathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
taking	VERB	O	O
diphenylhydantoin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
taking	VERB	O	O
diphenylhydantoin	NOUN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
generalized	ADJ	O	O
skin	NOUN	O	B-Entity
rash	NOUN	O	I-Entity
,	PUNCT	O	O
lymphadenopathy	NOUN	O	I-Entity
and	CCONJ	O	O
pure	ADJ	O	B-Entity
red	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
aplasia	NOUN	O	I-Entity
.	PUNCT	O	O

Skin	ADJ	O	B-Entity
rash	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
complication	NOUN	O	O
of	ADP	O	O
diphenylhydantoin	ADJ	O	I-Entity
treatment	NOUN	O	O
as	ADV	O	O
is	VERB	O	O
benign	ADJ	O	O
and	CCONJ	O	O
malignant	ADJ	O	O
lymphadenopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Pure	ADJ	O	B-Entity
red	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
aplasia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
diphenylhydantoin	ADJ	O	I-Entity
medication	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
exact	ADJ	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
diphenylhydantoin	NOUN	O	I-Entity
exerts	VERB	O	O
its	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
the	DET	O	O
time	NOUN	O	O
relation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
diphenylhydantoin	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
skin	NOUN	O	B-Entity
rash	NOUN	O	I-Entity
,	PUNCT	O	O
lymphadenopathy	NOUN	O	I-Entity
and	CCONJ	O	O
pure	ADJ	O	B-Entity
red	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
aplasia	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
suggestive	ADJ	O	O
of	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
connection	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (256433)

Continuous	ADJ	O	O
infusion	NOUN	O	O
tobramycin	ADV	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
carbenicillin	NOUN	O	I-Entity
for	ADP	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cure	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
is	VERB	O	O
adversely	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
1,000/mm3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
100/mm3	NUM	O	O
)	PUNCT	O	O
have	VERB	O	O
shown	VERB	O	O
a	DET	O	O
poor	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
antibiotics	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
overcome	VERB	O	O
the	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
tobramycin	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
by	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
and	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
intermittent	ADJ	O	O
carbenicillin	NOUN	O	I-Entity
.	PUNCT	O	O

Tobramycin	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
a	DET	O	O
total	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
carbenicillin	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
gm	INTJ	O	O
every	DET	O	O
four	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
125	NUM	O	O
infectious	ADJ	O	O
episodes	NOUN	O	O
in	ADP	O	O
116	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
myelosuppressive	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Pneumonia	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
infection	NOUN	O	I-Entity
and	CCONJ	O	O
61%	NUM	O	O
of	ADP	O	O
59	NUM	O	O
episodes	NOUN	O	O
were	VERB	O	O
cured	VERB	O	O
.	PUNCT	O	O

Gram	PROPN	O	O
-	PUNCT	O	O
negative	ADJ	O	O
bacilli	NOUN	O	O
were	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
causative	NOUN	O	O
organisms	NOUN	O	O
and	CCONJ	O	O
69%	NUM	O	O
of	ADP	O	O
these	DET	O	O
infections	NOUN	O	I-Entity
were	VERB	O	O
cured	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
pathogen	NOUN	O	O
was	VERB	O	O
Klebsiella	PROPN	O	O
pneumoniae	NOUN	O	I-Entity
and	CCONJ	O	O
this	DET	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
Escherichia	PROPN	O	O
coli	NOUN	O	O
and	CCONJ	O	O
Pseudomonas	PROPN	O	O
aeruginosa	NOUN	O	O
,	PUNCT	O	O
accounted	VERB	O	O
for	ADP	O	O
74%	NUM	O	O
of	ADP	O	O
all	DET	O	O
gram	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
negative	ADJ	O	I-Entity
bacillary	ADJ	O	I-Entity
infections	NOUN	O	I-Entity
.	PUNCT	O	O

Response	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
neutrophil	NOUN	O	O
count	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
62%	NUM	O	O
cure	NOUN	O	O
rate	NOUN	O	O
for	ADP	O	O
39	NUM	O	O
episodes	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
.	PUNCT	O	O

Azotemia	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
major	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
recognized	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
occurred	VERB	O	O
in	ADP	O	O
11%	NUM	O	O
of	ADP	O	O
episodes	NOUN	O	O
.	PUNCT	O	O

Major	ADJ	O	O
azotemia	NOUN	O	I-Entity
(	PUNCT	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
or	CCONJ	O	O
BUN	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
only	ADV	O	O
2%	NUM	O	O
.	PUNCT	O	O

Azotemia	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
related	VERB	O	O
to	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
or	CCONJ	O	O
serum	NOUN	O	O
tobramycin	NOUN	O	I-Entity
concentration	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
antibiotic	ADJ	O	O
regimen	NOUN	O	O
showed	VERB	O	O
both	CCONJ	O	O
therapeutic	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
acceptable	ADJ	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
for	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (448423)

Recurrent	PROPN	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
aminocaproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

Epsilon	PROPN	O	B-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
EACA	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
rebleeding	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
SAH	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
does	VERB	O	O
decrease	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
rebleeding	NOUN	O	O
,	PUNCT	O	O
several	ADJ	O	O
reports	NOUN	O	O
have	VERB	O	O
described	VERB	O	O
thrombotic	ADJ	O	I-Entity
complications	NOUN	O	O
of	ADP	O	O
EACA	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
complications	NOUN	O	O
have	VERB	O	O
included	VERB	O	O
clinical	ADJ	O	O
deterioration	NOUN	O	O
and	CCONJ	O	O
intracranial	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SAH	PROPN	O	I-Entity
,	PUNCT	O	O
arteriolar	ADJ	O	O
and	CCONJ	O	O
capillary	ADJ	O	O
fibrin	NOUN	O	O

thrombi	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
fibrinolytic	ADJ	O	O
syndromes	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
EACA	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
other	ADJ	O	O
thromboembolic	ADJ	O	B-Entity
phenomena	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
intravascular	ADJ	O	O
fibrin	NOUN	O	O
thrombi	NOUN	O	I-Entity
are	VERB	O	O
often	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
fibrinolytic	ADJ	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
EACA	PROPN	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
thrombi	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
disseminated	VERB	O	B-Entity
intravascular	ADJ	O	I-Entity
coagulation	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
"	PUNCT	O	O
consumption	NOUN	O	B-Entity
coagulopathies	NOUN	O	I-Entity
.	PUNCT	O	O

"	PUNCT	O	O
This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
subtotal	ADJ	O	O
infarction	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
thrombosis	NOUN	O	B-Entity
of	ADP	O	I-Entity
a	DET	O	I-Entity
normal	ADJ	O	I-Entity
renal	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
occlusion	NOUN	O	O
occurred	VERB	O	O
after	ADP	O	O
EACA	PROPN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
SAH	PROPN	O	I-Entity
and	CCONJ	O	O
histopathological	ADJ	O	O
documentation	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
SAH	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
corresponding	VERB	O	O
clinical	ADJ	O	O
event	NOUN	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
marked	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
abrupt	ADJ	O	O
neurological	ADJ	O	O
deterioration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (573555)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
propranolol	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
:	PUNCT	O	O
maternal	ADJ	O	O
and	CCONJ	O	O
fetal	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Propranolol	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	NOUN	O	O
blocking	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
found	VERB	O	O
an	DET	O	O
important	ADJ	O	O
position	NOUN	O	O
in	ADP	O	O
the	DET	O	O
practice	NOUN	O	O
of	ADP	O	O
medicine	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
pregnancies	NOUN	O	O
are	VERB	O	O
reported	VERB	O	O
where	ADV	O	O
chronic	ADJ	O	O
propranolol	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
serial	ADJ	O	O
pregnancies	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
propranolol	NOUN	O	I-Entity
therapy	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
examined	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
previously	ADV	O	O
reported	VERB	O	O
hypoglycemia	NOUN	O	I-Entity
,	PUNCT	O	O
hyperbilirubinemia	NOUN	O	I-Entity
,	PUNCT	O	O
polycythemia	NOUN	O	I-Entity
,	PUNCT	O	O
neonatal	ADJ	O	B-Entity
apnea	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
invariable	ADJ	O	O
and	CCONJ	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
statistically	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
propranolol	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Growth	PROPN	O	B-Entity
retardation	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
significant	ADJ	O	O
in	ADP	O	O
both	DET	O	O
of	ADP	O	O
our	ADJ	O	O
series	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (611664)

Use	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
idiopathic	ADJ	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
physiologic	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
autonomic	ADJ	O	O
dysfunction	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
all	DET	O	O
exhibited	VERB	O	O
markedly	ADV	O	O
reduced	VERB	O	O
plasma	NOUN	O	O
catecholamines	NOUN	O	I-Entity
and	CCONJ	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
both	DET	O	O
recumbent	NOUN	O	O
and	CCONJ	O	O
upright	ADJ	O	O
positions	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
marked	VERB	O	O
hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
pressor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
infused	VERB	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
propanolol	NOUN	O	I-Entity
administered	VERB	O	O
intravenously	ADV	O	O
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
produced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
supine	NOUN	O	O
and	CCONJ	O	O
upright	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
4	NUM	O	O
of	ADP	O	O
the	DET	O	O
5	NUM	O	O
individuals	NOUN	O	O
with	ADP	O	O
rises	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
11/6	NUM	O	O
to	ADP	O	O
22/11	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
-	SYM	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
elevated	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
of	ADP	O	O
these	DET	O	O
individuals	NOUN	O	O
with	ADP	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
order	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
-	PUNCT	O	O
35/15	NUM	O	O
-	PUNCT	O	O
25	NUM	O	O
mmg	NOUN	O	O
being	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
marked	VERB	O	O
hypertension	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
drug	NOUN	O	O
had	VERB	O	O
to	PART	O	O
be	VERB	O	O
withdrawn	VERB	O	O
.	PUNCT	O	O

Hemodynamic	ADJ	O	O
measurements	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
demonstrated	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
essentially	ADV	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
following	VERB	O	O
propranolol	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
propranolol	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
drug	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
idiopathic	ADJ	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (612112)

Total	ADJ	O	O
intravenous	ADJ	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
etomidate	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
etomidate	NOUN	O	I-Entity
required	VERB	O	O
to	PART	O	O
maintain	VERB	O	O
sleep	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
undergoing	VERB	O	O
surgery	NOUN	O	O
under	ADP	O	O
regional	ADJ	O	O
local	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Premedication	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
atropine	NOUN	O	I-Entity
0.5	NUM	O	O
mg	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sleep	NOUN	O	O
was	VERB	O	O
induced	VERB	O	O
and	CCONJ	O	O
maintained	VERB	O	O
by	ADP	O	O
intermittent	ADJ	O	O
intravenous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
etomidate	NOUN	O	I-Entity
0.1/mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
given	VERB	O	O
whenever	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
would	VERB	O	O
open	VERB	O	O
his	ADJ	O	O
eyes	NOUN	O	O
on	ADP	O	O
request	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
mean	ADJ	O	O
overall	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
etomidate	NOUN	O	I-Entity
17.4	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
after	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
pain	NOUN	O	I-Entity
and	CCONJ	O	O
myoclonia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
caused	VERB	O	O
the	DET	O	O
technique	NOUN	O	O
to	PART	O	O
be	VERB	O	O
abandoned	VERB	O	O
in	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
considered	VERB	O	O
unlikely	ADJ	O	O
that	DET	O	O
etomidate	NOUN	O	I-Entity
will	VERB	O	O
prove	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
hypnotic	ADJ	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
a	DET	O	O
totally	ADV	O	O
intravenous	ADJ	O	O
anesthetic	NOUN	O	O
technique	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
myoclonia	NOUN	O	I-Entity
after	ADP	O	O
prolonged	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (689020)

A	DET	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
tocolytic	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
mimetics	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
method	NOUN	O	O
permitting	VERB	O	O
measurement	NOUN	O	O
of	ADP	O	O
finger	NOUN	O	O
tremor	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
displacement	NOUN	O	O
-	PUNCT	O	O
time	NOUN	O	O
curve	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
test	NOUN	O	O
system	NOUN	O	O
with	ADP	O	O
simple	ADJ	O	O
amplitude	NOUN	O	O
calibration	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
computer	NOUN	O	O
program	NOUN	O	O
,	PUNCT	O	O
periods	NOUN	O	O
and	CCONJ	O	O
amplitudes	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
oscillations	NOUN	O	O
were	VERB	O	O
calculated	VERB	O	O
and	CCONJ	O	O
classified	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
actions	NOUN	O	O
of	ADP	O	O
fenoterol	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
hydrobromide	NOUN	O	I-Entity
,	PUNCT	O	O
ritodrin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCl	PROPN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
given	VERB	O	O
to	ADP	O	O
10	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
by	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
crossover	ADJ	O	O
study	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
by	ADP	O	O
this	DET	O	O
method	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
both	DET	O	O
substances	NOUN	O	O
raised	VERB	O	O
the	DET	O	O
mean	ADJ	O	O
tremor	NOUN	O	I-Entity
amplitude	NOUN	O	O
to	ADP	O	O
about	ADP	O	O
three	NUM	O	O
times	NOUN	O	O
the	DET	O	O
control	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
fenoterol	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
hydrobromide	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
amplitudes	NOUN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
faster	ADV	O	O
than	ADP	O	O
those	DET	O	O
following	VERB	O	O
ritodrin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCl	PROPN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (733189)

Bilateral	ADJ	O	O
retinal	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
choriocapillaris	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
corticosteroid	ADJ	O	I-Entity
suspensions	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
:	PUNCT	O	O
I.	PUNCT	O	O
Clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
well	ADV	O	O
-	PUNCT	O	O
documented	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
retinal	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
choriocapillaris	NOUN	O	I-Entity
occlusions	NOUN	O	I-Entity
with	ADP	O	O
blindness	NOUN	O	I-Entity
following	VERB	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
soft	ADJ	O	O
-	PUNCT	O	O
tissue	NOUN	O	O
injection	NOUN	O	O
with	ADP	O	O
methylprednisolone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
,	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
penicillin	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	O
observations	NOUN	O	O
included	VERB	O	O
hazy	ADJ	O	O
sensorium	NOUN	O	O
,	PUNCT	O	O
superior	ADJ	O	O
gaze	NOUN	O	O
palsy	NOUN	O	I-Entity
,	PUNCT	O	O
pupillary	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
conjunctival	ADJ	O	O
hemorrhages	NOUN	O	I-Entity
with	ADP	O	O
edema	NOUN	O	I-Entity
.	PUNCT	O	O

Follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
changes	NOUN	O	O
showed	VERB	O	O
marked	ADJ	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
constricted	VERB	O	O
visual	ADJ	O	O
fields	NOUN	O	O
,	PUNCT	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
pallor	NOUN	O	O
,	PUNCT	O	O
vascular	ADJ	O	O
attenuation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
chorioretinal	ADJ	O	B-Entity
atrophy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (816141)

Cephalothin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
developed	VERB	O	O
Coombs	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
cephalothin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
cephalothin	NOUN	O	I-Entity
IgG	PROPN	O	O
antibody	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
serum	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
eluates	NOUN	O	O
from	ADP	O	O
her	ADJ	O	O
erythrocytes	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
nonimmunologic	ADJ	O	O
binding	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
patient	NOUN	O	O
's	PART	O	O
serum	NOUN	O	O
proteins	NOUN	O	O
to	ADP	O	O
her	ADJ	O	O
own	ADJ	O	O
and	CCONJ	O	O
cephalothin	ADJ	O	I-Entity
-	PUNCT	O	O
coated	ADJ	O	O
normal	ADJ	O	O
red	ADJ	O	O
cells	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

Skin	NOUN	O	O
tests	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
lymphocyte	NOUN	O	O
stimulation	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
sensitized	VERB	O	O
to	ADP	O	O
cephalothin	VERB	O	I-Entity
and	CCONJ	O	O
also	ADV	O	O
to	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

Careful	ADJ	O	O
investigation	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemias	NOUN	O	I-Entity
reveals	VERB	O	O
the	DET	O	O
complexity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
mechanisms	NOUN	O	O
involved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (851038)

Kaliuretic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	ADJ	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Hypokalemia	PROPN	O	I-Entity
,	PUNCT	O	O
sometimes	ADV	O	O
severe	ADJ	O	O
,	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
some	DET	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
5	NUM	O	O
normokalemic	ADJ	O	O
patients	NOUN	O	O
by	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
plasma	NOUN	O	O
flow	NOUN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
plasma	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
and	CCONJ	O	O
sodium	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
,	PUNCT	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
aldosterone	NOUN	O	I-Entity
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Dopa	PROPN	O	I-Entity
intake	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
cause	VERB	O	O
an	DET	O	O
increased	VERB	O	O
excretion	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sometimes	ADV	O	O
also	ADV	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hypokalemic	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
normokalemic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
why	ADV	O	O
this	DET	O	O
effect	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
some	DET	O	O
individuals	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
others	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
our	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
aldosterone	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
this	DET	O	O
renal	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (891494)

Phenytoin	PROPN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
as	ADP	O	O
probable	ADJ	O	O
idiosyncratic	ADJ	O	O
reaction	NOUN	O	O
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
(	PUNCT	O	O
DPH	PROPN	O	I-Entity
)	PUNCT	O	O

encephalopathy	NOUN	O	I-Entity
with	ADP	O	O
increasing	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
EEG	PROPN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
changes	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Despite	ADP	O	O
adequate	ADJ	O	O
oral	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
DPH	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
daily	ADV	O	O
)	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
very	ADV	O	O
low	ADJ	O	O
(	PUNCT	O	O
2.8	NUM	O	O
microgramg	NOUN	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
encephalopathy	NOUN	O	I-Entity
was	VERB	O	O
probably	ADV	O	O
an	DET	O	O
idiosyncratic	ADJ	O	O
and	CCONJ	O	O
not	ADV	O	O
toxic	ADJ	O	O
or	CCONJ	O	O
allergic	ADJ	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
fact	NOUN	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
DPH	PROPN	O	I-Entity
was	VERB	O	O
normal	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
a	DET	O	O
retarded	ADJ	O	O
morbilliform	NOUN	O	O
rash	NOUN	O	I-Entity
during	ADP	O	O
DPH	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
protidogram	NOUN	O	O
was	VERB	O	O
normal	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
intradermic	ADJ	O	O
DPH	PROPN	O	I-Entity
injection	NOUN	O	O
had	VERB	O	O
no	DET	O	O
local	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
conclude	VERB	O	O
that	ADP	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
starting	VERB	O	O
DPH	PROPN	O	I-Entity
treatment	NOUN	O	O
an	DET	O	O
unexpected	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
EEG	PROPN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
changes	NOUN	O	O
occurring	VERB	O	O
simultaneously	ADV	O	O
,	PUNCT	O	O
should	VERB	O	O
alert	VERB	O	O
the	DET	O	O
physician	NOUN	O	O
to	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
need	NOUN	O	O
for	ADP	O	O
eliminating	VERB	O	O
DPH	PROPN	O	I-Entity
from	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
if	ADP	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
are	VERB	O	O
low	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (895432)

Effects	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
E-1	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
exercise	VERB	O	O
control	NOUN	O	O
(	PUNCT	O	O
EC	PROPN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
exercised	VERB	O	O
daily	ADJ	O	O
for	ADP	O	O
thirty	NUM	O	O
days	NOUN	O	O
on	ADP	O	O
a	DET	O	O
treadmill	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
mph	NOUN	O	O
,	PUNCT	O	O
2%	NUM	O	O
grade	NOUN	O	O
while	ADP	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sedentary	ADJ	O	O
-	PUNCT	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
)	PUNCT	O	O
group	NOUN	O	O
remained	VERB	O	O
sedentary	ADJ	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
final	ADJ	O	O
exercise	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
and	CCONJ	O	O
E	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
animals	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
group	NOUN	O	O
exhibited	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
Pp	PROPN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
greater	ADJ	O	O
mortality	NOUN	O	O
from	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
than	ADP	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
E	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
CPK	PROPN	O	O
activity	NOUN	O	O
for	ADP	O	O
E	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
animals	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
for	ADP	O	O
animals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
and	CCONJ	O	O
EC	PROPN	O	O
groups	NOUN	O	O
twenty	NUM	O	O
hours	NOUN	O	O
following	VERB	O	O
isoproterenol	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
isoproterenol	NOUN	O	I-Entity
treated	VERB	O	O
groups	NOUN	O	O
for	ADP	O	O
severity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
induced	VERB	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
heart	NOUN	O	O
weight	NOUN	O	O
to	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
ratios	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicated	VERB	O	O
that	DET	O	O
exercise	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
mortality	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
dosages	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
but	CCONJ	O	O
had	VERB	O	O
little	ADJ	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (931801)

Effect	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Glucarates	PROPN	O	I-Entity
on	ADP	O	O
basic	ADJ	O	O
antibiotic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Dehydrated	VERB	O	I-Entity
rats	NOUN	O	O
regularly	ADV	O	O
develop	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
aminoglycoside	NOUN	O	I-Entity
antibiotics	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
dextran	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
antibiotics	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
2,5-di	NUM	O	B-Entity
-	PUNCT	O	I-Entity
O	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
acetyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
glucaro-1,4	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
6,3-dilactone	NOUN	O	I-Entity
protected	VERB	O	O
rats	NOUN	O	O
against	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
kanamycin	NOUN	O	I-Entity
-	PUNCT	O	O
dextran	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
prevalent	ADJ	O	O
among	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
glucarates	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
to	ADP	O	O
other	ADJ	O	O
saccharic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
hexauronic	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
and	CCONJ	O	O
hexaaldonic	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
to	ADP	O	O
a	DET	O	O
lesser	ADJ	O	O
degree	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
to	ADP	O	O
a	DET	O	O
hexaaldose	NOUN	O	O
,	PUNCT	O	O
sugar	NOUN	O	B-Entity
alcohols	NOUN	O	I-Entity
,	PUNCT	O	O
substances	NOUN	O	O
inthe	VERB	O	O
TCA	PROPN	O	I-Entity
cycle	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
acidic	ADJ	O	O
compounds	NOUN	O	O
.	PUNCT	O	O

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Glucarates	PROPN	O	I-Entity
were	VERB	O	O
effective	ADJ	O	O
against	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
peptide	NOUN	O	O
antibiotics	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
various	ADJ	O	O
aminoglycoside	NOUN	O	I-Entity
antibitocis	NOUN	O	O
.	PUNCT	O	O

Dose	NOUN	O	O
-	PUNCT	O	O
responses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Glucarates	PROPN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
a	DET	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
glucarate	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
size	NOUN	O	O
of	ADP	O	O
dose	NOUN	O	O
,	PUNCT	O	O
approximately	ADV	O	O
the	DET	O	O
same	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
protection	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
against	ADP	O	O
renal	ADJ	O	B-Entity
damages	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
different	ADJ	O	O
basic	ADJ	O	O
antibiotics	NOUN	O	O
despite	ADP	O	O
large	ADJ	O	O
disparities	NOUN	O	O
in	ADP	O	O
administration	NOUN	O	O
doses	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
antibiotics	NOUN	O	O
.	PUNCT	O	O

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Glucarates	PROPN	O	I-Entity
had	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
to	PART	O	O
cure	VERB	O	O
it	PRON	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
excreted	VERB	O	O
acidic	ADJ	O	O
urine	NOUN	O	O
when	ADV	O	O
they	PRON	O	O
were	VERB	O	O
spared	VERB	O	O
from	ADP	O	O
renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
by	ADP	O	O
monosaccharides	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
glucarates	NOUN	O	I-Entity
against	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
basic	ADJ	O	O
antibiotics	NOUN	O	O
was	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (946593)

Paraplegia	PROPN	O	I-Entity
following	VERB	O	O
intrathecal	ADJ	O	O
methotrexate	NOUN	O	I-Entity
:	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
case	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
paraplegia	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
intrathecal	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	I-Entity
is	VERB	O	O
discribed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
following	VERB	O	O
factors	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
predispose	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
:	PUNCT	O	O
abnormal	ADJ	O	O
cerebrospinal	ADJ	O	O
dynamics	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
leukemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
epidural	ADJ	O	O
cerebrospinal	ADJ	O	O
leakage	NOUN	O	O
;	PUNCT	O	O
elevated	ADJ	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
methothexate	NOUN	O	I-Entity
concentration	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
abnormal	ADJ	O	O
cerebrospinal	ADJ	O	O
fluid	ADJ	O	O
dynamics	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
inappropriately	ADV	O	O
high	ADJ	O	O
methotrexate	NOUN	O	I-Entity
doses	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
calculations	NOUN	O	O
in	ADP	O	O
older	ADJ	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
neurotoxic	ADJ	O	I-Entity
preservatives	NOUN	O	O
in	ADP	O	O
commercially	ADV	O	O
available	ADJ	O	O
methotrexate	NOUN	O	I-Entity
preparations	NOUN	O	O
and	CCONJ	O	O
diluents	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	I-Entity
diluents	NOUN	O	O
of	ADP	O	O
unphysiologic	ADJ	O	O
pH	NOUN	O	O
,	PUNCT	O	O
ionic	ADJ	O	O
content	NOUN	O	O
and	CCONJ	O	O
osmolarity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	I-Entity
contaminants	NOUN	O	O
,	PUNCT	O	O
local	ADJ	O	O
folate	ADJ	O	B-Entity
deficiency	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cranial	ADJ	O	O
irradiation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
methotrexate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
employing	VERB	O	O
lower	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
leukemia	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
older	ADJ	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
leakage	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
preservative	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
methotrexate	NOUN	O	I-Entity
in	ADP	O	O
Elliott	PROPN	O	O
's	PART	O	O
B	PROPN	O	O
Solution	PROPN	O	O
at	ADP	O	O
a	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
not	ADV	O	O
more	ADJ	O	O
than	ADP	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
for	ADP	O	O
intrathecal	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Periodic	ADJ	O	O
monitoring	NOUN	O	O
of	ADP	O	O
cerebruspinal	ADJ	O	O
fluid	ADJ	O	O
methotrexate	NOUN	O	I-Entity
levels	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
predictive	ADJ	O	O
of	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (978847)

Centrally	ADV	O	O
mediated	VERB	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
intracisternal	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
carbachol	NOUN	O	I-Entity
in	ADP	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
carbachol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
guanethidine	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hexamethonium	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
phentolamine	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
conversely	ADV	O	O
,	PUNCT	O	O
potentiated	VERB	O	O
by	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

desmethylimipramine	NOUN	O	I-Entity
(	PUNCT	O	O
0.3	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

selectively	ADV	O	O
inhibited	VERB	O	O
the	DET	O	O
enlargement	NOUN	O	B-Entity
of	ADP	O	I-Entity
pulse	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
tachycardia	NOUN	O	I-Entity
following	VERB	O	O
i.c	NOUN	O	O
.	PUNCT	O	O

carbachol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

carbachol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
almost	ADV	O	O
completely	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
i.c	NOUN	O	O
.	PUNCT	O	O

atropine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
hexamethonium	NOUN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
i.c	PROPN	O	O
.	PUNCT	O	O

chlorpromazine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O

desmethylimipramine	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

carbachol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
after	ADP	O	O
sectioning	VERB	O	O
of	ADP	O	O
the	DET	O	O
bilateral	ADJ	O	O
cervical	ADJ	O	O
vagal	ADJ	O	O
nerves	NOUN	O	O
but	CCONJ	O	O
disappeared	VERB	O	O
after	ADP	O	O
sectioning	VERB	O	O
of	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
(	PUNCT	O	O
C7-C8	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

carbachol	NOUN	O	I-Entity
ortral	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
adrenergic	NOUN	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
sympathetic	ADJ	O	O
trunk	NOUN	O	O
is	VERB	O	O
the	DET	O	O
main	ADJ	O	O
pathway	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1117341)

Hyperglycemic	PROPN	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
amino	NOUN	O	I-Entity
compounds	NOUN	O	O
structurally	ADV	O	O
related	VERB	O	O
to	ADP	O	O
caproate	VERB	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
chronic	ADJ	O	O
feeding	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
amounts	NOUN	O	O
(	PUNCT	O	O
0.3	NUM	O	O
-	SYM	O	O
3%	NUM	O	O
of	ADP	O	O
diet	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
certain	ADJ	O	O
amino	ADJ	O	I-Entity
derivatives	NOUN	O	O
of	ADP	O	O
caproate	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
hyperglycemia	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
elevated	ADJ	O	O
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	O
curve	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
occasionally	ADV	O	O
,	PUNCT	O	O
glucosuria	NOUN	O	I-Entity
.	PUNCT	O	O

Effective	ADJ	O	O
compounds	NOUN	O	O
included	VERB	O	O
norleucine	NOUN	O	I-Entity
,	PUNCT	O	O
norvaline	NOUN	O	I-Entity
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
,	PUNCT	O	O
epsilon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproate	NOUN	O	I-Entity
,	PUNCT	O	O
methionine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
leucine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1158089)

Fatty	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tetracycline	ADV	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
relationships	NOUN	O	O
,	PUNCT	O	O
biochemical	ADJ	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sex	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
fatty	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tetracycline	ADV	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
rat	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
rat	NOUN	O	O
liver	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
rat	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
direct	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
dose	NOUN	O	O
of	ADP	O	O
tetracycline	NOUN	O	I-Entity
and	CCONJ	O	O
hepatic	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
provision	NOUN	O	O
of	ADP	O	O
adequate	ADJ	O	O
oleic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
substrate	NOUN	O	O
for	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
liver	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
direct	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
dose	NOUN	O	O
of	ADP	O	O
tetracycline	NOUN	O	I-Entity
and	CCONJ	O	O
both	DET	O	O
accumulation	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
output	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
by	ADP	O	O
livers	NOUN	O	O
from	ADP	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Marked	VERB	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
female	ADJ	O	O
and	CCONJ	O	O
male	ADJ	O	O
rats	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
base	NOUN	O	O
line	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
hepatic	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
and	CCONJ	O	O
output	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
.	PUNCT	O	O

Accumulation	PROPN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
triglyceride	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
per	NOUN	O	O
cent	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
graded	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
tetracycline	NOUN	O	I-Entity
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
male	ADJ	O	O
,	PUNCT	O	O
female	ADJ	O	O
and	CCONJ	O	O
pregnant	ADJ	O	O
rat	NOUN	O	O
livers	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
livers	NOUN	O	O
from	ADP	O	O
female	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
especially	ADV	O	O
pregnant	ADJ	O	O
female	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
strikingly	ADV	O	O
resistant	ADJ	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
tetracycline	NOUN	O	I-Entity
on	ADP	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
output	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
under	ADP	O	O
these	DET	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
sexes	NOUN	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
altered	VERB	O	O
disposition	NOUN	O	O
of	ADP	O	O
tetracycline	ADV	O	I-Entity
or	CCONJ	O	O
altered	VERB	O	O
uptake	NOUN	O	O
of	ADP	O	O
oleic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Depressed	ADJ	O	O
hepatic	ADJ	O	O
secretion	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
accounted	VERB	O	O
only	ADV	O	O
for	ADP	O	O
30	NUM	O	O
to	PART	O	O
50%	NUM	O	O
of	ADP	O	O
accumulated	VERB	O	O
hepatic	ADJ	O	O
triglyceride	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
additional	ADJ	O	O
mechanisms	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
the	DET	O	O
triglyceride	NOUN	O	I-Entity
-	PUNCT	O	O
rich	ADJ	O	O
fatty	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
tetracycline	ADV	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1280054)

Fatal	ADJ	O	O
myeloencephalopathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
intrathecal	ADJ	O	O
vincristine	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Vincristine	PROPN	O	I-Entity
was	VERB	O	O
accidentally	ADV	O	O
given	VERB	O	O
intrathecally	ADV	O	O
to	ADP	O	O
a	DET	O	O
child	NOUN	O	O
with	ADP	O	O
leukaemia	NOUN	O	I-Entity
,	PUNCT	O	O
producing	VERB	O	O
sensory	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
motor	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
encephalopathy	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

Separate	ADJ	O	O
times	NOUN	O	O
for	ADP	O	O
administering	VERB	O	O
vincristine	NOUN	O	I-Entity
and	CCONJ	O	O
intrathecal	ADJ	O	O
therapy	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1280707)

Progesterone	NOUN	O	I-Entity
potentiation	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmogenicity	NOUN	O	O
in	ADP	O	O
pentobarbital	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
beating	VERB	O	O
rat	ADJ	O	O
heart	NOUN	O	O
cell	NOUN	O	O
cultures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
progesterone	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmogenicity	NOUN	O	O
in	ADP	O	O
beating	VERB	O	O
rat	NOUN	O	O
heart	NOUN	O	O
myocyte	NOUN	O	O
cultures	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
determining	VERB	O	O
the	DET	O	O
bupivacaine	NOUN	O	I-Entity
AD50	PROPN	O	O
(	PUNCT	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
that	ADJ	O	O
caused	VERB	O	O
50%	NUM	O	O
of	ADP	O	O
all	DET	O	O
beating	VERB	O	O
rat	ADJ	O	O
heart	NOUN	O	O
myocyte	NOUN	O	O
cultures	NOUN	O	O
to	PART	O	O
become	VERB	O	O
arrhythmic	ADJ	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
determined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
1-hour	NUM	O	O
progesterone	NOUN	O	I-Entity
HCl	NOUN	O	I-Entity
exposure	NOUN	O	O
on	ADP	O	O
myocyte	NOUN	O	O
contractile	NOUN	O	O
rhythm	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
progesterone	NOUN	O	I-Entity
(	PUNCT	O	O
6.25	NUM	O	O
,	PUNCT	O	O
12.5	NUM	O	O
,	PUNCT	O	O
25	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
50	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
ml	ADV	O	O
)	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
and	CCONJ	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
AD50	PROPN	O	O
for	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

Estradiol	PROPN	O	I-Entity
treatment	NOUN	O	O
also	ADV	O	O
increased	VERB	O	O
the	DET	O	O
arrhythmogenicity	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
in	ADP	O	O
myocyte	NOUN	O	O
cultures	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
only	ADV	O	O
one	NUM	O	O
fourth	ADJ	O	O
as	ADV	O	O
potent	ADJ	O	O
as	ADP	O	O
progesterone	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	DET	O	O
progesterone	NOUN	O	I-Entity
nor	CCONJ	O	O
estradiol	ADJ	O	I-Entity
effects	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmogenicity	NOUN	O	O
were	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
progesterone	NOUN	O	I-Entity
pretreatment	NOUN	O	O

(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmogenicity	NOUN	O	O
in	ADP	O	O
intact	ADJ	O	O
pentobarbital	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
time	NOUN	O	O
to	PART	O	O
onset	NOUN	O	O
of	ADP	O	O
arrhythmia	NOUN	O	I-Entity
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
nonprogesterone	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
6.2	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
progesterone	NOUN	O	I-Entity
can	VERB	O	O
potentiate	VERB	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmogenicity	NOUN	O	O
both	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

Potentiation	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
arrhythmia	NOUN	O	I-Entity
in	ADP	O	O
myocyte	NOUN	O	O
cultures	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
at	ADV	O	O
least	ADJ	O	O
partly	ADV	O	O
mediated	VERB	O	O
at	ADP	O	O
the	DET	O	O
myocyte	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1289188)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
occurring	VERB	O	O
during	ADP	O	O
intravenous	ADJ	O	O
desferrioxamine	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
recovery	NOUN	O	O
after	ADP	O	O
haemodialysis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
transfusion	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
thalassemia	NOUN	O	I-Entity
was	VERB	O	O
undergoing	VERB	O	O
home	ADV	O	O
intravenous	ADJ	O	O
desferrioxamine	NOUN	O	I-Entity
(	PUNCT	O	O
DFX	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
totally	ADV	O	O
implanted	ADJ	O	O
system	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
his	ADJ	O	O
poor	ADJ	O	O
compliance	NOUN	O	O
with	ADP	O	O
the	DET	O	O
nightly	ADJ	O	O
subcutaneous	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Due	ADP	O	O
to	ADP	O	O
an	DET	O	O
accidental	ADJ	O	O
malfunctioning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
pump	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
inadvertently	ADV	O	O
administered	VERB	O	O
a	DET	O	O
toxic	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
which	ADJ	O	O
caused	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
progressive	ADJ	O	O
deterioration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
laboratory	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
adequate	ADJ	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
decision	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
to	PART	O	O
introduce	VERB	O	O
haemodialytical	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
remove	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
therapy	NOUN	O	O
reduce	VERB	O	O
the	DET	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
results	NOUN	O	O
obtained	VERB	O	O
,	PUNCT	O	O
haemodialysis	NOUN	O	O
can	VERB	O	O
therefore	ADV	O	O
be	VERB	O	O
suggested	VERB	O	O
as	ADP	O	O
a	DET	O	O
useful	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
rare	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
desferrioxamine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1359137)

Neuroleptic	ADJ	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

Can	VERB	O	O
it	PRON	O	O
be	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
bromocriptine	NOUN	O	I-Entity
?	PUNCT	O	O

Six	NUM	O	O
stable	ADJ	O	O
psychiatric	ADJ	O	O
outpatients	NOUN	O	O
with	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
amenorrhea	NOUN	O	I-Entity
/	SYM	O	O
oligomenorrhea	ADV	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
their	ADJ	O	O
neuroleptic	ADJ	O	B-Entity
medications	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
bromocriptine	NOUN	O	I-Entity
.	PUNCT	O	O

Daily	ADJ	O	O
dosages	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mg	NUM	O	O
corrected	VERB	O	O
the	DET	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
restored	VERB	O	O
menstruation	NOUN	O	O
in	ADP	O	O
four	NUM	O	O
of	ADP	O	O
the	DET	O	O
six	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
woman	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
developed	VERB	O	O
worsened	VERB	O	O
psychiatric	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
bromocriptine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
their	ADJ	O	O
menstrual	ADJ	O	O
irregularity	NOUN	O	O
successfully	ADV	O	O
corrected	VERB	O	O
with	ADP	O	O
bromocriptine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
suggests	VERB	O	O
that	ADP	O	O
bromocriptine	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
further	ADV	O	O
evaluated	VERB	O	O
as	ADP	O	O
potential	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
neuroleptic	ADJ	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
amenorrhea	NOUN	O	I-Entity
/	SYM	O	O
galactorrhea	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1360900)

Ethacrynic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
brain	NOUN	O	O
neurotransmitters	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
ethacrynic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
50%	NUM	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O

;	PUNCT	O	O
50	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
)	PUNCT	O	O
accelerated	VERB	O	O
the	DET	O	O
synthesis	NOUN	O	O
/	SYM	O	O
turnover	NOUN	O	O
of	ADP	O	O
5-hydroxytryptamine	NUM	O	I-Entity
(	PUNCT	O	O
5-HT	NUM	O	I-Entity
)	PUNCT	O	O
but	CCONJ	O	O
suppressed	VERB	O	O
the	DET	O	O
synthesis	NOUN	O	O
of	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
and	CCONJ	O	O
acetylcholine	NOUN	O	I-Entity
in	ADP	O	O
mouse	NOUN	O	O
brain	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
completely	ADV	O	O
antagonized	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
glutamate	NOUN	O	I-Entity
/	SYM	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
aminophosphonovaleric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
ethacrynic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
these	DET	O	O
neurotransmitter	NOUN	O	O
systems	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
differentially	ADV	O	O
modulated	VERB	O	O
,	PUNCT	O	O
probably	ADV	O	O
through	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
glutaminergic	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1361574)

Pharmacology	NOUN	O	O
of	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acidA	PROPN	O	I-Entity
receptor	NOUN	O	O
complex	NOUN	O	O
after	ADP	O	O
the	DET	O	O
in	ADP	O	O
vivo	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anxioselective	ADJ	O	O
and	CCONJ	O	O
anticonvulsant	ADJ	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carboline	NOUN	O	I-Entity
derivative	ADJ	O	O
abecarnil	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
rodents	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carboline	NOUN	O	I-Entity
derivative	ADJ	O	O
isopropyl-6-	NOUN	O	B-Entity
benzyloxy-4-methoxymethyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
carboline-3-carboxylate	NOUN	O	I-Entity
(	PUNCT	O	O
abecarrnil	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
ligand	NOUN	O	O
for	ADP	O	O
benzodiazepine	NOUN	O	I-Entity
receptors	NOUN	O	O
possessing	VERB	O	O
anxiolytic	ADJ	O	O
and	CCONJ	O	O
anticonvulsant	ADJ	O	O
properties	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
on	ADP	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA)A	PROPN	O	I-Entity
receptor	NOUN	O	O
complex	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

Added	VERB	O	O
in	ADP	O	O
vitro	NOUN	O	O
to	ADP	O	O
rat	VERB	O	O
cortical	ADJ	O	O
membrane	NOUN	O	O
preparation	NOUN	O	O
,	PUNCT	O	O
abecarnil	ADV	O	I-Entity
increased	VERB	O	O
[	PUNCT	O	O
3H]GABA	NUM	O	I-Entity
binding	VERB	O	O
,	PUNCT	O	O
enhanced	ADJ	O	O
muscimol	NOUN	O	I-Entity
-	PUNCT	O	O
stimulated	VERB	O	O
36Cl-	NOUN	O	O
uptake	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
the	DET	O	O
binding	NOUN	O	O
of	ADP	O	O
t-[35S]butylbicyclophosphorothionate	PROPN	O	I-Entity
(	PUNCT	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
induced	VERB	O	O
by	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
partial	ADJ	O	O
agonist	NOUN	O	O
Ro	PROPN	O	B-Entity
16	NUM	O	I-Entity
-	SYM	O	I-Entity
6028	NUM	O	I-Entity
(	PUNCT	O	O
tert	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
butyl-(S)-8-bromo-11,12,13,13a	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
tetrahydro-9-oxo-9H-	NOUN	O	I-Entity
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	NOUN	O	I-Entity
)	PUNCT	O	O
showed	VERB	O	O
very	ADV	O	O
weak	ADJ	O	O
efficacy	NOUN	O	O
in	ADP	O	O
these	DET	O	O
biochemical	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
to	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
abecarnil	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
decreased	VERB	O	O
in	ADP	O	O
a	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
(	PUNCT	O	O
0.25	NUM	O	O
-	SYM	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

manner	NOUN	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NOUN	O	I-Entity
binding	VERB	O	O
measured	VERB	O	O
ex	NOUN	O	O
vivo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cerebral	ADJ	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
both	DET	O	O
drugs	NOUN	O	O
at	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
antagonized	VERB	O	O
completely	ADV	O	O
the	DET	O	O
convulsant	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NUM	O	I-Entity
binding	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
isoniazide	NOUN	O	I-Entity
(	PUNCT	O	O
350	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NUM	O	I-Entity
binding	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
foot	NOUN	O	O
-	PUNCT	O	O
shock	NOUN	O	O
stress	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
better	ADV	O	O
correlate	VERB	O	O
the	DET	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
pharmacological	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
abecarnil	NOUN	O	I-Entity
on	ADP	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NUM	O	I-Entity
binding	VERB	O	O
,	PUNCT	O	O
exploratory	ADJ	O	O
motility	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
isoniazid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
,	PUNCT	O	O
abecarnil	ADV	O	I-Entity
produced	VERB	O	O
a	DET	O	O
paralleled	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
(	PUNCT	O	O
0.05	NUM	O	O
-	SYM	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
reduction	NOUN	O	O
of	ADP	O	O
both	DET	O	O
motor	NOUN	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
cortical	ADJ	O	O
[	PUNCT	O	O
35S]TBPS	NUM	O	O
binding	VERB	O	O
.	PUNCT	O	O

kg	X	O	O
of	ADP	O	O
this	DET	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carboline	NOUN	O	I-Entity
reduced	VERB	O	O
markedly	ADV	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
35S]TBPS	NUM	O	I-Entity
binding	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
isoniazid	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c.).(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (1395192)

Recurrent	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
postpartum	NOUN	O	O
patient	NOUN	O	O
receiving	VERB	O	O
bromocriptine	NOUN	O	I-Entity
.	PUNCT	O	O

Myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
puerperium	NOUN	O	O
is	VERB	O	O
infrequently	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Spasm	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	O
dissection	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
atheromatous	ADJ	O	O
etiology	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Bromocriptine	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
previous	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
puerperium	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
generally	ADV	O	O
regarded	VERB	O	O
as	ADP	O	O
"	PUNCT	O	O
safe	ADJ	O	O
,	PUNCT	O	O
"	PUNCT	O	O
possible	ADJ	O	O
serious	ADJ	O	O
cardiac	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
acknowledged	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1420650)

Asterixis	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
carbamazepine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
very	ADV	O	O
few	ADJ	O	O
reports	NOUN	O	O
about	ADP	O	O
asterixis	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
psychopharmacologic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
we	PRON	O	O
present	VERB	O	O
four	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
psychotropic	NOUN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
whom	NOUN	O	O
asterixis	NOUN	O	I-Entity
was	VERB	O	O
triggered	VERB	O	O
either	ADV	O	O
by	ADP	O	O
adding	VERB	O	O
carbamazepine	NOUN	O	I-Entity
(	PUNCT	O	O
CBZ	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
by	ADP	O	O
increasing	VERB	O	O
its	ADJ	O	O
dosage	NOUN	O	O
.	PUNCT	O	O

Neither	DET	O	O
dosage	NOUN	O	O
nor	CCONJ	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
were	VERB	O	O
in	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
range	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
consider	VERB	O	O
asterixis	NOUN	O	I-Entity
to	PART	O	O
be	VERB	O	O
an	DET	O	O
easily	ADV	O	O
overlooked	VERB	O	O
sign	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
occur	VERB	O	O
even	ADV	O	O
at	ADP	O	O
low	ADJ	O	O
or	CCONJ	O	O
moderate	ADJ	O	O
dosage	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
if	ADP	O	O
certain	ADJ	O	O
drugs	NOUN	O	O
as	ADP	O	O
lithium	NOUN	O	I-Entity
or	CCONJ	O	O
clozapine	NOUN	O	I-Entity
are	VERB	O	O
used	VERB	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
CBZ	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1423336)

Pharmacodynamics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

levodopa	NOUN	O	I-Entity
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
and	CCONJ	O	O
fluctuating	VERB	O	O
responses	NOUN	O	O
to	ADP	O	O
levodopa	VERB	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
was	VERB	O	O
concentration	NOUN	O	O
dependent	ADJ	O	O
and	CCONJ	O	O
was	VERB	O	O
fit	ADJ	O	O
to	ADP	O	O
an	DET	O	O
Emax	PROPN	O	O
model	NOUN	O	O
in	ADP	O	O
fluctuating	VERB	O	O
responders	NOUN	O	O
.	PUNCT	O	O

Stable	ADJ	O	O
responders	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
small	ADJ	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
.	PUNCT	O	O

Baseline	ADJ	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
were	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
fluctuating	VERB	O	O
patients	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
greater	ADJ	O	O
hypotensive	ADJ	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

Antiparkinsonian	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
temporally	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Phenylalanine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
large	ADJ	O	O
neutral	ADJ	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
LNAA	PROPN	O	O
)	PUNCT	O	O
competing	VERB	O	O
with	ADP	O	O
levodopa	NOUN	O	I-Entity
for	ADP	O	O
transport	NOUN	O	O
across	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
hypotensive	NOUN	O	I-Entity
and	CCONJ	O	O
antiparkinsonian	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
levodopa	NOUN	O	I-Entity
has	VERB	O	O
a	DET	O	O
central	ADJ	O	O
hypotensive	ADJ	O	I-Entity
action	NOUN	O	O
that	ADJ	O	O
parallels	VERB	O	O
the	DET	O	O
motor	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
fluctuating	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
we	PRON	O	O
observed	VERB	O	O
in	ADP	O	O
fluctuating	VERB	O	O
patients	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
stable	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1424076)

Syndrome	PROPN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
secretion	NOUN	O	I-Entity
of	ADP	O	I-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
after	ADP	O	O
infusional	ADJ	O	O
vincristine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
77-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
refractory	ADJ	O	O
multiple	NOUN	O	B-Entity
myeloma	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
4-day	NUM	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
.	PUNCT	O	O

Nine	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
her	ADJ	O	O
second	ADJ	O	O
cycle	NOUN	O	O
she	PRON	O	O
presented	VERB	O	O
with	ADP	O	O
lethargy	NOUN	O	I-Entity
and	CCONJ	O	O
weakness	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
hyponatremia	NOUN	O	I-Entity
.	PUNCT	O	O

Evaluation	NOUN	O	O
revealed	VERB	O	O
the	DET	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
secretion	NOUN	O	I-Entity
of	ADP	O	I-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
vincristine	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
normal	ADJ	O	O
serum	NOUN	O	O
sodium	NOUN	O	I-Entity
levels	NOUN	O	O
returned	VERB	O	O
,	PUNCT	O	O
further	ADV	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
without	ADP	O	O
vincristine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
this	DET	O	O
complication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1449452)

Heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
to	PART	O	O
digitalise	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
?	PUNCT	O	O

Despite	ADP	O	O
extensive	ADJ	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
digoxin	NOUN	O	I-Entity
is	VERB	O	O
still	ADV	O	O
not	ADV	O	O
well	ADV	O	O
defined	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
digoxin	NOUN	O	I-Entity
is	VERB	O	O
beneficial	ADJ	O	O
for	ADP	O	O
ventricular	ADJ	O	O
rate	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
the	DET	O	O
situation	NOUN	O	O
is	VERB	O	O
less	ADV	O	O
clear	ADJ	O	O
.	PUNCT	O	O

Digoxin	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
narrow	ADJ	O	O
therapeutic	NOUN	O	O
:	PUNCT	O	O
toxic	ADJ	O	O
ratio	NOUN	O	O
and	CCONJ	O	O
concentrations	NOUN	O	O
are	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
digoxin	NOUN	O	I-Entity
has	VERB	O	O
undesirable	ADJ	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
increasing	VERB	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
demands	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
causing	VERB	O	O
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

More	ADV	O	O
convincing	ADJ	O	O
evidence	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
showing	VERB	O	O
that	ADP	O	O
digoxin	NOUN	O	I-Entity
improves	VERB	O	O
symptoms	NOUN	O	O
or	CCONJ	O	O
exercise	NOUN	O	O
capacity	NOUN	O	O
.	PUNCT	O	O

Pooled	VERB	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
inotropic	ADJ	O	O
drugs	NOUN	O	O
shows	VERB	O	O
an	DET	O	O
excess	ADJ	O	O
mortality	NOUN	O	O
and	CCONJ	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
digoxin	NOUN	O	I-Entity
may	VERB	O	O
increase	VERB	O	O
mortality	NOUN	O	O
after	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Angiotensin	PROPN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
inhibitors	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
first	ADV	O	O
as	ADP	O	O
they	PRON	O	O
are	VERB	O	O
safer	ADJ	O	O
,	PUNCT	O	O
do	VERB	O	O
not	ADV	O	O
require	VERB	O	O
blood	NOUN	O	O
level	NOUN	O	O
monitoring	NOUN	O	O
,	PUNCT	O	O
modify	VERB	O	O
progression	NOUN	O	O
of	ADP	O	O
disease	NOUN	O	O
,	PUNCT	O	O
relieve	VERB	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
improve	VERB	O	O
exercise	NOUN	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
reduce	VERB	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Caution	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
exercised	VERB	O	O
in	ADP	O	O
using	VERB	O	O
digoxin	NOUN	O	I-Entity
until	ADP	O	O
large	ADJ	O	O
mortality	NOUN	O	O
trials	NOUN	O	O
are	VERB	O	O
completed	VERB	O	O
showing	VERB	O	O
either	CCONJ	O	O
benefit	NOUN	O	O
or	CCONJ	O	O
harm	NOUN	O	O
.	PUNCT	O	O

Until	ADP	O	O
then	ADV	O	O
digoxin	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
a	DET	O	O
third	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1522360)

Intravascular	ADJ	O	O
hemolysis	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
intermittent	ADJ	O	O
rifampin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
rifampin	NOUN	O	I-Entity
.	PUNCT	O	O

Intravascular	ADJ	O	O
hemolysis	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
rifampin	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
extremely	ADV	O	O
rare	ADJ	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
leprosy	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
hemolysis	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
rifampin	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1556529)

Zidovudine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
zidovudine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
38-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
AIDS	PROPN	O	I-Entity
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
whereby	ADV	O	O
the	DET	O	O
hepatitis	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
tolerated	VERB	O	O
well	ADV	O	O
an	DET	O	O
alternative	ADJ	O	O
reverse	NOUN	O	O
transcriptase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
2'3	NUM	O	B-Entity
'	PUNCT	O	I-Entity
dideoxyinosine	ADV	O	I-Entity
.	PUNCT	O	O

Physicians	NOUN	O	O
caring	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AIDS	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
hitherto	ADV	O	O
rarely	ADV	O	O
reported	VERB	O	O
complication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1563460)

Thoracic	PROPN	O	B-Entity
hematomyelia	NOUN	O	I-Entity
secondary	ADJ	O	O
to	PART	O	O
coumadin	VERB	O	I-Entity
anticoagulant	NOUN	O	O
therapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
thoracic	ADJ	O	B-Entity
hematomyelia	NOUN	O	I-Entity
secondary	ADJ	O	O
to	PART	O	O
anticoagulant	VERB	O	O
therapy	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1564030)

Mania	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Fluoxetine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
gaining	VERB	O	O
increased	VERB	O	O
acceptance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
adolescent	ADJ	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

Generally	ADV	O	O
safe	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
by	ADP	O	O
adults	NOUN	O	O
,	PUNCT	O	O
fluoxetine	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
induce	VERB	O	O
mania	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
depressed	ADJ	O	I-Entity
adolescents	NOUN	O	O
,	PUNCT	O	O
14	NUM	O	O
-	SYM	O	O
16	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
mania	NOUN	O	I-Entity
during	ADP	O	O
pharmacotherapy	NOUN	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
reported	VERB	O	O
here	ADV	O	O
.	PUNCT	O	O

Apparent	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
mania	NOUN	O	I-Entity
or	CCONJ	O	O
hypomania	NOUN	O	I-Entity
during	ADP	O	O
fluoxetine	NOUN	O	I-Entity
pharmacotherapy	NOUN	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
were	VERB	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
attention	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
deficit	NOUN	O	I-Entity
hyperactivity	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
and	CCONJ	O	O
affective	ADJ	O	O
instability	NOUN	O	O
;	PUNCT	O	O
major	ADJ	O	O
depression	NOUN	O	I-Entity
with	ADP	O	O
psychotic	ADJ	O	I-Entity
features	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
family	NOUN	O	O
history	NOUN	O	O
of	ADP	O	O
affective	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Further	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
optimal	ADJ	O	O
dosage	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
identify	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
that	ADJ	O	O
increase	VERB	O	O
individual	ADJ	O	O
vulnerability	NOUN	O	O
to	PART	O	O
fluoxetine	VERB	O	I-Entity
induced	VERB	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1615846)

Gemfibrozil	PROPN	O	I-Entity
-	PUNCT	O	O
lovastatin	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
primary	ADJ	O	O
hyperlipoproteinemias	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
specific	ADJ	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
retrospective	NOUN	O	O
,	PUNCT	O	O
observational	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
(	PUNCT	O	O
21	NUM	O	O
months	NOUN	O	O
/	SYM	O	O
patient	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
,	PUNCT	O	O
gemfibrozil	NOUN	O	I-Entity
-	PUNCT	O	O
lovastatin	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
80	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
mixed	ADJ	O	O
hyperlipidemia	NOUN	O	I-Entity
(	PUNCT	O	O
68%	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
atherosclerotic	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Because	ADP	O	O
ideal	ADJ	O	O
lipid	NOUN	O	O
targets	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
reached	VERB	O	O
(	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
LDL	PROPN	O	O
)	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
130	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
HDL	PROPN	O	O
)	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
35	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
/	SYM	O	O
HDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
4.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
diet	NOUN	O	O
plus	CCONJ	O	O
a	DET	O	O
single	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
gemfibrozil	NOUN	O	I-Entity
(	PUNCT	O	O
1.2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day)-lovastatin	NOUN	O	I-Entity
(	PUNCT	O	O
primarily	ADV	O	O
20	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

Follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
visits	NOUN	O	O
were	VERB	O	O
scheduled	VERB	O	O
with	ADP	O	O
2-drug	NUM	O	O
therapy	NOUN	O	O
every	DET	O	O
6	NUM	O	O
to	PART	O	O
8	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
10.3	NUM	O	O
visits	NOUN	O	O
per	ADP	O	O
patient	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
741	NUM	O	O
batteries	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
and	CCONJ	O	O
714	NUM	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
levels	NOUN	O	O
measured	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
714	NUM	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
9%	NUM	O	O
were	VERB	O	O
high	ADJ	O	O
;	PUNCT	O	O
only	ADV	O	O
1	NUM	O	O
(	PUNCT	O	O
0.1%	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
3	NUM	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
normal	ADJ	O	O
limit	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
2-drug	NUM	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
mean	ADJ	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
decreased	VERB	O	O
22%	NUM	O	O
from	ADP	O	O
255	NUM	O	O
to	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
dl	INTJ	O	O
,	PUNCT	O	O
triglyceride	NOUN	O	I-Entity
levels	NOUN	O	O
decreased	VERB	O	O
35%	NUM	O	O
from	ADP	O	O
236	NUM	O	O
to	ADP	O	O
154	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
LDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
decreased	VERB	O	O
26%	NUM	O	O
from	ADP	O	O
176	NUM	O	O
to	ADP	O	O
131	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
/	SYM	O	O
HDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
ratio	NOUN	O	O
decreased	VERB	O	O
24%	NUM	O	O
from	ADP	O	O
7.1	NUM	O	O
to	ADP	O	O
5.4	NUM	O	O
,	PUNCT	O	O
all	DET	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.0001	NUM	O	O
.	PUNCT	O	O

Myositis	PROPN	O	I-Entity
,	PUNCT	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
combination	NOUN	O	O
and	CCONJ	O	O
symptomatic	ADJ	O	O
enough	ADV	O	O
to	PART	O	O
discontinue	VERB	O	O
it	PRON	O	O
,	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
3%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
1%	NUM	O	O
with	ADP	O	O
concurrent	ADJ	O	O
high	ADJ	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
(	PUNCT	O	O
769	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
liter	ADV	O	O
)	PUNCT	O	O
;	PUNCT	O	O
no	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
rhabdomyolysis	NOUN	O	I-Entity
or	CCONJ	O	O
myoglobinuria.(ABSTRACT	ADJ	O	I-Entity
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (1655018)

Hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
in	ADP	O	O
Fanconi	PROPN	O	B-Entity
's	PART	O	I-Entity
anemia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
androgen	NOUN	O	I-Entity
and	CCONJ	O	O
corticosteroid	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
of	ADP	O	O
an	DET	O	O
11-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
who	NOUN	O	O
was	VERB	O	O
known	VERB	O	O
to	PART	O	O
have	VERB	O	O
Fanconi	PROPN	O	B-Entity
's	PART	O	I-Entity
anemia	NOUN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
androgens	NOUN	O	I-Entity
,	PUNCT	O	O
corticosteroids	NOUN	O	I-Entity
and	CCONJ	O	O
transfusions	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
his	ADJ	O	O
death	NOUN	O	O
he	PRON	O	O
was	VERB	O	O
readmitted	ADJ	O	O
because	ADP	O	O
of	ADP	O	O
aplastic	ADJ	O	O
crisis	NOUN	O	O
with	ADP	O	O
septicemia	NOUN	O	I-Entity
and	CCONJ	O	O
marked	VERB	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
died	VERB	O	O
of	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
bronchopneumonia	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
autopsy	NOUN	O	O
peliosis	NOUN	O	I-Entity
and	CCONJ	O	O
multiple	ADJ	O	O
hepatic	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
which	ADJ	O	O
histologically	ADV	O	O
proved	VERB	O	O
to	PART	O	O
be	VERB	O	O
well	ADV	O	O
-	PUNCT	O	O
differentiated	VERB	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
previous	ADJ	O	O
observations	NOUN	O	O
that	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
metastasizing	VERB	O	O
hepatic	ADJ	O	B-Entity
neoplasms	NOUN	O	I-Entity
and	CCONJ	O	O
peliosis	NOUN	O	I-Entity
can	VERB	O	O
develop	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
androgen-	NOUN	O	I-Entity
and	CCONJ	O	O
corticosteroid	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
Fanconi	PROPN	O	B-Entity
's	PART	O	I-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1735570)

Chronic	ADJ	O	O
lesion	NOUN	O	O
of	ADP	O	O
rostral	ADJ	O	O
ventrolateral	ADJ	O	O
medulla	NOUN	O	O
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
selective	ADJ	O	O
neuronal	ADJ	O	O
lesion	NOUN	O	O
of	ADP	O	O
rostral	ADJ	O	O
ventrolateral	ADJ	O	O
medulla	NOUN	O	O
on	ADP	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neurogenic	ADJ	O	O
tone	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
,	PUNCT	O	O
unrestrained	ADJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
restimulation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
area	NOUN	O	O
with	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
15	NUM	O	O
days	NOUN	O	O
postlesion	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
produce	VERB	O	O
a	DET	O	O
pressor	NOUN	O	O
response	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ganglionic	ADJ	O	O
blocker	NOUN	O	O
trimethaphan	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

The	DET	O	O
trimethaphan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
lesioned	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
-32	PUNCT	O	O

13	NUM	O	O
beats	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
sham	ADJ	O	O
rats	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
33	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
rostral	ADJ	O	O
ventrolateral	ADJ	O	O
medulla	NOUN	O	O
neurons	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
play	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
maintaining	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Spinal	ADJ	O	O
or	CCONJ	O	O
suprabulbar	ADJ	O	O
structures	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
gradual	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
lesioned	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1756784)

Damage	NOUN	O	B-Entity
of	ADP	O	I-Entity
substantia	NOUN	O	I-Entity
nigra	NOUN	O	I-Entity
pars	NOUN	O	I-Entity
reticulata	VERB	O	I-Entity
during	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
immunohistochemical	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
neurons	NOUN	O	O
,	PUNCT	O	O
astrocytes	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
-	PUNCT	O	O
protein	NOUN	O	O
extravasation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
has	VERB	O	O
a	DET	O	O
gating	VERB	O	O
function	NOUN	O	O
controlling	VERB	O	O
the	DET	O	O
spread	NOUN	O	O
of	ADP	O	O
epileptic	ADJ	O	B-Entity
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
models	NOUN	O	O
of	ADP	O	O
prolonged	ADJ	O	B-Entity
status	NOUN	O	I-Entity
epilepticus	VERB	O	I-Entity
the	DET	O	O
pars	NOUN	O	O
reticulata	NOUN	O	O
of	ADP	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
(	PUNCT	O	O
SNR	PROPN	O	O
)	PUNCT	O	O
suffers	VERB	O	O
from	ADP	O	O
a	DET	O	O
massive	ADJ	O	O
lesion	NOUN	O	O
which	ADJ	O	O
may	VERB	O	O
arise	VERB	O	O
from	ADP	O	O
a	DET	O	O
massive	ADJ	O	O
metabolic	NOUN	O	B-Entity
derangement	NOUN	O	I-Entity
and	CCONJ	O	O
hyperexcitation	NOUN	O	O
developing	VERB	O	O
in	ADP	O	O
the	DET	O	O
activated	VERB	O	O
SNR	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
systemic	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
surviving	VERB	O	O
20	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
were	VERB	O	O
perfusion	NOUN	O	O
-	PUNCT	O	O
fixed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
brains	NOUN	O	O
processed	VERB	O	O
for	ADP	O	O
immunohistochemical	ADJ	O	O
staining	NOUN	O	O
of	ADP	O	O
SNR	PROPN	O	O
.	PUNCT	O	O

Nissl	PROPN	O	O
-	PUNCT	O	O
staining	VERB	O	O
and	CCONJ	O	O
antibodies	NOUN	O	O
against	ADP	O	O
the	DET	O	O
neuron	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
calcium	NOUN	O	I-Entity
-	PUNCT	O	O
binding	VERB	O	O
protein	NOUN	O	O
,	PUNCT	O	O
parvalbumin	NOUN	O	O
,	PUNCT	O	O
served	VERB	O	O
to	PART	O	O
detect	VERB	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
SNR	PROPN	O	O
.	PUNCT	O	O

Antibodies	NOUN	O	O
against	ADP	O	O
the	DET	O	O
astroglia	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
cytoskeletal	NOUN	O	O
protein	NOUN	O	O
,	PUNCT	O	O
glial	ADJ	O	O
fibrillary	ADJ	O	O
acidic	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
GFAP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
against	ADP	O	O
the	DET	O	O
glial	ADJ	O	O
calcium	NOUN	O	I-Entity
-	PUNCT	O	O
binding	VERB	O	O
protein	NOUN	O	O
,	PUNCT	O	O
S-100	PROPN	O	O
protein	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
status	NOUN	O	O
of	ADP	O	O
astrocytes	NOUN	O	O
.	PUNCT	O	O

Immunohistochemical	ADJ	O	O
staining	VERB	O	O
for	ADP	O	O
serum	NOUN	O	O
-	PUNCT	O	O
albumin	NOUN	O	O
and	CCONJ	O	O
immunoglobulins	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
tissue	NOUN	O	O
was	VERB	O	O
taken	VERB	O	O
as	ADP	O	O
indicator	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
disturbances	NOUN	O	O
and	CCONJ	O	O
vasogenic	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
formation	NOUN	O	O
.	PUNCT	O	O

Immunohistochemical	ADJ	O	O
staining	VERB	O	O
indicated	VERB	O	O
loss	NOUN	O	O
of	ADP	O	O
GFAP	PROPN	O	O
-	PUNCT	O	O
staining	VERB	O	O
already	ADV	O	O
at	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
oval	ADJ	O	O
focus	NOUN	O	O
situated	VERB	O	O
in	ADP	O	O
the	DET	O	O
center	NOUN	O	O
of	ADP	O	O
SNR	PROPN	O	O
while	ADP	O	O
sparing	VERB	O	O
medial	ADJ	O	O
and	CCONJ	O	O
lateral	ADJ	O	O
aspects	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
2	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
parvalbumin	NOUN	O	O
-	PUNCT	O	O
staining	VERB	O	O
changed	VERB	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
SNR	PROPN	O	O
indicating	VERB	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
Nissl	PROPN	O	O
-	PUNCT	O	O
staining	VERB	O	O
visualized	VERB	O	O
some	DET	O	O
neuronal	ADJ	O	O
distortion	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
6	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
vasogenic	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
covered	VERB	O	O
the	DET	O	O
lesioned	VERB	O	B-Entity
SNR	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
further	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
surviving	VERB	O	O
1	NUM	O	O
to	PART	O	O
5	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
conventional	ADJ	O	O
paraffin	NOUN	O	O
-	PUNCT	O	O
sections	NOUN	O	O
confirmed	VERB	O	O
the	DET	O	O
neuronal	ADJ	O	O
and	CCONJ	O	O
glial	ADJ	O	O
damage	NOUN	O	B-Entity
of	ADP	O	I-Entity
SNR	PROPN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
cell	NOUN	O	O
elements	NOUN	O	O
may	VERB	O	O
suffer	VERB	O	O
in	ADP	O	O
common	ADJ	O	O
from	ADP	O	O
metabolic	NOUN	O	O
disturbance	NOUN	O	O
and	CCONJ	O	O
neurotransmitter	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
as	ADP	O	O
occur	VERB	O	O
during	ADP	O	O
massive	ADJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1760851)

Reduced	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
given	VERB	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
N-(2-hydroxypropyl)methacrylamide	PROPN	O	I-Entity
conjugates	VERB	O	O
:	PUNCT	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
general	ADJ	O	O
acute	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
late	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX	PROPN	O	I-Entity
)	PUNCT	O	O
given	VERB	O	O
either	DET	O	O
as	ADP	O	O
free	ADJ	O	O
drug	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
N-(2-hydroxypropyl)methacrylamide	PROPN	O	I-Entity
(	PUNCT	O	O
HPMA	PROPN	O	I-Entity
)	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
HPMA	PROPN	O	I-Entity
copolymers	NOUN	O	O
,	PUNCT	O	O
DOX	PROPN	O	I-Entity
was	VERB	O	O
covalently	ADV	O	O
bound	VERB	O	O
via	ADP	O	O
peptide	NOUN	O	O
linkages	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
either	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
biodegradable	NOUN	O	O
(	PUNCT	O	O
Gly	PROPN	O	O
-	PUNCT	O	O
Gly	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
degradable	ADJ	O	O
by	ADP	O	O
lysosomal	ADJ	O	O
proteinases	NOUN	O	O
(	PUNCT	O	O
Gly	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Phe	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Leu	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Gly	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
biodegradable	NOUN	O	O
conjugate	NOUN	O	O
containing	VERB	O	O
galactosamine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
;	PUNCT	O	O
this	DET	O	O
residue	NOUN	O	O
was	VERB	O	O
targeted	VERB	O	O
to	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
.	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
and	CCONJ	O	O
polymer	ADJ	O	O
-	PUNCT	O	O
bound	VERB	O	O
DOX	PROPN	O	I-Entity
,	PUNCT	O	O
all	DET	O	O
animals	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
transient	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
maximal	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
polymer	NOUN	O	O
-	PUNCT	O	O
bound	VERB	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
those	DET	O	O
that	ADJ	O	O
received	VERB	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
the	DET	O	O
unmodified	ADJ	O	O
parent	NOUN	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
and	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
deaths	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
either	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
or	CCONJ	O	O
the	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
and	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
;	PUNCT	O	O
in	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
histological	ADJ	O	O
investigations	NOUN	O	O
revealed	VERB	O	O
marked	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Sequential	ADJ	O	O
measurements	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
in	ADP	O	O
surviving	VERB	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
either	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
or	CCONJ	O	O
the	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
and	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
approximately	ADV	O	O
30%	NUM	O	O
in	ADP	O	O
function	NOUN	O	O
beginning	VERB	O	O
at	ADP	O	O
the	DET	O	O
4th	ADJ	O	O
week	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
given	VERB	O	O
the	DET	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
conjugates	NOUN	O	O
containing	VERB	O	O
DOX	PROPN	O	I-Entity
exhibited	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
histological	ADJ	O	O
change	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
DOX	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
conjugates	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
killed	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1779253)

Topical	ADJ	O	O
0.025%	NUM	O	O
capsaicin	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	O
post	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
herpetic	ADJ	O	I-Entity
neuralgia	NOUN	O	I-Entity
:	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
predictors	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
course	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
-	PUNCT	O	O
course	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
and	CCONJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
topical	ADJ	O	O
capsaicin	NOUN	O	I-Entity
,	PUNCT	O	O
39	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
post	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
herpetic	ADJ	O	I-Entity
neuralgia	NOUN	O	I-Entity
(	PUNCT	O	O
PHN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
median	ADJ	O	O
duration	NOUN	O	O
24	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
0.025%	NUM	O	O
capsaicin	NOUN	O	I-Entity
cream	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
therapy	NOUN	O	O
the	DET	O	O
patients	NOUN	O	O
rated	VERB	O	O
their	ADJ	O	O
pain	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
verbal	ADJ	O	O
outcome	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Nineteen	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
48.7%	NUM	O	O
)	PUNCT	O	O
substantially	ADV	O	O
improved	VERB	O	O
after	ADP	O	O
the	DET	O	O
8-week	NUM	O	O
trial	NOUN	O	O
;	PUNCT	O	O
5	NUM	O	O
(	PUNCT	O	O
12.8%	NUM	O	O
)	PUNCT	O	O
discontinued	VERB	O	O
therapy	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
intolerable	ADJ	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
burning	VERB	O	O
sensations	NOUN	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
mastitis	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
15	NUM	O	O
(	PUNCT	O	O
38.5%	NUM	O	O
)	PUNCT	O	O
reported	VERB	O	O
no	DET	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

Treatment	PROPN	O	O
effect	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
dependent	ADJ	O	O
on	ADP	O	O
patient	NOUN	O	O
's	PART	O	O
age	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
or	CCONJ	O	O
localization	NOUN	O	O
of	ADP	O	O
PHN	PROPN	O	I-Entity
(	PUNCT	O	O
trigeminal	ADJ	O	O
involvement	NOUN	O	O
was	VERB	O	O
excluded	VERB	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sensory	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
or	CCONJ	O	O
pain	NOUN	O	I-Entity
character	NOUN	O	O
.	PUNCT	O	O

Treatment	PROPN	O	O
response	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
-	PUNCT	O	O
course	NOUN	O	O
or	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
burning	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
confirmed	VERB	O	O
in	ADP	O	O
controlled	VERB	O	O
trials	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
randomized	ADJ	O	O
study	NOUN	O	O
might	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
analgesic	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
in	ADP	O	O
PHN	PROPN	O	I-Entity
is	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
both	DET	O	O
interference	NOUN	O	O
with	ADP	O	O
neuropeptide	ADJ	O	O
metabolism	NOUN	O	O
and	CCONJ	O	O
morphological	ADJ	O	O
changes	NOUN	O	O
(	PUNCT	O	O
perhaps	ADV	O	O
degeneration	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
nociceptive	ADJ	O	O
afferents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1837756)

Serotonin	PROPN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
paranoia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
ventral	ADJ	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
.	PUNCT	O	O

Antidepressants	NOUN	O	O
have	VERB	O	O
previously	ADV	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
paranoid	ADJ	O	I-Entity
reactions	NOUN	O	O
in	ADP	O	O
psychiatric	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
paranoid	ADJ	O	I-Entity
exacerbation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
fluoxetine	VERB	O	I-Entity
and	CCONJ	O	O
amitriptyline	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
here	ADV	O	O
.	PUNCT	O	O

Elements	NOUN	O	O
common	ADJ	O	O
to	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
included	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
paranoid	ADJ	O	I-Entity
symptomatology	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
concomitant	ADJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
psychotic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Complicated	VERB	O	O
depressive	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
(	PUNCT	O	O
including	VERB	O	O
atypicality	NOUN	O	O
of	ADP	O	O
course	NOUN	O	O
and	CCONJ	O	O
symptomatology	NOUN	O	O
,	PUNCT	O	O
chronicity	NOUN	O	O
,	PUNCT	O	O
psychosis	NOUN	O	I-Entity
,	PUNCT	O	O
bipolarity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
secondary	ADJ	O	O
onset	NOUN	O	O
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
psychosis	NOUN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
present	VERB	O	O
particular	ADJ	O	O
vulnerability	NOUN	O	O
to	ADP	O	O
paranoid	ADJ	O	I-Entity
exacerbations	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
pharmacology	NOUN	O	O
and	CCONJ	O	O
neurobiology	NOUN	O	O
of	ADP	O	O
paranoia	NOUN	O	I-Entity
remain	VERB	O	O
cryptic	ADJ	O	O
,	PUNCT	O	O
several	ADJ	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
5HT3	NUM	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
dopamine	NOUN	O	I-Entity
release	NOUN	O	O
,	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
noradrenergic	ADJ	O	O
receptor	NOUN	O	O
downregulation	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
GABAB	PROPN	O	O
receptor	NOUN	O	O
upregulation	NOUN	O	O
acting	VERB	O	O
in	ADP	O	O
the	DET	O	O
vicinity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
(	PUNCT	O	O
possibly	ADV	O	O
in	ADP	O	O
lateral	ADJ	O	O
orbitofrontal	NOUN	O	O
or	CCONJ	O	O
anterior	ADJ	O	O
cingulate	NOUN	O	O
circuits	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
might	VERB	O	O
apply	VERB	O	O
to	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
cases	NOUN	O	O
call	VERB	O	O
attention	NOUN	O	O
to	ADP	O	O
possible	ADJ	O	O
paranoid	ADJ	O	I-Entity
exacerbations	NOUN	O	O
with	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
blockers	NOUN	O	O
in	ADP	O	O
select	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
raise	VERB	O	O
neurobiological	ADJ	O	O
considerations	NOUN	O	O
regarding	VERB	O	O
paranoia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1858969)

Five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
encephalitis	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
loiasis	NOUN	O	I-Entity
with	ADP	O	O
diethylcarbamazine	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
encephalitis	NOUN	O	I-Entity
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
diethylcarbamazine	NOUN	O	I-Entity
(	PUNCT	O	O
DEC	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
Congolese	PROPN	O	O
patients	NOUN	O	O
with	ADP	O	O
Loa	PROPN	O	O
loa	NOUN	O	O
filariasis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
notable	ADJ	O	O
fact	NOUN	O	O
was	VERB	O	O
that	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
hospitalized	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
began	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
whom	NOUN	O	O
particularly	ADV	O	O
strict	ADJ	O	O
therapeutic	ADJ	O	O
precautions	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
,	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
initial	ADJ	O	O
dose	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
DEC	PROPN	O	I-Entity
,	PUNCT	O	O
very	ADV	O	O
gradual	ADJ	O	O
dose	NOUN	O	O
increases	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
associated	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
allergic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
encephalitis	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
microfilaremia	NOUN	O	I-Entity
is	VERB	O	O
evident	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (1905439)

Delirium	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
woman	NOUN	O	O
possibly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
.	PUNCT	O	O

Misoprostol	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
gastrointestinal	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
gynecologic	ADJ	O	O
problems	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
an	DET	O	O
89-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
in	ADP	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
care	NOUN	O	O
facility	NOUN	O	O
became	VERB	O	O
confused	ADJ	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Her	ADJ	O	O
delirium	NOUN	O	I-Entity
significantly	ADV	O	O
improved	VERB	O	O
after	ADP	O	O
misoprostol	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
her	ADJ	O	O
mental	ADJ	O	O
status	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
a	DET	O	O
week	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
no	DET	O	O
other	ADJ	O	O
factors	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
changed	VERB	O	O
significantly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
delirium	NOUN	O	I-Entity
experienced	VERB	O	O
by	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
possibly	ADV	O	O
resulted	VERB	O	O
from	ADP	O	O
misoprostol	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1943082)

Hepatocellular	ADJ	O	O
oxidant	ADJ	O	O
stress	NOUN	O	O
following	VERB	O	O
intestinal	ADJ	O	O
ischemia	NOUN	O	I-Entity
-	PUNCT	O	O
reperfusion	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Reperfusion	PROPN	O	O
of	ADP	O	O
ischemic	ADJ	O	I-Entity
intestine	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
liver	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
hepatocellular	ADJ	O	O
enzyme	NOUN	O	O
release	NOUN	O	O
into	ADP	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
bile	NOUN	O	O
flow	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neutrophil	ADJ	O	O
sequestration	NOUN	O	O
within	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pathophysiology	NOUN	O	O
underlying	VERB	O	O
this	DET	O	O
acute	ADJ	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
oxidants	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
relative	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
indirect	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
assessing	VERB	O	O
oxidant	ADJ	O	O
exposure	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
a	DET	O	O
standardized	ADJ	O	O
intestinal	ADJ	O	O
ischemia	NOUN	O	I-Entity
-	PUNCT	O	O
reperfusion	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Hepatic	ADJ	O	O
tissue	NOUN	O	O
was	VERB	O	O
assayed	VERB	O	O
for	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
products	NOUN	O	O
and	CCONJ	O	O
oxidized	VERB	O	B-Entity
and	CCONJ	O	I-Entity
reduced	VERB	O	I-Entity
glutathione	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
hepatic	ADJ	O	O
tissue	NOUN	O	O
total	ADJ	O	O
glutathione	NOUN	O	I-Entity
following	VERB	O	O
intestinal	ADJ	O	O
ischemia	NOUN	O	I-Entity
-	PUNCT	O	O
reperfusion	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Oxidized	VERB	O	B-Entity
glutathione	NOUN	O	I-Entity
(	PUNCT	O	O
GSSG	PROPN	O	I-Entity
)	PUNCT	O	O
increased	VERB	O	O
significantly	ADV	O	O
following	VERB	O	O
30	NUM	O	O
and	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
reperfusion	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
GSSG	PROPN	O	I-Entity
within	ADP	O	O
hepatic	ADJ	O	O
tissue	NOUN	O	O
during	ADP	O	O
intestinal	ADJ	O	O
reperfusion	NOUN	O	O
suggests	VERB	O	O
exposure	NOUN	O	O
of	ADP	O	O
hepatocytes	NOUN	O	O
to	ADP	O	O
an	DET	O	O
oxidant	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
also	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
tissue	NOUN	O	O
GSSG	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
more	ADV	O	O
sensitive	ADJ	O	O
indicator	NOUN	O	O
of	ADP	O	O
oxidant	ADJ	O	O
stress	NOUN	O	O
than	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
products	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2021990)

Diphenhydramine	NOUN	O	I-Entity
prevents	VERB	O	O
the	DET	O	O
haemodynamic	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
in	ADP	O	O
ICU	PROPN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
histamine	NOUN	O	I-Entity
2	NUM	O	O
(	PUNCT	O	O
H2	PROPN	O	O
)	PUNCT	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
produces	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
arterial	NOUN	O	O
pressure	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
vasodilatation	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
may	VERB	O	O
be	VERB	O	O
because	ADP	O	O
cimetidine	ADJ	O	I-Entity
acts	VERB	O	O
as	ADP	O	O
a	DET	O	O
histamine	NOUN	O	I-Entity
agonist	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
histamine	NOUN	O	I-Entity
1(H1	NUM	O	O
)	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
diphenhydramine	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
haemodynamic	ADJ	O	O
changes	NOUN	O	O
observed	VERB	O	O
after	ADP	O	O
cimetidine	NOUN	O	I-Entity
in	ADP	O	O
ICU	PROPN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
random	ADJ	O	O
fashion	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
received	VERB	O	O
cimetidine	ADV	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
iv	NOUN	O	O
on	ADP	O	O
one	NUM	O	O
day	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
other	ADJ	O	O
,	PUNCT	O	O
a	DET	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
diphenhydramine	NOUN	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
iv	NOUN	O	O
with	ADP	O	O
cimetidine	NOUN	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
iv	NOUN	O	O
.	PUNCT	O	O

11.4	NUM	O	O
mmHg	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
two	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
an	DET	O	O
H1	PROPN	O	O
antagonist	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
hypotension	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
iv	ADJ	O	O
cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
vasodilating	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
is	VERB	O	O
mediated	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
through	ADP	O	O
the	DET	O	O
H1	PROPN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2083961)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
rifampicin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
23-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
bacteriologically	ADV	O	O
proven	VERB	O	O
pulmonary	ADJ	O	B-Entity
tuberculosis	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
various	ADJ	O	O
regimens	NOUN	O	O
of	ADP	O	O
antituberculosis	NOUN	O	O
drugs	NOUN	O	O
for	ADP	O	O
nearly	ADV	O	O
15	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Rifampicin	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
thrice	ADV	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
drug	NOUN	O	O
regimen	NOUN	O	O
and	CCONJ	O	O
each	DET	O	O
time	NOUN	O	O
he	PRON	O	O
developed	VERB	O	O
untoward	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
like	ADP	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
and	CCONJ	O	O
fever	NOUN	O	I-Entity
with	ADP	O	O
chills	NOUN	O	O
and	CCONJ	O	O
rigors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2131034)

Severe	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
and	CCONJ	O	O
motor	NOUN	O	O
loss	NOUN	O	O
after	ADP	O	O
intrathecal	ADJ	O	O

thiotepa	NOUN	O	I-Entity
combination	NOUN	O	O
chemotherapy	NOUN	O	O
:	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
delayed	VERB	O	O
neurologic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
(	PUNCT	O	O
IT	PROPN	O	O
)	PUNCT	O	O
combination	NOUN	O	O
chemotherapy	NOUN	O	O
including	VERB	O	O
thiotepa	NOUN	O	I-Entity
(	PUNCT	O	O
TSPA	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

Both	DET	O	O
cases	NOUN	O	O
developed	VERB	O	O
axonal	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
with	ADP	O	O
motor	NOUN	O	O
predominance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
extremities	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
IT	NOUN	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Neurologic	ADJ	O	B-Entity
toxicities	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
with	ADP	O	O
IT	PROPN	O	O
-	PUNCT	O	O
methotrexate	NOUN	O	I-Entity
,	PUNCT	O	O
IT	NOUN	O	O
-	PUNCT	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
and	CCONJ	O	O
IT	NOUN	O	O
-	PUNCT	O	O
TSPA	PROPN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
axonal	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity

In	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
TSPA	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
IT	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
combination	NOUN	O	O
with	ADP	O	O
MTX	PROPN	O	I-Entity
,	PUNCT	O	O
ara	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
C	PROPN	O	I-Entity
and	CCONJ	O	O
radiotherapy	ADJ	O	O
could	VERB	O	O
cause	VERB	O	O
severe	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
unexpected	ADJ	O	O
complication	NOUN	O	O
indicates	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
further	ADJ	O	O
toxicology	NOUN	O	O
research	NOUN	O	O
on	ADP	O	O
IT	NOUN	O	O
-	PUNCT	O	O
TSPA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2173761)

Effects	NOUN	O	O
of	ADP	O	O
cromakalim	NOUN	O	I-Entity
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
on	ADP	O	O
large	ADJ	O	O
epicardial	ADJ	O	O
and	CCONJ	O	O
small	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

bolus	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
cromakalim	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	X	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
-	SYM	O	O
100	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	VERB	O	O
)	PUNCT	O	O
on	ADP	O	O
large	ADJ	O	O
(	PUNCT	O	O
circumflex	NOUN	O	O
artery	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
small	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
systemic	ADJ	O	O
hemodynamics	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
chronically	ADV	O	O
instrumented	ADJ	O	O
conscious	ADJ	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
compared	VERB	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
0.03	NUM	O	O
-	SYM	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nitroglycerin	PROPN	O	I-Entity
,	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
0.3	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
selectively	ADV	O	O
increased	VERB	O	O
circumflex	NOUN	O	O
artery	NOUN	O	O
diameter	NOUN	O	O
(	PUNCT	O	O
CxAD	PROPN	O	O
)	PUNCT	O	O
without	ADP	O	O
simultaneously	ADV	O	O
affecting	VERB	O	O
any	DET	O	O
other	ADJ	O	O
cardiac	ADJ	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
hemodynamic	NOUN	O	O
parameter	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
cromakalim	NOUN	O	I-Entity
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
at	ADP	O	O
all	DET	O	O
doses	NOUN	O	O
and	CCONJ	O	O
nitroglycerin	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
higher	ADJ	O	O
than	ADP	O	O
0.3	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	VERB	O	O
simultaneously	ADV	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
increased	VERB	O	O
CxAD	PROPN	O	O
,	PUNCT	O	O
coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
coronary	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
aortic	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Cromakalim	PROPN	O	I-Entity
was	VERB	O	O
approximately	ADV	O	O
8-	NUM	O	O
to	PART	O	O
9.5-fold	NUM	O	O
more	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
pinacidil	NOUN	O	I-Entity
in	ADP	O	O
increasing	VERB	O	O
CxAD	PROPN	O	O
.	PUNCT	O	O

Vasodilation	PROPN	O	O
of	ADP	O	O
large	ADJ	O	O
and	CCONJ	O	O
small	ADJ	O	O
coronary	ADJ	O	O
vessels	NOUN	O	O
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cromakalim	NOUN	O	I-Entity
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
prior	ADV	O	O
combined	VERB	O	O
beta	NOUN	O	B-Entity
adrenergic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
muscarinic	ADJ	O	I-Entity
receptors	NOUN	O	I-Entity
blockade	VERB	O	I-Entity
but	CCONJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
was	VERB	O	O
abolished	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
circumflex	NOUN	O	O
artery	NOUN	O	O
blood	NOUN	O	O
flow	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
constant	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
increases	NOUN	O	O
in	ADP	O	O
CxAD	PROPN	O	O
induced	VERB	O	O
by	ADP	O	O
cromakalim	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
pinacidil	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	X	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
68	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
whereas	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
preferentially	ADV	O	O
and	CCONJ	O	O
flow	VERB	O	O
-	PUNCT	O	O
independently	ADV	O	O
dilates	VERB	O	O
large	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
,	PUNCT	O	O
cromakalim	NOUN	O	I-Entity
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
dilate	VERB	O	O
both	DET	O	O
large	ADJ	O	O
and	CCONJ	O	O
small	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
and	CCONJ	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
dependent	ADJ	O	O
upon	ADP	O	O
the	DET	O	O
simultaneous	ADJ	O	O
beta	NOUN	O	O
adrenoceptors	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
rise	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	O
metabolic	ADJ	O	O
demand	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
two	NUM	O	O
mechanisms	NOUN	O	O
at	ADP	O	O
least	ADJ	O	O
,	PUNCT	O	O
direct	ADJ	O	O
vasodilation	NOUN	O	O
and	CCONJ	O	O
flow	NOUN	O	O
dependency	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
cromakalim-	NOUN	O	I-Entity
and	CCONJ	O	O
pinacidil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
CxAD	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (2217015)

Mefenamic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
females	NOUN	O	O
with	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
oliguric	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
occurring	VERB	O	O
simultaneously	ADV	O	O
in	ADP	O	O
two	NUM	O	O
elderly	ADJ	O	O
females	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neutropenia	NOUN	O	I-Entity
was	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
maturation	NOUN	O	O
arrest	NOUN	O	O
of	ADP	O	O
the	DET	O	O
myeloid	ADJ	O	O
series	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
hypothyroid	ADJ	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
clear	ADJ	O	O
whether	ADP	O	O
this	DET	O	O
was	VERB	O	O
a	DET	O	O
predisposing	NOUN	O	O
factor	NOUN	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
these	DET	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
would	VERB	O	O
seem	VERB	O	O
prudent	ADJ	O	O
not	ADV	O	O
to	PART	O	O
use	VERB	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
hypothyroid	ADJ	O	I-Entity
patients	NOUN	O	O
until	ADP	O	O
the	DET	O	O
hypothyroidism	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
corrected	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2239937)

Etiology	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
in	ADP	O	O
hemodialysis	NOUN	O	O
patients	NOUN	O	O
on	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
of	ADP	O	O
39	NUM	O	O
dialysis	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
36%	NUM	O	O
)	PUNCT	O	O
became	VERB	O	O
hypercalcemic	ADJ	O	I-Entity
after	ADP	O	O
switching	VERB	O	O
to	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
as	ADP	O	O
their	ADJ	O	O
principal	ADJ	O	O
phosphate	NOUN	O	I-Entity
binder	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
identify	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
indirect	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
intestinal	ADJ	O	O
calcium	NOUN	O	I-Entity
reabsorption	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
turnover	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
these	DET	O	O
14	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
results	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
eucalcemic	ADJ	O	O
patients	NOUN	O	O
matched	VERB	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
length	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
on	ADP	O	O
dialysis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
etiology	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
experiencing	VERB	O	O
hypercalcemic	ADJ	O	I-Entity
episodes	NOUN	O	O
with	ADP	O	O
peak	NOUN	O	O
calcium	NOUN	O	I-Entity
values	NOUN	O	O
of	ADP	O	O
2.7	NUM	O	O
to	PART	O	O
3.8	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
10.7	NUM	O	O
to	PART	O	O
15.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypercalcemic	NOUN	O	I-Entity
group	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
calcium	NOUN	O	I-Entity
concentration	NOUN	O	O
obtained	VERB	O	O
during	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
before	ADP	O	O
the	DET	O	O
switch	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
value	NOUN	O	O
obtained	VERB	O	O
during	ADP	O	O
the	DET	O	O
7	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
observation	NOUN	O	O
after	ADP	O	O
the	DET	O	O
switch	NOUN	O	O
(	PUNCT	O	O
2.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
eucalcemic	ADJ	O	O
patients	NOUN	O	O
exhibited	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
mean	ADJ	O	O
calcium	NOUN	O	I-Entity
values	NOUN	O	O
over	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
2.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

CaCO3	PROPN	O	I-Entity
dosage	NOUN	O	O
,	PUNCT	O	O
calculated	VERB	O	O
dietary	ADJ	O	O
calcium	NOUN	O	I-Entity
intake	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
circulating	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
metabolites	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Physical	ADJ	O	O
activity	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
predialysis	NOUN	O	O
serum	NOUN	O	O
bicarbonate	NOUN	O	I-Entity
levels	NOUN	O	O
also	ADV	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2320485)

Methyldopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
15	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
presenting	NOUN	O	O
as	ADP	O	O
near	ADV	O	O
-	PUNCT	O	O
syncope	NOUN	O	I-Entity
.	PUNCT	O	O

Methyldopa	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
antihypertensive	ADJ	O	O
medication	NOUN	O	O
which	ADJ	O	O
is	VERB	O	O
available	ADJ	O	O
generically	ADV	O	O
and	CCONJ	O	O
under	ADP	O	O
the	DET	O	O
trade	NOUN	O	O
name	NOUN	O	O
Aldomet	PROPN	O	I-Entity
that	ADJ	O	O
is	VERB	O	O
widely	ADV	O	O
prescribed	VERB	O	O
in	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
population	NOUN	O	O
and	CCONJ	O	O
infrequently	ADV	O	O
used	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Methyldopa	PROPN	O	I-Entity
causes	VERB	O	O
an	DET	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	NOUN	O	I-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
small	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
take	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
15-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	B-Entity
department	NOUN	O	I-Entity
with	ADP	O	O
near	ADV	O	O
-	PUNCT	O	O
syncope	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
boy	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
methyldopa	NOUN	O	I-Entity
during	ADP	O	O
a	DET	O	O
trauma	NOUN	O	I-Entity
admission	NOUN	O	O
seven	NUM	O	O
weeks	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

Transfusion	NOUN	O	O
and	CCONJ	O	O
corticosteroid	NOUN	O	I-Entity
therapy	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
complete	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
brief	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
autoimmune	ADJ	O	O
and	CCONJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemias	NOUN	O	I-Entity
is	VERB	O	O
provided	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2358093)

The	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
safety	NOUN	O	O
of	ADP	O	O
danazol	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
hereditary	ADJ	O	B-Entity
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
safety	NOUN	O	O
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
danazol	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
established	VERB	O	O
in	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
settings	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
information	NOUN	O	O
exists	VERB	O	O
as	ADP	O	O
to	ADP	O	O
its	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
safety	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
investigated	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
safety	NOUN	O	O
of	ADP	O	O
danazol	NOUN	O	I-Entity
by	ADP	O	O
performing	VERB	O	O
a	DET	O	O
retrospective	ADJ	O	O
chart	NOUN	O	O
review	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
female	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
hereditary	ADJ	O	B-Entity
angioedema	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
danazol	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
continuous	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
or	CCONJ	O	O
longer	ADJ	O	O
.	PUNCT	O	O

Menstrual	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
(	PUNCT	O	O
79%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
(	PUNCT	O	O
60%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
muscle	NOUN	O	B-Entity
cramps	NOUN	O	I-Entity
/	SYM	O	O
myalgias	NOUN	O	I-Entity
(	PUNCT	O	O
40%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
transaminase	NOUN	O	O
elevations	NOUN	O	O
(	PUNCT	O	O
40%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
despite	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
,	PUNCT	O	O
danazol	NOUN	O	I-Entity
has	VERB	O	O
proven	VERB	O	O
to	PART	O	O
be	VERB	O	O
remarkably	ADV	O	O
safe	ADJ	O	O
over	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2383364)

Patient	ADJ	O	O
tolerance	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
chlorhexidine	NOUN	O	B-Entity
diphosphanilate	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
topical	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
burns	NOUN	O	I-Entity
.	PUNCT	O	O

Effective	ADJ	O	O
topical	ADJ	O	O
antimicrobial	ADJ	O	O
agents	NOUN	O	O
decrease	VERB	O	O
infection	NOUN	O	I-Entity
and	CCONJ	O	O
mortality	NOUN	O	O
in	ADP	O	O
burn	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Chlorhexidine	PROPN	O	B-Entity
phosphanilate	NOUN	O	I-Entity
(	PUNCT	O	O
CHP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
broad	ADJ	O	O
-	PUNCT	O	O
spectrum	NOUN	O	O
antimicrobial	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
evaluated	VERB	O	O
as	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
burn	NOUN	O	I-Entity
wound	NOUN	O	O
dressing	VERB	O	O
in	ADP	O	O
cream	NOUN	O	O
form	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
preliminary	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
reported	VERB	O	O
that	ADP	O	O
it	PRON	O	O
was	VERB	O	O
painful	ADJ	O	O
upon	ADP	O	O
application	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
compared	VERB	O	O
various	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
CHP	PROPN	O	I-Entity
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
a	DET	O	O
tolerable	ADJ	O	O
concentration	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
with	ADP	O	O
retention	NOUN	O	O
of	ADP	O	O
antimicrobial	ADJ	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
burn	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
with	ADP	O	O
two	NUM	O	O
similar	ADJ	O	O
burns	NOUN	O	I-Entity
which	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
separately	ADV	O	O
treated	VERB	O	O
,	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
pairs	NOUN	O	O
of	ADP	O	O
treatments	NOUN	O	O
at	ADP	O	O
successive	ADJ	O	O
12-h	NUM	O	O
intervals	NOUN	O	O
over	ADP	O	O
a	DET	O	O
3-day	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
burn	NOUN	O	I-Entity
site	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
each	DET	O	O
of	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
CHP	NOUN	O	I-Entity
concentrations	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
0.25	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
to	ADP	O	O
2	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
,	PUNCT	O	O
their	ADJ	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
per	NOUN	O	O
cent	NOUN	O	O
silver	NOUN	O	B-Entity
sulphadiazine	NOUN	O	I-Entity
(	PUNCT	O	O
AgSD	PROPN	O	I-Entity
)	PUNCT	O	O
cream	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
antimicrobial	ADJ	O	O
agent	NOUN	O	O
frequently	ADV	O	O
used	VERB	O	O
for	ADP	O	O
topical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
burn	NOUN	O	I-Entity
wounds	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
other	ADJ	O	O
site	NOUN	O	O
was	VERB	O	O
always	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
AgSD	PROPN	O	I-Entity
cream	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
CHP	PROPN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
'	PART	O	O
ratings	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
on	ADP	O	O
an	DET	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
0.25	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
CHP	NOUN	O	I-Entity
cream	NOUN	O	O
was	VERB	O	O
closest	ADJ	O	O
to	ADP	O	O
AgSD	VERB	O	I-Entity
in	ADP	O	O
pain	NOUN	O	I-Entity
tolerance	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
differed	VERB	O	O
statistically	ADV	O	O
from	ADP	O	O
AgSD	PROPN	O	I-Entity
or	CCONJ	O	O
from	ADP	O	O
each	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
ease	NOUN	O	O
of	ADP	O	O
application	NOUN	O	O
of	ADP	O	O
CHP	PROPN	O	I-Entity
creams	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
satisfactory	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
AgSD	PROPN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
formulations	NOUN	O	O
at	ADP	O	O
or	CCONJ	O	O
below	ADP	O	O
0.5	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
CHP	NOUN	O	I-Entity
may	VERB	O	O
prove	VERB	O	O
acceptable	ADJ	O	O
for	ADP	O	O
wound	NOUN	O	O
care	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
vehicle	NOUN	O	O
system	NOUN	O	O
needs	VERB	O	O
pharmaceutical	ADJ	O	O
improvement	NOUN	O	O
to	PART	O	O
render	VERB	O	O
it	PRON	O	O
more	ADV	O	O
tolerable	ADJ	O	O
and	CCONJ	O	O
easier	ADJ	O	O
to	PART	O	O
use	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2400986)

Dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
busulfan	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Busulfan	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
neurotoxic	NOUN	O	I-Entity
in	ADP	O	O
animals	NOUN	O	O
and	CCONJ	O	O
humans	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
acute	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
remains	VERB	O	O
poorly	ADV	O	O
characterized	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
here	ADV	O	O
a	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
123	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
6.5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
receiving	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
busulfan	NOUN	O	I-Entity
in	ADP	O	O
combined	VERB	O	O
chemotherapy	NOUN	O	O
before	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
malignant	NOUN	O	O
solid	ADJ	O	O
tumors	NOUN	O	I-Entity
,	PUNCT	O	O
brain	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
excluded	VERB	O	O
.	PUNCT	O	O

Busulfan	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

Ninety	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
given	VERB	O	O
anticonvulsive	ADJ	O	O
prophylaxis	NOUN	O	O
;	PUNCT	O	O
7	NUM	O	O
(	PUNCT	O	O
7.5%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
seizures	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
busulfan	NOUN	O	I-Entity
course	NOUN	O	O
or	CCONJ	O	O
within	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
dosing	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
total	ADJ	O	O
busulfan	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
taken	VERB	O	O
into	ADP	O	O
account	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
incidence	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
under	ADP	O	O
16	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
(	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
57	NUM	O	O
,	PUNCT	O	O
1.7%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
under	ADP	O	O
600	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	PROPN	O	O
(	PUNCT	O	O
6	NUM	O	O
of	ADP	O	O
39	NUM	O	O
,	PUNCT	O	O
15.4%	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
600-mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
busulfan	NOUN	O	I-Entity
total	ADJ	O	O
dose	NOUN	O	O
with	ADP	O	O
continuous	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

infusion	NOUN	O	O
of	ADP	O	O
clonazepam	NOUN	O	I-Entity
;	PUNCT	O	O
none	NOUN	O	O
had	VERB	O	O
any	DET	O	O
neurological	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Busulfan	PROPN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
a	DET	O	O
gas	NOUN	O	O
chromatographic	NOUN	O	O
-	PUNCT	O	O
mass	NOUN	O	O
spectrometry	NOUN	O	O
assay	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
of	ADP	O	O
9	NUM	O	O
children	NOUN	O	O
without	ADP	O	O
central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
under	ADP	O	O
600	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	PROPN	O	O
busulfan	NOUN	O	I-Entity
with	ADP	O	O
clonazepam	NOUN	O	I-Entity
:	PUNCT	O	O

busulfan	NOUN	O	I-Entity
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
:	PUNCT	O	O
plasma	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
1.39	NUM	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
significantly	ADV	O	O
different	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
:	PUNCT	O	O
plasma	NOUN	O	O
ratio	NOUN	O	O
previously	ADV	O	O
defined	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
16-mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
total	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
busulfan	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
busulfan	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
efficiently	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
clonazepam	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
busulfan	NOUN	O	I-Entity
dose	NOUN	O	O
calculated	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
increased	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
close	ADJ	O	O
to	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
incidence	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
plasma	NOUN	O	O
pharmacokinetic	NOUN	O	O
studies	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
faster	ADV	O	O
busulfan	NOUN	O	I-Entity
clearance	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
adults	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
new	ADJ	O	O
dose	NOUN	O	O
may	VERB	O	O
approximate	VERB	O	O
more	ADV	O	O
closely	ADV	O	O
the	DET	O	O
adult	NOUN	O	O
systemic	ADJ	O	O
exposure	NOUN	O	O
obtained	VERB	O	O
after	ADP	O	O
the	DET	O	O
usual	ADJ	O	O
16-mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
total	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
potential	ADJ	O	O
inferences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
anticancer	NOUN	O	O
or	CCONJ	O	O
myeloablative	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
busulfan	NOUN	O	I-Entity
dose	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
infants	NOUN	O	O
undergoing	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
reconsidered	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
pharmacokinetic	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2429800)

Histamine	ADJ	O	I-Entity
antagonists	NOUN	O	O
and	CCONJ	O	O
d	PUNCT	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
cardiac	ADJ	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Hemodynamic	PROPN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
histamine	NOUN	O	I-Entity
release	NOUN	O	O
by	ADP	O	O
bolus	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
0.35	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

H1-	PUNCT	O	O
and	CCONJ	O	O
H2-histamine	ADJ	O	I-Entity
antagonists	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
before	ADP	O	O
dosing	VERB	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
fashion	NOUN	O	O
to	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
-	PUNCT	O	O
-placebo	PROPN	O	O
;	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
-	PUNCT	O	O
-cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
;	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
-	PUNCT	O	O
-chlorpheniramine	NUM	O	I-Entity
,	PUNCT	O	O
0.1	NUM	O	O

mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
4	NUM	O	O
-	PUNCT	O	O
-cimetidine	NOUN	O	I-Entity
plus	CCONJ	O	O
chlorpheniramine	NOUN	O	I-Entity
.	PUNCT	O	O

Histamine	PROPN	O	I-Entity
release	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
most	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
highest	ADJ	O	O
level	NOUN	O	O
2	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
dosing	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
1	NUM	O	O
had	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
negative	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
plasma	NOUN	O	O
histamine	NOUN	O	I-Entity
change	NOUN	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.58	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
not	ADV	O	O
present	ADJ	O	O
in	ADP	O	O
group	NOUN	O	O
4	NUM	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
the	DET	O	O
hemodynamic	ADJ	O	O
changes	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
dosing	NOUN	O	O
are	VERB	O	O
only	ADV	O	O
partially	ADV	O	O
explained	VERB	O	O
by	ADP	O	O
histamine	ADJ	O	I-Entity
release	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2453942)

Convulsant	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
and	CCONJ	O	O
regional	ADJ	O	O
brain	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
and	CCONJ	O	O
dopamine	NOUN	O	I-Entity
.	PUNCT	O	O

Lindane	PROPN	O	I-Entity
(	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
hexachlorocyclohexane	NOUN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
organochlorine	NOUN	O	O
insecticide	NOUN	O	O
with	ADP	O	O
known	VERB	O	O
neurotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

Its	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
well	ADV	O	O
understood	VERB	O	O
although	ADP	O	O
it	PRON	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
lindane	NOUN	O	I-Entity
acts	VERB	O	O
as	ADP	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
antagonist	NOUN	O	O
at	ADP	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA)-A	PROPN	O	I-Entity
receptor	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
GABAergic	PROPN	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
systems	NOUN	O	O
by	ADP	O	O
measuring	VERB	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
7	NUM	O	O
brain	NOUN	O	O
areas	NOUN	O	O
at	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
animals	NOUN	O	O
suffered	VERB	O	O
tonic	ADJ	O	O
convulsions	NOUN	O	I-Entity
at	ADP	O	O
18.3	NUM	O	O

1.4	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
lindane	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
was	VERB	O	O
only	ADV	O	O
slightly	ADV	O	O
but	CCONJ	O	O
significantly	ADV	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
colliculi	NOUN	O	O
without	ADP	O	O
modifications	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
areas	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
mesencephalon	NOUN	O	O
and	CCONJ	O	O
that	DET	O	O
of	ADP	O	O
its	ADJ	O	O
metabolite	NOUN	O	O
DOPAC	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
mesencephalon	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2484903)

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
methimazole	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hepatocellular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
and	CCONJ	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
lupus	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
in	ADP	O	O
most	ADJ	O	O
circumstances	NOUN	O	O
131I	NUM	O	O
is	VERB	O	O
the	DET	O	O
therapy	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2553470)

Anticonvulsant	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

MK-801	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
noncompetitive	ADJ	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
anticonvulsant	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
using	VERB	O	O
two	NUM	O	O
seizure	NOUN	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
coadministration	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
and	CCONJ	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

First	ADV	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
MK-801	PROPN	O	I-Entity
produced	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
anticonvulsant	ADJ	O	O
action	NOUN	O	O
with	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
different	ADJ	O	O
biochemical	ADJ	O	O
mechanisms	NOUN	O	O
control	NOUN	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
two	NUM	O	O
models	NOUN	O	O
.	PUNCT	O	O

Second	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
anticonvulsant	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
only	ADV	O	O
occurred	VERB	O	O
after	ADP	O	O
initial	ADJ	O	O
periods	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
is	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
demonstration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
conclusion	NOUN	O	O
derived	VERB	O	O
from	ADP	O	O
in	ADP	O	O
vitro	ADJ	O	O
experiments	NOUN	O	O
that	ADJ	O	O
MK-801	VERB	O	I-Entity
binding	VERB	O	O
requires	VERB	O	O
agonist	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
opening	NOUN	O	O
of	ADP	O	O
the	DET	O	O
channel	NOUN	O	O
sites	NOUN	O	O
of	ADP	O	O
the	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
.	PUNCT	O	O

Third	ADV	O	O
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
is	VERB	O	O
relatively	ADV	O	O
easy	ADJ	O	O
to	PART	O	O
block	VERB	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
lithium	NOUN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
by	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
anticonvulsants	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
more	ADV	O	O
difficult	ADJ	O	O
to	PART	O	O
terminate	VERB	O	O
ongoing	ADJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
and	CCONJ	O	O
block	VERB	O	O
the	DET	O	O
lethality	NOUN	O	O
of	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
30	NUM	O	O
or	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
during	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
,	PUNCT	O	O
gradually	ADV	O	O
reduced	VERB	O	O
electrical	ADJ	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
and	CCONJ	O	O
greatly	ADV	O	O
enhanced	VERB	O	O
the	DET	O	O
survival	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
and	CCONJ	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
further	ADV	O	O
supported	VERB	O	O
by	ADP	O	O
results	NOUN	O	O
showing	VERB	O	O
that	ADP	O	O
nonconvulsive	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
were	VERB	O	O
synergistic	ADJ	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2614930)

Nifedipine	PROPN	O	I-Entity
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
autonomic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
80	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
diabetic	ADJ	O	I-Entity
male	NOUN	O	O
with	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
autonomic	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
ventricular	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
70/min	NUM	O	O
which	ADJ	O	O
slowed	VERB	O	O
down	PART	O	O
to	ADP	O	O
30	NUM	O	O
-	PUNCT	O	O
40/min	NUM	O	O
when	ADV	O	O
nifedipine	NOUN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
3	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
which	ADJ	O	O
he	PRON	O	O
was	VERB	O	O
paced	VERB	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
70/min	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
inconsistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
established	VERB	O	O
finding	VERB	O	O
that	ADP	O	O
nifedipine	NOUN	O	I-Entity
induces	VERB	O	O
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
normally	ADV	O	O
innervated	VERB	O	O
hearts	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
hearts	NOUN	O	O
deprived	VERB	O	O
of	ADP	O	O
compensatory	NOUN	O	O
sympathetic	ADJ	O	O
drive	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2625524)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
in	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
75	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
(	PUNCT	O	O
100%	NUM	O	O
death	NOUN	O	O
rate	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
cocaine	NOUN	O	I-Entity
70	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
82%	NUM	O	O
death	NOUN	O	O
rate	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
lower	VERB	O	O
the	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
at	ADP	O	O
most	ADJ	O	O
doses	NOUN	O	O
tested	VERB	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
two	NUM	O	O
highest	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
lowering	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
reach	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
at	ADP	O	O
any	DET	O	O
dose	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
central	ADJ	O	O
dopamine	NOUN	O	I-Entity
blocker	NOUN	O	O
haloperidol	NOUN	O	I-Entity
against	ADP	O	O
death	NOUN	O	O
from	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
amphetamine	NOUN	O	I-Entity
exposure	NOUN	O	O
without	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
demonstrated	VERB	O	O
an	DET	O	O
ability	NOUN	O	O
to	PART	O	O
reduce	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
without	ADP	O	O
significantly	ADV	O	O
reducing	VERB	O	O
mortality	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2650911)

Autoradiographic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
in	ADP	O	O
nuclei	NOUN	O	O
of	ADP	O	O
diethylstilbesterol	NOUN	O	I-Entity
induced	VERB	O	O
hamster	NOUN	O	O
renal	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
.	PUNCT	O	O

Estrogen	NOUN	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
were	VERB	O	O
demonstrated	VERB	O	O
by	ADP	O	O
autoradiography	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
transplantable	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
primary	ADJ	O	O
diethylstilbesterol	NOUN	O	I-Entity

induced	VERB	O	O
renal	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
in	ADP	O	O
three	NUM	O	O
hamsters	NOUN	O	O
.	PUNCT	O	O

Radiolabelling	VERB	O	O
,	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
3H-17	NUM	O	O
beta	NOUN	O	O
estradiol	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
increased	VERB	O	O
only	ADV	O	O
over	ADP	O	O
the	DET	O	O
nuclei	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
cells	NOUN	O	O
;	PUNCT	O	O
stereologic	ADJ	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
4.5-	NOUN	O	O
to	ADP	O	O
6.7-times	NOUN	O	O
higher	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
reduced	VERB	O	O
silver	NOUN	O	I-Entity
grains	NOUN	O	O
over	ADP	O	O
nuclei	NOUN	O	O
than	ADP	O	O
cytoplasm	NOUN	O	O
of	ADP	O	O
these	DET	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
rapid	ADJ	O	O
tubular	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
estradiol	NOUN	O	I-Entity
which	ADJ	O	O
peaked	VERB	O	O
in	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
1	NUM	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
published	VERB	O	O
report	NOUN	O	O
documenting	VERB	O	O
the	DET	O	O
preferential	ADJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
binding	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
to	ADP	O	O
nuclei	NOUN	O	O
of	ADP	O	O
cells	NOUN	O	O
in	ADP	O	O
estrogen	NOUN	O	I-Entity
induced	VERB	O	O
hamster	NOUN	O	O
renal	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2710809)

Bradycardia	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
biperiden	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
38-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	ADJ	O	O
suffering	NOUN	O	O
from	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
postzosteric	NOUN	O	I-Entity
trigeminal	ADJ	O	B-Entity
neuralgia	NOUN	O	I-Entity
,	PUNCT	O	O
intravenous	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
biperiden	NOUN	O	B-Entity
lactate	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
paradoxical	ADJ	O	O
reaction	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
considerable	ADJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
dysarthria	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dysphagia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
back	ADV	O	O
to	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
12	NUM	O	O
hours	NOUN	O	O
upon	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
orciprenaline	NOUN	O	I-Entity
under	ADP	O	O
cardiac	ADJ	O	O
monitoring	NOUN	O	O
in	ADP	O	O
an	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

Bradycardia	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
biperiden	NOUN	O	I-Entity
is	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
speed	NOUN	O	O
of	ADP	O	O
injection	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
dual	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
drugs	NOUN	O	O
on	ADP	O	O
muscarine	NOUN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2718706)

Deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
labetalol	NOUN	O	I-Entity
with	ADP	O	O
halothane	NOUN	O	I-Entity
,	PUNCT	O	O
enflurane	NOUN	O	I-Entity
or	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
for	ADP	O	O
middle	ADJ	O	O
-	PUNCT	O	O
ear	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
feasibility	NOUN	O	O
of	ADP	O	O
using	VERB	O	O
labetalol	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
alpha-	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	NOUN	O	O
blocking	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
agent	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
inhalation	NOUN	O	O
anaesthetics	NOUN	O	O
(	PUNCT	O	O
halothane	NOUN	O	I-Entity
,	PUNCT	O	O
enflurane	NOUN	O	I-Entity
or	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
23	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
middle	ADJ	O	O
-	PUNCT	O	O
ear	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

10	NUM	O	O
min	NOUN	O	O
in	ADP	O	O
the	DET	O	O
halothane	NOUN	O	I-Entity
(	PUNCT	O	O
H	PROPN	O	I-Entity
)	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
79	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

11	NUM	O	O
min	NOUN	O	O
in	ADP	O	O
the	DET	O	O
enflurane	NOUN	O	I-Entity
(	PUNCT	O	O
E	PROPN	O	I-Entity
)	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
from	ADP	O	O
80	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

15	NUM	O	O
min	NOUN	O	O
in	ADP	O	O
the	DET	O	O
isoflurane	NOUN	O	I-Entity
(	PUNCT	O	O
I	PRON	O	I-Entity
)	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
H	PROPN	O	I-Entity
concentration	NOUN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inspiratory	ADJ	O	O
gas	NOUN	O	O
was	VERB	O	O
0.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.1	NUM	O	O
vol%	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADJ	O	O
E	PROPN	O	I-Entity
concentration	NOUN	O	O
1.6	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

I	PRON	O	I-Entity
concentration	VERB	O	O
1.0	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	I-Entity
for	ADP	O	O
lowering	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
,	PUNCT	O	O
0.52	NUM	O	O
-	SYM	O	O
0.59	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
stable	ADJ	O	O
without	ADP	O	O
tachy-	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
operating	NOUN	O	O
conditions	NOUN	O	O
regarding	VERB	O	O
bleeding	VERB	O	I-Entity
were	VERB	O	O
estimated	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
rose	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
from	ADP	O	O
the	DET	O	O
values	NOUN	O	O
before	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
returned	VERB	O	O
postoperatively	ADV	O	O
to	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
the	DET	O	O
isoflurane	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
hypotension	NOUN	O	I-Entity
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
rebound	NOUN	O	O
phenomenon	NOUN	O	O
in	ADP	O	O
either	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
or	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
labetalol	NOUN	O	I-Entity
induces	VERB	O	O
easily	ADV	O	O
adjustable	ADJ	O	O
hypotension	NOUN	O	I-Entity
without	ADP	O	O
compensatory	NOUN	O	O
tachycardia	NOUN	O	I-Entity
and	CCONJ	O	O
rebound	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2765447)

Convulsion	NOUN	O	I-Entity
following	VERB	O	O
intravenous	ADJ	O	O
fluorescein	NOUN	O	I-Entity
angiography	NOUN	O	O
.	PUNCT	O	O

Tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
followed	VERB	O	O
intravenous	ADJ	O	O
fluorescein	NOUN	O	I-Entity
injection	NOUN	O	O
for	ADP	O	O
fundus	NOUN	O	O
angiography	NOUN	O	O
in	ADP	O	O
a	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
precautions	NOUN	O	O
this	DET	O	O
adverse	ADJ	O	O
reaction	NOUN	O	O
recurred	VERB	O	O
on	ADP	O	O
re	ADP	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
intravenous	ADJ	O	O
fluorescein	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2767010)

Pharmacology	NOUN	O	O
of	ADP	O	O
ACC-9653	PROPN	O	I-Entity
(	PUNCT	O	O
phenytoin	VERB	O	I-Entity
prodrug	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ACC-9653	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
disodium	NOUN	O	B-Entity
phosphate	NOUN	O	I-Entity
ester	NOUN	O	I-Entity
of	ADP	O	O
3-hydroxymethyl-5,5-diphenylhydantoin	PROPN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
prodrug	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
with	ADP	O	O
advantageous	ADJ	O	O
physicochemical	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

ACC-9653	NOUN	O	I-Entity
is	VERB	O	O
rapidly	ADV	O	O
converted	VERB	O	O
enzymatically	ADV	O	O
to	PART	O	O
phenytoin	VERB	O	I-Entity
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

ACC-9653	PUNCT	O	I-Entity
and	CCONJ	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity

have	VERB	O	O
equivalent	ADJ	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maximal	ADJ	O	O
electroshock	NOUN	O	O
(	PUNCT	O	O
MES	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
mice	NOUN	O	O
following	VERB	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

ACC-9653	PUNCT	O	I-Entity
and	CCONJ	O	O
8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
.	PUNCT	O	O

ACC-9653	NOUN	O	I-Entity
and	CCONJ	O	O
phenytoin	NOUN	O	B-Entity
sodium	NOUN	O	I-Entity
have	VERB	O	O
similar	ADJ	O	O
antiarrhythmic	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
ouabain	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
anesthetized	ADJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ACC-9653	PROPN	O	I-Entity
or	CCONJ	O	O
phenytoin	VERB	O	B-Entity
sodium	NOUN	O	I-Entity
necessary	ADJ	O	O
to	PART	O	O
convert	VERB	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
were	VERB	O	O
24	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Only	ADV	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
displayed	VERB	O	O
in	ADP	O	O
vitro	ADJ	O	O
antiarrhythmic	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
strophanthidin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
guinea	NOUN	O	O
pig	NOUN	O	O
right	ADV	O	O
atria	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
anesthetized	ADJ	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ACC-9653	PROPN	O	I-Entity
(	PUNCT	O	O
31	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
infused	VERB	O	O
over	ADP	O	O
15	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
responses	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
an	DET	O	O
equimolar	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
(	PUNCT	O	O
21	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ACC-9653	PROPN	O	I-Entity
and	CCONJ	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
treatments	NOUN	O	O
produced	VERB	O	O
similar	ADJ	O	O
marked	VERB	O	O
reductions	NOUN	O	O
in	ADP	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
contractile	ADJ	O	O
force	NOUN	O	O
(	PUNCT	O	O
LVdP	PROPN	O	O
/	SYM	O	O
dt	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
occurred	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
maximum	ADJ	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
toxicity	NOUN	O	I-Entity
studies	NOUN	O	O
of	ADP	O	O
ACC-9653	PROPN	O	I-Entity
and	CCONJ	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
were	VERB	O	O
carried	VERB	O	O
out	PART	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
rabbits	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dogs	NOUN	O	O
by	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
local	ADJ	O	O
irritation	NOUN	O	O
of	ADP	O	O
ACC-9653	PROPN	O	I-Entity
was	VERB	O	O
markedly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
following	VERB	O	O
i.m	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2818777)

Phenytoin	PROPN	O	I-Entity
induced	VERB	O	O
fatal	ADJ	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
61	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
female	NOUN	O	O
developed	VERB	O	O
fatal	ADJ	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
phenytoin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
typical	ADJ	O	O
multisystem	NOUN	O	O
clinical	ADJ	O	O
pattern	NOUN	O	O
precedes	VERB	O	O
the	DET	O	O
manifestations	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
hematologic	NOUN	O	O
,	PUNCT	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
pathologic	ADJ	O	O
features	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
mixed	ADJ	O	O
hepatocellular	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
drug	NOUN	O	B-Entity
hypersensitivity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
phenytoin	NOUN	O	I-Entity
who	NOUN	O	O
presents	VERB	O	O
a	DET	O	O
viral	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
illness	NOUN	O	O
,	PUNCT	O	O
early	ADJ	O	O
recognition	NOUN	O	O
and	CCONJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
are	VERB	O	O
mandatory	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (2884595)

Treatment	NOUN	O	O
of	ADP	O	O
lethal	ADJ	O	O
pertussis	NOUN	O	B-Entity
vaccine	NOUN	O	I-Entity
reaction	NOUN	O	O
with	ADP	O	O
histamine	NOUN	O	I-Entity
H1	NUM	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
mortality	NOUN	O	O
after	ADP	O	O
pertussis	NOUN	O	I-Entity
immunization	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

Without	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
73	NUM	O	O
of	ADP	O	O
92	NUM	O	O
animals	NOUN	O	O
(	PUNCT	O	O
80%	NUM	O	O
)	PUNCT	O	O
died	VERB	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
bovine	ADJ	O	O
serum	NOUN	O	O
albumin	NOUN	O	O
(	PUNCT	O	O
BSA	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
+	SYM	O	O
7	NUM	O	O
of	ADP	O	O
pertussis	NOUN	O	I-Entity
immunization	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
3	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
cyproheptadine	NOUN	O	I-Entity
,	PUNCT	O	O
2	NUM	O	O
mg	NUM	O	O
mianserin	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
2	NUM	O	O
mg	NUM	O	O
chlorpheniramine	NOUN	O	I-Entity
,	PUNCT	O	O
only	ADV	O	O
5	NUM	O	O
of	ADP	O	O
105	NUM	O	O
animals	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
died	VERB	O	O
after	ADP	O	O
receiving	VERB	O	O
BSA	PROPN	O	O
on	ADP	O	O
day	NOUN	O	O
+	SYM	O	O
7	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blockade	PROPN	O	O
of	ADP	O	O
histamine	NOUN	O	I-Entity
H1	NOUN	O	O
receptors	NOUN	O	O
may	VERB	O	O
reduce	VERB	O	O
mortality	NOUN	O	O
in	ADP	O	O
pertussis	NOUN	O	I-Entity
immunization	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2904523)

Support	NOUN	O	O
for	ADP	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
hypertension	NOUN	O	I-Entity
hypothesis	NOUN	O	O
:	PUNCT	O	O
18	NUM	O	O
hour	NOUN	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
after	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
adrenaline	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
study	NOUN	O	O
6	NUM	O	O
h	NOUN	O	O
infusions	NOUN	O	O
of	ADP	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O

15	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
;	PUNCT	O	O
1	NUM	O	O
ng	NOUN	O	O
=	SYM	O	O
5.458	NUM	O	O
pmol	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
noradrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
;	PUNCT	O	O
1	NUM	O	O
ng	NOUN	O	O
=	SYM	O	O
5.911	NUM	O	O
pmol	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
5%	NUM	O	O
dextrose	NOUN	O	I-Entity
solution	NOUN	O	O
(	PUNCT	O	O
5.4	NUM	O	O
ml	PROPN	O	O
/	SYM	O	O
h	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
to	ADP	O	O
ten	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
2	NUM	O	O
weeks	NOUN	O	O
apart	ADV	O	O
.	PUNCT	O	O

Adrenaline	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
noradrenaline	ADV	O	I-Entity
,	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
delayed	VERB	O	O
and	CCONJ	O	O
protracted	VERB	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
the	DET	O	O
total	ADJ	O	O
postinfusion	NOUN	O	O
period	NOUN	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
were	VERB	O	O
6	NUM	O	O
(	PUNCT	O	O
SEM	NOUN	O	O
2)%	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
(	PUNCT	O	O
2)%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
higher	ADJ	O	O
than	ADP	O	O
after	ADP	O	O
dextrose	ADJ	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
ANOVA	PROPN	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
"	PUNCT	O	O
stress	NOUN	O	O
"	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
230	NUM	O	O
pg	NOUN	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
6	NUM	O	O
h	PART	O	O
cause	VERB	O	O
a	DET	O	O
delayed	VERB	O	O
and	CCONJ	O	O
protracted	VERB	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
strong	ADJ	O	O
support	NOUN	O	O
for	ADP	O	O
the	DET	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
hypertension	NOUN	O	I-Entity
hypothesis	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2907577)

Effect	NOUN	O	O
of	ADP	O	O
alkylxanthines	NOUN	O	I-Entity
on	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Adenosine	ADJ	O	I-Entity
antagonists	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
previously	ADV	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
of	ADP	O	O
benefit	NOUN	O	O
in	ADP	O	O
some	DET	O	O
ischaemic	NOUN	O	I-Entity
and	CCONJ	O	O
nephrotoxic	ADJ	O	I-Entity
models	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ARF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
alkylxanthines	NOUN	O	I-Entity
with	ADP	O	O
different	ADJ	O	O
potencies	NOUN	O	O
as	ADP	O	O
adenosine	NOUN	O	I-Entity
antagonists	NOUN	O	O
8-phenyltheophylline	NUM	O	I-Entity
,	PUNCT	O	O
theophylline	NOUN	O	I-Entity
and	CCONJ	O	O
enprofylline	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
developing	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
4	NUM	O	O
daily	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
biochemical	ADJ	O	O
(	PUNCT	O	O
plasma	NOUN	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
functional	ADJ	O	O
(	PUNCT	O	O
urine	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
[	PUNCT	O	O
3H]inulin	PROPN	O	O
and	CCONJ	O	O
[	PUNCT	O	O
14C]p	NUM	O	B-Entity
-	PUNCT	O	I-Entity
aminohippuric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
clearances	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
morphological	ADJ	O	O
(	PUNCT	O	O
degree	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
)	PUNCT	O	O
indices	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
any	DET	O	O
improvement	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
largely	ADV	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
exerted	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
vehicle	NOUN	O	O
(	PUNCT	O	O
polyethylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
and	CCONJ	O	O
NaOH	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
any	DET	O	O
consistent	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
noted	VERB	O	O
with	ADP	O	O
the	DET	O	O
alkylxanthines	NOUN	O	I-Entity
tested	VERB	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
adenosine	NOUN	O	I-Entity
plays	VERB	O	O
little	ADJ	O	O
,	PUNCT	O	O
if	ADP	O	O
any	DET	O	O
,	PUNCT	O	O
pathophysiological	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ARF	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2931989)

Adverse	ADJ	O	O
ocular	ADJ	O	O
reactions	NOUN	O	O
possibly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
isotretinoin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
261	NUM	O	O
adverse	ADJ	O	O
ocular	ADJ	O	O
reactions	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
237	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
isotretinoin	ADV	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
cystic	ADJ	O	O
acne	NOUN	O	I-Entity
.	PUNCT	O	O

Blepharoconjunctivitis	PROPN	O	I-Entity
,	PUNCT	O	O
subjective	ADJ	O	O
complaints	NOUN	O	O
of	ADP	O	O
dry	ADJ	O	B-Entity
eyes	NOUN	O	I-Entity
,	PUNCT	O	O
blurred	ADJ	O	B-Entity
vision	NOUN	O	I-Entity
,	PUNCT	O	O
contact	NOUN	O	O
lens	NOUN	O	O
intolerance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
photodermatitis	NOUN	O	I-Entity
are	VERB	O	O
reversible	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

More	ADV	O	O
serious	ADJ	O	O
ocular	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
include	VERB	O	O
papilledema	NOUN	O	I-Entity
,	PUNCT	O	O
pseudotumor	NOUN	O	B-Entity
cerebri	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
white	ADJ	O	O
or	CCONJ	O	O
gray	ADJ	O	O
subepithelial	ADJ	O	O
corneal	ADJ	O	B-Entity
opacities	NOUN	O	I-Entity
;	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
these	DET	O	O
are	VERB	O	O
reversible	ADJ	O	O
if	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

Isotretinoin	PROPN	O	I-Entity
is	VERB	O	O
contraindicated	VERB	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
many	ADJ	O	O
reported	VERB	O	O
congenital	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
after	ADP	O	O
maternal	ADJ	O	O
use	NOUN	O	O
(	PUNCT	O	O
including	VERB	O	O
microphthalmos	NOUN	O	I-Entity
,	PUNCT	O	O
orbital	ADJ	O	O
hypertelorism	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
optic	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
hypoplasia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (2933998)

Procaterol	PROPN	O	I-Entity
and	CCONJ	O	O
terbutaline	NOUN	O	I-Entity
in	ADP	O	O
bronchial	ADJ	O	B-Entity
asthma	NOUN	O	I-Entity
.	PUNCT	O	O

Procaterol	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
beta-2	NOUN	O	O
adrenoceptor	NOUN	O	O
stimulant	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
cross	VERB	O	O
-	PUNCT	O	O
over	ADP	O	O
trial	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bronchial	ADJ	O	B-Entity
asthma	NOUN	O	I-Entity
.	PUNCT	O	O

Oral	PROPN	O	O
procaterol	NOUN	O	I-Entity
50	NUM	O	O
micrograms	NOUN	O	O
b.d	NOUN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
procaterol	NOUN	O	I-Entity
100	NUM	O	O
micrograms	NOUN	O	O
b.d	ADJ	O	O
.	PUNCT	O	O

terbutaline	NOUN	O	I-Entity
5	NUM	O	O
mg	NUM	O	O
t.i.d	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
best	ADJ	O	O
clinical	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
asthmatic	ADJ	O	I-Entity
and	CCONJ	O	O
tremorgenic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
procaterol	NOUN	O	I-Entity
were	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
.	PUNCT	O	O

Procaterol	PROPN	O	I-Entity
appeared	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
tested	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
twice	ADJ	O	O
daily	ADJ	O	O
regimen	NOUN	O	O
would	VERB	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
suitable	ADJ	O	O
with	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2974281)

Subacute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
B	NOUN	O	O
24/76	NUM	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
heart	NOUN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
in	ADP	O	O
correlation	NOUN	O	O
with	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

24/76	NUM	O	O
i.e.	X	O	O
1-(2,4-dichlorophenoxy)-3[2	NUM	O	O
-	PUNCT	O	O
3,4-dimethoxyphenyl)ethanolamino]-prop	NUM	O	O
an-2-ol	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
beta	NOUN	O	O
1-adrenoceptor	NUM	O	O
blocking	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
2-adrenoceptor	NOUN	O	O
stimulating	VERB	O	O
properties	NOUN	O	O
with	ADP	O	O
propranolol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
heart	NOUN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
correlation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
neither	CCONJ	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
nor	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
suppress	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
two	NUM	O	O
beta	NOUN	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
influenced	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hypertrophy	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
different	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
reproducible	ADJ	O	O
extent	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
suppress	VERB	O	O
the	DET	O	O
increased	VERB	O	O
ornithine	NOUN	O	I-Entity
decarboxylase	NOUN	O	O
activity	NOUN	O	O
with	ADP	O	O
both	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
in	ADP	O	O
hypertrophied	VERB	O	B-Entity
hearts	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
mass	NOUN	O	O
.	PUNCT	O	O

Neither	DET	O	O
propranolol	NOUN	O	I-Entity
nor	CCONJ	O	O
B	NOUN	O	O
24/76	NUM	O	O
could	VERB	O	O
stop	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
characteristic	ADJ	O	O
myosin	NOUN	O	O
isoenzyme	NOUN	O	O
pattern	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypertrophied	ADJ	O	I-Entity
rat	NOUN	O	O
heart	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
investigations	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
provide	VERB	O	O
any	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
B	NOUN	O	O
24/76	NUM	O	O
have	VERB	O	O
the	DET	O	O
potency	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
isoproterenol	NOUN	O	I-Entity
from	ADP	O	O
producing	VERB	O	O
heart	NOUN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3074291)

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
oxitropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
and	CCONJ	O	O
of	ADP	O	O
slow	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
theophylline	NOUN	O	I-Entity
on	ADP	O	O
nocturnal	ADJ	O	O
asthma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
inhaled	VERB	O	O
antimuscarinic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
oxitropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
a	DET	O	O
slow	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
theophylline	NOUN	O	I-Entity
preparation	NOUN	O	O
upon	ADP	O	O
nocturnal	ADJ	O	O
asthma	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
samples	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
:	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
oxitropium	NOUN	O	I-Entity
at	ADP	O	O
600	NUM	O	O
micrograms	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
at	ADP	O	O
400	NUM	O	O
micrograms	NOUN	O	O
t.i.d	NUM	O	O
.	PUNCT	O	O

(	PUNCT	O	O
6	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
whereas	ADP	O	O
11	NUM	O	O
received	VERB	O	O
theophylline	NOUN	O	I-Entity
at	ADP	O	O
300	NUM	O	O
mg	NUM	O	O
b.i.d	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
noticed	VERB	O	O
between	ADP	O	O
results	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
either	DET	O	O
active	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
with	ADP	O	O
either	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
oxitropium	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
subject	NOUN	O	O
reported	VERB	O	O
side	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
oxitropium	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
three	NUM	O	O
subjects	NOUN	O	O
reporting	VERB	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
and	CCONJ	O	O
tremors	NOUN	O	I-Entity
after	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

Oxitropium	NOUN	O	I-Entity
proves	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
valuable	ADJ	O	O
alternative	NOUN	O	O
to	ADP	O	O
theophylline	NOUN	O	I-Entity
in	ADP	O	O
nocturnal	ADJ	O	O
asthma	NOUN	O	I-Entity
,	PUNCT	O	O
since	ADP	O	O
it	PRON	O	O
is	VERB	O	O
equally	ADV	O	O
potent	ADJ	O	O
,	PUNCT	O	O
safer	ADJ	O	O
and	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
require	VERB	O	O
the	DET	O	O
titration	NOUN	O	O
of	ADP	O	O
dosage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3083835)

Penicillin	PROPN	O	I-Entity
anaphylaxis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
penicillin	NOUN	O	I-Entity
anaphylaxis	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
terminology	NOUN	O	O
,	PUNCT	O	O
occurrence	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
,	PUNCT	O	O
pathogenesis	NOUN	O	O
,	PUNCT	O	O
prevention	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
anaphylaxis	NOUN	O	I-Entity
are	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Emergency	NOUN	O	O
physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
oral	ADJ	O	O
penicillin	NOUN	O	I-Entity
anaphylaxis	NOUN	O	I-Entity
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
its	ADJ	O	O
occurrence	NOUN	O	O
by	ADP	O	O
prescribing	VERB	O	O
the	DET	O	O
antibiotic	NOUN	O	O
judiciously	ADV	O	O
and	CCONJ	O	O
knowledgeably	ADV	O	O
and	CCONJ	O	O
to	PART	O	O
offer	VERB	O	O
optimal	ADJ	O	O
medical	ADJ	O	O
therapy	NOUN	O	O
once	ADP	O	O
this	DET	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
reaction	NOUN	O	O
has	VERB	O	O
begun	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3084231)

Reversible	ADJ	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dementia	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Reversible	ADJ	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dementia	NOUN	O	I-Entity
was	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
a	DET	O	O
21-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
3-year	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
insidious	ADJ	O	O
progressive	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
global	ADJ	O	O
cognitive	ADJ	O	O
abilities	NOUN	O	O
documented	VERB	O	O
by	ADP	O	O
serial	ADJ	O	O
neuropsychological	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
pathophysiological	ADJ	O	O
mechanisms	NOUN	O	O
which	ADJ	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
operative	ADJ	O	O
in	ADP	O	O
this	DET	O	O
case	NOUN	O	O
include	VERB	O	O
:	PUNCT	O	O
a	DET	O	O
direct	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
;	PUNCT	O	O
a	DET	O	O
paradoxical	ADJ	O	O
epileptogenic	ADJ	O	O
effect	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
indirect	ADJ	O	O
CNS	PROPN	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
mediated	VERB	O	O
through	ADP	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperammonemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3088653)

Reversal	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
of	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
by	ADP	O	O
pre-	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
training	NOUN	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
modulating	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
retention	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
paradigm	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Scopolamine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
methyl	ADJ	O	B-Entity
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
induced	VERB	O	O
an	DET	O	O
amnesia	NOUN	O	I-Entity
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
latency	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Naloxone	PROPN	O	I-Entity
(	PUNCT	O	O
0.3	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
injected	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
training	NOUN	O	O
attenuated	VERB	O	O
the	DET	O	O
retention	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
peak	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
antagonized	VERB	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
demonstrating	VERB	O	O
the	DET	O	O
opioid	ADJ	O	O
specificity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
naloxone	NOUN	O	I-Entity
effect	NOUN	O	O
.	PUNCT	O	O

Post	PROPN	O	O
-	PUNCT	O	O
training	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
or	CCONJ	O	O
as	ADP	O	O
a	DET	O	O
split	NOUN	O	O
dose	NOUN	O	O
also	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

Control	NOUN	O	O
experiments	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
neither	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	I-Entity
sensitivity	NOUN	O	O
(	PUNCT	O	O
pre	VERB	O	O
-	PUNCT	O	O
training	NOUN	O	O
naloxone	NOUN	O	I-Entity
)	PUNCT	O	O
nor	CCONJ	O	O
an	DET	O	O
induced	VERB	O	O
aversive	ADJ	O	O
state	NOUN	O	O
(	PUNCT	O	O
post	NOUN	O	O
-	PUNCT	O	O
training	NOUN	O	O
naloxone	NOUN	O	I-Entity
)	PUNCT	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
retention	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3109094)

Electron	PROPN	O	O
microscopic	ADJ	O	O
investigations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lesions	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
urinary	ADJ	O	I-Entity
bladder	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
prevention	NOUN	O	O
by	ADP	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O

Fully	ADV	O	O
developed	VERB	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
nearly	ADV	O	O
complete	ADJ	O	O
detachment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
urothelium	NOUN	O	O
,	PUNCT	O	O
severe	ADJ	O	O
submucosal	NOUN	O	O
edema	NOUN	O	I-Entity
owing	VERB	O	O
to	ADP	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
microvascular	ADJ	O	O
bed	NOUN	O	O
and	CCONJ	O	O
focal	ADJ	O	O
muscle	NOUN	O	O
necroses	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
initial	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
attack	NOUN	O	O
by	ADP	O	O
the	DET	O	O
cyclophosphamide	NOUN	O	I-Entity
metabolites	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
fragmentation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
luminal	ADJ	O	I-Entity
membrane	NOUN	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
breaks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
cell	NOUN	O	O
membranes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
superficial	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
plasma	NOUN	O	O
membranes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intermediate	ADJ	O	O
and	CCONJ	O	O
basal	ADJ	O	O
cells	NOUN	O	O
,	PUNCT	O	O
intercellular	ADJ	O	O
and	CCONJ	O	O
intracellular	ADJ	O	O
edema	NOUN	O	I-Entity
and	CCONJ	O	O
disintegration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
desmosomes	NOUN	O	O
and	CCONJ	O	O
hemidesmosomes	NOUN	O	O
lead	VERB	O	O
to	ADP	O	O
progressive	ADJ	O	O
degeneration	NOUN	O	O
and	CCONJ	O	O
detachment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
epithelial	ADJ	O	O
cells	NOUN	O	O
with	ADP	O	O
exposure	NOUN	O	O
and	CCONJ	O	O
splitting	NOUN	O	O
of	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
membrane	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
effectively	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3125850)

Increase	VERB	O	O
in	ADP	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
during	ADP	O	O
suxamethonium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
inhibition	NOUN	O	O
by	ADP	O	O
alfentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
1.5	NUM	O	O
mg	NUM	O	O
kg-1	NUM	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
32	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
6.9	NUM	O	O
yr	NOUN	O	O
)	PUNCT	O	O
pretreated	VERB	O	O
with	ADP	O	O
either	DET	O	O
physiological	ADJ	O	O
saline	NOUN	O	O
or	CCONJ	O	O
alfentanil	NOUN	O	I-Entity
50	NUM	O	O
micrograms	NOUN	O	O
kg-1	ADJ	O	O
.	PUNCT	O	O

Anaesthesia	PROPN	O	O
was	VERB	O	O
induced	VERB	O	O
with	ADP	O	O
thiopentone	NOUN	O	I-Entity
5	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
suxamethonium	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
alfentanil	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
during	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.7	NUM	O	O
(	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
cm	VERB	O	O
H2O	NOUN	O	I-Entity
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
alfentanil	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
7.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

(	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
cm	VERB	O	O
H2O	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
was	VERB	O	O
directly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
(	PUNCT	O	O
regression	NOUN	O	O
line	NOUN	O	O
:	PUNCT	O	O
y	PRON	O	O
=	SYM	O	O
0.5	NUM	O	O
+	SYM	O	O
4.78x	NUM	O	O
with	ADP	O	O
r	NOUN	O	O
of	ADP	O	O
0.78	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
increases	VERB	O	O
significantly	ADV	O	O
during	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
healthy	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Alfentanil	PROPN	O	I-Entity
50	NUM	O	O
micrograms	NOUN	O	O
kg-1	VERB	O	O
effectively	ADV	O	O
inhibits	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
;	PUNCT	O	O
moreover	ADV	O	O
,	PUNCT	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
remains	VERB	O	O
at	ADP	O	O
its	ADJ	O	O
control	NOUN	O	O
value	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3155884)

Acute	ADJ	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
normalizes	VERB	O	O
the	DET	O	O
resistance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
cardiotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
in	ADP	O	O
streptozotocin	NOUN	O	I-Entity
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
morphometric	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
earlier	ADV	O	O
reported	VERB	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
streptozotocin	NOUN	O	I-Entity
diabetes	NOUN	O	I-Entity
against	ADP	O	O
the	DET	O	O
cardiotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
ISO	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
to	ADP	O	O
135	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
crystalline	ADJ	O	O
insulin	NOUN	O	O
,	PUNCT	O	O
ISO	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
subcutaneously	ADV	O	O
and	CCONJ	O	O
when	ADV	O	O
ISO	PROPN	O	I-Entity
induced	VERB	O	O
fibrosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
was	VERB	O	O
morphometrically	ADV	O	O
analyzed	VERB	O	O
7	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
highly	ADV	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.83	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
p	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
slope	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
glucose	NOUN	O	I-Entity
after	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
appeared	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
myocardial	ADJ	O	O
content	NOUN	O	O
of	ADP	O	O
catecholamines	NOUN	O	I-Entity
was	VERB	O	O
estimated	VERB	O	O
in	ADP	O	O
these	DET	O	O
8	NUM	O	O
day	NOUN	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
norepinephrine	NOUN	O	I-Entity
content	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
while	ADP	O	O
epinephrine	NOUN	O	I-Entity
remained	VERB	O	O
unchanged	ADJ	O	O
.	PUNCT	O	O

An	DET	O	O
enhanced	ADJ	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
activity	NOUN	O	O
with	ADP	O	O
a	DET	O	O
consequent	ADJ	O	O
down	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptors	NOUN	O	O
could	VERB	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
explain	VERB	O	O
this	DET	O	O
catecholamine	NOUN	O	I-Entity
resistance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rapid	ADJ	O	O
reversion	NOUN	O	O
after	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
excludes	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
streptozotocin	NOUN	O	I-Entity
in	ADP	O	O
itself	PRON	O	O
causes	VERB	O	O
the	DET	O	O
ISO	PROPN	O	I-Entity
resistance	NOUN	O	O
and	CCONJ	O	O
points	NOUN	O	O
towards	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
insulin	NOUN	O	O
effect	NOUN	O	O
on	ADP	O	O
myocardial	ADJ	O	O
catecholamine	NOUN	O	I-Entity
sensitivity	NOUN	O	O
in	ADP	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
phenomenon	NOUN	O	O
described	VERB	O	O
might	VERB	O	O
elucidate	VERB	O	O
pathogenetic	ADJ	O	O
mechanisms	NOUN	O	O
behind	ADP	O	O
toxic	ADJ	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
degeneration	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
possibly	ADV	O	O
have	VERB	O	O
relevance	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
cardiovascular	ADJ	O	O
complications	NOUN	O	O
in	ADP	O	O
diabetic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3191389)

Differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
on	ADP	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
muscarinic	ADJ	O	O
cholinergic	NOUN	O	O
agonist	NOUN	O	O
pilocarpine	NOUN	O	I-Entity
induces	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
widespread	ADJ	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
forebrain	NOUN	O	O
.	PUNCT	O	O

anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
sodium	NOUN	O	B-Entity
salicylate	NOUN	O	I-Entity
,	PUNCT	O	O
phenylbutazone	NOUN	O	I-Entity
,	PUNCT	O	O
indomethacin	NOUN	O	I-Entity
,	PUNCT	O	O
ibuprofen	NOUN	O	I-Entity
and	CCONJ	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
salicylate	NOUN	O	I-Entity
,	PUNCT	O	O
ED50	PROPN	O	O
103	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
60	NUM	O	O
-	SYM	O	O
174	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
phenylbutazone	NOUN	O	I-Entity
,	PUNCT	O	O
59	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
-	SYM	O	O
70	NUM	O	O
)	PUNCT	O	O
converted	VERB	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
convulsant	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
200	NUM	O	O
mg	ADV	O	O
/	SYM	O	O
kg	X	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
convulsant	ADJ	O	O
one	NOUN	O	O
.	PUNCT	O	O

Indomethacin	PROPN	O	I-Entity
,	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ibuprofen	NOUN	O	I-Entity
,	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
modulate	VERB	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Mefenamic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
26	NUM	O	O
(	PUNCT	O	O
22	NUM	O	O
-	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
protected	VERB	O	O
rats	NOUN	O	O
from	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
380	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
differentially	ADV	O	O
modulate	VERB	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3289726)

Acute	ADJ	O	B-Entity
neurologic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
etoposide	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
malignant	ADJ	O	B-Entity
glioma	NOUN	O	I-Entity
.	PUNCT	O	O

Etoposide	PROPN	O	I-Entity
(	PUNCT	O	O
VP-16	PROPN	O	B-Entity
-	SYM	O	I-Entity
213	NUM	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
many	ADJ	O	O
solid	ADJ	O	O
tumors	NOUN	O	I-Entity
and	CCONJ	O	O
hematologic	ADJ	O	B-Entity
malignancies	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
used	VERB	O	O
in	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
autologous	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
agent	NOUN	O	O
has	VERB	O	O
activity	NOUN	O	O
against	ADP	O	O
several	ADJ	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
resistant	ADJ	O	O
cancers	NOUN	O	I-Entity
including	VERB	O	O
malignant	ADJ	O	B-Entity
glioma	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
of	ADP	O	O
eight	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
75%	NUM	O	O
)	PUNCT	O	O
who	NOUN	O	O
we	PRON	O	O
treated	VERB	O	O
for	ADP	O	O
recurrent	ADJ	O	O
or	CCONJ	O	O
resistant	ADJ	O	O
glioma	NOUN	O	I-Entity
,	PUNCT	O	O
sudden	ADJ	O	O
severe	ADJ	O	O
neurologic	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
developed	VERB	O	O
a	DET	O	O
median	NOUN	O	O
of	ADP	O	O
9	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
etoposide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
have	VERB	O	O
included	VERB	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
papilledema	NOUN	O	I-Entity
,	PUNCT	O	O
somnolence	NOUN	O	I-Entity
,	PUNCT	O	O
exacerbation	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sharp	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
abnormalities	NOUN	O	O
resolved	VERB	O	O
rapidly	ADV	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

brain	NOUN	O	O
scans	NOUN	O	O
demonstrated	VERB	O	O
stability	NOUN	O	O
in	ADP	O	O
tumor	NOUN	O	I-Entity
size	NOUN	O	O
and	CCONJ	O	O
peritumor	NOUN	O	O
edema	NOUN	O	I-Entity
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
pretransplant	NOUN	O	O
scans	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
complication	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
represent	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
new	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
etoposide	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
malignant	ADJ	O	B-Entity
glioma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3297909)

Progressive	ADJ	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
after	ADP	O	O
thiabendazole	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
27-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
developed	VERB	O	O
jaundice	ADV	O	I-Entity
2	NUM	O	O
wk	ADP	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
thiabendazole	NOUN	O	I-Entity
.	PUNCT	O	O

Cholestasis	NOUN	O	I-Entity
persisted	VERB	O	O
for	ADP	O	O
3	NUM	O	O
yr	INTJ	O	O
,	PUNCT	O	O
at	ADP	O	O
which	ADJ	O	O
time	NOUN	O	O
a	DET	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Prominent	ADJ	O	O
fibrosis	NOUN	O	I-Entity
and	CCONJ	O	O
hepatocellular	ADJ	O	O
regeneration	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
present	ADJ	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
lobular	ADJ	O	O
architecture	NOUN	O	O
was	VERB	O	O
preserved	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
represents	VERB	O	O
an	DET	O	O
example	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
idiosyncratic	ADJ	O	O
"	PUNCT	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
liver	NOUN	O	I-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
which	ADJ	O	O
the	DET	O	O
primary	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
injury	NOUN	O	O
is	VERB	O	O
the	DET	O	O
bile	NOUN	O	O
duct	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
autoimmune	ADJ	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
destruction	NOUN	O	I-Entity
is	VERB	O	O
suggested	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3323259)

Differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
1,4-dihydropyridine	NUM	O	I-Entity
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
:	PUNCT	O	O
therapeutic	ADJ	O	O
implications	NOUN	O	O
.	PUNCT	O	O

Increasing	VERB	O	O
recognition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
has	VERB	O	O
stimulated	VERB	O	O
research	NOUN	O	O
into	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blocking	VERB	O	I-Entity
agents	NOUN	O	I-Entity
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
applications	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
parallel	VERB	O	O
their	ADJ	O	O
tissue	NOUN	O	O
selectivity	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
verapamil	ADV	O	I-Entity
and	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
roughly	ADV	O	O
equipotent	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
actions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
and	CCONJ	O	O
vascular	ADJ	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
dihydropyridine	NOUN	O	I-Entity
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
potent	ADJ	O	O
peripheral	ADJ	O	O
vasodilator	NOUN	O	O
agents	NOUN	O	O
that	ADJ	O	O
exert	VERB	O	O
minimal	ADJ	O	O
electrophysiologic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
nodal	NOUN	O	O
or	CCONJ	O	O
conduction	NOUN	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dihydropyridine	NOUN	O	I-Entity
available	ADJ	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
,	PUNCT	O	O
nifedipine	NOUN	O	I-Entity
controls	VERB	O	O
angina	NOUN	O	I-Entity
and	CCONJ	O	O
hypertension	NOUN	O	I-Entity
with	ADP	O	O
minimal	ADJ	O	O
depression	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
members	NOUN	O	O
of	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
indications	NOUN	O	O
for	ADP	O	O
which	ADJ	O	O
they	PRON	O	O
may	VERB	O	O
offer	VERB	O	O
advantages	NOUN	O	O
over	ADP	O	O
current	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Once	ADV	O	O
or	CCONJ	O	O
twice	ADV	O	O
daily	ADV	O	O
dosage	NOUN	O	O
possible	ADJ	O	O
with	ADP	O	O
nitrendipine	NOUN	O	I-Entity
and	CCONJ	O	O
nisoldipine	NOUN	O	I-Entity
offers	VERB	O	O
a	DET	O	O
convenient	ADJ	O	O
administration	NOUN	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
encourages	VERB	O	O
patient	ADJ	O	O
compliance	NOUN	O	O
in	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
coronary	ADJ	O	O
vasodilating	NOUN	O	O
properties	NOUN	O	O
of	ADP	O	O
nisoldipine	NOUN	O	I-Entity
have	VERB	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
investigation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
angina	NOUN	O	I-Entity
.	PUNCT	O	O

Selectivity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
cerebrovascular	ADJ	O	O
bed	NOUN	O	O
makes	VERB	O	O
nimodipine	NOUN	O	I-Entity
potentially	ADV	O	O
useful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
migraine	ADJ	O	B-Entity
headache	NOUN	O	I-Entity
,	PUNCT	O	O
dementia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
general	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
dihydropyridine	NOUN	O	I-Entity
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
are	VERB	O	O
usually	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
facial	ADJ	O	O
flushing	NOUN	O	I-Entity
,	PUNCT	O	O
palpitations	NOUN	O	I-Entity
,	PUNCT	O	O
edema	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
anorexia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dizziness	NOUN	O	I-Entity
being	VERB	O	O
the	DET	O	O
more	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3323599)

The	DET	O	O
enhancement	NOUN	O	O
of	ADP	O	O
aminonucleoside	NOUN	O	I-Entity
nephrosis	NOUN	O	I-Entity
by	ADP	O	O
the	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
protamine	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
focal	ADJ	O	B-Entity
segmental	ADJ	O	I-Entity
glomerular	ADJ	O	I-Entity
sclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
FSGS	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
developed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
the	DET	O	O
combined	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
AMNS	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
protamine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
(	PUNCT	O	O
PS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
uninephrectomized	VERB	O	O
three	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
,	PUNCT	O	O
received	VERB	O	O
daily	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
AMNS	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg/100	NUM	O	O
g	NOUN	O	O
body	NOUN	O	O

wt	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
PS	PROPN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
separated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
mg/100	PROPN	O	O
g	NOUN	O	O
body	NOUN	O	O
wt	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
four	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
developed	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
finally	ADV	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
course	NOUN	O	O
curve	NOUN	O	O
of	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
dropped	VERB	O	O
and	CCONJ	O	O
showed	VERB	O	O
significant	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
that	DET	O	O
of	ADP	O	O
each	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
,	PUNCT	O	O
AMNS	PROPN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
PS	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
saline	ADV	O	O
injected	VERB	O	O
.	PUNCT	O	O

Their	ADJ	O	O
glomeruli	NOUN	O	O
showed	VERB	O	O
changes	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
FSGS	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
ultrastructural	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
stage	NOUN	O	O
revealed	VERB	O	O
significant	ADJ	O	O
lack	NOUN	O	O
of	ADP	O	O
particles	NOUN	O	O
of	ADP	O	O
perfused	VERB	O	O
ruthenium	NOUN	O	I-Entity
red	ADJ	O	O
on	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
externa	NOUN	O	O
and	CCONJ	O	O
marked	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
epithelial	ADJ	O	O
cell	NOUN	O	O
cytoplasm	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
PS	PROPN	O	I-Entity
enhances	VERB	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
AMNS	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
glomerulus	NOUN	O	O
and	CCONJ	O	O
readily	ADV	O	O
produces	VERB	O	O
progressive	ADJ	O	O
FSGS	PROPN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
the	DET	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3339945)

Theophylline	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
pregnant	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
theophylline	NOUN	O	I-Entity
is	VERB	O	O
altered	VERB	O	O
in	ADP	O	O
advanced	ADJ	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
20	NUM	O	O
days	NOUN	O	O
pregnant	ADJ	O	O
and	CCONJ	O	O
nonpregnant	ADJ	O	O
rats	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
strain	NOUN	O	O
received	VERB	O	O
infusions	NOUN	O	O
of	ADP	O	O
aminophylline	NOUN	O	I-Entity
until	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
maximal	ADJ	O	O
seizures	NOUN	O	I-Entity
which	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
28	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Theophylline	PROPN	O	I-Entity
concentrations	NOUN	O	O
at	ADP	O	O
this	DET	O	O
endpoint	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
CSF	PROPN	O	O
were	VERB	O	O
similar	ADJ	O	O
but	CCONJ	O	O
serum	NOUN	O	O
(	PUNCT	O	O
free	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
brain	NOUN	O	O
concentrations	NOUN	O	O
were	VERB	O	O
slightly	ADV	O	O
different	ADJ	O	O
in	ADP	O	O
pregnant	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Theophylline	PROPN	O	I-Entity
serum	NOUN	O	O
protein	NOUN	O	O
binding	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
equilibrium	NOUN	O	O
dialysis	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
pregnant	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Fetal	ADJ	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
at	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
mother	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
maternal	ADJ	O	O
brain	NOUN	O	O
and	CCONJ	O	O
CSF	PROPN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
correlated	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
the	DET	O	O
former	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
advanced	ADJ	O	O
pregnancy	NOUN	O	O
has	VERB	O	O
a	DET	O	O
negligible	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
response	NOUN	O	O
to	ADP	O	O
theophylline	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3375885)

Hyperkalemia	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
indomethacin	NOUN	O	I-Entity
and	CCONJ	O	O
naproxen	NOUN	O	I-Entity
and	CCONJ	O	O
reversed	VERB	O	O
by	ADP	O	O
fludrocortisone	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
described	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
whom	NOUN	O	O
hyperkalemia	NOUN	O	I-Entity
and	CCONJ	O	O
inappropriate	ADJ	O	O
hypoaldosteronism	NOUN	O	I-Entity
were	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
both	DET	O	O
indomethacin	NOUN	O	I-Entity
and	CCONJ	O	O
naproxen	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
major	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
likely	ADJ	O	O
that	ADP	O	O
preexisting	VERB	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
predisposed	VERB	O	O
this	DET	O	O
patient	NOUN	O	O
to	PART	O	O
type	VERB	O	B-Entity
IV	PROPN	O	I-Entity
renal	ADJ	O	I-Entity
tubular	ADJ	O	I-Entity
acidosis	NOUN	O	I-Entity
with	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthetase	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
he	PRON	O	O
was	VERB	O	O
unable	ADJ	O	O
to	PART	O	O
discontinue	VERB	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
fludrocortisone	NOUN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
,	PUNCT	O	O
correcting	VERB	O	O
the	DET	O	O
hyperkalemia	NOUN	O	I-Entity
and	CCONJ	O	O
allowing	VERB	O	O
indomethacin	NOUN	O	I-Entity
therapy	NOUN	O	O
to	PART	O	O
be	VERB	O	O
continued	VERB	O	O
safely	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (3383127)

Hypotension	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
cisplatin	NOUN	O	I-Entity
and	CCONJ	O	O
5-fluorouracil	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiac	PROPN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
developed	VERB	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
colorectal	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
CDDP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
5-fluorouracil	NUM	O	I-Entity
(	PUNCT	O	O
5-FU	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
severe	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
presentation	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
evaluation	NOUN	O	O
(	PUNCT	O	O
hemodynamic	NOUN	O	O
,	PUNCT	O	O
echocardiographic	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
scintigraphic	ADJ	O	O
)	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
suggest	VERB	O	O
new	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
influenced	VERB	O	O
by	ADP	O	O
CDDP	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3409843)

Fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
an	DET	O	O
epileptic	ADJ	O	I-Entity
woman	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Despite	ADP	O	O
concerns	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
only	ADV	O	O
the	DET	O	O
fourth	ADJ	O	O
documented	VERB	O	O
and	CCONJ	O	O
published	VERB	O	O
report	NOUN	O	O
.	PUNCT	O	O

Carbamazepine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
physicians	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
exceedingly	ADV	O	O
rare	ADJ	O	O
but	CCONJ	O	O
potentially	ADV	O	O
fatal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
better	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
clinical	ADJ	O	O
than	ADP	O	O
by	ADP	O	O
laboratory	NOUN	O	O
monitoring	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3423103)

Participation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
bulbospinal	ADJ	O	O
serotonergic	ADJ	O	O
pathway	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
brain	NOUN	O	O
in	ADP	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
micrograms	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
microliter	NOUN	O	O
)	PUNCT	O	O
into	ADP	O	O
a	DET	O	O
region	NOUN	O	O
adjacent	ADJ	O	O
to	ADP	O	O
the	DET	O	O
ventrolateral	ADJ	O	O
surface	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
oblongata	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
urethane	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Intramedullary	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
saline	ADJ	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
prior	ADJ	O	O
spinal	ADJ	O	O
transection	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
bilateral	ADJ	O	O
vagotomy	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
prior	ADJ	O	O
bilateral	ADJ	O	O
vagotomy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
spinal	ADJ	O	O
transection	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
selective	ADJ	O	O
destruction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
5-HT	ADJ	O	I-Entity
nerves	NOUN	O	O
,	PUNCT	O	O
produced	VERB	O	O
by	ADP	O	O
bilateral	ADJ	O	O
spinal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
5,7-dihydroxytryptamine	NUM	O	I-Entity
,	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vasodepressor	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
bradycardiac	NOUN	O	I-Entity
responses	NOUN	O	O
to	ADP	O	O
clonidine	NOUN	O	I-Entity
microinjected	VERB	O	O
into	ADP	O	O
the	DET	O	O
area	NOUN	O	O
near	ADP	O	O
the	DET	O	O
ventrolateral	ADJ	O	O
surface	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
oblongata	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
a	DET	O	O
bulbospinal	ADJ	O	O
serotonergic	ADJ	O	O
pathway	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
is	VERB	O	O
brought	VERB	O	O
about	PART	O	O
by	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
sympathetic	ADJ	O	O
efferent	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
vagal	ADJ	O	O
efferent	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3439580)

Hypertension	NOUN	O	I-Entity
in	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
imipramine	NOUN	O	I-Entity
.	PUNCT	O	O

Hypertension	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
finding	NOUN	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
described	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
Imipramine	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
190/160	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
4-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
with	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
who	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
Imipramine	PROPN	O	I-Entity
to	PART	O	O
control	VERB	O	O
a	DET	O	O
behavior	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
determined	VERB	O	O
later	ADV	O	O
that	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
's	PART	O	O
tumor	NOUN	O	I-Entity
was	VERB	O	O
recurring	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
hypertensive	ADJ	O	I-Entity
episode	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
she	PRON	O	O
had	VERB	O	O
no	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
elevation	NOUN	O	O
at	ADP	O	O
initial	ADJ	O	O
diagnosis	NOUN	O	O
and	CCONJ	O	O
none	NOUN	O	O
following	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Imipramine	PROPN	O	I-Entity
(	PUNCT	O	O
when	ADV	O	O
she	PRON	O	O
was	VERB	O	O
in	ADP	O	O
florid	ADJ	O	O
relapse	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
believe	VERB	O	O
that	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
rather	ADV	O	O
than	ADP	O	O
her	ADJ	O	O
underlying	ADJ	O	O
disease	NOUN	O	O
alone	ADV	O	O
caused	VERB	O	O
her	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
for	ADP	O	O
this	DET	O	O
reaction	NOUN	O	O
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
be	VERB	O	O
increased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
vasoactive	ADJ	O	O
catecholamines	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
interference	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
physiologic	ADJ	O	O
inactivation	NOUN	O	O
by	ADP	O	O
Imipramine	PROPN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
this	DET	O	O
experience	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
urge	VERB	O	O
extreme	ADJ	O	O
caution	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
tricyclic	ADJ	O	O
antidepressants	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
active	ADJ	O	O
neuroblastoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3475563)

Rechallenge	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
oral	ADJ	O	B-Entity
candidiasis	NOUN	O	I-Entity
or	CCONJ	O	O
hoarseness	NOUN	O	I-Entity
with	ADP	O	O
beclomethasone	NOUN	O	B-Entity
dipropionate	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
158	NUM	O	O
asthmatic	ADJ	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
on	ADP	O	O
inhaled	VERB	O	O
beclomethasone	NOUN	O	I-Entity
,	PUNCT	O	O
15	NUM	O	O
(	PUNCT	O	O
9.5%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
either	CCONJ	O	O
hoarseness	NOUN	O	I-Entity
(	PUNCT	O	O
8)	PROPN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
thrush	NOUN	O	I-Entity
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	ADV	O	O
their	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
subsided	VERB	O	O
,	PUNCT	O	O
seven	NUM	O	O
of	ADP	O	O
these	DET	O	O
15	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
rechallenged	VERB	O	O
with	ADP	O	O
inhaled	VERB	O	O
beclomethasone	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
included	VERB	O	O
five	NUM	O	O
cases	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
hoarseness	NOUN	O	I-Entity
and	CCONJ	O	O
three	NUM	O	O
who	NOUN	O	O
developed	VERB	O	O
Candidiasis	PROPN	O	I-Entity
.	PUNCT	O	O

Oral	PROPN	O	O
thrush	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
recur	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
60%	NUM	O	O
(	PUNCT	O	O
3/5	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hoarseness	NOUN	O	I-Entity
had	VERB	O	O
recurrence	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
restarted	VERB	O	O
on	ADP	O	O
inhaled	VERB	O	O
beclomethasone	NOUN	O	I-Entity
when	ADV	O	O
clinically	ADV	O	O
indicated	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
high	ADJ	O	O
recurrence	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
who	NOUN	O	O
develop	VERB	O	O
hoarseness	NOUN	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
re	ADP	O	O
-	PUNCT	O	O
challenged	VERB	O	O
.	PUNCT	O	O

Concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
prednisone	NOUN	O	I-Entity
and	CCONJ	O	O
topical	ADJ	O	O
beclomethasone	NOUN	O	I-Entity
may	VERB	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
hoarseness	NOUN	O	I-Entity
or	CCONJ	O	O
candidiasis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3533179)

Cyclophosphamide	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
dosing	NOUN	O	O
as	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
undergo	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
are	VERB	O	O
generally	ADV	O	O
immunosuppressed	VERB	O	O
with	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYA	PROPN	O	I-Entity
)	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
usually	ADV	O	O
calculated	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
weight	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
these	DET	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
CYA	PROPN	O	I-Entity
,	PUNCT	O	O
serious	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
definitive	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
such	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Since	ADP	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
toxicity	NOUN	O	I-Entity
generally	ADV	O	O
correlates	VERB	O	O
with	ADP	O	O
dose	NOUN	O	O
per	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
retrospectively	ADV	O	O
calculated	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
CYA	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
transplanted	VERB	O	O
at	ADP	O	O
our	ADJ	O	O
institution	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
CYA	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
per	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O

Eighty	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
to	PART	O	O
receive	VERB	O	O
CYA	PROPN	O	I-Entity
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
d	PROPN	O	O
for	ADP	O	O
four	NUM	O	O
days	NOUN	O	O
as	ADP	O	O
preparation	NOUN	O	O
for	ADP	O	O
marrow	NOUN	O	O
grafting	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
84	NUM	O	O
transplants	NOUN	O	O
for	ADP	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
Wiskott	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Aldrich	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
severe	ADJ	O	B-Entity
combined	VERB	O	I-Entity
immunodeficiency	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Fourteen	NUM	O	O
of	ADP	O	O
84	NUM	O	O
(	PUNCT	O	O
17%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
signs	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
CYA	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
within	ADP	O	O
ten	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
receiving	VERB	O	O
1	NUM	O	O
to	ADP	O	O
4	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
CYA	PROPN	O	I-Entity
.	PUNCT	O	O

Six	NUM	O	O
of	ADP	O	O
the	DET	O	O
14	NUM	O	O
patients	NOUN	O	O
died	VERB	O	O
with	ADP	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
CYA	PROPN	O	I-Entity
per	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
was	VERB	O	O
calculated	VERB	O	O
for	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
daily	ADJ	O	O
CYA	PROPN	O	I-Entity
dose	NOUN	O	O
:	PUNCT	O	O
Group	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
CYA	PROPN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
1.55	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2/d	NOUN	O	O
;	PUNCT	O	O
Group	PROPN	O	O
2	NUM	O	O
,	PUNCT	O	O
CYA	PROPN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
1.55	NUM	O	O

Cardiotoxicity	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
CYA	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
1/32	NUM	O	O
(	PUNCT	O	O
3%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
1	NUM	O	O
and	CCONJ	O	O
in	ADP	O	O
13/52	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
2	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
caused	VERB	O	O
or	CCONJ	O	O
contributed	VERB	O	O
to	ADP	O	O
death	NOUN	O	O
in	ADP	O	O
0/32	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
1	NUM	O	O
v	NOUN	O	O
6/52	NUM	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
2	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.25	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
CYA	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
correlates	VERB	O	O
with	ADP	O	O
CYA	PROPN	O	I-Entity
dosage	NOUN	O	O
as	ADP	O	O
calculated	VERB	O	O
by	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
immunodeficiencies	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
effectively	ADV	O	O
prepared	ADJ	O	O
for	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
grafting	VERB	O	O
at	ADP	O	O
a	DET	O	O
CYA	PROPN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
1.55	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2/d	NOUN	O	O
for	ADP	O	O
four	NUM	O	O
days	NOUN	O	O
with	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
than	ADP	O	O
patients	NOUN	O	O
whose	ADJ	O	O
CYA	PROPN	O	I-Entity
dosage	NOUN	O	O
is	VERB	O	O
calculated	VERB	O	O
based	VERB	O	O
on	ADP	O	O
weight	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
reaffirms	VERB	O	O
the	DET	O	O
principle	NOUN	O	O
that	ADJ	O	O
drug	NOUN	O	O
toxicity	NOUN	O	I-Entity
correlates	VERB	O	O
with	ADP	O	O
dose	NOUN	O	O
per	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3538855)

Studies	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
aminoglycoside	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
epidemiology	NOUN	O	O
of	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
fully	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
human	ADJ	O	O
volunteers	NOUN	O	O
indicate	VERB	O	O
aminoglycosides	NOUN	O	I-Entity
cause	VERB	O	O
proximal	ADJ	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
in	ADP	O	O
most	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
rarely	ADV	O	O
,	PUNCT	O	O
if	ADP	O	O
ever	ADV	O	O
,	PUNCT	O	O
cause	VERB	O	O
glomerular	ADJ	O	B-Entity
or	CCONJ	O	I-Entity
tubular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
aminoglycosides	NOUN	O	I-Entity
in	ADP	O	O
seriously	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
developing	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
during	ADP	O	O
therapy	NOUN	O	O
ranges	NOUN	O	O
from	ADP	O	O
8	NUM	O	O
to	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
attributable	ADJ	O	O
risk	NOUN	O	O
is	VERB	O	O
70%	NUM	O	O
to	PART	O	O
80%	NUM	O	O
.	PUNCT	O	O

Further	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
data	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
aminoglycoside	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
advanced	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
initial	ADJ	O	O
estimated	VERB	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
possibly	ADV	O	O
,	PUNCT	O	O
female	ADJ	O	O
gender	NOUN	O	O
all	DET	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Other	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
shock	NOUN	O	I-Entity
,	PUNCT	O	O
appear	VERB	O	O
to	PART	O	O
have	VERB	O	O
an	DET	O	O
additive	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
models	NOUN	O	O
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
developing	VERB	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3685052)

Flurothyl	PROPN	O	I-Entity
seizure	NOUN	O	I-Entity
thresholds	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
treated	VERB	O	O
neonatally	ADV	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
monosodium	ADJ	O	B-Entity
glutamate	NOUN	O	I-Entity
(	PUNCT	O	O
MSG	PROPN	O	I-Entity
)	PUNCT	O	O
:	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
parameters	NOUN	O	O
in	ADP	O	O
flurothyl	NOUN	O	I-Entity
seizure	NOUN	O	I-Entity
testing	NOUN	O	O
.	PUNCT	O	O

Monosodium	ADJ	O	B-Entity
glutamate	NOUN	O	I-Entity
(	PUNCT	O	O
MSG	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
to	ADP	O	O
neonatal	ADJ	O	O
rodents	NOUN	O	O
produces	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
results	NOUN	O	O
in	ADP	O	O
numerous	ADJ	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
deficits	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
studies	NOUN	O	O
were	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
neonatal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
MSG	PROPN	O	I-Entity
produced	VERB	O	O
permanent	ADJ	O	O
alterations	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
,	PUNCT	O	O
since	ADP	O	O
previous	ADJ	O	O
investigations	NOUN	O	O
were	VERB	O	O
inconclusive	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
flurothyl	NOUN	O	I-Entity
ether	NOUN	O	I-Entity
seizure	NOUN	O	I-Entity
screening	VERB	O	O
technique	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
neonatal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
MSG	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
g	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
g	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MSG	PROPN	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
whole	ADJ	O	O
brain	NOUN	O	O
weight	NOUN	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
seizure	NOUN	O	I-Entity
threshold	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
naloxone	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
challenge	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
ineffective	ADJ	O	O
in	ADP	O	O
altering	VERB	O	O
the	DET	O	O
seizure	NOUN	O	I-Entity
thresholds	NOUN	O	O
of	ADP	O	O
either	DET	O	O
control	NOUN	O	O
of	ADP	O	O
MSG	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Flurothyl	PROPN	O	I-Entity
ether	NOUN	O	I-Entity
produced	VERB	O	O
hypothermia	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
flurothyl	NOUN	O	I-Entity
exposure	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
hypothermia	NOUN	O	I-Entity
to	PART	O	O
seizure	NOUN	O	I-Entity
induction	NOUN	O	O
was	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

Flurothyl	PROPN	O	I-Entity
seizure	NOUN	O	I-Entity
testing	NOUN	O	O
proved	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
reliable	ADJ	O	O
technique	NOUN	O	O
with	ADP	O	O
which	ADJ	O	O
to	PART	O	O
evaluate	VERB	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3708328)

Susceptibility	NOUN	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
after	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
or	CCONJ	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
vinyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
GABA	PROPN	O	I-Entity
into	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
.	PUNCT	O	O

Pilocarpine	PROPN	O	I-Entity
,	PUNCT	O	O
given	VERB	O	O
intraperitoneally	ADV	O	O
to	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
reproduces	VERB	O	O
the	DET	O	O
neuropathological	ADJ	O	O
sequelae	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
and	CCONJ	O	O
provides	VERB	O	O
a	DET	O	O
relevant	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
for	ADP	O	O
studying	VERB	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
buildup	NOUN	O	O
of	ADP	O	O
convulsive	ADJ	O	I-Entity
activity	NOUN	O	O
and	CCONJ	O	O
pathways	NOUN	O	O
operative	VERB	O	O
in	ADP	O	O
the	DET	O	O
generalization	NOUN	O	O
and	CCONJ	O	O
propagation	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
forebrain	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
manipulating	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA)-mediated	VERB	O	I-Entity
synaptic	ADJ	O	O
inhibition	NOUN	O	O
within	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
on	ADP	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
microinjections	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
,	PUNCT	O	O
150	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
synthesizing	VERB	O	O
enzyme	NOUN	O	O
,	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
glutamic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
decarboxylase	NOUN	O	O
,	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
pars	NOUN	O	O
reticulata	VERB	O	O
(	PUNCT	O	O
SNR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bilaterally	ADV	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
convulsant	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
100	NUM	O	O
and	CCONJ	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
severe	ADJ	O	O
motor	NOUN	O	O
limbic	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

Electroencephalographic	PROPN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
monitoring	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
profound	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Morphological	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
frontal	NOUN	O	O
forebrain	ADJ	O	O
sections	NOUN	O	O
with	ADP	O	O
light	NOUN	O	O
microscopy	NOUN	O	O
revealed	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
formation	NOUN	O	O
,	PUNCT	O	O
thalamus	NOUN	O	O
,	PUNCT	O	O
amygdala	NOUN	O	O
,	PUNCT	O	O
olfactory	ADJ	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
and	CCONJ	O	O
neocortex	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
typically	ADV	O	O
observed	VERB	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
exceeding	VERB	O	O
350	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
intrastriatal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
augment	VERB	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
200	NUM	O	O
mg	ADV	O	O
/	SYM	O	O
kg	ADV	O	O
.	PUNCT	O	O

Application	NOUN	O	O
of	ADP	O	O
an	DET	O	O
irreversible	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
transaminase	NOUN	O	O
,	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
vinyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
GABA	PROPN	O	I-Entity
(	PUNCT	O	O
D	PROPN	O	B-Entity
,	PUNCT	O	I-Entity
L-4-amino	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
hex-5-enoic	PROPN	O	I-Entity
acid	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
5	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
SNR	PROPN	O	O
,	PUNCT	O	O
bilaterally	ADV	O	O
,	PUNCT	O	O
suppressed	VERB	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
electrographic	ADJ	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
380	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
sufficient	ADJ	O	O
to	PART	O	O
protect	VERB	O	O
animals	NOUN	O	O
from	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

Microinjections	NOUN	O	O
of	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
vinyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
GABA	PROPN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
dorsal	NOUN	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
bilaterally	ADV	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
380	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
is	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
synaptic	ADJ	O	O
inhibition	NOUN	O	O
within	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3746148)

Non	PROPN	O	O
-	PUNCT	O	O
invasive	ADJ	O	O
detection	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
by	ADP	O	O
body	NOUN	O	O
surface	NOUN	O	O
electrocardiographic	ADJ	O	O
mapping	NOUN	O	O
after	ADP	O	O
dipyridamole	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

Electrocardiographic	PROPN	O	O
changes	NOUN	O	O
after	ADP	O	O
dipyridamole	NOUN	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
0.568	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg/4	PROPN	O	O
min	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
41	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
after	ADP	O	O
submaximal	ADJ	O	O
treadmill	NOUN	O	O
exercise	NOUN	O	O
by	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
body	NOUN	O	O
surface	NOUN	O	O
mapping	VERB	O	O
technique	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
;	PUNCT	O	O
19	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
MI	PROPN	O	I-Entity
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
14	NUM	O	O
with	ADP	O	O
anterior	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
ANT	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
eight	NUM	O	O
with	ADP	O	O
inferior	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
INF	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
dipyridamole	NOUN	O	I-Entity
,	PUNCT	O	O
ischemic	ADJ	O	I-Entity
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
depression	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
mV	NOUN	O	O
or	CCONJ	O	O
more	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
84%	NUM	O	O
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
MI	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
29%	NUM	O	O
of	ADP	O	O
the	DET	O	O
ANT	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
63%	NUM	O	O
of	ADP	O	O
the	DET	O	O
INF	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
61%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
ST	PROPN	O	O
depression	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
84%	NUM	O	O
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
MI	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
43%	NUM	O	O
of	ADP	O	O
the	DET	O	O
ANT	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
38%	NUM	O	O
of	ADP	O	O
the	DET	O	O
INF	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MI	PROPN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
61%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
individual	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
obvious	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
body	NOUN	O	O
surface	NOUN	O	O
distribution	NOUN	O	O
of	ADP	O	O
ST	PROPN	O	O
depression	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
tests	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
pressure	NOUN	O	O
rate	NOUN	O	O
product	NOUN	O	O
after	ADP	O	O
dipyridamole	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
that	DET	O	O
during	ADP	O	O
the	DET	O	O
treadmill	NOUN	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
is	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
inhomogenous	ADJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
dipyridamole	NOUN	O	I-Entity
ECG	PROPN	O	O
test	NOUN	O	O
is	VERB	O	O
as	ADV	O	O
useful	ADJ	O	O
as	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
ECG	NOUN	O	O
test	NOUN	O	O
for	ADP	O	O
the	DET	O	O
assessment	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3798047)

Bradycardia	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
methylprednisolone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
5	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
intravenous	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
MP	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
daily	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
decline	NOUN	O	O
in	ADP	O	O
pulse	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
most	ADJ	O	O
pronounced	ADJ	O	O
on	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
5	NUM	O	O
patients	NOUN	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
complaints	NOUN	O	O
of	ADP	O	O
substernal	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Electrocardiographic	ADJ	O	O
registrations	NOUN	O	O
showed	VERB	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Careful	ADJ	O	O
observation	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
MP	PROPN	O	I-Entity
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
MP	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
contraindicated	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
known	VERB	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3812624)

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
downbeat	ADJ	O	B-Entity
nystagmus	NOUN	O	I-Entity
and	CCONJ	O	O
oscillopsia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O

Downbeat	ADJ	O	B-Entity
nystagmus	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
structural	ADJ	O	O
lesions	NOUN	O	O
at	ADP	O	O
the	DET	O	O
craniocervical	ADJ	O	O
junction	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
has	VERB	O	O
occasionally	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
a	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
metabolic	ADJ	O	O
imbalance	NOUN	O	O
or	CCONJ	O	O
drug	NOUN	O	O
intoxication	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
recorded	VERB	O	O
the	DET	O	O
eye	NOUN	O	O
movements	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
reversible	ADJ	O	O
downbeat	ADJ	O	B-Entity
nystagmus	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
nystagmus	NOUN	O	I-Entity
of	ADP	O	O
both	DET	O	O
patients	NOUN	O	O
resolved	VERB	O	O
after	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
carbamazepine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
downbeat	ADJ	O	B-Entity
nystagmus	NOUN	O	I-Entity
who	NOUN	O	O
are	VERB	O	O
taking	VERB	O	O
anticonvulsant	ADJ	O	O
medications	NOUN	O	O
,	PUNCT	O	O
consideration	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
given	VERB	O	O
to	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
dose	NOUN	O	O
before	ADP	O	O
further	ADJ	O	O
investigation	NOUN	O	O
is	VERB	O	O
undertaken	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3831029)

Improvement	NOUN	O	O
by	ADP	O	O
denopamine	NOUN	O	I-Entity
(	PUNCT	O	O
TA-064	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
pentobarbital	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
heart	NOUN	O	O
-	PUNCT	O	O
lung	NOUN	O	O
preparation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
denopamine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
orally	ADV	O	O
active	ADJ	O	O
beta	NOUN	O	O
1-adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
improving	VERB	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
dog	NOUN	O	O
heart	NOUN	O	O
-	PUNCT	O	O
lung	NOUN	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

Cardiac	PROPN	O	O
functions	NOUN	O	O
depressed	VERB	O	O
by	ADP	O	O
pentobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
118	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

SD	PUNCT	O	O
)	PUNCT	O	O
such	ADJ	O	O
that	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
and	CCONJ	O	O
maximum	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
rise	NOUN	O	O
of	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
LV	PROPN	O	O
dP	PROPN	O	O
/	SYM	O	O
dt	PROPN	O	O
max	NOUN	O	O
)	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
about	ADV	O	O
35%	NUM	O	O
and	CCONJ	O	O
26%	NUM	O	O
of	ADP	O	O
the	DET	O	O
respective	ADJ	O	O
controls	NOUN	O	O
were	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
denopamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
300	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
100	NUM	O	O
micrograms	NOUN	O	O
denopamine	NOUN	O	I-Entity
,	PUNCT	O	O
almost	ADV	O	O
complete	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
performance	NOUN	O	O
was	VERB	O	O
attained	VERB	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
slight	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
arrhythmias	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
these	DET	O	O
doses	NOUN	O	O
of	ADP	O	O
denopamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
warrant	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
denopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3832950)

Clonazepam	PROPN	O	I-Entity
monotherapy	NOUN	O	O
for	ADP	O	O
epilepsy	NOUN	O	I-Entity
in	ADP	O	O
childhood	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
-	PUNCT	O	O
range	NOUN	O	O
one	NUM	O	O
month	NOUN	O	O
to	ADP	O	O
14	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
other	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
than	ADP	O	O
infantile	ADJ	O	B-Entity
spasms	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
clonazepam	NOUN	O	I-Entity
.	PUNCT	O	O

Disappearance	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
normalization	NOUN	O	O
of	ADP	O	O
abnormal	ADJ	O	O
EEG	PROPN	O	O
with	ADP	O	O
disappearance	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
recognized	VERB	O	O
in	ADP	O	O
77%	NUM	O	O
and	CCONJ	O	O
50%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
disappeared	VERB	O	O
in	ADP	O	O
71%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
generalized	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
89%	NUM	O	O
of	ADP	O	O
partial	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
drowsiness	NOUN	O	I-Entity
and	CCONJ	O	O
ataxia	NOUN	O	I-Entity
was	VERB	O	O
only	ADV	O	O
5%	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (3833372)

Postmarketing	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
timolol	NOUN	O	I-Entity
-	PUNCT	O	O
hydrochlorothiazide	NOUN	O	I-Entity
antihypertensive	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
postmarketing	NOUN	O	O
surveillance	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
-	PUNCT	O	O
ratio	NOUN	O	O
combination	NOUN	O	O
containing	VERB	O	O
10	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
timolol	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
and	CCONJ	O	O
25	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
hydrochlorothiazide	NOUN	O	I-Entity
,	PUNCT	O	O
administered	VERB	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
to	ADP	O	O
hypertensive	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
decreased	VERB	O	O
25	NUM	O	O
mmHg	NOUN	O	O
and	CCONJ	O	O
mean	VERB	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
declined	VERB	O	O
15	NUM	O	O
mmHg	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
of	ADP	O	O
timolol	NOUN	O	I-Entity
-	PUNCT	O	O
hydrochlorothiazide	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
,	PUNCT	O	O
both	DET	O	O
comparisons	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
antihypertensive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
more	ADV	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
1,453	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
2,658	NUM	O	O
adverse	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
being	VERB	O	O
fatigue	NOUN	O	I-Entity
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
weakness	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3864191)

Salicylate	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Gunn	PROPN	O	O
rat	NOUN	O	O
:	PUNCT	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
prostaglandins	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
prostaglandins	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
analgesic	NOUN	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Gunn	PROPN	O	O
strain	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
homozygous	ADJ	O	O
Gunn	PROPN	O	O
rats	NOUN	O	O
have	VERB	O	O
unconjugated	VERB	O	O
hyperbilirubinemia	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
glucuronyl	NOUN	O	I-Entity
transferase	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
marked	VERB	O	O
bilirubin	NOUN	O	I-Entity
deposition	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
medulla	NOUN	O	O
and	CCONJ	O	O
papilla	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
rats	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
highly	ADV	O	O
susceptible	ADJ	O	O
to	PART	O	O
develop	VERB	O	O
papillary	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
with	ADP	O	O
analgesic	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
:	PUNCT	O	O
jj	NOUN	O	O
and	CCONJ	O	O
jJ	PROPN	O	O
rats	NOUN	O	O
treated	VERB	O	O
either	CCONJ	O	O
with	ADP	O	O
aspirin	NOUN	O	I-Entity
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
or	CCONJ	O	O
sham	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
,	PUNCT	O	O
slices	NOUN	O	O
of	ADP	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
outer	ADJ	O	O
and	CCONJ	O	O
inner	ADJ	O	O
medulla	NOUN	O	O
from	ADP	O	O
one	NUM	O	O
kidney	NOUN	O	O
were	VERB	O	O
incubated	VERB	O	O
in	ADP	O	O
buffer	NOUN	O	O
and	CCONJ	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
radioimmunoassay	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
marked	ADJ	O	O
corticomedullary	ADJ	O	O
gradient	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

PGE2	ADJ	O	I-Entity
synthesis	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
outer	ADJ	O	O
medulla	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
cortex	ADJ	O	O
or	CCONJ	O	O
inner	ADJ	O	O
medulla	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
jj	PROPN	O	O
(	PUNCT	O	O
38	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
treatment	NOUN	O	O
reduced	VERB	O	O
PGE2	PROPN	O	I-Entity
synthesis	NOUN	O	O
in	ADP	O	O
all	DET	O	O
regions	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
outer	ADJ	O	O
medullary	NOUN	O	O
PGE2	PROPN	O	I-Entity
remained	VERB	O	O
higher	ADV	O	O
in	ADP	O	O
jj	NOUN	O	O
(	PUNCT	O	O
18	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

PGF2	PUNCT	O	B-Entity
alpha	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
outer	ADJ	O	O
medulla	NOUN	O	O
of	ADP	O	O
jj	PROPN	O	O
rats	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
aspirin	NOUN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
were	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
aspirin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
jj	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
jJ	ADJ	O	O
rats	NOUN	O	O
as	ADP	O	O
evidenced	VERB	O	O
by	ADP	O	O
:	PUNCT	O	O
increased	VERB	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
hematuria	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
increased	VERB	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
increase	VERB	O	O
in	ADP	O	O
outer	ADJ	O	O
medullary	ADJ	O	O
histopathologic	ADJ	O	O
lesions	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.005	NUM	O	O
compared	VERB	O	O
to	ADP	O	O
either	DET	O	O
sham	ADJ	O	O
-	PUNCT	O	O
treated	VERB	O	O
jj	NOUN	O	O
or	CCONJ	O	O
aspirin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
jJ	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
enhanced	VERB	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
maintenance	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
morphological	ADJ	O	O
integrity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
pathological	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
medullary	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
and	CCONJ	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3895875)

Prophylactic	ADJ	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
suspected	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
hundred	NUM	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
seen	VERB	O	O
within	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
entered	VERB	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
randomized	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
vs	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
1	NUM	O	O
hour	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
or	CCONJ	O	O
sustained	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
among	ADP	O	O
the	DET	O	O
204	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
1.5%	NUM	O	O
.	PUNCT	O	O

Lidocaine	PROPN	O	I-Entity
,	PUNCT	O	O
given	VERB	O	O
in	ADP	O	O
a	DET	O	O
300	NUM	O	O
mg	NUM	O	O
dose	NOUN	O	O
intramuscularly	ADV	O	O
followed	VERB	O	O
by	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
intravenously	ADV	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
sustained	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
warning	NOUN	O	O
arrhythmias	NOUN	O	I-Entity
between	ADP	O	O
15	NUM	O	O
and	CCONJ	O	O
45	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
plasma	NOUN	O	O
lidocaine	NOUN	O	I-Entity
level	NOUN	O	O
10	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
that	DET	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
plasma	NOUN	O	O
lidocaine	NOUN	O	I-Entity
level	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
agents	NOUN	O	O
was	VERB	O	O
no	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
that	DET	O	O
in	ADP	O	O
patients	NOUN	O	O
not	ADV	O	O
on	ADP	O	O
beta	NOUN	O	O
blocking	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
1-hour	NUM	O	O
study	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
lidocaine	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
lidocaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
four	NUM	O	O
patients	NOUN	O	O
died	VERB	O	O
from	ADP	O	O
asystole	NOUN	O	I-Entity
,	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
had	VERB	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
can	VERB	O	O
not	ADV	O	O
advocate	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
prophylactically	ADV	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
hours	NOUN	O	O
of	ADP	O	O
suspected	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3925479)

Evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
cholinergic	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Experiments	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
tested	VERB	O	O
previous	ADJ	O	O
evidence	NOUN	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
cholinergic	NOUN	O	O
systems	NOUN	O	O
promotes	VERB	O	O
catalepsy	ADJ	O	I-Entity
and	CCONJ	O	O
that	DET	O	O
cholinergic	ADJ	O	O
mechanisms	NOUN	O	O
need	VERB	O	O
to	PART	O	O
be	VERB	O	O
intact	ADJ	O	O
for	ADP	O	O
full	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Large	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cholinomimetic	NOUN	O	O
,	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
could	VERB	O	O
induce	VERB	O	O
catalepsy	NOUN	O	I-Entity
when	ADV	O	O
peripheral	ADJ	O	O
cholinergic	NOUN	O	O
receptors	NOUN	O	O
were	VERB	O	O
blocked	VERB	O	O
.	PUNCT	O	O

Low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
pronounced	ADJ	O	O
enhancement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
muscarinic	ADJ	O	O
receptor	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
disrupted	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Intracranial	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
an	DET	O	O
acetylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
synthesis	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
hemicholinium	NOUN	O	I-Entity
,	PUNCT	O	O
prevented	VERB	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
that	ADJ	O	O
is	VERB	O	O
usually	ADV	O	O
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
that	ADJ	O	O
is	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
neuroleptics	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
haloperidol	NOUN	O	I-Entity
is	VERB	O	O
actually	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
intrinsic	ADJ	O	O
central	ADJ	O	O
cholinergic	NOUN	O	O
systems	NOUN	O	O
.	PUNCT	O	O

Alternatively	ADV	O	O
,	PUNCT	O	O
activation	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
systems	NOUN	O	O
could	VERB	O	O
promote	VERB	O	O
catalepsy	ADJ	O	I-Entity
by	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
dopaminergic	ADJ	O	O
systems	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3975902)

Cardiovascular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
sodium	NOUN	O	B-Entity
pentobarbital	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
barium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
ingestion	NOUN	O	O
.	PUNCT	O	O

Barium	PROPN	O	I-Entity
-	PUNCT	O	O
supplemented	VERB	O	O
Long	PROPN	O	O
-	PUNCT	O	O
Evans	PROPN	O	O
hooded	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
hypertension	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
evident	ADJ	O	O
after	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
of	ADP	O	O
barium	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
ml	VERB	O	O
mineral	NOUN	O	O
fortified	VERB	O	O
water	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

myocardial	ADJ	O	O
excitability	NOUN	O	O
,	PUNCT	O	O
contractility	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
characteristics	NOUN	O	O
at	ADP	O	O
16	NUM	O	O
months	NOUN	O	O
revealed	VERB	O	O
other	ADJ	O	O
significant	ADJ	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
disturbances	NOUN	O	B-Entity
within	ADP	O	I-Entity
the	DET	O	I-Entity
cardiovascular	ADJ	O	I-Entity
system	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
distinctive	ADJ	O	O
aspect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
barium	NOUN	O	I-Entity
effect	NOUN	O	O
was	VERB	O	O
a	DET	O	O
demonstrated	VERB	O	O
hypersensitivity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
sodium	NOUN	O	B-Entity
pentobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

Under	ADP	O	O
barbiturate	NOUN	O	I-Entity
anesthesia	NOUN	O	O
,	PUNCT	O	O
virtually	ADV	O	O
all	DET	O	O
of	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
contractile	NOUN	O	O
indices	NOUN	O	O
were	VERB	O	O
depressed	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
rats	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
corresponding	ADJ	O	O
control	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
ketamine	VERB	O	I-Entity
and	CCONJ	O	O
xylazine	VERB	O	I-Entity
anesthesia	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
pentobarbital	NOUN	O	I-Entity
in	ADP	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
linked	VERB	O	O
specifically	ADV	O	O
to	ADP	O	O
this	DET	O	O
anesthetic	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
representative	ADJ	O	O
of	ADP	O	O
a	DET	O	O
generalized	ADJ	O	O
anesthetic	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
myocardial	ADJ	O	O
pathophysiologic	NOUN	O	O
and	CCONJ	O	O
metabolic	NOUN	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
barium	NOUN	O	I-Entity
were	VERB	O	O
manifest	ADJ	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	NOUN	O	O
employed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
contractile	ADJ	O	O
element	NOUN	O	O
shortening	VERB	O	O
velocity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiac	ADJ	O	O
muscle	NOUN	O	O
fibers	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
slower	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
significant	ADJ	O	O
disturbances	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	O
energy	NOUN	O	O
metabolism	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
rats	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
reduced	VERB	O	O
contractile	NOUN	O	O
element	NOUN	O	O
shortening	VERB	O	O
velocity	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
excitability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiac	ADJ	O	O
conduction	NOUN	O	O
system	NOUN	O	O
was	VERB	O	O
depressed	VERB	O	O
preferentially	ADV	O	O
in	ADP	O	O
the	DET	O	O
atrioventricular	ADJ	O	O
nodal	ADJ	O	O
region	NOUN	O	O
of	ADP	O	O
hearts	NOUN	O	O
from	ADP	O	O
barium	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
altered	VERB	O	O
cardiac	ADJ	O	O
contractility	NOUN	O	O
and	CCONJ	O	O
excitability	NOUN	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
myocardial	ADJ	O	O
metabolic	NOUN	O	B-Entity
disturbances	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
hypersensitivity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
sodium	NOUN	O	B-Entity
pentobarbital	ADJ	O	I-Entity
suggest	VERB	O	O
the	DET	O	O
existence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
heretofore	ADV	O	O
undescribed	NOUN	O	O
cardiomyopathic	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
barium	NOUN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
experimental	ADJ	O	O
findings	NOUN	O	O
represent	VERB	O	O
the	DET	O	O
first	ADJ	O	O
indication	NOUN	O	O
that	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
long	ADJ	O	O
barium	NOUN	O	I-Entity
ingestion	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
significant	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
mammalian	ADJ	O	O
cardiovascular	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3987172)

Propranolol	PROPN	O	I-Entity
antagonism	NOUN	O	O
of	ADP	O	O
phenylpropanolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Phenylpropanolamine	PROPN	O	I-Entity
(	PUNCT	O	O
PPA	PROPN	O	I-Entity
)	PUNCT	O	O
overdose	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Subjects	NOUN	O	O
received	VERB	O	O
propranolol	NOUN	O	I-Entity
either	ADV	O	O
by	ADP	O	O
mouth	NOUN	O	O
for	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
before	ADP	O	O
PPA	PROPN	O	I-Entity
or	CCONJ	O	O
as	ADP	O	O
a	DET	O	O
rapid	ADJ	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
after	ADP	O	O
PPA	PROPN	O	I-Entity
.	PUNCT	O	O

PPA	PROPN	O	I-Entity
,	PUNCT	O	O
75	NUM	O	O
mg	ADV	O	O
alone	ADV	O	O
,	PUNCT	O	O
increased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
31	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
diastolic	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
propranolol	ADJ	O	I-Entity
pretreatment	NOUN	O	O
antagonized	VERB	O	O
this	DET	O	O
increase	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Intravenous	PROPN	O	O
propranolol	NOUN	O	I-Entity
after	ADP	O	O
PPA	PROPN	O	I-Entity
also	ADV	O	O
decreased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Left	VERB	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
(	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
echocardiography	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
PPA	PROPN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
stroke	NOUN	O	I-Entity
volume	NOUN	O	O
30%	NUM	O	O
(	PUNCT	O	O
from	ADP	O	O
62.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Intravenous	ADJ	O	O
propranolol	NOUN	O	I-Entity
reversed	VERB	O	O
these	DET	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
PPA	PROPN	O	I-Entity
28%	NUM	O	O
(	PUNCT	O	O
from	ADP	O	O
1710	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

sec	PROPN	O	O
/	SYM	O	O
cm5	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
further	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
22%	NUM	O	O
(	PUNCT	O	O
to	ADP	O	O
2660	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
PPA	PROPN	O	I-Entity
increases	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
increasing	VERB	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
propranolol	NOUN	O	I-Entity
antagonizes	VERB	O	O
this	DET	O	O
increase	NOUN	O	O
by	ADP	O	O
reversing	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
on	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
.	PUNCT	O	O

That	DET	O	O
propranolol	NOUN	O	I-Entity
antagonizes	VERB	O	O
the	DET	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
is	VERB	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
propranolol	NOUN	O	I-Entity
enhances	VERB	O	O
the	DET	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
probably	ADV	O	O
because	ADP	O	O
PPA	PROPN	O	I-Entity
has	VERB	O	O
less	ADJ	O	O
beta	NOUN	O	O
2	NUM	O	O
activity	NOUN	O	O
than	ADP	O	O
does	VERB	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3990093)

Mesangial	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
aminonucleoside	NOUN	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
mesangial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
development	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
the	DET	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
model	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
received	VERB	O	O
repeated	VERB	O	O
subcutaneous	ADJ	O	O
PAN	PROPN	O	I-Entity
injections	NOUN	O	O
;	PUNCT	O	O
five	NUM	O	O
controls	NOUN	O	O
received	VERB	O	O
saline	ADJ	O	O
only	ADV	O	O
.	PUNCT	O	O

After	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
rats	NOUN	O	O
were	VERB	O	O
severely	ADV	O	O
proteinuric	ADJ	O	I-Entity
(	PUNCT	O	O
190	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

80	NUM	O	O
mg/24	NOUN	O	O
hr	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
colloidal	ADJ	O	O
carbon	NOUN	O	I-Entity
(	PUNCT	O	O
CC	PROPN	O	O
)	PUNCT	O	O
intravenously	ADV	O	O
.	PUNCT	O	O

At	ADP	O	O
5	NUM	O	O
months	NOUN	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
7.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

3.4%	NUM	O	O
of	ADP	O	O
the	DET	O	O
glomeruli	NOUN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
rats	NOUN	O	O
;	PUNCT	O	O
glomeruli	NOUN	O	O
of	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

Glomeruli	PROPN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
rats	NOUN	O	O
contained	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
CC	NOUN	O	O
than	ADP	O	O
glomeruli	NOUN	O	O
of	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Glomeruli	PROPN	O	O
with	ADP	O	O
sclerosis	NOUN	O	I-Entity
contained	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
CC	NOUN	O	O
than	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
sclerotic	ADJ	O	O
glomeruli	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
kidneys	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
mesangial	ADJ	O	O
CC	PROPN	O	O
clearance	NOUN	O	O
from	ADP	O	O
the	DET	O	O
mesangium	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
during	ADP	O	O
chronic	ADJ	O	O
PAN	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
this	DET	O	O
preferential	ADJ	O	O
CC	PROPN	O	O
localization	NOUN	O	O
within	ADP	O	O
the	DET	O	O
lesions	NOUN	O	O
is	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
an	DET	O	O
increased	VERB	O	O
CC	PROPN	O	O
uptake	NOUN	O	O
shortly	ADV	O	O
after	ADP	O	O
injection	NOUN	O	O
in	ADP	O	O
apparent	ADJ	O	O
vulnerable	ADJ	O	O
areas	NOUN	O	O
where	ADV	O	O
sclerosis	NOUN	O	I-Entity
will	VERB	O	O
develop	VERB	O	O
subsequently	ADV	O	O
.	PUNCT	O	O

Cluster	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
random	ADJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
lesions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
glomeruli	NOUN	O	O
in	ADP	O	O
concordance	NOUN	O	O
with	ADP	O	O
the	DET	O	O
random	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
mesangial	ADJ	O	O
areas	NOUN	O	O
with	ADP	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
remnant	ADJ	O	O
kidney	NOUN	O	O
model	NOUN	O	O
in	ADP	O	O
PAN	PROPN	O	I-Entity
nephrosis	NOUN	O	I-Entity
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
"	PUNCT	O	O
mesangial	ADJ	O	O
overloading	NOUN	O	O
.	PUNCT	O	O
"	PUNCT	O	O


-DOCSTART- (4010471)

Relationship	NOUN	O	O
between	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
hippocampal	ADJ	O	O
nicotinic	ADJ	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
mice	NOUN	O	O
derived	VERB	O	O
from	ADP	O	O
a	DET	O	O
classical	ADJ	O	O
F2	NOUN	O	O
and	CCONJ	O	O
backcross	ADJ	O	O
genetic	ADJ	O	O
design	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
bungarotoxin	NOUN	O	O
nicotinic	ADJ	O	O
receptor	NOUN	O	O
concentration	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
sensitive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
convulsant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
had	VERB	O	O
greater	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
bungarotoxin	NOUN	O	O
binding	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
than	ADP	O	O
seizure	NOUN	O	I-Entity
insensitive	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
binding	VERB	O	O
sites	NOUN	O	O
from	ADP	O	O
seizure	NOUN	O	I-Entity
sensitive	ADJ	O	O
and	CCONJ	O	O
resistant	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
equally	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
dithiothreitol	NOUN	O	I-Entity
,	PUNCT	O	O
trypsin	NOUN	O	O
or	CCONJ	O	O
heat	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
it	PRON	O	O
appears	VERB	O	O
that	ADP	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
seizure	NOUN	O	I-Entity
sensitive	ADJ	O	O
and	CCONJ	O	O
insensitive	ADJ	O	O
animals	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
hippocampal	ADJ	O	O
nicotinic	ADJ	O	O
receptor	NOUN	O	O
concentration	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
with	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
bungarotoxin	NOUN	O	O
binding	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (4082192)

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
p	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminophenol	NOUN	O	I-Entity
in	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
bis(p	NUM	O	B-Entity
-	PUNCT	O	I-Entity
nitrophenyl	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
phosphate	NOUN	O	I-Entity
on	ADP	O	O
acetaminophen	NOUN	O	I-Entity
and	CCONJ	O	O
p	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminophenol	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
metabolism	NOUN	O	O
in	ADP	O	O
Fischer	PROPN	O	O
344	NUM	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Acetaminophen	PROPN	O	I-Entity
(	PUNCT	O	O
APAP	PROPN	O	I-Entity
)	PUNCT	O	O
produces	VERB	O	O
proximal	ADJ	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
in	ADP	O	O
Fischer	PROPN	O	O
344	NUM	O	O
(	PUNCT	O	O
F344	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
p	PUNCT	O	B-Entity
-	PUNCT	O	I-Entity
aminophenol	NOUN	O	I-Entity
(	PUNCT	O	O
PAP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
known	VERB	O	O
potent	ADJ	O	O
nephrotoxicant	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
identified	VERB	O	O
as	ADP	O	O
a	DET	O	O
metabolite	NOUN	O	O
of	ADP	O	O
APAP	PROPN	O	I-Entity
in	ADP	O	O
F344	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
PAP	PROPN	O	I-Entity
formation	NOUN	O	O
is	VERB	O	O
a	DET	O	O
requisite	ADJ	O	O
step	NOUN	O	O
in	ADP	O	O
APAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
bis(p	NUM	O	B-Entity
-	PUNCT	O	I-Entity
nitrophenyl	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
phosphate	NOUN	O	I-Entity
(	PUNCT	O	O
BNPP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
acylamidase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
APAP	PROPN	O	I-Entity
and	CCONJ	O	O
PAP	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
metabolism	NOUN	O	O
was	VERB	O	O
determined	ADJ	O	O
.	PUNCT	O	O

BNPP	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
8	NUM	O	O
mM	PROPN	O	O
)	PUNCT	O	O
reduced	VERB	O	O
APAP	PROPN	O	I-Entity
deacetylation	NOUN	O	O
and	CCONJ	O	O
covalent	NOUN	O	O
binding	VERB	O	O
in	ADP	O	O
F344	PROPN	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
homogenates	NOUN	O	O
in	ADP	O	O
a	DET	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
BNPP	PROPN	O	I-Entity
prior	ADV	O	O
to	ADP	O	O
APAP	PROPN	O	I-Entity
or	CCONJ	O	O
PAP	PROPN	O	I-Entity
administration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
marked	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
APAP	PROPN	O	I-Entity
(	PUNCT	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O

nephrotoxicity	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
PAP	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
result	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
altered	VERB	O	O
disposition	NOUN	O	O
of	ADP	O	O
either	DET	O	O
APAP	PROPN	O	I-Entity
or	CCONJ	O	O
acetylated	VERB	O	O
metabolites	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
or	CCONJ	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
and	CCONJ	O	O
hepatic	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

Rather	ADV	O	O
,	PUNCT	O	O
BNPP	PROPN	O	I-Entity
pretreatment	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
fraction	NOUN	O	O
of	ADP	O	O
APAP	PROPN	O	I-Entity
excreted	VERB	O	O
as	ADP	O	O
PAP	PROPN	O	I-Entity
by	ADP	O	O
64	NUM	O	O
and	CCONJ	O	O
75%	NUM	O	O
after	ADP	O	O
APAP	PROPN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
750	NUM	O	O
and	CCONJ	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

BNPP	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
the	DET	O	O
excretion	NOUN	O	O
of	ADP	O	O
APAP	PROPN	O	I-Entity
or	CCONJ	O	O
any	DET	O	O
of	ADP	O	O
its	ADJ	O	O
non	NOUN	O	O
-	PUNCT	O	O
deacetylated	VERB	O	O
metabolites	NOUN	O	O
nor	CCONJ	O	O
did	VERB	O	O
BNPP	PROPN	O	I-Entity
alter	VERB	O	O
excretion	NOUN	O	O
of	ADP	O	O
PAP	PROPN	O	I-Entity
or	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
after	ADP	O	O
PAP	PROPN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
150	NUM	O	O
and	CCONJ	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
BNPP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
APAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
APAP	PROPN	O	I-Entity
deacetylation	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
PAP	PROPN	O	I-Entity
formation	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
accounts	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
APAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (4082466)

Morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
newborn	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
neonates	NOUN	O	O
suffered	VERB	O	O
from	ADP	O	O
generalized	ADJ	O	O
seizures	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
morphine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
for	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	NOUN	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
received	VERB	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
32	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
hr	PROPN	O	O
and	CCONJ	O	O
40	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
hr	ADV	O	O
larger	ADJ	O	O
than	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
neonates	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
6	NUM	O	O
-	SYM	O	O
24	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O

/	SYM	O	O
hr	INTJ	O	O
and	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	PROPN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
neonates	NOUN	O	O
was	VERB	O	O
excessive	ADJ	O	O
(	PUNCT	O	O
60	NUM	O	O
and	CCONJ	O	O
90	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Other	ADJ	O	O
known	VERB	O	O
reasons	NOUN	O	O
for	ADP	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
ruled	VERB	O	O
out	PART	O	O
and	CCONJ	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
stopped	VERB	O	O
a	DET	O	O
few	ADJ	O	O
hours	NOUN	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
reoccur	VERB	O	O
in	ADP	O	O
the	DET	O	O
subsequent	ADJ	O	O
8	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
intravenous	ADJ	O	O
morphine	NOUN	O	I-Entity
should	VERB	O	O
not	ADV	O	O
exceed	VERB	O	O
20	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
in	ADP	O	O
neonates	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (4631913)

Effect	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
on	ADP	O	O
Pseudomonas	PROPN	O	B-Entity
infections	NOUN	O	I-Entity
in	ADP	O	O
monkeys	NOUN	O	O
.	PUNCT	O	O

Leukocytosis	PROPN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
monkeys	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
or	CCONJ	O	O
intratracheal	ADJ	O	O
inoculation	NOUN	O	O
of	ADP	O	O
2.0	NUM	O	O
to	ADP	O	O
2.5	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
vincristine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
leukopenia	NOUN	O	I-Entity
in	ADP	O	O
4	NUM	O	O
to	PART	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Pseudomonas	PROPN	O	O
organisms	NOUN	O	O
in	ADP	O	O
monkeys	NOUN	O	O
given	VERB	O	O
vincristine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
4	NUM	O	O
days	NOUN	O	O
previously	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
fatal	ADJ	O	O
infection	NOUN	O	I-Entity
in	ADP	O	O
11	NUM	O	O
of	ADP	O	O
14	NUM	O	O
monkeys	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
none	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
receiving	VERB	O	O
Pseudomonas	PROPN	O	O
alone	ADV	O	O
died	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
an	DET	O	O
antimetabolite	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
leukopenia	NOUN	O	I-Entity
predisposes	NOUN	O	O
to	ADP	O	O
severe	ADJ	O	O
Pseudomonas	PROPN	O	O
sepsis	NOUN	O	I-Entity
and	CCONJ	O	O
that	ADP	O	O
such	ADJ	O	O
monkeys	NOUN	O	O
may	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
biological	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
comparative	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
antimicrobial	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6106951)

Central	ADJ	O	O
excitatory	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
flurazepam	NOUN	O	I-Entity
.	PUNCT	O	O

Toxic	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
flurazepam	NOUN	O	I-Entity
(	PUNCT	O	O
FZP	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
cats	NOUN	O	O
,	PUNCT	O	O
mice	NOUN	O	O
and	CCONJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
caused	VERB	O	O
an	DET	O	O
apparent	ADJ	O	O
central	ADJ	O	O
excitation	NOUN	O	O
,	PUNCT	O	O
most	ADJ	O	O
clearly	ADV	O	O
seen	VERB	O	O
as	ADP	O	O
clonic	ADJ	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
superimposed	VERB	O	O
on	ADP	O	O
general	ADJ	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
lethal	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
death	NOUN	O	O
was	VERB	O	O
always	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Comparing	VERB	O	O
the	DET	O	O
relative	ADJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
central	ADJ	O	O
depression	NOUN	O	I-Entity
and	CCONJ	O	O
excitation	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
rats	NOUN	O	O
were	VERB	O	O
least	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
convulsions	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
first	ADJ	O	O
cause	ADP	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
consciousness	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
cats	NOUN	O	O
most	ADV	O	O
clearly	ADV	O	O
showed	VERB	O	O
marked	ADJ	O	O
central	ADJ	O	O
excitatory	ADJ	O	O
actions	NOUN	O	O
.	PUNCT	O	O

Signs	NOUN	O	O
of	ADP	O	O
FZP	PROPN	O	I-Entity
toxocity	NOUN	O	I-Entity
in	ADP	O	O
cats	NOUN	O	O
included	VERB	O	O
excessive	ADJ	O	O
salivation	NOUN	O	I-Entity
,	PUNCT	O	O
extreme	ADJ	O	O
apprehensive	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
retching	NOUN	O	O
,	PUNCT	O	O
muscle	NOUN	O	B-Entity
tremors	NOUN	O	I-Entity
and	CCONJ	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
FZP	PROPN	O	I-Entity
and	CCONJ	O	O
pentylenetetrazol	NOUN	O	I-Entity
(	PUNCT	O	O
PTZ	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
shown	VERB	O	O
by	ADP	O	O
pretreating	VERB	O	O
mice	NOUN	O	O
with	ADP	O	O
FZP	PROPN	O	I-Entity
before	ADP	O	O
PTZ	PROPN	O	I-Entity
challenge	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
function	NOUN	O	O
of	ADP	O	O
dose	NOUN	O	O
,	PUNCT	O	O
FZP	PROPN	O	I-Entity
first	ADV	O	O
protected	VERB	O	O
against	ADP	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
convulsions	NOUN	O	I-Entity
again	ADV	O	O
emerged	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
doses	NOUN	O	O
of	ADP	O	O
FZP	PROPN	O	I-Entity
were	VERB	O	O
lower	ADJ	O	O
than	ADP	O	O
those	DET	O	O
that	ADJ	O	O
would	VERB	O	O
alone	ADV	O	O
cause	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
relevant	ADJ	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
FZP	PROPN	O	I-Entity
in	ADP	O	O
clinical	ADJ	O	O
situations	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
there	ADV	O	O
is	VERB	O	O
increased	VERB	O	O
neural	ADJ	O	O
excitability	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
epilepsy	NOUN	O	I-Entity
or	CCONJ	O	O
sedative	NOUN	O	O
-	PUNCT	O	O
hypnotic	ADJ	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6299641)

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
atenolol	NOUN	O	I-Entity
(	PUNCT	O	O
cardioselective	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
nonselective	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
both	DET	O	O
exercise-	NOUN	O	O
and	CCONJ	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
experiments	NOUN	O	O
involving	VERB	O	O
nine	NUM	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

7	NUM	O	O
bpm	NOUN	O	O
after	ADP	O	O
atenolol	NOUN	O	I-Entity
and	CCONJ	O	O
138	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

6	NUM	O	O
bpm	NOUN	O	O
after	ADP	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
tachycardia	NOUN	O	I-Entity
were	VERB	O	O
determined	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
atropine	NOUN	O	I-Entity
(	PUNCT	O	O
0.04	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
IV	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Isoproterenol	PROPN	O	I-Entity
sensitivity	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
as	ADP	O	O
the	DET	O	O
intravenous	ADJ	O	O
dose	NOUN	O	O
that	ADJ	O	O
increased	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
by	ADP	O	O
25	NUM	O	O
bpm	NOUN	O	O
(	PUNCT	O	O
CD25	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
1.8	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

8.3	NUM	O	O
micrograms	NOUN	O	O
after	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
8.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

1.7	NUM	O	O
micrograms	NOUN	O	O
after	ADP	O	O
atenolol	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
atropine	NOUN	O	I-Entity
the	DET	O	O
CD25	NOUN	O	O
was	VERB	O	O
unchanged	ADJ	O	O
after	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
2.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.3	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
atenolol	NOUN	O	I-Entity
(	PUNCT	O	O
7.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

1.3	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
reduced	VERB	O	O
after	ADP	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
24.8	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5.0	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
remained	VERB	O	O
different	ADJ	O	O
from	ADP	O	O
atenolol	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
change	NOUN	O	O
with	ADP	O	O
propranolol	NOUN	O	I-Entity
sensitivity	NOUN	O	O
was	VERB	O	O
calculated	VERB	O	O
as	ADP	O	O
the	DET	O	O
apparent	ADJ	O	O
Ka	PROPN	O	O
,	PUNCT	O	O
this	DET	O	O
was	VERB	O	O
unchanged	ADJ	O	O
by	ADP	O	O
atropine	NOUN	O	I-Entity
(	PUNCT	O	O
11.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
results	NOUN	O	O
largely	ADV	O	O
from	ADP	O	O
beta	NOUN	O	O
1-receptor	NUM	O	O
activation	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
both	DET	O	O
cardioselective	ADJ	O	O
and	CCONJ	O	O
nonselective	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
isoproterenol	NOUN	O	I-Entity
activates	VERB	O	O
both	DET	O	O
beta	NOUN	O	O
1-	NUM	O	O
and	CCONJ	O	O
beta	NOUN	O	O
2-receptors	NOUN	O	O
so	ADP	O	O
that	ADP	O	O
after	ADP	O	O
cardioselective	ADJ	O	O
blockade	NOUN	O	O
there	ADV	O	O
remains	VERB	O	O
a	DET	O	O
beta	NOUN	O	O
2-component	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
blocked	VERB	O	O
with	ADP	O	O
a	DET	O	O
nonselective	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6305660)

Hormones	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
hypothesized	VERB	O	O
that	ADP	O	O
progestins	NOUN	O	I-Entity
could	VERB	O	O
equilibrate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
estrogenic	ADJ	O	O
stimulation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
mammary	ADJ	O	O
and	CCONJ	O	O
endometrial	ADJ	O	O
target	NOUN	O	O
tissues	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
hormonal	ADJ	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
schedule	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
conjugated	VERB	O	B-Entity
estrogens	NOUN	O	I-Entity
(	PUNCT	O	O
Premarin	PROPN	O	I-Entity
)	PUNCT	O	O
1.25	NUM	O	O
mg	NUM	O	O

/	DET	O	O
day	NOUN	O	O
for	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
Medroxyprogesterone	PROPN	O	B-Entity
acetate	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
each	DET	O	O
month	NOUN	O	O
.	PUNCT	O	O

Mastodynia	PROPN	O	I-Entity
was	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
examination	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
light	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
breast	NOUN	O	O
firmness	NOUN	O	O
in	ADP	O	O
12	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
moderate	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
breast	NOUN	O	O
nodularity	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
women	NOUN	O	O
.	PUNCT	O	O

Themography	PROPN	O	O
confirmed	VERB	O	O
the	DET	O	O
existence	NOUN	O	O
of	ADP	O	O
an	DET	O	O
excessive	ADJ	O	O
breast	NOUN	O	O
stimulation	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
women	NOUN	O	O
who	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
moderate	ADJ	O	O
mastodynia	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
7	NUM	O	O
women	NOUN	O	O
who	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
severe	ADJ	O	O
mastodynia	NOUN	O	I-Entity
.	PUNCT	O	O

Normalization	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
halving	VERB	O	O
the	DET	O	O
estrogen	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6310832)

Early	ADJ	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
on	ADP	O	O
cyclosporine	NOUN	O	I-Entity
.	PUNCT	O	O

Eighty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
renal	NOUN	O	O
,	PUNCT	O	O
seventeen	ADJ	O	O
heart	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Seventeen	NUM	O	O
renal	ADJ	O	O
patients	NOUN	O	O
received	VERB	O	O
azathioprine	NOUN	O	I-Entity
(	PUNCT	O	O
Aza	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
prednisone	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
immunosuppression	NOUN	O	O
with	ADP	O	O
21	NUM	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
prednisone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
others	NOUN	O	O
received	VERB	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
prednisone	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
randomized	ADJ	O	O
Aza	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
more	ADJ	O	O
overall	ADJ	O	O
infections	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
more	ADJ	O	O
nonviral	ADJ	O	O
infections	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
the	DET	O	O
randomized	ADJ	O	O
cyclosporine	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Heart	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
patients	NOUN	O	O
had	VERB	O	O
more	ADJ	O	O
infections	NOUN	O	I-Entity
than	ADP	O	O
cyclosporine	ADJ	O	I-Entity
renal	ADJ	O	O
patients	NOUN	O	O
but	CCONJ	O	O
fewer	ADJ	O	O
infections	NOUN	O	I-Entity
than	ADP	O	O
the	DET	O	O
Aza	PROPN	O	I-Entity
renal	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
infectious	ADJ	O	O
deaths	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
on	ADP	O	O
cyclosporine	NOUN	O	I-Entity
or	CCONJ	O	O
Aza	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
infection	NOUN	O	I-Entity
played	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
out	ADP	O	O
of	ADP	O	O
6	NUM	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
deaths	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
8	NUM	O	O
out	ADP	O	O
of	ADP	O	O
9	NUM	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
deaths	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
patients	NOUN	O	O
on	ADP	O	O
cyclosporine	NOUN	O	I-Entity
had	VERB	O	O
the	DET	O	O
fewest	ADJ	O	O
bacteremias	NOUN	O	I-Entity
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
site	NOUN	O	O
of	ADP	O	O
infection	NOUN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
preponderance	NOUN	O	O
of	ADP	O	O
abdominal	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
in	ADP	O	O
liver	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
intrathoracic	ADJ	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
heart	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
urinary	ADJ	O	B-Entity
tract	NOUN	O	I-Entity
infections	NOUN	O	I-Entity
in	ADP	O	O
renal	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Pulmonary	ADJ	O	O
infections	NOUN	O	I-Entity
were	VERB	O	O
less	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
renal	NOUN	O	O
patients	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
Aza	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Aza	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
staphylococcal	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
than	ADP	O	O
all	DET	O	O
other	ADJ	O	O
transplant	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.005	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
fungal	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
occurred	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Cytomegalovirus	PROPN	O	O
(	PUNCT	O	O
CMV	PROPN	O	O
)	PUNCT	O	O
shedding	VERB	O	O
or	CCONJ	O	O
serological	ADJ	O	O
rises	NOUN	O	O
in	ADP	O	O
antibody	NOUN	O	O
titer	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
occurred	VERB	O	O
in	ADP	O	O
78%	NUM	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
patients	NOUN	O	O
and	CCONJ	O	O
76%	NUM	O	O
of	ADP	O	O
Aza	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
cyclosporine	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
15%	NUM	O	O
had	VERB	O	O
symptoms	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
CMV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Serological	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
Epstein	PROPN	O	B-Entity
Barr	PROPN	O	I-Entity
Virus	PROPN	O	I-Entity
infection	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
20%	NUM	O	O
of	ADP	O	O
65	NUM	O	O
cyclosporine	NOUN	O	I-Entity
patients	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
had	VERB	O	O
associated	VERB	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
developed	VERB	O	O
a	DET	O	O
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6316193)

Structure	PROPN	O	O
-	PUNCT	O	O
activity	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
relationships	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antagonism	NOUN	O	O
of	ADP	O	O
picrotoxin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
by	ADP	O	O
cholecystokinin	NOUN	O	I-Entity
,	PUNCT	O	O
fragments	NOUN	O	O
and	CCONJ	O	O
analogues	NOUN	O	O
of	ADP	O	O
cholecystokinin	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Intraperitoneal	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
cholecystokinin	NOUN	O	B-Entity
octapeptide	NOUN	O	I-Entity
sulphate	NOUN	O	O
ester	NOUN	O	O
(	PUNCT	O	O
CCK-8-SE	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
nonsulphated	VERB	O	O
cholecystokinin	NOUN	O	B-Entity
octapeptide	NOUN	O	I-Entity
(	PUNCT	O	O
CCK-8-NS	PROPN	O	I-Entity
)	PUNCT	O	O
enhanced	VERB	O	O
the	DET	O	O
latency	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
picrotoxin	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
analogues	NOUN	O	O
CCK-8-SE	PROPN	O	I-Entity
and	CCONJ	O	O
CCK-8-NS	PROPN	O	I-Entity
(	PUNCT	O	O
dose	NOUN	O	O
range	NOUN	O	O
0.2	NUM	O	O
-	SYM	O	O
6.4	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
caerulein	ADJ	O	I-Entity
dose	NOUN	O	O
range	NOUN	O	O
0.1	NUM	O	O
-	SYM	O	O
0.8	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
bell	NOUN	O	O
-	PUNCT	O	O
shaped	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
curves	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
greatest	ADJ	O	O
maximum	ADJ	O	O
inhibition	NOUN	O	O
for	ADP	O	O
CCK-8-NS	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
peptide	NOUN	O	O
CCK-5	PROPN	O	O
-	PUNCT	O	O
8	PROPN	O	O
had	VERB	O	O
weak	ADJ	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
the	DET	O	O
octapeptides	NOUN	O	O
,	PUNCT	O	O
3.2	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
larger	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
drug	NOUN	O	O
,	PUNCT	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
totally	ADV	O	O
prevented	VERB	O	O
picrotoxin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
peptides	NOUN	O	O
tested	VERB	O	O
was	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
.	PUNCT	O	O

Experiments	NOUN	O	O
with	ADP	O	O
analogues	NOUN	O	O
and	CCONJ	O	O
derivatives	NOUN	O	O
of	ADP	O	O
CCK-5	PROPN	O	O
-	PUNCT	O	O
8	PROPN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
alanyl	NOUN	O	O
derivatives	NOUN	O	O
of	ADP	O	O
CCK-5	PROPN	O	O
-	PUNCT	O	O
8	NUM	O	O
were	VERB	O	O
enhanced	VERB	O	O
and	CCONJ	O	O
that	ADP	O	O
they	PRON	O	O
were	VERB	O	O
equipotent	NOUN	O	O
with	ADP	O	O
CCK-8-SE	PROPN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
CCK-2	PROPN	O	O
-	PUNCT	O	O
8	PROPN	O	O
analogues	NOUN	O	O
,	PUNCT	O	O
Ser(SO3H)7-Ac	PROPN	O	O
-	PUNCT	O	O
CCK-2	PROPN	O	O
-	PUNCT	O	O
8-SE	PROPN	O	O
and	CCONJ	O	O
Thr(SO3H)7-Ac	PROPN	O	O
-	PUNCT	O	O
CCK-2	PROPN	O	O
-	PUNCT	O	O
8-SE	PROPN	O	O
and	CCONJ	O	O
Hyp(SO3H)-Ac	PROPN	O	O
-	PUNCT	O	O
CCK-2	PROPN	O	O
-	PUNCT	O	O
8-SE	PROPN	O	O
were	VERB	O	O
slightly	ADV	O	O
more	ADV	O	O
active	ADJ	O	O
than	ADP	O	O
CCK-8-SE	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6321816)

Vasopressin	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
contributor	NOUN	O	O
to	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
pressor	NOUN	O	O
agent	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
process	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
.	PUNCT	O	O

Vasopressin	PROPN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
DOCA	PROPN	O	I-Entity
-	PUNCT	O	O
salt	NOUN	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
substantial	ADJ	O	O
in	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	NOUN	O	I-Entity
after	ADP	O	O
DOCA	PROPN	O	I-Entity
-	PUNCT	O	O
salt	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
DDAVP	PROPN	O	I-Entity
which	ADJ	O	O
has	VERB	O	O
antidiuretic	ADJ	O	O
action	NOUN	O	O
but	CCONJ	O	O
minimal	ADJ	O	O
vasopressor	NOUN	O	O
effect	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
increase	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
observed	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
pressor	NOUN	O	O
action	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
this	DET	O	O
model	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
enhanced	VERB	O	O
pressor	NOUN	O	O
responsiveness	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hormone	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Increased	VERB	O	O
secretion	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
from	ADP	O	O
neurohypophysis	NOUN	O	O
also	ADV	O	O
promotes	VERB	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hormone	NOUN	O	O
as	ADP	O	O
a	DET	O	O
pathogenetic	ADJ	O	O
factor	NOUN	O	O
in	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
unproportional	ADJ	O	O
release	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
plasma	NOUN	O	O
osmolality	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
an	DET	O	O
adjusting	VERB	O	O
control	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
II	PROPN	O	O
forming	NOUN	O	O
and	CCONJ	O	O
receptor	NOUN	O	O
binding	NOUN	O	O
capacity	NOUN	O	O
for	ADP	O	O
sodium	NOUN	O	I-Entity
balance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
human	ADJ	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6453500)

Toxic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
disulfiram	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
non	NOUN	O	O
-	PUNCT	O	O
alcoholic	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
reversible	ADJ	O	O
toxic	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
non	NOUN	O	O
-	PUNCT	O	O
alcoholic	ADJ	O	O
woman	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
disulfiram	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6517710)

Atrial	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
involving	VERB	O	O
the	DET	O	O
heart	NOUN	O	O
of	ADP	O	O
F-344	PROPN	O	O
rats	NOUN	O	O
ingesting	VERB	O	O
quinacrine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
.	PUNCT	O	O

Quinacrine	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
is	VERB	O	O
toxic	ADJ	O	O
for	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
of	ADP	O	O
F-344	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
500	NUM	O	O
ppm	NOUN	O	O
quinacrine	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
all	DET	O	O
developed	VERB	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
left	VERB	O	O
atrial	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
lesion	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
and	CCONJ	O	O
dilatation	NOUN	O	O
and	CCONJ	O	O
focal	ADJ	O	O
myocardial	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
.	PUNCT	O	O

Rats	NOUN	O	O
died	VERB	O	O
from	ADP	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
with	ADP	O	O
severe	ADJ	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
congestion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lungs	NOUN	O	O
,	PUNCT	O	O
liver	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
organs	NOUN	O	O
.	PUNCT	O	O

Seventy	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
250	NUM	O	O
ppm	ADJ	O	O
quinacrine	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
and	CCONJ	O	O
1,000	NUM	O	O
ppm	NOUN	O	O
sodium	NOUN	O	B-Entity
nitrite	NOUN	O	I-Entity
simultaneously	ADV	O	O
in	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
had	VERB	O	O
thrombosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
atria	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
untreated	ADJ	O	O
control	NOUN	O	O
rats	NOUN	O	O
in	ADP	O	O
this	DET	O	O
laboratory	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
atrial	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

Sodium	NOUN	O	B-Entity
nitrite	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
quinacrine	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
no	DET	O	O
additional	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6529939)

Alternating	VERB	O	B-Entity
sinus	ADJ	O	I-Entity
rhythm	NOUN	O	I-Entity
and	CCONJ	O	O
intermittent	ADJ	O	O
sinoatrial	ADJ	O	B-Entity
block	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
.	PUNCT	O	O

Alternating	VERB	O	B-Entity
sinus	ADJ	O	I-Entity
rhythm	NOUN	O	I-Entity
and	CCONJ	O	O
intermittent	ADJ	O	O
sinoatrial	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
S	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
A	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
block	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
57-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
,	PUNCT	O	O
under	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
angina	NOUN	O	I-Entity
with	ADP	O	O
80	NUM	O	O
mg	NUM	O	O
propranolol	NOUN	O	I-Entity
daily	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
these	DET	O	O
basic	ADJ	O	O
sinus	ADJ	O	O
cycles	NOUN	O	O
,	PUNCT	O	O
alternating	VERB	O	B-Entity
rhythm	NOUN	O	I-Entity
started	VERB	O	O
with	ADP	O	O
the	DET	O	O
longer	ADV	O	O
P	NOUN	O	O
-	PUNCT	O	O
P	NOUN	O	O
interval	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
recording	NOUN	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
regular	ADJ	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
with	ADP	O	O
intermittent	ADJ	O	O
2/1	NUM	O	O
S	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
A	NOUN	O	I-Entity
block	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Atropine	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
given	VERB	O	O
intravenously	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
shortening	NOUN	O	O
of	ADP	O	O
all	DET	O	O
P	NOUN	O	O
-	PUNCT	O	O
P	NOUN	O	O
intervals	NOUN	O	O
without	ADP	O	O
changing	VERB	O	O
the	DET	O	O
rhythm	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
abnormal	ADJ	O	O
rhythm	NOUN	O	O
disappeared	VERB	O	O
with	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
when	ADV	O	O
the	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
restarted	VERB	O	O
a	DET	O	O
2/1	NUM	O	O
S	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
A	NOUN	O	I-Entity
block	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
accepted	VERB	O	O
as	ADP	O	O
evidence	NOUN	O	O
for	ADP	O	O
propranolol	NOUN	O	I-Entity
being	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
this	DET	O	O
conduction	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6585590)

Antitumor	PROPN	O	O
effect	NOUN	O	O
,	PUNCT	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
IgM	PROPN	O	O
solid	ADJ	O	O
immunocytoma	NOUN	O	I-Entity
-	PUNCT	O	O
bearing	VERB	O	O
LOU	PROPN	O	O
/	SYM	O	O
M	PROPN	O	O
/	SYM	O	O
WSL	PROPN	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Antitumor	PROPN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
LOU	PROPN	O	O
/	SYM	O	O
M	PROPN	O	O
/	SYM	O	O
WSL	PROPN	O	O
inbred	ADJ	O	O
rats	NOUN	O	O
each	DET	O	O
bearing	VERB	O	O
a	DET	O	O
transplantable	ADJ	O	O
solid	ADJ	O	O
IgM	PROPN	O	O
immunocytoma	NOUN	O	I-Entity
.	PUNCT	O	O

Animals	NOUN	O	O
with	ADP	O	O
a	DET	O	O
tumor	NOUN	O	I-Entity
(	PUNCT	O	O
diameter	NOUN	O	O
,	PUNCT	O	O
15.8	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

3.3	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
iv	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
on	ADP	O	O
5	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
1	NUM	O	O
weekly	ADJ	O	O
injection	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
dose	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
0.015	NUM	O	O
-	SYM	O	O
4.0	NUM	O	O

Tumor	PROPN	O	I-Entity
regression	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Complete	ADJ	O	O
disappearance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
with	ADP	O	O
1.0	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Histologic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
scored	VERB	O	O
as	ADP	O	O
grade	NOUN	O	O
III	PROPN	O	O
was	VERB	O	O
only	ADV	O	O
observed	VERB	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Light	NOUN	O	O
microscopic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
above	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
albuminuria	NOUN	O	I-Entity
and	CCONJ	O	O
very	ADV	O	O
low	ADJ	O	O
serum	NOUN	O	O
albumin	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
group	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
1.0	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
albumin	NOUN	O	O
level	NOUN	O	O
decreased	VERB	O	O
from	ADP	O	O
33.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Ascites	NOUN	O	I-Entity
and	CCONJ	O	O
hydrothorax	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
same	ADJ	O	O
experiments	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
bearing	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
no	DET	O	O
major	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
antitumor	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
simultaneously	ADV	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
LOU	PROPN	O	O
/	SYM	O	O
M	PROPN	O	O
/	SYM	O	O
WSL	PROPN	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Albuminuria	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
extremely	ADV	O	O
low	ADJ	O	O
serum	NOUN	O	O
albumin	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
so	ADV	O	O
ascites	NOUN	O	I-Entity
and	CCONJ	O	O
hydrothorax	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
necessarily	ADV	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
observed	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6615679)

Intraoperative	ADJ	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
timolol	NOUN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
eye	NOUN	O	O
drops	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
69-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
was	VERB	O	O
concurrently	ADV	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
pilocarpine	NOUN	O	B-Entity
nitrate	NOUN	O	I-Entity
and	CCONJ	O	O
timolol	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
eye	NOUN	O	O
drops	VERB	O	O
,	PUNCT	O	O
developed	VERB	O	O
a	DET	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
became	VERB	O	O
hypotensive	ADJ	O	I-Entity
during	ADP	O	O
halothane	NOUN	O	I-Entity
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
timolol	NOUN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
were	VERB	O	O
subsequently	ADV	O	O
identified	VERB	O	O
in	ADP	O	O
a	DET	O	O
24-h	NUM	O	O
collection	NOUN	O	O
of	ADP	O	O
urine	NOUN	O	O
.	PUNCT	O	O

Timolol	PROPN	O	I-Entity
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
pilocarpine	NOUN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
removed	VERB	O	O
during	ADP	O	O
surgery	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
timolol	NOUN	O	I-Entity
(	PUNCT	O	O
2.6	NUM	O	O
ng	INTJ	O	O
ml-1	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
partial	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
blockade	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
postulated	VERB	O	O
that	ADP	O	O
this	DET	O	O
action	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
enhanced	VERB	O	O
during	ADP	O	O
halothane	NOUN	O	I-Entity
anaesthesia	NOUN	O	O
with	ADP	O	O
resultant	ADJ	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Pilocarpine	PROPN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
had	VERB	O	O
a	DET	O	O
contributory	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6627074)

Succinylcholine	PROPN	O	I-Entity
apnoea	NOUN	O	I-Entity
:	PUNCT	O	O
attempted	VERB	O	O
reversal	NOUN	O	O
with	ADP	O	O
anticholinesterases	NOUN	O	O
.	PUNCT	O	O

Anticholinesterases	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
antagonize	VERB	O	O
prolonged	ADJ	O	O
neuromuscular	ADJ	O	B-Entity
blockade	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
later	ADV	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
homozygous	ADJ	O	O
for	ADP	O	O
atypical	ADJ	O	O
plasma	NOUN	O	O
cholinesterase	NOUN	O	O
.	PUNCT	O	O

Edrophonium	PROPN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
given	VERB	O	O
74	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
,	PUNCT	O	O
when	ADV	O	O
train	NOUN	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
four	NUM	O	O
stimulation	NOUN	O	O
was	VERB	O	O
characteristic	ADJ	O	O
of	ADP	O	O
phase	NOUN	O	O
II	PROPN	O	O
block	NOUN	O	O
,	PUNCT	O	O
produced	VERB	O	O
partial	ADJ	O	O
antagonism	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
sustained	VERB	O	O
.	PUNCT	O	O

Repeated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
edrophonium	NOUN	O	I-Entity
to	ADP	O	O
70	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
neostigmine	NOUN	O	I-Entity
to	ADP	O	O
2.5	NUM	O	O
mg	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
antagonize	VERB	O	O
or	CCONJ	O	O
augment	VERB	O	O
the	DET	O	O
block	NOUN	O	O
.	PUNCT	O	O

Spontaneous	ADJ	O	O
respiration	NOUN	O	O
recommenced	VERB	O	O
200	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
succinylcholine	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
anticholinesterases	NOUN	O	O
are	VERB	O	O
only	ADV	O	O
partially	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
restoring	VERB	O	O
neuromuscular	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
succinylcholine	NOUN	O	I-Entity
apnoea	NOUN	O	I-Entity
despite	ADP	O	O
muscle	NOUN	O	O
twitch	NOUN	O	O
activity	NOUN	O	O
typical	ADJ	O	O
of	ADP	O	O
phase	NOUN	O	O
II	PROPN	O	O
block	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6631522)

Effect	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
on	ADP	O	O
[	PUNCT	O	B-Entity
omega	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
I-131]heptadecanoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
myocardial	ADJ	O	O
scintigraphy	NOUN	O	O
and	CCONJ	O	O
echocardiography	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
serial	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
on	ADP	O	O
dynamic	ADJ	O	O
myocardial	ADJ	O	O
scintigraphy	NOUN	O	O
with	ADP	O	O
[	PUNCT	O	B-Entity
omega	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
I-131]heptadecanoic	PROPN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
I-131	PROPN	O	B-Entity
HA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
global	ADJ	O	O
left	NOUN	O	O
-	PUNCT	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
determined	VERB	O	O
echocardiographically	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
nine	NUM	O	O
mongrel	NOUN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
extractable	ADJ	O	O
myocardial	NOUN	O	O
lipid	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
postmortem	NOUN	O	O
between	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
and	CCONJ	O	O
then	ADV	O	O
progressive	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
global	ADJ	O	O
LV	PROPN	O	O
function	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
a	DET	O	O
cumulative	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
t1/2	NOUN	O	O
of	ADP	O	O
the	DET	O	O
I-131	PROPN	O	B-Entity
HA	PROPN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
at	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
alteration	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
extractable	ADJ	O	O
myocardial	NOUN	O	O
lipids	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
control	NOUN	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
those	DET	O	O
treated	VERB	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
changes	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
an	DET	O	O
alteration	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
dynamic	ADJ	O	O
imaging	NOUN	O	O
with	ADP	O	O
I-131	PROPN	O	B-Entity
HA	PROPN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
the	DET	O	O
initiating	VERB	O	O
factor	NOUN	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6673474)

Hemodynamics	PROPN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
metabolism	NOUN	O	O
under	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
work	NOUN	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
dogs	NOUN	O	O
under	ADP	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SNP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
trimetaphan	NOUN	O	I-Entity
(	PUNCT	O	O
TMP	PROPN	O	I-Entity
)	PUNCT	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
20%	NUM	O	O
and	CCONJ	O	O

Regarding	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
,	PUNCT	O	O
aortic	ADJ	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
sinus	ADJ	O	O
metabolic	NOUN	O	O
data	NOUN	O	O
(	PUNCT	O	O
pH	NOUN	O	O
,	PUNCT	O	O
pO2	NOUN	O	O
,	PUNCT	O	O
pCO2	PUNCT	O	O
)	PUNCT	O	O
we	PRON	O	O
could	VERB	O	O
confirm	VERB	O	O
that	DET	O	O
nitroprusside	NOUN	O	I-Entity
hypotension	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
safely	ADV	O	O
used	VERB	O	O
to	PART	O	O
30%	NUM	O	O
mean	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
decrease	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
,	PUNCT	O	O
trimetaphan	ADP	O	I-Entity
hypotension	NOUN	O	I-Entity
to	ADP	O	O
20%	NUM	O	O
mean	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
decrease	NOUN	O	O
.	PUNCT	O	O

Cardiac	PROPN	O	O
work	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
during	ADP	O	O
SNP	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Myocardial	ADJ	O	O
O2	PROPN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
O2	PROPN	O	I-Entity
availability	NOUN	O	O
were	VERB	O	O
directly	ADV	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
coronary	ADJ	O	O
perfusion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6687006)

Evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
selective	ADJ	O	O
brain	NOUN	O	O
noradrenergic	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
locomotor	NOUN	O	O
stimulant	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
rats	NOUN	O	O
received	VERB	O	O
the	DET	O	O
noradrenaline	NOUN	O	I-Entity
neurotoxin	NOUN	O	O
DSP4	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
7	NUM	O	O
days	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
DSP4	PROPN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
increased	VERB	O	O
rearings	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stereotypies	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
DSP4	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
DSP4	PROPN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
noradrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
uptake	NOUN	O	O
blocking	VERB	O	O
agent	NOUN	O	O
,	PUNCT	O	O
desipramine	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
prevents	VERB	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
action	NOUN	O	O
of	ADP	O	O
DSP4	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
noradrenergic	ADJ	O	O
neurones	NOUN	O	O
in	ADP	O	O
the	DET	O	O
locomotor	NOUN	O	O
stimulant	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6695685)

Accelerated	ADJ	O	B-Entity
junctional	ADJ	O	I-Entity
rhythms	NOUN	O	I-Entity
during	ADP	O	O
oral	ADJ	O	O
verapamil	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
atrioventricular	NOUN	O	O
(	PUNCT	O	O
AV	PROPN	O	O
)	PUNCT	O	O
dissociation	NOUN	O	O
and	CCONJ	O	O
accelerated	VERB	O	B-Entity
junctional	ADJ	O	I-Entity
rhythms	NOUN	O	I-Entity
in	ADP	O	O
59	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
oral	ADJ	O	O
verapamil	NOUN	O	I-Entity
.	PUNCT	O	O

Accelerated	ADJ	O	B-Entity
junctional	ADJ	O	I-Entity
rhythms	NOUN	O	I-Entity
and	CCONJ	O	O
AV	NOUN	O	O
dissociation	NOUN	O	O
were	VERB	O	O
frequent	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
supraventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
AV	PROPN	O	O
nodal	ADJ	O	O
reentry	NOUN	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
administration	NOUN	O	O
to	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
an	DET	O	O
asymptomatic	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
activity	NOUN	O	O
of	ADP	O	O
these	DET	O	O
junctional	ADJ	O	O
pacemakers	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
various	ADJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
syndromes	NOUN	O	O
,	PUNCT	O	O
verapamil	ADV	O	I-Entity
neither	DET	O	O
increased	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
junctional	ADJ	O	O
rhythms	NOUN	O	O
nor	CCONJ	O	O
suppressed	VERB	O	O
their	ADJ	O	O
role	NOUN	O	O
as	ADP	O	O
escape	VERB	O	O
rhythms	NOUN	O	O
under	ADP	O	O
physiologically	ADV	O	O
appropriate	ADJ	O	O
circumstances	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6806735)

Treatment	NOUN	O	O
of	ADP	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
platinum	NOUN	O	I-Entity
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
,	PUNCT	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
hexamethylmelamine	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
last	ADJ	O	O
2	NUM	O	O
1/2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
38	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cisplatinum	NOUN	O	I-Entity
(	PUNCT	O	O
CPDD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
50	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
,	PUNCT	O	O
30	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	I-Entity
,	PUNCT	O	O
300	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
hexamethylmelamine	NOUN	O	I-Entity
(	PUNCT	O	O
HMM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
6	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

14	NUM	O	O
of	ADP	O	O
the	DET	O	O
38	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
with	ADP	O	O
radiation	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
with	ADP	O	O
both	CCONJ	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
radiation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
17	NUM	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
any	DET	O	O
treatment	NOUN	O	O
before	ADP	O	O
CPDD	PROPN	O	I-Entity
combination	NOUN	O	O
.	PUNCT	O	O

Hematologic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
moderate	ADJ	O	O
and	CCONJ	O	O
with	ADP	O	O
reversible	ADJ	O	O
anemia	NOUN	O	I-Entity
developing	VERB	O	O
in	ADP	O	O
71%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
from	ADP	O	O
CPDD	PROPN	O	I-Entity
were	VERB	O	O
universal	ADJ	O	O
.	PUNCT	O	O

HMM	PROPN	O	I-Entity
gastrointestinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
necessitated	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
reversible	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (6884395)

Nontraumatic	ADJ	O	O
dissecting	VERB	O	B-Entity
aneurysm	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
basilar	ADJ	O	O
artery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
nontraumatic	ADJ	O	O
dissecting	VERB	O	B-Entity
aneurysm	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
basilar	ADJ	O	O
artery	NOUN	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
smoke	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
a	DET	O	O
young	ADJ	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
locked	VERB	O	B-Entity
-	PUNCT	O	I-Entity
in	PART	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6893265)

Propylthiouracil	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
is	VERB	O	O
of	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
damage	NOUN	O	O
,	PUNCT	O	O
proven	VERB	O	O
by	ADP	O	O
rechallenge	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
presents	VERB	O	O
a	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
histologic	ADJ	O	O
picture	NOUN	O	O
resembling	VERB	O	O
chronic	ADJ	O	B-Entity
active	ADJ	O	I-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
remission	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6985297)

Studies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
bepridil	NOUN	O	I-Entity
.	PUNCT	O	O

Bepridil	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
novel	NOUN	O	O
active	ADJ	O	O
compound	NOUN	O	O
for	ADP	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
anginal	ADJ	O	B-Entity
attacks	NOUN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
persistent	ADJ	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
tachycardial	ADJ	O	I-Entity
effect	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
which	ADJ	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vitro	ADJ	O	O
perfusion	NOUN	O	O
of	ADP	O	O
bepridil	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
life	NOUN	O	O
-	PUNCT	O	O
support	NOUN	O	O
medium	NOUN	O	O
for	ADP	O	O
isolated	ADJ	O	O
sino	ADJ	O	O
-	PUNCT	O	O
atrial	ADJ	O	O
tissue	NOUN	O	O
from	ADP	O	O
rabbit	NOUN	O	O
heart	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
action	NOUN	O	O
potential	NOUN	O	O
(	PUNCT	O	O
AP	PROPN	O	O
)	PUNCT	O	O
spike	VERB	O	O
frequency	NOUN	O	O
(	PUNCT	O	O
recorded	VERB	O	O
by	ADP	O	O
KCl	PROPN	O	I-Entity
microelectrodes	NOUN	O	O
)	PUNCT	O	O
starting	VERB	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
X	PROPN	O	O
10(-6	NUM	O	O
)	PUNCT	O	O
M.	PROPN	O	O

Bepridil	PROPN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
X	PROPN	O	O
10(-6	NUM	O	O
)	PUNCT	O	O

In	ADP	O	O
vivo	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
bepridil	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
(	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
bepridil	NOUN	O	I-Entity
reduces	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
by	ADP	O	O
acting	VERB	O	O
directly	ADV	O	O
on	ADP	O	O
the	DET	O	O
sinus	ADJ	O	O
node	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
results	VERB	O	O
in	ADP	O	O
a	DET	O	O
flattening	NOUN	O	O
of	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
0	NUM	O	O
and	CCONJ	O	O
phase	NOUN	O	O
4	NUM	O	O
slope	NOUN	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
a	DET	O	O
longer	ADV	O	O
AP	PROPN	O	O
duration	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
time	NOUN	O	O
constants	NOUN	O	O
of	ADP	O	O
slow	ADJ	O	O
inward	NOUN	O	O
ionic	ADJ	O	O
currents	NOUN	O	O
(	PUNCT	O	O
already	ADV	O	O
demonstrated	VERB	O	O
elsewhere	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
to	ADP	O	O
an	DET	O	O
increased	VERB	O	O
time	NOUN	O	O
constant	ADJ	O	O
for	ADP	O	O
deactivation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
outward	ADJ	O	O
potassium	NOUN	O	I-Entity
current	ADJ	O	O
(	PUNCT	O	O
Ip	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (6985498)

Hepatitis	PROPN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
acidosis	NOUN	O	I-Entity
after	ADP	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
methoxyflurane	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
69-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
operated	VERB	O	O
for	ADP	O	O
acute	ADJ	O	B-Entity
cholecystitis	NOUN	O	I-Entity
under	ADP	O	O
methoxyflurane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
developed	VERB	O	O
postoperatively	ADV	O	O
a	DET	O	O
hepatic	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
acidosis	NOUN	O	I-Entity
.	PUNCT	O	O

Massive	ADJ	O	O
bleeding	NOUN	O	I-Entity
appeared	VERB	O	O
during	ADP	O	O
surgery	NOUN	O	O
which	ADJ	O	O
lasted	VERB	O	O
for	ADP	O	O
six	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7018927)

Pituitary	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
-	PUNCT	O	O
releasing	VERB	O	O
hormone	NOUN	O	O
during	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
6-hour	NUM	O	O
infusion	NOUN	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
on	ADP	O	O
serum	NOUN	O	O
prolactin	NOUN	O	O
and	CCONJ	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
LH	PROPN	O	O
)	PUNCT	O	O

Control	NOUN	O	O
patients	NOUN	O	O
received	VERB	O	O
infusions	NOUN	O	O
of	ADP	O	O
0.9%	NUM	O	O
NaCl	PROPN	O	I-Entity
solution	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
infusions	NOUN	O	O
,	PUNCT	O	O
significant	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
an	DET	O	O
abolished	ADJ	O	O
pituitary	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
LH	PROPN	O	O
-	PUNCT	O	O
RH	PROPN	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
responses	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7121659)

Antirifampicin	PROPN	O	O
antibodies	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
rifampicin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

5	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
with	ADP	O	O
thrombopenia	NOUN	O	I-Entity
and	CCONJ	O	O
hemolysis	NOUN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
reintroduction	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Antibodies	NOUN	O	O
suggested	VERB	O	O
to	PART	O	O
be	VERB	O	O
of	ADP	O	O
the	DET	O	O
IgM	PROPN	O	O
class	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
all	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hematological	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
acute	ADJ	O	B-Entity
tubular	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
biopsied	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
indistinguishable	ADJ	O	O
from	ADP	O	O
that	DET	O	O
of	ADP	O	O
ischemic	ADJ	O	O
origin	NOUN	O	O
,	PUNCT	O	O
raised	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
a	DET	O	O
vascular	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
damage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7147232)

Cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
adenosine	NOUN	O	B-Entity
triphosphate	NOUN	O	I-Entity
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
on	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
denervated	VERB	O	O
hearts	NOUN	O	O
.	PUNCT	O	O

Adenosine	PROPN	O	B-Entity
triphosphate	NOUN	O	I-Entity
(	PUNCT	O	O
ATP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SNP	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
and	CCONJ	O	O
control	VERB	O	O
hypotension	NOUN	O	I-Entity
during	ADP	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

SNP	PROPN	O	I-Entity
is	VERB	O	O
authorized	VERB	O	O
for	ADP	O	O
clinical	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
USA	PROPN	O	O
and	CCONJ	O	O
UK	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ATP	PROPN	O	I-Entity
is	VERB	O	O
clinically	ADV	O	O
used	VERB	O	O
in	ADP	O	O
other	ADJ	O	O
countries	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
Japan	PROPN	O	O
.	PUNCT	O	O

ATP	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
dogs	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
SNP	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
dogs	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
by	ADP	O	O
30%	NUM	O	O
to	PART	O	O
70%	NUM	O	O
of	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
measured	VERB	O	O
major	ADJ	O	O
cardiovascular	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Hypotension	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ATP	PROPN	O	I-Entity
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
mean	ADJ	O	O
pulmonary	ADJ	O	O
arterial	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
central	ADJ	O	O
venous	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rate	NOUN	O	O
pressure	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
body	NOUN	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
all	ADJ	O	O
these	DET	O	O
variables	NOUN	O	O
returned	VERB	O	O
normal	ADJ	O	O
within	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
ATP	PROPN	O	I-Entity
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

During	ADP	O	O
hypotension	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
SNP	PROPN	O	I-Entity
similar	ADJ	O	O
decreases	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
mean	ADJ	O	O
pulmonary	ADJ	O	O
arterial	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
central	ADJ	O	O
venous	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rate	NOUN	O	O
pressure	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
oxygen	NOUN	O	I-Entity
content	NOUN	O	O
difference	NOUN	O	O
between	ADP	O	O
arterial	NOUN	O	O
and	CCONJ	O	O
mixed	ADJ	O	O
venous	ADJ	O	O
blood	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
increased	VERB	O	O
.	PUNCT	O	O

Recoveries	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
shown	VERB	O	O
within	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
SNP	PROPN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

Both	DET	O	O
ATP	PROPN	O	I-Entity
and	CCONJ	O	O
SNP	PROPN	O	I-Entity
should	VERB	O	O
act	VERB	O	O
on	ADP	O	O
the	DET	O	O
pacemaker	NOUN	O	O
tissue	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7173007)

Comparative	ADJ	O	O
study	NOUN	O	O
:	PUNCT	O	O
Endografine	PROPN	O	I-Entity
(	PUNCT	O	O
diatrizoate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
Vasurix	PROPN	O	B-Entity
polyvidone	NOUN	O	I-Entity
(	PUNCT	O	O
acetrizoate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
Dimer	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
X	PROPN	O	I-Entity
(	PUNCT	O	O
iocarmate	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
Hexabrix	PROPN	O	I-Entity
(	PUNCT	O	O
ioxaglate	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
hysterosalpingography	NOUN	O	O
.	PUNCT	O	O

Side	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
hysterosalpingography	NOUN	O	O
with	ADP	O	O
Dimer	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
X	PROPN	O	I-Entity
,	PUNCT	O	O
Hexabrix	PROPN	O	I-Entity
,	PUNCT	O	O
Vasurix	PROPN	O	B-Entity
polyvidone	NOUN	O	I-Entity
and	CCONJ	O	O
Endografine	PROPN	O	I-Entity
in	ADP	O	O
142	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
receiving	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
four	NUM	O	O
tested	VERB	O	O
media	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
from	ADP	O	O
replies	NOUN	O	O
to	ADP	O	O
postal	ADJ	O	O
questionnaires	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Dimer	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
X	PROPN	O	I-Entity
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
dizziness	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Endografine	PROPN	O	I-Entity
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Hexabrix	PROPN	O	I-Entity
and	CCONJ	O	O
Vasurix	PROPN	O	B-Entity
polyvidone	NOUN	O	I-Entity
are	VERB	O	O
considered	VERB	O	O
the	DET	O	O
best	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
for	ADP	O	O
hysterosalpingography	NOUN	O	O
and	CCONJ	O	O
perhaps	ADV	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
low	ADJ	O	O
toxicity	NOUN	O	I-Entity
Hexabrix	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
preferred	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7176945)

Post	PROPN	O	O
-	PUNCT	O	O
suxamethonium	ADJ	O	I-Entity
pains	NOUN	O	I-Entity
in	ADP	O	O
Nigerian	ADJ	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Contrary	ADJ	O	O
to	ADP	O	O
an	DET	O	O
earlier	ADJ	O	O
report	NOUN	O	O
by	ADP	O	O
Coxon	PROPN	O	O
,	PUNCT	O	O
scoline	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
occurs	VERB	O	O
in	ADP	O	O
African	ADJ	O	O
negroes	NOUN	O	O
.	PUNCT	O	O

About	ADP	O	O
62%	NUM	O	O
of	ADP	O	O
the	DET	O	O
out	ADV	O	O
-	PUNCT	O	O
patients	NOUN	O	O
developed	VERB	O	O
scoline	ADJ	O	I-Entity
pain	NOUN	O	I-Entity
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
about	ADV	O	O
26%	NUM	O	O
among	ADP	O	O
the	DET	O	O
in	ADP	O	O
-	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
abolition	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
fasciculations	NOUN	O	I-Entity
(	PUNCT	O	O
by	ADP	O	O
0.075mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
dose	NOUN	O	O
of	ADP	O	O
Fazadinium	PROPN	O	I-Entity
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
scoline	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	CCONJ	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
agent	NOUN	O	O
(	PUNCT	O	O
Althesin	PROPN	O	I-Entity
or	CCONJ	O	O
Thiopentone	PROPN	O	I-Entity
)	PUNCT	O	O
nor	CCONJ	O	O
the	DET	O	O
salt	NOUN	O	O
preparation	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
used	VERB	O	O
(	PUNCT	O	O
chloride	NOUN	O	I-Entity
or	CCONJ	O	O
bromide	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
affected	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
scoline	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7315949)

Medial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
arterial	ADJ	O	O
spasm	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
media	NOUN	O	O
of	ADP	O	O
the	DET	O	O
saphenous	ADJ	O	O
artery	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
distal	ADJ	O	O
branch	NOUN	O	O
,	PUNCT	O	O
vasoconstriction	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
norepinephrine	PROPN	O	I-Entity
produced	VERB	O	O
many	ADJ	O	O
cell	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
cell	NOUN	O	O
hernias	NOUN	O	I-Entity
within	ADP	O	O
15	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
medial	ADJ	O	O
changes	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
other	ADJ	O	O
instances	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	O
spasm	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7369302)

Abnormalities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pupil	NOUN	O	O
and	CCONJ	O	O
visual	ADJ	O	O
-	PUNCT	O	O
evoked	VERB	O	O
potential	NOUN	O	O
in	ADP	O	O
quinine	NOUN	O	I-Entity
amblyopia	NOUN	O	I-Entity
.	PUNCT	O	O

Total	ADJ	O	O
blindness	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
tonic	NOUN	O	B-Entity
pupillary	ADJ	O	I-Entity
response	NOUN	O	O
,	PUNCT	O	O
denervation	NOUN	O	O
supersensitivity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
abnormal	ADJ	O	O
visual	ADJ	O	O
-	PUNCT	O	O
evoked	VERB	O	O
potentials	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
a	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
for	ADP	O	O
leg	NOUN	O	B-Entity
cramps	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
transient	ADJ	O	O
tonic	NOUN	O	B-Entity
pupillary	ADJ	O	I-Entity
response	NOUN	O	O
,	PUNCT	O	O
denervation	NOUN	O	O
supersensitivity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
abnormal	ADJ	O	O
visual	ADJ	O	O
-	PUNCT	O	O
evoked	VERB	O	O
potentials	NOUN	O	O
in	ADP	O	O
quinine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
to	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7378868)

Suxamethonium	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
jaw	NOUN	O	B-Entity
stiffness	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
atypical	ADJ	O	O
cholinesterase	NOUN	O	O
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
11-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
halothane	NOUN	O	I-Entity
,	PUNCT	O	O
nitrous	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
and	CCONJ	O	O
oxygen	NOUN	O	I-Entity
,	PUNCT	O	O
pancuronium	NOUN	O	I-Entity
0.4	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
suxamethonium	VERB	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
this	DET	O	O
a	DET	O	O
marked	ADJ	O	O
jaw	NOUN	O	B-Entity
stiffness	NOUN	O	I-Entity
occurred	VERB	O	O
which	ADJ	O	O
lasted	VERB	O	O
for	ADP	O	O
two	NUM	O	O
minutes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
anaesthesia	NOUN	O	O
were	VERB	O	O
terminated	VERB	O	O
.	PUNCT	O	O

Four	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
apnoea	NOUN	O	I-Entity
ensued	ADV	O	O
and	CCONJ	O	O
he	PRON	O	O
suffered	VERB	O	O
generalized	VERB	O	O
severe	ADJ	O	O
myalgia	NOUN	O	I-Entity
lasting	VERB	O	O
for	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
atypical	ADJ	O	O
plasma	NOUN	O	O
cholinesterase	NOUN	O	O
with	ADP	O	O
a	DET	O	O
dibucaine	NOUN	O	I-Entity
number	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
,	PUNCT	O	O
indicating	VERB	O	O
homozygocity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
prolonged	ADJ	O	B-Entity
jaw	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
after	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
atypical	ADJ	O	O
cholinesterase	NOUN	O	O
despite	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
pancuronium	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7411769)

Indomethacin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperkalemia	NOUN	O	I-Entity
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
gouty	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
three	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
severe	ADJ	O	O
,	PUNCT	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
hyperkalemia	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
developed	VERB	O	O
after	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
gouty	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
with	ADP	O	O
indomethacin	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
complication	NOUN	O	O
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
an	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthesis	NOUN	O	O
and	CCONJ	O	O
consequent	ADJ	O	O
hyporeninemic	ADJ	O	B-Entity
hypoaidosteronism	NOUN	O	I-Entity
.	PUNCT	O	O

Careful	ADJ	O	O
attention	NOUN	O	O
to	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
balance	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
indomethacin	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
those	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
or	CCONJ	O	O
preexisting	VERB	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
will	VERB	O	O
help	VERB	O	O
prevent	VERB	O	O
this	DET	O	O
potentially	ADV	O	O
serious	ADJ	O	O
complication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7457821)

Etomidate	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
foreshortened	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
etomidate	NOUN	O	I-Entity
for	ADP	O	O
outpatient	NOUN	O	O
cystoscopy	NOUN	O	O
was	VERB	O	O
embarked	VERB	O	O
upon	ADP	O	O
.	PUNCT	O	O

Unpremedicated	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
fentanyl	NOUN	O	I-Entity
1	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
etomidate	NOUN	O	I-Entity
0.3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

Anaesthesia	PROPN	O	O
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
intermittent	ADJ	O	O
etomidate	NOUN	O	I-Entity
in	ADP	O	O
2	NUM	O	O
-	SYM	O	O
4	NUM	O	O
mg	NUM	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Venous	ADJ	O	O
pain	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
68%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
50%	NUM	O	O
had	VERB	O	O
redness	NOUN	O	O
,	PUNCT	O	O
pain	NOUN	O	I-Entity
or	CCONJ	O	O
swelling	VERB	O	I-Entity
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
site	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
some	DET	O	O
cases	NOUN	O	O
lasting	VERB	O	O
up	PART	O	O
to	ADP	O	O
three	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Skeletal	ADJ	O	O
movements	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
;	PUNCT	O	O
30%	NUM	O	O
experienced	VERB	O	O
respiratory	ADJ	O	B-Entity
upset	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
sufficiently	ADV	O	O
severe	ADJ	O	O
to	PART	O	O
necessitate	VERB	O	O
abandoning	VERB	O	O
the	DET	O	O
technique	NOUN	O	O
.	PUNCT	O	O

Nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	VERB	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
40%	NUM	O	O
and	CCONJ	O	O
25%	NUM	O	O
had	VERB	O	O
disturbing	ADJ	O	O
emergence	NOUN	O	O
psychoses	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7477981)

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
are	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
fluoxetine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
seven	NUM	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
responsive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
challenge	NOUN	O	O
with	ADP	O	O
the	DET	O	O
mixed	VERB	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
,	PUNCT	O	O
apomorphine	NOUN	O	I-Entity
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
twice	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
11	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

After	ADP	O	O
fluoxetine	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
47%	NUM	O	O
improvement	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
without	ADP	O	O
modification	NOUN	O	O
of	ADP	O	O
parkinsonian	ADJ	O	I-Entity
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dyskinesias	NOUN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
predominantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
limbs	NOUN	O	O
during	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
and	CCONJ	O	O
disappearance	NOUN	O	O
of	ADP	O	O
dystonic	ADJ	O	B-Entity
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
onset-	ADJ	O	O
and	CCONJ	O	O
end	VERB	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dyskinesias	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
limbs	NOUN	O	O
during	ADP	O	O
choreic	NOUN	O	B-Entity
mid	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
dose	NOUN	O	I-Entity
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
increased	VERB	O	O
brain	NOUN	O	O
serotoninergic	ADJ	O	O
transmission	NOUN	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
may	VERB	O	O
reduce	VERB	O	O
levodopa-	PROPN	O	I-Entity
or	CCONJ	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
without	ADP	O	O
aggravating	VERB	O	O
parkinsonian	ADJ	O	I-Entity
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7479194)

A	DET	O	O
large	ADJ	O	O
population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
study	NOUN	O	O
of	ADP	O	O
trimethoprim	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
sulfamethoxazole	NOUN	O	I-Entity
,	PUNCT	O	O
trimethoprim	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cephalexin	NOUN	O	I-Entity
for	ADP	O	O
uncommon	ADJ	O	O
serious	ADJ	O	O
drug	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
45-day	ADJ	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
study	NOUN	O	O
of	ADP	O	O
232,390	NUM	O	O
people	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
prescribed	VERB	O	O
trimethoprim	ADV	O	B-Entity
-	PUNCT	O	I-Entity
sulfamethoxazole	NOUN	O	I-Entity
(	PUNCT	O	O
TMP	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
SMZ	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
266,951	NUM	O	O
prescribed	VERB	O	O
trimethoprim	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
196,397	NUM	O	O
prescribed	VERB	O	O
cephalexin	NOUN	O	I-Entity
,	PUNCT	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
liver	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
blood	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
skin	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
referral	NOUN	O	O
or	CCONJ	O	O
hospitalization	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	O
important	ADJ	O	O
idiopathic	ADJ	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
persons	NOUN	O	O
prescribed	VERB	O	O
TMP	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
SMZ	PROPN	O	I-Entity
(	PUNCT	O	O
5.2/100,000	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
those	DET	O	O
prescribed	VERB	O	O
trimethoprim	NOUN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
3.8/100,000	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
those	DET	O	O
prescribed	VERB	O	O
cephalexin	NOUN	O	I-Entity
was	VERB	O	O
somewhat	ADV	O	O
lower	ADJ	O	O
(	PUNCT	O	O
2.0/100,000	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Only	ADV	O	O
five	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
blood	NOUN	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
was	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
TMP	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
SMZ	PROPN	O	I-Entity
;	PUNCT	O	O
of	ADP	O	O
seven	NUM	O	O
with	ADP	O	O
erythema	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
four	NUM	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
TMP	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
SMZ	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	B-Entity
epidermal	ADJ	O	I-Entity
necrolysis	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
took	VERB	O	O
cephalexin	NOUN	O	I-Entity
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
parenchymal	ADJ	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
occurred	VERB	O	O
,	PUNCT	O	O
none	NOUN	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
study	NOUN	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7492040)

Clinical	ADJ	O	O
safety	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
MI	PROPN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
MI	PROPN	O	I-Entity
,	PUNCT	O	O
no	DET	O	O
patient	NOUN	O	O
died	VERB	O	O
;	PUNCT	O	O
exhibited	VERB	O	O
bradydysrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
;	PUNCT	O	O
or	CCONJ	O	O
experienced	VERB	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0%	NUM	O	O
to	PART	O	O
11%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Despite	ADP	O	O
theoretical	ADJ	O	O
concerns	NOUN	O	O
that	ADJ	O	O
lidocaine	VERB	O	I-Entity
may	VERB	O	O
enhance	VERB	O	O
cocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
MI	PROPN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
cardiovascular	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
central	ADJ	O	I-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7644931)

Paclitaxel	PROPN	O	I-Entity
3-hour	NUM	O	O
infusion	NOUN	O	O
given	VERB	O	O
alone	ADJ	O	O
and	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
carboplatin	NOUN	O	I-Entity
:	PUNCT	O	O
preliminary	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
escalation	NOUN	O	O
trials	NOUN	O	O
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity
(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
;	PUNCT	O	O
Bristol	PROPN	O	O
-	PUNCT	O	O
Myers	PROPN	O	O
Squibb	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O
by	ADP	O	O
3-hour	NUM	O	O
infusion	NOUN	O	O
was	VERB	O	O
combined	VERB	O	O
with	ADP	O	O
carboplatin	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
/	SYM	O	O
II	PROPN	O	O
study	NOUN	O	O
directed	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Carboplatin	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
at	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
target	NOUN	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
time	NOUN	O	O
curve	NOUN	O	O
of	ADP	O	O
6.0	NUM	O	O
by	ADP	O	O
the	DET	O	O
Calvert	PROPN	O	O
formula	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
paclitaxel	NOUN	O	I-Entity
was	VERB	O	O
escalated	VERB	O	O
in	ADP	O	O
patient	ADJ	O	O
cohorts	NOUN	O	O
from	ADP	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
(	PUNCT	O	O
dose	NOUN	O	O
level	NOUN	O	O
I	PRON	O	O
)	PUNCT	O	O
to	ADP	O	O
175	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
225	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
225	NUM	O	O
mg	ADV	O	O
/	SYM	O	O
m2	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
expanded	VERB	O	O
for	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
since	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
level	NOUN	O	O
achieved	VERB	O	O
(	PUNCT	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
required	VERB	O	O
modification	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
nonhematologic	ADJ	O	O
toxicities	NOUN	O	I-Entity
(	PUNCT	O	O
arthralgia	NOUN	O	I-Entity
and	CCONJ	O	O
sensory	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Toxicities	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
trial	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
alone	ADV	O	O
at	ADP	O	O
identical	ADJ	O	O
dose	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Carboplatin	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
add	VERB	O	O
to	ADP	O	O
the	DET	O	O
hematologic	ADJ	O	B-Entity
toxicities	NOUN	O	I-Entity
observed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O

the	DET	O	O
paclitaxel	NOUN	O	I-Entity
/	SYM	O	O
carboplatin	NOUN	O	I-Entity
combination	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
dosed	VERB	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7661171)

The	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
on	ADP	O	O
indomethacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADV	O	O
well	ADV	O	O
compensated	VERB	O	O
cirrhosis	NOUN	O	I-Entity
.	PUNCT	O	O

Misoprostol	PROPN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
acutely	ADV	O	O
counteract	VERB	O	O
the	DET	O	O
indomethacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADV	O	O
well	ADV	O	O
compensated	VERB	O	O
cirrhotic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
was	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
.	PUNCT	O	O

Parameters	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
hemodynamics	NOUN	O	O
and	CCONJ	O	O
tubular	ADJ	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
water	NOUN	O	O
handling	VERB	O	O
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
clearance	NOUN	O	O
techniques	NOUN	O	O
in	ADP	O	O
26	NUM	O	O
well	ADV	O	O
compensated	VERB	O	O
cirrhotic	ADJ	O	I-Entity
patients	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
indomethacin	NOUN	O	I-Entity
and	CCONJ	O	O
various	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
200-micrograms	NUM	O	O
dose	NOUN	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
totally	ADV	O	O
abolish	VERB	O	O
the	DET	O	O
deleterious	ADJ	O	O
renal	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
800-micrograms	NUM	O	O
dose	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
worsening	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
hemodynamics	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
is	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
until	ADP	O	O
this	DET	O	O
apparent	ADJ	O	O
ability	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
micrograms	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
the	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
is	VERB	O	O
confirmed	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
frequent	ADJ	O	O
dosing	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
would	VERB	O	O
be	VERB	O	O
prudent	ADJ	O	O
to	PART	O	O
avoid	VERB	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cirrhosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7671401)

Increased	ADJ	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
angio	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
oedema	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
inhibitor	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
drugs	NOUN	O	O
are	VERB	O	O
well	ADV	O	O
recognized	VERB	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
or	CCONJ	O	O
chronic	ADJ	O	O
urticaria	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
angio	ADV	O	B-Entity
-	PUNCT	O	I-Entity
oedema	NOUN	O	I-Entity
.	PUNCT	O	O

Angiotensin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
ACE	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
inhibitors	NOUN	O	I-Entity
,	PUNCT	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
introduced	VERB	O	O
in	ADP	O	O
Europe	PROPN	O	O
in	ADP	O	O
the	DET	O	O
middle	NOUN	O	O
of	ADP	O	O
the	DET	O	O
eighties	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
has	VERB	O	O
increased	VERB	O	O
progressively	ADV	O	O
.	PUNCT	O	O

Soon	ADV	O	O
after	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
ACE	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	O
bouts	NOUN	O	O
of	ADP	O	O
angio	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
oedema	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
wish	VERB	O	O
to	PART	O	O
draw	VERB	O	O
attention	NOUN	O	O
to	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
ACE	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
after	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
angio	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
oedema	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7727612)

Myoclonus	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
lorazepam	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
very	ADV	O	O
-	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
birth	NOUN	O	O
-	PUNCT	O	O
weight	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Lorazepam	PROPN	O	I-Entity
is	VERB	O	O
being	VERB	O	O
used	VERB	O	O
with	ADP	O	O
increasing	VERB	O	O
frequency	NOUN	O	O
as	ADP	O	O
a	DET	O	O
sedative	NOUN	O	O
in	ADP	O	O
the	DET	O	O
newborn	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
young	ADJ	O	O
infant	NOUN	O	O
.	PUNCT	O	O

Concern	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
raised	VERB	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
lorazepam	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
very	ADV	O	O
-	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
birth	NOUN	O	O
-	PUNCT	O	O
weight	NOUN	O	O
(	PUNCT	O	O
VLBW	PROPN	O	O
;	PUNCT	O	O
<	X	O	O
1,500	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
young	ADJ	O	O
infants	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
birth	NOUN	O	O
weight	NOUN	O	O
<	SYM	O	O
1,500	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
experienced	VERB	O	O
myoclonus	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lorazepam	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
potential	ADJ	O	O
neurotoxic	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
vehicle	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Injectable	ADJ	O	O
lorazepam	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
in	ADP	O	O
VLBW	PROPN	O	O
infants	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7739955)

right	ADV	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
during	ADP	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
of	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
efforts	NOUN	O	O
on	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
in	ADP	O	O
acute	ADJ	O	O
circulatory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
from	ADP	O	O
myocardial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
acute	ADJ	O	O
viral	ADJ	O	O
myocarditis	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
had	VERB	O	O
a	DET	O	O
carbamazepine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
eosinophilic	NOUN	O	B-Entity
myocarditis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
had	VERB	O	O
cardiac	NOUN	O	O
hemosiderosis	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
acute	ADJ	O	O
cardiogenic	ADJ	O	B-Entity
shock	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
introducer	NOUN	O	O
sheath	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
pacemaker	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sterile	ADJ	O	O
pacing	NOUN	O	O
wires	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
readily	ADV	O	O
available	ADJ	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
should	VERB	O	O
the	DET	O	O
need	NOUN	O	O
arise	VERB	O	O
to	PART	O	O
terminate	VERB	O	O
resistant	ADJ	O	O
cardiac	ADJ	O	O
dysrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
cardiocirculatory	ADJ	O	O
arrest	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
extreme	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
dysrhythmias	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
48	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
admission	NOUN	O	O
to	ADP	O	O
the	DET	O	O
pediatric	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
(	PUNCT	O	O
PICU	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
second	ADJ	O	O
event	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
death	NOUN	O	O
,	PUNCT	O	O
within	ADP	O	O
10	NUM	O	O
to	PART	O	O
60	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
cardiac	ADJ	O	O
pacing	NOUN	O	O
during	ADP	O	O
resuscitative	ADJ	O	O
efforts	NOUN	O	O
in	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
have	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
value	NOUN	O	O
in	ADP	O	O
and	CCONJ	O	O
of	ADP	O	O
itself	PRON	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
if	ADP	O	O
temporary	ADJ	O	O
hemodynamic	ADJ	O	O
stability	NOUN	O	O
is	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
this	DET	O	O
procedure	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
provide	VERB	O	O
additional	ADJ	O	O
time	NOUN	O	O
needed	VERB	O	O
to	PART	O	O
institute	VERB	O	O
other	ADJ	O	O
therapeutic	ADJ	O	O
modalities	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7931490)

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
granisetron	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
5-hydroxytryptamine-3	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
the	DET	O	O
antiemetic	ADJ	O	O
effects	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
granisetron	NOUN	O	I-Entity
(	PUNCT	O	O
Kytril	PROPN	O	I-Entity
;	PUNCT	O	O
SmithKline	PROPN	O	O
Beecham	PROPN	O	O
Pharmaceuticals	PROPN	O	O
,	PUNCT	O	O
Philadelphia	PROPN	O	O
,	PUNCT	O	O
PA	PROPN	O	O
)	PUNCT	O	O
when	ADV	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
intravenous	NOUN	O	O
(	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
dose	NOUN	O	O
for	ADP	O	O
prophylaxis	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
eighty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
naive	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
81	NUM	O	O
to	PART	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
one	NUM	O	O
of	ADP	O	O
four	NUM	O	O
granisetron	NOUN	O	I-Entity
doses	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
40	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
before	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
on	ADP	O	O
an	DET	O	O
inpatient	ADJ	O	O
basis	NOUN	O	O
for	ADP	O	O
18	NUM	O	O
to	PART	O	O
24	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vital	ADJ	O	O
signs	NOUN	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
,	PUNCT	O	O
retching	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
appetite	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
granisetron	NOUN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
40	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
a	DET	O	O
major	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
<	PUNCT	O	O
or	CCONJ	O	O
=	NUM	O	O
two	NUM	O	O
vomiting	NOUN	O	I-Entity
or	CCONJ	O	O
retching	VERB	O	O
episodes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
antiemetic	ADJ	O	O
rescue	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
23%	NUM	O	O
,	PUNCT	O	O
57%	NUM	O	O
,	PUNCT	O	O
58%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
60%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
complete	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
no	DET	O	O
vomiting	NOUN	O	I-Entity
or	CCONJ	O	O
retching	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
antiemetic	ADJ	O	O
rescue	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
18%	NUM	O	O
,	PUNCT	O	O
41%	NUM	O	O
,	PUNCT	O	O
40%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
47%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
longer	ADJ	O	O
time	NOUN	O	O
to	PART	O	O
first	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0015	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fewer	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
additional	ADJ	O	O
antiemetic	ADJ	O	O
medication	NOUN	O	O
in	ADP	O	O
the	DET	O	O
10-micrograms	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
dosing	VERB	O	O
groups	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
5-micrograms	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
dosing	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
granisetron	NOUN	O	I-Entity
dose	NOUN	O	O
increased	VERB	O	O
,	PUNCT	O	O
appetite	NOUN	O	O
return	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.040	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Headache	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
frequently	ADV	O	O
reported	VERB	O	O
adverse	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
20%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
10-	NOUN	O	O
,	PUNCT	O	O
20-	PROPN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
40-micrograms	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
dose	NOUN	O	O
of	ADP	O	O
granisetron	NOUN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
controlling	VERB	O	O
vomiting	VERB	O	I-Entity
in	ADP	O	O
57%	NUM	O	O
to	PART	O	O
60%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
cisplatin	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
81	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
totally	ADV	O	O
prevented	VERB	O	O
vomiting	VERB	O	I-Entity
in	ADP	O	O
40%	NUM	O	O
to	PART	O	O
47%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Granisetron	PROPN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
at	ADP	O	O
all	DET	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7949506)

Adverse	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
adverse	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
atrioventricular	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
AV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
block	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
hyperaldosteronism	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
verapamil	ADV	O	I-Entity
480	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
and	CCONJ	O	O
spironolactone	NOUN	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
minimal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
0.15	NUM	O	O
mg	NUM	O	O
bid	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
she	PRON	O	O
developed	VERB	O	O
complete	ADJ	O	O
AV	NOUN	O	B-Entity
block	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
resolved	VERB	O	O
upon	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
all	DET	O	O
medications	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
65-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
extended	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
verapamil	ADV	O	I-Entity
240	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
0.15	NUM	O	O
mg	NUM	O	O
bid	NOUN	O	O
she	PRON	O	O
developed	VERB	O	O
complete	ADJ	O	O
AV	NOUN	O	B-Entity
block	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
resolved	VERB	O	O
after	ADP	O	O
all	DET	O	O
therapy	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
An	DET	O	O
adverse	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

Caution	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
in	ADP	O	O
combining	VERB	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
have	VERB	O	O
sinus	NOUN	O	O
or	CCONJ	O	O
AV	NOUN	O	O
node	NOUN	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7967231)

Pharmacological	ADJ	O	O
studies	NOUN	O	O
on	ADP	O	O
a	DET	O	O
new	ADJ	O	O
dihydrothienopyridine	NOUN	O	B-Entity
calcium	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
S-312-d	PROPN	O	I-Entity
.	PUNCT	O	O

S-312	NOUN	O	I-Entity
,	PUNCT	O	O
S-312-d	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
S-312-l	PROPN	O	I-Entity
,	PUNCT	O	O
L	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
anticonvulsant	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
audiogenic	ADJ	O	B-Entity
tonic	NOUN	O	I-Entity
convulsions	NOUN	O	I-Entity
in	ADP	O	O
DBA/2	PROPN	O	O
mice	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
ED50	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
18.4	NUM	O	O
(	PUNCT	O	O
12.8	NUM	O	O
-	SYM	O	O
27.1	NUM	O	O
)	PUNCT	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O

and	CCONJ	O	O
15.0	NUM	O	O
(	PUNCT	O	O
10.2	NUM	O	O
-	SYM	O	O
23.7	NUM	O	O
)	PUNCT	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
that	DET	O	O
of	ADP	O	O
flunarizine	NOUN	O	I-Entity
was	VERB	O	O
34.0	NUM	O	O
(	PUNCT	O	O
26.0	NUM	O	O
-	SYM	O	O
44.8	NUM	O	O

Although	ADP	O	O
moderate	ADJ	O	O
anticonvulsant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
S-312-d	PROPN	O	I-Entity
in	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
against	ADP	O	O
the	DET	O	O
clonic	ADJ	O	O
convulsions	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
85	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
bemegride	NOUN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
no	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
convulsions	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
N	NUM	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
electroshock	NOUN	O	O
in	ADP	O	O
Slc	PROPN	O	O
:	PUNCT	O	O
ddY	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

S-312-d	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
of	ADP	O	O
certain	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8096565)

Transmural	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
with	ADP	O	O
sumatriptan	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
sumatriptan	NOUN	O	I-Entity
,	PUNCT	O	O
tightness	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chest	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
an	DET	O	O
unknown	ADJ	O	O
mechanism	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
3	NUM	O	O
-	PUNCT	O	O
5%	NUM	O	O
of	ADP	O	O
users	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
sumatriptan	ADJ	O	I-Entity
6	NUM	O	O
mg	NUM	O	O
subcutaneously	NOUN	O	O
for	ADP	O	O
cluster	NOUN	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
underlying	VERB	O	O
ischaemic	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
or	CCONJ	O	O
Prinzmetal	PROPN	O	B-Entity
's	PART	O	I-Entity
angina	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8135424)

Flumazenil	PROPN	O	I-Entity
induces	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	O
in	ADP	O	O
mixed	ADJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
diazepam	NOUN	O	I-Entity
intoxications	NOUN	O	O
.	PUNCT	O	O

Administration	PROPN	O	O
of	ADP	O	O
the	DET	O	O
benzodiazepine	NOUN	O	I-Entity
antagonist	NOUN	O	O
flumazenil	NOUN	O	I-Entity
may	VERB	O	O
unmask	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
mixed	ADJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
benzodiazepine	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
received	VERB	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
cocaine	NOUN	O	I-Entity
IP	PROPN	O	O
alone	ADV	O	O
,	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
diazepam	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
minutes	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
groups	NOUN	O	O
were	VERB	O	O
challenged	VERB	O	O
with	ADP	O	O
vehicle	NOUN	O	O
or	CCONJ	O	O
flumazenil	NOUN	O	I-Entity
5	NUM	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
IP	PROPN	O	O
.	PUNCT	O	O

Animal	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
(	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
death	NOUN	O	O
(	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cortical	ADJ	O	O
EEG	PROPN	O	O
tracings	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
flumazenil	NOUN	O	I-Entity
to	ADP	O	O
animals	NOUN	O	O
after	ADP	O	O
they	PRON	O	O
had	VERB	O	O
received	VERB	O	O
a	DET	O	O
combination	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
animals	NOUN	O	O
received	VERB	O	O
cocaine	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
resulted	VERB	O	O
in	ADP	O	O
100%	NUM	O	O
developing	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
2	NUM	O	O
received	VERB	O	O
diazepam	NOUN	O	I-Entity
alone	ADV	O	O
followed	VERB	O	O
by	ADP	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
3	NUM	O	O
received	VERB	O	O
diazepam	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
flumazenil	NOUN	O	I-Entity
.	PUNCT	O	O

Animals	NOUN	O	O
became	VERB	O	O
somnolent	ADJ	O	O
after	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
then	ADV	O	O
active	ADJ	O	O
after	ADP	O	O
flumazenil	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
resulted	VERB	O	O
in	ADP	O	O
no	DET	O	O
overt	ADJ	O	O
or	CCONJ	O	O
EEG	PROPN	O	O
-	PUNCT	O	O
detectable	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
50%	NUM	O	O
incidence	NOUN	O	O
of	ADP	O	O
death	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
5	NUM	O	O
received	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
followed	VERB	O	O
later	ADV	O	O
by	ADV	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
flumazenil	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
90%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	O
,	PUNCT	O	O
100%	NUM	O	O

Group	PROPN	O	O
6	NUM	O	O
received	VERB	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
10	NUM	O	O
mg	NUM	O	O

/	SYM	O	O
kg	X	O	O
flumazenil	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
also	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
90%	NUM	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Flumazenil	PROPN	O	I-Entity
can	VERB	O	O
unmask	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
increase	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
death	NOUN	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
diazepam	NOUN	O	I-Entity
intoxications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8160791)

Mechanisms	PROPN	O	O
for	ADP	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
radical	ADJ	O	O
scavengers	NOUN	O	O
on	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
for	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
radical	ADJ	O	O
scavengers	NOUN	O	O
on	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
GM)-mediated	VERB	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
GM	PROPN	O	I-Entity
at	ADP	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
sc	NOUN	O	O
for	ADP	O	O
13	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
rats	NOUN	O	O
induced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
RBF	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
inulin	NOUN	O	O
clearance	NOUN	O	O
(	PUNCT	O	O
CIn	PROPN	O	O
)	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
marked	ADJ	O	O
tubular	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
guanosine	NOUN	O	B-Entity
3',5'-cyclic	NUM	O	I-Entity
monophosphate	NOUN	O	I-Entity
(	PUNCT	O	O
cGMP	PROPN	O	I-Entity
)	PUNCT	O	O
excretion	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
renin	NOUN	O	O
and	CCONJ	O	O
endothelin-1	ADJ	O	O
contents	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Superoxide	ADJ	O	I-Entity
dismutase	NOUN	O	O
(	PUNCT	O	O
SOD	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
dimethylthiourea	NOUN	O	I-Entity
(	PUNCT	O	O
DMTU	PROPN	O	I-Entity
)	PUNCT	O	O
significantly	ADV	O	O
lessened	VERB	O	O
the	DET	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
decrement	NOUN	O	O
in	ADP	O	O
CIn	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
SOD	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
marked	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
RBF	PROPN	O	O
,	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
cGMP	PROPN	O	I-Entity
excretion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
renin	NOUN	O	O
and	CCONJ	O	O
endothelin-1	NOUN	O	O
content	NOUN	O	O
.	PUNCT	O	O

SOD	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
attenuate	VERB	O	O
the	DET	O	O
tubular	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
DMTU	PROPN	O	I-Entity
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
tubular	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
lipid	NOUN	O	O
peroxidation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
renal	ADJ	O	O
hemodynamics	NOUN	O	O
and	CCONJ	O	O
vasoactive	ADJ	O	O
substances	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
SOD	PROPN	O	O
nor	CCONJ	O	O
DMTU	PROPN	O	I-Entity
affected	VERB	O	O
the	DET	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
GM	PROPN	O	I-Entity
content	NOUN	O	O
in	ADP	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
1	PUNCT	O	O
)	PUNCT	O	O
both	CCONJ	O	O
SOD	PROPN	O	O
and	CCONJ	O	O
DMTU	PROPN	O	I-Entity
have	VERB	O	O
protective	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
mechanisms	NOUN	O	O
for	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
effects	NOUN	O	O
differ	VERB	O	O
for	ADP	O	O
SOD	PROPN	O	O
and	CCONJ	O	O
DMTU	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
)	PUNCT	O	O
superoxide	NOUN	O	I-Entity
anions	NOUN	O	O
play	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	O
vasoconstriction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8184922)

Assessment	PROPN	O	O
of	ADP	O	O
cardiomyocyte	NOUN	O	O
DNA	PROPN	O	O
synthesis	NOUN	O	O
during	ADP	O	O
hypertrophy	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
cardiomyocytes	NOUN	O	O
to	PART	O	O
synthesize	VERB	O	O
DNA	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	PART	O	O
experimentally	ADV	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Isoproterenol	PROPN	O	I-Entity
delivered	VERB	O	O
by	ADP	O	O
osmotic	ADJ	O	O
minipump	NOUN	O	O
implantation	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
C3Heb	PROPN	O	O
/	SYM	O	O
FeJ	PROPN	O	O
mice	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
46%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
weight	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
19.3%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
cardiomyocyte	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
DNA	NOUN	O	O
synthesis	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
assessed	VERB	O	O
by	ADP	O	O
autoradiographic	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
isolated	ADJ	O	O
cardiomyocytes	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
control	NOUN	O	O
or	CCONJ	O	O
hypertrophic	ADJ	O	B-Entity
hearts	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
capacity	NOUN	O	O
for	ADP	O	O
reactive	ADJ	O	O
DNA	NOUN	O	O
synthesis	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
subject	ADJ	O	O
to	ADP	O	O
genetic	ADJ	O	O
regulation	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
the	DET	O	O
strains	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
comprising	VERB	O	O
the	DET	O	O
extremes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nuclear	ADJ	O	O
number	NOUN	O	O
survey	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
adult	NOUN	O	O
mouse	NOUN	O	O
atrial	NOUN	O	O
and	CCONJ	O	O
ventricular	ADJ	O	O
cardiomyocytes	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
synthesize	VERB	O	O
DNA	PROPN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8188982)

Central	ADJ	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
ANP	PROPN	O	O
in	ADP	O	O
normotensive	ADJ	O	O
and	CCONJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
compare	VERB	O	O
influence	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
(	PUNCT	O	O
AVP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
atrial	ADJ	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
ANP	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
normotensive	NOUN	O	O
(	PUNCT	O	O
WKY	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
(	PUNCT	O	O
SHR	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

injections	NOUN	O	O
of	ADP	O	O
either	DET	O	O
vehicle	NOUN	O	O
or	CCONJ	O	O
1	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
ng	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
25	NUM	O	O
,	PUNCT	O	O
125	NUM	O	O
and	CCONJ	O	O
500	NUM	O	O
ng	NOUN	O	O
of	ADP	O	O
ANP	PROPN	O	O
.	PUNCT	O	O

Sensitivity	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
component	NOUN	O	O
of	ADP	O	O
baroreflex	NOUN	O	O
(	PUNCT	O	O
CCB	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
expressed	VERB	O	O
as	ADP	O	O
a	DET	O	O
slope	NOUN	O	O
of	ADP	O	O
the	DET	O	O
regression	NOUN	O	O
line	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
relationships	NOUN	O	O
between	ADP	O	O
systolic	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
SAP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
HR	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
HRp	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
phenylephrine	NOUN	O	I-Entity
(	PUNCT	O	O
Phe)-induced	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SN)-induced	VERB	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

CCB	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
either	DET	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
AVP	PROPN	O	I-Entity
,	PUNCT	O	O
ANP	PROPN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
peptides	NOUN	O	O
together	ADV	O	O
.	PUNCT	O	O

Increases	NOUN	O	O
of	ADP	O	O
MAP	PROPN	O	O
occurred	VERB	O	O
after	ADP	O	O
LV	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
ng	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
in	ADP	O	O
WKY	PROPN	O	O
and	CCONJ	O	O
of	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
ng	NOUN	O	O
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

ANP	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
in	ADP	O	O
both	DET	O	O
strains	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
abolished	VERB	O	O
AVP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
MAP	PROPN	O	O
increase	NOUN	O	O
in	ADP	O	O
WKY	PROPN	O	O
and	CCONJ	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

CCB	PROPN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
WKY	PROPN	O	O
and	CCONJ	O	O
SHR	PROPN	O	O
after	ADP	O	O
LV	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
during	ADP	O	O
SN	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
SHR	PROPN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
WKY	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
ANP	PROPN	O	O
,	PUNCT	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
ANP	PROPN	O	O
+	PROPN	O	O
AVP	PROPN	O	I-Entity
decreased	VERB	O	O
CCB	PROPN	O	O
during	ADP	O	O
Phe	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
MAP	PROPN	O	O
elevation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
centrally	ADV	O	O
applied	VERB	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
ANP	PROPN	O	O
exert	VERB	O	O
differential	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
baroreflex	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
WKY	PROPN	O	O
and	CCONJ	O	O
SHR	PROPN	O	O
and	CCONJ	O	O
suggest	VERB	O	O
interaction	NOUN	O	O
of	ADP	O	O
these	DET	O	O
two	NUM	O	O
peptides	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
regulation	NOUN	O	O
at	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8308951)

Cutaneous	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
warfarin	VERB	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
anticoagulant	NOUN	O	O
causing	VERB	O	O
an	DET	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
intercerebral	ADJ	O	O
hematoma	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coagulopathy	NOUN	O	I-Entity
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
39-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
had	VERB	O	O
spread	VERB	O	O
a	DET	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
type	NOUN	O	O
rat	NOUN	O	O
poison	NOUN	O	O
around	ADP	O	O
her	ADJ	O	O
house	NOUN	O	O
weekly	ADV	O	O
using	VERB	O	O
her	ADJ	O	O
bare	ADJ	O	O
hands	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
washing	NOUN	O	O
post	NOUN	O	O
application	NOUN	O	O
.	PUNCT	O	O

Percutaneous	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
causing	VERB	O	O
coagulopathy	NOUN	O	I-Entity
,	PUNCT	O	O
reported	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
in	ADP	O	O
the	DET	O	O
past	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
risk	NOUN	O	O
if	ADP	O	O
protective	ADJ	O	O
measures	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
gloves	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
not	ADV	O	O
used	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
with	ADP	O	O
piroxicam	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
she	PRON	O	O
took	VERB	O	O
occasionally	ADV	O	O
,	PUNCT	O	O
may	VERB	O	O
have	VERB	O	O
exacerbated	VERB	O	O
the	DET	O	O
coagulopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8312343)

Pediatric	ADJ	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
without	ADP	O	O
chronic	ADJ	O	O
maintenance	NOUN	O	O
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

Indications	NOUN	O	O
for	ADP	O	O
transplantation	NOUN	O	O
were	VERB	O	O
idiopathic	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
52%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
congenital	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
35%	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
prior	ADJ	O	O
repair	NOUN	O	O
(	PUNCT	O	O
71%	NUM	O	O
and	CCONJ	O	O
29%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypertrophic	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
3%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
doxorubicin	VERB	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
managed	VERB	O	O
with	ADP	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
azathioprine	NOUN	O	I-Entity
.	PUNCT	O	O

Steroids	NOUN	O	I-Entity
were	VERB	O	O
given	VERB	O	O
to	ADP	O	O
39%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
for	ADP	O	O
refractory	ADJ	O	O
rejection	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
weaning	VERB	O	O
was	VERB	O	O
always	ADV	O	O
attempted	VERB	O	O
and	CCONJ	O	O
generally	ADV	O	O
successful	ADJ	O	O
(	PUNCT	O	O
64%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
14%	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
maintenance	NOUN	O	O
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
have	VERB	O	O
been	VERB	O	O
no	DET	O	O
deaths	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
rejection	NOUN	O	O
or	CCONJ	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Freedom	NOUN	O	O
from	ADP	O	O
serious	ADJ	O	O
infections	NOUN	O	I-Entity
was	VERB	O	O
83%	NUM	O	O
at	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
and	CCONJ	O	O
65%	NUM	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Cytomegalovirus	PROPN	O	B-Entity
infections	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
successfully	ADV	O	O
with	ADP	O	O
ganciclovir	NOUN	O	I-Entity
in	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
60%	NUM	O	O
)	PUNCT	O	O
have	VERB	O	O
undergone	VERB	O	O
annual	ADJ	O	O
catheterizations	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
sign	NOUN	O	O
of	ADP	O	O
graft	NOUN	O	O
atherosclerosis	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
14%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hypertension	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
28%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
disabled	ADJ	O	O
and	CCONJ	O	O
no	DET	O	O
lymphoproliferative	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
was	VERB	O	O
observed.(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (8312983)

Delirium	NOUN	O	I-Entity
during	ADP	O	O
fluoxetine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
a	DET	O	O
few	ADJ	O	O
reports	NOUN	O	O
exist	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
SSRIs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
some	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
high	ADJ	O	O
serum	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
citalopram	NOUN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
600	NUM	O	O
nmol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
somnolence	NOUN	O	I-Entity
and	CCONJ	O	O
movement	NOUN	O	B-Entity
difficulties	NOUN	O	I-Entity
.	PUNCT	O	O

Widespread	ADJ	O	O
cognitive	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
delirium	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
linked	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
blood	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
SSRIs	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
hyperkinetic	ADJ	O	I-Entity
delirium	NOUN	O	I-Entity
connected	VERB	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
serum	NOUN	O	O
total	ADJ	O	O
fluoxetine	NOUN	O	I-Entity
(	PUNCT	O	O
fluoxetine	NOUN	O	I-Entity
plus	CCONJ	O	O
desmethylfluoxetine	NOUN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8318674)

Pulmonary	PROPN	O	B-Entity
edema	NOUN	O	I-Entity
and	CCONJ	O	O
shock	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
aracytine	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
C	PROPN	O	I-Entity
for	ADP	O	O
lymphoma	NOUN	O	I-Entity
;	PUNCT	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
and	CCONJ	O	O
PAF	PROPN	O	O
.	PUNCT	O	O

Four	NUM	O	O
out	ADP	O	O
of	ADP	O	O
23	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
Ara	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
C	PROPN	O	I-Entity
for	ADP	O	O
lymphomas	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
institution	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
strikingly	ADV	O	O
similar	ADJ	O	O
syndrome	NOUN	O	O
during	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
shock	NOUN	O	I-Entity
,	PUNCT	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
metabolic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
and	CCONJ	O	O
leukocytosis	NOUN	O	I-Entity
.	PUNCT	O	O

Thorough	PROPN	O	O
bacteriological	ADJ	O	O
screening	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
provide	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Sequential	ADJ	O	O
biological	ADJ	O	O
assays	NOUN	O	O
of	ADP	O	O
IL-1	PROPN	O	O
,	PUNCT	O	O
IL-2	PROPN	O	O
,	PUNCT	O	O
TNF	PROPN	O	O
and	CCONJ	O	O
PAF	PROPN	O	O
were	VERB	O	O
performed	VERB	O	O
during	ADP	O	O
Ara	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
C	PROPN	O	I-Entity
infusion	NOUN	O	O
to	ADP	O	O
ten	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
four	NUM	O	O
who	NOUN	O	O
developed	VERB	O	O
the	DET	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
TNF	PROPN	O	O
and	CCONJ	O	O
PAF	PROPN	O	O
are	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
septic	ADJ	O	O
shock	NOUN	O	I-Entity
and	CCONJ	O	O
adult	NOUN	O	B-Entity
respiratory	ADJ	O	I-Entity
distress	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
hypothesize	VERB	O	O
that	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
Ara	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
C	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
cytokine	NOUN	O	O
release	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8392553)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
clentiazem	NOUN	O	I-Entity
against	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
clentiazem	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
1,5-benzothiazepine	NUM	O	I-Entity
calcium	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
2-week	NUM	O	O
chronic	ADJ	O	O
epinephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
of	ADP	O	O
30	NUM	O	O
rats	NOUN	O	O
died	VERB	O	O
within	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
ischemic	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
and	CCONJ	O	O
fibrosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
ventricles	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
atrial	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
papillary	ADJ	O	O
muscle	NOUN	O	O
contractile	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
isoproterenol	NOUN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
responses	NOUN	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
were	VERB	O	O
normal	ADJ	O	O
or	CCONJ	O	O
enhanced	ADJ	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
clentiazem	NOUN	O	I-Entity
prevented	VERB	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
death	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O

.05	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
attenuated	VERB	O	O
the	DET	O	O
ventricular	ADJ	O	O
ischemic	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
and	CCONJ	O	O
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O
Left	VERB	O	O
atrial	ADJ	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
papillary	ADJ	O	O
muscle	NOUN	O	O
contractile	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
isoproterenol	NOUN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
in	ADP	O	O
groups	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
clentiazem	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
clentiazem	NOUN	O	I-Entity
restored	VERB	O	O
left	VERB	O	O
atrial	ADJ	O	O
responses	NOUN	O	O
and	CCONJ	O	O
enhanced	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
papillary	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
isoproterenol	VERB	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
clentiazem	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
adrenoceptors	NOUN	O	O
.	PUNCT	O	O

Interestingly	ADV	O	O
,	PUNCT	O	O
clentiazem	NOUN	O	I-Entity
,	PUNCT	O	O
infused	VERB	O	O
alone	ADV	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
decreased	ADJ	O	O
adrenergic	ADJ	O	O
receptor	NOUN	O	O
densities	NOUN	O	O
in	ADP	O	O
the	DET	O	O
left	NOUN	O	O
ventricle	NOUN	O	O
.	PUNCT	O	O

Clentiazem	PROPN	O	I-Entity
also	ADV	O	O
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
the	DET	O	O
enhanced	VERB	O	O
responses	NOUN	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
clentiazem	NOUN	O	I-Entity
partially	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
maximal	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
clentiazem	NOUN	O	I-Entity
attenuated	ADJ	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
possibly	ADV	O	O
through	ADP	O	O
its	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
adrenergic	ADJ	O	O
pathway	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8511251)

Cocaine	PROPN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
ischemia	NOUN	O	I-Entity
probably	ADV	O	O
induced	VERB	O	O
by	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
and	CCONJ	O	O
calcium	NOUN	O	I-Entity
blocking	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8603459)

Doxorubicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
monitored	VERB	O	O
by	ADP	O	O
ECG	PROPN	O	O
in	ADP	O	O
freely	ADV	O	O
moving	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
laboratory	NOUN	O	O
animals	NOUN	O	O
,	PUNCT	O	O
histology	NOUN	O	O
is	VERB	O	O
most	ADV	O	O
commonly	ADV	O	O
used	VERB	O	O
to	PART	O	O
study	VERB	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
this	DET	O	O
model	NOUN	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
doxorubicin	ADJ	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
ECG	PROPN	O	O
of	ADP	O	O
freely	ADV	O	O
moving	VERB	O	O
BALB	PROPN	O	O
/	SYM	O	O
c	X	O	O
mice	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
ICRF-187	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
protective	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

11.8	NUM	O	O
ms	NOUN	O	O
in	ADP	O	O
week	NOUN	O	O
10	NUM	O	O
(	PUNCT	O	O
7	NUM	O	O
weekly	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
doxorubicin	NOUN	O	I-Entity
given	VERB	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
sacrifice	NOUN	O	O
the	DET	O	O
hearts	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
were	VERB	O	O
enlarged	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
atria	NOUN	O	O
were	VERB	O	O
hypertrophic	ADJ	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
this	DET	O	O
schedule	NOUN	O	O
exerted	VERB	O	O
more	ADJ	O	O
toxicity	NOUN	O	I-Entity
than	ADP	O	O
needed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
protective	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
protection	NOUN	O	O
of	ADP	O	O
ICRF-187	PROPN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
schedule	NOUN	O	O
with	ADP	O	O
lower	ADJ	O	O
general	ADJ	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
6	NUM	O	O
weekly	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
doxorubicin	NOUN	O	I-Entity
given	VERB	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
this	DET	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
animals	NOUN	O	O
'	PART	O	O
hearts	NOUN	O	O
appeared	VERB	O	O
normal	ADJ	O	O
after	ADP	O	O
sacrifice	NOUN	O	O
and	CCONJ	O	O
ICRF-187	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
given	VERB	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
doxorubicin	NOUN	O	I-Entity
)	PUNCT	O	O
provided	VERB	O	O
almost	ADV	O	O
full	ADJ	O	O
protection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
this	DET	O	O
new	ADJ	O	O
model	NOUN	O	O
is	VERB	O	O
very	ADV	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
enables	VERB	O	O
monitoring	NOUN	O	O
of	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
with	ADP	O	O
time	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
result	VERB	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
that	ADJ	O	O
allows	VERB	O	O
the	DET	O	O
testing	NOUN	O	O
of	ADP	O	O
protectors	NOUN	O	O
against	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
as	ADP	O	O
demonstrated	VERB	O	O
by	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
ICRF-187	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8659767)

Epinephrine	PROPN	O	I-Entity
dysrhythmogenicity	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
enhanced	VERB	O	O
by	ADP	O	O
subtoxic	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
bupivacaine	NOUN	O	I-Entity
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
may	VERB	O	O
both	DET	O	O
precipitate	VERB	O	O
dysrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
circulating	VERB	O	O
bupivacaine	NOUN	O	I-Entity
during	ADP	O	O
regional	ADJ	O	O
anesthesia	NOUN	O	O
could	VERB	O	O
potentiate	VERB	O	O
dysrhythmogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
examined	VERB	O	O
whether	ADP	O	O
bupivacaine	NOUN	O	I-Entity
alters	VERB	O	O
the	DET	O	O
dysrhythmogenicity	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
,	PUNCT	O	O
healthy	ADJ	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
anesthetized	ADJ	O	O
dogs	NOUN	O	O
with	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
conscious	ADJ	O	O
dogs	NOUN	O	O
received	VERB	O	O
10	NUM	O	O
micrograms.kg-1.min-1	ADJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Seventeen	NUM	O	O
animals	NOUN	O	O
responded	VERB	O	O
with	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
(	PUNCT	O	O
VT	PROPN	O	I-Entity
)	PUNCT	O	O
within	ADP	O	O
3	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
3	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
responders	NOUN	O	O
randomly	ADV	O	O
received	VERB	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
bupivacaine	NOUN	O	I-Entity
or	CCONJ	O	O
saline	NOUN	O	O
over	ADP	O	O
5	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
10	NUM	O	O
micrograms.kg-1.min-1	ADJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
bupivacaine	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
caused	VERB	O	O
fewer	ADJ	O	O
prodysrhythmic	ADJ	O	O
effects	NOUN	O	O
than	ADP	O	O
without	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

VT	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
fewer	ADJ	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
a	DET	O	O
later	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	ADV	O	O
were	VERB	O	O
more	ADJ	O	O
sinoatrial	ADJ	O	O
beats	NOUN	O	O
and	CCONJ	O	O
less	ADJ	O	O
ectopies	NOUN	O	O
.	PUNCT	O	O

Epinephrine	PROPN	O	I-Entity
shortened	VERB	O	O
QT	PROPN	O	O
less	ADJ	O	O
after	ADP	O	O
bupivacaine	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
control	NOUN	O	O
animals	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
day	NOUN	O	O
after	ADP	O	O
experimental	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
six	NUM	O	O
additional	ADJ	O	O
halothane	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	ADJ	O	O
dogs	NOUN	O	O
received	VERB	O	O
4	NUM	O	O
micrograms.kg-1.min-1	ADJ	O	O
epinephrine	NOUN	O	I-Entity
until	ADP	O	O
VT	PROPN	O	I-Entity
appeared	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
45	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	INTJ	O	O
/	SYM	O	O
kg	X	O	O
bupivacaine	NOUN	O	I-Entity
was	VERB	O	O
injected	VERB	O	O
over	ADP	O	O
5	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
again	ADV	O	O
followed	VERB	O	O
by	ADP	O	O
4	NUM	O	O
micrograms.kg-1.min-1	ADJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
prodysrhythmic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
epinephrine	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
mitigated	VERB	O	O
by	ADP	O	O
preceding	VERB	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

Bupivacaine	PROPN	O	I-Entity
antagonizes	VERB	O	O
epinephrine	NOUN	O	I-Entity
dysrhythmogenicity	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
dogs	NOUN	O	O
susceptible	ADJ	O	O
to	ADP	O	O
VT	PROPN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
anesthetized	ADJ	O	O
dogs	NOUN	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
postinfarct	NOUN	O	O
dysrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
systemic	ADJ	O	O
subtoxic	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
administration	NOUN	O	O
enhances	VERB	O	O
the	DET	O	O
dysrhythmogenicity	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8667442)

Milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
1,25(OH)2D	NUM	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
hypoparathyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

Milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
first	ADV	O	O
described	VERB	O	O
70	NUM	O	O
years	NOUN	O	O
ago	ADV	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
peptic	ADJ	O	B-Entity
ulcer	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
large	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
and	CCONJ	O	O
alkali	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
with	ADP	O	O
current	ADJ	O	O
ulcer	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
H-2	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
omeprazole	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sucralfate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
has	VERB	O	O
decreased	VERB	O	O
significantly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
classic	ADJ	O	O
triad	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
alkalosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
remains	VERB	O	O
the	DET	O	O
hallmark	NOUN	O	O
of	ADP	O	O
the	DET	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

Milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
can	VERB	O	O
present	VERB	O	O
serious	ADJ	O	O
and	CCONJ	O	O
occasionally	ADV	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
illness	NOUN	O	O
unless	ADP	O	O
diagnosed	VERB	O	O
and	CCONJ	O	O
treated	VERB	O	O
appropriately	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
presents	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
hypoparathyroidism	NOUN	O	I-Entity
who	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
and	CCONJ	O	O
calcitriol	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
two	NUM	O	O
admissions	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
pamidronate	NOUN	O	I-Entity
on	ADP	O	O
his	ADJ	O	O
first	ADJ	O	O
admission	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
hydrocortisone	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
illustrates	VERB	O	O
intravenous	ADJ	O	O
pamidronate	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
valuable	ADJ	O	O
therapeutic	ADJ	O	O
tool	NOUN	O	O
when	ADV	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
presents	VERB	O	O
as	ADP	O	O
hypercalcemic	ADJ	O	B-Entity
emergency	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8748050)

Encephalopathy	ADJ	O	I-Entity
during	ADP	O	O
amitriptyline	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
are	VERB	O	O
neuroleptic	ADJ	O	B-Entity
malignant	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
serotonin	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
spectrum	NOUN	O	O
disorders	NOUN	O	O
?	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
encephalopathy	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
amitriptyline	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
a	DET	O	O
remission	NOUN	O	O
of	ADP	O	O
unipolar	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
could	VERB	O	O
have	VERB	O	O
been	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
having	VERB	O	O
either	CCONJ	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
serotonin	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
SS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
determinant	NOUN	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
dopamine	NOUN	O	I-Entity
/	PUNCT	O	O
serotonin	ADJ	O	I-Entity
imbalance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
NMS	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
that	ADJ	O	O
develops	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antidepressants	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
NMS	PROPN	O	I-Entity
and	CCONJ	O	O
SS	PROPN	O	I-Entity
are	VERB	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
drugs	NOUN	O	O
with	ADP	O	O
both	DET	O	O
antidopaminergic	ADJ	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8755612)

Genetic	ADJ	O	O
separation	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
growth	NOUN	O	O
and	CCONJ	O	O
hemorrhagic	ADJ	O	I-Entity
phenotypes	NOUN	O	O
in	ADP	O	O
an	DET	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tumor	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
Fischer	PROPN	O	O
344	NUM	O	O
(	PUNCT	O	O
F344	PROPN	O	O
)	PUNCT	O	O
rat	NOUN	O	O
induces	VERB	O	O
growth	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
,	PUNCT	O	O
hemorrhagic	ADJ	O	I-Entity
pituitary	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

Ten	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
(	PUNCT	O	O
DES	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
caused	VERB	O	O
female	NOUN	O	O
F344	PROPN	O	O
rat	NOUN	O	O
pituitaries	NOUN	O	O
to	PART	O	O
grow	VERB	O	O
to	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
109.2	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

1.4	NUM	O	O
mg	NUM	O	O
for	ADP	O	O
untreated	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
become	VERB	O	O
highly	ADV	O	O
hemorrhagic	ADJ	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
same	ADJ	O	O
DES	PROPN	O	I-Entity
treatment	NOUN	O	O
produced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
growth	NOUN	O	O
(	PUNCT	O	O
8.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

An	DET	O	O
F1	NOUN	O	O
hybrid	NOUN	O	O
of	ADP	O	O
F344	PROPN	O	O
and	CCONJ	O	O
BN	PROPN	O	O
exhibited	VERB	O	O
significant	ADJ	O	O
pituitary	ADJ	O	O
growth	NOUN	O	O
after	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
DES	PROPN	O	I-Entity
treatment	NOUN	O	O
with	ADP	O	O
an	DET	O	O
average	ADJ	O	O
mass	NOUN	O	O
of	ADP	O	O
26.3	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
F1	PROPN	O	O
hybrid	NOUN	O	O
tumors	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
hemorrhagic	ADJ	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
hemoglobin	NOUN	O	O
content	NOUN	O	O
and	CCONJ	O	O
outward	ADJ	O	O
appearance	NOUN	O	O
identical	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
BN	PROPN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
DES	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
pituitary	NOUN	O	O
growth	NOUN	O	O
exhibited	VERB	O	O
quantitative	ADJ	O	O
,	PUNCT	O	O
additive	ADJ	O	O
inheritance	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hemorrhagic	ADJ	O	I-Entity
phenotype	NOUN	O	O
exhibited	VERB	O	O
recessive	ADJ	O	O
,	PUNCT	O	O
epistatic	ADJ	O	O
inheritance	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
160	NUM	O	O
F2	NOUN	O	O
pituitaries	NOUN	O	O
exhibited	VERB	O	O
the	DET	O	O
hemorrhagic	ADJ	O	I-Entity
phenotype	NOUN	O	O
;	PUNCT	O	O
36	NUM	O	O
of	ADP	O	O
the	DET	O	O
160	NUM	O	O
F2	NOUN	O	O
pituitaries	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
F344	PROPN	O	O
range	NOUN	O	O
of	ADP	O	O
mass	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
31	NUM	O	O
of	ADP	O	O
these	DET	O	O
were	VERB	O	O
not	ADV	O	O
hemorrhagic	ADJ	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
hemorrhagic	ADJ	O	I-Entity
phenotype	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
merely	ADV	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
extensive	ADJ	O	O
growth	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hemorrhagic	ADJ	O	I-Entity
F2	NOUN	O	O
pituitaries	NOUN	O	O
were	VERB	O	O
all	ADV	O	O
among	ADP	O	O
the	DET	O	O
most	ADV	O	O
massive	ADJ	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
genes	NOUN	O	O
regulate	VERB	O	O
both	DET	O	O
phenotypes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8808730)

Increased	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
neuronal	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	O
afferent	NOUN	O	O
pathways	NOUN	O	O
following	VERB	O	O
chronic	ADJ	O	O
bladder	NOUN	O	B-Entity
irritation	NOUN	O	I-Entity
.	PUNCT	O	O

Immunocytochemical	ADJ	O	O
techniques	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
examine	VERB	O	O
alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
neuronal	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
NOS	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
bladder	NOUN	O	O
pathways	NOUN	O	O
following	VERB	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
irritation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
urinary	ADJ	O	I-Entity
tract	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Chemical	PROPN	O	O
cystitis	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYP	PROPN	O	I-Entity
)	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
metabolized	VERB	O	O
to	ADP	O	O
acrolein	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
irritant	NOUN	O	O
eliminated	VERB	O	O
in	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
.	PUNCT	O	O

Injection	NOUN	O	O
of	ADP	O	O
CYP	PROPN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
,	PUNCT	O	O
75	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

Fos	PROPN	O	O
-	PUNCT	O	O
IR	PROPN	O	O
in	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
changed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
receiving	VERB	O	O
chronic	ADJ	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O

In	ADP	O	O
control	NOUN	O	O
animals	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
acutely	ADV	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
,	PUNCT	O	O
only	ADV	O	O
small	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
-	PUNCT	O	O
IR	PROPN	O	O
cells	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
-	SYM	O	O
0.7	NUM	O	O
cell	NOUN	O	O
profiles	NOUN	O	O
/	SYM	O	O
sections	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
L6-S1	PROPN	O	O
dorsal	NOUN	O	O
root	NOUN	O	O
ganglia	NOUN	O	O
(	PUNCT	O	O
DRG	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
CYP	PROPN	O	I-Entity
administration	NOUN	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
.002	PUNCT	O	O
)	PUNCT	O	O
increased	VERB	O	O
bladder	NOUN	O	O
weight	NOUN	O	O
by	ADP	O	O
60%	NUM	O	O
and	CCONJ	O	O
increased	VERB	O	O
(	PUNCT	O	O
7-	NOUN	O	O
to	ADP	O	O
11-fold	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
-	PUNCT	O	O
immunoreactive	ADJ	O	O
(	PUNCT	O	O
IR	PROPN	O	O
)	PUNCT	O	O
afferent	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
L6-S1	PROPN	O	O
DRG	PROPN	O	O
.	PUNCT	O	O

Bladder	NOUN	O	O
afferent	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
L6-S1	PROPN	O	O
DRG	PROPN	O	O
labeled	VERB	O	O
by	ADP	O	O
Fluorogold	PROPN	O	O
(	PUNCT	O	O
40	NUM	O	O
microliters	NOUN	O	O
)	PUNCT	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
wall	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
exhibit	VERB	O	O
NOS	PROPN	O	O
-	PUNCT	O	O
IR	PROPN	O	O
in	ADP	O	O
control	NOUN	O	O
animals	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
following	VERB	O	O
chronic	ADJ	O	O
CYP	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
afferent	NOUN	O	O
neurons	NOUN	O	O
were	VERB	O	O
NOS	PROPN	O	O
-	PUNCT	O	O
IR	PROPN	O	O
:	PUNCT	O	O


-DOCSTART- (8819482)

Effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
calcium	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
CD-832	PROPN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
partial	ADJ	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
CD-832	NOUN	O	I-Entity
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
ISO)-induced	VERB	O	I-Entity
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
partial	ADJ	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
circumflex	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
and	CCONJ	O	O
findings	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
for	ADP	O	O
nifedipine	NOUN	O	I-Entity
or	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
,	PUNCT	O	O
3-min	NUM	O	O
periods	NOUN	O	O
of	ADP	O	O
intracoronary	ADJ	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
maximal	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
pressure	NOUN	O	O
rise	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
percentage	NOUN	O	O
segmental	NOUN	O	O
shortening	VERB	O	O
and	CCONJ	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
elevation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
epicardial	ADJ	O	O
electrocardiogram	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
control	NOUN	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
stenosis	NOUN	O	I-Entity
was	VERB	O	O
performed	VERB	O	O
,	PUNCT	O	O
equihypotensive	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
CD-832	PROPN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nifedipine	NOUN	O	I-Entity

(	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O

30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
infused	VERB	O	O
5	NUM	O	O
min	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
second	ADJ	O	O
and	CCONJ	O	O
third	ADJ	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
CD-832	PROPN	O	I-Entity
and	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
CD-832	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O

<	X	O	O
.01	PUNCT	O	O
)	PUNCT	O	O
at	ADP	O	O
3	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

Diltiazem	PROPN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
percentage	NOUN	O	O
segmental	NOUN	O	O
shortening	VERB	O	O
from	ADP	O	O
34	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

.01	PUNCT	O	O
)	PUNCT	O	O
at	ADP	O	O
3	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
CD-832	PROPN	O	I-Entity
improves	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
during	ADP	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
stenosis	NOUN	O	I-Entity
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
negative	ADJ	O	O
chronotropic	ADJ	O	O
property	NOUN	O	O
of	ADP	O	O
CD-832	PROPN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
CD-832	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8825380)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
recombinant	NOUN	O	O
human	ADJ	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
-	PUNCT	O	O
I	PRON	O	O
on	ADP	O	O
chronic	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
recently	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
recombinant	NOUN	O	O
hGH	NOUN	O	O
exacerbates	VERB	O	O
renal	ADJ	O	O
functional	ADJ	O	O
and	CCONJ	O	O
structural	ADJ	O	O
injury	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O

nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

IGF	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
is	VERB	O	O
a	DET	O	O
safer	ADJ	O	O
alternative	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
growth	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
PAN	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
glomerulopathy	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
seven	NUM	O	O
serial	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
over	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

rhIGF	VERB	O	O
-	PUNCT	O	O
I	PRON	O	O
improved	VERB	O	O
weight	NOUN	O	O
gain	NOUN	O	O
by	ADP	O	O
14%	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
without	ADP	O	O
altering	VERB	O	O
hematocrit	NOUN	O	O
or	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

I	PRON	O	O
treatment	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
PAN	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

0.06	NUM	O	O
mL	PROPN	O	O
/	SYM	O	O
min/100	PROPN	O	O
g	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
in	ADP	O	O
untreated	ADJ	O	O
PAN	PROPN	O	I-Entity
nephropathy	ADJ	O	I-Entity
animals	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O

The	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
GFR	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
enhanced	ADJ	O	O
glomerular	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
or	CCONJ	O	O
increased	VERB	O	O
segmental	ADJ	O	O
glomerulosclerosis	NOUN	O	I-Entity
,	PUNCT	O	O
tubulointerstitial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
malondialdehyde	NOUN	O	I-Entity
content	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
PAN	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
rhIGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
increased	VERB	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
and	CCONJ	O	O
GH	PROPN	O	O
receptor	NOUN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
altering	VERB	O	O
the	DET	O	O
steady	ADJ	O	O
state	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
receptor	NOUN	O	O
mRNA	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
with	ADP	O	O
intact	ADJ	O	O
kidneys	NOUN	O	O
,	PUNCT	O	O
rhIGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
administration	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
4	PUNCT	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
weight	NOUN	O	O
gain	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
GFR	PROPN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	O
planar	NOUN	O	O
area	NOUN	O	O
,	PUNCT	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
malondialdehyde	NOUN	O	I-Entity
content	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
glomerular	ADJ	O	O
or	CCONJ	O	O
tubulointerstitial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
untreated	ADJ	O	O
animals	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
:	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
rhIGF	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
improves	VERB	O	O
growth	NOUN	O	O
and	CCONJ	O	O
GFR	PROPN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
PAN	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
unlike	ADP	O	O
rhGH	PROPN	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
rhIGF	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
does	VERB	O	O
not	ADV	O	O
worsen	VERB	O	O
renal	ADJ	O	O
functional	ADJ	O	O
and	CCONJ	O	O
structural	ADJ	O	O
injury	NOUN	O	O
in	ADP	O	O
this	DET	O	O
disease	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8829135)

Nefiracetam	PROPN	O	I-Entity
(	PUNCT	O	O
DM-9384	PROPN	O	I-Entity
)	PUNCT	O	O
reverses	VERB	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
response	NOUN	O	O
:	PUNCT	O	O

Nefiracetam	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
pyrrolidone	NOUN	O	I-Entity
derivative	ADJ	O	O
which	ADJ	O	O
attenuates	VERB	O	O
scopolamine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
learning	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
post	VERB	O	I-Entity
-	PUNCT	O	I-Entity
training	VERB	O	I-Entity
consolidation	NOUN	O	I-Entity
deficits	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
that	DET	O	O
apomorphine	NOUN	O	I-Entity
inhibits	VERB	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
retention	NOUN	O	O
when	ADV	O	O
given	VERB	O	O
during	ADP	O	O
training	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
defined	VERB	O	O
10	NUM	O	O
-	PUNCT	O	O
12h	NUM	O	O
post	NOUN	O	O
-	PUNCT	O	O
training	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
nefiracetam	NOUN	O	I-Entity
to	PART	O	O
attenuate	VERB	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
dopaminergic	ADJ	O	O
agonism	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
step	NOUN	O	O
-	PUNCT	O	O
down	PART	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
paradigm	NOUN	O	O
was	VERB	O	O
employed	VERB	O	O
and	CCONJ	O	O
nefiracetam	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
during	ADP	O	O
training	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
10	NUM	O	O
-	PUNCT	O	O
12h	NUM	O	O
post	NOUN	O	O
-	PUNCT	O	O
training	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
consolidation	NOUN	O	O
.	PUNCT	O	O

Co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
nefiracetam	NOUN	O	I-Entity
and	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
during	ADP	O	O
training	NOUN	O	O
or	CCONJ	O	O
10h	NUM	O	O
thereafter	ADV	O	O
produced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
amnesic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
nefiracetam	NOUN	O	I-Entity
during	ADP	O	O
training	NOUN	O	O
completely	ADV	O	O
reversed	VERB	O	O
the	DET	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
apomorphine	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
10h	NUM	O	O
post	NOUN	O	O
-	PUNCT	O	O
training	NOUN	O	O
time	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
converse	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
true	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
dopaminergic	ADJ	O	O
mechanism	NOUN	O	O
as	ADP	O	O
nefiracetam	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
millimolar	ADJ	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
displace	VERB	O	O
either	CCONJ	O	O
[	PUNCT	O	O
3H]SCH	SYM	O	B-Entity
23390	NUM	O	I-Entity
or	CCONJ	O	O
[	PUNCT	O	O
3H]spiperone	NUM	O	I-Entity
binding	VERB	O	O
from	ADP	O	O
D1	PROPN	O	O
or	CCONJ	O	O
D2	PROPN	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
subtypes	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
nefiracetam	NOUN	O	I-Entity
augments	VERB	O	O
molecular	ADJ	O	O
processes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
which	ADJ	O	O
ultimately	ADV	O	O
lead	VERB	O	O
to	ADP	O	O
consolidation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8957205)

Human	ADJ	O	O
corticotropin	NOUN	O	I-Entity
-	PUNCT	O	O
releasing	VERB	O	O
hormone	NOUN	O	O
and	CCONJ	O	O
thyrotropin	NOUN	O	I-Entity
-	PUNCT	O	O
releasing	VERB	O	O
hormone	NOUN	O	O
modulate	VERB	O	O
the	DET	O	O
hypercapnic	ADJ	O	I-Entity
ventilatory	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Human	PROPN	O	O
corticotropin	NOUN	O	I-Entity
-	PUNCT	O	O
releasing	VERB	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
hCRH	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
thyrotropin	NOUN	O	I-Entity
-	PUNCT	O	O
releasing	VERB	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
TRH	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
stimulate	VERB	O	O
ventilation	NOUN	O	O
after	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
subsequent	ADJ	O	O
CO2-rebreathing	VERB	O	I-Entity
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
young	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
first	ADJ	O	O
test	NOUN	O	O
0.9%	NUM	O	O
NaCl	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
subjects	NOUN	O	O
received	VERB	O	O
0.9%	NUM	O	O
NaCl	PROPN	O	I-Entity
i.v	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
CO2-response	NOUN	O	I-Entity
curves	VERB	O	O
for	ADP	O	O
the	DET	O	O
two	NUM	O	O
tests	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
within	ADP	O	O
the	DET	O	O
same	ADJ	O	O
subject	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
hCRH	PROPN	O	O
group	NOUN	O	O
a	DET	O	O
marked	ADJ	O	O
parallel	NOUN	O	O
shift	NOUN	O	O
of	ADP	O	O
the	DET	O	O
CO2-response	PROPN	O	I-Entity
curve	NOUN	O	O
to	ADP	O	O
the	DET	O	O
left	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
hCRH	PROPN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

hCRH	NOUN	O	O
and	CCONJ	O	O
TRH	PROPN	O	O
caused	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CO2	PROPN	O	I-Entity
threshold	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
CO2-response	NOUN	O	I-Entity
curves	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
nearly	ADV	O	O
identical	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
an	DET	O	O
additive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
both	DET	O	O
releasing	VERB	O	O
hormones	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hypercapnic	ADJ	O	I-Entity
ventilatory	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
presumably	ADV	O	O
independent	ADJ	O	O
of	ADP	O	O
central	ADJ	O	O
chemosensitivity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8985298)

Lamivudine	PROPN	O	I-Entity
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
suppressing	VERB	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
DNA	NOUN	O	O
in	ADP	O	O
Chinese	PROPN	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
carriers	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
2',3'-dideoxy	NUM	O	B-Entity
cytosine	NOUN	O	I-Entity
analogue	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
potent	ADJ	O	O
inhibitory	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
replication	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
single	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
its	ADJ	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
Chinese	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBsAg	PROPN	O	I-Entity
)	PUNCT	O	O
carriers	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
Chinese	ADJ	O	O
HBsAg	NOUN	O	I-Entity
carriers	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
lamivudine	NOUN	O	I-Entity
orally	ADV	O	O
in	ADP	O	O
dosages	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
mg	CCONJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
300	NUM	O	O
mg	NUM	O	O
daily	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
for	ADP	O	O
each	DET	O	O
dosage	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
36	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lamivudine	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
DNA	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
90%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.001	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
25	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
was	VERB	O	O
slightly	ADV	O	O
less	ADJ	O	O
effective	ADJ	O	O
than	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.011	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
300	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.005	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
it	PRON	O	O
still	ADV	O	O
induced	VERB	O	O
94%	NUM	O	O
suppression	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
DNA	PROPN	O	O
after	ADP	O	O
the	DET	O	O
fourth	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
e	NOUN	O	O
antigen	NOUN	O	O
status	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
aminotransferase	DET	O	O
levels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
4-week	NUM	O	O
course	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
was	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
DNA	PROPN	O	O
in	ADP	O	O
Chinese	PROPN	O	O
HBsAg	PROPN	O	I-Entity
carriers	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lamivudine	NOUN	O	I-Entity
administration	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
prolonged	VERB	O	O
suppression	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
DNA	PROPN	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8996419)

Population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
various	ADJ	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Four	NUM	O	O
studies	NOUN	O	O
published	VERB	O	O
since	ADP	O	O
December	PROPN	O	O
,	PUNCT	O	O
1995	NUM	O	O
,	PUNCT	O	O
reported	VERB	O	O
that	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
(	PUNCT	O	O
OCs	PROPN	O	I-Entity
)	PUNCT	O	O
containing	VERB	O	O
the	DET	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
gestodene	NOUN	O	I-Entity
or	CCONJ	O	O
desogestrel	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
OCs	PROPN	O	I-Entity
containing	VERB	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
re	VERB	O	O
-	PUNCT	O	O
examine	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
and	CCONJ	O	O
OC	PROPN	O	I-Entity
use	NOUN	O	O
with	ADP	O	O
a	DET	O	O
different	ADJ	O	O
study	NOUN	O	O
design	NOUN	O	O
and	CCONJ	O	O
analysis	NOUN	O	O
to	PART	O	O
avoid	VERB	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
bias	NOUN	O	O
and	CCONJ	O	O
confounding	NOUN	O	O
of	ADP	O	O
the	DET	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
women	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
recorded	VERB	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
deep	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
vein	NOUN	O	I-Entity
thrombosis	NOUN	O	I-Entity
,	PUNCT	O	O
venous	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
not	ADV	O	O
otherwise	ADV	O	O
specified	VERB	O	O
,	PUNCT	O	O
or	CCONJ	O	O
pulmonary	ADJ	O	O
embolus	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
an	DET	O	O
anticoagulant	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
as	ADP	O	O
potential	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
did	VERB	O	O
a	DET	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
to	PART	O	O
estimate	VERB	O	O
and	CCONJ	O	O
compare	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
the	DET	O	O
main	ADJ	O	O
OC	PROPN	O	I-Entity
preparations	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
nested	VERB	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
to	PART	O	O
calculate	VERB	O	O
the	DET	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
OC	PROPN	O	I-Entity
,	PUNCT	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
potential	ADJ	O	O
confounding	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
matched	VERB	O	O
cases	NOUN	O	O
to	ADP	O	O
controls	NOUN	O	O
by	ADP	O	O
exact	ADJ	O	O
year	NOUN	O	O
of	ADP	O	O
birth	NOUN	O	O
,	PUNCT	O	O
practice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
current	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
OCs	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
a	DET	O	O
multiple	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
model	NOUN	O	O
that	ADJ	O	O
included	VERB	O	O
body	NOUN	O	O
-	PUNCT	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
cycles	NOUN	O	O
,	PUNCT	O	O
change	NOUN	O	O
in	ADP	O	O
type	NOUN	O	O
of	ADP	O	O
OC	PROPN	O	I-Entity
prescribed	VERB	O	O
within	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
the	DET	O	O
event	NOUN	O	O
,	PUNCT	O	O
previous	ADJ	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
concurrent	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
:	PUNCT	O	O
85	NUM	O	O
women	NOUN	O	O
met	VERB	O	O
the	DET	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
for	ADP	O	O
VTE	PROPN	O	I-Entity
,	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
were	VERB	O	O
users	NOUN	O	O
of	ADP	O	O
progestagen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
OCs	PROPN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
83	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
OCs	PROPN	O	I-Entity
,	PUNCT	O	O
43	NUM	O	O
were	VERB	O	O
recorded	VERB	O	O
as	ADP	O	O
deep	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
vein	NOUN	O	I-Entity
thrombosis	NOUN	O	I-Entity
,	PUNCT	O	O
35	NUM	O	O
as	ADP	O	O
pulmonary	ADJ	O	O
thrombosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
five	NUM	O	O
as	ADP	O	O
venous	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
not	ADV	O	O
otherwise	ADV	O	O
specified	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
crude	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
per	ADP	O	O
10,000	NUM	O	O
woman	NOUN	O	O
-	PUNCT	O	O
years	NOUN	O	O
was	VERB	O	O
4.10	NUM	O	O
in	ADP	O	O
current	ADJ	O	O
users	NOUN	O	O
of	ADP	O	O
any	DET	O	O
OC	PROPN	O	I-Entity
,	PUNCT	O	O
3.10	NUM	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
OCs	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
4.96	NUM	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
OCs	NOUN	O	I-Entity
was	VERB	O	O
1.68	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.04	NUM	O	O
-	SYM	O	O
2.75	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Logistic	ADJ	O	O
regression	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
between	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
and	CCONJ	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
OCs	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
desogestrel	NOUN	O	I-Entity
with	ADP	O	O
20	NUM	O	O
g	NOUN	O	O
ethinyloestradiol	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
gestodene	NOUN	O	I-Entity
or	CCONJ	O	O
desogestrel	NOUN	O	I-Entity
with	ADP	O	O
30	NUM	O	O
g	NOUN	O	O
ethinyloestradiol	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
all	DET	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
OCs	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
for	ADP	O	O
VTE	PROPN	O	I-Entity
were	VERB	O	O
3.49	NUM	O	O
(	PUNCT	O	O
1.21	NUM	O	O
-	SYM	O	O
10.12	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
desogestrel	NOUN	O	I-Entity
plus	CCONJ	O	O
20	NUM	O	O
g	NOUN	O	O
ethinyloestradiol	NOUN	O	I-Entity
and	CCONJ	O	O
1.18	NUM	O	O
(	PUNCT	O	O
0.66	NUM	O	O
-	SYM	O	O
2.17	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
other	ADJ	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
previously	ADV	O	O
reported	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
OCs	NOUN	O	I-Entity
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
products	NOUN	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
been	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
residual	ADJ	O	O
confounding	NOUN	O	O
by	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increased	VERB	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
products	NOUN	O	O
containing	VERB	O	O
20	NUM	O	O
micrograms	NOUN	O	O
ethinyloestradiol	ADJ	O	I-Entity
and	CCONJ	O	O
desogestrel	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
30	NUM	O	O
micrograms	NOUN	O	O
product	NOUN	O	O
is	VERB	O	O
biologically	ADV	O	O
implausible	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
preferential	ADJ	O	O
prescribing	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
confounding	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9061777)

MK-801	NOUN	O	I-Entity
augments	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
electrographic	ADJ	O	O
seizure	NOUN	O	I-Entity
but	CCONJ	O	O
protects	VERB	O	O
against	ADP	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O

The	DET	O	O
authors	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
anticonvulsant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

Intraperitoneal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
induced	VERB	O	O
tonic	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
clonic	ADJ	O	I-Entity
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

Scopolamine	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pentobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
prevented	VERB	O	O
development	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
behavioral	ADJ	O	O
seizure	NOUN	O	I-Entity
but	CCONJ	O	O
MK-801	PROPN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

An	DET	O	O
electrical	ADJ	O	O
seizure	NOUN	O	I-Entity
measured	VERB	O	O
with	ADP	O	O
hippocampal	ADJ	O	O
EEG	PROPN	O	O
appeared	VERB	O	O
in	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

Scopolamine	PROPN	O	I-Entity
and	CCONJ	O	O
pentobarbital	NOUN	O	I-Entity
blocked	VERB	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
electrographic	ADJ	O	O
seizure	NOUN	O	I-Entity
,	PUNCT	O	O
MK-801	PROPN	O	I-Entity
treatment	NOUN	O	O
augmented	VERB	O	O
the	DET	O	O
electrographic	ADJ	O	O
seizure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Brain	VERB	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
examining	VERB	O	O
the	DET	O	O
hippocampus	NOUN	O	O
microscopically	ADV	O	O
.	PUNCT	O	O

Pilocarpine	PROPN	O	I-Entity
produced	VERB	O	O
neuronal	ADJ	O	B-Entity
death	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
showed	VERB	O	O
pyknotic	ADJ	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Pentobarbital	ADJ	O	I-Entity
,	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
MK-801	PROPN	O	I-Entity
protected	VERB	O	O
the	DET	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
though	ADV	O	O
in	ADP	O	O
the	DET	O	O
MK-801-treated	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pyramidal	NOUN	O	O
cells	NOUN	O	O
of	ADP	O	O
hippocampus	NOUN	O	O
appeared	VERB	O	O
darker	ADJ	O	O
than	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
is	VERB	O	O
initiated	VERB	O	O
by	ADP	O	O
cholinergic	ADJ	O	O
overstimulation	NOUN	O	O
and	CCONJ	O	O
propagated	VERB	O	O
by	ADP	O	O
glutamatergic	ADJ	O	O
transmission	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
which	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
through	ADP	O	O
an	DET	O	O
excitatory	NOUN	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9071336)

Paclitaxel	PROPN	O	I-Entity
,	PUNCT	O	O
5-fluorouracil	NUM	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
:	PUNCT	O	O

5-Fluorouracil	NUM	O	I-Entity
plus	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
and	CCONJ	O	O
paclitaxel	NOUN	O	I-Entity

(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
;	PUNCT	O	O
Bristol	PROPN	O	O
-	PUNCT	O	O
Myers	PROPN	O	O
Squibb	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
effective	ADJ	O	O
salvage	NOUN	O	O
therapies	NOUN	O	O
for	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity
and	CCONJ	O	O
5-fluorouracil	NUM	O	I-Entity
have	VERB	O	O
additive	ADJ	O	O
cytotoxicity	NOUN	O	I-Entity
in	ADP	O	O
MCF-7	PROPN	O	O
cell	NOUN	O	O
lines	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
trial	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
175	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
over	ADP	O	O
3	NUM	O	O
hours	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
I	PRON	O	O
followed	VERB	O	O
by	ADP	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
300	NUM	O	O
mg	NOUN	O	O
over	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
before	ADP	O	O
5-fluorouracil	SYM	O	I-Entity
350	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
3	NUM	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
TFL	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Analysis	PROPN	O	O
is	VERB	O	O
reported	VERB	O	O
on	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
who	NOUN	O	O
received	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
192	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
TFL	PROPN	O	O
:	PUNCT	O	O
nine	NUM	O	O
cycles	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
grade	NOUN	O	O
3/4	NUM	O	O
neutropenia	NOUN	O	I-Entity
requiring	VERB	O	O
hospitalization	NOUN	O	O
;	PUNCT	O	O
seven	NUM	O	O
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
cycles	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
required	VERB	O	O
granulocyte	ADJ	O	B-Entity
colony	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
stimulating	VERB	O	I-Entity
factor	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
neutropenia	NOUN	O	I-Entity
;	PUNCT	O	O
no	DET	O	O
patient	NOUN	O	O
required	VERB	O	O
platelet	NOUN	O	O
transfusions	NOUN	O	O
.	PUNCT	O	O

Grade	PROPN	O	O
3/4	NUM	O	O
nonhematologic	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
uncommon	ADJ	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
19	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
prior	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
(	PUNCT	O	O
58%	NUM	O	O
)	PUNCT	O	O
responded	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
nine	NUM	O	O
of	ADP	O	O
15	NUM	O	O
(	PUNCT	O	O
60%	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
prior	ADV	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	ADJ	O	O
paclitaxel	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
19	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

TFL	PROPN	O	O
is	VERB	O	O
an	DET	O	O
active	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
regimen	NOUN	O	O
in	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9125676)

Efficacy	NOUN	O	O
and	CCONJ	O	O
proarrhythmia	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
for	ADP	O	O
sustained	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
torsades	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
presumable	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
for	ADP	O	O
sustained	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

Eighty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
with	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
inducible	NOUN	O	O
sustained	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
or	CCONJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
received	VERB	O	O
oral	ADJ	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
oral	ADJ	O	O
loading	NOUN	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
,	PUNCT	O	O
continuous	ADJ	O	O
electrocardiographic	ADJ	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
monitoring	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Those	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
prevented	VERB	O	O
induction	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
or	CCONJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
were	VERB	O	O
discharged	VERB	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
followed	VERB	O	O
up	PART	O	O
on	ADP	O	O
an	DET	O	O
outpatient	NOUN	O	O
basis	NOUN	O	O
for	ADP	O	O
21	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
oral	ADJ	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
in	ADP	O	O
35	NUM	O	O
(	PUNCT	O	O
43%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
remained	VERB	O	O
inducible	ADJ	O	O
in	ADP	O	O
40	NUM	O	O
(	PUNCT	O	O
49%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
(	PUNCT	O	O
2.5%	NUM	O	O
)	PUNCT	O	O

patients	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
even	ADV	O	O
40	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
once	ADV	O	O
daily	ADV	O	O
.	PUNCT	O	O

Four	NUM	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
from	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
oral	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	DET	O	O
ECG	PROPN	O	O
[	PUNCT	O	O
sinus	ADJ	O	O
-	PUNCT	O	O
cycle	NOUN	O	O
length	NOUN	O	O
(	PUNCT	O	O
SCL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
QT	PROPN	O	O
or	CCONJ	O	O
QTc	PROPN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
U	PROPN	O	O
wave	NOUN	O	O
]	PUNCT	O	O
nor	CCONJ	O	O
clinical	ADJ	O	O
parameters	NOUN	O	O
identified	VERB	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Risk	VERB	O	O
factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
were	VERB	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
an	DET	O	O
U	PROPN	O	O
wave	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.049	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
female	ADJ	O	O
gender	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significant	ADJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
corrected	VERB	O	O
changes	NOUN	O	O
of	ADP	O	O
SCL	PROPN	O	O
,	PUNCT	O	O
QT	PROPN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
QTc	PROPN	O	O
interval	NOUN	O	O
(	PUNCT	O	O

During	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
,	PUNCT	O	O
seven	NUM	O	O
(	PUNCT	O	O
20%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
nonfatal	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
recurrence	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
(	PUNCT	O	O
6%	NUM	O	O
)	PUNCT	O	O

One	NUM	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
had	VERB	O	O
recurrent	ADJ	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
after	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
successful	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
.	PUNCT	O	O

Torsades	PROPN	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
occurred	VERB	O	O
early	ADV	O	O
during	ADP	O	O
treatment	NOUN	O	O
even	ADV	O	O
with	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
.	PUNCT	O	O

Pronounced	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
surface	NOUN	O	O
ECG	PROPN	O	O
(	PUNCT	O	O
cycle	NOUN	O	O
length	NOUN	O	O
,	PUNCT	O	O
QT	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
QTc	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
might	VERB	O	O
identify	VERB	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

Other	ADJ	O	O
ECG	PROPN	O	O
parameters	NOUN	O	O
before	ADP	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
identify	VERB	O	O
patients	NOUN	O	O
at	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

Recurrence	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
are	VERB	O	O
high	ADJ	O	O
despite	ADP	O	O
complete	ADJ	O	O
suppression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
during	ADP	O	O
programmed	VERB	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
programmed	ADJ	O	O
electrical	ADJ	O	O
stimulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
of	ADP	O	O
limited	VERB	O	O
prognostic	ADJ	O	O
value	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9128918)

Chronic	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
neurons	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
induce	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
for	ADP	O	O
extended	VERB	O	O
periods	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
and	CCONJ	O	O
examine	VERB	O	O
its	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
dopaminergic	ADJ	O	O
systems	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

Hyperprolactinemia	PROPN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Palkovits	PROPN	O	O
'	PART	O	O
microdissection	NOUN	O	O
technique	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	VERB	O	O
neurotransmitter	ADJ	O	O
concentrations	NOUN	O	O
in	ADP	O	O
several	ADJ	O	O
areas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	NOUN	O	I-Entity
)	PUNCT	O	O
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
median	ADJ	O	O
eminence	NOUN	O	O
(	PUNCT	O	O
ME	PROPN	O	O
)	PUNCT	O	O
increased	VERB	O	O
by	ADP	O	O
84%	NUM	O	O
over	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
produced	VERB	O	O
a	DET	O	O
50%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
DA	PROPN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ME	PROPN	O	O
over	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
DA	PROPN	O	I-Entity
response	NOUN	O	O
was	VERB	O	O
lost	VERB	O	O
if	ADP	O	O
a	DET	O	O
9-month	NUM	O	O
long	ADJ	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
1	NUM	O	O
1/2	NUM	O	O
month	NOUN	O	O
-	PUNCT	O	O
long	ADJ	O	O
extremely	ADV	O	O
high	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
PRL	PROPN	O	O
levels	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
implantation	NOUN	O	O
of	ADP	O	O
MMQ	PROPN	O	O
cells	NOUN	O	O
under	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
capsule	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
DA	PROPN	O	I-Entity
,	PUNCT	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
NE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-HT	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
their	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
arcuate	ADJ	O	O
nucleus	NOUN	O	O
(	PUNCT	O	O
AN	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
medial	ADJ	O	O
preoptic	ADJ	O	O
area	NOUN	O	O
(	PUNCT	O	O
MPA	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
caudate	NOUN	O	O
putamen	NOUN	O	O
(	PUNCT	O	O
CP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
(	PUNCT	O	O
SN	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
zona	VERB	O	O
incerta	NOUN	O	O
(	PUNCT	O	O
ZI	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
5-hydroxyindoleacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
5-HIAA	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
AN	NOUN	O	O
after	ADP	O	O
6-months	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
DA	PROPN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
AN	NOUN	O	O
after	ADP	O	O
9-months	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
specifically	ADV	O	O
affects	VERB	O	O
TIDA	PROPN	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
these	DET	O	O
effects	NOUN	O	O
vary	VERB	O	O
,	PUNCT	O	O
depending	VERB	O	O
on	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
age	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
decrease	NOUN	O	O
in	ADP	O	O
hypothalamic	NOUN	O	O
dopamine	NOUN	O	I-Entity
function	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increases	NOUN	O	O
in	ADP	O	O
PRL	PROPN	O	O
secretion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9132810)

Treatment	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
disseminated	VERB	O	O
necrotizing	VERB	O	O
leukoencephalopathy	NOUN	O	I-Entity
with	ADP	O	O
characteristic	ADJ	O	O
contrast	NOUN	O	O
enhancement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
white	ADJ	O	O
matter	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
unique	ADJ	O	O
contrast	NOUN	O	O
enhancement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
white	ADJ	O	O
matter	NOUN	O	O
on	ADP	O	O
T1-weighted	VERB	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
images	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
disseminated	VERB	O	O
necrotizing	NOUN	O	O
leukoencephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
developed	VERB	O	O
from	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methotrexate	NOUN	O	I-Entity
.	PUNCT	O	O

Necropsy	PROPN	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
revealed	VERB	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
myelination	NOUN	O	I-Entity
and	CCONJ	O	O
necrosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
white	ADJ	O	O
matter	NOUN	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
mechanisms	NOUN	O	O
causing	VERB	O	O
such	ADJ	O	O
a	DET	O	O
leukoencephalopathy	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9158667)

Thrombotic	ADJ	O	I-Entity
complications	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
during	ADP	O	O
all	DET	O	B-Entity
-	PUNCT	O	I-Entity
trans	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
occlusion	NOUN	O	B-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
vessels	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
APL	PROPN	O	I-Entity
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
all	DET	O	B-Entity
-	PUNCT	O	I-Entity
trans	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
ATRA	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
recently	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
APL	PROPN	O	I-Entity
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ATRA	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
further	ADV	O	O
supports	VERB	O	O
the	DET	O	O
concern	NOUN	O	O
about	ADP	O	O
thromboembolic	ADJ	O	I-Entity
complications	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ATRA	PROPN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
APL	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
43-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
presented	VERB	O	O
all	ADJ	O	O
the	DET	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
APL	PROPN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
protocol	NOUN	O	O
with	ADP	O	O
ATRA	PROPN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
completely	ADV	O	O
reversible	ADJ	O	O
after	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
of	ADP	O	O
APL	PROPN	O	I-Entity
was	VERB	O	O
achieved	VERB	O	O
and	CCONJ	O	O
therapy	NOUN	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
ATRA	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
valid	ADJ	O	O
therapeutic	ADJ	O	O
choice	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
APL	PROPN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
procoagulant	NOUN	O	O
tendency	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
corrected	VERB	O	O
.	PUNCT	O	O

Thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
by	ADP	O	O
using	VERB	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9197951)

Pupillary	ADJ	O	O
changes	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
stimulant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
30-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
a	DET	O	O
subject	NOUN	O	O
in	ADP	O	O
a	DET	O	O
study	NOUN	O	O
evaluating	VERB	O	O
the	DET	O	O
anticraving	VERB	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
stimulant	NOUN	O	O
medication	NOUN	O	O
diethylpropion	NOUN	O	I-Entity
(	PUNCT	O	O
DEP	PROPN	O	I-Entity
)	PUNCT	O	O
became	VERB	O	O
manic	ADJ	O	I-Entity
during	ADP	O	O
his	ADJ	O	O
second	ADJ	O	O
week	NOUN	O	O
on	ADP	O	O
the	DET	O	O
study	NOUN	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Pupillometric	PROPN	O	O
changes	NOUN	O	O
while	ADP	O	O
on	ADP	O	O
DEP	PROPN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
power	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-Entity
oscillation	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
dramatically	ADV	O	O
different	ADJ	O	O
than	ADP	O	O
those	DET	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
eight	NUM	O	O
other	ADJ	O	O
study	NOUN	O	O
subjects	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
become	VERB	O	O
manic	ADJ	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
large	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
power	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-Entity
oscillation	NOUN	O	I-Entity
occurred	VERB	O	O
a	DET	O	O
few	ADJ	O	O
days	NOUN	O	O
before	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
became	VERB	O	O
fully	ADV	O	O
manic	ADJ	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
medication	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
power	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-Entity
oscillation	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
of	ADP	O	O
utility	NOUN	O	O
in	ADP	O	O
identifying	VERB	O	O
persons	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
manic	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
during	ADP	O	O
the	DET	O	O
medical	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
psychomotor	NOUN	O	O
stimulants	NOUN	O	O
or	CCONJ	O	O
sympathomimetic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9272404)

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
wanted	VERB	O	O
to	PART	O	O
test	VERB	O	O
whether	ADP	O	O
assessment	NOUN	O	O
of	ADP	O	O
both	DET	O	O
a	DET	O	O
central	ADJ	O	O
pain	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
signal	NOUN	O	O
(	PUNCT	O	O
chemo	NOUN	O	O
-	PUNCT	O	O
somatosensory	NOUN	O	O
evoked	VERB	O	O
potential	NOUN	O	O
,	PUNCT	O	O
CSSEP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
concomitantly	ADV	O	O
recorded	VERB	O	O
peripheral	ADJ	O	O
signal	NOUN	O	O
(	PUNCT	O	O
negative	ADJ	O	O
mucosal	NOUN	O	O
potential	NOUN	O	O
,	PUNCT	O	O
NMP	PROPN	O	O
)	PUNCT	O	O
allows	VERB	O	O
for	ADP	O	O
separation	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
NSAIDs	PROPN	O	O
.	PUNCT	O	O

For	ADP	O	O
this	DET	O	O
purpose	NOUN	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
were	VERB	O	O
created	VERB	O	O
in	ADP	O	O
which	ADJ	O	O
NSAIDs	PROPN	O	O
had	VERB	O	O
previously	ADV	O	O
been	VERB	O	O
observed	VERB	O	O
to	PART	O	O
produce	VERB	O	O
effects	NOUN	O	O
on	ADP	O	O
phasic	NOUN	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
pain	NOUN	O	I-Entity
by	ADP	O	O
either	DET	O	O
central	ADJ	O	O
or	CCONJ	O	O
peripheral	ADJ	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
threefold	VERB	O	O
cross	NOUN	O	O
-	PUNCT	O	O
over	PART	O	O
design	NOUN	O	O
,	PUNCT	O	O
18	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
males	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
females	NOUN	O	O
;	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
26	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
either	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
400	NUM	O	O
mg	NUM	O	O
ibuprofen	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
800	NUM	O	O
mg	NUM	O	O
ibuprofen	NOUN	O	I-Entity
.	PUNCT	O	O

Phasic	PROPN	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
short	ADJ	O	O
pulses	NOUN	O	O
of	ADP	O	O
CO2	PROPN	O	I-Entity
to	ADP	O	O
the	DET	O	O
nasal	ADJ	O	O
mucosa	NOUN	O	O
(	PUNCT	O	O
stimulus	NOUN	O	O
duration	NOUN	O	O
500	NUM	O	O
ms	NOUN	O	O
,	PUNCT	O	O
interval	NOUN	O	O
approximately	ADV	O	O
60	NUM	O	O
s	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
the	DET	O	O
nasal	ADJ	O	O
cavity	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
dry	ADJ	O	O
air	NOUN	O	O
of	ADP	O	O
controlled	VERB	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
humidity	NOUN	O	O
and	CCONJ	O	O
flow	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
0%	NUM	O	O
relative	ADJ	O	O
humidity	NOUN	O	O
,	PUNCT	O	O
145	NUM	O	O
ml.s-1	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
CSSEPs	NOUN	O	O
as	ADP	O	O
central	ADJ	O	O
and	CCONJ	O	O
NMPs	NOUN	O	O
as	ADP	O	O
peripheral	ADJ	O	O
correlates	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
CO2	PROPN	O	I-Entity
stimuli	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
subjects	NOUN	O	O
rated	VERB	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
both	DET	O	O
phasic	NOUN	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
pain	NOUN	O	I-Entity
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scales	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
described	VERB	O	O
earlier	ADV	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
ibuprofen	NOUN	O	I-Entity
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
tonic	NOUN	O	O
pain	NOUN	O	I-Entity
but	CCONJ	O	O
-	PUNCT	O	O
relative	NOUN	O	O
to	ADP	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
correlates	NOUN	O	O
of	ADP	O	O
phasic	NOUN	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ibuprofen	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
stimuli	NOUN	O	O
under	ADP	O	O
these	DET	O	O
special	ADJ	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
advantage	NOUN	O	O
of	ADP	O	O
this	DET	O	O
pain	NOUN	O	I-Entity
model	NOUN	O	O
is	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
obtaining	VERB	O	O
peripheral	ADJ	O	O
pain	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
activity	NOUN	O	O
directly	ADV	O	O
using	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
invasive	ADJ	O	O
technique	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9323412)

Acute	PROPN	O	O
severe	ADJ	O	O
depression	NOUN	O	I-Entity
following	VERB	O	O
peri	NOUN	O	O
-	PUNCT	O	O
operative	NOUN	O	O
ondansetron	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
41-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
strong	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
presented	VERB	O	O
for	ADP	O	O
abdominal	ADJ	O	O
hysterectomy	NOUN	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
anaesthetic	NOUN	O	O
where	ADV	O	O
ondansetron	NOUN	O	I-Entity
prophylaxis	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

She	PRON	O	O
had	VERB	O	O
developed	VERB	O	O
a	DET	O	O
severe	ADJ	O	O
acute	ADJ	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
almost	ADV	O	O
immediately	ADV	O	O
thereafter	ADV	O	O
,	PUNCT	O	O
possibly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
serotonin	NOUN	O	I-Entity
antagonist	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
years	NOUN	O	O
before	ADP	O	O
she	PRON	O	O
had	VERB	O	O
experienced	VERB	O	O
a	DET	O	O
self	NOUN	O	O
-	PUNCT	O	O
limited	VERB	O	O
puerperal	ADJ	O	O
depressive	ADJ	O	B-Entity
episode	NOUN	O	I-Entity
.	PUNCT	O	O

Anaesthesia	PROPN	O	O
with	ADP	O	O
a	DET	O	O
propofol	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
avoidance	NOUN	O	O
of	ADP	O	O
serotonin	NOUN	O	I-Entity
antagonists	NOUN	O	O
provided	VERB	O	O
a	DET	O	O
nausea	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
postoperative	ADJ	O	O
course	NOUN	O	O
without	ADP	O	O
exacerbation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
depression	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9382023)

Hypertensive	ADJ	O	I-Entity
response	NOUN	O	O
during	ADP	O	O
dobutamine	NOUN	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
3,129	NUM	O	O
dobutamine	NOUN	O	I-Entity
stress	NOUN	O	O
echocardiographic	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
hypertensive	ADJ	O	I-Entity
response	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
>	NOUN	O	O
or	CCONJ	O	O
=	SYM	O	O
220	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
and/or	CCONJ	O	O
diastolic	ADJ	O	O
BP	PROPN	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
110	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
1%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
this	DET	O	O
response	NOUN	O	O
more	ADV	O	O
often	ADV	O	O
had	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
higher	ADJ	O	O
resting	VERB	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O

BP	PROPN	O	O
before	ADP	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9428298)

Continuously	ADV	O	O
nebulized	VERB	O	O
albuterol	NOUN	O	I-Entity
in	ADP	O	O
severe	ADJ	O	O
exacerbations	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
retrospective	NOUN	O	O
,	PUNCT	O	O
case	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analysis	NOUN	O	O
comparing	VERB	O	O
patients	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
medical	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
exacerbations	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
continuously	ADV	O	O
nebulized	VERB	O	O
albuterol	NOUN	O	I-Entity
(	PUNCT	O	O
CNA	PROPN	O	O
)	PUNCT	O	O
versus	ADP	O	O
intermittent	ADJ	O	O
albuterol	NOUN	O	I-Entity
(	PUNCT	O	O
INA	PROPN	O	O
)	PUNCT	O	O
treatments	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Forty	NUM	O	O
matched	VERB	O	O
pairs	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
asthma	NOUN	O	I-Entity
are	VERB	O	O
compared	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
dysrhythmias	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Symptomatic	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
occur	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9538487)

Hyperosmolar	ADJ	O	B-Entity
nonketotic	ADJ	O	I-Entity
coma	NOUN	O	I-Entity
precipitated	VERB	O	O
by	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
10-year	NUM	O	O
history	NOUN	O	O
of	ADP	O	O
manic	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
hyperosmolar	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
nonketotic	ADJ	O	I-Entity
coma	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
gave	VERB	O	O
a	DET	O	O
five	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
history	NOUN	O	O
of	ADP	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
polydipsia	NOUN	O	I-Entity
,	PUNCT	O	O
during	ADP	O	O
which	ADJ	O	O
time	NOUN	O	O
urinalysis	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
negative	ADJ	O	O
for	ADP	O	O
glucose	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
hyperglycaemia	NOUN	O	I-Entity
,	PUNCT	O	O
he	PRON	O	O
remained	VERB	O	O
polyuric	ADJ	O	I-Entity
despite	ADP	O	O
normal	ADJ	O	O
blood	NOUN	O	O
glucose	NOUN	O	I-Entity
concentrations	NOUN	O	O
;	PUNCT	O	O
water	NOUN	O	O
deprivation	NOUN	O	O
testing	VERB	O	O
indicated	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
,	PUNCT	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
lithium	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesize	VERB	O	O
that	ADP	O	O
when	ADV	O	O
this	DET	O	O
man	NOUN	O	O
developed	VERB	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
chronic	ADJ	O	O
polyuria	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
was	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
precipitate	VERB	O	O
hyperosmolar	ADJ	O	O
dehydration	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9570197)

Effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intracoronary	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
on	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
large	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
cocaine	NOUN	O	I-Entity
causes	VERB	O	O
a	DET	O	O
profound	ADJ	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
left	VERB	O	I-Entity
ventricular	ADJ	O	I-Entity
(	PUNCT	O	I-Entity
LV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
systolic	ADJ	O	I-Entity
function	NOUN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
LV	PROPN	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
done	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
intracoronary	ADJ	O	O
cocaine	NOUN	O	I-Entity
concentration	NOUN	O	O
on	ADP	O	O
LV	PROPN	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
women	NOUN	O	O
aged	VERB	O	O
39	NUM	O	O
to	PART	O	O
72	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
referred	VERB	O	O
for	ADP	O	O
cardiac	ADJ	O	O
catheterization	NOUN	O	O
for	ADP	O	O
the	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
measured	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
arterial	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
LV	PROPN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
first	ADJ	O	O
derivative	ADJ	O	O
(	PUNCT	O	O
dP	PROPN	O	O
/	SYM	O	O
dt	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
LV	PROPN	O	O
volumes	NOUN	O	O
and	CCONJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
final	ADJ	O	O
2	NUM	O	O
to	PART	O	O
3	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
a	DET	O	O
15-minute	ADJ	O	O
intracoronary	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
(	PUNCT	O	O
n=10	INTJ	O	O
,	PUNCT	O	O
control	NOUN	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
cocaine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
min	NOUN	O	O
(	PUNCT	O	O
n=10	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

With	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
drug	NOUN	O	O
concentration	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
coronary	ADJ	O	O
sinus	NOUN	O	O
was	VERB	O	O
3.0+/-0.4	NUM	O	O
(	PUNCT	O	O
mean+/-SD	NOUN	O	O
)	PUNCT	O	O

/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
in	ADP	O	O
magnitude	NOUN	O	O
to	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
cocaine	NOUN	O	I-Entity
concentration	NOUN	O	O
reported	VERB	O	O
in	ADP	O	O
abusers	NOUN	O	O
dying	VERB	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

Cocaine	PROPN	O	I-Entity
induced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
LV	PROPN	O	O
dP	PROPN	O	O
/	SYM	O	O
dt	X	O	O
(	PUNCT	O	O
positive	ADJ	O	O
or	CCONJ	O	O
negative	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
LV	PROPN	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
caused	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	O
and	CCONJ	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressures	NOUN	O	O
,	PUNCT	O	O
LV	PROPN	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
LV	PROPN	O	O
end	NOUN	O	O
-	PUNCT	O	O
systolic	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
LV	PROPN	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
intracoronary	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
sufficient	ADJ	O	O
in	ADP	O	O
amount	NOUN	O	O
to	PART	O	O
achieve	VERB	O	O
a	DET	O	O
high	ADJ	O	O
drug	NOUN	O	O
concentration	NOUN	O	O
in	ADP	O	O
coronary	ADJ	O	O
sinus	NOUN	O	O
blood	NOUN	O	O
causes	VERB	O	O
a	DET	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
LV	PROPN	O	I-Entity
systolic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
diastolic	ADJ	O	I-Entity
performance	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9646784)

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
paradoxical	ADJ	O	O
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
several	ADJ	O	O
new	ADJ	O	O
anticoagulant	NOUN	O	O
drugs	NOUN	O	O
are	VERB	O	O
in	ADP	O	O
development	NOUN	O	O
,	PUNCT	O	O
heparin	NOUN	O	I-Entity
remains	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
most	ADJ	O	O
anticoagulation	NOUN	O	O
needs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
are	VERB	O	O
meritorious	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
do	VERB	O	O
exist	VERB	O	O
.	PUNCT	O	O

Important	ADJ	O	O
untoward	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
including	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
osteoporosis	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
,	PUNCT	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
,	PUNCT	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
other	ADJ	O	O
than	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
alopecia	NOUN	O	I-Entity
will	VERB	O	O
be	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
this	DET	O	O
article	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9725303)

Nonopaque	PROPN	O	O
crystal	NOUN	O	O
deposition	NOUN	O	O
causing	VERB	O	O
ureteric	ADJ	O	B-Entity
obstruction	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
undergoing	VERB	O	O
indinavir	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
unique	ADJ	O	O
CT	NOUN	O	O
features	NOUN	O	O
of	ADP	O	O
ureteric	ADJ	O	B-Entity
calculi	NOUN	O	I-Entity
in	ADP	O	O
six	NUM	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
indinavir	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
commonly	ADV	O	O
used	VERB	O	O
HIV	PROPN	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
urolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Ureteric	PROPN	O	B-Entity
obstruction	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
precipitated	VERB	O	O
indinavir	NOUN	O	I-Entity
crystals	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
difficult	ADJ	O	O
to	PART	O	O
diagnose	VERB	O	O
with	ADP	O	O
unenhanced	ADJ	O	O
CT	PROPN	O	O
.	PUNCT	O	O

contrast	NOUN	O	O
material	NOUN	O	O
to	PART	O	O
enable	VERB	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
ureteric	ADJ	O	B-Entity
stones	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
obstruction	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
who	NOUN	O	O
receive	VERB	O	O
indinavir	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9759693)

Ischemic	PROPN	O	B-Entity
colitis	NOUN	O	I-Entity
and	CCONJ	O	O
sumatriptan	ADJ	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Sumatriptan	PROPN	O	B-Entity
succinate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
serotonin-1	NOUN	O	I-Entity
(	PUNCT	O	O
5-hydroxytryptamine-1	PUNCT	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
antimigraine	ADJ	O	O
drug	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
reported	VERB	O	O
to	PART	O	O
act	VERB	O	O
by	ADP	O	O
selectively	ADV	O	O
constricting	VERB	O	O
intracranial	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
published	VERB	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
,	PUNCT	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
occurring	NOUN	O	O
after	ADP	O	O
sumatriptan	ADJ	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
serious	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	B-Entity
colitis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
migraine	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
sumatriptan	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9782254)

51	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
medically	ADV	O	O
refractory	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
underwent	VERB	O	O
stereotactic	ADJ	O	O
posteromedial	ADJ	O	O
pallidotomy	NOUN	O	O
between	ADP	O	O
August	PROPN	O	O
1993	NUM	O	O
and	CCONJ	O	O
February	PROPN	O	O
1997	NUM	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
bradykinesia	NOUN	O	I-Entity
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
assessment	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
blinded	VERB	O	O
ratings	NOUN	O	O
of	ADP	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
UPDRS	PROPN	O	O
)	PUNCT	O	O

85	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
dyskinesias	NOUN	O	I-Entity
were	VERB	O	O
relieved	VERB	O	O
of	ADP	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
whether	ADP	O	O
the	DET	O	O
pallidotomies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
the	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
or	CCONJ	O	O
radiofrequency	NOUN	O	O
methods	NOUN	O	O
.	PUNCT	O	O

About	ADV	O	O
2/3	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
both	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
and	CCONJ	O	O
radiofrequency	NOUN	O	O
groups	NOUN	O	O
showed	VERB	O	O
improvements	NOUN	O	O
in	ADP	O	O
bradykinesia	NOUN	O	I-Entity
and	CCONJ	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
when	ADV	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
group	NOUN	O	O
neither	CCONJ	O	O
the	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
nor	CCONJ	O	O
the	DET	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
UPDRS	PROPN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
group	NOUN	O	O
(	PUNCT	O	O
3.4%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
a	DET	O	O
homonymous	ADJ	O	B-Entity
hemianopsia	NOUN	O	I-Entity
9	NUM	O	O
months	NOUN	O	O
following	VERB	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
27.7%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
became	VERB	O	O
transiently	ADV	O	O
confused	ADJ	O	O
postoperatively	ADV	O	O
.	PUNCT	O	O

Gamma	PROPN	O	O
Knife	PROPN	O	O
pallidotomy	NOUN	O	O
is	VERB	O	O
as	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
radiofrequency	NOUN	O	O
pallidotomy	NOUN	O	O
in	ADP	O	O
controlling	VERB	O	O
certain	ADJ	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
only	ADJ	O	O
practical	ADJ	O	O
technique	NOUN	O	O
available	ADJ	O	O
in	ADP	O	O
certain	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
those	DET	O	O
who	NOUN	O	O
take	VERB	O	O
anticoagulants	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
bleeding	NOUN	O	I-Entity
diatheses	NOUN	O	O
or	CCONJ	O	O
serious	ADJ	O	O
systemic	ADJ	O	O
medical	ADJ	O	O
illnesses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9831002)

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
1-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
probably	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
had	VERB	O	O
defects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supratentorial	ADJ	O	O
brain	NOUN	O	O
including	VERB	O	O
the	DET	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
striatum	NOUN	O	O
(	PUNCT	O	O
multicystic	ADJ	O	B-Entity
encephalomalacia	NOUN	O	I-Entity
)	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
perinatal	ADJ	O	O
hypoxic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ischemic	NOUN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
predisposing	NOUN	O	O
factor	NOUN	O	O
causing	VERB	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
methylphenidate	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
via	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
uptake	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
therefore	ADV	O	O
dopaminergic	ADJ	O	O
systems	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
(	PUNCT	O	O
mainly	ADV	O	O
the	DET	O	O
midbrain	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
were	VERB	O	O
unlikely	ADJ	O	O
to	PART	O	O
participate	VERB	O	O
in	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
relative	ADJ	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
ergic	ADJ	O	O
deficiency	NOUN	O	O
might	VERB	O	O
occur	VERB	O	O
because	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
mimetic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
strikingly	ADV	O	O
effective	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
patient	ADJ	O	O
with	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
probably	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9869655)

Differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
17alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
ethinylestradiol	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
neutral	ADJ	O	O
and	CCONJ	O	O
acidic	ADJ	O	O
pathways	NOUN	O	O
of	ADP	O	O
bile	ADJ	O	B-Entity
salt	NOUN	O	I-Entity
synthesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
17alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
ethinylestradiol	NOUN	O	I-Entity
(	PUNCT	O	O
EE	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
neutral	ADJ	O	O
and	CCONJ	O	O
acidic	ADJ	O	O
biosynthetic	ADJ	O	O
pathways	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	B-Entity
salt	NOUN	O	I-Entity
(	PUNCT	O	O
BS	PROPN	O	I-Entity
)	PUNCT	O	O
synthesis	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intact	ADJ	O	O
enterohepatic	ADJ	O	O
circulation	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
bile	NOUN	O	O
diversion	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
BS	PROPN	O	I-Entity
synthesis	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
this	DET	O	O
purpose	NOUN	O	O
,	PUNCT	O	O
bile	ADJ	O	B-Entity
salt	NOUN	O	I-Entity
pool	NOUN	O	O
composition	NOUN	O	O
,	PUNCT	O	O
synthesis	NOUN	O	O
of	ADP	O	O
individual	ADJ	O	O
BS	PROPN	O	I-Entity
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
hepatic	ADJ	O	O
activities	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
expression	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
cholesterol	NOUN	O	I-Entity
7alpha	NUM	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
(	PUNCT	O	O
CYP7A	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sterol	NOUN	O	I-Entity
27-hydroxylase	NOUN	O	O
(	PUNCT	O	O
CYP27	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
of	ADP	O	O
other	ADJ	O	O
enzymes	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
BS	PROPN	O	I-Entity
synthesis	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
analyzed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
EE	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
3	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
its	ADJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

BS	NOUN	O	I-Entity
pool	NOUN	O	O
size	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
27%	NUM	O	O
but	CCONJ	O	O
total	ADJ	O	O
BS	PROPN	O	I-Entity
synthesis	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
EE	NOUN	O	I-Entity
in	ADP	O	O
intact	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Synthesis	NOUN	O	O
of	ADP	O	O
cholate	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
68%	NUM	O	O
in	ADP	O	O
EE	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
that	DET	O	O
of	ADP	O	O
chenodeoxycholate	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
60%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
recently	ADV	O	O
identified	VERB	O	O
Delta22-isomer	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
muricholate	NOUN	O	O
contributed	VERB	O	O
for	ADP	O	O
5.4%	NUM	O	O
and	CCONJ	O	O
18.3	NUM	O	O
%	NOUN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.01	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
pool	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
EE	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
bile	NOUN	O	O
after	ADP	O	O
exhaustion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pool	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
clear	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
BS	PROPN	O	I-Entity
synthesis	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
bile	NOUN	O	O
-	PUNCT	O	O
diverted	VERB	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
EE	PROPN	O	I-Entity
,	PUNCT	O	O
yet	CCONJ	O	O
biliary	ADJ	O	O
BS	PROPN	O	I-Entity
composition	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
minimally	ADV	O	O
affected	VERB	O	O
.	PUNCT	O	O

Activity	NOUN	O	O
of	ADP	O	O
CYP7A	PROPN	O	O
was	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
EE	PROPN	O	I-Entity
in	ADP	O	O
both	DET	O	O
intact	ADJ	O	O
and	CCONJ	O	O
bile	NOUN	O	O
-	PUNCT	O	O
diverted	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
CYP27	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
.	PUNCT	O	O

Hepatic	ADJ	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
CYP7A	PROPN	O	O
were	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
EE	PROPN	O	I-Entity
in	ADP	O	O
bile	NOUN	O	O
-	PUNCT	O	O
diverted	VERB	O	O
rats	NOUN	O	O
only	ADV	O	O
;	PUNCT	O	O
CYP27	NUM	O	O
mRNA	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
sterol	NOUN	O	I-Entity
12alpha	NUM	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
and	CCONJ	O	O
lithocholate	NOUN	O	O

6beta	NUM	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
were	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
bile	NOUN	O	O
diversion	NOUN	O	O
and	CCONJ	O	O
suppressed	VERB	O	O
by	ADP	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
17alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
ethinylestradiol	NOUN	O	I-Entity
(	PUNCT	O	O
EE)-induced	VERB	O	I-Entity
intrahepatic	ADJ	O	B-Entity
cholestasis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
selective	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neutral	ADJ	O	O
pathway	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	B-Entity
salt	NOUN	O	I-Entity
(	PUNCT	O	O
BS	PROPN	O	I-Entity
)	PUNCT	O	O
synthesis	NOUN	O	O
.	PUNCT	O	O

Simultaneous	ADJ	O	O
impairment	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
enzymes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BS	PROPN	O	I-Entity
biosynthetic	NOUN	O	O
pathways	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
overall	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
EE	NOUN	O	I-Entity
on	ADP	O	O
BS	PROPN	O	I-Entity
synthesis	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9881641)

Glibenclamide	PROPN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
hypotension	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
helodermin	NOUN	O	I-Entity
assessed	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
helodermin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
basic	ADJ	O	O
35-amino	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
peptide	NOUN	O	O
isolated	VERB	O	O
from	ADP	O	O
the	DET	O	O
venom	NOUN	O	O
of	ADP	O	O
a	DET	O	O
lizard	NOUN	O	O
salivary	ADJ	O	O
gland	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
focusing	VERB	O	O
on	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
ATP	PROPN	O	I-Entity
sensitive	ADJ	O	O
K+	PROPN	O	I-Entity
(	PUNCT	O	O
K(ATP	PROPN	O	I-Entity
)	PUNCT	O	O
)	PUNCT	O	O
channels	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
responses	NOUN	O	O
.	PUNCT	O	O

Helodermin	PROPN	O	I-Entity
produced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
with	ADP	O	O
approximately	ADV	O	O
similar	ADJ	O	O
potency	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
to	ADP	O	O
VIP	PROPN	O	O
.	PUNCT	O	O

Hypotension	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
both	DET	O	O
peptides	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
by	ADP	O	O
glibenclamide	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
abolished	VERB	O	O
a	DET	O	O
levcromakalim	NOUN	O	I-Entity
-	PUNCT	O	O
produced	VERB	O	O
decrease	NOUN	O	O
in	ADP	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Oxyhemoglobin	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
helodermin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
shortened	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh)-produced	VERB	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
helodermin	NOUN	O	I-Entity
-	PUNCT	O	O
produced	VERB	O	O
hypotension	NOUN	O	I-Entity
is	VERB	O	O
partly	ADV	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
glibenclamide	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
K+	PROPN	O	I-Entity
channels	NOUN	O	O
(	PUNCT	O	O
K(ATP	PROPN	O	I-Entity
)	PUNCT	O	O
channels	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
presumably	ADV	O	O
exist	VERB	O	O
on	ADP	O	O
arterial	ADJ	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

EDRF	PROPN	O	O
(	PUNCT	O	O
endothelium	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
relaxing	VERB	O	O
factor)/nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
peptide	NOUN	O	O
-	PUNCT	O	O
produced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9889429)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	I-Entity
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
tablets	NOUN	O	O
for	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
psoriasis	NOUN	O	I-Entity
.	PUNCT	O	O

Thirteen	NUM	O	O
psoriatic	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
therapy	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
25	NUM	O	O
months	NOUN	O	O
with	ADP	O	O
a	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
antihypertensive	ADJ	O	O
effects	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Seven	NUM	O	O
of	ADP	O	O
the	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
exhibited	VERB	O	O
a	DET	O	O
subclinical	ADJ	O	O
hypertensive	ADJ	O	I-Entity
state	NOUN	O	O
before	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	DET	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
of	ADP	O	O
these	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
decreased	VERB	O	O
significantly	ADV	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
within	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
thereafter	ADV	O	O
for	ADP	O	O
25	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
adverse	ADJ	O	O
events	NOUN	O	O
during	ADP	O	O
combined	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
and	CCONJ	O	O
nifedipine	NOUN	O	I-Entity
included	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
9	NUM	O	O
of	ADP	O	O
the	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
development	NOUN	O	O
of	ADP	O	O
gingival	NOUN	O	B-Entity
hyperplasia	NOUN	O	I-Entity
in	ADP	O	O
2	NUM	O	O
of	ADP	O	O
the	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
nifedipine	NOUN	O	I-Entity
is	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
hypertensive	ADJ	O	I-Entity
psoriatic	ADJ	O	I-Entity
patients	NOUN	O	O
under	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
that	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
gingival	NOUN	O	B-Entity
hyperplasia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10087562)

Torsade	PROPN	O	B-Entity
de	PROPN	O	I-Entity
pointes	VERB	O	I-Entity
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
during	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
intermittent	ADJ	O	O
dobutamine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
describe	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
56-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
,	PUNCT	O	O
severe	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
and	CCONJ	O	O
torsade	VERB	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
during	ADP	O	O
one	NUM	O	O
cycle	NOUN	O	O
of	ADP	O	O
intermittent	ADJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
mcg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
min	NOUN	O	O
)	PUNCT	O	O

dobutamine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
of	ADP	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
during	ADP	O	O
intermittent	ADJ	O	O
dobutamine	NOUN	O	I-Entity
supports	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
unpredictable	ADJ	O	O
fatal	ADJ	O	O
arrhythmias	NOUN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
even	ADV	O	O
with	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
rhythm	NOUN	O	O
disturbances	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
proarrhythmic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Dubutamine	PROPN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10219427)

Positive	ADJ	O	O
skin	NOUN	O	O
tests	NOUN	O	O
in	ADP	O	O
late	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
radiographic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
last	ADJ	O	O
few	ADJ	O	O
years	NOUN	O	O
delayed	VERB	O	O
reactions	NOUN	O	O
several	ADJ	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
radiographic	ADJ	O	O
and	CCONJ	O	O
contrast	ADJ	O	B-Entity
materials	NOUN	O	I-Entity
(	PUNCT	O	O
PRC	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
with	ADP	O	O
increasing	VERB	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
report	VERB	O	O
two	NUM	O	O
observations	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
delayed	VERB	O	O
reactions	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
intradermoreactions	NOUN	O	O
(	PUNCT	O	O
IDR	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
patch	NOUN	O	O
tests	NOUN	O	O
to	ADP	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
ionic	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
ionic	ADJ	O	O
PRC	PROPN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
angiography	NOUN	O	O
by	ADP	O	O
the	DET	O	O
venous	ADJ	O	O
route	NOUN	O	O
in	ADP	O	O
patient	NOUN	O	O
n	CCONJ	O	O
degree	NOUN	O	O
1	NUM	O	O
a	DET	O	O
biphasic	ADJ	O	O
reaction	NOUN	O	O
with	ADP	O	O
an	DET	O	O
immediate	ADJ	O	O
reaction	NOUN	O	O
(	PUNCT	O	O
dyspnea	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
consciousness	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
delayed	VERB	O	O
macro	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
papular	ADJ	O	I-Entity
rash	NOUN	O	I-Entity
appeared	VERB	O	O
,	PUNCT	O	O
whilst	ADV	O	O
patient	ADJ	O	O
n	CCONJ	O	O
degree	NOUN	O	O
2	NUM	O	O
developed	VERB	O	O
a	DET	O	O
generalised	ADJ	O	O
sensation	NOUN	O	O
of	ADP	O	O
heat	NOUN	O	O
,	PUNCT	O	O
persistent	ADJ	O	O
pain	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
site	NOUN	O	O
of	ADP	O	O
injection	NOUN	O	O
immediately	ADV	O	O
and	CCONJ	O	O
a	DET	O	O
generalised	VERB	O	O
macro	NOUN	O	O
-	PUNCT	O	O
papular	ADJ	O	O
reaction	NOUN	O	O
after	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
skin	NOUN	O	O
tests	NOUN	O	O
revealed	VERB	O	O
positive	ADJ	O	O
delayed	VERB	O	O
reactions	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
48	NUM	O	O
hours	NOUN	O	O
by	ADP	O	O
IDR	PROPN	O	O
and	CCONJ	O	O
patch	NOUN	O	O
tests	NOUN	O	O
to	PART	O	O
only	ADV	O	O
some	DET	O	O
PRC	PROPN	O	I-Entity
with	ADP	O	O
common	ADJ	O	O
chains	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
structures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
positive	ADJ	O	O
skin	NOUN	O	O
tests	NOUN	O	O
are	VERB	O	O
in	ADP	O	O
favour	NOUN	O	O
of	ADP	O	O
immunological	ADJ	O	O
reactions	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
help	VERB	O	O
in	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
allergy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10327032)

Risk	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
hyperammonemic	ADJ	O	B-Entity
encephalopathy	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
with	ADP	O	O
the	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
dehydration	NOUN	O	I-Entity
and	CCONJ	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
1986	NUM	O	O
to	ADP	O	O
1998	NUM	O	O
,	PUNCT	O	O
29	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
32	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
hyperammonemic	NOUN	O	B-Entity
encephalopathy	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-fluorouracil	PROPN	O	I-Entity
(	PUNCT	O	O
5-FU	PUNCT	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
decompensated	VERB	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Onset	PROPN	O	O
of	ADP	O	O
hyperammonemic	ADJ	O	B-Entity
encephalopathy	NOUN	O	I-Entity
varied	VERB	O	O
from	ADP	O	O
0.5	NUM	O	O
to	PART	O	O
5	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
:	PUNCT	O	O
2.6	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

Plasma	PROPN	O	O
ammonium	NOUN	O	I-Entity
level	NOUN	O	O
ranged	VERB	O	O
from	ADP	O	O
248	NUM	O	O
to	ADP	O	O
2387	NUM	O	O
microg%	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
:	PUNCT	O	O
626	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
32	NUM	O	O
episodes	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
(	PUNCT	O	O
81%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
various	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
azotemia	NOUN	O	I-Entity
,	PUNCT	O	O
18	NUM	O	O
(	PUNCT	O	O
56%	NUM	O	O
)	PUNCT	O	O
occurred	VERB	O	O
during	ADP	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
and	CCONJ	O	O
14	NUM	O	O
(	PUNCT	O	O
44%	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
infection	NOUN	O	I-Entity
occurred	VERB	O	O
during	ADP	O	O
periods	NOUN	O	O
of	ADP	O	O
dehydration	NOUN	O	I-Entity
.	PUNCT	O	O

Higher	ADJ	O	O
plasma	NOUN	O	O
ammonium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
more	ADV	O	O
rapid	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
(	PUNCT	O	O
p=0.003	PUNCT	O	O
and	CCONJ	O	O
0.0006	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
nine	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
high	ADJ	O	O
daily	ADJ	O	O
doses	NOUN	O	O
(	PUNCT	O	O
2600	NUM	O	O
or	CCONJ	O	O
1800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
(	PUNCT	O	O
p=0.0001	NOUN	O	O
and	CCONJ	O	O

In	ADP	O	O
25	NUM	O	O
out	ADP	O	O
of	ADP	O	O
32	NUM	O	O
episodes	NOUN	O	O
(	PUNCT	O	O
78%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
ammonium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
status	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
adequate	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
hyperammonemic	ADJ	O	B-Entity
encephalopathy	NOUN	O	I-Entity
can	VERB	O	O
occur	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
.	PUNCT	O	O

Azotemia	PROPN	O	I-Entity
,	PUNCT	O	O
body	NOUN	O	O
fluid	ADJ	O	O
insufficiency	NOUN	O	O
and	CCONJ	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
were	VERB	O	O
frequently	ADV	O	O
found	VERB	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
therefore	ADV	O	O
important	ADJ	O	O
to	PART	O	O
recognize	VERB	O	O
this	DET	O	O
condition	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10390729)

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
and	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
on	ADP	O	O
conditioned	VERB	O	O
place	NOUN	O	O
preference	NOUN	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
motor	NOUN	O	O
activity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
unselective	ADJ	O	O
potassium	NOUN	O	I-Entity
(	PUNCT	O	O
K(+)-	PROPN	O	I-Entity
)	PUNCT	O	O
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
quinine	NOUN	O	I-Entity
(	PUNCT	O	O
12.5	NUM	O	O
,	PUNCT	O	O
25	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
conditioned	VERB	O	O
place	NOUN	O	O
preference	NOUN	O	O
and	CCONJ	O	O
biphasic	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
motor	NOUN	O	O
activity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Quinine	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
block	VERB	O	O
voltage-	NOUN	O	O
,	PUNCT	O	O
calcium-	ADJ	O	I-Entity
and	CCONJ	O	O
ATP	PROPN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
K(+)-channels	NOUN	O	I-Entity
while	ADP	O	O
4-aminopyridine	NUM	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
block	VERB	O	O
voltage	NOUN	O	O
-	PUNCT	O	O
sensitive	ADJ	O	O
K(+)-channels	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
counterbalanced	ADJ	O	O
method	NOUN	O	O
,	PUNCT	O	O
quinine	ADV	O	I-Entity
attenuated	ADJ	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
place	NOUN	O	O
preference	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
4-aminopyridine	NUM	O	I-Entity
was	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
motor	NOUN	O	O
activity	NOUN	O	O
test	NOUN	O	O
measured	VERB	O	O
with	ADP	O	O
an	DET	O	O
Animex	PROPN	O	O
-	PUNCT	O	O
activity	NOUN	O	O
meter	NOUN	O	O
neither	DET	O	O
of	ADP	O	O
the	DET	O	O
K(+)-channel	PROPN	O	I-Entity
blockers	NOUN	O	O
affected	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypoactivity	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
both	DET	O	O
K(+)-channel	NUM	O	I-Entity
blockers	NOUN	O	O
prevented	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
4-aminopyridine	NUM	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
K(+)-channels	NOUN	O	I-Entity
in	ADP	O	O
morphine	NOUN	O	I-Entity
reward	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
also	ADV	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
K(+)-channels	NOUN	O	I-Entity
sensitive	ADJ	O	O
to	ADP	O	O
these	DET	O	O
blockers	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
sufficient	ADJ	O	O
to	PART	O	O
prevent	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypoactivity	NOUN	O	I-Entity
whereas	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
connected	VERB	O	O
to	ADP	O	O
both	DET	O	O
quinine-	NOUN	O	I-Entity
and	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
K(+)-channels	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10401555)

Nociceptin	PROPN	O	I-Entity
/	SYM	O	O
orphanin	ADV	O	B-Entity
FQ	PROPN	O	I-Entity
and	CCONJ	O	O
nocistatin	NOUN	O	I-Entity
on	ADP	O	O
learning	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
impairment	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O

Nociceptin	PROPN	O	I-Entity
,	PUNCT	O	O
also	ADV	O	O
known	VERB	O	O
as	ADP	O	O
orphanin	NOUN	O	B-Entity
FQ	PROPN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
endogenous	ADJ	O	O
ligand	NOUN	O	O
for	ADP	O	O
the	DET	O	O
orphan	NOUN	O	O
opioid	ADJ	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
receptor	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
ORL1	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
involves	VERB	O	O
in	ADP	O	O
various	ADJ	O	O
functions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
nocistatin	NOUN	O	I-Entity
is	VERB	O	O
recently	ADV	O	O
isolated	VERB	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
precursor	NOUN	O	O
as	ADP	O	O
nociceptin	NOUN	O	I-Entity
and	CCONJ	O	O
blocks	NOUN	O	O
nociceptin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
allodynia	NOUN	O	I-Entity
and	CCONJ	O	O
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
nociceptin	NOUN	O	I-Entity
/	SYM	O	O
orphanin	NOUN	O	B-Entity
FQ	PROPN	O	I-Entity
and	CCONJ	O	O
nocistatin	NOUN	O	I-Entity
could	VERB	O	O
modulate	VERB	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
muscarinic	ADJ	O	O
cholinergic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
of	ADP	O	O
Y	PROPN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
and	CCONJ	O	O
step	VERB	O	O
-	PUNCT	O	O
down	PART	O	O
type	NOUN	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
tasks	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
nocistatin	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
-	SYM	O	O
5.0	NUM	O	O
nmol	NOUN	O	O
mouse-1	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O

administered	VERB	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
performance	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
training	NOUN	O	O
session	NOUN	O	O
of	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
or	CCONJ	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
behaviours	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
lower	ADJ	O	O
per	ADP	O	O
cent	NOUN	O	O
alternation	NOUN	O	O
and	CCONJ	O	O
shorter	ADJ	O	O
median	ADJ	O	O
step	NOUN	O	O
-	PUNCT	O	O
down	PART	O	O
latency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
retention	NOUN	O	O
test	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
nociceptin	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
and/or	CCONJ	O	O
5.0	NUM	O	O
nmol	NOUN	O	O
mouse-1	NOUN	O	O
,	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
nocistatin	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
and/or	CCONJ	O	O
5.0	NUM	O	O
nmol	NOUN	O	O
mouse-1	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
performance	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
training	NOUN	O	O
session	NOUN	O	O
of	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
,	PUNCT	O	O
attenuated	VERB	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
impairment	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
and	CCONJ	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
behaviours	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
nocistatin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
biologically	ADV	O	O
active	ADJ	O	O
peptide	NOUN	O	O
,	PUNCT	O	O
ameliorates	VERB	O	O
impairments	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
and	CCONJ	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
suggested	VERB	O	O
that	ADP	O	O
these	DET	O	O
peptides	NOUN	O	O
play	VERB	O	O
opposite	ADJ	O	O
roles	NOUN	O	O
in	ADP	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10427794)

Meloxicam	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
cytolytic	ADJ	O	O
hepatitis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
meloxicam	NOUN	O	I-Entity
.	PUNCT	O	O

Recently	ADV	O	O
introduced	VERB	O	O
in	ADP	O	O
Belgium	PROPN	O	O
,	PUNCT	O	O
meloxicam	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
nonsteroidal	ADJ	O	O
antiinflammatory	ADJ	O	O
drug	NOUN	O	O
with	ADP	O	O
selective	ADJ	O	O
action	NOUN	O	O
on	ADP	O	O
the	DET	O	O
inducible	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
cyclooxygenase	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	O
cytolytic	NOUN	O	O
hepatitis	NOUN	O	I-Entity
occurred	VERB	O	O
rapidly	ADV	O	O
after	ADP	O	O
meloxicam	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
antinuclear	ADJ	O	O
antibodies	NOUN	O	O
suggesting	VERB	O	O
a	DET	O	O
hypersensitivity	NOUN	O	I-Entity
mechanism	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
meloxicam	NOUN	O	I-Entity
related	VERB	O	O
liver	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
demonstrates	VERB	O	O
the	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
hepatic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10462057)

Induction	NOUN	O	O
of	ADP	O	O
apoptosis	NOUN	O	O
by	ADP	O	O
remoxipride	NOUN	O	I-Entity
metabolites	NOUN	O	O
in	ADP	O	O
HL60	PROPN	O	O
and	CCONJ	O	O
CD34+/CD19-	PROPN	O	O
human	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
progenitor	NOUN	O	O
cells	NOUN	O	O
:	PUNCT	O	O
potential	ADJ	O	O
relevance	NOUN	O	O
to	ADP	O	O
remoxipride	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
antipsychotic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
remoxipride	NOUN	O	I-Entity
[	PUNCT	O	O
(	PUNCT	O	B-Entity
S)-(-)-3-bromo	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	PROPN	O	I-Entity
amide	NOUN	O	I-Entity
]	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acquired	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
examined	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
remoxipride	NOUN	O	I-Entity
,	PUNCT	O	O
three	NUM	O	O
pyrrolidine	NOUN	O	I-Entity
ring	NOUN	O	O
metabolites	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
aromatic	ADJ	O	O
ring	NOUN	O	O
metabolites	NOUN	O	O
of	ADP	O	O
the	DET	O	O
parent	NOUN	O	O
compound	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
HL60	PROPN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
human	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
progenitor	NOUN	O	O
(	PUNCT	O	O
HBMP	PROPN	O	O
)	PUNCT	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Apoptosis	PROPN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
fluorescence	NOUN	O	O
microscopy	NOUN	O	O
in	ADP	O	O
Hoechst	PROPN	O	B-Entity
33342-	PROPN	O	I-Entity
and	CCONJ	O	O
propidium	NOUN	O	B-Entity
iodide	ADV	O	I-Entity
stained	VERB	O	O
cell	NOUN	O	O
samples	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
catechol	NOUN	O	I-Entity
and	CCONJ	O	O
hydroquinone	NOUN	O	I-Entity
metabolites	NOUN	O	O
,	PUNCT	O	O
NCQ436	PROPN	O	I-Entity
and	CCONJ	O	O
NCQ344	PROPN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
HL60	PROPN	O	O
and	CCONJ	O	O
HBMP	PROPN	O	O
cells	NOUN	O	O
in	ADP	O	O
a	DET	O	O
time-	NOUN	O	O
and	CCONJ	O	O
concentration	NOUN	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
phenols	NOUN	O	I-Entity
,	PUNCT	O	O
NCR181	PROPN	O	O
,	PUNCT	O	O
FLA873	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
FLA797	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
derivatives	NOUN	O	O
formed	VERB	O	O
by	ADP	O	O
oxidation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pyrrolidine	NOUN	O	I-Entity
ring	NOUN	O	O
,	PUNCT	O	O
FLA838	PROPN	O	O
,	PUNCT	O	O
NCM001	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
NCL118	PROPN	O	O
,	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
necrosis	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
cells	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
NCQ436	PROPN	O	I-Entity
but	CCONJ	O	O
NCQ344	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
biphasic	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
both	DET	O	O
cell	NOUN	O	O
types	NOUN	O	O
,	PUNCT	O	O
inducing	VERB	O	O
apoptosis	NOUN	O	O
at	ADP	O	O
lower	ADJ	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
necrosis	NOUN	O	I-Entity
at	ADP	O	O
higher	ADJ	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
catechol	NOUN	O	I-Entity
and	CCONJ	O	O
hydroquinone	NOUN	O	I-Entity
metabolites	NOUN	O	O
of	ADP	O	O
remoxipride	NOUN	O	I-Entity
have	VERB	O	O
direct	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
HL60	PROPN	O	O
and	CCONJ	O	O
HBMP	PROPN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
apoptosis	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
phenol	NOUN	O	I-Entity
metabolites	NOUN	O	O
were	VERB	O	O
inactive	ADJ	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
benzene	NOUN	O	I-Entity
-	PUNCT	O	O
derived	VERB	O	O
catechol	NOUN	O	I-Entity
and	CCONJ	O	O
hydroquinone	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
phenol	NOUN	O	I-Entity
,	PUNCT	O	O
induce	VERB	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
HBMP	PROPN	O	O
cells	NOUN	O	O

We	PRON	O	O
propose	VERB	O	O
that	DET	O	O
remoxipride	NOUN	O	I-Entity
and	CCONJ	O	O
benzene	NOUN	O	I-Entity
may	VERB	O	O
induce	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
via	ADP	O	O
production	NOUN	O	O
of	ADP	O	O
similar	ADJ	O	O
reactive	ADJ	O	O
metabolites	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
NCQ436	PROPN	O	I-Entity
and	CCONJ	O	O
NCQ344	PROPN	O	I-Entity
to	PART	O	O
induce	VERB	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
HBMP	PROPN	O	O
cells	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
underlying	VERB	O	O
acquired	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
that	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
remoxipride	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10510854)

Synthesis	NOUN	O	O
and	CCONJ	O	O
preliminary	ADJ	O	O
pharmacological	ADJ	O	O
investigations	NOUN	O	O
of	ADP	O	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	NUM	O	I-Entity
derivatives	NOUN	O	O
as	ADP	O	O
potential	ADJ	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
synthesis	NOUN	O	O
and	CCONJ	O	O
preliminary	ADJ	O	O
pharmacological	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
potential	ADJ	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
structure	NOUN	O	O
of	ADP	O	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	NUM	O	I-Entity
(	PUNCT	O	O
7	NUM	O	O
)	PUNCT	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Compound	PROPN	O	O
7e	PROPN	O	O
,	PUNCT	O	O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	NUM	O	B-Entity
dro-1H-	NOUN	O	I-Entity
indol-2-one	NOUN	O	I-Entity
,	PUNCT	O	O
from	ADP	O	O
this	DET	O	O
series	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
affinities	NOUN	O	O
at	ADP	O	O
the	DET	O	O
5-HT1A	PROPN	O	O
and	CCONJ	O	O
5-HT2A	NUM	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
affinity	NOUN	O	O
at	ADP	O	O
the	DET	O	O
D2	PROPN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

7e	PUNCT	O	O
exhibits	VERB	O	O
a	DET	O	O
high	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
indicating	VERB	O	O
its	ADJ	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
nature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10672628)

Sub	PROPN	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
oxide	NOUN	O	I-Entity
synthesis	NOUN	O	O
modifies	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
NADPH	PROPN	O	I-Entity
-	PUNCT	O	O
diaphorase	NOUN	O	O
neurons	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

NG	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
nitro	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	PROPN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
NOS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
induces	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
undergoes	VERB	O	O
rapid	ADJ	O	O
tolerance	NOUN	O	O
,	PUNCT	O	O
showing	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
after	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
influence	VERB	O	O
dopaminergic	ADJ	O	O
neurotransmission	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

Neuroleptic	ADJ	O	O
drugs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
block	VERB	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
,	PUNCT	O	O
also	ADV	O	O
cause	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rodents	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
subchronic	ADJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
neurons	NOUN	O	O
in	ADP	O	O
areas	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
motor	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

Male	VERB	O	O
albino	ADJ	O	O
Swiss	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
sub	NOUN	O	O
-	PUNCT	O	O
chronically	ADV	O	O
(	PUNCT	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

or	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Catalepsy	PROPN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Reduced	VERB	O	O
nicotinamide	NOUN	O	B-Entity
adenine	NOUN	O	I-Entity
dinucleotide	ADJ	O	I-Entity
phosphate	NOUN	O	I-Entity
-	PUNCT	O	O
diaphorase	NOUN	O	O
(	PUNCT	O	O
NADPH	PROPN	O	I-Entity
-	PUNCT	O	O
d	PROPN	O	O
)	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
sub	NOUN	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
produced	VERB	O	O
tolerance	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
and	CCONJ	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
also	ADV	O	O
induced	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
NADPH	PROPN	O	I-Entity
-	PUNCT	O	O
d	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dorsal	NOUN	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
caudate	NOUN	O	O
and	CCONJ	O	O
accumbens	VERB	O	O
nuclei	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
pedunculopontine	NOUN	O	O
tegmental	ADJ	O	O
nucleus	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
NADPH	PROPN	O	I-Entity
-	PUNCT	O	O
d	PROPN	O	O
neuron	NOUN	O	O
number	NOUN	O	O
in	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
,	PUNCT	O	O
pars	NOUN	O	O
compacta	VERB	O	O
in	ADP	O	O
both	DET	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
results	NOUN	O	O
give	VERB	O	O
further	ADJ	O	O
support	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
NO	NOUN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
motor	NOUN	O	O
behavior	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
it	PRON	O	O
may	VERB	O	O
take	VERB	O	O
part	NOUN	O	O
in	ADP	O	O
the	DET	O	O
synaptic	ADJ	O	O
changes	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
antipsychotic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10677406)

Prolonged	VERB	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
occurs	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
both	CCONJ	O	O
dobutamine	NOUN	O	I-Entity
and	CCONJ	O	O
exercise	NOUN	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischaemia	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
pharmacological	ADJ	O	O
stress	NOUN	O	O
leads	VERB	O	O
to	ADP	O	O
prolonged	VERB	O	O
but	CCONJ	O	O
reversible	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
seen	VERB	O	O
after	ADP	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	ADJ	O	O
crossover	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
systolic	NOUN	O	O
and	CCONJ	O	O
diastolic	NOUN	O	O
left	VERB	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
after	ADP	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
dobutamine	NOUN	O	I-Entity
induced	VERB	O	O
ischaemia	NOUN	O	I-Entity
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
:	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	B-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
angiographically	ADV	O	O
proven	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
normal	ADJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
:	PUNCT	O	O
Treadmill	NOUN	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
dobutamine	NOUN	O	I-Entity
stress	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
different	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
maximum	ADJ	O	O
double	ADJ	O	O
product	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.53	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ST	PROPN	O	O
depression	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.63	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
either	DET	O	O
form	NOUN	O	O
of	ADP	O	O
stress	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
at	ADP	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
(	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
-5.6	PROPN	O	O
(	PUNCT	O	O
1.5)%	PROPN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
-6.1	PROPN	O	O
(	PUNCT	O	O
2.2)%	PROPN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0	NUM	O	O
.	PUNCT	O	O
01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
30	NUM	O	O
and	CCONJ	O	O
45	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
dobutamine	NOUN	O	I-Entity
(	PUNCT	O	O
-10.8	PROPN	O	O
(	PUNCT	O	O
1.8)%	NUM	O	O
and	CCONJ	O	O
-5	NUM	O	O
.	PUNCT	O	O

Regional	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
worst	ADJ	O	O
affected	ADJ	O	O
segment	NOUN	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
-27.9	PROPN	O	O
(	PUNCT	O	O
7.2)%	PUNCT	O	O
and	CCONJ	O	O
-28.6	PUNCT	O	O
(	PUNCT	O	O
5.7)%	X	O	O
,	PUNCT	O	O
both	DET	O	O
p	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
dobutamine	NOUN	O	I-Entity

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
dobutamine	NOUN	O	I-Entity
induced	VERB	O	O
ischaemia	NOUN	O	I-Entity
results	NOUN	O	O
in	ADP	O	O
prolonged	VERB	O	O
reversible	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
presumed	VERB	O	O
to	PART	O	O
be	VERB	O	O
myocardial	ADJ	O	B-Entity
stunning	ADJ	O	I-Entity
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
seen	VERB	O	O
after	ADP	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Dobutamine	PROPN	O	I-Entity
induced	VERB	O	O
ischaemia	NOUN	O	I-Entity
could	VERB	O	O
therefore	ADV	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
further	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10713017)

Anorexigens	PROPN	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
:	PUNCT	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
surveillance	NOUN	O	O
of	ADP	O	O
North	ADJ	O	O
American	ADJ	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	O
suppressants	NOUN	O	O
in	ADP	O	O
Europe	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
PPH	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
fenfluramine	ADJ	O	I-Entity
appetite	NOUN	O	O
suppressants	NOUN	O	O
became	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
but	CCONJ	O	O
were	VERB	O	O
withdrawn	VERB	O	O
in	ADP	O	O
September	PROPN	O	O
1997	NUM	O	O
because	ADP	O	O
of	ADP	O	O
concerns	NOUN	O	O
over	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
surveillance	NOUN	O	O
study	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
at	ADP	O	O
12	NUM	O	O
large	ADJ	O	O
referral	ADJ	O	O
centers	NOUN	O	O
in	ADP	O	O
North	PROPN	O	O
America	PROPN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
collected	VERB	O	O
on	ADP	O	O
patients	NOUN	O	O
seen	VERB	O	O
from	ADP	O	O
September	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
1996	NUM	O	O
,	PUNCT	O	O
to	ADP	O	O
December	PROPN	O	O
31	NUM	O	O
,	PUNCT	O	O
1997	NUM	O	O
,	PUNCT	O	O
included	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
severity	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
identifiable	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
were	VERB	O	O
classed	VERB	O	O
as	ADP	O	O
PPH	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
history	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
exposure	NOUN	O	O
also	ADV	O	O
was	VERB	O	O
taken	VERB	O	O
with	ADP	O	O
special	ADJ	O	O
attention	NOUN	O	O
on	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antidepressants	NOUN	O	O
,	PUNCT	O	O
anorexigens	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
amphetamines	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
hundred	NUM	O	O
seventy	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
,	PUNCT	O	O
205	NUM	O	O
with	ADP	O	O
PPH	PROPN	O	I-Entity
and	CCONJ	O	O
374	NUM	O	O
with	ADP	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
from	ADP	O	O
other	ADJ	O	O
causes	NOUN	O	O
(	PUNCT	O	O
secondary	ADJ	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
[	PUNCT	O	O
SPH	PROPN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
medications	NOUN	O	O
surveyed	VERB	O	O
,	PUNCT	O	O
only	ADV	O	O
the	DET	O	O
fenfluramines	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
preferential	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
PPH	PROPN	O	I-Entity
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
SPH	PROPN	O	O
(	PUNCT	O	O
adjusted	VERB	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
use	NOUN	O	O
>	SYM	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
7.5	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.7	NUM	O	O
to	PART	O	O
32.4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
association	NOUN	O	O
with	ADP	O	O
PPH	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
increasing	VERB	O	O
duration	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
specificity	NOUN	O	O
for	ADP	O	O
fenfluramines	NOUN	O	I-Entity
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
previous	ADJ	O	O
studies	NOUN	O	O
indicating	VERB	O	O
that	ADP	O	O
fenfluramines	NOUN	O	I-Entity
are	VERB	O	O
causally	ADV	O	O
related	VERB	O	O
to	ADP	O	O
PPH	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
high	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
anorexigen	NOUN	O	O
use	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SPH	PROPN	O	O
also	ADV	O	O
raises	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
precipitate	VERB	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
underlying	ADJ	O	O
conditions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
SPH	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (10726030)

Clinical	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
,	PUNCT	O	O
first	ADV	O	O
used	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
the	DET	O	O
clotting	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
clinically	ADV	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
thrombosis	NOUN	O	I-Entity
for	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
50	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
several	ADJ	O	O
new	ADJ	O	O
anticoagulant	NOUN	O	O
drugs	NOUN	O	O
are	VERB	O	O
in	ADP	O	O
development	NOUN	O	O
,	PUNCT	O	O
heparin	NOUN	O	I-Entity
remains	VERB	O	O
the	DET	O	O
anticoagulant	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
acute	ADJ	O	O
thrombotic	ADJ	O	I-Entity
episodes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
are	VERB	O	O
meritorious	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
do	VERB	O	O
exist	VERB	O	O
.	PUNCT	O	O

Bleeding	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
untoward	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O

Major	ADJ	O	O
bleeding	NOUN	O	I-Entity
is	VERB	O	O
of	ADP	O	O
primary	ADJ	O	O
concern	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
additional	ADJ	O	O
important	ADJ	O	O
untoward	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
include	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
osteoporosis	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
,	PUNCT	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
,	PUNCT	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
other	ADJ	O	O
than	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
alopecia	NOUN	O	I-Entity
,	PUNCT	O	O
transaminasemia	NOUN	O	O
,	PUNCT	O	O
hyperkalemia	NOUN	O	I-Entity
,	PUNCT	O	O
hypoaldosteronism	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
priapism	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
are	VERB	O	O
relatively	ADV	O	O
rare	ADJ	O	O
in	ADP	O	O
a	DET	O	O
given	VERB	O	O
individual	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
given	VERB	O	O
the	DET	O	O
extremely	ADV	O	O
widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
some	DET	O	O
are	VERB	O	O
quite	ADV	O	O
common	ADJ	O	O
,	PUNCT	O	O
particularly	ADV	O	O
HITT	PROPN	O	I-Entity
and	CCONJ	O	O
osteoporosis	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
reasonable	ADJ	O	O
incidences	NOUN	O	O
of	ADP	O	O
many	ADJ	O	O
of	ADP	O	O
these	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
"	PUNCT	O	O
softly	ADV	O	O
"	PUNCT	O	O
deduced	VERB	O	O
from	ADP	O	O
current	ADJ	O	O
reports	NOUN	O	O
dealing	VERB	O	O
with	ADP	O	O
unfractionated	ADJ	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
present	NOUN	O	O
the	DET	O	O
incidences	NOUN	O	O
of	ADP	O	O
these	DET	O	O
side	ADJ	O	O
effects	NOUN	O	O
with	ADP	O	O
newer	ADJ	O	O
low	ADJ	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
heparins	NOUN	O	I-Entity
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
much	ADJ	O	O
less	ADV	O	O
common	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (10764869)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
on	ADP	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
FK506	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
,	PUNCT	O	O
Prograf	PROPN	O	O
;	PUNCT	O	O
Fujisawa	PROPN	O	O
USA	PROPN	O	O
,	PUNCT	O	O
Inc	PROPN	O	O
,	PUNCT	O	O
Deerfield	PROPN	O	O
,	PUNCT	O	O
Illinois	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
immunosuppression	NOUN	O	O
after	ADP	O	O
orthotropic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
58-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
after	ADP	O	O
orthotropic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
serial	ADJ	O	O
neuro	NOUN	O	O
-	PUNCT	O	O
ophthalmologic	ADJ	O	O
examinations	NOUN	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
episodic	ADJ	O	O
deterioration	NOUN	O	O
of	ADP	O	O
vision	NOUN	O	O
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
clinical	ADJ	O	O
features	NOUN	O	O
resembling	VERB	O	O
ischemic	ADJ	O	B-Entity
optic	NOUN	O	I-Entity
neuropathies	NOUN	O	I-Entity
.	PUNCT	O	O

Deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
occurred	VERB	O	O
despite	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tacrolimus	NOUN	O	I-Entity
.	PUNCT	O	O

Tacrolimus	PROPN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
immunosuppressive	ADJ	O	O
agents	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
optic	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10770468)

Hypercalcemia	PROPN	O	I-Entity
,	PUNCT	O	O
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mood	NOUN	O	O
stabilizers	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
a	DET	O	O
bipolar	ADJ	O	I-Entity
patient	NOUN	O	O
receiving	VERB	O	O
maintenance	NOUN	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
bradyarrhythmia	NOUN	O	I-Entity
prompted	VERB	O	O
the	DET	O	O
authors	NOUN	O	O
to	PART	O	O
conduct	VERB	O	O
a	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
printout	NOUN	O	O
of	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
that	ADJ	O	O
presented	VERB	O	O
during	ADP	O	O
a	DET	O	O
1-year	ADJ	O	O
period	NOUN	O	O
was	VERB	O	O
generated	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
eliminating	VERB	O	O
spurious	ADJ	O	O
hypercalcemias	NOUN	O	I-Entity
or	CCONJ	O	O
those	DET	O	O
associated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
fluids	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
identified	VERB	O	O
18	NUM	O	O
non	ADJ	O	O
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
hypercalcemias	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
malignancies	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
medical	ADJ	O	O
conditions	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
(	PUNCT	O	O
group	NOUN	O	O
B	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
two	NUM	O	O
control	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
generated	VERB	O	O
:	PUNCT	O	O
group	NOUN	O	O
C1	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
included	VERB	O	O
age-	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
-	PUNCT	O	O
comparable	ADJ	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
bipolar	NOUN	O	I-Entity
normocalcemic	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
C2	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
included	VERB	O	O
bipolar	NOUN	O	I-Entity
normocalcemic	ADJ	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
anticonvulsant	ADJ	O	O
mood	NOUN	O	O
stabilizers	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
medical	ADJ	O	O
diseases	NOUN	O	O
and	CCONJ	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
had	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
frequencies	NOUN	O	O
of	ADP	O	O
conduction	NOUN	O	O
defects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10933650)

Attenuation	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
lipid	NOUN	O	O
nanosphere	NOUN	O	O
(	PUNCT	O	O
NS-718	PROPN	O	O
)	PUNCT	O	O
incorporating	VERB	O	O
amphotericin	NOUN	O	B-Entity
B.	PROPN	O	I-Entity
NS-718	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
lipid	NOUN	O	O
nanosphere	ADV	O	O
incorporating	VERB	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
against	ADP	O	O
pathogenic	ADJ	O	O
fungi	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
low	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
NS-718	PROPN	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
Fungizone	PROPN	O	I-Entity
(	PUNCT	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
sodium	NOUN	O	I-Entity
deoxycholate	NOUN	O	I-Entity
;	PUNCT	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
AmB	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
vitro	NOUN	O	O
using	VERB	O	O
renal	ADJ	O	O
cell	NOUN	O	O
cultures	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
by	ADP	O	O
biochemical	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
histopathological	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
and	CCONJ	O	O
pharmacokinetic	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
following	VERB	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
formulation	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Incubation	NOUN	O	O
with	ADP	O	O
NS-718	PROPN	O	O
resulted	VERB	O	O
in	ADP	O	O
significantly	ADV	O	O
less	ADJ	O	O
damage	NOUN	O	O
of	ADP	O	O
cultured	ADJ	O	O
human	ADJ	O	O
renal	ADJ	O	O
proximal	ADJ	O	O
tubular	ADJ	O	O
epithelial	ADJ	O	O
cells	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
AmB.	PROPN	O	I-Entity
Serum	PROPN	O	O
blood	NOUN	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
concentrations	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
an	DET	O	O
iv	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
AmB	NOUN	O	I-Entity
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
those	DET	O	O
given	VERB	O	O
the	DET	O	O
same	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
NS-718	PROPN	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
showed	VERB	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
in	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
AmB	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
but	CCONJ	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
NS-718-treated	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Amphotericin	PROPN	O	B-Entity
B	PROPN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
in	ADP	O	O
NS-718-treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
AmB	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
incorporation	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
into	ADP	O	O
lipid	NOUN	O	O
nanospheres	NOUN	O	O
of	ADP	O	O
NS-718	PROPN	O	O
attenuates	VERB	O	O
the	DET	O	O
nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B.	PROPN	O	I-Entity


-DOCSTART- (10939760)

Patterns	NOUN	O	O
of	ADP	O	O
sulfadiazine	NOUN	O	I-Entity
acute	ADJ	O	B-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Sulfadiazine	PROPN	O	I-Entity
acute	ADJ	O	B-Entity
nephrotoxicity	NOUN	O	I-Entity
is	VERB	O	O
reviving	VERB	O	O
specially	ADV	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
toxoplasmosis	NOUN	O	I-Entity
in	ADP	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Under	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
sulfadiazine	NOUN	O	I-Entity
they	PRON	O	O
developed	VERB	O	O
oliguria	NOUN	O	I-Entity
,	PUNCT	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
showed	VERB	O	O
multiple	ADJ	O	O
radiolucent	ADJ	O	O
renal	ADJ	O	B-Entity
calculi	NOUN	O	I-Entity
in	ADP	O	O
echography	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
nephrostomy	NOUN	O	O
tube	NOUN	O	O
had	VERB	O	O
to	PART	O	O
be	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
for	ADP	O	O
ureteral	ADJ	O	B-Entity
lithiasis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
functional	ADJ	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
sulfadiazine	NOUN	O	I-Entity
requires	VERB	O	O
exquisite	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
water	NOUN	O	O
ingestion	NOUN	O	O
and	CCONJ	O	O
possibly	ADV	O	O
the	DET	O	O
alcalinization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10960401)

Downbeat	ADJ	O	B-Entity
nystagmus	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
documents	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
dizziness	NOUN	O	I-Entity
with	ADP	O	O
downbeating	VERB	O	B-Entity
nystagmus	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
a	DET	O	O
relatively	ADV	O	O
large	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
IV	PROPN	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analgesia	NOUN	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
there	ADV	O	O
have	VERB	O	O
been	VERB	O	O
case	NOUN	O	O
reports	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
morphine	NOUN	O	I-Entity
with	ADP	O	O
these	DET	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
signs	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
documented	VERB	O	O
with	ADP	O	O
IV	PROPN	O	O
or	CCONJ	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analgesia	NOUN	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10975596)

Hemodynamic	PROPN	O	O
and	CCONJ	O	O
antiadrenergic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
dronedarone	NOUN	O	I-Entity
and	CCONJ	O	O
amiodarone	NOUN	O	I-Entity
in	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
a	DET	O	O
healed	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
hemodynamic	NOUN	O	O
and	CCONJ	O	O
antiadrenergic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
dronedarone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
noniodinated	ADJ	O	O
compound	NOUN	O	O
structurally	ADV	O	O
related	VERB	O	O
to	ADP	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
after	ADP	O	O
prolonged	ADJ	O	O
oral	ADJ	O	O
administration	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
at	ADP	O	O
rest	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
sympathetic	ADJ	O	O
stimulation	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
dogs	NOUN	O	O
with	ADP	O	O
a	DET	O	O
healed	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
dogs	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
randomly	ADV	O	O
received	VERB	O	O
orally	ADV	O	O
dronedarone	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
3-week	NUM	O	O
washout	NOUN	O	O
between	ADP	O	O
consecutive	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MBP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
positive	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
increase	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
+	PROPN	O	O
LVdP	PROPN	O	O
/	SYM	O	O
dt	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
echocardiographically	ADV	O	O
assessed	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
(	PUNCT	O	O
LVEF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fractional	ADJ	O	O
shortening	NOUN	O	O
(	PUNCT	O	O
FS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
chronotropic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
isoproterenol	VERB	O	I-Entity
and	CCONJ	O	O
exercise	VERB	O	O
-	PUNCT	O	O
induced	VERB	O	O
sympathetic	ADJ	O	O
stimulation	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
under	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
posttreatment	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Resting	VERB	O	O
values	NOUN	O	O
of	ADP	O	O
LVEF	PROPN	O	O
,	PUNCT	O	O
FS	PROPN	O	O
,	PUNCT	O	O
+	PROPN	O	O
LVdP	PROPN	O	O
/	SYM	O	O
dt	INTJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
MBP	PROPN	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
whatever	ADJ	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dosing	NOUN	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
resting	VERB	O	O
HR	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
and	CCONJ	O	O
dose	VERB	O	O
-	PUNCT	O	O
dependently	ADV	O	O
lowered	VERB	O	O
after	ADP	O	O
dronedarone	NOUN	O	I-Entity
and	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
lesser	ADJ	O	O
extent	NOUN	O	O
after	ADP	O	O
amiodarone	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
dronedarone	NOUN	O	I-Entity
and	CCONJ	O	O
amiodarone	NOUN	O	I-Entity
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
dronedarone	NOUN	O	I-Entity
and	CCONJ	O	O
amiodarone	NOUN	O	I-Entity
displayed	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
antiadrenergic	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
impair	VERB	O	O
the	DET	O	O
resting	VERB	O	O
left	VERB	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
dronedarone	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
particularly	ADV	O	O
suitable	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
clinical	ADJ	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
compromising	VERB	O	O
the	DET	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10985896)

Phase	NOUN	O	O
2	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
platinum	NOUN	O	I-Entity
/	SYM	O	O
paclitaxel	ADV	O	I-Entity
-	PUNCT	O	O
refractory	ADJ	O	O
ovarian	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
fallopian	ADJ	O	I-Entity
tube	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
and	CCONJ	O	O
primary	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
peritoneum	NOUN	O	I-Entity
.	PUNCT	O	O

Several	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
Doxil	PROPN	O	I-Entity
)	PUNCT	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
active	ADJ	O	O
antineoplastic	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
platinum	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
dose	NOUN	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
dosing	ADJ	O	O
regimen	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O

q	INTJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
being	VERB	O	O
severe	ADJ	O	O
erythrodysesthesia	NOUN	O	I-Entity
(	PUNCT	O	O
"	PUNCT	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
"	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
stomatitis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
wished	VERB	O	O
to	PART	O	O
develop	VERB	O	O
a	DET	O	O
more	ADV	O	O
tolerable	ADJ	O	O
liposomal	ADJ	O	O
doxorubicin	ADJ	O	I-Entity
treatment	NOUN	O	O
regimen	NOUN	O	O
and	CCONJ	O	O
document	NOUN	O	O
its	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
in	ADP	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
defined	VERB	O	O
patient	ADJ	O	O
population	NOUN	O	O
with	ADP	O	O
platinum	NOUN	O	I-Entity
/	PUNCT	O	O
paclitaxel	NOUN	O	I-Entity
-	PUNCT	O	O
refractory	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
ovarian	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
fallopian	ADJ	O	I-Entity
tube	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
or	CCONJ	O	O
primary	ADJ	O	O
peritoneal	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
with	ADP	O	O
platinum	NOUN	O	I-Entity
/	PUNCT	O	O
paclitaxel	NOUN	O	I-Entity
-	PUNCT	O	O
refractory	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
stable	ADJ	O	O
or	CCONJ	O	O
progressive	ADJ	O	O
disease	NOUN	O	O
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
or	CCONJ	O	O
previous	ADJ	O	O
objective	ADJ	O	O
response	NOUN	O	O
<3	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
duration	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
q	INTJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
(	PUNCT	O	O
8%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
experienced	VERB	O	O
grade	NOUN	O	O
2	NUM	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
stomatitis	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
no	DET	O	O
episodes	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
diarrhea	NOUN	O	I-Entity
requiring	VERB	O	O
hospitalization	NOUN	O	O
for	ADP	O	O
hydration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
courses	NOUN	O	O
of	ADP	O	O
liposomal	NOUN	O	O
doxorubicin	NOUN	O	I-Entity
administered	VERB	O	O
on	ADP	O	O
this	DET	O	O
protocol	NOUN	O	O
was	VERB	O	O
2	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
-	PUNCT	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
modified	VERB	O	O
liposomal	ADJ	O	O
doxorubicin	ADJ	O	I-Entity
regimen	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
less	ADJ	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
stomatitis	NOUN	O	I-Entity
,	PUNCT	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
)	PUNCT	O	O
than	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
FDA	PROPN	O	O
-	PUNCT	O	O
approved	VERB	O	O
dose	NOUN	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

Definite	PROPN	O	O
,	PUNCT	O	O
although	ADP	O	O
limited	VERB	O	O
,	PUNCT	O	O
antineoplastic	ADJ	O	O
activity	NOUN	O	O
is	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
well	ADV	O	O
-	PUNCT	O	O
defined	VERB	O	O
platinum-	NOUN	O	I-Entity
and	CCONJ	O	O
paclitaxel	NOUN	O	I-Entity
-	PUNCT	O	O
refractory	ADJ	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10986547)

Efficacy	NOUN	O	O
of	ADP	O	O
olanzapine	NOUN	O	I-Entity
in	ADP	O	O
acute	ADJ	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Olanzipine	PROPN	O	I-Entity
HGGW	PROPN	O	O
Study	PROPN	O	O
Group	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
olanzapine	NOUN	O	I-Entity
vs	ADP	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
115	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
manic	ADJ	O	I-Entity
or	CCONJ	O	O
mixed	ADJ	O	O
,	PUNCT	O	O
were	VERB	O	O
randomized	ADJ	O	O
to	ADP	O	O
olanzapine	NOUN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
to	PART	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
55	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
60	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
measure	NOUN	O	O
was	VERB	O	O
the	DET	O	O
Young	PROPN	O	O
-	PUNCT	O	O
Mania	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
Y	PROPN	O	O
-	PUNCT	O	O
MRS	PROPN	O	O
)	PUNCT	O	O
total	ADJ	O	O
score	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
Extrapyramidal	ADJ	O	B-Entity
Symptom	PROPN	O	I-Entity
(	PUNCT	O	O
EPS	PROPN	O	I-Entity
)	PUNCT	O	O
rating	NOUN	O	O
scales	NOUN	O	O
,	PUNCT	O	O
laboratory	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
electrocardiograms	NOUN	O	O
,	PUNCT	O	O
vital	ADJ	O	O
signs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
weight	NOUN	O	O
change	NOUN	O	O
.	PUNCT	O	O

Olanzapine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
greater	ADJ	O	O
mean	NOUN	O	O
(	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

Olanzapine	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
(	PUNCT	O	O
65%	NUM	O	O
vs	ADP	O	O
43%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
euthymia	NOUN	O	O
(	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
EPSs	NOUN	O	I-Entity
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
olanzapine	ADV	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
greater	ADJ	O	O
mean	NOUN	O	O
(	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

SD	PUNCT	O	O
)	PUNCT	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
than	ADP	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2.1	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

2.3	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
experienced	VERB	O	O
more	ADJ	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
emergent	ADJ	O	O
somnolence	NOUN	O	I-Entity
(	PUNCT	O	O
21	NUM	O	O
patients	NOUN	O	O
[	PUNCT	O	O
38.2%	NUM	O	O
]	PUNCT	O	O
vs	ADP	O	O
5	NUM	O	O
[	PUNCT	O	O
8.3%	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Olanzapine	PROPN	O	I-Entity
demonstrated	VERB	O	O
greater	ADJ	O	O
efficacy	NOUN	O	O
than	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
generally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11026989)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pupil	NOUN	O	B-Entity
dilation	NOUN	O	I-Entity
with	ADP	O	O
tropicamide	NOUN	O	I-Entity
on	ADP	O	O
vision	NOUN	O	O
and	CCONJ	O	O
driving	VERB	O	O
simulator	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pupil	NOUN	O	B-Entity
dilation	NOUN	O	I-Entity
on	ADP	O	O
vision	NOUN	O	O
and	CCONJ	O	O
driving	VERB	O	O
ability	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
tests	NOUN	O	O
on	ADP	O	O
various	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
driving	VERB	O	O
simulator	NOUN	O	O
performance	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
12	NUM	O	O
healthy	ADJ	O	O
drivers	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
pupil	NOUN	O	B-Entity
dilation	NOUN	O	I-Entity
using	VERB	O	O
guttae	NOUN	O	O
tropicamide	ADV	O	I-Entity
1%	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Pupillary	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
deterioration	NOUN	O	O
in	ADP	O	O
CT	PROPN	O	O
and	CCONJ	O	O
HCVA	PROPN	O	O
only	ADV	O	O
.	PUNCT	O	O

Pupillary	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
vision	NOUN	O	O
and	CCONJ	O	O
daylight	NOUN	O	O
driving	VERB	O	O
performance	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
people	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11105626)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
isotretinoin	ADJ	O	B-Entity
embryopathy	ADJ	O	I-Entity
with	ADP	O	O
bilateral	ADJ	O	O
anotia	NOUN	O	I-Entity
and	CCONJ	O	O
Taussig	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Bing	PROPN	O	I-Entity
malformation	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
newborn	ADJ	O	O
infant	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
congenital	ADJ	O	O
anomalies	NOUN	O	O
(	PUNCT	O	O
anotia	NOUN	O	I-Entity
and	CCONJ	O	O
Taussig	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Bing	PROPN	O	I-Entity
malformation	NOUN	O	I-Entity
)	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
isotretinoin	ADV	O	I-Entity
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trimester	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
paper	NOUN	O	O
we	PRON	O	O
aim	VERB	O	O
to	PART	O	O
draw	VERB	O	O
to	ADP	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
caution	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
when	ADV	O	O
prescribing	VERB	O	O
vitamin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
drugs	NOUN	O	O
to	ADP	O	O
women	NOUN	O	O
of	ADP	O	O
childbearing	VERB	O	O
years	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11135381)

Effect	NOUN	O	O
of	ADP	O	O
methoxamine	NOUN	O	I-Entity
on	ADP	O	O
maximum	ADJ	O	O
urethral	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
genuine	ADJ	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
crossover	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
a	DET	O	O
selective	ADJ	O	O
alpha1-adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-Entity
stress	NOUN	O	I-Entity
incontinence	NOUN	O	I-Entity
.	PUNCT	O	O

Half	ADJ	O	O
log	NOUN	O	O
incremental	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
methoxamine	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
saline	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
genuine	ADJ	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
while	ADP	O	O
measuring	VERB	O	O
maximum	ADJ	O	O
urethral	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MUP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
symptomatic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Methoxamine	PROPN	O	I-Entity
evoked	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
MUP	PROPN	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
but	CCONJ	O	O
caused	VERB	O	O
a	DET	O	B-Entity
significant	ADJ	O	I-Entity
rise	NOUN	O	I-Entity
in	ADP	O	I-Entity
systolic	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
significant	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
at	ADP	O	O
maximum	ADJ	O	O
dosage	NOUN	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
piloerection	NOUN	O	O
,	PUNCT	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cold	ADJ	O	O
extremities	NOUN	O	O
were	VERB	O	O
experienced	VERB	O	O
in	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
usefulness	NOUN	O	O
of	ADP	O	O
direct	ADJ	O	O
,	PUNCT	O	O
peripherally	ADV	O	O
acting	VERB	O	O
sub	NOUN	O	O
-	PUNCT	O	O
type	NOUN	O	O
-	PUNCT	O	O
selective	ADJ	O	O
alpha1-adrenoceptor	NOUN	O	O
agonists	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
limited	VERB	O	O
by	ADP	O	O
associated	VERB	O	O
piloerection	NOUN	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11176729)

Toleration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
inhibitors	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
ATLAS	PROPN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Assessment	PROPN	O	O
of	ADP	O	O
Treatment	PROPN	O	O
with	ADP	O	O
Lisinopril	PROPN	O	I-Entity
and	CCONJ	O	O
Survival	PROPN	O	O
.	PUNCT	O	O

BACKGROUND	PROPN	O	O
:	PUNCT	O	O
Treatment	NOUN	O	O
with	ADP	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
ACE	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
inhibitors	NOUN	O	I-Entity
reduces	VERB	O	O
mortality	NOUN	O	O
and	CCONJ	O	O
morbidity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
most	ADV	O	O
affected	ADJ	O	O
patients	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
receiving	VERB	O	O
these	DET	O	O
agents	NOUN	O	O
or	CCONJ	O	O
are	VERB	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
doses	NOUN	O	O
lower	ADJ	O	O
than	ADP	O	O
those	DET	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
efficacious	ADJ	O	O
in	ADP	O	O
trials	NOUN	O	O
,	PUNCT	O	O
primarily	ADV	O	O
because	ADP	O	O
of	ADP	O	O
concerns	NOUN	O	O
about	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
at	ADP	O	O
the	DET	O	O
recommended	VERB	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examines	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
high-	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
lisinopril	NOUN	O	I-Entity
in	ADP	O	O
CHF	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Assessment	PROPN	O	O
of	ADP	O	O
Lisinopril	PROPN	O	I-Entity
and	CCONJ	O	O
Survival	PROPN	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
previous	ADJ	O	O
ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
treatment	NOUN	O	O
were	VERB	O	O
stabilized	VERB	O	O
receiving	VERB	O	O
medium	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
lisinopril	NOUN	O	I-Entity
(	PUNCT	O	O
12.5	NUM	O	O
or	CCONJ	O	O
15.0	NUM	O	O
mg	NUM	O	O
once	ADV	O	O
daily	ADV	O	O
[	PUNCT	O	O
OD	PROPN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
2	NUM	O	O
to	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
randomized	ADJ	O	O
to	PART	O	O
high-	VERB	O	O
(	PUNCT	O	O
35.0	NUM	O	O
or	CCONJ	O	O
32.5	NUM	O	O
mg	NUM	O	O
OD	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
(	PUNCT	O	O
5.0	NUM	O	O
or	CCONJ	O	O
2.5	NUM	O	O
mg	NUM	O	O
OD	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
New	PROPN	O	O
York	PROPN	O	O
Heart	PROPN	O	O
Association	PROPN	O	O
classes	NOUN	O	O
II	PROPN	O	O
to	ADP	O	O
IV	PROPN	O	O
CHF	PROPN	O	I-Entity
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fractions	NOUN	O	O
of	ADP	O	O
no	DET	O	O
greater	ADJ	O	O
than	ADP	O	O
0.30	NUM	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
3164	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	ADJ	O	O
and	CCONJ	O	O
followed	VERB	O	O
up	PART	O	O
for	ADP	O	O
a	DET	O	O
median	NOUN	O	O
of	ADP	O	O
46	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
discontinuation	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
focus	NOUN	O	O
on	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
405	NUM	O	O
patients	NOUN	O	O
not	ADV	O	O
previously	ADV	O	O
receiving	VERB	O	O
an	DET	O	O
ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
,	PUNCT	O	O
doses	NOUN	O	O
in	ADP	O	O
only	ADV	O	O
4.2%	NUM	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
titrated	VERB	O	O
to	ADP	O	O
the	DET	O	O
medium	NOUN	O	O
doses	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
randomization	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
symptoms	NOUN	O	O
possibly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
2.0%	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
because	ADP	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
or	CCONJ	O	O
hyperkalemia	NOUN	O	I-Entity
(	PUNCT	O	O
2.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Subgroups	NOUN	O	O
presumed	VERB	O	O
to	PART	O	O
be	VERB	O	O
at	ADP	O	O
higher	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
intolerance	NOUN	O	O
(	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
<	X	O	O

creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
132.6	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
[	PUNCT	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
]	PUNCT	O	O
;	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
>	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
70	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
)	PUNCT	O	O
generally	ADV	O	O
tolerated	VERB	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
strategy	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
most	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
CHF	PROPN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
successfully	ADV	O	O
titrated	VERB	O	O
to	ADP	O	O
and	CCONJ	O	O
maintained	VERB	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
more	ADV	O	O
aggressive	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11229942)

Cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
ethanol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cocaethylene	NOUN	O	I-Entity
cardiotoxity	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
ethanol	NOUN	O	I-Entity
abuse	NOUN	O	I-Entity
.	PUNCT	O	O

Simultaneous	ADJ	O	O
abuse	NOUN	O	B-Entity
of	ADP	O	I-Entity
cocaine	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
ethanol	NOUN	O	I-Entity
affects	VERB	O	O
12	NUM	O	O
million	NUM	O	O
Americans	PROPN	O	O
annually	ADV	O	O
.	PUNCT	O	O

Their	ADJ	O	O
combined	ADJ	O	O
cardiac	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
independent	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
each	DET	O	O
drug	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
cocaethylene	NOUN	O	I-Entity
(	PUNCT	O	O
CE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
formed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
ethanol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
delineate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
CE	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
combined	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
ethanol	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
simulating	VERB	O	O
their	ADJ	O	O
abuse	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
dogs	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
1	PUNCT	O	O
)	PUNCT	O	O
three	NUM	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
boluses	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
7.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
with	ADP	O	O
ethanol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
)	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
IV	PROPN	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
C+E	PROPN	O	O
,	PUNCT	O	O

n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
three	NUM	O	O
cocaine	NOUN	O	I-Entity
boluses	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
C	PROPN	O	O
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
ethanol	NOUN	O	I-Entity
infusion	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
E	PROPN	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
4	PUNCT	O	O
)	PUNCT	O	O
placebo	NOUN	O	O
boluses	NOUN	O	O
and	CCONJ	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
of	ADP	O	O
eight	NUM	O	O
dogs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
C+E	PROPN	O	O
group	NOUN	O	O
experienced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
collapse	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
dramatic	ADJ	O	O
hemodynamic	NOUN	O	O
changes	NOUN	O	O
occurred	VERB	O	O
after	ADP	O	O
each	DET	O	O
cocaine	NOUN	O	I-Entity
bolus	NOUN	O	O
in	ADP	O	O
the	DET	O	O
C+E	NOUN	O	O
and	CCONJ	O	O
C	PROPN	O	O
only	ADV	O	O
groups	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
persistent	ADJ	O	O
hemodynamic	NOUN	O	O
changes	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
C+E	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Peak	PROPN	O	O
CE	PROPN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
45%	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
+	X	O	O
/-	PUNCT	O	O

22%	NUM	O	O
to	ADP	O	O
69%	NUM	O	O
)	PUNCT	O	O
decrease	NOUN	O	B-Entity
in	ADP	O	I-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
56%	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
+	X	O	O
/-	PUNCT	O	O

Ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
were	VERB	O	O
primarily	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
C+E	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
four	NUM	O	O
of	ADP	O	O
eight	NUM	O	O
dogs	NOUN	O	O
experienced	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
ethanol	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
toxic	ADJ	O	O
than	ADP	O	O
either	DET	O	O
substance	NOUN	O	O
alone	ADV	O	O
.	PUNCT	O	O

Co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
prolonged	ADJ	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
dysrhythmogenic	ADJ	O	O
.	PUNCT	O	O

Peak	PROPN	O	O
serum	NOUN	O	O
cocaethylene	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
prolonged	ADJ	O	O
myocardial	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11299446)

Worsening	PROPN	O	O
of	ADP	O	O
Parkinsonism	PROPN	O	I-Entity
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
veralipride	NOUN	O	I-Entity
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
menopause	NOUN	O	O
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
has	VERB	O	O
shown	VERB	O	O
a	DET	O	O
marked	ADJ	O	O
worsening	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
motor	NOUN	O	O
functions	NOUN	O	O
following	VERB	O	O
therapy	NOUN	O	O
of	ADP	O	O
menopause	NOUN	O	O
related	VERB	O	O
symptoms	NOUN	O	O
with	ADP	O	O
veralipride	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
symptoms	NOUN	O	O
back	ADV	O	O
to	ADP	O	O
baseline	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
emphasize	VERB	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
dopaminergic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
veralipride	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11366874)

Viracept	PROPN	O	I-Entity
and	CCONJ	O	O
irregular	ADJ	O	B-Entity
heartbeat	NOUN	O	I-Entity
warning	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
group	NOUN	O	O
of	ADP	O	O
doctors	NOUN	O	O
in	ADP	O	O
Boston	PROPN	O	O
warn	VERB	O	O
that	ADP	O	O
the	DET	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
Viracept	PROPN	O	I-Entity
may	VERB	O	O
cause	VERB	O	O
an	DET	O	O
irregular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
beat	VERB	O	I-Entity
,	PUNCT	O	O
known	VERB	O	O
as	ADP	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
.	PUNCT	O	O

Bradycardia	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
Viracept	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HIV	NOUN	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11380496)

Frequency	PROPN	O	O
of	ADP	O	O
appearance	NOUN	O	O
of	ADP	O	O
myeloperoxidase	NOUN	O	O
-	PUNCT	O	O
antineutrophil	NOUN	O	O
cytoplasmic	NOUN	O	O
antibody	NOUN	O	O
(	PUNCT	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Myeloperoxidase	PROPN	O	O
antineutrophil	NOUN	O	O
cytoplasmic	ADJ	O	O
antibody	NOUN	O	O
(	PUNCT	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA)-positive	PROPN	O	O
vasculitis	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
(	PUNCT	O	O
PTU	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
in	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
was	VERB	O	O
suspected	VERB	O	O
of	ADP	O	O
being	VERB	O	O
related	VERB	O	O
to	ADP	O	O
PTU	PROPN	O	I-Entity
because	ADP	O	O
the	DET	O	O
titres	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
decreased	VERB	O	O
when	ADV	O	O
PTU	PROPN	O	I-Entity
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

Nevertheless	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
have	VERB	O	O
been	VERB	O	O
no	DET	O	O
studies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
and	CCONJ	O	O
vasculitis	NOUN	O	I-Entity
during	ADP	O	O
PTU	PROPN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
in	ADP	O	O
untreated	ADJ	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
sought	VERB	O	O
to	PART	O	O
address	VERB	O	O
these	DET	O	O
parameters	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
102	NUM	O	O
untreated	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
vasculitis	NOUN	O	I-Entity
after	ADP	O	O
starting	VERB	O	O
PTU	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
later	ADV	O	O
excluded	VERB	O	O
because	ADP	O	O
of	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
PTU	PROPN	O	I-Entity
or	CCONJ	O	O
because	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
period	NOUN	O	O
was	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
titres	NOUN	O	O
of	ADP	O	O
all	DET	O	O
102	NUM	O	O
untreated	ADJ	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
within	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
range	NOUN	O	O
(	PUNCT	O	O
below	ADP	O	O
10	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
(	PUNCT	O	O
4.1%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
73	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
for	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
at	ADP	O	O
13	NUM	O	O
,	PUNCT	O	O
16	NUM	O	O
and	CCONJ	O	O
17	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
PTU	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
of	ADP	O	O
them	PRON	O	O
,	PUNCT	O	O
the	DET	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
titres	NOUN	O	O
transiently	ADV	O	O
increased	VERB	O	O
to	ADP	O	O
12.8	NUM	O	O
and	CCONJ	O	O
15.0	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
ml	INTJ	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
despite	ADP	O	O
continued	VERB	O	O
PTU	PROPN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
vasculitic	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
developed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
third	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
titre	NOUN	O	O
increased	VERB	O	O
to	ADP	O	O
204	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
and	CCONJ	O	O
she	PRON	O	O
developed	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
oral	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
and	CCONJ	O	O
polyarthralgia	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
symptoms	NOUN	O	O
resolved	VERB	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
stopping	VERB	O	O
PTU	PROPN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
titre	NOUN	O	O
decreased	VERB	O	O
to	ADP	O	O
20.7	NUM	O	O

U	PROPN	O	O
/	PUNCT	O	O
ml	NOUN	O	O
by	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
discontinuing	VERB	O	O
PTU	PROPN	O	I-Entity
.	PUNCT	O	O

PTU	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
MPO	PROPN	O	O
-	PUNCT	O	O
ANCA	PROPN	O	O
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
closely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11385188)

Prevalence	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
asymptomatic	ADJ	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
outpatient	NOUN	O	O
young	ADJ	O	O
asymptomatic	ADJ	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
and	CCONJ	O	O
32	NUM	O	O
age	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
controls	NOUN	O	O
underwent	VERB	O	O
resting	VERB	O	O
and	CCONJ	O	O
exercise	VERB	O	O
electrocardiography	NOUN	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Doppler	PROPN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Findings	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
12	NUM	O	O
(	PUNCT	O	O
34%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
(	PUNCT	O	O
9%	NUM	O	O
)	PUNCT	O	O
controls	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
resting	VERB	O	O
and	CCONJ	O	O
peak	ADJ	O	O
exercise	NOUN	O	O
abnormal	ADJ	O	B-Entity
left	VERB	O	I-Entity
ventricular	NOUN	O	I-Entity
filling	NOUN	O	I-Entity
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
38	NUM	O	O
and	CCONJ	O	O
35%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
19	NUM	O	O
and	CCONJ	O	O
9%	NUM	O	O
of	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.11	NUM	O	O
and	CCONJ	O	O
0.02	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
myocardial	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
common	ADJ	O	O
(	PUNCT	O	O
38%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
young	ADJ	O	O
asymptomatic	ADJ	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11395263)

Cardioprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Picrorrhiza	PROPN	O	O
kurroa	NOUN	O	O
against	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ethanol	NOUN	O	I-Entity
extract	NOUN	O	O
of	ADP	O	O
Picrorrhiza	PROPN	O	O
kurroa	NOUN	O	O
rhizomes	NOUN	O	O
and	CCONJ	O	O
roots	NOUN	O	O
(	PUNCT	O	O
PK	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
lipid	ADJ	O	O
metabolism	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
tissue	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

day(-1	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
and	CCONJ	O	O
maintained	VERB	O	O
the	DET	O	O
rats	NOUN	O	O
at	ADP	O	O
near	ADP	O	O
normal	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11401944)

Phase	NOUN	O	O
2	NUM	O	O
early	ADJ	O	O
afterdepolarization	NOUN	O	O
as	ADP	O	O
a	DET	O	O
trigger	NOUN	O	O
of	ADP	O	O
polymorphic	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
acquired	VERB	O	O
long	ADV	O	B-Entity
-	PUNCT	O	I-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
:	PUNCT	O	O
direct	ADJ	O	O
evidence	NOUN	O	O
from	ADP	O	O
intracellular	ADJ	O	O
recordings	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
wall	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
phase	NOUN	O	O
2	NUM	O	O
early	ADJ	O	O
afterdepolarization	NOUN	O	O
(	PUNCT	O	O
EAD	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
producing	VERB	O	O
a	DET	O	O
trigger	NOUN	O	O
to	PART	O	O
initiate	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
TdP	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
and	CCONJ	O	O
azimilide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
transmural	ADJ	O	O
dispersion	NOUN	O	O
of	ADP	O	O
repolarization	NOUN	O	O
(	PUNCT	O	O
TDR	PROPN	O	O
)	PUNCT	O	O
to	ADP	O	O
transmural	ADJ	O	O
propagation	NOUN	O	O
of	ADP	O	O
EAD	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
TdP	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

-	PUNCT	O	O
Sotalol	PROPN	O	I-Entity
preferentially	ADV	O	O
prolonged	VERB	O	O
action	NOUN	O	O
potential	ADJ	O	O
duration	NOUN	O	O
(	PUNCT	O	O
APD	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
M	PROPN	O	O
cells	NOUN	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
100	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
TDR	PROPN	O	O
.	PUNCT	O	O

Azimilide	PROPN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
significantly	ADV	O	O
prolonged	ADJ	O	O
APD	PROPN	O	O
and	CCONJ	O	O
QT	PROPN	O	O
interval	NOUN	O	O
at	ADP	O	O
concentrations	NOUN	O	O
from	ADP	O	O
0.1	NUM	O	O
to	ADP	O	O
10	NUM	O	O

Unlike	ADP	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
,	PUNCT	O	O
azimilide	NOUN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
3	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
epicardial	ADJ	O	O
APD	PROPN	O	O
markedly	ADV	O	O
,	PUNCT	O	O
causing	VERB	O	O
a	DET	O	O
diminished	ADJ	O	O
TDR	PROPN	O	O
.	PUNCT	O	O

Although	ADP	O	O
both	DET	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
and	CCONJ	O	O
azimilide	NOUN	O	I-Entity
rarely	ADV	O	O
induced	VERB	O	O
EADs	NOUN	O	O
in	ADP	O	O
canine	NOUN	O	O
left	VERB	O	O
ventricles	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
produced	VERB	O	O
frequent	ADJ	O	O
EADs	NOUN	O	O
in	ADP	O	O
rabbits	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
more	ADV	O	O
pronounced	ADJ	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
TDR	PROPN	O	O
by	ADP	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
facilitated	VERB	O	O
transmural	ADJ	O	O
propagation	NOUN	O	O
of	ADP	O	O
EADs	NOUN	O	O
that	ADJ	O	O
initiated	VERB	O	O
multiple	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
TdP	PROPN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
of	ADP	O	O
6	NUM	O	O
rabbit	NOUN	O	O
left	VERB	O	O
ventricles	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
note	ADV	O	O
,	PUNCT	O	O
although	ADP	O	O
azimilide	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
to	PART	O	O
10	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
APD	PROPN	O	O
more	ADJ	O	O
than	ADP	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
,	PUNCT	O	O
its	ADJ	O	O
EADs	NOUN	O	O
often	ADV	O	O
failed	VERB	O	O
to	PART	O	O
propagate	VERB	O	O
transmurally	ADV	O	O
,	PUNCT	O	O
probably	ADV	O	O
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
diminished	ADJ	O	O
TDR	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
provides	VERB	O	O
the	DET	O	O
first	ADJ	O	O
direct	ADJ	O	O
evidence	NOUN	O	O
from	ADP	O	O
intracellular	ADJ	O	O
action	NOUN	O	O
potential	ADJ	O	O
recordings	NOUN	O	O
that	ADJ	O	O
phase	VERB	O	O
2	NUM	O	O
EAD	PROPN	O	O
can	VERB	O	O
be	VERB	O	O
generated	VERB	O	O
from	ADP	O	O
intact	ADJ	O	O
ventricular	ADJ	O	O
wall	NOUN	O	O
and	CCONJ	O	O
produce	VERB	O	O
a	DET	O	O
trigger	NOUN	O	O
to	PART	O	O
initiate	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
TdP	PROPN	O	I-Entity
under	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11425091)

Prenatal	ADJ	O	O
cocaine	NOUN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
cranial	ADJ	O	O
sonographic	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
preterm	NOUN	O	B-Entity
infants	NOUN	O	I-Entity
.	PUNCT	O	O

Prenatal	ADJ	O	O
cocaine	NOUN	O	I-Entity
exposure	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
linked	VERB	O	O
with	ADP	O	O
subependymal	ADJ	O	O
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
cysts	NOUN	O	I-Entity
that	ADJ	O	O
are	VERB	O	O
detectable	ADJ	O	O
on	ADP	O	O
cranial	ADJ	O	O
sonography	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
born	VERB	O	O
at	ADP	O	O
term	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
sought	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
prenatal	ADJ	O	O
cocaine	NOUN	O	I-Entity
exposure	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
subependymal	ADJ	O	B-Entity
cysts	NOUN	O	I-Entity
in	ADP	O	O
preterm	NOUN	O	B-Entity
infants	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
retrospectively	ADV	O	O
reviewed	VERB	O	O
the	DET	O	O
medical	ADJ	O	O
records	NOUN	O	O
and	CCONJ	O	O
cranial	ADJ	O	O
sonograms	NOUN	O	O
obtained	VERB	O	O
during	ADP	O	O
a	DET	O	O
1-year	NUM	O	O
period	NOUN	O	O
on	ADP	O	O
122	NUM	O	O
premature	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
<	SYM	O	I-Entity
36	NUM	O	I-Entity
weeks	NOUN	O	I-Entity
of	ADP	O	I-Entity
gestation	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
infants	NOUN	O	I-Entity
.	PUNCT	O	O

Infants	NOUN	O	O
were	VERB	O	O
categorized	VERB	O	O
into	ADP	O	O
1	NUM	O	O
of	ADP	O	O
2	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
those	DET	O	O
exposed	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
not	ADV	O	O
exposed	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Infants	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
group	NOUN	O	O
if	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
maternal	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
or	CCONJ	O	O
if	ADP	O	O
maternal	ADJ	O	O
or	CCONJ	O	O
neonatal	ADJ	O	O
urine	NOUN	O	O
toxicology	NOUN	O	O
results	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
delivery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
subependymal	ADJ	O	B-Entity
cysts	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
117	NUM	O	O
remaining	VERB	O	O
infants	NOUN	O	O
was	VERB	O	O
14%	NUM	O	O
(	PUNCT	O	O
16	NUM	O	O
of	ADP	O	O
117	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
subependymal	ADJ	O	B-Entity
cysts	NOUN	O	I-Entity
in	ADP	O	O
infants	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
prenatally	ADV	O	O
was	VERB	O	O
44%	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
of	ADP	O	O
18	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
8%	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
of	ADP	O	O
99	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
unexposed	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

We	PRON	O	O
found	VERB	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
subependymal	NOUN	O	B-Entity
cyst	NOUN	O	I-Entity
formation	NOUN	O	O
in	ADP	O	O
preterm	NOUN	O	B-Entity
infants	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
prenatally	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (11439380)

Thalidomide	PROPN	O	I-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
metastatic	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
thalidomide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuropathy	NOUN	O	I-Entity
using	VERB	O	O
electrodiagnostic	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
androgen	NOUN	O	I-Entity
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
thalidomide	NOUN	O	I-Entity
underwent	VERB	O	O
neurologic	ADJ	O	O
examinations	NOUN	O	O
and	CCONJ	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
studies	NOUN	O	O
(	PUNCT	O	O
NCS	PROPN	O	O
)	PUNCT	O	O
prior	ADV	O	O
to	ADP	O	O
and	CCONJ	O	O
at	ADP	O	O
3-month	NUM	O	O
intervals	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Thalidomide	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
in	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
for	ADP	O	O
lack	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
67	NUM	O	O
patients	NOUN	O	O
initially	ADV	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
24	NUM	O	O
remained	VERB	O	O
on	ADP	O	O
thalidomide	NOUN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
remained	VERB	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
remained	VERB	O	O
at	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Neuropathy	PROPN	O	I-Entity
may	VERB	O	O
thus	ADV	O	O
be	VERB	O	O
a	DET	O	O
common	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
older	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
SNAP	PROPN	O	O
index	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
monitor	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
early	ADJ	O	O
detection	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11474137)

Overexpression	NOUN	O	O
of	ADP	O	O
copper	NOUN	O	I-Entity
/	PUNCT	O	O
zinc	NOUN	O	I-Entity
-	PUNCT	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
protects	VERB	O	O
from	ADP	O	O
kanamycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
participation	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
in	ADP	O	O
aminoglycoside	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ototoxicity	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
deduced	VERB	O	O
from	ADP	O	O
observations	NOUN	O	O
that	ADJ	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
iron	NOUN	O	I-Entity
complexes	NOUN	O	O
catalyze	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
radicals	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
antioxidants	NOUN	O	O
attenuate	VERB	O	O
ototoxicity	NOUN	O	I-Entity
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
hypothesized	VERB	O	O
that	ADP	O	O
overexpression	NOUN	O	O
of	ADP	O	O
Cu	PROPN	O	I-Entity
/	SYM	O	O
Zn	PROPN	O	I-Entity
-	PUNCT	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
(	PUNCT	O	O
h	PROPN	O	O
-	PUNCT	O	O
SOD1	PROPN	O	O
)	PUNCT	O	O
should	VERB	O	O
protect	VERB	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
from	ADP	O	O
ototoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Transgenic	ADJ	O	O
and	CCONJ	O	O
nontransgenic	ADJ	O	O
littermates	NOUN	O	O
received	VERB	O	O
kanamycin	NOUN	O	I-Entity
(	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
beginning	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
after	ADP	O	O
birth	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
nontransgenic	ADJ	O	O
animals	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
threshold	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kanamycin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
45	NUM	O	O
-	SYM	O	O
50	NUM	O	O
dB	NOUN	O	O
higher	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
saline	ADJ	O	O
-	PUNCT	O	O
injected	VERB	O	O
controls	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
transgenic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
kanamycin	VERB	O	I-Entity
increased	VERB	O	O
the	DET	O	O
threshold	NOUN	O	O
by	ADP	O	O
only	ADV	O	O
15	NUM	O	O
dB	NOUN	O	O
over	ADP	O	O
the	DET	O	O
respective	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protection	NOUN	O	O
by	ADP	O	O
overexpression	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
oxidant	ADJ	O	O
stress	NOUN	O	O
plays	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ototoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11708428)

Prednisone	NOUN	O	I-Entity
induces	VERB	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
glial	ADJ	O	O
cerebral	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
whether	ADP	O	O
prednisone	NOUN	O	I-Entity
(	PUNCT	O	O
PDN	PROPN	O	I-Entity
)	PUNCT	O	O
produces	VERB	O	O
anxiety	NOUN	O	I-Entity
and/or	CCONJ	O	O
cerebral	ADJ	O	O
glial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
moderate	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
PDN	PROPN	O	I-Entity
released	VERB	O	O
from	ADP	O	O
a	DET	O	O
subcutaneous	ADJ	O	O
implant	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
implants	NOUN	O	O
containing	VERB	O	O
PDN	PROPN	O	I-Entity
equivalent	NOUN	O	O
to	ADP	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
implants	NOUN	O	O
contained	VERB	O	O
no	DET	O	O
PDN	PROPN	O	I-Entity
.	PUNCT	O	O

Anxiety	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
an	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
and	CCONJ	O	O
elevated	VERB	O	O
plus	CCONJ	O	O
-	PUNCT	O	O
maze	NOUN	O	O
devices	NOUN	O	O
.	PUNCT	O	O

Anxiety	NOUN	O	I-Entity
was	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
PDN	PROPN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
transformation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
microglia	NOUN	O	O
assessed	VERB	O	O
by	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
intersections	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
PDN	NOUN	O	I-Entity
groups	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
controls	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prefrontal	ADJ	O	O
cortex	NOUN	O	O
(	PUNCT	O	O
moderate	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
24.1	NUM	O	O
;	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
23.6	NUM	O	O
;	PUNCT	O	O
controls	NOUN	O	O
18.7	NUM	O	O
;	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
stained	VERB	O	O
microglia	NOUN	O	O
cells	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
PDN	PROPN	O	I-Entity
treated	VERB	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prefrontal	NOUN	O	O
cortex	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
moderate	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
29.1	NUM	O	O
;	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
28.4	NUM	O	O
;	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
17.7	NUM	O	O
cells	NOUN	O	O
per	ADP	O	O
field	NOUN	O	O
;	PUNCT	O	O
p	X	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Subacute	PROPN	O	O
exposure	NOUN	O	O
to	ADP	O	O
PDN	PROPN	O	I-Entity
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
reactivity	NOUN	O	O
of	ADP	O	O
microglia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
relevance	NOUN	O	O
of	ADP	O	O
these	DET	O	O
features	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
using	VERB	O	O
PDN	PROPN	O	I-Entity
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
elucidated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11745287)

Phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
and	CCONJ	O	O
liposomal	ADJ	O	O

doxorubicin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
cervix	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
and	CCONJ	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
Phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
cervical	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
(	PUNCT	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
curve	NOUN	O	O
[	PUNCT	O	O
AUC	PROPN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
Doxil	PROPN	O	I-Entity
;	PUNCT	O	O
starting	VERB	O	O
dose	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
cervical	ADJ	O	I-Entity
carcinoma	NOUN	O	I-Entity
to	PART	O	O
determine	VERB	O	O
antitumor	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
profile	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assessable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
35	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assessable	ADJ	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
myelosuppression	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
Grade	PROPN	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
in	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
thrombocytopenia	NOUN	O	I-Entity
in	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neutropenic	ADJ	O	B-Entity
fever	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
five	NUM	O	O
infusion	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
reactions	NOUN	O	O
during	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
discontinuation	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Grade	PROPN	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
nonhematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
included	VERB	O	O
nausea	NOUN	O	I-Entity
in	ADP	O	O
17	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
emesis	NOUN	O	I-Entity
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
in	ADP	O	O
9	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
mucositis	NOUN	O	I-Entity
and/or	CCONJ	O	O
stomatitis	NOUN	O	I-Entity
in	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
constipation	NOUN	O	I-Entity
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
and	CCONJ	O	O
liposomal	ADJ	O	O

doxorubicin	NOUN	O	I-Entity
has	VERB	O	O
modest	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
cervical	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11799346)

Antimicrobial	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
(	PUNCT	O	O
antibiomania	NOUN	O	I-Entity
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
reports	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
reviewed	VERB	O	O
reported	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
antibiotic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
MEDLINE	PROPN	O	O
and	CCONJ	O	O
PsychLit	PROPN	O	O
search	NOUN	O	O
for	ADP	O	O
reports	NOUN	O	O
of	ADP	O	O
antibiotic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
reports	NOUN	O	O
of	ADP	O	O
antimicrobial	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
6	NUM	O	O
cases	NOUN	O	O
implicating	VERB	O	O
clarithromycin	NOUN	O	I-Entity
,	PUNCT	O	O
13	NUM	O	O
implicating	VERB	O	O
isoniazid	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
case	NOUN	O	O
each	DET	O	O
implicating	VERB	O	O
erythromycin	NOUN	O	I-Entity
and	CCONJ	O	O
amoxicillin	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
clarithromycin	NOUN	O	I-Entity
was	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
23	NUM	O	O
(	PUNCT	O	O
27.6%	NUM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
,	PUNCT	O	O
ciprofloxacin	NOUN	O	I-Entity
in	ADP	O	O
12	NUM	O	O
(	PUNCT	O	O
14.4%	NUM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ofloxacin	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Cotrimoxazole	PROPN	O	I-Entity
,	PUNCT	O	O
metronidazole	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
erythromycin	NOUN	O	I-Entity
were	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
15	NUM	O	O
reported	VERB	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
reported	VERB	O	O
by	ADP	O	O
the	DET	O	O
FDA	PROPN	O	O
showed	VERB	O	O
clarithromycin	NOUN	O	I-Entity
and	CCONJ	O	O
ciprofloxacin	NOUN	O	I-Entity
to	PART	O	O
be	VERB	O	O
the	DET	O	O
most	ADV	O	O
frequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
mania	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
mania	NOUN	O	I-Entity
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
antimicrobials	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
research	NOUN	O	O
clearly	ADV	O	O
is	VERB	O	O
required	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
antimicrobial	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
an	DET	O	O
antimicrobial	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
manic	ADJ	O	I-Entity
episode	NOUN	O	O
among	ADP	O	O
various	ADJ	O	O
demographic	ADJ	O	O
populations	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
continue	VERB	O	O
to	PART	O	O
have	VERB	O	O
persistent	ADJ	O	O
affective	ADJ	O	O
disorders	NOUN	O	O
once	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
episode	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
occurs	VERB	O	O
while	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
is	VERB	O	O
taking	VERB	O	O
antibiotics	NOUN	O	O
,	PUNCT	O	O
subsides	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
elected	VERB	O	O
to	PART	O	O
name	VERB	O	O
this	DET	O	O
syndrome	NOUN	O	O
"	PUNCT	O	O
antibiomania	NOUN	O	I-Entity
.	PUNCT	O	O
"	PUNCT	O	O


-DOCSTART- (11835460)

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
dyskinesias	NOUN	O	I-Entity
are	VERB	O	O
very	ADV	O	O
uncommon	ADJ	O	O
.	PUNCT	O	O

Usually	ADV	O	O
they	PRON	O	O
occur	VERB	O	O
simultaneously	ADV	O	O
with	ADP	O	O
limb	NOUN	O	O
peak	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
choreatic	ADJ	O	B-Entity
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
leftward	ADJ	O	O
and	CCONJ	O	O
upward	ADJ	O	O
deviations	NOUN	O	O
of	ADP	O	O
gaze	NOUN	O	O
during	ADP	O	O
the	DET	O	O
peak	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hypothesize	VERB	O	O
that	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
dopaminergic	ADJ	O	O
denervation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
caudate	NOUN	O	O
nucleus	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
for	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
these	DET	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induce	NOUN	O	O
ocular	ADJ	O	B-Entity
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11915580)

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
with	ADP	O	O
diclofenac	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
cross	VERB	O	O
-	PUNCT	O	O
over	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
syndrome	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
painful	ADJ	O	O
uterine	NOUN	O	O
contractility	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
hypersecretion	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	O
prostaglandins	NOUN	O	I-Entity
;	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
are	VERB	O	O
the	DET	O	O
first	ADJ	O	O
choice	NOUN	O	O
for	ADP	O	O
its	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
myometrial	ADJ	O	O
cells	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
targets	NOUN	O	O
of	ADP	O	O
the	DET	O	O
relaxant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
(	PUNCT	O	O
GTN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
NO	NOUN	O	I-Entity
donor	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
diclofenac	NOUN	O	I-Entity
(	PUNCT	O	O
DCF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
during	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
menstrual	ADJ	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

cross	NOUN	O	O
-	PUNCT	O	O
over	PART	O	O
,	PUNCT	O	O
controlled	VERB	O	O
design	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
DCF	PROPN	O	I-Entity
per	ADP	O	O
os	NOUN	O	O
or	CCONJ	O	O
GTN	PROPN	O	I-Entity
patches	VERB	O	O
the	DET	O	O
first	ADJ	O	O
days	NOUN	O	O
of	ADP	O	O
menses	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
menstrual	ADJ	O	O
cramps	NOUN	O	O
became	VERB	O	O
unendurable	ADJ	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
up	ADV	O	O
to	ADP	O	O
3	NUM	O	O
doses	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
DCF	NOUN	O	I-Entity
or	CCONJ	O	O
2.5	NUM	O	O
mg/24	NOUN	O	O

h	PUNCT	O	O
transdermal	ADJ	O	O
GTN	PROPN	O	I-Entity
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
needs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
score	NOUN	O	O
(	PUNCT	O	O
DPI	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
variable	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
treatments	NOUN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
DPI	PROPN	O	O
by	ADP	O	O
the	DET	O	O
30th	ADJ	O	O
minute	NOUN	O	O
(	PUNCT	O	O
GTN	PROPN	O	I-Entity
,	PUNCT	O	O
-12.8	NUM	O	O

DCF	PROPN	O	I-Entity
,	PUNCT	O	O
-18.9	NUM	O	O

However	ADV	O	O
,	PUNCT	O	O
DCF	PROPN	O	I-Entity
continued	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
pelvic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
for	ADP	O	O
two	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
GTN	PROPN	O	I-Entity
scores	NOUN	O	O
remained	VERB	O	O
more	ADV	O	O
or	CCONJ	O	O
less	ADV	O	O
stable	ADJ	O	O
after	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
for	ADP	O	O
DFC	PROPN	O	O
(	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
hour	NOUN	O	O
:	PUNCT	O	O

GTN	PROPN	O	I-Entity
,	PUNCT	O	O
-12.8	NUM	O	O

16.6	NUM	O	O
and	CCONJ	O	O
after	ADP	O	O
two	NUM	O	O
hours	NOUN	O	O
:	PUNCT	O	O
GTN	PROPN	O	I-Entity
,	PUNCT	O	O
-23.7	NUM	O	O

Low	VERB	O	B-Entity
back	PART	O	I-Entity
pain	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
relieved	VERB	O	O
by	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Headache	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
GTN	PROPN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
DCF	PROPN	O	I-Entity
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
stopped	VERB	O	O
using	VERB	O	O
GTN	PROPN	O	I-Entity
because	ADP	O	O
headache	NOUN	O	I-Entity
--	PUNCT	O	O
attributed	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
--	PUNCT	O	O
became	VERB	O	O
intolerable	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
GTN	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
reduced	VERB	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
by	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
DCF	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11936424)

Temocapril	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
SH	PROPN	O	O
group	NOUN	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
modulates	NOUN	O	O
glomerular	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
temocapril	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
SH	PROPN	O	O
group	NOUN	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
inhibited	VERB	O	O
glomerular	ADJ	O	O
hypertrophy	NOUN	O	I-Entity
and	CCONJ	O	O
prevented	VERB	O	O
glomerulosclerosis	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Nephrosis	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
(	PUNCT	O	O
15mg/100	PROPN	O	O
g	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
(	PUNCT	O	O
SD	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
,	PUNCT	O	O
i	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ii	PUNCT	O	O
)	PUNCT	O	O

PAN	PROPN	O	I-Entity
/	PUNCT	O	O
temocapril	NOUN	O	I-Entity
(	PUNCT	O	O
13	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
iii	PUNCT	O	O
)	PUNCT	O	O
temocapril	NOUN	O	I-Entity
(	PUNCT	O	O
14	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
untreated	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Temocapril	PROPN	O	I-Entity
(	PUNCT	O	O
8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
killed	VERB	O	O
at	ADP	O	O
weeks	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
or	CCONJ	O	O
20	NUM	O	O
.	PUNCT	O	O

Systolic	PROPN	O	O
BP	PROPN	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
high	ADJ	O	O
at	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
normal	ADJ	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
/	SYM	O	O
temocapril	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
protein	NOUN	O	O
excretion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
,	PUNCT	O	O
peaking	VERB	O	O
at	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
decreased	VERB	O	O
at	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
rose	VERB	O	O
again	ADV	O	O
significantly	ADV	O	O
at	ADP	O	O
14	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Temocapril	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
attenuate	VERB	O	O
proteinuria	NOUN	O	I-Entity
at	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
did	VERB	O	O
markedly	ADV	O	O
lower	ADJ	O	O
it	PRON	O	O
from	ADP	O	O
weeks	NOUN	O	O
4	NUM	O	O
to	ADP	O	O
20	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
glomerulosclerosis	NOUN	O	I-Entity
index	NOUN	O	O
(	PUNCT	O	O
GSI	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
6.21	NUM	O	O
%	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
respectively	ADV	O	O
25.35	NUM	O	O
%	NOUN	O	O
and	CCONJ	O	O
30.49	NUM	O	O
%	NOUN	O	O
at	ADP	O	O
14	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	O
tuft	NOUN	O	O
area	NOUN	O	O
to	ADP	O	O
the	DET	O	O
area	NOUN	O	O
of	ADP	O	O
Bowman	PROPN	O	O
's	PART	O	O
capsules	NOUN	O	O
(	PUNCT	O	O
GT	PROPN	O	O
/	SYM	O	O
BC	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
/	SYM	O	O
temocapril	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
appears	VERB	O	O
that	ADP	O	O
temocapril	NOUN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
retarding	VERB	O	O
renal	ADJ	O	O
progression	NOUN	O	O
and	CCONJ	O	O
protected	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
PAN	PROPN	O	I-Entity
neprotic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11988250)

Pulmonary	PROPN	O	B-Entity
hypertension	NOUN	O	I-Entity
after	ADP	O	O
ibuprofen	NOUN	O	I-Entity
prophylaxis	NOUN	O	O
in	ADP	O	O
very	ADV	O	O
preterm	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
three	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypoxaemia	NOUN	O	I-Entity
after	ADP	O	O
ibuprofen	NOUN	O	I-Entity
administration	NOUN	O	O
during	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
patent	NOUN	O	B-Entity
ductus	NOUN	O	I-Entity
arteriosus	NOUN	O	I-Entity
with	ADP	O	O
ibuprofen	NOUN	O	I-Entity
in	ADP	O	O
premature	ADJ	O	O
infants	NOUN	O	O
born	VERB	O	O
at	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
28	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

Hypoxaemia	PROPN	O	I-Entity
resolved	VERB	O	O
quickly	ADV	O	O
on	ADP	O	O
inhaled	VERB	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
investigators	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
similar	ADJ	O	O
trials	NOUN	O	O
pay	VERB	O	O
close	ADJ	O	O
attention	NOUN	O	O
to	ADP	O	O
pulmonary	ADJ	O	O
pressure	NOUN	O	O
if	ADP	O	O
hypoxaemia	NOUN	O	I-Entity
occurs	VERB	O	O
after	ADP	O	O
prophylactic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ibuprofen	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12051122)

Hyponatremia	PROPN	O	I-Entity
and	CCONJ	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
diuretic	NOUN	O	I-Entity
hormone	NOUN	O	I-Entity
reported	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
Vincristine	PROPN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
over	ADP	O	O
-	PUNCT	O	O
representation	NOUN	O	O
of	ADP	O	O
Asians	PROPN	O	O
?	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
used	VERB	O	O
a	DET	O	O
pharmaceutical	ADJ	O	O
company	NOUN	O	O
's	PART	O	O
global	ADJ	O	O
safety	NOUN	O	O
database	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
reporting	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
hyponatremia	NOUN	O	I-Entity
and/or	CCONJ	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
secretion	NOUN	O	I-Entity
of	ADP	O	I-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
diuretic	NOUN	O	I-Entity
hormone	NOUN	O	I-Entity
(	PUNCT	O	O
SIADH	PROPN	O	I-Entity
)	PUNCT	O	O
among	ADP	O	O
vincristine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
at	ADP	O	O
-	PUNCT	O	O
risk	NOUN	O	O
population	NOUN	O	O
subgroups	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
searched	VERB	O	O
the	DET	O	O
Eli	PROPN	O	O
Lilly	PROPN	O	O
and	CCONJ	O	O
Company	PROPN	O	O
's	PART	O	O
computerized	ADJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
database	NOUN	O	O
for	ADP	O	O
all	DET	O	O
reported	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
hyponatremia	NOUN	O	I-Entity
and/or	CCONJ	O	O
SIADH	PROPN	O	I-Entity
as	ADP	O	O
of	ADP	O	O
1	NUM	O	O
November	PROPN	O	O
1999	NUM	O	O
that	ADJ	O	O
had	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
during	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
76	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hyponatremia	NOUN	O	I-Entity
and/or	CCONJ	O	O
SIADH	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
vincristine	NOUN	O	I-Entity
use	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

Approximately	ADV	O	O
75%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
leukemia	NOUN	O	I-Entity
or	CCONJ	O	O
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
Asian	ADJ	O	O
patients	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
at	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
hyponatremia	NOUN	O	I-Entity
and/or	CCONJ	O	O
SIADH	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
vincristine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
reported	VERB	O	O
rate	NOUN	O	O
of	ADP	O	O
SIADH	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
vincristine	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
low	ADJ	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
caring	VERB	O	O
for	ADP	O	O
Asian	ADJ	O	O
oncology	NOUN	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
potential	ADJ	O	O
serious	ADJ	O	O
but	CCONJ	O	O
reversible	ADJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12059909)

Delayed	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
of	ADP	O	O
DBA/2	PROPN	O	O
and	CCONJ	O	O
C57BL/6	PROPN	O	O
female	ADJ	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
describes	VERB	O	O
the	DET	O	O
delayed	VERB	O	O
development	NOUN	O	O
of	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
bladder	NOUN	O	O
pathology	NOUN	O	O
in	ADP	O	O
a	DET	O	O
susceptible	ADJ	O	O
strain	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
(	PUNCT	O	O
DBA/2	PROPN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
a	DET	O	O
resistant	ADJ	O	O
strain	NOUN	O	O
(	PUNCT	O	O
C57BL/6	PROPN	O	O
)	PUNCT	O	O
when	ADV	O	O
both	DET	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
dose	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CY	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Inbred	ADJ	O	O
DBA/2	NOUN	O	O
and	CCONJ	O	O
C57BL/6	PUNCT	O	O
female	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
CY	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
on	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
during	ADP	O	O
100	NUM	O	O
days	NOUN	O	O
by	ADP	O	O
light	ADJ	O	O
microscopy	NOUN	O	O
using	VERB	O	O
different	ADJ	O	O
staining	NOUN	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
by	ADP	O	O
conventional	ADJ	O	O
electron	NOUN	O	O
microscopy	NOUN	O	O
.	PUNCT	O	O

Early	ADV	O	O
CY	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
typical	ADJ	O	O
haemorrhagic	ADJ	O	I-Entity
cystitis	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
strains	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
completely	ADV	O	O
repaired	VERB	O	O
in	ADP	O	O
about	ADV	O	O
7	NUM	O	O
-	SYM	O	O
10	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
CY	PROPN	O	I-Entity
injection	NOUN	O	O
ulcerous	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
ulcerous	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
cystitis	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
86%	NUM	O	O
of	ADP	O	O
DBA/2	NUM	O	O
mice	NOUN	O	O
but	CCONJ	O	O
only	ADV	O	O
in	ADP	O	O
4%	NUM	O	O
of	ADP	O	O
C57BL/6	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Delayed	VERB	O	O
cystitis	NOUN	O	I-Entity
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
infiltration	NOUN	O	O
and	CCONJ	O	O
transepithelial	ADJ	O	O
passage	NOUN	O	O
into	ADP	O	O
the	DET	O	O
lumen	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
frequent	ADJ	O	O
exfoliation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
urothelium	NOUN	O	O
.	PUNCT	O	O

Delayed	VERB	O	O
cystitis	NOUN	O	I-Entity
still	ADV	O	O
persisted	VERB	O	O
in	ADP	O	O
DBA/2	PROPN	O	O
mice	NOUN	O	O
100	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
delayed	VERB	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
CY	PROPN	O	I-Entity
in	ADP	O	O
female	ADJ	O	O
DBA/2	NOUN	O	O
mice	NOUN	O	O
causes	VERB	O	O
a	DET	O	O
bladder	NOUN	O	O
pathology	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
C57BL/6	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
pathology	NOUN	O	O
resembles	VERB	O	O
interstitial	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
perhaps	ADV	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
for	ADP	O	O
studies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12119460)

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	PROPN	O	I-Entity
/	SYM	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
three	NUM	O	O
-	PUNCT	O	O
weekly	NOUN	O	O
mitomycin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
advanced	ADJ	O	O
gastric	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
24-hour	NUM	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-fluorouracil	PROPN	O	I-Entity
(	PUNCT	O	O
5-FU	NUM	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
FA	PROPN	O	I-Entity
)	PUNCT	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
new	ADJ	O	O
multidrug	NOUN	O	O
chemotherapy	NOUN	O	O
regimens	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
gastric	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
AGC	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
low	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
with	ADP	O	O
3-weekly	PROPN	O	O
bolus	NOUN	O	O
5-FU	NUM	O	I-Entity
,	PUNCT	O	O
FA	PROPN	O	I-Entity
and	CCONJ	O	O
mitomycin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
(	PUNCT	O	O
MMC	PROPN	O	I-Entity
)	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
a	DET	O	O
low	ADJ	O	O
toxicity	NOUN	O	I-Entity
rate	NOUN	O	O
and	CCONJ	O	O
response	NOUN	O	O
rates	NOUN	O	O
comparable	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
regimens	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
ELF	PROPN	O	O
,	PUNCT	O	O
FAM	PROPN	O	O
or	CCONJ	O	O
FAMTX	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
promising	ADJ	O	O
median	ADJ	O	O
overall	ADJ	O	O
survival	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
improve	VERB	O	O
this	DET	O	O
MMC	PROPN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
schedule	NOUN	O	O
we	PRON	O	O
initiated	VERB	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-FU	NUM	O	I-Entity
/	SYM	O	O
FA	PROPN	O	I-Entity
and	CCONJ	O	O
3-weekly	NUM	O	O
bolus	NOUN	O	O
MMC	PROPN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
February	PROPN	O	O
,	PUNCT	O	O
1998	NUM	O	O
to	ADP	O	O
September	PROPN	O	O
,	PUNCT	O	O
2000	NUM	O	O
we	PRON	O	O
recruited	VERB	O	O
33	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
AGC	PROPN	O	I-Entity
to	PART	O	O
receive	VERB	O	O
weekly	ADV	O	O
24-hour	NUM	O	O
5-FU	NUM	O	I-Entity
2,600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
preceded	VERB	O	O
by	ADP	O	O
2-hour	NUM	O	O
FA	PROPN	O	I-Entity
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
2-week	NUM	O	O
rest	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

MMC	PROPN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
added	VERB	O	O
in	ADP	O	O
3-weekly	PROPN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

18	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
primary	ADJ	O	O
AGC	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
showed	VERB	O	O
a	DET	O	O
relapsed	VERB	O	O
AGC	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
worst	ADJ	O	O
toxicities	NOUN	O	I-Entity
(	PUNCT	O	O
%	NOUN	O	O
)	PUNCT	O	O
observed	VERB	O	O
were	VERB	O	O
(	PUNCT	O	O
CTC	PROPN	O	O
-	PUNCT	O	O
NCI	PROPN	O	O
1/2/3	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O

leukopenia	NOUN	O	I-Entity
45.5/18.2/6.1	NOUN	O	O
,	PUNCT	O	O
thrombocytopenia	NOUN	O	I-Entity
33.3/9.1/6.1	NUM	O	O
,	PUNCT	O	O
vomitus	NOUN	O	I-Entity
24.2/9.1/0	NUM	O	O
,	PUNCT	O	O
diarrhea	NOUN	O	I-Entity
36.4/6.1/3.0	NUM	O	O
,	PUNCT	O	O
stomatitis	NOUN	O	I-Entity
18.2/9.1/0	NUM	O	O
,	PUNCT	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
12.1/0/0	NUM	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
hemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
HUS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-FU	NUM	O	I-Entity
/	SYM	O	O
FA	PROPN	O	I-Entity
/	SYM	O	O
MMC	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
outpatient	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
AGC	PROPN	O	I-Entity
(	PUNCT	O	O
objective	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
54.6%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
an	DET	O	O
alternative	NOUN	O	O
to	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimens	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
to	PART	O	O
be	VERB	O	O
considered	VERB	O	O
that	ADP	O	O
possibly	ADV	O	O
HUS	PROPN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12165618)

Persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
type	NOUN	O	I-Entity
1-infected	VERB	O	I-Entity
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indinavir	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Prolonged	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
indinavir	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
complications	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
monitor	VERB	O	O
indinavir	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
type	NOUN	O	I-Entity
1-infected	VERB	O	I-Entity
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indinavir	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Urinary	ADJ	O	O
pH	NOUN	O	O
,	PUNCT	O	O
albumin	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
erythrocytes	NOUN	O	O
,	PUNCT	O	O
leukocytes	NOUN	O	O
,	PUNCT	O	O
bacteria	NOUN	O	O
and	CCONJ	O	O
crystals	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
culture	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
every	DET	O	O
3	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
96	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
routinely	ADV	O	O
determined	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

Steady	ADJ	O	O
-	PUNCT	O	O
state	NOUN	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
indinavir	NOUN	O	I-Entity
were	VERB	O	O
done	VERB	O	O
at	ADP	O	O
week	NOUN	O	O
4	NUM	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
indinavir	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
(	PUNCT	O	O
>	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
75	NUM	O	O
cells/	NOUN	O	O
micro	ADJ	O	O
L	NOUN	O	O
in	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
consecutive	ADJ	O	O
visits	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
96	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
53%	NUM	O	O
.	PUNCT	O	O

Persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
was	VERB	O	O
frequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
mild	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
albumin	NOUN	O	O
/	SYM	O	O
creatinine	NOUN	O	I-Entity
ratio	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
microscopic	ADJ	O	O
hematuria	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
>	X	O	O
50%	NUM	O	O
above	ADP	O	O
normal	ADJ	O	O
was	VERB	O	O
33%	NUM	O	O
after	ADP	O	O
96	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
more	ADV	O	O
frequently	ADV	O	O
had	VERB	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
50%	NUM	O	O
above	ADP	O	O
normal	ADJ	O	O
than	ADP	O	O
those	DET	O	O
children	NOUN	O	O
without	ADP	O	O
persistent	NOUN	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
children	NOUN	O	O
younger	ADJ	O	O
than	ADP	O	O
5.6	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
persistent	ADV	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
frequent	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
older	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
higher	ADJ	O	O
cumulative	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
an	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
>	SYM	O	O
19	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
L	PROPN	O	O
x	PROPN	O	O
h	PROPN	O	O
or	CCONJ	O	O
a	DET	O	O
peak	NOUN	O	O
serum	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
indinavir	NOUN	O	I-Entity
>	SYM	O	O
12	NUM	O	O
mg	NUM	O	O

In	ADP	O	O
4	NUM	O	O
children	NOUN	O	O
,	PUNCT	O	O
indinavir	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
because	ADP	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Subsequently	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
decreased	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
urine	NOUN	O	O
albumin	NOUN	O	O
/	SYM	O	O
creatinine	NOUN	O	I-Entity
ratios	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
zero	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
leukocyturia	NOUN	O	I-Entity
disappeared	VERB	O	O
within	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indinavir	NOUN	O	I-Entity
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
cumulative	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
more	ADV	O	O
frequently	ADV	O	O
had	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
>	X	O	O
50%	NUM	O	O
above	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
children	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
nephrolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

Indinavir	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
must	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
closely	ADV	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
,	PUNCT	O	O
age	NOUN	O	O

<	X	O	O
5.6	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
of	ADP	O	O
indinavir	NOUN	O	I-Entity
>	SYM	O	O
19	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
L	PROPN	O	O
x	PROPN	O	O
h	X	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
C(max	PROPN	O	O
)	PUNCT	O	O


-DOCSTART- (12359538)

Utility	NOUN	O	O
of	ADP	O	O
troponin	NOUN	O	O
I	PRON	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Baseline	PROPN	O	O
electrocardiogram	NOUN	O	O
abnormalities	NOUN	O	O
and	CCONJ	O	O
market	NOUN	O	O
elevations	NOUN	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
myocardial	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
make	VERB	O	O
accurate	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
difficult	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
outcomes	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
troponin	DET	O	O
positivity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
admitted	VERB	O	O
for	ADP	O	O
exclusion	NOUN	O	O
of	ADP	O	O
MI	PROPN	O	I-Entity
.	PUNCT	O	O

Outcomes	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
admitted	VERB	O	O
for	ADP	O	O
possible	ADJ	O	O
MI	PROPN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
rule	NOUN	O	O
-	PUNCT	O	O
in	ADP	O	O
protocol	NOUN	O	O
that	ADJ	O	O
included	VERB	O	O
serial	ADJ	O	O
sampling	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
(	PUNCT	O	O
CK	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
troponin	NOUN	O	O
I	PRON	O	O
(	PUNCT	O	O
cTnI	PROPN	O	O
)	PUNCT	O	O
over	ADP	O	O
eight	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Outcomes	NOUN	O	O
included	VERB	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
MI	PROPN	O	I-Entity
(	PUNCT	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O

>	X	O	O
or=	SYM	O	O
4	NUM	O	O
,	PUNCT	O	O
cardiac	ADJ	O	B-Entity
death	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
significant	ADJ	O	O
coronary	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
>	PUNCT	O	O
or=50%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
246	NUM	O	O
admitted	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
34	NUM	O	O
(	PUNCT	O	O
14%	NUM	O	O
)	PUNCT	O	O
met	VERB	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
MI	PROPN	O	I-Entity
and	CCONJ	O	O
38	NUM	O	O
(	PUNCT	O	O
16%	NUM	O	O
)	PUNCT	O	O

Three	NUM	O	O
of	ADP	O	O
the	DET	O	O
four	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
significant	ADJ	O	O
disease	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
cTnI	VERB	O	O
elevations	NOUN	O	O
met	VERB	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
MI	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
had	VERB	O	O
a	DET	O	O
peak	NOUN	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
level	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mL.	ADJ	O	O
Sensitivities	NOUN	O	O
,	PUNCT	O	O
specificities	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
positive	ADJ	O	O
and	CCONJ	O	O
negative	ADJ	O	O
likelihood	NOUN	O	O
ratios	NOUN	O	O
for	ADP	O	O
predicting	VERB	O	O
cardiac	ADJ	O	B-Entity
death	NOUN	O	I-Entity
or	CCONJ	O	O
significant	ADJ	O	O
disease	NOUN	O	O
were	VERB	O	O
high	ADJ	O	O
for	ADP	O	O
both	DET	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
MI	PROPN	O	I-Entity
and	CCONJ	O	O
cTnI	PROPN	O	O
and	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Most	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
cTnI	PROPN	O	O
elevations	NOUN	O	O
meet	VERB	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
MI	PROPN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
underlying	VERB	O	O
significant	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Troponin	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
have	VERB	O	O
an	DET	O	O
equivalent	ADJ	O	O
diagnostic	ADJ	O	O
accuracy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
for	ADP	O	O
diagnosing	VERB	O	O
necrosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
suspected	VERB	O	O
MI	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12372954)

Acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
nicergoline	NOUN	O	I-Entity
(	PUNCT	O	O
Sermion	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
(	PUNCT	O	O
AIN	PROPN	O	I-Entity
)	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
nicergoline	NOUN	O	I-Entity
(	PUNCT	O	O
Sermion	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
50-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
hospital	NOUN	O	O
for	ADP	O	O
fever	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Before	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
nicergoline	NOUN	O	I-Entity
and	CCONJ	O	O
bendazac	NOUN	O	B-Entity
lysine	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
at	ADP	O	O
ophthalmologic	ADJ	O	O
department	NOUN	O	O
.	PUNCT	O	O

Thereafter	ADV	O	O
,	PUNCT	O	O
he	PRON	O	O
experienced	VERB	O	O
intermittent	ADJ	O	O
fever	NOUN	O	I-Entity
and	CCONJ	O	O
skin	NOUN	O	B-Entity
rash	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
arthralgia	NOUN	O	I-Entity
and	CCONJ	O	O
fever	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
findings	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
eosinophilia	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
)	PUNCT	O	O
suggested	VERB	O	O
AIN	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
which	ADJ	O	O
was	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
pathologic	ADJ	O	O
findings	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
lymphocyte	ADJ	O	O
transformation	NOUN	O	O
test	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
result	NOUN	O	O
against	ADP	O	O
nicergoline	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
consisted	VERB	O	O
of	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
nicergoline	NOUN	O	I-Entity
and	CCONJ	O	O
intravenous	ADJ	O	O
methylprednisolone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
his	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
completely	ADV	O	O
recovered	VERB	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
nicergoline	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
AIN	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12452552)

Neuroleptic	ADJ	O	B-Entity
malignant	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
complicated	VERB	O	O
by	ADP	O	O
massive	ADJ	O	O
intestinal	ADJ	O	O
bleeding	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CRF	PROPN	O	I-Entity
)	PUNCT	O	O
developed	VERB	O	O
neuroleptic	ADJ	O	B-Entity
malignant	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
levomepromazine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
typical	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
NMS	PROPN	O	I-Entity
,	PUNCT	O	O
massive	ADJ	O	O
intestinal	ADJ	O	O
bleeding	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
during	ADP	O	O
the	DET	O	O
episode	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
NMS	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
CRF	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
complicated	VERB	O	O
by	ADP	O	O
intestinal	ADJ	O	O
bleeding	NOUN	O	I-Entity
and	CCONJ	O	O
needs	VERB	O	O
special	ADJ	O	O
caution	NOUN	O	O
for	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12487093)

Adrenaline	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
destroy	VERB	O	O
the	DET	O	O
BBB	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
triphenyltetrazolium	NOUN	O	I-Entity
(	PUNCT	O	O
TTC	PROPN	O	I-Entity
)	PUNCT	O	O
staining	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
slices	NOUN	O	O
just	ADV	O	O
after	ADP	O	O
giving	VERB	O	O
adrenaline	NOUN	O	I-Entity
for	ADP	O	O
30	NUM	O	O
s.	NOUN	O	O

In	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
whole	ADJ	O	O
brain	NOUN	O	O
sections	NOUN	O	O
exhibited	VERB	O	O
complete	ADJ	O	O
staining	NOUN	O	O
with	ADP	O	O
TTC	PROPN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
adrenaline	NOUN	O	I-Entity
infusion	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
s	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
large	ADJ	O	O
unstained	ADJ	O	O
areas	NOUN	O	O
in	ADP	O	O
the	DET	O	O
left	ADJ	O	O
brain	NOUN	O	O
in	ADP	O	O
right	ADV	O	O
-	PUNCT	O	O
pawed	VERB	O	O
animals	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vice	NOUN	O	O
versa	ADV	O	O
in	ADP	O	O
left	VERB	O	O
-	PUNCT	O	O
pawed	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
results	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
breakdown	NOUN	O	O
of	ADP	O	O
BBB	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (12498738)

Carvedilol	PROPN	O	I-Entity
protects	VERB	O	O
against	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mitochondrial	ADJ	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Several	ADJ	O	O
cytopathic	ADJ	O	O
mechanisms	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
mediate	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
cumulative	ADJ	O	O
and	CCONJ	O	O
irreversible	ADJ	O	O
cardiomyopathy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Recent	ADJ	O	O
evidence	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
are	VERB	O	O
key	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenic	ADJ	O	O
process	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
carvedilol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
nonselective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
potent	ADJ	O	O
antioxidant	NOUN	O	O
properties	NOUN	O	O
,	PUNCT	O	O
protects	VERB	O	O
against	ADP	O	O
the	DET	O	O
cardiac	NOUN	O	O
and	CCONJ	O	O
hepatic	ADJ	O	O
mitochondrial	ADJ	O	O
bioenergetic	ADJ	O	O
dysfunction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
subchronic	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Heart	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
mitochondria	NOUN	O	O
were	VERB	O	O
isolated	VERB	O	O
from	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
sc	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
carvedilol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Heart	NOUN	O	O
mitochondria	ADV	O	O
isolated	ADJ	O	O
from	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
exhibited	VERB	O	O
depressed	ADJ	O	O
rates	NOUN	O	O
for	ADP	O	O
state	NOUN	O	O
3	NUM	O	O
respiration	NOUN	O	O
(	PUNCT	O	O
336	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Mitochondrial	ADJ	O	O
calcium	NOUN	O	I-Entity
-	PUNCT	O	O
loading	NOUN	O	O
capacity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
NADH	PROPN	O	O
-	PUNCT	O	O
dehydrogenase	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
suppressed	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	O
mitochondria	NOUN	O	O
from	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
treatment	NOUN	O	O
also	ADV	O	O
caused	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
RCR	PROPN	O	O
for	ADP	O	O
liver	NOUN	O	O
mitochondria	NOUN	O	O
(	PUNCT	O	O
3.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Coadministration	NOUN	O	O
of	ADP	O	O
carvedilol	NOUN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
cellular	ADJ	O	O
vacuolization	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
myocytes	NOUN	O	O
and	CCONJ	O	O
prevented	VERB	O	O
the	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
on	ADP	O	O
mitochondrial	ADJ	O	O
respiration	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
heart	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
.	PUNCT	O	O

Carvedilol	PROPN	O	I-Entity
also	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
mitochondrial	ADJ	O	O
Ca(2	PROPN	O	I-Entity
+	PROPN	O	O
)	PUNCT	O	O
loading	NOUN	O	O
capacity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	O
complexes	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
mitochondria	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Carvedilol	PROPN	O	I-Entity
by	ADP	O	O
itself	PRON	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
parameters	NOUN	O	O
measured	VERB	O	O
for	ADP	O	O
heart	NOUN	O	O
or	CCONJ	O	O
liver	NOUN	O	O
mitochondria	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
this	DET	O	O
protection	NOUN	O	O
by	ADP	O	O
carvedilol	NOUN	O	I-Entity
against	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
structural	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
cardiac	ADJ	O	O
tissue	NOUN	O	O
damage	NOUN	O	O
may	VERB	O	O
afford	VERB	O	O
significant	ADJ	O	O
clinical	ADJ	O	O
advantage	NOUN	O	O
in	ADP	O	O
minimizing	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
cardiomyopathy	NOUN	O	I-Entity
that	ADJ	O	O
accompanies	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
doxorubicin	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12523489)

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
is	VERB	O	O
more	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
adenosine	NOUN	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
than	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
and	CCONJ	O	O
antagonists	NOUN	O	O
on	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
adenosine	NOUN	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	B-Entity
the	DET	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
seems	VERB	O	O
that	ADP	O	O
adenosine	ADJ	O	I-Entity
A1	PROPN	O	O
and	CCONJ	O	O
A2	NOUN	O	O
receptors	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
this	DET	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
:	PUNCT	O	O
2-p-(2-carboxyethyl)phenethylamino-5'-N	NUM	O	B-Entity
-	PUNCT	O	I-Entity
ethylcarboxamidoadenosine	NOUN	O	I-Entity
(	PUNCT	O	O
CGS	PROPN	O	B-Entity
21680	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O

A2A	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
N6-cyclopentyladenosine	PROPN	O	I-Entity
(	PUNCT	O	O
CPA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
A1	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5'-N	NUM	O	B-Entity
-	PUNCT	O	I-Entity
ethylcarboxamidoadenosine	NOUN	O	I-Entity
(	PUNCT	O	O
NECA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
A2/A1	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
significantly	ADV	O	O
and	CCONJ	O	O
dose	VERB	O	O
-	PUNCT	O	O
dependently	ADV	O	O
decreased	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

CPA	NOUN	O	I-Entity
reduced	VERB	O	O
cocaine	NOUN	O	I-Entity
action	NOUN	O	O
at	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
which	ADJ	O	O
,	PUNCT	O	O
given	VERB	O	O
alone	ADV	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
motility	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
CGS	PROPN	O	B-Entity
21680	NUM	O	I-Entity
and	CCONJ	O	O
NECA	PROPN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
which	ADJ	O	O
,	PUNCT	O	O
given	VERB	O	O
alone	ADJ	O	O
,	PUNCT	O	O
decreased	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
both	DET	O	O
adenosine	NOUN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
although	ADP	O	O
agonists	NOUN	O	O
of	ADP	O	O
A1	NOUN	O	O
receptors	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
have	VERB	O	O
stronger	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
it	PRON	O	O
.	PUNCT	O	O

The	DET	O	O
selective	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
A2	NOUN	O	O
adenosine	NOUN	O	I-Entity
receptor	NOUN	O	O
by	ADP	O	O
DMPX	PROPN	O	I-Entity
(	PUNCT	O	O
3,7-dimethyl-1-propargylxanthine	NUM	O	I-Entity
)	PUNCT	O	O
significantly	ADV	O	O
enhanced	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Caffeine	PROPN	O	I-Entity
had	VERB	O	O
similar	ADJ	O	O
action	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

CPT	PROPN	O	I-Entity
(	PUNCT	O	O
8-cyclopentyltheophylline)--A1	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
show	VERB	O	O
any	DET	O	O
influence	NOUN	O	O
in	ADP	O	O
this	DET	O	O
test	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
decreased	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
doses	NOUN	O	O
than	ADP	O	O
those	DET	O	O
which	ADJ	O	O
were	VERB	O	O
active	ADJ	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
selective	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
A2	PROPN	O	O
adenosine	NOUN	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
DMPX	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
caffeine	NOUN	O	I-Entity
)	PUNCT	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
all	DET	O	O
adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
(	PUNCT	O	O
A1	PROPN	O	O
and	CCONJ	O	O
A2	NOUN	O	O
)	PUNCT	O	O
reduce	VERB	O	O
cocaine-	NOUN	O	I-Entity
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
indicate	VERB	O	O
that	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
is	VERB	O	O
more	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
adenosine	NOUN	O	I-Entity
receptor	NOUN	O	O
agonists	NOUN	O	O
(	PUNCT	O	O
particularly	ADV	O	O
A1	PROPN	O	O
receptors	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12535818)

Amiodarone	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bradyarrhythmia	NOUN	O	I-Entity
requiring	VERB	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	O
prior	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	PROPN	O	O
:	PUNCT	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
(	PUNCT	O	O
AF	PROPN	O	I-Entity
)	PUNCT	O	O
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bradyarrhythmia	NOUN	O	I-Entity
requiring	VERB	O	O
a	DET	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
.	PUNCT	O	O

Reports	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
bradyarrhythmia	NOUN	O	I-Entity
during	ADP	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
are	VERB	O	O
infrequent	ADJ	O	O
and	CCONJ	O	O
limited	ADJ	O	O
to	ADP	O	O
studies	NOUN	O	O
assessing	VERB	O	O
the	DET	O	O
therapy	NOUN	O	O
's	PART	O	O
use	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
study	NOUN	O	O
cohort	NOUN	O	O
of	ADP	O	O
8,770	NUM	O	O
patients	NOUN	O	O
age	NOUN	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
65	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
a	DET	O	O
new	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
AF	PROPN	O	I-Entity
was	VERB	O	O
identified	VERB	O	O
from	ADP	O	O
a	DET	O	O
provincewide	NOUN	O	O
database	NOUN	O	O
of	ADP	O	O
Quebec	PROPN	O	O
residents	NOUN	O	O
with	ADP	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
between	ADP	O	O
1991	NUM	O	O
and	CCONJ	O	O
1999	NUM	O	O
.	PUNCT	O	O

Using	VERB	O	O
a	DET	O	O
nested	VERB	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
477	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
bradyarrhythmia	NOUN	O	I-Entity
requiring	VERB	O	O
a	DET	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
(	PUNCT	O	O
1:4	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
1,908	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Multivariable	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
OR	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
pacemaker	NOUN	O	O
insertion	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
controlling	VERB	O	O
for	ADP	O	O
baseline	NOUN	O	O
risk	NOUN	O	O
factors	NOUN	O	O
and	CCONJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
sotalol	NOUN	O	I-Entity
,	PUNCT	O	O

Class	PROPN	O	O
I	PRON	O	O
antiarrhythmic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
digoxin	NOUN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
pacemaker	NOUN	O	O
insertion	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
:	PUNCT	O	O
2.14	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	PROPN	O	O
]	PUNCT	O	O
:	PUNCT	O	O
1.30	NUM	O	O
to	ADP	O	O
3.54	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Digoxin	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
other	ADJ	O	O
medication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
pacemaker	NOUN	O	O
insertion	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
:	PUNCT	O	O
1.78	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.37	NUM	O	O
to	ADP	O	O
2.31	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
AF	PROPN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
previous	ADJ	O	O
MI	PROPN	O	I-Entity
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bradyarrhythmia	NOUN	O	I-Entity
requiring	VERB	O	O
a	DET	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
finding	NOUN	O	O
of	ADP	O	O
an	DET	O	O
augmented	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
pacemaker	NOUN	O	O
insertion	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
women	NOUN	O	O
receiving	VERB	O	O
amiodarone	NOUN	O	I-Entity
requires	VERB	O	O
further	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12559315)

Indomethacin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
morphologic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
epithelium	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
morphologic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
urothelium	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
indomethacin	NOUN	O	I-Entity
.	PUNCT	O	O

Nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
poorly	ADV	O	O
recognized	VERB	O	O
and	CCONJ	O	O
under	ADP	O	O
-	PUNCT	O	O
reported	VERB	O	O
condition	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
tiaprofenic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
indomethacin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
this	DET	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
established	VERB	O	O
:	PUNCT	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
one	NUM	O	O
intraperitoneal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
indomethacin	ADJ	O	I-Entity
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
oral	ADJ	O	O
indomethacin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
3.25	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
daily	ADV	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
indomethacin	VERB	O	I-Entity
groups	NOUN	O	O
revealed	VERB	O	O
statistically	ADV	O	O
increased	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
mast	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mucosa	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
penetration	NOUN	O	O
of	ADP	O	O
lanthanum	NOUN	O	B-Entity
nitrate	NOUN	O	I-Entity
through	ADP	O	O
intercellular	ADJ	O	O
areas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
epithelium	NOUN	O	O
.	PUNCT	O	O

Indomethacin	PROPN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
histopathologic	ADJ	O	O
findings	NOUN	O	O
typical	ADJ	O	O
of	ADP	O	O
interstitial	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
leaky	ADJ	O	O
bladder	NOUN	O	O
epithelium	NOUN	O	O
and	CCONJ	O	O
mucosal	NOUN	O	O
mastocytosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
true	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
clarified	VERB	O	O
by	ADP	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12644816)

An	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
androgen	NOUN	O	I-Entity
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
antiangiogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
various	ADJ	O	O
solid	ADJ	O	O
and	CCONJ	O	O
haematological	ADJ	O	B-Entity
malignancies	NOUN	O	I-Entity
.	PUNCT	O	O

Thalidomide	PROPN	O	I-Entity
blocks	NOUN	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
angiogenic	ADJ	O	O
agents	NOUN	O	O
including	VERB	O	O
bFGF	PROPN	O	O
,	PUNCT	O	O
VEGF	PROPN	O	O
and	CCONJ	O	O
IL-6	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
undertook	VERB	O	O
an	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
thalidomide	NOUN	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
once	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
6	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
androgen	NOUN	O	I-Entity
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
underwent	VERB	O	O
regular	ADJ	O	O
measurement	NOUN	O	O
of	ADP	O	O
prostate	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
PSA	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
electrolytes	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
bFGF	NOUN	O	O
and	CCONJ	O	O
VEGF	PROPN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
effects	NOUN	O	O
included	VERB	O	O
constipation	NOUN	O	I-Entity
,	PUNCT	O	O
morning	NOUN	O	O
drowsiness	NOUN	O	I-Entity
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
and	CCONJ	O	O
rash	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
resulted	VERB	O	O
in	ADP	O	O
withdrawal	NOUN	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
by	ADP	O	O
three	NUM	O	O
men	NOUN	O	O
.	PUNCT	O	O

Evidence	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
sensory	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
nine	NUM	O	O
of	ADP	O	O
13	NUM	O	O
men	NOUN	O	O
before	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
seven	NUM	O	O
men	NOUN	O	O
who	NOUN	O	O
completed	VERB	O	O
six	NUM	O	O
months	NOUN	O	O
on	ADP	O	O
thalidomide	NOUN	O	I-Entity
,	PUNCT	O	O
subclinical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
four	NUM	O	O
before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
all	DET	O	O
seven	NUM	O	O
at	ADP	O	O
repeat	NOUN	O	O
testing	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
thalidomide	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
option	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
failed	VERB	O	O
other	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
provided	VERB	O	O
close	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
is	VERB	O	O
maintained	VERB	O	O
for	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12677626)

Central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
for	ADP	O	O
lumbar	NOUN	O	O
plexus	NOUN	O	O
block	NOUN	O	O
:	PUNCT	O	O

Central	PROPN	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cardiac	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
is	VERB	O	O
a	DET	O	O
recognized	VERB	O	O
complication	NOUN	O	O
of	ADP	O	O
regional	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Levobupivacaine	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
pure	ADJ	O	O
S(-	PROPN	O	O
)	PUNCT	O	O

enantiomer	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
improve	VERB	O	O
the	DET	O	O
cardiac	ADJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
2	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
grand	ADJ	O	B-Entity
mal	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
following	VERB	O	O
accidental	ADJ	O	O
intravascular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

Immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
0.5%	NUM	O	O
with	ADP	O	O
epinephrine	NOUN	O	I-Entity
2.5	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
grand	ADJ	O	B-Entity
mal	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
despite	ADP	O	O
negative	ADJ	O	O
aspiration	NOUN	O	O
for	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
epinephrine	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
thiopental	NOUN	O	I-Entity
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
succinylcholine	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Neither	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
preoperatively	ADV	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
antagonist	NOUN	O	O
medications	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
have	VERB	O	O
masked	VERB	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
the	DET	O	O
unintentional	ADJ	O	O
intravascular	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
with	ADP	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
safer	ADJ	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
profile	NOUN	O	O
than	ADP	O	O
racemic	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
if	ADP	O	O
adequate	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
reach	VERB	O	O
the	DET	O	O
circulation	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
will	VERB	O	O
result	VERB	O	O
in	ADP	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	ADJ	O	O
concentrations	NOUN	O	O
sufficient	ADJ	O	O
to	ADP	O	O
result	VERB	O	O
in	ADP	O	O
central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
manifestations	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
2	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12699527)

Anaesthetic	ADJ	O	O
complications	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
myotonia	NOUN	O	B-Entity
congenita	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
study	NOUN	O	O
and	CCONJ	O	O
comparison	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
myotonic	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Myotonia	PROPN	O	B-Entity
congenita	NOUN	O	I-Entity
(	PUNCT	O	O
MC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
defect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
skeletal	ADJ	O	O
muscle	NOUN	O	O
chloride	NOUN	O	I-Entity
channel	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
sustained	ADJ	O	B-Entity
membrane	NOUN	O	I-Entity
depolarisation	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
previously	ADV	O	O
healthy	ADJ	O	O
32-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
muscle	NOUN	O	B-Entity
spasm	NOUN	O	I-Entity
and	CCONJ	O	O
secondary	ADJ	O	O
ventilation	NOUN	O	O
difficulties	NOUN	O	O
following	VERB	O	O
a	DET	O	O
preoperative	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
muscle	NOUN	O	B-Entity
spasms	NOUN	O	I-Entity
disappeared	VERB	O	O
spontaneously	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
surgery	NOUN	O	O
proceeded	VERB	O	O
without	ADP	O	O
further	ADJ	O	O
problems	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
subsequently	ADV	O	O
questioned	VERB	O	O
,	PUNCT	O	O
she	PRON	O	O
reported	VERB	O	O
minor	ADJ	O	O
symptoms	NOUN	O	O
suggesting	VERB	O	O
a	DET	O	O
myotonic	ADJ	O	B-Entity
condition	NOUN	O	I-Entity
.	PUNCT	O	O

Myotonia	PROPN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
EMG	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
MC	PROPN	O	I-Entity
was	VERB	O	O
confirmed	VERB	O	O
genetically	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
give	VERB	O	O
a	DET	O	O
brief	ADJ	O	O
overview	NOUN	O	O
of	ADP	O	O
ion	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
disorders	NOUN	O	I-Entity
including	VERB	O	O
malignant	ADJ	O	B-Entity
hyperthermia	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
anaesthetic	ADJ	O	O
considerations	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12752472)

Respiratory	ADJ	O	O
pattern	NOUN	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Apnea	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
occur	VERB	O	O
during	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
systematic	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
ictal	ADJ	O	O
respiratory	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
are	VERB	O	O
few	ADJ	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
sought	VERB	O	O
to	PART	O	O
generate	VERB	O	O
information	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
interictal	ADJ	O	O
period	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Twelve	NUM	O	O
rats	NOUN	O	O
(	PUNCT	O	O
six	NUM	O	O
chronically	ADV	O	O
epileptic	ADJ	O	I-Entity
animals	NOUN	O	O
and	CCONJ	O	O
six	NUM	O	O
controls	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
anesthetized	VERB	O	O
,	PUNCT	O	O
given	VERB	O	O
tracheotomies	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subjected	VERB	O	O
to	ADP	O	O
hyperventilation	NOUN	O	I-Entity
or	CCONJ	O	O
hypoventilation	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hyperventilation	NOUN	O	I-Entity
maneuver	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
spontaneous	ADJ	O	O
ventilation	NOUN	O	O
in	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
control	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
VE	PROPN	O	O
had	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
epileptic	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
VE	PROPN	O	O
was	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
increase	NOUN	O	O
in	ADP	O	O
TE	PROPN	O	O
peak	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
epileptic	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
VE	PROPN	O	O
was	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
TE	PROPN	O	O
peak	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
have	VERB	O	O
an	DET	O	O
altered	VERB	O	O
ability	NOUN	O	O
to	PART	O	O
react	VERB	O	O
to	ADP	O	O
(	PUNCT	O	O
or	CCONJ	O	O
compensate	VERB	O	O
for	ADP	O	O
)	PUNCT	O	O
blood	NOUN	O	O
gas	NOUN	O	O
changes	NOUN	O	O
with	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
ventilation	NOUN	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
it	PRON	O	O
is	VERB	O	O
centrally	ADV	O	O
determined	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
speculate	VERB	O	O
on	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
relation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
findings	NOUN	O	O
on	ADP	O	O
treating	VERB	O	O
different	ADJ	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
conditions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12828076)

Increased	VERB	O	O
serum	NOUN	O	O
soluble	ADJ	O	O
Fas	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
paracetamol	VERB	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

Experimental	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
apoptosis	NOUN	O	O
via	ADP	O	O
the	DET	O	O
Fas	PROPN	O	O
/	SYM	O	O
Fas	PROPN	O	O
Ligand	PROPN	O	O
signaling	VERB	O	O
system	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
soluble	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
Fas	PROPN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

METHODOLOGY	NOUN	O	O
:	PUNCT	O	O
Serum	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
sFas	PROPN	O	O
(	PUNCT	O	O
soluble	ADJ	O	O
Fas	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
ELISA	PROPN	O	O
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
10	NUM	O	O
normal	ADJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
and	CCONJ	O	O
interferon	NOUN	O	O
-	PUNCT	O	O
gamma	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
determined	VERB	O	O
by	ADP	O	O
ELISA	PROPN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
sFas	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
median	NOUN	O	O
,	PUNCT	O	O
26.8	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
6.9	NUM	O	O
-	SYM	O	O
52.7	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
8.6	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
6.5	NUM	O	O
-	SYM	O	O
12.0	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
paracetamol	VERB	O	I-Entity
overdose	NOUN	O	I-Entity
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
28.7	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
12.8	NUM	O	O
-	SYM	O	O
52.7	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
those	DET	O	O
due	ADJ	O	O
to	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
A	NOUN	O	O
to	ADP	O	O
E	PROPN	O	O
hepatitis	NOUN	O	I-Entity
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
12.5	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
6.9	NUM	O	O
-	SYM	O	O
46.0	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
serum	NOUN	O	O
sFas	PROPN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
aspartate	ADJ	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.613	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
increased	VERB	O	O
concentration	NOUN	O	O
of	ADP	O	O
sFas	PROPN	O	O
in	ADP	O	O
serum	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
may	VERB	O	O
reflect	VERB	O	O
activation	NOUN	O	O
of	ADP	O	O
Fas	PROPN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
this	DET	O	O
together	ADV	O	O
with	ADP	O	O
increased	VERB	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
factor	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
cell	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12865514)

Bilateral	ADJ	O	O
subthalamic	ADJ	O	O
nucleus	NOUN	O	O
stimulation	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
frequency	NOUN	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subthalamic	ADJ	O	O
nucleus	NOUN	O	O
(	PUNCT	O	O
STN	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
ameliorate	VERB	O	O
the	DET	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
severe	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity

(	PUNCT	O	O
Stages	PROPN	O	O
III	PROPN	O	O
-	PUNCT	O	O
V	PROPN	O	O
on	ADP	O	O
Hoehn	PROPN	O	O
and	CCONJ	O	O
Yahr	PROPN	O	O
scale	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
particularly	ADV	O	O
bradykinesia	NOUN	O	I-Entity
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
levodopa	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
underwent	VERB	O	O
bilateral	ADJ	O	O
implantation	NOUN	O	O
of	ADP	O	O
electrodes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
STN	PROPN	O	O
.	PUNCT	O	O

Preoperative	ADJ	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
assessments	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
"	PUNCT	O	O
on	ADP	O	O
"	PUNCT	O	O
and	CCONJ	O	O
"	PUNCT	O	O
off	ADP	O	O
"	PUNCT	O	O
drug	NOUN	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
using	VERB	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
,	PUNCT	O	O
Hoehn	PROPN	O	O
and	CCONJ	O	O
Yahr	PROPN	O	O
staging	NOUN	O	O
,	PUNCT	O	O
England	PROPN	O	O
activities	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
living	VERB	O	O
score	NOUN	O	O
and	CCONJ	O	O
video	NOUN	O	O
recordings	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
parts	NOUN	O	O
II	PROPN	O	O
and	CCONJ	O	O
III	PROPN	O	O
)	PUNCT	O	O
off	ADP	O	O
medication	NOUN	O	O
improved	VERB	O	O
by	ADP	O	O
62%	NUM	O	O
and	CCONJ	O	O
61%	NUM	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p<0.0005	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
subscores	NOUN	O	O
for	ADP	O	O
the	DET	O	O
akinesia	NOUN	O	I-Entity
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
gait	NOUN	O	O
also	ADV	O	O
improved	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
decreased	VERB	O	O
from	ADP	O	O
813	NUM	O	O
mg	NUM	O	O
to	ADP	O	O
359	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
subthalamic	ADJ	O	O
nucleus	NOUN	O	O
stimulation	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
reduces	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
off	ADP	O	O
"	PUNCT	O	O
phase	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
improves	VERB	O	O
the	DET	O	O
axial	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
reduces	VERB	O	O
levodopa	NOUN	O	I-Entity
requirements	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
is	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
controlling	VERB	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12912689)

Ocular	ADJ	O	O
motility	NOUN	O	O
changes	NOUN	O	O
after	ADP	O	O
subtenon	NOUN	O	O
carboplatin	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
for	ADP	O	O
retinoblastoma	NOUN	O	I-Entity
.	PUNCT	O	O

Focal	PROPN	O	O
subtenon	NOUN	O	O
carboplatin	NOUN	O	I-Entity
injections	NOUN	O	O
have	VERB	O	O
recently	ADV	O	O
been	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
presumably	ADV	O	O
toxicity	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
adjunct	NOUN	O	O
to	ADP	O	O
systemic	ADJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
intraocular	NOUN	O	O
retinoblastoma	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
our	ADJ	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
with	ADP	O	O
abnormal	ADJ	O	B-Entity
ocular	ADJ	O	I-Entity
motility	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
subtenon	NOUN	O	O
carboplatin	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
noted	VERB	O	O
abnormal	ADJ	O	B-Entity
ocular	ADJ	O	I-Entity
motility	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
retinoblastoma	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
subtenon	NOUN	O	O
carboplatin	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
ocular	ADJ	O	O
manipulation	NOUN	O	O
under	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
their	ADJ	O	O
eyes	NOUN	O	O
by	ADP	O	O
forced	VERB	O	O
duction	NOUN	O	O
testing	NOUN	O	O
,	PUNCT	O	O
comparing	VERB	O	O
ocular	ADJ	O	O
motility	NOUN	O	O
after	ADP	O	O
tumor	NOUN	O	I-Entity
control	NOUN	O	O
with	ADP	O	O
ocular	ADJ	O	O
motility	NOUN	O	O
at	ADP	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

Limitation	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	O
motility	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
all	DET	O	O
12	NUM	O	O
eyes	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
intraocular	NOUN	O	O
retinoblastoma	NOUN	O	I-Entity
with	ADP	O	O
1	NUM	O	O
to	ADP	O	O
6	NUM	O	O
injections	NOUN	O	O
of	ADP	O	O
subtenon	NOUN	O	O
carboplatin	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
multimodality	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
revealed	VERB	O	O
many	ADJ	O	O
lipophages	NOUN	O	O
in	ADP	O	O
the	DET	O	O
periorbital	ADJ	O	O
fat	NOUN	O	O
surrounding	VERB	O	O
the	DET	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
eye	NOUN	O	O
,	PUNCT	O	O
indicative	ADJ	O	O
of	ADP	O	O
phagocytosis	NOUN	O	O
of	ADP	O	O
previously	ADV	O	O
existing	VERB	O	O
fat	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
suggesting	VERB	O	O
prior	ADV	O	O
fat	ADJ	O	O
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
enucleations	NOUN	O	O
were	VERB	O	O
technically	ADV	O	O
difficult	ADJ	O	O
and	CCONJ	O	O
hazardous	ADJ	O	O
for	ADP	O	O
globe	NOUN	O	O
rupture	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
extensive	ADJ	O	O
orbital	ADJ	O	O
soft	ADJ	O	O
tissue	NOUN	O	O
adhesions	NOUN	O	O
.	PUNCT	O	O

Subtenon	PROPN	O	O
carboplatin	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
fibrosis	NOUN	O	I-Entity
of	ADP	O	O
orbital	ADJ	O	O
soft	ADJ	O	O
tissues	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
mechanical	ADJ	O	O
restriction	NOUN	O	O
of	ADP	O	O
eye	NOUN	O	O
movements	NOUN	O	O
and	CCONJ	O	O
making	VERB	O	O
subsequent	ADJ	O	O
enucleation	NOUN	O	O
difficult	ADJ	O	O
.	PUNCT	O	O

Subtenon	PROPN	O	O
carboplatin	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
free	ADJ	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
use	NOUN	O	O
is	VERB	O	O
best	ADV	O	O
restricted	ADJ	O	O
to	ADP	O	O
specific	ADJ	O	O
indications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12948256)

Ethambutol	PROPN	O	I-Entity
and	CCONJ	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
ethambutol	NOUN	O	I-Entity
and	CCONJ	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Thirteen	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
after	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
ethambutol	NOUN	O	I-Entity
for	ADP	O	O
tuberculosis	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
lung	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
lymph	NOUN	O	I-Entity
node	NOUN	O	I-Entity
at	ADP	O	O
Siriraj	PROPN	O	O
Hospital	PROPN	O	O
between	ADP	O	O
1997	NUM	O	O
and	CCONJ	O	O
2001	NUM	O	O
were	VERB	O	O
retrospectively	ADV	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

RESULTS	VERB	O	O
:	PUNCT	O	O
All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
between	ADP	O	O
1	NUM	O	O
to	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
=	SYM	O	O
2.9	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
starting	VERB	O	O
ethambutol	NOUN	O	I-Entity
therapy	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dosage	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
13	NUM	O	O
to	ADP	O	O
20	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
=	SYM	O	O
17	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
irreversible	ADJ	O	O
visual	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
,	PUNCT	O	O
4	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
diabetes	NOUN	O	B-Entity
mellitus	VERB	O	I-Entity
,	PUNCT	O	O
glaucoma	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
heavy	ADJ	O	O
smoking	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Early	ADJ	O	O
recognition	NOUN	O	O
of	ADP	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ethambutol	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
low	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
prompt	ADJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
particularly	ADV	O	O
in	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
,	PUNCT	O	O
glaucoma	NOUN	O	I-Entity
or	CCONJ	O	O
who	NOUN	O	O
are	VERB	O	O
heavy	ADJ	O	O
smokers	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12950111)

Treatment	NOUN	O	O
of	ADP	O	O
compensatory	NOUN	O	O
gustatory	NOUN	O	B-Entity
hyperhidrosis	NOUN	O	I-Entity
with	ADP	O	O
topical	ADJ	O	O
glycopyrrolate	NOUN	O	I-Entity
.	PUNCT	O	O

Gustatory	PROPN	O	B-Entity
hyperhidrosis	NOUN	O	I-Entity
is	VERB	O	O
facial	ADJ	O	O
sweating	NOUN	O	I-Entity
usually	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
eating	NOUN	O	O
of	ADP	O	O
hot	ADJ	O	O
spicy	ADJ	O	O
food	NOUN	O	O
or	CCONJ	O	O
even	ADV	O	O
smelling	VERB	O	O
this	DET	O	O
food	NOUN	O	O
.	PUNCT	O	O

Current	ADJ	O	O
options	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
include	VERB	O	O
oral	ADJ	O	O
anticholinergic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
topical	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
anticholinergics	NOUN	O	O
or	CCONJ	O	O
aluminum	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
botulinum	NOUN	O	O
toxin	NOUN	O	O
.	PUNCT	O	O

Thirteen	NUM	O	O
patients	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
to	ADP	O	O
date	NOUN	O	O
with	ADP	O	O
1.5%	NUM	O	O
or	CCONJ	O	O
2%	NUM	O	O
topical	ADJ	O	O
glycopyrrolate	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
gustatory	NOUN	O	B-Entity
hyperhidrosis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
interfered	VERB	O	O
with	ADP	O	O
their	ADJ	O	O
social	ADJ	O	O
activities	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
transthroacic	NOUN	O	O
endoscopic	NOUN	O	O
sympathectomy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
compensatory	NOUN	O	O
focal	ADJ	O	O
hyperhidrosis	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
applying	VERB	O	O
topical	ADJ	O	O
glycopyrrolate	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
subjective	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
excellent	ADJ	O	O
(	PUNCT	O	O
no	DET	O	O
sweating	VERB	O	I-Entity
after	ADP	O	O
eating	VERB	O	O
hot	ADJ	O	O
spicy	ADJ	O	O
food	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
77%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fair	ADJ	O	O
(	PUNCT	O	O
clearly	ADV	O	O
reduced	VERB	O	O
sweating	VERB	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
23%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
effects	NOUN	O	O
included	VERB	O	O
a	DET	O	O
mildly	ADV	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
sore	ADJ	O	B-Entity
throat	NOUN	O	I-Entity
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2%	NUM	O	O
glycopyrrolate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
light	ADJ	O	O
headache	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
1.5%	NUM	O	O
glycopyrrolate	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
topical	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
a	DET	O	O
glycopyrrolate	NOUN	O	I-Entity
pad	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
safe	ADJ	O	O
,	PUNCT	O	O
efficacious	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
convenient	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
moderate	ADJ	O	O
to	PART	O	O
severe	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
gustatory	NOUN	O	B-Entity
hyperhidrosis	NOUN	O	I-Entity
in	ADP	O	O
post	NOUN	O	O
transthoracic	NOUN	O	O
endoscopic	NOUN	O	O
sympathectomy	NOUN	O	O
or	CCONJ	O	O
sympathicotomy	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
few	ADJ	O	O
side	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14616590)

Pharmacological	ADJ	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
galenic	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
without	ADP	O	O
soyabean	ADJ	O	O
oil	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	O
,	PUNCT	O	O
pharmacodynamics	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
galenic	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
(	PUNCT	O	O
AM149	PROPN	O	O
1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
does	VERB	O	O
not	ADV	O	O
contain	VERB	O	O
soyabean	ADJ	O	O
oil	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
(	PUNCT	O	O
Disoprivan	PROPN	O	I-Entity
1%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
cross	NOUN	O	O
-	PUNCT	O	O
over	PART	O	O
study	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
intravenous	ADJ	O	O
bolus	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
mg.kg-1	NOUN	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	PROPN	O	O
propofol	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
for	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
following	VERB	O	O
drug	NOUN	O	O
administration	NOUN	O	O
and	CCONJ	O	O
evaluated	VERB	O	O
according	VERB	O	O
to	ADP	O	O
a	DET	O	O
three	NUM	O	O
-	PUNCT	O	O
compartment	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacodynamic	ADJ	O	O
parameters	NOUN	O	O
assessed	VERB	O	O
included	VERB	O	O
induction	NOUN	O	O
and	CCONJ	O	O
emergence	NOUN	O	O
times	NOUN	O	O
,	PUNCT	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
on	ADP	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Owing	VERB	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
thrombophlebitis	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
terminated	VERB	O	O
prematurely	ADV	O	O
and	CCONJ	O	O
only	ADV	O	O
the	DET	O	O
data	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
parallel	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
analysed	VERB	O	O
.	PUNCT	O	O

Pain	VERB	O	I-Entity
on	ADP	O	O
injection	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
vs.	X	O	O
20%	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
thrombophlebitis	NOUN	O	I-Entity
(	PUNCT	O	O
93.3	NUM	O	O
vs.	X	O	O
6.6%	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.001	PUNCT	O	O
)	PUNCT	O	O
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
with	ADP	O	O
AM149	NOUN	O	O
than	ADP	O	O
with	ADP	O	O
Disoprivan	PROPN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
both	DET	O	O
formulations	NOUN	O	O
had	VERB	O	O
similar	ADJ	O	O
pharmacokinetic	NOUN	O	O
and	CCONJ	O	O
pharmacodynamic	ADJ	O	O
profiles	NOUN	O	O
the	DET	O	O
new	ADJ	O	O
formulation	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
suitable	ADJ	O	O
for	ADP	O	O
clinical	ADJ	O	O
use	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
the	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
thrombophlebitis	NOUN	O	I-Entity
produced	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (14748761)

Vinorelbine	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
meta	NOUN	O	O
-	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
randomized	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
vinorelbine	NOUN	O	I-Entity
(	PUNCT	O	O
VNR	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
these	DET	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
a	DET	O	O
meta	NOUN	O	O
-	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
comparing	VERB	O	O
VNR	PROPN	O	I-Entity
with	ADP	O	O
other	ADJ	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
malignancies	NOUN	O	I-Entity
.	PUNCT	O	O

Randomized	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
comparing	VERB	O	O
VNR	PROPN	O	I-Entity
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	I-Entity
were	VERB	O	O
searched	VERB	O	O
in	ADP	O	O
Medline	PROPN	O	O
,	PUNCT	O	O
Embase	PROPN	O	O
,	PUNCT	O	O
Evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
Medicine	PROPN	O	O
Reviews	PROPN	O	O
databases	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Cochrane	PROPN	O	O
library	NOUN	O	O
from	ADP	O	O
1987	NUM	O	O
to	ADP	O	O
2002	NUM	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
19	NUM	O	O
trials	NOUN	O	O
,	PUNCT	O	O
involving	VERB	O	O
2441	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
VNR	PROPN	O	I-Entity
and	CCONJ	O	O
2050	NUM	O	O
control	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
with	ADP	O	O
VNR	PROPN	O	I-Entity
was	VERB	O	O
1.19%	NUM	O	O
[	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
0.75	NUM	O	O
;	PUNCT	O	O
1.67	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
between	ADP	O	O
VNR	PROPN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
drugs	NOUN	O	O
[	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
:	PUNCT	O	O
0.92	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
(	PUNCT	O	O
0.54	NUM	O	O
;	PUNCT	O	O
1.55	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VNR	PROPN	O	I-Entity
cardiac	ADJ	O	O
events	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
vindesine	NOUN	O	I-Entity
(	PUNCT	O	O
VDS	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
cardiotoxic	ADJ	O	I-Entity
drugs	NOUN	O	O
[	PUNCT	O	O
fluorouracil	NOUN	O	I-Entity
,	PUNCT	O	O
anthracyclines	NOUN	O	I-Entity
,	PUNCT	O	O
gemcitabine	NOUN	O	I-Entity
(	PUNCT	O	O
GEM	PROPN	O	I-Entity
)	PUNCT	O	O
em	DET	O	O
leader	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Even	ADV	O	O
if	ADP	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
reach	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
few	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
trials	NOUN	O	O
excluding	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
cardiac	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
trials	NOUN	O	O
including	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
cardiac	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
.	PUNCT	O	O

Vinorelbine	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
concern	NOUN	O	O
about	ADP	O	O
1%	NUM	O	O
of	ADP	O	O
treated	VERB	O	O
patients	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
VNR	PROPN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
other	ADJ	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
indications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15018178)

MRI	NOUN	O	O
findings	NOUN	O	O
of	ADP	O	O
hypoxic	ADJ	O	O
cortical	ADJ	O	O
laminar	NOUN	O	O
necrosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
with	ADP	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
crisis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
findings	NOUN	O	O
of	ADP	O	O
a	DET	O	O
5-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
rapidly	ADV	O	O
installing	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
crisis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
trimethoprim	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
sulfomethoxazole	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
cerebral	ADJ	O	B-Entity
anoxia	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
permanent	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

Magnetic	ADJ	O	O
Resonance	PROPN	O	O
imaging	NOUN	O	O
revealed	VERB	O	O
cortical	ADJ	O	O
laminar	NOUN	O	O
necrosis	NOUN	O	I-Entity
in	ADP	O	O
arterial	ADJ	O	O
border	NOUN	O	O
zones	NOUN	O	O
in	ADP	O	O
both	DET	O	O
cerebral	ADJ	O	O
hemispheres	NOUN	O	O
,	PUNCT	O	O
ischemic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
subcortical	ADJ	O	O
white	ADJ	O	O
matter	NOUN	O	O
of	ADP	O	O
left	VERB	O	O
cerebral	ADJ	O	O
hemisphere	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
left	ADJ	O	O
putamen	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
cortical	ADJ	O	O
laminar	NOUN	O	O
necrosis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
classic	ADJ	O	O
entity	NOUN	O	O
in	ADP	O	O
adulthood	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
conditions	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
depletions	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
are	VERB	O	O
few	ADJ	O	O
reports	NOUN	O	O
available	ADJ	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15094729)

The	DET	O	O
natural	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
Vigabatrin	PROPN	O	I-Entity
associated	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
electing	VERB	O	O
to	PART	O	O
continue	VERB	O	O
their	ADJ	O	O
medication	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
natural	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
known	VERB	O	O
to	PART	O	O
have	VERB	O	O
Vigabatrin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
changes	NOUN	O	O
who	NOUN	O	O
elected	VERB	O	O
to	PART	O	O
continue	VERB	O	O
the	DET	O	O
medication	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
good	ADJ	O	O
seizure	NOUN	O	I-Entity
control	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
taking	VERB	O	O
Vigabatrin	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
5	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
range	VERB	O	O
5	NUM	O	O
-	SYM	O	O
12	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
entered	VERB	O	O
into	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
surveillance	NOUN	O	O
programme	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
already	ADV	O	O
published	VERB	O	O
methodology	NOUN	O	O
(	PUNCT	O	O
Eye	PROPN	O	O
2002	NUM	O	O
;	PUNCT	O	O
16;567	NUM	O	O
-	PUNCT	O	O
571	NUM	O	O
)	PUNCT	O	O
monocular	ADJ	O	O
mean	ADJ	O	O
radial	ADJ	O	O
degrees	NOUN	O	O
(	PUNCT	O	O
MRDs	PROPN	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
I/4e	PROPN	O	O
isopter	NOUN	O	O
on	ADP	O	O
Goldmann	PROPN	O	O
perimetry	NOUN	O	O
was	VERB	O	O
calculated	VERB	O	O
for	ADP	O	O
the	DET	O	O
right	ADJ	O	O
eye	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
discovery	NOUN	O	O
of	ADP	O	O
a	DET	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defect	NOUN	O	I-Entity
and	CCONJ	O	O
again	ADV	O	O
after	ADP	O	O
not	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
deterioration	NOUN	O	B-Entity
in	ADP	O	I-Entity
visual	ADJ	O	I-Entity
field	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
discontinued	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Established	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
presumed	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
Vigabatrin	PROPN	O	I-Entity
therapy	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
usually	ADV	O	O
progress	NOUN	O	O
in	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
continuing	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
give	VERB	O	O
support	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
Vigabatrin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
idiosyncratic	ADJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
rather	ADV	O	O
than	ADP	O	O
dose	VERB	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15096374)

Induction	NOUN	O	O
of	ADP	O	O
rosaceiform	NOUN	O	O
dermatitis	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
facial	ADJ	O	B-Entity
inflammatory	ADJ	O	I-Entity
dermatoses	NOUN	O	I-Entity
with	ADP	O	O
tacrolimus	NOUN	O	I-Entity
ointment	NOUN	O	O
.	PUNCT	O	O

Tacrolimus	PROPN	O	I-Entity
ointment	NOUN	O	O
is	VERB	O	O
increasingly	ADV	O	O
used	VERB	O	O
for	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
sensitive	ADJ	O	O
areas	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
the	DET	O	O
face	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
recent	ADJ	O	O
observations	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
aggravated	VERB	O	O
rosacea	NOUN	O	I-Entity
and	CCONJ	O	O
perioral	ADJ	O	B-Entity
dermatitis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
rosaceiform	NOUN	O	O
dermatitis	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
tacrolimus	DET	O	I-Entity
ointment	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
inflammatory	ADJ	O	B-Entity
facial	ADJ	O	I-Entity
dermatoses	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
tacrolimus	DET	O	I-Entity
ointment	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
ineffectiveness	NOUN	O	O
of	ADP	O	O
standard	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Within	ADP	O	O
2	NUM	O	O
to	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
initially	ADV	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
rosacea	NOUN	O	I-Entity
and	CCONJ	O	O
1	NUM	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
acne	NOUN	O	I-Entity
experienced	ADJ	O	O
sudden	ADJ	O	O
worsening	NOUN	O	O
with	ADP	O	O
pustular	ADJ	O	O
rosaceiform	NOUN	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
eyelid	NOUN	O	O
eczema	NOUN	O	I-Entity
,	PUNCT	O	O
rosaceiform	NOUN	O	O
periocular	ADJ	O	B-Entity
dermatitis	NOUN	O	I-Entity
gradually	ADV	O	O
appeared	VERB	O	O
after	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
atopic	NOUN	O	B-Entity
dermatitis	NOUN	O	I-Entity
,	PUNCT	O	O
telangiectatic	ADJ	O	O
and	CCONJ	O	O
papular	ADJ	O	B-Entity
rosacea	NOUN	O	I-Entity
insidiously	ADV	O	O
appeared	VERB	O	O
after	ADP	O	O
5	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
observations	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
rosaceiform	NOUN	O	O
dermatitis	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
tacrolimus	NOUN	O	I-Entity
ointment	NOUN	O	O
is	VERB	O	O
heterogeneous	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
factors	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
vasoactive	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
,	PUNCT	O	O
proliferation	NOUN	O	O
of	ADP	O	O
Demodex	PROPN	O	O
due	ADJ	O	O
to	ADP	O	O
local	ADJ	O	O
immunosuppression	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
occlusive	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ointment	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
observed	ADJ	O	O
phenomena	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15229250)

Structural	ADJ	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brains	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
subjects	NOUN	O	O
who	NOUN	O	O
use	VERB	O	O
methamphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
visualize	VERB	O	O
,	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
profile	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
human	ADJ	O	I-Entity
brain	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
MA	PROPN	O	I-Entity
)	PUNCT	O	O
abuse	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
subjects	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
used	VERB	O	O
MA	PROPN	O	I-Entity
chronically	ADV	O	O
have	VERB	O	O
revealed	VERB	O	O
deficits	NOUN	O	O
in	ADP	O	O
dopaminergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
systems	NOUN	O	O
and	CCONJ	O	O
cerebral	ADJ	O	O
metabolic	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
MRI	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
new	ADJ	O	O
computational	ADJ	O	O
brain	NOUN	O	O
-	PUNCT	O	O
mapping	NOUN	O	O
techniques	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
determined	VERB	O	O
the	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
brain	NOUN	O	O
alterations	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
MA	PROPN	O	I-Entity
abuse	NOUN	O	O
in	ADP	O	O
human	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
related	VERB	O	O
these	DET	O	O
deficits	NOUN	O	O
to	ADP	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
resolution	NOUN	O	O
MRI	PROPN	O	O
and	CCONJ	O	O
surface	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
computational	ADJ	O	O
image	NOUN	O	O
analyses	NOUN	O	O
to	PART	O	O
map	VERB	O	O
regional	ADJ	O	O
abnormalities	NOUN	O	B-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
cortex	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
hippocampus	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
white	ADJ	O	I-Entity
matter	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
ventricles	NOUN	O	I-Entity
in	ADP	O	O
22	NUM	O	O
human	ADJ	O	O
subjects	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
MA	NOUN	O	I-Entity
and	CCONJ	O	O
21	NUM	O	O
age	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
,	PUNCT	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Cortical	ADJ	O	O
maps	NOUN	O	O
revealed	VERB	O	O
severe	ADJ	O	O
gray	ADJ	O	O
-	PUNCT	O	O
matter	NOUN	O	O
deficits	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cingulate	NOUN	O	O
,	PUNCT	O	O
limbic	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
paralimbic	ADJ	O	O
cortices	NOUN	O	O
of	ADP	O	O
MA	NOUN	O	I-Entity
abusers	NOUN	O	O
(	PUNCT	O	O
averaging	VERB	O	O
11.3%	NUM	O	O
below	ADP	O	O
control	NOUN	O	O
;	PUNCT	O	O

On	ADP	O	O
average	ADJ	O	O
,	PUNCT	O	O
MA	PROPN	O	I-Entity
abusers	NOUN	O	O
had	VERB	O	O
7.8%	NUM	O	O
smaller	ADJ	O	O
hippocampal	NOUN	O	O
volumes	NOUN	O	O
than	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
;	PUNCT	O	O
left	ADV	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
;	PUNCT	O	O
right	ADV	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
significant	ADJ	O	O
white	ADJ	O	O
-	PUNCT	O	O
matter	NOUN	O	O
hypertrophy	NOUN	O	I-Entity
(	PUNCT	O	O
7.0%	NUM	O	O
;	PUNCT	O	O

MRI	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
maps	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
chronic	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
abuse	NOUN	O	O
causes	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	O
deterioration	NOUN	O	O
that	ADJ	O	O
contributes	VERB	O	O
to	ADP	O	O
impaired	ADJ	O	B-Entity
memory	NOUN	O	I-Entity
performance	NOUN	O	I-Entity
.	PUNCT	O	O

MA	NOUN	O	I-Entity
may	VERB	O	O
selectively	ADV	O	O
damage	VERB	O	O
the	DET	O	O
medial	ADJ	O	O
temporal	ADJ	O	O
lobe	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
metabolic	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cingulate	NOUN	O	O
-	PUNCT	O	O
limbic	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
inducing	VERB	O	O
neuroadaptation	NOUN	O	O
,	PUNCT	O	O
neuropil	ADJ	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
.	PUNCT	O	O

Prominent	ADJ	O	O
white	ADJ	O	O
-	PUNCT	O	O
matter	NOUN	O	O
hypertrophy	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
altered	VERB	O	O
myelination	NOUN	O	O
and	CCONJ	O	O
adaptive	ADJ	O	O
glial	ADJ	O	O
changes	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
gliosis	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
brain	NOUN	O	O
substrates	NOUN	O	O
may	VERB	O	O
help	VERB	O	O
account	VERB	O	O
for	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
MA	PROPN	O	I-Entity
abuse	NOUN	O	O
,	PUNCT	O	O
providing	VERB	O	O
therapeutic	ADJ	O	O
targets	NOUN	O	O
for	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
brain	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15265979)

Disruption	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
lipid	NOUN	O	O
homeostasis	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
after	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
peroxisome	NOUN	O	O
proliferator	NOUN	O	O
-	PUNCT	O	O
activated	VERB	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
target	NOUN	O	O
gene	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
efficacious	ADJ	O	O
and	CCONJ	O	O
widely	ADV	O	O
used	VERB	O	O
antiarrhythmic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
cause	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
gain	VERB	O	O
insight	NOUN	O	O
into	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
this	DET	O	O
unwanted	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
mice	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
various	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
and	CCONJ	O	O
examined	VERB	O	O
for	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
hepatic	ADJ	O	O
histology	NOUN	O	O
and	CCONJ	O	O
gene	NOUN	O	O
regulation	NOUN	O	O
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
induced	VERB	O	O
hepatomegaly	NOUN	O	I-Entity
,	PUNCT	O	O
hepatocyte	NOUN	O	O
microvesicular	ADJ	O	O
lipid	NOUN	O	O
accumulation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
triglycerides	NOUN	O	I-Entity
and	CCONJ	O	O
glucose	NOUN	O	I-Entity
.	PUNCT	O	O

Northern	ADJ	O	O
blot	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
RNA	PROPN	O	O
revealed	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
genes	NOUN	O	O
critical	ADJ	O	O
for	ADP	O	O
fatty	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
oxidation	NOUN	O	O
,	PUNCT	O	O
lipoprotein	NOUN	O	O
assembly	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lipid	ADJ	O	O
transport	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
these	DET	O	O
genes	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
hepatomegaly	NOUN	O	I-Entity
in	ADP	O	O
PPARalpha	PROPN	O	O
knockout	NOUN	O	O
[	PUNCT	O	O
PPARalpha-/-	PROPN	O	O
]	PUNCT	O	O
mice	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
were	VERB	O	O
dependent	ADJ	O	O
upon	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
functional	ADJ	O	O
PPARalpha	PROPN	O	O
gene	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
PPARalpha-/-	PROPN	O	O
mice	NOUN	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
rate	NOUN	O	O
and	CCONJ	O	O
extent	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
inability	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
to	PART	O	O
directly	ADV	O	O
activate	VERB	O	O
either	DET	O	O
human	ADJ	O	O
or	CCONJ	O	O
mouse	NOUN	O	O
PPARalpha	PROPN	O	O
transiently	ADV	O	O
expressed	VERB	O	O
in	ADP	O	O
human	ADJ	O	O
HepG2	PROPN	O	O
hepatoma	NOUN	O	I-Entity
cells	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
this	DET	O	O
receptor	NOUN	O	O
were	VERB	O	O
indirect	ADJ	O	O
.	PUNCT	O	O

Based	VERB	O	O
upon	ADP	O	O
these	DET	O	O
results	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
amiodarone	NOUN	O	I-Entity
disrupts	VERB	O	O
hepatic	ADJ	O	O
lipid	NOUN	O	O
homeostasis	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
increased	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
PPARalpha	PROPN	O	O
target	NOUN	O	O
genes	NOUN	O	O
is	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
this	DET	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
important	ADJ	O	O
new	ADJ	O	O
mechanistic	ADJ	O	O
information	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
hepatotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
and	CCONJ	O	O
indicate	VERB	O	O
that	ADP	O	O
PPARalpha	PROPN	O	O
protects	VERB	O	O
against	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15276093)

Safety	NOUN	O	O
and	CCONJ	O	O
compliance	NOUN	O	O
with	ADP	O	O
once	ADV	O	O
-	PUNCT	O	O
daily	ADV	O	O
niacin	ADV	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
as	ADP	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Impact	PROPN	O	O
of	ADP	O	O
Medical	PROPN	O	O
Subspecialty	PROPN	O	O
on	ADP	O	O
Patient	PROPN	O	O
Compliance	PROPN	O	O
to	ADP	O	O
Treatment	PROPN	O	O
(	PUNCT	O	O
IMPACT	PROPN	O	O
)	PUNCT	O	O
study	NOUN	O	O
.	PUNCT	O	O

Niacin	PROPN	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
combination	NOUN	O	O
product	NOUN	O	O
approved	VERB	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
hypercholesterolemia	NOUN	O	I-Entity
and	CCONJ	O	O
mixed	ADJ	O	O
dyslipidemia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
labeled	VERB	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
bedtime	NOUN	O	O
niacin	ADV	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
when	ADV	O	O
dosed	VERB	O	O
as	ADP	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
patient	ADJ	O	O
compliance	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
various	ADJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
4,499	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
dyslipidemia	NOUN	O	I-Entity
requiring	VERB	O	O
drug	NOUN	O	O
intervention	NOUN	O	O
was	VERB	O	O
enrolled	VERB	O	O
at	ADP	O	O
1,081	NUM	O	O
sites	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
1	NUM	O	O
tablet	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
niacin	ADV	O	I-Entity
extended	VERB	O	O
-	PUNCT	O	O
release/20	NOUN	O	O
mg	NUM	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
)	PUNCT	O	O
once	ADV	O	O
nightly	ADV	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
2	NUM	O	O
tablets	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
dietary	ADJ	O	O
counseling	NOUN	O	O
,	PUNCT	O	O
educational	ADJ	O	O
materials	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
reminders	NOUN	O	O
to	PART	O	O
call	VERB	O	O
a	DET	O	O
toll	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
number	NOUN	O	O
that	ADJ	O	O
provided	VERB	O	O
further	ADJ	O	O
education	NOUN	O	O
about	ADP	O	O
dyslipidemia	NOUN	O	I-Entity
and	CCONJ	O	O
niacin	ADV	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
.	PUNCT	O	O

Primary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
study	NOUN	O	O
compliance	NOUN	O	O
,	PUNCT	O	O
increases	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
transaminases	NOUN	O	O
to	ADP	O	O
>	SYM	O	O
3	NUM	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
limit	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Compliance	NOUN	O	O
to	ADP	O	O
niacin	ADV	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
was	VERB	O	O
77%	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
3,245	NUM	O	O
patients	NOUN	O	O
completing	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Flushing	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
,	PUNCT	O	O
reported	VERB	O	O
by	ADP	O	O
18%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
leading	VERB	O	O
to	ADP	O	O
discontinuation	NOUN	O	O
by	ADP	O	O
6%	NUM	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
and/or	CCONJ	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
>	NOUN	O	O
3	NUM	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
limit	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
was	VERB	O	O
<	X	O	O
0.3%	NUM	O	O
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
to	ADP	O	O
>	SYM	O	O
5	NUM	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
limit	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
occurred	VERB	O	O
in	ADP	O	O
0.24%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
myopathy	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Niacin	ADV	O	B-Entity
extended	VERB	O	I-Entity
-	PUNCT	O	I-Entity
release	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
lovastatin	NOUN	O	I-Entity
1,000/40	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
dosed	VERB	O	O
as	ADP	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
good	ADJ	O	O
compliance	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
very	ADV	O	O
low	ADJ	O	O
incidences	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
liver	NOUN	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15282950)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
Terminalia	PROPN	O	B-Entity
chebula	NOUN	O	I-Entity
against	ADP	O	O
experimental	ADJ	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
.	PUNCT	O	O

Cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ethanolic	ADJ	O	B-Entity
extract	NOUN	O	I-Entity
of	ADP	O	I-Entity
Terminalia	PROPN	O	I-Entity
chebula	ADJ	O	I-Entity
fruits	NOUN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
wt	X	O	O
)	PUNCT	O	O
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O

wt	X	O	O
)	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
isoproterenol	NOUN	O	I-Entity
administered	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
lipid	NOUN	O	O
peroxides	NOUN	O	I-Entity
increased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
confirm	VERB	O	O
the	DET	O	O
myocardial	ADJ	O	O
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

T.	PROPN	O	B-Entity
chebula	NOUN	O	I-Entity
extract	NOUN	O	I-Entity
pretreatment	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
ameliorate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
on	ADP	O	O
lipid	ADJ	O	O
peroxide	NOUN	O	I-Entity
formation	NOUN	O	O
and	CCONJ	O	O
retained	VERB	O	O
the	DET	O	O
activities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diagnostic	ADJ	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15321332)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
anxiety	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
droperidol	NOUN	O	I-Entity
used	VERB	O	O
with	ADP	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

Postoperatively	ADV	O	O
,	PUNCT	O	O
she	PRON	O	O
was	VERB	O	O
given	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analgesia	NOUN	O	O
device	NOUN	O	O
delivering	VERB	O	O
boluses	NOUN	O	O
of	ADP	O	O
diamorphine	NOUN	O	I-Entity
0.5	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
droperidol	VERB	O	I-Entity
0.025	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
droperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychological	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
made	VERB	O	O
straight	ADV	O	O
away	ADV	O	O
although	ADP	O	O
on	ADP	O	O
subsequent	ADJ	O	O
close	ADJ	O	O
questioning	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
gave	VERB	O	O
a	DET	O	O
very	ADV	O	O
clear	ADJ	O	O
history	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
she	PRON	O	O
had	VERB	O	O
received	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
only	ADV	O	O
0.9	NUM	O	O
mg	NUM	O	O
droperidol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
syringe	NOUN	O	O
containing	VERB	O	O
diamorphine	NOUN	O	I-Entity
only	ADV	O	O
was	VERB	O	O
substituted	VERB	O	O
and	CCONJ	O	O
her	ADJ	O	O
unease	NOUN	O	O
resolved	VERB	O	O
completely	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (15366550)

Accurate	ADJ	O	O
patient	NOUN	O	O
history	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
differentiating	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	ADV	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
discussed	VERB	O	O
herein	ADV	O	O
initially	ADV	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
neurogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	VERB	O	I-Entity
(	PUNCT	O	O
DI	PROPN	O	I-Entity
)	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
a	DET	O	O
traumatic	ADJ	O	B-Entity
brain	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
nursing	NOUN	O	O
staff	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
reviewing	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
health	NOUN	O	O
history	NOUN	O	O
with	ADP	O	O
his	ADJ	O	O
family	NOUN	O	O
,	PUNCT	O	O
discovered	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
polydipsia	NOUN	O	I-Entity
and	CCONJ	O	O
long	ADV	O	O
-	PUNCT	O	O
standing	VERB	O	O
lithium	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
DI	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
because	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
not	ADV	O	O
received	VERB	O	O
lithium	NOUN	O	I-Entity
since	ADP	O	O
being	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
,	PUNCT	O	O
his	ADJ	O	O
treatment	NOUN	O	O
changed	VERB	O	O
to	PART	O	O
focus	VERB	O	O
on	ADP	O	O
nephrogenic	ADJ	O	B-Entity
DI	NOUN	O	I-Entity
.	PUNCT	O	O

By	ADP	O	O
combining	VERB	O	O
information	NOUN	O	O
from	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
history	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
radiologic	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
critical	ADJ	O	O
care	NOUN	O	O
team	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
self	NOUN	O	O
-	PUNCT	O	O
treating	VERB	O	O
his	ADJ	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
DI	PROPN	O	I-Entity
and	CCONJ	O	O
developed	VERB	O	O
neurogenic	ADJ	O	B-Entity
DI	PROPN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
brain	NOUN	O	B-Entity
trauma	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
successful	ADJ	O	O
treatment	NOUN	O	O
required	VERB	O	O
that	DET	O	O
nephrogenic	ADJ	O	O
and	CCONJ	O	O
neurogenic	ADJ	O	B-Entity
DI	NOUN	O	I-Entity
be	VERB	O	O
treated	VERB	O	O
concomitantly	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (15482540)

Factors	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
ribavirin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Interferon	PROPN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
combination	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
produces	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
factors	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
ribavirin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Eighty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	NOUN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
interferon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alpha-2b	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
MU	PROPN	O	O
administered	VERB	O	O
intramuscularly	ADV	O	O
for	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
ribavirin	NOUN	O	I-Entity
administered	VERB	O	O
orally	ADV	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
600	NUM	O	O
mg	NUM	O	O
or	CCONJ	O	O
800	NUM	O	O
mg	NUM	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
hemoglobin	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
10	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dL	PROPN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Ribavirin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
18	NUM	O	O
(	PUNCT	O	O
20.5%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dL	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
hemoglobin	NOUN	O	O
concentrations	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
week	NOUN	O	O
2	NUM	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
hemoglobin	NOUN	O	O
concentrations	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Such	ADJ	O	O
factors	NOUN	O	O
as	ADP	O	O
sex	NOUN	O	O
(	PUNCT	O	O
female	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
age	NOUN	O	O
(	PUNCT	O	O
>	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
60	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
ribavirin	NOUN	O	I-Entity
dose	NOUN	O	O
by	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	VERB	O	O
or	CCONJ	O	O
more	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
by	ADP	O	O
univariate	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Careful	ADJ	O	O
administration	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
>	PART	O	O
or	CCONJ	O	O
=	SYM	O	O
60	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
female	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
ribavirin	NOUN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	VERB	O	O
or	CCONJ	O	O
more	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (15605432)

Oxidative	ADJ	O	O
damage	NOUN	O	O
precedes	VERB	O	O
nitrative	ADJ	O	O
damage	NOUN	O	O
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	O
mitochondrial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
elevated	VERB	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
(	PUNCT	O	O
ROS)/nitrogen	PROPN	O	I-Entity
species	NOUN	O	O
(	PUNCT	O	O
RNS	PROPN	O	O
)	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
adriamycin	ADJ	O	I-Entity
(	PUNCT	O	O
ADR)-induced	ADJ	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
actually	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
cardiomyocyte	NOUN	O	O

B6C3	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
ADR	PROPN	O	I-Entity
.	PUNCT	O	O

Ultrastructural	ADJ	O	O
damage	NOUN	O	O
and	CCONJ	O	O
levels	NOUN	O	O
of	ADP	O	O
4-hydroxy-2-nonenal	ADJ	O	I-Entity
(	PUNCT	O	O
4HNE)-protein	ADJ	O	I-Entity
adducts	NOUN	O	O
and	CCONJ	O	O
3-nitrotyrosine	NUM	O	I-Entity
(	PUNCT	O	O
3NT	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
4HNE	NUM	O	I-Entity
protein	NOUN	O	O
adducts	NOUN	O	O
by	ADP	O	O
immunogold	ADJ	O	O
electron	NOUN	O	O
microscopy	NOUN	O	O
showed	VERB	O	O
appearance	NOUN	O	O
of	ADP	O	O
4HNE	NUM	O	I-Entity
protein	NOUN	O	O
adducts	NOUN	O	O
in	ADP	O	O
mitochondria	NOUN	O	O
as	ADV	O	O
early	ADV	O	O
as	ADP	O	O
3	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
peak	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
decline	NOUN	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

3NT	DET	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
all	DET	O	O
subcellular	ADJ	O	O
compartments	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
subsequently	ADV	O	O
declined	VERB	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
showed	VERB	O	O
ADR	PROPN	O	I-Entity
induced	VERB	O	O
4HNE	NUM	O	I-Entity
-	PUNCT	O	O
protein	NOUN	O	O
adducts	NOUN	O	O
in	ADP	O	O
mitochondria	NOUN	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
point	NOUN	O	O
as	ADP	O	O
when	ADV	O	O
mitochondrial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
initially	ADV	O	O
appeared	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
document	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
that	ADP	O	O
mitochondrial	ADJ	O	B-Entity
oxidative	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
precedes	VERB	O	O
nitrative	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
progressive	ADJ	O	O
nature	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
suggests	VERB	O	O
that	ADP	O	O
mitochondria	NOUN	O	O
,	PUNCT	O	O
not	ADV	O	O
other	ADJ	O	O
subcellular	ADJ	O	O
organelles	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
the	DET	O	O
major	ADJ	O	O
site	NOUN	O	O
of	ADP	O	O
intracellular	ADJ	O	O
injury	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15609701)

Sotalol	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sustained	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
left	VERB	O	O
ventricular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
was	VERB	O	O
referred	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
hospital	NOUN	O	O
for	ADP	O	O
symptomatic	ADJ	O	O
incessant	ADJ	O	O
sustained	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
(	PUNCT	O	O
VT	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
nifekalant	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
sustained	VERB	O	O
VT	PROPN	O	I-Entity
was	VERB	O	O
terminated	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
alternate	ADJ	O	O
class	NOUN	O	O
III	NUM	O	O
agent	NOUN	O	O
,	PUNCT	O	O
sotalol	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
effective	ADJ	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
VT	PROPN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
one	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
switching	VERB	O	O
over	ADP	O	O
nifekalant	NOUN	O	I-Entity
to	ADP	O	O
sotalol	VERB	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
short	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
ST	PROPN	O	O
elevation	NOUN	O	O
was	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
ECG	PROPN	O	O
monitoring	NOUN	O	O
at	ADP	O	O
almost	ADV	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
for	ADP	O	O
three	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

ST	NOUN	O	O
elevation	NOUN	O	O
with	ADP	O	O
chest	NOUN	O	O
discomfort	NOUN	O	O
disappeared	VERB	O	O
since	ADP	O	O
he	PRON	O	O
began	VERB	O	O
taking	VERB	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O

Coronary	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
properties	NOUN	O	O
of	ADP	O	O
sotalol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15614572)

Effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antidepressant	NOUN	O	O
trazodone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
5-HT	NUM	O	I-Entity
2A/2C	NUM	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
behaviors	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

RATIONALE	NOUN	O	O
:	PUNCT	O	O
5-Hydroxytryptamine	NUM	O	I-Entity
,	PUNCT	O	O
via	ADP	O	O
stimulation	NOUN	O	O
of	ADP	O	O
5-HT	NUM	O	I-Entity
2C	NUM	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
exerts	VERB	O	O
a	DET	O	O
tonic	NOUN	O	O
inhibitory	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
dopaminergic	ADJ	O	O
neurotransmission	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
5-HT	NUM	O	I-Entity
2A	NUM	O	O
receptors	NOUN	O	O
enhances	VERB	O	O
stimulated	VERB	O	O
DAergic	PROPN	O	O
neurotransmission	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
antidepressant	NOUN	O	O
trazodone	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
5-HT	NUM	O	I-Entity
2A/2C	NUM	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
trazodone	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
behaviors	NOUN	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
functional	ADJ	O	O
status	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nigrostriatal	ADJ	O	O
DAergic	PROPN	O	O
system	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
trazodone	NOUN	O	I-Entity
on	ADP	O	O
dexamphetamine-	NOUN	O	I-Entity
and	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
oral	ADJ	O	B-Entity
stereotypies	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
ergometrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
wet	ADJ	O	O
dog	NOUN	O	O
shake	NOUN	O	O
(	PUNCT	O	O
WDS	PROPN	O	O
)	PUNCT	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
penile	ADJ	O	O
erections	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
investigated	VERB	O	O
whether	ADP	O	O
trazodone	NOUN	O	I-Entity
induces	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Trazodone	NOUN	O	I-Entity
at	ADP	O	O
2.5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
mg	NUM	O	O

did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
antagonize	VERB	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O

stereotypy	NOUN	O	O
and	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
mg	NUM	O	O

/	SYM	O	O
kg)-induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

trazodone	NOUN	O	I-Entity
enhanced	VERB	O	O
dexamphetamine	NOUN	O	I-Entity
stereotypy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
antagonized	VERB	O	O
haloperidol	NOUN	O	I-Entity
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
ergometrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
WDS	PROPN	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
penile	ADJ	O	O
erections	NOUN	O	O
.	PUNCT	O	O

Trazodone	NOUN	O	I-Entity
at	ADP	O	O
30	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
mg	NUM	O	O

induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
antagonized	VERB	O	O
apomorphine	NOUN	O	I-Entity
and	CCONJ	O	O
dexamphetamine	NOUN	O	I-Entity
stereotypies	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
trazodone	NOUN	O	I-Entity
at	ADP	O	O
2.5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
block	VERB	O	O
pre-	NOUN	O	O
and	CCONJ	O	O
postsynaptic	ADJ	O	O
striatal	ADJ	O	O
D2	PROPN	O	O
DA	PROPN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
at	ADP	O	O
30	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	VERB	O	O
it	PRON	O	O
blocks	VERB	O	O
postsynaptic	ADJ	O	O
striatal	ADJ	O	O
D2	PROPN	O	O
DA	PROPN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
at	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
trazodone	NOUN	O	I-Entity
blocks	NOUN	O	O
5-HT	NUM	O	I-Entity
2A	NUM	O	O
and	CCONJ	O	O
5-HT	NUM	O	I-Entity
2C	NUM	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
trazodone	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
by	ADP	O	O
blocking	VERB	O	O
the	DET	O	O
5-HT	NUM	O	I-Entity
2C	NUM	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
releases	VERB	O	O
the	DET	O	O
nigrostriatal	ADJ	O	O
DAergic	PROPN	O	O
neurons	NOUN	O	O
from	ADP	O	O
tonic	NOUN	O	O
inhibition	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
5-HT	NUM	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
thereby	ADV	O	O
potentiates	VERB	O	O
dexamphetamine	ADJ	O	I-Entity
stereotypy	NOUN	O	O
and	CCONJ	O	O
antagonizes	VERB	O	O
haloperidol	NOUN	O	I-Entity
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15625689)

Swallowing	VERB	O	B-Entity
abnormalities	NOUN	O	I-Entity
and	CCONJ	O	O
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Gastrointestinal	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
known	VERB	O	O
for	ADP	O	O
almost	ADV	O	O
two	NUM	O	O
centuries	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
many	ADJ	O	O
aspects	NOUN	O	O
concerning	VERB	O	O
their	ADJ	O	O
pathophysiology	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
completely	ADV	O	O
clarified	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
characterize	VERB	O	O
the	DET	O	O
oropharyngeal	ADJ	O	O
dynamics	NOUN	O	O
in	ADP	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

Fifteen	NUM	O	O
dyskinetic	NOUN	O	I-Entity
,	PUNCT	O	O
12	NUM	O	O
nondyskinetic	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
about	ADP	O	O
dysphagia	NOUN	O	I-Entity
and	CCONJ	O	O
evaluated	VERB	O	O
with	ADP	O	O
the	DET	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
Parts	PROPN	O	O
II	PROPN	O	O
and	CCONJ	O	O
III	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
Hoehn	PROPN	O	O
and	CCONJ	O	O
Yahr	PROPN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Deglutition	PROPN	O	O
was	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
modified	VERB	O	O
barium	NOUN	O	I-Entity
swallow	VERB	O	O
with	ADP	O	O
videofluoroscopy	NOUN	O	O
.	PUNCT	O	O

Nondyskinetic	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
dyskinetic	ADJ	O	I-Entity
ones	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
less	ADJ	O	O
oropharyngeal	NOUN	O	O
swallowing	VERB	O	O
efficiency	NOUN	O	O
(	PUNCT	O	O
OPSE	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
liquid	NOUN	O	O
food	NOUN	O	O
than	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
Dunnett	PROPN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dyskinetic	ADJ	O	I-Entity
patients	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
greater	ADJ	O	O
OPSE	PROPN	O	O
than	ADP	O	O
nondyskinetic	ADJ	O	O
(	PUNCT	O	O
Dunnett	PROPN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.06	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
using	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
greater	ADJ	O	O
OPSE	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
smaller	ADJ	O	O
oral	ADJ	O	O
transit	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
Pearson	PROPN	O	O
's	PART	O	O
correlation	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
and	CCONJ	O	O
0.08	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
the	DET	O	O
report	NOUN	O	O
of	ADP	O	O
dysphagia	NOUN	O	I-Entity
nor	CCONJ	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
PD	PROPN	O	I-Entity
severity	NOUN	O	O
parameters	NOUN	O	O
correlated	VERB	O	O
to	ADP	O	O
the	DET	O	O
videofluoroscopic	NOUN	O	O
variables	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
dyskinetic	ADJ	O	I-Entity
patients	NOUN	O	O
performed	VERB	O	O
better	ADV	O	O
in	ADP	O	O
swallowing	VERB	O	O
function	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
explained	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
levodopa	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
levodopa	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
deglutition	NOUN	O	O
and	CCONJ	O	O
confirm	VERB	O	O
that	DET	O	O
dysphagia	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
good	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
deglutition	NOUN	O	O
alterations	NOUN	O	O
in	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15627798)

Inhibition	NOUN	O	O
of	ADP	O	O
nuclear	ADJ	O	O
factor	NOUN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
activation	NOUN	O	O
attenuates	VERB	O	O
tubulointerstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
.	PUNCT	O	O

:	PUNCT	O	O
Animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
can	VERB	O	O
show	VERB	O	O
residual	ADJ	O	O
areas	NOUN	O	O
of	ADP	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

kinases	NOUN	O	O
and	CCONJ	O	O
macrophages	NOUN	O	O
in	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
structural	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
renal	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
or	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
+	SYM	O	O
pyrrolidine	NOUN	O	B-Entity
dithiocarbamate	NOUN	O	I-Entity
(	PUNCT	O	O
PDTC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
38	NUM	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
,	PUNCT	O	O
40	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
twice	ADJ	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
9	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
38	NUM	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
+	CCONJ	O	O
PDTC	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
28	NUM	O	O
with	ADP	O	O
0.15	NUM	O	O
M	PROPN	O	O
NaCl	PROPN	O	I-Entity
solution	NOUN	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
presented	VERB	O	O
a	DET	O	O
transitory	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
ED-1	NOUN	O	O
,	PUNCT	O	O
MAP	PROPN	O	O
kinases	NOUN	O	O
and	CCONJ	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
staining	VERB	O	O
were	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
cortex	NOUN	O	O
from	ADP	O	O
all	DET	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
killed	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
30	NUM	O	O
also	ADV	O	O
presented	VERB	O	O
fibrosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
renal	NOUN	O	O
cortex	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
PDTC	PROPN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
and	CCONJ	O	O
structural	ADJ	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
activation	NOUN	O	O
attenuates	VERB	O	O
tubulointerstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15630069)

Glucose	PROPN	O	I-Entity
metabolism	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
frequently	ADV	O	O
sampled	VERB	O	O
intravenous	ADJ	O	O
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
minimal	ADJ	O	O
model	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
diabetes	NOUN	O	B-Entity
mellitus	VERB	O	I-Entity
may	VERB	O	O
be	VERB	O	O
increasing	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
certain	ADJ	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
remains	VERB	O	O
unclear	ADJ	O	O
whether	ADP	O	O
atypical	ADJ	O	O
agents	NOUN	O	O
are	VERB	O	O
directly	ADV	O	O
affecting	VERB	O	O
glucose	NOUN	O	I-Entity
metabolism	NOUN	O	O
or	CCONJ	O	O
simply	ADV	O	O
increasing	VERB	O	O
known	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
diabetes	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
2	NUM	O	O
drugs	NOUN	O	O
most	ADV	O	O
clearly	ADV	O	O
implicated	VERB	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
using	VERB	O	O
a	DET	O	O
frequently	ADV	O	O
sampled	VERB	O	O
intravenous	ADJ	O	O
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
design	NOUN	O	O
in	ADP	O	O
stable	ADJ	O	O
,	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
evaluated	VERB	O	O
using	VERB	O	O
a	DET	O	O
frequently	ADV	O	O
sampled	VERB	O	O
intravenous	ADJ	O	O
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Bergman	PROPN	O	O
minimal	ADJ	O	O
model	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
Fifty	NUM	O	O
subjects	NOUN	O	O
signed	VERB	O	O
informed	ADJ	O	O
consent	NOUN	O	O
and	CCONJ	O	O
41	NUM	O	O
underwent	VERB	O	O
the	DET	O	O
frequently	ADV	O	O
sampled	VERB	O	O
intravenous	ADJ	O	O
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
nonobese	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
or	CCONJ	O	O
schizoaffective	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
matched	VERB	O	O
by	ADP	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
either	DET	O	O
clozapine	NOUN	O	I-Entity
,	PUNCT	O	O
olanzapine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Fasting	VERB	O	O
plasma	NOUN	O	O
glucose	NOUN	O	I-Entity
and	CCONJ	O	O
fasting	VERB	O	O
serum	NOUN	O	O
insulin	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
insulin	NOUN	O	B-Entity
sensitivity	NOUN	O	I-Entity
index	NOUN	O	O
,	PUNCT	O	O
homeostasis	NOUN	O	O
model	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
glucose	NOUN	O	I-Entity
effectiveness	NOUN	O	O
.	PUNCT	O	O

28.9	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
29.5	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

17.5	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
olanzapine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
40.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

33.7	NUM	O	O
(	PUNCT	O	O
risperidone	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Fasting	VERB	O	O
serum	NOUN	O	O
insulin	NOUN	O	O
concentrations	NOUN	O	O
differed	VERB	O	O
among	ADP	O	O
groups	NOUN	O	O
(	PUNCT	O	O
F(33	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
3.35	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.047	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
>	X	O	O
olanzapine	ADJ	O	I-Entity
>	X	O	O
risperidone	NOUN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.32	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.15	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
insulin	NOUN	O	B-Entity
sensitivity	NOUN	O	I-Entity
index	NOUN	O	O
among	ADP	O	O
groups	NOUN	O	O
(	PUNCT	O	O
F(33	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
10.66	NUM	O	O
;	PUNCT	O	O
P<.001	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
<	X	O	O
olanzapine	ADJ	O	I-Entity
<	X	O	O
risperidone	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
subjects	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
exhibiting	VERB	O	O
significant	ADJ	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
subjects	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
vs	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
-4.29	NOUN	O	O
;	PUNCT	O	O
P<.001	PUNCT	O	O
;	PUNCT	O	O
olanzapine	ADJ	O	I-Entity
vs	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
-3.62	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
[	PUNCT	O	O
P<.001	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
homeostasis	NOUN	O	O
model	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
also	ADV	O	O
differed	VERB	O	O
significantly	ADV	O	O
among	ADP	O	O
groups	NOUN	O	O
(	PUNCT	O	O
F(33	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
4.92	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
>	X	O	O
olanzapine	ADJ	O	I-Entity
>	X	O	O
risperidone	NOUN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
vs	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.94	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.006	NUM	O	O
;	PUNCT	O	O
olanzapine	ADV	O	I-Entity
vs	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
t(33	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.42	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
among	ADP	O	O
groups	NOUN	O	O
in	ADP	O	O
glucose	NOUN	O	I-Entity
effectiveness	NOUN	O	O
(	PUNCT	O	O
F(30	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
4.18	NUM	O	O
;	PUNCT	O	O

P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
<	X	O	O
olanzapine	ADJ	O	I-Entity
<	X	O	O
risperidone	NOUN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
t(30	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
-2.59	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
t(30	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
-2.34	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
nonobese	VERB	O	O
clozapine-	NOUN	O	I-Entity
and	CCONJ	O	O

olanzapine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
displayed	VERB	O	O
significant	ADJ	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
and	CCONJ	O	O
impairment	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	I-Entity
effectiveness	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
taking	VERB	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
must	VERB	O	O
be	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15815446)

Focal	ADJ	O	O
cerebral	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
:	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
during	ADP	O	O
reperfusion	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
180	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
temporary	ADJ	O	O
middle	ADJ	O	B-Entity
cerebral	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
on	ADP	O	O
ischemic	ADJ	O	B-Entity
brain	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
permeability	NOUN	O	O
was	VERB	O	O
determined	ADJ	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
manipulated	VERB	O	O
by	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
following	ADJ	O	O
schedules	NOUN	O	O
during	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
reperfusion	NOUN	O	O
:	PUNCT	O	O
Control	NOUN	O	O
,	PUNCT	O	O
normotensive	ADJ	O	O
reperfusion	NOUN	O	O
;	PUNCT	O	O
90/hypertension	NUM	O	I-Entity
(	PUNCT	O	O
90/HTN	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
35	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
90	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
reperfusion	NOUN	O	O
only	ADV	O	O
;	PUNCT	O	O
15/hypertension	NUM	O	I-Entity
(	PUNCT	O	O
15/HTN	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
normotensive	ADJ	O	O
reperfusion	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
75	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
normotension	NOUN	O	O
.	PUNCT	O	O

Part	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
eight	NUM	O	O
rats	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
brain	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
staining	VERB	O	O
tissue	NOUN	O	O
using	VERB	O	O
2,3,5-triphenyltetrazolium	NUM	O	B-Entity
chloride	NOUN	O	I-Entity
and	CCONJ	O	O
edema	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
microgravimetry	NOUN	O	O
.	PUNCT	O	O

Brain	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	B-Entity
hemisphere	NOUN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
less	ADJ	O	O
in	ADP	O	O
the	DET	O	O
15/HTN	NUM	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

SD	PUNCT	O	O
)	PUNCT	O	O
versus	ADP	O	O
the	DET	O	O
90/HTN	NUM	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Specific	ADJ	O	O
gravity	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
15/HTN	NUM	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
1.043	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.002	PUNCT	O	O
)	PUNCT	O	O
versus	ADP	O	O
the	DET	O	O
90/HTN	PROPN	O	I-Entity
(	PUNCT	O	O
1.036	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O
0.003	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
(	PUNCT	O	O
1.037	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Evans	PROPN	O	B-Entity
Blue	PROPN	O	I-Entity
(	PUNCT	O	O
mug	NOUN	O	O
g-1	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
tissue	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
90/HTN	NUM	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
24.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

4.1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
in	ADP	O	O
turn	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
the	DET	O	O
15/HTN	NUM	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
7.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
supports	VERB	O	O
a	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
during	ADP	O	O
reperfusion	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
short	ADJ	O	O
interval	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
decreases	VERB	O	O
brain	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
edema	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
sustained	VERB	O	O
hypertension	NOUN	O	I-Entity
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
vasogenic	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15817013)

People	NOUN	O	O
aged	VERB	O	O
over	PART	O	O
75	NUM	O	O
in	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
on	ADP	O	O
warfarin	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
500	NUM	O	O
patient	ADJ	O	O
-	PUNCT	O	O
years	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
people	NOUN	O	O
aged	VERB	O	O
76	NUM	O	O
and	CCONJ	O	O
older	ADJ	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
on	ADP	O	O
adjusted	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
warfarin	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
recently	ADV	O	O
been	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
aged	VERB	O	O
76	NUM	O	O
and	CCONJ	O	O
older	ADJ	O	O
admitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
major	ADJ	O	O
healthcare	NOUN	O	O
network	NOUN	O	O
between	ADP	O	O
July	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
2001	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
June	PROPN	O	O
30	NUM	O	O
,	PUNCT	O	O
2002	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
on	ADP	O	O
warfarin	NOUN	O	I-Entity
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

Information	NOUN	O	O
regarding	VERB	O	O
major	ADJ	O	O
bleeding	NOUN	O	I-Entity
episodes	NOUN	O	O
,	PUNCT	O	O
strokes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
warfarin	ADJ	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
from	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
relatives	NOUN	O	O
,	PUNCT	O	O
primary	ADJ	O	O
physicians	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
medical	ADJ	O	O
records	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
on	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
530	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
28	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
53	NUM	O	O
major	ADJ	O	O
hemorrhages	NOUN	O	I-Entity
,	PUNCT	O	O
for	ADP	O	O
an	DET	O	O
annual	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
10.0%	NUM	O	O
,	PUNCT	O	O
including	VERB	O	O
24	NUM	O	O
(	PUNCT	O	O
45.3%	NUM	O	O
)	PUNCT	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
and	CCONJ	O	O
five	NUM	O	O
(	PUNCT	O	O
9.4%	NUM	O	O
)	PUNCT	O	O
fatal	ADJ	O	O
bleeds	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
annual	ADJ	O	O
stroke	NOUN	O	I-Entity
rate	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
2.6%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
hemorrhage	NOUN	O	I-Entity
was	VERB	O	O
high	ADJ	O	O
in	ADP	O	O
this	DET	O	O
old	ADJ	O	O
,	PUNCT	O	O
frail	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
excluding	VERB	O	O
fatalities	NOUN	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
no	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
sequelae	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
stroke	NOUN	O	I-Entity
rate	NOUN	O	O
on	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
demonstrating	VERB	O	O
how	ADV	O	O
effective	ADJ	O	O
warfarin	ADJ	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (15859361)

Safety	NOUN	O	O
of	ADP	O	O
celecoxib	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
adverse	ADJ	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
paracetamol	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
nimesulide	NOUN	O	I-Entity
associated	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
common	ADJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Acetaminophen	PROPN	O	I-Entity
(	PUNCT	O	O
paracetamol	NOUN	O	I-Entity
--	PUNCT	O	O
P	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
Nimesulide	PROPN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
widely	ADV	O	O
used	ADJ	O	O
analgesic	NOUN	O	O
-	PUNCT	O	O
antipyretic	ADJ	O	O
/	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
hypersensitivity	NOUN	O	I-Entity
reactions	NOUN	O	O
to	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
is	VERB	O	O
generally	ADV	O	O
low	ADJ	O	O
.	PUNCT	O	O

Celecoxib	PROPN	O	I-Entity
(	PUNCT	O	O
CE	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
high	ADJ	O	O
selectivity	NOUN	O	O
and	CCONJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
COX-2	PROPN	O	O
enzyme	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
tolerability	NOUN	O	O
of	ADP	O	O
CE	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
documented	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
cutaneous	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
P	PROPN	O	I-Entity
and	CCONJ	O	O
N	PROPN	O	I-Entity
associated	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
to	PART	O	O
classic	ADJ	O	O
NSAIDs	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
studied	VERB	O	O
9	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
P	PROPN	O	I-Entity
and	CCONJ	O	O
N	PROPN	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
associated	VERB	O	O
reactions	NOUN	O	O
to	ADP	O	O
classic	ADJ	O	O
NSAIDs	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
P	NOUN	O	I-Entity
and	CCONJ	O	O
N	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
was	VERB	O	O
based	VERB	O	O
in	ADP	O	O
vivo	NOUN	O	O
challenge	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
three	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
cumulative	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
CE	PROPN	O	I-Entity
in	ADP	O	O
refracted	VERB	O	O
doses	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
challenge	NOUN	O	O
was	VERB	O	O
considered	VERB	O	O
positive	ADJ	O	O
if	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
of	ADP	O	O
the	DET	O	O
following	VERB	O	O
appeared	VERB	O	O
:	PUNCT	O	O
erythema	NOUN	O	I-Entity
,	PUNCT	O	O
rush	NOUN	O	O
or	CCONJ	O	O
urticaria	NOUN	O	I-Entity
-	PUNCT	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
reaction	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
eight	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
88.8%	NUM	O	O
)	PUNCT	O	O
tolerated	VERB	O	O
CE	PROPN	O	I-Entity
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
angioedema	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
lips	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Only	ADV	O	O
one	NUM	O	O
hypersensitivity	ADJ	O	I-Entity
reaction	NOUN	O	O
to	ADP	O	O
CE	PROPN	O	I-Entity
was	VERB	O	O
documented	VERB	O	O
among	ADP	O	O
9	NUM	O	O
P	NOUN	O	I-Entity
and	CCONJ	O	O
N	NOUN	O	I-Entity
-	PUNCT	O	O
highly	ADV	O	O
NSAIDs	NOUN	O	O
intolerant	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
CE	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
reasonably	ADV	O	O
safe	ADJ	O	O
alternative	NOUN	O	O
to	PART	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
subjects	NOUN	O	O
who	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
P	NOUN	O	I-Entity
and	CCONJ	O	O
N.	PROPN	O	I-Entity


-DOCSTART- (15882284)

Case	PROPN	O	O
-	PUNCT	O	O
control	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
regular	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
use	NOUN	O	O
and	CCONJ	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Studies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
end	VERB	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
ESRD	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
given	VERB	O	O
conflicting	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
examine	VERB	O	O
this	DET	O	O
association	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
with	ADP	O	O
incident	NOUN	O	O
cases	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
cases	NOUN	O	O
were	VERB	O	O
all	DET	O	O
patients	NOUN	O	O
entering	VERB	O	O
the	DET	O	O
local	ADJ	O	O
dialysis	NOUN	O	O
program	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
area	NOUN	O	O
between	ADP	O	O
June	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
1995	NUM	O	O
and	CCONJ	O	O
November	PROPN	O	O
30	NUM	O	O
,	PUNCT	O	O
1997	NUM	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
classified	VERB	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
underlying	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
had	VERB	O	O
presumably	ADV	O	O
led	VERB	O	O
them	PRON	O	O
to	ADP	O	O
ESRD	PROPN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
specific	ADJ	O	O
groups	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
risks	NOUN	O	O
were	VERB	O	O
1.56	NUM	O	O
(	PUNCT	O	O
1.05	NUM	O	O
-	SYM	O	O
2.30	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
1.03	NUM	O	O
(	PUNCT	O	O
0.60	NUM	O	O
-	SYM	O	O
1.76	NUM	O	O
)	PUNCT	O	O

for	ADP	O	O
pyrazolones	NOUN	O	I-Entity
,	PUNCT	O	O
0.80	NUM	O	O
(	PUNCT	O	O
0.39	NUM	O	O
-	SYM	O	O
1.63	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
paracetamol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
0.94	NUM	O	O
(	PUNCT	O	O
0.57	NUM	O	O
-	SYM	O	O
1.56	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
nonaspirin	NOUN	O	O
NSAIDs	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
aspirin	NOUN	O	I-Entity
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
cumulated	VERB	O	O
dose	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
was	VERB	O	O
particularly	ADV	O	O
high	ADJ	O	O
among	ADP	O	O
the	DET	O	O
subset	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
vascular	ADJ	O	O
nephropathy	NOUN	O	I-Entity
as	ADP	O	O
underlying	ADJ	O	O
disease	NOUN	O	O
[	PUNCT	O	O
2.35	NUM	O	O
(	PUNCT	O	O
1.17	NUM	O	O
-	SYM	O	O
4.72	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
nonaspirin	ADJ	O	O
analgesic	NOUN	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
NSAIDs	PROPN	O	O
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
chronic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
may	VERB	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15953230)

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
amisulpride	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
cause	NOUN	O	O
for	ADP	O	O
prolonged	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
deliberate	ADJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
poisoning	VERB	O	I-Entity
with	ADP	O	O
5	NUM	O	O
g	NOUN	O	O
and	CCONJ	O	O
3.6	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
amisulpride	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
and	CCONJ	O	O
hypocalcaemia	NOUN	O	I-Entity
were	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
respond	VERB	O	O
to	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

calcium	NOUN	O	B-Entity
gluconate	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15987266)

Growth	PROPN	O	O
-	PUNCT	O	O
associated	VERB	O	O
protein	NOUN	O	O
43	NUM	O	O
expression	NOUN	O	O
in	ADP	O	O
hippocampal	ADJ	O	O
molecular	ADJ	O	O
layer	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
epileptic	ADJ	O	I-Entity
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
cycloheximide	NOUN	O	I-Entity
.	PUNCT	O	O

GAP43	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
linked	VERB	O	O
with	ADP	O	O
mossy	NOUN	O	O
fiber	NOUN	O	O
sprouting	NOUN	O	O
(	PUNCT	O	O
MFS	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
various	ADJ	O	O
experimental	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
how	ADV	O	O
GAP43	ADJ	O	O
expression	NOUN	O	O
(	PUNCT	O	O
GAP43-ir	PROPN	O	O
)	PUNCT	O	O
correlates	VERB	O	O
with	ADP	O	O
MFS	PROPN	O	O
,	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
intensity	NOUN	O	O
(	PUNCT	O	O
densitometry	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
extension	NOUN	O	O
(	PUNCT	O	O
width	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
GAP43-ir	PROPN	O	O
in	ADP	O	O
the	DET	O	O
inner	ADJ	O	O
molecular	ADJ	O	O
layer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
(	PUNCT	O	O
IML	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
rats	NOUN	O	O
subject	VERB	O	O
to	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
Pilo	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
previously	ADV	O	O
injected	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
cycloheximide	NOUN	O	I-Entity
(	PUNCT	O	O
CHX	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
MFS	PROPN	O	O
.	PUNCT	O	O

CHX	PROPN	O	I-Entity
was	VERB	O	O
injected	VERB	O	O
before	ADP	O	O
the	DET	O	O
Pilo	PROPN	O	I-Entity
injection	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Pilo	PROPN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
CHX	PROPN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Densitometry	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
regarding	VERB	O	O
GAP43-ir	PROPN	O	O
in	ADP	O	O
the	DET	O	O
IML	PROPN	O	O
between	ADP	O	O
Pilo	PROPN	O	I-Entity
,	PUNCT	O	O
CHX+Pilo	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
width	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GAP43-ir	PROPN	O	O
band	NOUN	O	O
in	ADP	O	O
the	DET	O	O
IML	PROPN	O	O
showed	VERB	O	O
that	ADP	O	O
CHX+Pilo	PROPN	O	I-Entity
and	CCONJ	O	O
control	NOUN	O	O
animals	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
larger	ADJ	O	O
band	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
that	DET	O	O
in	ADP	O	O
the	DET	O	O
Pilo	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
current	ADJ	O	O
finding	NOUN	O	O
that	ADP	O	O
animals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CHX+Pilo	PROPN	O	I-Entity
group	NOUN	O	O
have	VERB	O	O
a	DET	O	O
GAP43-ir	PROPN	O	O
band	NOUN	O	O
in	ADP	O	O
the	DET	O	O
IML	PROPN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
reinforces	VERB	O	O
prior	ADV	O	O
data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
MFS	PROPN	O	O
in	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
change	NOUN	O	O
in	ADP	O	O
GAP43-ir	PROPN	O	O
present	ADJ	O	O
in	ADP	O	O
Pilo	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
was	VERB	O	O
a	DET	O	O
thinning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
band	NOUN	O	O
to	ADP	O	O
a	DET	O	O
very	ADV	O	O
narrow	ADJ	O	O
layer	NOUN	O	O
just	ADV	O	O
above	ADP	O	O
the	DET	O	O
granule	NOUN	O	O
cell	NOUN	O	O
layer	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
hilar	ADJ	O	O
cell	NOUN	O	O
projections	NOUN	O	O
that	ADJ	O	O
express	VERB	O	O
GAP-43	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (15991002)

Nicotine	NOUN	O	I-Entity
antagonizes	VERB	O	O

caffeine-	X	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
pentylenetetrazole	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiogenic	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Nicotine	PROPN	O	I-Entity
and	CCONJ	O	O
caffeine	NOUN	O	I-Entity
are	VERB	O	O
widely	ADV	O	O
consumed	VERB	O	O
licit	NOUN	O	O
psychoactive	ADJ	O	O
drugs	NOUN	O	O
worldwide	ADV	O	O
.	PUNCT	O	O

Although	ADP	O	O
some	DET	O	O
studies	NOUN	O	O
in	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
indicate	VERB	O	O
clear	ADJ	O	O
pharmacological	ADJ	O	O
interactions	NOUN	O	O
between	ADP	O	O
them	PRON	O	O
,	PUNCT	O	O
no	DET	O	O
studies	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
interaction	NOUN	O	O
on	ADP	O	O
anxiety	NOUN	O	I-Entity
responses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
investigates	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
on	ADP	O	O
anxiety	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
caffeine	NOUN	O	I-Entity
and	CCONJ	O	O
another	DET	O	O
anxiogenic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
pentylenetetrazole	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

test	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
on	ADP	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

Adult	NOUN	O	O
male	NOUN	O	O
Swiss	PROPN	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
32	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
-	SYM	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
10	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
70	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O

Nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
-	SYM	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
itself	PRON	O	O
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
any	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
EPM	PROPN	O	O
test	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
70	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
produced	VERB	O	O
an	DET	O	O
anxiogenic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
apparent	ADJ	O	O
with	ADP	O	O
decreases	NOUN	O	O
in	ADP	O	O
open	ADJ	O	O
-	PUNCT	O	O
arm	NOUN	O	O
time	NOUN	O	O
and	CCONJ	O	O
entry	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
pretreatment	NOUN	O	O
blocked	VERB	O	O
the	DET	O	O
caffeine-	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
pentylenetetrazole	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
antagonistic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
on	ADP	O	O
caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
is	VERB	O	O
specific	ADJ	O	O
to	ADP	O	O
caffeine	NOUN	O	I-Entity
,	PUNCT	O	O
instead	ADV	O	O
of	ADP	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
anxiolytic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
extend	VERB	O	O
the	DET	O	O
current	ADJ	O	O
findings	NOUN	O	O
on	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
nicotine	NOUN	O	I-Entity
and	CCONJ	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16034922)

Hormone	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HT	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
for	ADP	O	O
controlling	VERB	O	O
menopausal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
management	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
osteoporosis	NOUN	O	I-Entity
and	CCONJ	O	O
dementia	NOUN	O	I-Entity
in	ADP	O	O
older	ADJ	O	O
women	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
evidence	NOUN	O	O
supporting	VERB	O	O
its	ADJ	O	O
use	NOUN	O	O
for	ADP	O	O
these	DET	O	O
indications	NOUN	O	O
is	VERB	O	O
largely	ADV	O	O
observational	ADJ	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
HT	PROPN	O	O
on	ADP	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
transient	ADJ	O	B-Entity
ischaemic	NOUN	O	I-Entity
attacks	NOUN	O	I-Entity
,	PUNCT	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
colorectal	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
ovarian	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
dementia	NOUN	O	I-Entity
,	PUNCT	O	O
fractures	NOUN	O	I-Entity
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

SELECTION	PROPN	O	O
CRITERIA	NOUN	O	O
:	PUNCT	O	O
Randomised	VERB	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
HT	PROPN	O	O
(	PUNCT	O	O
oestrogens	VERB	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
progestogens	NOUN	O	I-Entity
)	PUNCT	O	O
versus	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
taken	VERB	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
one	NUM	O	O
year	NOUN	O	O
by	ADP	O	O
perimenopausal	NOUN	O	O
or	CCONJ	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
or	CCONJ	O	O
coronary	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
's	PART	O	O
use	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
after	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
after	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oestrogen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
HT	PROPN	O	O
also	ADV	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
and	CCONJ	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
only	ADJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
HT	PROPN	O	O
were	VERB	O	O
a	DET	O	O
decreased	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
fractures	NOUN	O	I-Entity
and	CCONJ	O	O
colon	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
women	NOUN	O	O
over	ADP	O	O
65	NUM	O	O
years	NOUN	O	O
taking	VERB	O	O
continuous	ADJ	O	O
combined	ADJ	O	O
HT	PROPN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
dementia	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
combined	ADJ	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
one	NUM	O	O
trial	NOUN	O	O
analysed	VERB	O	O
subgroups	NOUN	O	O
of	ADP	O	O
2839	NUM	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
50	NUM	O	O
to	PART	O	O
59	NUM	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
women	NOUN	O	O
taking	VERB	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
and	CCONJ	O	O
1637	NUM	O	O
taking	VERB	O	O
oestrogen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
HT	PROPN	O	O
,	PUNCT	O	O
versus	ADP	O	O
similar	ADJ	O	O
-	PUNCT	O	O
sized	ADJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
significantly	ADV	O	O
increased	VERB	O	O
risk	NOUN	O	O
reported	VERB	O	O
was	VERB	O	O
for	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
taking	VERB	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
;	PUNCT	O	O
their	ADJ	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
remained	VERB	O	O
very	ADV	O	O
low	ADJ	O	O
.	PUNCT	O	O

HT	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
indicated	VERB	O	O
for	ADP	O	O
the	DET	O	O
routine	ADJ	O	O
management	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16083708)

Drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
liver	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
461	NUM	O	O
incidences	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
Spanish	ADJ	O	O
registry	NOUN	O	O
over	ADP	O	O
a	DET	O	O
10-year	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Progress	NOUN	O	O
in	ADP	O	O
the	DET	O	O
understanding	NOUN	O	O
of	ADP	O	O
susceptibility	NOUN	O	O
factors	NOUN	O	O
to	ADP	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
liver	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
DILI	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
predictability	NOUN	O	O
are	VERB	O	O
hampered	VERB	O	O
by	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
systematic	ADJ	O	O
programs	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
bona	ADJ	O	O
fide	ADJ	O	O
cases	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
cooperative	ADJ	O	O
network	NOUN	O	O
was	VERB	O	O
created	VERB	O	O
in	ADP	O	O
1994	NUM	O	O
in	ADP	O	O
Spain	PROPN	O	O
to	PART	O	O
identify	VERB	O	O
all	DET	O	O
suspicions	NOUN	O	O
of	ADP	O	O
DILI	PROPN	O	I-Entity
following	VERB	O	O
a	DET	O	O
prospective	NOUN	O	O
structured	VERB	O	O
report	NOUN	O	O
form	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
characterized	VERB	O	O
according	VERB	O	O
to	ADP	O	O
hepatocellular	NOUN	O	O
,	PUNCT	O	O
cholestatic	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mixed	ADJ	O	O
laboratory	NOUN	O	O
criteria	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
histologic	ADJ	O	O
criteria	NOUN	O	O
when	ADV	O	O
available	ADJ	O	O
.	PUNCT	O	O

Since	ADP	O	O
April	PROPN	O	O
1994	NUM	O	O
to	ADP	O	O
August	PROPN	O	O
2004	NUM	O	O
,	PUNCT	O	O
461	NUM	O	O
out	ADP	O	O
of	ADP	O	O
570	NUM	O	O
submitted	VERB	O	O
cases	NOUN	O	O
,	PUNCT	O	O
involving	VERB	O	O
505	NUM	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
deemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
DILI	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
antiinfective	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
was	VERB	O	O
the	DET	O	O
more	ADV	O	O
frequently	ADV	O	O
incriminated	VERB	O	O
,	PUNCT	O	O
amoxicillin	ADV	O	B-Entity
-	PUNCT	O	I-Entity
clavulanate	NOUN	O	I-Entity
accounting	NOUN	O	O
for	ADP	O	O
the	DET	O	O
12.8%	NUM	O	O
of	ADP	O	O
the	DET	O	O
whole	ADJ	O	O
series	NOUN	O	O
.	PUNCT	O	O

Indeed	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
and	CCONJ	O	O
death	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
was	VERB	O	O
11.7%	NUM	O	O
if	ADP	O	O
patients	NOUN	O	O
had	VERB	O	O
jaundice	ADV	O	I-Entity
at	ADP	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
corresponding	ADJ	O	O
figure	NOUN	O	O
was	VERB	O	O
3.8%	NUM	O	O
in	ADP	O	O
nonjaundiced	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
were	VERB	O	O
female	ADJ	O	O
sex	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
=	SYM	O	O
25	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
4.1	NUM	O	O
-	PUNCT	O	O
151	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O

95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.6	NUM	O	O
-	PUNCT	O	O
37	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.009	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
plasma	NOUN	O	O
bilirubin	NOUN	O	I-Entity
value	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
=	SYM	O	O
1.15	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.09	NUM	O	O
-	PUNCT	O	O
1.22	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O

Patients	NOUN	O	O
with	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hepatocellular	NOUN	O	O
jaundice	NOUN	O	I-Entity
have	VERB	O	O
11.7%	NUM	O	O
chance	NOUN	O	O
of	ADP	O	O
progressing	VERB	O	O
to	ADP	O	O
death	NOUN	O	O
or	CCONJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Amoxicillin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
clavulanate	PROPN	O	I-Entity
stands	VERB	O	O
out	PART	O	O
as	ADP	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
drug	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
DILI	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16092435)

Morphological	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
on	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
evoked	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
on	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardiopathy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Adriamycin	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
evoked	VERB	O	O
fully	ADV	O	O
developed	VERB	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
ADR	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16112787)

In	ADP	O	O
vivo	NOUN	O	O
evidences	NOUN	O	O
suggesting	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
vancomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
protection	NOUN	O	O
by	ADP	O	O
erdosteine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aims	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
examine	VERB	O	O
vancomycin	NOUN	O	I-Entity
(	PUNCT	O	O
VCM)-induced	VERB	O	I-Entity
oxidative	ADJ	O	O
stress	NOUN	O	O
that	ADJ	O	O
promotes	VERB	O	O
production	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
(	PUNCT	O	O
ROS	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
erdosteine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
expectorant	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
also	ADV	O	O
antioxidant	ADJ	O	O
properties	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
kidney	NOUN	O	O
tissue	NOUN	O	O
against	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
VCM	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
sham	NOUN	O	O
,	PUNCT	O	O
VCM	PROPN	O	I-Entity
and	CCONJ	O	O
VCM	PROPN	O	I-Entity
plus	CCONJ	O	O
erdosteine	NOUN	O	I-Entity
.	PUNCT	O	O

VCM	PROPN	O	I-Entity
was	VERB	O	O
administrated	VERB	O	O
intraperitoneally	ADV	O	O
(	PUNCT	O	O
i.p	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O

Erdosteine	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
.	PUNCT	O	O

VCM	PROPN	O	I-Entity
administration	NOUN	O	O
to	PART	O	O
control	VERB	O	O
rats	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
renal	ADJ	O	O
malondialdehyde	NOUN	O	I-Entity
(	PUNCT	O	O
MDA	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
urinary	ADJ	O	O

(	PUNCT	O	O
NAG	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
)	PUNCT	O	O
excretion	NOUN	O	O
but	CCONJ	O	O
decreased	VERB	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
(	PUNCT	O	O
SOD	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
catalase	NOUN	O	O
(	PUNCT	O	O
CAT	PROPN	O	O
)	PUNCT	O	O
activities	NOUN	O	O
.	PUNCT	O	O

Erdosteine	PROPN	O	I-Entity
administration	NOUN	O	O
with	ADP	O	O
VCM	PROPN	O	I-Entity
injections	NOUN	O	O
caused	VERB	O	O
significantly	ADV	O	O
decreased	ADJ	O	O
renal	ADJ	O	O
MDA	PROPN	O	I-Entity
and	CCONJ	O	O
urinary	ADJ	O	O
NAG	PROPN	O	O
excretion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
SOD	PROPN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
CAT	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
VCM	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

Erdosteine	PROPN	O	I-Entity
showed	VERB	O	O
histopathological	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
VCM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
dilatation	NOUN	O	O
of	ADP	O	O
tubular	NOUN	O	O
lumens	NOUN	O	O
,	PUNCT	O	O
extensive	ADJ	O	O
epithelial	ADJ	O	O
cell	NOUN	O	O
vacuolization	NOUN	O	O
,	PUNCT	O	O
atrophy	VERB	O	I-Entity
,	PUNCT	O	O
desquamation	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
necrosis	NOUN	O	I-Entity
in	ADP	O	O
VCM	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
more	ADV	O	O
than	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
erdosteine	NOUN	O	I-Entity
groups	NOUN	O	O
.	PUNCT	O	O

Erdosteine	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
marked	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
oxidative	ADJ	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
VCM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
with	ADP	O	O
erdosteine	NOUN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
VCM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
kidney	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
both	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
histological	ADJ	O	O
levels	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16309808)

Does	VERB	O	O
domperidone	NOUN	O	I-Entity
potentiate	VERB	O	O
mirtazapine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
restless	ADJ	O	B-Entity
legs	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
?	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
now	ADV	O	O
evidence	NOUN	O	O
to	PART	O	O
suggest	VERB	O	O
a	DET	O	O
central	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
restless	ADJ	O	B-Entity
legs	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
RLS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
RLS	PROPN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
dramatically	ADV	O	O
improved	VERB	O	O
by	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
dopamine	NOUN	O	I-Entity
agonists	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
central	ADJ	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
can	VERB	O	O
induce	VERB	O	O
or	CCONJ	O	O
aggravate	VERB	O	O
RLS	PROPN	O	I-Entity
symptoms	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
previous	ADJ	O	O
report	NOUN	O	O
regarding	VERB	O	O
whether	ADP	O	O
domperidone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
peripheral	ADJ	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
also	ADV	O	O
induce	VERB	O	O
or	CCONJ	O	O
aggravate	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
RLS	PROPN	O	I-Entity
.	PUNCT	O	O

Mirtazapine	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
noradrenergic	ADJ	O	O
and	CCONJ	O	O
specific	ADJ	O	O
serotonergic	ADJ	O	O
antidepressant	NOUN	O	O
(	PUNCT	O	O
NaSSA	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
RLS	PROPN	O	I-Entity
in	ADP	O	O
several	ADJ	O	O
recent	ADJ	O	O
publications	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
report	VERB	O	O
here	ADV	O	O
a	DET	O	O
depressed	ADJ	O	O
patient	NOUN	O	O
comorbid	NOUN	O	O
with	ADP	O	O
postprandial	ADJ	O	B-Entity
dyspepsia	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
RLS	PROPN	O	I-Entity
after	ADP	O	O
mirtazapine	NOUN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
added	VERB	O	O
to	ADP	O	O
his	ADJ	O	O
domperidone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
patient	NOUN	O	O
started	VERB	O	O
to	PART	O	O
have	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
RLS	PROPN	O	I-Entity
only	ADV	O	O
after	ADP	O	O
he	PRON	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
mirtazapine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
his	ADJ	O	O
RLS	PROPN	O	I-Entity
symptoms	NOUN	O	O
resolved	VERB	O	O
completely	ADV	O	O
upon	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
his	ADJ	O	O
mirtazapine	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
a	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
mirtazapine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
RLS	PROPN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
support	VERB	O	O
a	DET	O	O
potentiating	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
domperione	NOUN	O	I-Entity
on	ADP	O	O
mirtazapine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
RLS	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
mirtazapine	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
RLS	PROPN	O	I-Entity
in	ADP	O	O
some	DET	O	O
individuals	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
those	DET	O	O
receiving	VERB	O	O
concomitant	ADJ	O	O
dopamine	NOUN	O	I-Entity
D2	NOUN	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16323982)

Antiandrogenic	ADJ	O	O
therapy	NOUN	O	O
can	VERB	O	O
cause	VERB	O	O
coronary	ADJ	O	B-Entity
arterial	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

AIM	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
change	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
metabolism	NOUN	O	O
by	ADP	O	O
antiandrogen	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
with	ADP	O	O
a	DET	O	O
2.5	NUM	O	O
years	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
cholesterols	NOUN	O	I-Entity
(	PUNCT	O	O
C	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
triglycerides	NOUN	O	I-Entity
(	PUNCT	O	O
TG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
lipoproteins	NOUN	O	O
(	PUNCT	O	O
LP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
apolipoproteins	NOUN	O	O
(	PUNCT	O	O
Apo	PROPN	O	O
)	PUNCT	O	O

fi	X	O	O
les	ADV	O	O
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
mean	ADJ	O	O
age	NOUN	O	O
60	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
risk	NOUN	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
stage	NOUN	O	O
:	PUNCT	O	O
T1cN0M0	NOUN	O	O
,	PUNCT	O	O
Gleason	PROPN	O	O
score	NOUN	O	O
:	PUNCT	O	O
2	NUM	O	O
-	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
cyproterone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
CPA	PROPN	O	I-Entity
)	PUNCT	O	O
without	ADP	O	O
surgical	ADJ	O	O
management	NOUN	O	O
or	CCONJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
decreases	NOUN	O	O
of	ADP	O	O
HDL	PROPN	O	O
-	PUNCT	O	O
C	PROPN	O	O
,	PUNCT	O	O
Apo	PROPN	O	O
A	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
and	CCONJ	O	O
Apo	PROPN	O	O
A	PROPN	O	O
-	PUNCT	O	O
II	PROPN	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
VLDL	PROPN	O	O
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
CPA	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
years	NOUN	O	O
on	ADP	O	O
CPA	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
out	ADP	O	O
of	ADP	O	O
twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
coronary	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Ischaemic	PROPN	O	O
coronary	ADJ	O	B-Entity
arteriosclerosis	NOUN	O	I-Entity
with	ADP	O	O
an	DET	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
16.6%	NUM	O	O
as	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
CPA	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
mediated	VERB	O	O
through	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
HDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
,	PUNCT	O	O
Apo	PROPN	O	O
A	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
and	CCONJ	O	O
Apo	PROPN	O	O

pro	NOUN	O	O
fi	X	O	O
les	X	O	O
,	PUNCT	O	O
other	ADJ	O	O
than	ADP	O	O
the	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
hyperglyceridemic	ADJ	O	B-Entity
effect	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
estrogen	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16369751)

5-Fluorouracil	NUM	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
fluoro	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
alanine	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiotoxicity	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
occurring	VERB	O	O
during	ADP	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
for	ADP	O	O
malignancies	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
herein	ADV	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
70-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
whom	NOUN	O	O
a	DET	O	O
high	ADJ	O	O
serum	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
fluoro	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
alanine	NOUN	O	I-Entity
(	PUNCT	O	O
FBAL	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
unresectable	ADJ	O	O
colon	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
metastases	NOUN	O	O
to	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
lung	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
referred	VERB	O	O
to	ADP	O	O
us	PRON	O	O
for	ADP	O	O
chemotherapy	NOUN	O	O
from	ADP	O	O
an	DET	O	O
affiliated	ADJ	O	O
hospital	NOUN	O	O
;	PUNCT	O	O
he	PRON	O	O
had	VERB	O	O
no	DET	O	O
cardiac	ADJ	O	O
history	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
a	DET	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-FU	PROPN	O	I-Entity
(	PUNCT	O	O
1000	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
during	ADP	O	O
which	ADJ	O	O
precordial	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
with	ADP	O	O
right	ADJ	O	B-Entity
bundle	ADJ	O	I-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
occurred	VERB	O	O
concomitantly	ADV	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
serum	NOUN	O	O
FBAL	PROPN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
1955	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
ml	ADV	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
precordial	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
electrocardiographic	ADJ	O	O
changes	NOUN	O	O
disappeared	VERB	O	O
spontaneously	ADV	O	O
after	ADP	O	O
the	DET	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
5-FU	PROPN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
precordial	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
considered	VERB	O	O
to	PART	O	O
have	VERB	O	O
been	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
5-FU	NUM	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
5-FU	PROPN	O	I-Entity
was	VERB	O	O
abandoned	VERB	O	O
.	PUNCT	O	O

Instead	ADV	O	O
,	PUNCT	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
S-1	PROPN	O	O
(	PUNCT	O	O
a	DET	O	O
derivative	NOUN	O	O
of	ADP	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
at	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
week	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
instituted	VERB	O	O
,	PUNCT	O	O
because	ADP	O	O
S-1	PROPN	O	O
has	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
dihydropyrimidine	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
catalyzes	VERB	O	O
the	DET	O	O
degradative	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
into	ADP	O	O
FBAL	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
FBAL	PROPN	O	I-Entity
concentration	NOUN	O	O
subsequently	ADV	O	O
decreased	VERB	O	O
to	ADP	O	O
352	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
ml	INTJ	O	O
,	PUNCT	O	O
the	DET	O	O
same	ADJ	O	O
as	ADP	O	O
the	DET	O	O
value	NOUN	O	O
measured	VERB	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
S-1	PROPN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Thereafter	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
cardiac	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
experience	NOUN	O	O
of	ADP	O	O
this	DET	O	O
case	NOUN	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
suggests	VERB	O	O
that	ADP	O	O
FBAL	PROPN	O	I-Entity
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
5-FU	NUM	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

S-1	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
safely	ADV	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16565833)

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
time	NOUN	O	O
interval	NOUN	O	O
between	ADP	O	O
monoHER	PROPN	O	I-Entity
and	CCONJ	O	O
doxorubicin	ADJ	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
against	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
its	ADJ	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
anthracyclin	NOUN	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX	PROPN	O	I-Entity
)	PUNCT	O	O
continues	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
widely	ADV	O	O
used	VERB	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
presumably	ADV	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
radicals	NOUN	O	O
by	ADP	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O

Reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
particularly	ADV	O	O
affect	VERB	O	O
the	DET	O	O
cardiac	ADJ	O	O
myocytes	NOUN	O	O
because	ADP	O	O
these	DET	O	O
cells	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
relatively	ADV	O	O
poor	ADJ	O	O
antioxidant	ADJ	O	O
defense	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
semisynthetic	ADJ	O	O
flavonoid	NOUN	O	I-Entity
monohydroxyethylrutoside	NOUN	O	I-Entity
(	PUNCT	O	O
monoHER	PROPN	O	I-Entity
)	PUNCT	O	O
showed	VERB	O	O
cardioprotection	NOUN	O	O
against	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
through	ADP	O	O
its	ADJ	O	O
radical	ADJ	O	O
scavenging	NOUN	O	O
and	CCONJ	O	O
iron	NOUN	O	I-Entity
chelating	VERB	O	O
properties	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
relatively	ADV	O	O
short	ADJ	O	O
final	ADJ	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
of	ADP	O	O
monoHER	PROPN	O	I-Entity
(	PUNCT	O	O
about	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
expected	VERB	O	O
that	ADP	O	O
the	DET	O	O
time	NOUN	O	O
interval	NOUN	O	O
between	ADP	O	O
monoHER	PROPN	O	I-Entity
and	CCONJ	O	O
DOX	PROPN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
of	ADP	O	O
influence	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
monoHER	PROPN	O	I-Entity
.	PUNCT	O	O

Six	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
BALB	PROPN	O	O
/	SYM	O	O
c	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
,	PUNCT	O	O
DOX	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

preceded	VERB	O	O
by	ADP	O	O
monoHER	PROPN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
or	CCONJ	O	O
120	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Their	ADJ	O	O
cardiac	ADJ	O	O
tissues	NOUN	O	O
were	VERB	O	O
processed	VERB	O	O
for	ADP	O	O
light	NOUN	O	O
microscopy	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
which	ADJ	O	O
cardiomyocyte	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
according	VERB	O	O
to	ADP	O	O
Billingham	PROPN	O	O
(	PUNCT	O	O
in	ADP	O	O
Cancer	PROPN	O	I-Entity
Treat	PROPN	O	O
Rep	PROPN	O	O
62(6):865	NUM	O	O
-	SYM	O	O
872	NUM	O	O
,	PUNCT	O	O
1978	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Microscopic	PROPN	O	O
evaluation	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
DOX	PROPN	O	I-Entity
alone	ADV	O	O
induced	VERB	O	O
significant	ADJ	O	O
cardiac	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
damaged	VERB	O	O
cardiomyocytes	NOUN	O	O
was	VERB	O	O
9.6-fold	ADJ	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
4.4	NUM	O	O
-	SYM	O	O
21.0	NUM	O	O
)	PUNCT	O	O
higher	ADJ	O	O
in	ADP	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DOX	PROPN	O	I-Entity
alone	ADV	O	O
than	ADP	O	O
that	DET	O	O
in	ADP	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
aberrant	ADJ	O	O
cardiomyocytes	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DOX	PROPN	O	I-Entity
preceded	VERB	O	O
by	ADP	O	O
monoHER	PROPN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
in	ADP	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
ranged	VERB	O	O
from	ADP	O	O
1.6	NUM	O	O
to	ADP	O	O
2.8	NUM	O	O
(	PUNCT	O	O
mean	VERB	O	O
2.2	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.2	NUM	O	O
-	SYM	O	O
4.1	NUM	O	O
,	PUNCT	O	O
P=0.019	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
by	ADP	O	O
adding	VERB	O	O
monoHER	PROPN	O	I-Entity
before	ADP	O	O
DOX	PROPN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
4.4-fold	ADJ	O	O
reduction	NOUN	O	O
(	PUNCT	O	O
P<0.001	PROPN	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
2.3	NUM	O	O
-	SYM	O	O
8.2	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
abnormal	ADJ	O	O
cardiomyocytes	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
depend	VERB	O	O
on	ADP	O	O
the	DET	O	O
time	NOUN	O	O
interval	NOUN	O	O
between	ADP	O	O
monoHER	PROPN	O	I-Entity
and	CCONJ	O	O
DOX	PROPN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
P=0.345	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
in	ADP	O	O
an	DET	O	O
outpatient	NOUN	O	O
clinical	ADJ	O	O
setting	NOUN	O	O
monoHER	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
shortly	ADV	O	O
before	ADP	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16723784)

Clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
during	ADP	O	O
bepridil	NOUN	O	I-Entity
administration	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
flutter	NOUN	O	I-Entity
.	PUNCT	O	O

Bepridil	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
(	PUNCT	O	O
Bpd	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
attracted	VERB	O	O
attention	NOUN	O	O
as	ADP	O	O
an	DET	O	O
effective	ADJ	O	O
drug	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
(	PUNCT	O	O
AF	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
(	PUNCT	O	O
AFL	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
Tdp	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Bpd	PROPN	O	I-Entity
requiring	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Bpd	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
459	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
361	NUM	O	O
males	NOUN	O	O
,	PUNCT	O	O
63+/-12	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
comprising	VERB	O	O
378	NUM	O	O
AF	PROPN	O	I-Entity
and	CCONJ	O	O
81	NUM	O	O
AFL	NOUN	O	I-Entity
cases	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
marked	VERB	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
0.55	NUM	O	O
s	NOUN	O	O
in	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
bradycardia	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
40	NUM	O	O
beats	NOUN	O	O
/	SYM	O	O

min	NOUN	O	O
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
and	CCONJ	O	O
general	ADJ	O	O
fatigue	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
each	DET	O	O
.	PUNCT	O	O

In	ADP	O	O
4	NUM	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
,	PUNCT	O	O
Tdp	PROPN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
triggering	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
Tdp	PROPN	O	I-Entity
were	VERB	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
sudden	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
backgrounds	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
Tdp	PROPN	O	I-Entity
other	ADJ	O	O
than	ADP	O	O
LAD	PROPN	O	O
and	CCONJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
larger	ADJ	O	O
and	CCONJ	O	O
older	ADJ	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
Tdp	PROPN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Careful	ADJ	O	O
observation	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
ECG	PROPN	O	O
should	VERB	O	O
always	ADV	O	O
be	VERB	O	O
done	VERB	O	O
during	ADP	O	O
Bpd	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16731636)

Enhanced	VERB	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
in	ADP	O	O
transgenic	ADJ	O	O
rats	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
brain	NOUN	O	O
angiotensinogen	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
previously	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
a	DET	O	O
permanent	ADJ	O	O
deficiency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
(	PUNCT	O	O
RAS	PROPN	O	O
)	PUNCT	O	O
may	VERB	O	O
increase	VERB	O	O
the	DET	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
baroreflex	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

agonist	NOUN	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
Iso	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
isolated	ADJ	O	O
hearts	NOUN	O	O
,	PUNCT	O	O
Iso	PROPN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
greater	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
left	VERB	O	O
ventricular	NOUN	O	O
(	PUNCT	O	O
LV	PROPN	O	O
)	PUNCT	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
maximal	ADJ	O	O
contraction	NOUN	O	O
(	PUNCT	O	O
+	PROPN	O	O
dP	PROPN	O	O
/	SYM	O	O
dt(max	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
TGR	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
(	PUNCT	O	O
SD	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

LV	PROPN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
Iso	PROPN	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
TGR	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
SD	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
g	NOUN	O	O
LV	PROPN	O	O
wt/100	PROPN	O	O

The	DET	O	O
greater	ADJ	O	O
LV	PROPN	O	B-Entity
hypertrophy	NOUN	O	I-Entity
in	ADP	O	O
TGR	PROPN	O	O
rats	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
more	ADV	O	O
pronounced	ADJ	O	O
downregulation	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
AR	PROPN	O	O
and	CCONJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
LV	PROPN	O	O
beta	NOUN	O	O
-	PUNCT	O	O
AR	PROPN	O	O
kinase-1	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
in	ADP	O	O
SD	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
AR	PROPN	O	O
antagonist	NOUN	O	O
metoprolol	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
in	ADP	O	O
TGR	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
SD	NOUN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
-9.9	PUNCT	O	O

1.5%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
parasympathetic	ADJ	O	O
blockade	NOUN	O	O
by	ADP	O	O
atropine	NOUN	O	I-Entity
on	ADP	O	O
HR	PROPN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
strains	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
TGR	PROPN	O	O
are	VERB	O	O
more	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
AR	PROPN	O	O
agonist	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
inotropic	NOUN	O	I-Entity
response	NOUN	O	O
and	CCONJ	O	O
hypertrophy	NOUN	O	I-Entity
,	PUNCT	O	O
possibly	ADV	O	O
due	ADP	O	O
to	ADP	O	O
chronically	ADV	O	O
low	ADJ	O	O
sympathetic	ADJ	O	O
outflow	NOUN	O	O
directed	VERB	O	O
to	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16801510)

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
injection	NOUN	O	O
drug	NOUN	O	O
users	NOUN	O	O
receiving	VERB	O	O
methadone	NOUN	O	I-Entity
:	PUNCT	O	O
high	ADJ	O	O
frequency	NOUN	O	O
in	ADP	O	O
hospitalized	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
prolongs	VERB	O	O
the	DET	O	O
QT	PROPN	O	O
interval	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
inpatient	NOUN	O	O
setting	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
QT	PROPN	O	B-Entity
interval	NOUN	O	I-Entity
prolongation	NOUN	O	I-Entity
with	ADP	O	O
methadone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
dose	NOUN	O	O
dependence	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
cofactors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
remain	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
systematic	ADJ	O	O
,	PUNCT	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
comparing	VERB	O	O
active	ADJ	O	O
or	CCONJ	O	O
former	ADJ	O	O
intravenous	ADJ	O	O
drug	NOUN	O	O
users	NOUN	O	O
receiving	VERB	O	O
methadone	NOUN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
not	ADV	O	O
receiving	VERB	O	O
methadone	NOUN	O	I-Entity
among	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
hospitalized	VERB	O	O
over	ADP	O	O
a	DET	O	O
5-year	ADJ	O	O
period	NOUN	O	O
in	ADP	O	O
a	DET	O	O
tertiary	ADJ	O	O
care	NOUN	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
167	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
methadone	NOUN	O	I-Entity
fulfilled	VERB	O	O
the	DET	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
injection	NOUN	O	O
drug	NOUN	O	O
users	NOUN	O	O
not	ADV	O	O
receiving	VERB	O	O
methadone	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
methadone	NOUN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
demographic	ADJ	O	O
,	PUNCT	O	O
biological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
potential	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
167	NUM	O	O
methadone	NOUN	O	I-Entity
maintenance	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
QTc	PROPN	O	O
prolongation	NOUN	O	O
to	ADP	O	O
0.50	NUM	O	O
second((1/2	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
longer	NOUN	O	O
was	VERB	O	O
16.2%	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
0%	NUM	O	O
in	ADP	O	O
80	NUM	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
3.6%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
methadone	NOUN	O	I-Entity
group	NOUN	O	O
presented	VERB	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

QTc	ADJ	O	O
length	NOUN	O	O
was	VERB	O	O
weakly	ADV	O	O
but	CCONJ	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
methadone	NOUN	O	I-Entity
daily	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
Spearman	PROPN	O	O
rank	NOUN	O	O
correlation	NOUN	O	O
coefficient	NOUN	O	O
,	PUNCT	O	O
0.20	NUM	O	O
;	PUNCT	O	O
P<.01	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
allowed	VERB	O	O
attribution	NOUN	O	O
of	ADP	O	O
31.8%	NUM	O	O
of	ADP	O	O
QTc	PROPN	O	O
variability	NOUN	O	O
to	ADP	O	O
methadone	NOUN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
cytochrome	NOUN	O	O

P-450	PROPN	O	O
3A4	NUM	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
,	PUNCT	O	O
hypokalemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
altered	VERB	O	O
liver	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

QT	NOUN	O	B-Entity
interval	NOUN	O	I-Entity
prolongation	NOUN	O	I-Entity
in	ADP	O	O
methadone	NOUN	O	I-Entity
maintenance	NOUN	O	O
patients	NOUN	O	O
hospitalized	VERB	O	O
in	ADP	O	O
a	DET	O	O
tertiary	ADJ	O	O
care	NOUN	O	O
center	NOUN	O	O
is	VERB	O	O
a	DET	O	O
frequent	ADJ	O	O
finding	NOUN	O	O
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
presence	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P-450	PROPN	O	O
3A4	NUM	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
function	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O

Long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
can	VERB	O	O
occur	VERB	O	O
with	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
methadone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16810074)

Mechanisms	PROPN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
deficiency	NOUN	O	O
:	PUNCT	O	O
focus	VERB	O	O
on	ADP	O	O
venous	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Loss	NOUN	O	O
of	ADP	O	O
endothelial	ADJ	O	O
cell	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
hypertension	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
hallmark	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Experimental	ADJ	O	O
hypertension	NOUN	O	I-Entity
created	VERB	O	O
by	ADP	O	O
the	DET	O	O
removal	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
involves	VERB	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
decreased	VERB	O	O
arterial	ADJ	O	O
vasodilator	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
increased	VERB	O	O
venous	ADJ	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
(	PUNCT	O	O
venomotor	NOUN	O	O
)	PUNCT	O	O
tone	NOUN	O	O
plays	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
Nomega	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
nitro	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
(	PUNCT	O	O
LNNA	PROPN	O	I-Entity
)	PUNCT	O	O
hypertension	NOUN	O	I-Entity
through	ADP	O	O
these	DET	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
inhibitor	NOUN	O	O
LNNA	PROPN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
g	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
in	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

5	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
in	ADP	O	O
LNNA	PROPN	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Maximal	PROPN	O	O
contraction	NOUN	O	O
to	ADP	O	O
norepinephrine	NOUN	O	I-Entity
was	VERB	O	O
modestly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
arteries	NOUN	O	O
from	ADP	O	O
LNNA	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
whereas	ADP	O	O
the	DET	O	O
maximum	ADJ	O	O
contraction	NOUN	O	O
to	ADP	O	O
ET-1	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
(	PUNCT	O	O
54%	NUM	O	O
control	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Maximum	ADJ	O	O
contraction	NOUN	O	O
of	ADP	O	O
vena	NOUN	O	O
cava	NOUN	O	O
to	ADP	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
37%	NUM	O	O
control	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
was	VERB	O	O
reduced	VERB	O	O
but	CCONJ	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
ET-1	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
circulatory	ADJ	O	O
filling	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
measure	NOUN	O	O
of	ADP	O	O
venomotor	NOUN	O	O
tone	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
elevated	VERB	O	O
in	ADP	O	O
LNNA	PROPN	O	I-Entity
hypertension	NOUN	O	I-Entity
at	ADP	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
LNNA	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
superoxide	NOUN	O	I-Entity
scavenger	NOUN	O	O
tempol	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
300	NUM	O	O
micromol	NOUN	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
but	CCONJ	O	O
caused	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
LNNA	PROPN	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
-18	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
ganglionic	ADJ	O	O
blockade	NOUN	O	O
with	ADP	O	O
hexamethonium	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
greater	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
LNNA	PROPN	O	I-Entity
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
76	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Carotid	ADJ	O	O
arteries	NOUN	O	O
,	PUNCT	O	O
vena	NOUN	O	O
cava	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sympathetic	ADJ	O	O
ganglia	NOUN	O	O
from	ADP	O	O
LNNA	PROPN	O	I-Entity
rats	NOUN	O	O
had	VERB	O	O
higher	ADJ	O	O
basal	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
from	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
while	ADP	O	O
NO	DET	O	I-Entity
deficiency	NOUN	O	O
increases	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
sympathetic	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
arterial	NOUN	O	O
and	CCONJ	O	O
venous	ADJ	O	O
vessels	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
impact	NOUN	O	O
on	ADP	O	O
veins	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
make	VERB	O	O
a	DET	O	O
major	ADJ	O	O
contribution	NOUN	O	O
to	ADP	O	O
this	DET	O	O
form	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16867246)

Association	PROPN	O	O
of	ADP	O	O
DRD2	PROPN	O	O
polymorphisms	NOUN	O	O
and	CCONJ	O	O
chlorpromazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
extrapyramidal	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
Chinese	ADJ	O	O
schizophrenic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Extrapyramidal	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
EPS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
most	ADV	O	O
commonly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
typical	ADJ	O	O
antipsychotic	ADJ	O	O
drugs	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
affinity	NOUN	O	O
with	ADP	O	O
the	DET	O	O
D2	PROPN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
many	ADJ	O	O
research	NOUN	O	O
groups	NOUN	O	O
have	VERB	O	O
reported	VERB	O	O
on	ADP	O	O
the	DET	O	O
positive	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
genetic	ADJ	O	O
variations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DRD2	PROPN	O	O
gene	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
therapeutic	ADJ	O	O
response	NOUN	O	O
in	ADP	O	O
schizophrenia	NOUN	O	I-Entity
patients	NOUN	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
variations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
receptor	NOUN	O	O
in	ADP	O	O
modulating	VERB	O	O
receptor	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
DRD2	PROPN	O	O
plays	VERB	O	O
in	ADP	O	O
chlorpromazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
EPS	PROPN	O	I-Entity
in	ADP	O	O
schizophrenic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
identified	VERB	O	O
seven	NUM	O	O
SNP(single	PROPN	O	O
nucleotide	NOUN	O	O
polymorphism	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
-141Cins	NOUN	O	O
>	PART	O	O
del	NOUN	O	O
,	PUNCT	O	O
TaqIB	PROPN	O	O
,	PUNCT	O	O
TaqID	PROPN	O	O
,	PUNCT	O	O
Ser311Cys	PROPN	O	O
,	PUNCT	O	O
rs6275	NOUN	O	O
,	PUNCT	O	O
rs6277	NOUN	O	O
and	CCONJ	O	O
TaqIA	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
DRD2	PROPN	O	O
gene	NOUN	O	O
in	ADP	O	O
146	NUM	O	O
schizophrenic	ADJ	O	I-Entity
inpatients	NOUN	O	O
(	PUNCT	O	O
59	NUM	O	O
with	ADP	O	O
EPS	PROPN	O	I-Entity
and	CCONJ	O	O
87	NUM	O	O
without	ADP	O	O
EPS	PROPN	O	I-Entity
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Simpson	PROPN	O	O
-	PUNCT	O	O
Angus	PROPN	O	O
Scale	PROPN	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
chlorpromazine	NOUN	O	I-Entity
after	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
results	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
lend	VERB	O	O
strong	ADJ	O	O
support	NOUN	O	O
to	ADP	O	O
the	DET	O	O
view	NOUN	O	O
that	ADP	O	O
the	DET	O	O
genetic	ADJ	O	O
variation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DRD2	PROPN	O	O
gene	NOUN	O	O
plays	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
individually	ADV	O	O
variable	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
chlorpromazine	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
in	ADP	O	O
Chinese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
confirmed	VERB	O	O
a	DET	O	O
previous	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
DRD2	PROPN	O	O
and	CCONJ	O	O
EPS	PROPN	O	I-Entity
in	ADP	O	O
Caucasians	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (16876986)

Physical	ADJ	O	O
training	NOUN	O	O
decreases	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
subsequent	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Regular	ADJ	O	O
motor	NOUN	O	O
activity	NOUN	O	O
has	VERB	O	O
many	ADJ	O	O
benefits	NOUN	O	O
for	ADP	O	O
mental	ADJ	O	O
and	CCONJ	O	O
physical	ADJ	O	O
condition	NOUN	O	O
but	CCONJ	O	O
its	ADJ	O	O
implications	NOUN	O	O
for	ADP	O	O
epilepsy	NOUN	O	I-Entity
are	VERB	O	O
still	ADV	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
elucidate	VERB	O	O
this	DET	O	O
problem	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
studied	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
physical	ADJ	O	O
activity	NOUN	O	O
on	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
subsequent	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Thereafter	ADV	O	O
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
injections	NOUN	O	O
in	ADP	O	O
trained	VERB	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
trained	VERB	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
measured	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
latency	NOUN	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
motor	NOUN	O	O
sign	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
when	ADV	O	O
it	PRON	O	O
occurred	VERB	O	O
within	ADP	O	O
the	DET	O	O
6-h	NUM	O	O
observation	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
when	ADV	O	O
the	DET	O	O
acute	ADJ	O	O
period	NOUN	O	O
ended	VERB	O	O
.	PUNCT	O	O

All	ADJ	O	O
these	DET	O	O
behavioral	ADJ	O	O
parameters	NOUN	O	O
showed	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
changes	NOUN	O	O
suggesting	VERB	O	O
that	ADP	O	O
regular	ADJ	O	O
physical	ADJ	O	O
exercises	NOUN	O	O
decrease	VERB	O	O
susceptibility	NOUN	O	O
to	PART	O	O
subsequently	ADV	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
ameliorate	VERB	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
experimentally	ADV	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16880771)

Tonic	ADJ	O	O
dopaminergic	ADJ	O	O
stimulation	NOUN	O	O
impairs	ADP	O	B-Entity
associative	ADJ	O	I-Entity
learning	NOUN	O	I-Entity
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Endogenous	PROPN	O	O
dopamine	NOUN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
central	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
salience	NOUN	O	O
coding	NOUN	O	O
during	ADP	O	O
associative	ADJ	O	O
learning	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
precursor	NOUN	O	O
levodopa	NOUN	O	I-Entity
enhances	VERB	O	O
learning	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
levodopa	NOUN	O	I-Entity
increases	VERB	O	O
both	DET	O	O
phasic	NOUN	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
dopaminergic	ADJ	O	O
neurotransmission	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
critical	ADJ	O	O
mechanism	NOUN	O	O
mediating	VERB	O	O
the	DET	O	O
enhancement	NOUN	O	O
of	ADP	O	O
learning	NOUN	O	O
is	VERB	O	O
unresolved	ADJ	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
received	VERB	O	O
the	DET	O	O
tonically	ADV	O	O
stimulating	VERB	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
pergolide	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
vs	ADP	O	O
placebo	NOUN	O	O
120	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
training	VERB	O	O
on	ADP	O	O
each	DET	O	O
training	NOUN	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
significantly	ADV	O	O
impaired	VERB	O	B-Entity
novel	ADJ	O	I-Entity
word	NOUN	O	I-Entity
learning	VERB	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
also	ADV	O	O
showed	VERB	O	O
restricted	VERB	O	O
emotional	ADJ	O	O
responses	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
PLACEBO	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
'	PUNCT	O	O
flattened	VERB	O	O
'	PUNCT	O	O
affect	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
learning	VERB	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
tonic	ADJ	O	O
occupation	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
impairs	ADP	O	O
learning	NOUN	O	O
by	ADP	O	O
competition	NOUN	O	O
with	ADP	O	O
phasic	ADJ	O	O
dopamine	NOUN	O	I-Entity
signals	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
phasic	NOUN	O	O
signaling	VERB	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
critical	ADJ	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
dopamine	NOUN	O	I-Entity
enhances	VERB	O	O
associative	ADJ	O	O
learning	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16906379)

Minocycline	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
fulfilling	VERB	O	O
the	DET	O	O
criteria	NOUN	O	O
of	ADP	O	O
polyarteritis	NOUN	O	B-Entity
nodosa	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
minocycline	NOUN	O	I-Entity
for	ADP	O	O
palmoplantar	NOUN	O	B-Entity
pustulosis	NOUN	O	I-Entity
developed	VERB	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
myalgias	NOUN	O	I-Entity
,	PUNCT	O	O
polyneuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
testicular	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
elevated	VERB	O	O
C	PROPN	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
CRP	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
manifestations	NOUN	O	O
met	VERB	O	O
the	DET	O	O
American	PROPN	O	O
College	PROPN	O	O
of	ADP	O	O
Rheumatology	PROPN	O	O
1990	NUM	O	O
criteria	NOUN	O	O
for	ADP	O	O
the	DET	O	O
classification	NOUN	O	O
of	ADP	O	O
polyarteritis	NOUN	O	B-Entity
nodosa	NOUN	O	I-Entity
.	PUNCT	O	O

Stopping	VERB	O	O
minocycline	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
amelioration	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
normalization	NOUN	O	O
of	ADP	O	O
CRP	PROPN	O	O
level	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
minocycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
satisfying	VERB	O	O
the	DET	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

Differential	ADJ	O	O
diagnosis	NOUN	O	O
for	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
disease	NOUN	O	O
is	VERB	O	O
invaluable	ADJ	O	O
even	ADV	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
classical	ADJ	O	O
polyarteritis	NOUN	O	B-Entity
nodosa	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16911931)

Intramuscular	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
lamivudine	NOUN	O	I-Entity
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
recurrence	NOUN	O	O
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Combined	VERB	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
(	PUNCT	O	O
HBIg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lamivudine	NOUN	O	I-Entity
in	ADP	O	O
prophylaxis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
has	VERB	O	O
significantly	ADV	O	O
improved	VERB	O	O
the	DET	O	O
survival	NOUN	O	O
of	ADP	O	O
HBsAg	PROPN	O	I-Entity
positive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
outcomes	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
retrospective	ADJ	O	O
chart	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
organ	ADJ	O	O
transplant	NOUN	O	O
database	NOUN	O	O
identified	VERB	O	O
51	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
43	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
8	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
transplanted	VERB	O	O
for	ADP	O	O
benign	ADJ	O	O
HBV	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
cirrhotic	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
between	ADP	O	O
June	PROPN	O	O
2002	NUM	O	O
and	CCONJ	O	O
December	PROPN	O	O
2004	NUM	O	O
who	NOUN	O	O
had	VERB	O	O
survived	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
daily	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	NUM	O	O
lamivudine	NOUN	O	I-Entity
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
transplantation	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
enabled	VERB	O	O
57.1%	NUM	O	O
(	PUNCT	O	O
4/7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
62.5%	NUM	O	O
(	PUNCT	O	O
5/8	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
HBV	PROPN	O	O
-	PUNCT	O	O
DNA	PROPN	O	O
and	CCONJ	O	O
HBeAg	PROPN	O	I-Entity
positive	ADJ	O	O
patients	NOUN	O	O
respectively	ADV	O	O
to	PART	O	O
convert	VERB	O	O
to	PART	O	O
be	VERB	O	O
negative	ADJ	O	O
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
intramuscular	ADJ	O	O
HBIg	NOUN	O	O
can	VERB	O	O
effectively	ADV	O	O
prevent	VERB	O	O
allograft	NOUN	O	O
from	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16920333)

Anticonvulsant	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
eslicarbazepine	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
BIA	PROPN	O	B-Entity
2	NUM	O	I-Entity
-	SYM	O	I-Entity
093	NUM	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
microperfusion	NOUN	O	O
of	ADP	O	O
picrotoxin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
of	ADP	O	O
freely	ADV	O	O
moving	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Eslicarbazepine	PROPN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
BIA	PROPN	O	B-Entity
2	NUM	O	I-Entity
-	SYM	O	I-Entity
093	NUM	O	I-Entity
,	PUNCT	O	O
S-(-)-10-acetoxy-10,11-dihydro-5H	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dibenzo	PROPN	O	I-Entity
/	PUNCT	O	I-Entity
b	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
f	PROPN	O	I-Entity
/	SYM	O	I-Entity
azepine-5-carboxamide	ADV	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
now	ADV	O	O
in	ADP	O	O
Phase	PROPN	O	O
III	NUM	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
designed	VERB	O	O
with	ADP	O	O
the	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
improving	VERB	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
structurally	ADV	O	O
related	VERB	O	O
drugs	NOUN	O	O
carbamazepine	NOUN	O	I-Entity
(	PUNCT	O	O
CBZ	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
oxcarbazepine	NOUN	O	I-Entity
(	PUNCT	O	O
OXC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
eslicarbazepine	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
whole	ADJ	O	O
-	PUNCT	O	O
animal	NOUN	O	O
model	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
partial	ADJ	O	O
seizures	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
elicited	VERB	O	O
repeatedly	ADV	O	O
on	ADP	O	O
different	ADJ	O	O
days	NOUN	O	O
without	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
threshold	NOUN	O	O
or	CCONJ	O	O
seizure	NOUN	O	I-Entity
patterns	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
threshold	NOUN	O	O
doses	NOUN	O	O
of	ADP	O	O
picrotoxin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
average	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
was	VERB	O	O
2.3+/-1.2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
average	ADJ	O	O
seizure	NOUN	O	I-Entity
duration	NOUN	O	O
was	VERB	O	O
39.5+/-8.4s	NUM	O	O
.	PUNCT	O	O

Pre	PROPN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
2h	NUM	O	O
before	ADP	O	O
picrotoxin	NOUN	O	I-Entity
microperfusion	NOUN	O	O
prevented	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
75%	NUM	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Lower	ADJ	O	O
doses	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
10mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
suppress	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
10mg	PROPN	O	O
/	SYM	O	O

kg	INTJ	O	O
,	PUNCT	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
seizures	NOUN	O	I-Entity
duration	NOUN	O	O
(	PUNCT	O	O
24.3+/-6.8s	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
number	NOUN	O	O
(	PUNCT	O	O
1.6+/-0.34	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
eslicarbazepine	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
behavioral	ADJ	O	O
/	SYM	O	O
EEG	PROPN	O	O
patterns	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
including	VERB	O	O
sleep	NOUN	O	O
/	SYM	O	O
wakefulness	NOUN	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17028363)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
prolonged	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
slimming	VERB	O	O
pills	NOUN	O	O
containing	VERB	O	O
anthraquinones	NOUN	O	I-Entity
.	PUNCT	O	O

Chinese	ADJ	O	B-Entity
herbal	ADJ	O	I-Entity
medicine	NOUN	O	O
preparations	NOUN	O	O
are	VERB	O	O
widely	ADV	O	O
available	ADJ	O	O
and	CCONJ	O	O
often	ADV	O	O
regarded	VERB	O	O
by	ADP	O	O
the	DET	O	O
public	NOUN	O	O
as	ADP	O	O
natural	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
remedies	NOUN	O	O
for	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
medical	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Nephropathy	PROPN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
Chinese	ADJ	O	B-Entity
herbs	NOUN	O	I-Entity
has	VERB	O	O
previously	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
usually	ADV	O	O
involving	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
aristolochic	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
23-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
prolonged	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
proprietary	ADJ	O	O
Chinese	ADJ	O	B-Entity
herbal	ADJ	O	I-Entity
slimming	NOUN	O	O
pill	NOUN	O	O
that	ADJ	O	O
contained	VERB	O	O
anthraquinone	NOUN	O	I-Entity
derivatives	NOUN	O	O
,	PUNCT	O	O
extracted	VERB	O	O
from	ADP	O	O
Rhizoma	PROPN	O	O
Rhei	PROPN	O	O
(	PUNCT	O	O
rhubarb	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
probably	ADV	O	O
aggravated	VERB	O	O
by	ADP	O	O
the	DET	O	O
concomitant	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
diclofenac	NOUN	O	I-Entity
.	PUNCT	O	O

Renal	ADJ	O	O
pathology	NOUN	O	O
was	VERB	O	O
that	ADP	O	O
of	ADP	O	O
hypocellular	ADJ	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Spontaneous	ADJ	O	O
renal	NOUN	O	O
recovery	NOUN	O	O
occurred	VERB	O	O
upon	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
slimming	NOUN	O	O
pills	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
mild	ADJ	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
and	CCONJ	O	O
tubular	NOUN	O	O
atrophy	NOUN	O	I-Entity
was	VERB	O	O
still	ADV	O	O
evident	ADJ	O	O
histologically	ADV	O	O
4	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Although	ADP	O	O
a	DET	O	O
causal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
anthraquinone	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
herbal	ADJ	O	O
agent	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
proven	VERB	O	O
,	PUNCT	O	O
phytotherapy	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
interstitial	ADJ	O	O
nephropathy	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
present	VERB	O	O
with	ADP	O	O
unexplained	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17035713)

Chloroacetaldehyde	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
sulfhydryl	NOUN	O	I-Entity
reagent	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
critical	ADJ	O	O
thiol	NOUN	O	I-Entity
groups	NOUN	O	O
in	ADP	O	O
ifosfamide	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Chloroacetaldehyde	PROPN	O	I-Entity
(	PUNCT	O	O
CAA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
metabolite	NOUN	O	O
of	ADP	O	O
the	DET	O	O
alkylating	VERB	O	O
agent	NOUN	O	O
ifosfamide	NOUN	O	I-Entity
(	PUNCT	O	O
IFO	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
putatively	ADV	O	O
responsible	ADJ	O	O
for	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
following	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
tumor	NOUN	O	I-Entity
therapy	NOUN	O	O
with	ADP	O	O
IFO	PROPN	O	I-Entity
.	PUNCT	O	O

Depletion	NOUN	O	O
of	ADP	O	O
sulfhydryl	NOUN	O	I-Entity
(	PUNCT	O	O
SH	PROPN	O	I-Entity
)	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
work	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
CAA	PROPN	O	I-Entity
on	ADP	O	O
human	ADJ	O	O
proximal	NOUN	O	O
tubule	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
culture	NOUN	O	O
(	PUNCT	O	O
hRPTEC	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	I-Entity
of	ADP	O	O
CAA	PROPN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
protein	NOUN	O	O
content	NOUN	O	O
,	PUNCT	O	O
cell	NOUN	O	O
number	NOUN	O	O
,	PUNCT	O	O
LDH	PROPN	O	O
release	NOUN	O	O
,	PUNCT	O	O
trypan	ADJ	O	B-Entity
blue	ADJ	O	I-Entity
exclusion	NOUN	O	O
assay	NOUN	O	O
and	CCONJ	O	O
caspase-3	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Free	ADJ	O	O
thiols	NOUN	O	I-Entity
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
method	NOUN	O	O
of	ADP	O	O
Ellman	PROPN	O	O
.	PUNCT	O	O

CAA	PROPN	O	I-Entity
reduced	VERB	O	O
hRPTEC	NOUN	O	O
cell	NOUN	O	O
number	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
induced	VERB	O	O
a	DET	O	O
loss	NOUN	O	O
in	ADP	O	O
free	ADJ	O	O
intracellular	ADJ	O	O
thiols	NOUN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
necrosis	NOUN	O	I-Entity
markers	NOUN	O	O
.	PUNCT	O	O

CAA	PROPN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
acrolein	ADV	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
cysteine	NOUN	O	I-Entity

B.	PROPN	O	O
Caspase	PROPN	O	O
activation	NOUN	O	O
by	ADP	O	O
cisplatin	NOUN	O	I-Entity
was	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
CAA	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
cells	NOUN	O	O
stained	VERB	O	O
with	ADP	O	O
fluorescent	NOUN	O	O
dyes	NOUN	O	O
targeting	VERB	O	O
lysosomes	NOUN	O	O
,	PUNCT	O	O
CAA	PROPN	O	I-Entity
induced	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
lysosomal	ADJ	O	O
size	NOUN	O	O
and	CCONJ	O	O
lysosomal	ADJ	O	O
leakage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
CAA	PROPN	O	I-Entity
on	ADP	O	O
cysteine	NOUN	O	I-Entity
protease	NOUN	O	O
activities	NOUN	O	O
and	CCONJ	O	O
thiols	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
reproduced	VERB	O	O
in	ADP	O	O
cell	NOUN	O	O
lysate	NOUN	O	O
.	PUNCT	O	O

Acidification	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
slowed	VERB	O	O
the	DET	O	O
reaction	NOUN	O	O
of	ADP	O	O
CAA	PROPN	O	I-Entity
with	ADP	O	O
thiol	NOUN	O	I-Entity
donors	NOUN	O	O
,	PUNCT	O	O
could	VERB	O	O
also	ADV	O	O
attenuate	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
CAA	PROPN	O	I-Entity
on	ADP	O	O
necrosis	NOUN	O	I-Entity
markers	NOUN	O	O
,	PUNCT	O	O
thiol	NOUN	O	I-Entity
depletion	NOUN	O	O
and	CCONJ	O	O
cysteine	NOUN	O	I-Entity
protease	NOUN	O	O
inhibition	NOUN	O	O
in	ADP	O	O
living	VERB	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
CAA	PROPN	O	I-Entity
directly	ADV	O	O
reacts	VERB	O	O
with	ADP	O	O
cellular	ADJ	O	O
protein	NOUN	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
protein	NOUN	O	O
thiols	NOUN	O	I-Entity
,	PUNCT	O	O
mediating	VERB	O	O
its	ADJ	O	O
toxicity	NOUN	O	I-Entity
on	ADP	O	O
hRPTEC	PROPN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
acidification	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
an	DET	O	O
option	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
IFO	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17042797)

Stereological	ADJ	O	O
methods	NOUN	O	O
reveal	VERB	O	O
the	DET	O	O
robust	ADJ	O	O
size	NOUN	O	O
and	CCONJ	O	O
stability	NOUN	O	O
of	ADP	O	O
ectopic	NOUN	O	O
hilar	ADJ	O	O
granule	NOUN	O	O
cells	NOUN	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
dentate	ADJ	O	O
granule	NOUN	O	O
cell	NOUN	O	O
neurogenesis	NOUN	O	O
increases	VERB	O	O
greatly	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
many	ADJ	O	O
of	ADP	O	O
the	DET	O	O
new	ADJ	O	O
neurons	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
develop	VERB	O	O
ectopically	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hilar	ADJ	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
formation	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
ectopic	NOUN	O	O
hilar	ADJ	O	O
granule	NOUN	O	O
cells	NOUN	O	O
could	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
spontaneous	ADJ	O	O
seizures	NOUN	O	I-Entity
that	ADJ	O	O
ultimately	ADV	O	O
develop	VERB	O	O
after	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
quantify	VERB	O	O
this	DET	O	O
population	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
ectopic	NOUN	O	O
hilar	ADJ	O	O
granule	NOUN	O	O
cells	NOUN	O	O
was	VERB	O	O
estimated	VERB	O	O
using	VERB	O	O
unbiased	ADJ	O	O
stereology	NOUN	O	O
at	ADP	O	O
different	ADJ	O	O
times	NOUN	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hilar	ADJ	O	O
ectopic	NOUN	O	O
granule	NOUN	O	O
cell	NOUN	O	O
population	NOUN	O	O
after	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
is	VERB	O	O
substantial	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
stable	ADJ	O	O
over	ADP	O	O
time	NOUN	O	O
.	PUNCT	O	O

Interestingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
population	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
behavioral	ADJ	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
more	ADJ	O	O
ectopic	ADJ	O	O
granule	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hilus	NOUN	O	O
have	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
behavioral	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
new	ADJ	O	O
insight	NOUN	O	O
into	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
ectopic	ADJ	O	O
hilar	ADJ	O	O
granule	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17069550)

A	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
galantamine	NOUN	O	I-Entity
in	ADP	O	O
autistic	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Post	PROPN	O	O
-	PUNCT	O	O
mortem	PROPN	O	O
studies	NOUN	O	O
have	VERB	O	O
reported	VERB	O	O
abnormalities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cholinergic	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
galantamine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
acetylcholinesterase	NOUN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
nicotinic	ADJ	O	O
receptor	NOUN	O	O
modulator	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
interfering	VERB	O	O
behaviors	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	I-Entity
.	PUNCT	O	O

Thirteen	NUM	O	O
medication	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
8.8	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

3.5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
participated	VERB	O	O
in	ADP	O	O
a	DET	O	O
12-week	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
galantamine	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
parent	NOUN	O	O
-	PUNCT	O	O
rated	VERB	O	O
irritability	NOUN	O	I-Entity
and	CCONJ	O	O
social	ADJ	O	O
withdrawal	NOUN	O	O
on	ADP	O	O
the	DET	O	O
ABC	PROPN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
emotional	ADJ	O	O
lability	NOUN	O	O
and	CCONJ	O	O
inattention	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Conners	PROPN	O	O
'	PART	O	O
Parent	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
--	PUNCT	O	O
Revised	VERB	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
galantamine	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
apart	ADV	O	O
from	ADP	O	O
headaches	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
open	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
galantamine	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
beneficial	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
interfering	VERB	O	O
behaviors	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
aggression	NOUN	O	I-Entity
,	PUNCT	O	O
behavioral	ADJ	O	B-Entity
dyscontrol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
inattention	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17151160)

Randomized	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
olanzapine	NOUN	O	I-Entity
versus	ADP	O	O
risperidone	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
episode	NOUN	O	O
schizophrenia	NOUN	O	I-Entity
:	PUNCT	O	O
4-month	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
authors	NOUN	O	O
compared	VERB	O	O
4-month	ADJ	O	O
treatment	NOUN	O	O
outcomes	NOUN	O	O
for	ADP	O	O
olanzapine	NOUN	O	I-Entity
versus	ADP	O	O
risperidone	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
episode	NOUN	O	O
schizophrenia	NOUN	O	I-Entity
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
twelve	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
70%	NUM	O	O
male	ADJ	O	O
;	PUNCT	O	O
mean	ADJ	O	O
age=23.3	ADJ	O	O
years	NOUN	O	O
[	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
5.1	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
episode	NOUN	O	O
schizophrenia	NOUN	O	I-Entity
(	PUNCT	O	O
75%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
schizophreniform	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
17%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
schizoaffective	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
8%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
6	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Response	NOUN	O	O
rates	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
olanzapine	NOUN	O	I-Entity
(	PUNCT	O	O
43.7%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI=28.8%-58.6%	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
54.3%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI=39.9%-68.7%	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
those	DET	O	O
responding	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
more	ADJ	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
olanzapine	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
40.9%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI=16.8%-65.0%	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
risperidone	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
18.9%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI=0%-39.2%	PROPN	O	O
)	PUNCT	O	O
had	VERB	O	O
subsequent	ADJ	O	O
ratings	NOUN	O	O
not	ADV	O	O
meeting	VERB	O	O
response	NOUN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

Negative	ADJ	O	O
symptom	NOUN	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
measures	NOUN	O	O
of	ADP	O	O
parkinsonism	NOUN	O	I-Entity
and	CCONJ	O	O
akathisia	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
medications	NOUN	O	O
.	PUNCT	O	O

Extrapyramidal	ADJ	O	B-Entity
symptom	NOUN	O	I-Entity
severity	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
1.4	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=1.2	NUM	O	O
-	PUNCT	O	O
1.6	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
1.2	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=1.0	NUM	O	O
-	PUNCT	O	O
1.4	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
.	PUNCT	O	O

Significantly	ADV	O	O
more	ADJ	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
occurred	VERB	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
weight	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
weight	NOUN	O	O
was	VERB	O	O
17.3%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=14.2%-20.5%	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
and	CCONJ	O	O
11.3%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=8.4%-14.3%	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

Body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
24.3	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=22.8	NUM	O	O
-	PUNCT	O	O
25.7	NUM	O	O
)	PUNCT	O	O
versus	ADP	O	O
28.2	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=26.7	NUM	O	O
-	PUNCT	O	O
29.7	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
and	CCONJ	O	O
23.9	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=22.5	NUM	O	O
-	PUNCT	O	O
25.3	NUM	O	O
)	PUNCT	O	O
versus	ADP	O	O
26.7	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI=25.2	NUM	O	O
-	PUNCT	O	O
28.2	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Clinical	ADJ	O	O
outcomes	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
were	VERB	O	O
equal	ADJ	O	O
to	ADP	O	O
those	DET	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
response	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
stable	ADJ	O	O
.	PUNCT	O	O

Olanzapine	PROPN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
an	DET	O	O
advantage	NOUN	O	O
for	ADP	O	O
motor	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
medications	NOUN	O	O
caused	VERB	O	O
substantial	ADJ	O	O
rapid	ADJ	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
was	VERB	O	O
greater	ADJ	O	O
with	ADP	O	O
olanzapine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17159032)

Early	ADV	O	O
paracentral	ADJ	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
hydroxychloroquine	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
review	VERB	O	O
the	DET	O	O
natural	ADJ	O	O
history	NOUN	O	O
and	CCONJ	O	O
ocular	ADJ	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
hydroxychloroquine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
who	NOUN	O	O
attended	VERB	O	O
an	DET	O	O
ophthalmic	ADJ	O	O
screening	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Records	NOUN	O	O
of	ADP	O	O
262	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
taking	VERB	O	O
hydroxychloroquine	NOUN	O	I-Entity
and	CCONJ	O	O
screened	VERB	O	O
in	ADP	O	O
the	DET	O	O
Department	PROPN	O	O
of	ADP	O	O
Ophthalmology	PROPN	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
13.4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
hydroxychloroquine	VERB	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
1.5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
used	VERB	O	O
a	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
and	CCONJ	O	O
color	NOUN	O	O
vision	NOUN	O	O
assessment	NOUN	O	O
,	PUNCT	O	O
funduscopy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Humphrey	PROPN	O	O
10	NUM	O	O
-	SYM	O	O
2	NUM	O	O
visual	ADJ	O	O
field	NOUN	O	O
testing	NOUN	O	O
and	CCONJ	O	O
shows	VERB	O	O
that	ADP	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
appeared	VERB	O	O
before	ADP	O	O
any	DET	O	O
corresponding	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
any	DET	O	O
other	ADJ	O	O
tested	VERB	O	O
clinical	ADJ	O	O
parameters	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
defects	NOUN	O	O
were	VERB	O	O
reproducible	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
test	NOUN	O	O
parameters	NOUN	O	O
were	VERB	O	O
reliable	ADJ	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
taking	VERB	O	O
hydroxychloroquine	NOUN	O	I-Entity
can	VERB	O	O
demonstrate	VERB	O	O
a	DET	O	O
toxic	ADJ	O	O
reaction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
retina	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
known	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17223814)

Peri	PROPN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
atrioventricular	ADJ	O	B-Entity
block	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
epirubicin	NOUN	O	I-Entity
and	CCONJ	O	O
paclitaxel	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
for	ADP	O	O
mastectomy	NOUN	O	O
and	CCONJ	O	O
immediate	ADJ	O	O
latissimus	NOUN	O	O
dorsi	NOUN	O	O
flap	NOUN	O	O
reconstruction	NOUN	O	O
having	VERB	O	O
been	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
breast	NOUN	O	I-Entity
6	NUM	O	O
months	NOUN	O	O
previously	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
preceding	ADJ	O	O
months	NOUN	O	O
she	PRON	O	O
had	VERB	O	O
received	VERB	O	O
neo	ADV	O	O
-	PUNCT	O	O
adjuvant	ADJ	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
epirubicin	NOUN	O	I-Entity
,	PUNCT	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
bradycardic	ADJ	O	I-Entity
at	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
assessment	NOUN	O	O
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
cardiac	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Second	ADJ	O	O
degree	NOUN	O	O
Mobitz	PROPN	O	O
type	NOUN	O	O
II	PROPN	O	O
atrioventricular	NOUN	O	B-Entity
block	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
on	ADP	O	O
electrocardiogram	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
temporary	ADJ	O	O
transvenous	ADJ	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
instituted	VERB	O	O
in	ADP	O	O
the	DET	O	O
peri	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
discuss	VERB	O	O
how	ADV	O	O
evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
guidelines	NOUN	O	O
would	VERB	O	O
not	ADV	O	O
have	VERB	O	O
been	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
this	DET	O	O
case	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
how	ADV	O	O
chemotherapy	NOUN	O	O
can	VERB	O	O
exhibit	VERB	O	O
substantial	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
develop	VERB	O	O
over	ADP	O	O
many	ADJ	O	O
years	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17255138)

Risks	NOUN	O	O
and	CCONJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
COX-2	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
vs	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
NSAIDs	NOUN	O	O
:	PUNCT	O	O
does	VERB	O	O
their	ADJ	O	O
cardiovascular	NOUN	O	O
risk	NOUN	O	O
exceed	VERB	O	O
their	ADJ	O	O
gastrointestinal	ADJ	O	O
benefit	NOUN	O	O
?	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
AMI	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
COX-2	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
may	VERB	O	O
offset	VERB	O	O
their	ADJ	O	O
gastrointestinal	ADJ	O	O
(	PUNCT	O	O
GI	PROPN	O	O
)	PUNCT	O	O
benefit	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
(	PUNCT	O	O
NS	PROPN	O	O
)	PUNCT	O	O

non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
steroidal	ADJ	O	I-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
inflammatory	ADJ	O	I-Entity
drugs	NOUN	O	I-Entity
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
risks	NOUN	O	O
of	ADP	O	O
hospitalization	NOUN	O	O
for	ADP	O	O
AMI	PROPN	O	I-Entity
and	CCONJ	O	O
GI	PROPN	O	B-Entity
bleeding	VERB	O	I-Entity
among	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
using	VERB	O	O
COX-2	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
,	PUNCT	O	O
NS	PROPN	O	O
-	PUNCT	O	O
NSAIDs	PROPN	O	O
and	CCONJ	O	O
acetaminophen	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
retrospective	ADJ	O	O
cohort	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
administrative	ADJ	O	O
data	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
>	PART	O	O
or	CCONJ	O	O
=	SYM	O	O
65	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
who	NOUN	O	O
filled	VERB	O	O
a	DET	O	O
prescription	NOUN	O	O
for	ADP	O	O
NSAID	PROPN	O	O
or	CCONJ	O	O
acetaminophen	NOUN	O	I-Entity
during	ADP	O	O
1999	NUM	O	O
-	SYM	O	O
2002	NUM	O	O
.	PUNCT	O	O

Person	NOUN	O	O
-	PUNCT	O	O
years	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
among	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
were	VERB	O	O
:	PUNCT	O	O
75,761	NUM	O	O
to	ADP	O	O
acetaminophen	NOUN	O	I-Entity
,	PUNCT	O	O
42,671	NUM	O	O
to	PART	O	O
rofecoxib	VERB	O	I-Entity
65,860	NUM	O	O
to	PART	O	O
celecoxib	VERB	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
37,495	NUM	O	O
to	ADP	O	O
NS	PROPN	O	O
-	PUNCT	O	O
NSAIDs	PROPN	O	O
.	PUNCT	O	O

Among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
they	PRON	O	O
were	VERB	O	O
:	PUNCT	O	O
14,671	NUM	O	O
to	PART	O	O
rofecoxib	VERB	O	I-Entity
,	PUNCT	O	O
22,875	NUM	O	O
to	PART	O	O
celecoxib	VERB	O	I-Entity
,	PUNCT	O	O
9,832	NUM	O	O
to	PART	O	O
NS	PROPN	O	O
-	PUNCT	O	O
NSAIDs	PROPN	O	O
and	CCONJ	O	O
38,048	NUM	O	O
to	ADP	O	O
acetaminophen	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
adjusted	ADJ	O	O
hazard	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
hospitalization	NOUN	O	O
for	ADP	O	O
AMI	PROPN	O	I-Entity
/	SYM	O	O
GI	PROPN	O	O
vs	ADP	O	O
the	DET	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
aspirin	NOUN	O	I-Entity
)	PUNCT	O	O

group	NOUN	O	O
were	VERB	O	O
:	PUNCT	O	O
rofecoxib	NOUN	O	I-Entity
1.27	NUM	O	O
(	PUNCT	O	O
1.13	NUM	O	O
,	PUNCT	O	O
1.42	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
celecoxib	NOUN	O	I-Entity
0.93	NUM	O	O
(	PUNCT	O	O
0.83	NUM	O	O
,	PUNCT	O	O
1.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
naproxen	NOUN	O	I-Entity
1.59	NUM	O	O
(	PUNCT	O	O
1.31	NUM	O	O
,	PUNCT	O	O
1.93	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diclofenac	NOUN	O	I-Entity
1.17	NUM	O	O
(	PUNCT	O	O
0.99	NUM	O	O
,	PUNCT	O	O
1.38	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ibuprofen	NOUN	O	I-Entity
1.05	NUM	O	O
(	PUNCT	O	O
0.74	NUM	O	O
,	PUNCT	O	O
1.51	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
they	PRON	O	O
were	VERB	O	O
:	PUNCT	O	O
rofecoxib	NOUN	O	I-Entity
1.73	NUM	O	O
(	PUNCT	O	O
1.52	NUM	O	O
,	PUNCT	O	O
1.98	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
celecoxib	NOUN	O	I-Entity
1.34	NUM	O	O
(	PUNCT	O	O
1.19	NUM	O	O
,	PUNCT	O	O
1.52	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ibuprofen	NOUN	O	I-Entity
1.51	NUM	O	O
(	PUNCT	O	O
0.95	NUM	O	O
,	PUNCT	O	O
2.41	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diclofenac	NOUN	O	I-Entity
1.69	NUM	O	O
(	PUNCT	O	O
1.35	NUM	O	O
,	PUNCT	O	O
2.10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
naproxen	NOUN	O	I-Entity
1.35	NUM	O	O
(	PUNCT	O	O
0.97	NUM	O	O
,	PUNCT	O	O
1.88	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
acetaminophen	NOUN	O	I-Entity
1.29	NUM	O	O
(	PUNCT	O	O
1.17	NUM	O	O
,	PUNCT	O	O
1.42	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
naproxen	NOUN	O	I-Entity
seemed	VERB	O	O
to	PART	O	O
carry	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
AMI	PROPN	O	I-Entity
/	SYM	O	O
GI	PROPN	O	B-Entity
bleeding	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
AMI	PROPN	O	I-Entity
/	SYM	O	O
GI	PROPN	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
celecoxib	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
and	CCONJ	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
better	ADJ	O	O
than	ADP	O	O
those	DET	O	O
of	ADP	O	O
rofecoxib	NOUN	O	I-Entity
and	CCONJ	O	O
NS	PROPN	O	O
-	PUNCT	O	O
NSAIDs	PROPN	O	O
.	PUNCT	O	O

Among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
both	CCONJ	O	O
celecoxib	NOUN	O	I-Entity
and	CCONJ	O	O
naproxen	NOUN	O	I-Entity
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
least	ADJ	O	O
toxic	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (17297207)

Quinine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	B-Entity
malaria	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
reported	VERB	O	O
that	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-Entity
malaria	NOUN	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
jaundice	NOUN	O	I-Entity
who	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
arrhythmia	NOUN	O	I-Entity
(	PUNCT	O	O
premature	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
contraction	NOUN	O	I-Entity
)	PUNCT	O	O
while	ADP	O	O
getting	VERB	O	O
quinine	ADJ	O	I-Entity
infusion	NOUN	O	O
was	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
man	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
,	PUNCT	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
hospital	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
chill	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
,	PUNCT	O	O
jaundice	ADV	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
laboratory	NOUN	O	O
examination	NOUN	O	O
showed	VERB	O	O
Plasmodium	PROPN	O	O
falciparum	NOUN	O	O
(	PUNCT	O	O
+	CCONJ	O	O
+	SYM	O	O
+	SYM	O	O
+	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
bilirubin	NOUN	O	I-Entity
8.25	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
conjugated	VERB	O	O

bilirubin	NOUN	O	I-Entity
4.36	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
unconjugated	VERB	O	O
bilirubin	NOUN	O	I-Entity
3.89	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
potassium	NOUN	O	I-Entity

3.52	NUM	O	O
meq	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
Patient	PROPN	O	O
was	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
severe	ADJ	O	B-Entity
malaria	NOUN	O	I-Entity
with	ADP	O	O
jaundice	NOUN	O	I-Entity
and	CCONJ	O	O
got	VERB	O	O
quinine	ADJ	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
dextrose	NOUN	O	I-Entity
5%	NUM	O	O
500	NUM	O	O
mg/8	ADJ	O	O
hour	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
vomitus	NOUN	O	I-Entity
,	PUNCT	O	O
diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
tinnitus	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
hearing	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
30	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
infusion	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
felt	VERB	O	O
palpitation	NOUN	O	I-Entity
and	CCONJ	O	O
electrocardiography	NOUN	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
recording	NOUN	O	O
showed	VERB	O	O
premature	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
contraction	NOUN	O	I-Entity
(	PUNCT	O	O
PVC	PROPN	O	I-Entity
)	PUNCT	O	O

>	X	O	O
5	NUM	O	O
x	SYM	O	O
/	SYM	O	O
minute	NOUN	O	O
,	PUNCT	O	O
trigemini	NOUN	O	O
,	PUNCT	O	O
constant	ADJ	O	O
type	NOUN	O	O
--	PUNCT	O	O
sinoatrial	ADJ	O	B-Entity
block	NOUN	O	I-Entity
,	PUNCT	O	O
positive	ADJ	O	O
U	PROPN	O	O
wave	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
50	NUM	O	O
mg	NUM	O	O
intravenously	ADV	O	O
followed	VERB	O	O
by	ADP	O	O
infusion	NOUN	O	O
1500	NUM	O	O
mg	NUM	O	O
in	ADP	O	O
dextrose	ADJ	O	I-Entity
5%/24	NUM	O	O
hour	NOUN	O	O
and	CCONJ	O	O
potassium	NOUN	O	B-Entity
aspartate	NOUN	O	I-Entity
tablet	NOUN	O	O
.	PUNCT	O	O

Quinine	PROPN	O	I-Entity
infusion	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
changed	VERB	O	O
with	ADP	O	O
sulfate	NOUN	O	O
quinine	NOUN	O	I-Entity
tablets	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
hours	NOUN	O	O
later	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
felt	VERB	O	O
better	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
PVC	PROPN	O	I-Entity
reduced	VERB	O	O
to	ADP	O	O
4	NUM	O	O
-	SYM	O	O
5	NUM	O	O
x	PROPN	O	O
/	SYM	O	O
minute	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
third	ADJ	O	O
day	NOUN	O	O
ECG	PROPN	O	O
was	VERB	O	O
normal	ADJ	O	O
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
was	VERB	O	O
3.34	NUM	O	O
meq	NOUN	O	O
/	SYM	O	O
L.	PROPN	O	O

Quinine	PROPN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
quinidine	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
chincona	NOUN	O	O
alkaloid	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
arrhythmic	ADJ	O	I-Entity
property	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
also	ADV	O	O
pro	ADV	O	O
-	PUNCT	O	O
arrhythmic	NOUN	O	I-Entity
that	ADJ	O	O
can	VERB	O	O
cause	VERB	O	O
various	ADJ	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
severe	ADJ	O	O
arrhythmia	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
multiple	ADJ	O	O
PVC	PROPN	O	I-Entity
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
parenteral	NOUN	O	O
quinine	NOUN	O	I-Entity
must	VERB	O	O
be	VERB	O	O
done	VERB	O	O
carefully	ADV	O	O
and	CCONJ	O	O
with	ADP	O	O
good	ADJ	O	O
observation	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
pro	ADJ	O	O
-	PUNCT	O	O
arrhythmic	ADJ	O	I-Entity
effect	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
older	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
heart	NOUN	O	B-Entity
diseases	NOUN	O	I-Entity
or	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
electrolyte	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
hypokalemia	NOUN	O	I-Entity
)	PUNCT	O	O
which	ADJ	O	O
frequently	ADV	O	O
occurs	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
vomiting	NOUN	O	I-Entity
and	CCONJ	O	O
or	CCONJ	O	O
diarrhea	NOUN	O	I-Entity
in	ADP	O	O
malaria	NOUN	O	I-Entity
cases	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17346443)

Penicillamine	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
lichenoid	NOUN	O	B-Entity
dermatitis	NOUN	O	I-Entity
and	CCONJ	O	O
utility	NOUN	O	O
of	ADP	O	O
zinc	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
Wilson	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
SPECT	PROPN	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
autosomal	ADJ	O	O
recessive	ADJ	O	O
disorder	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
copper	NOUN	O	I-Entity
metabolism	NOUN	O	O
with	ADP	O	O
consequent	ADJ	O	O
copper	NOUN	O	I-Entity
accumulation	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
many	ADJ	O	O
tissues	NOUN	O	O
and	CCONJ	O	O
consequent	ADJ	O	O
hepatic	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
neurologic	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
psychiatric	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
chronic	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
;	PUNCT	O	O
moreover	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
presenting	VERB	O	O
also	ADV	O	O
with	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
state	NOUN	O	O
anxiety	NOUN	O	I-Entity
without	ADP	O	O
depression	NOUN	O	I-Entity
,	PUNCT	O	O
99mTc	NUM	O	O
-	PUNCT	O	O
ECD	PROPN	O	O
-	PUNCT	O	O
SPECT	PROPN	O	O
showed	VERB	O	O
cortical	ADJ	O	O
hypoperfusion	NOUN	O	O
in	ADP	O	O
frontal	NOUN	O	O
lobes	NOUN	O	O
,	PUNCT	O	O
more	ADJ	O	O
marked	ADJ	O	O
on	ADP	O	O
the	DET	O	O
left	ADJ	O	O
frontal	ADJ	O	O
lobe	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
penicillamine	NOUN	O	I-Entity
was	VERB	O	O
interrupted	VERB	O	O
after	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
lichenoid	NOUN	O	B-Entity
dermatitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
zinc	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
permitted	VERB	O	O
to	PART	O	O
continue	VERB	O	O
the	DET	O	O
successful	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
without	ADP	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
case	NOUN	O	O
the	DET	O	O
therapy	NOUN	O	O
with	ADP	O	O
zinc	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
represented	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
a	DET	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patient	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
appeared	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
the	DET	O	O
zinc	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
allowed	VERB	O	O
us	PRON	O	O
to	PART	O	O
avoid	VERB	O	O
other	ADJ	O	O
potentially	ADV	O	O
toxic	ADJ	O	O
chelating	VERB	O	O
drugs	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
observation	NOUN	O	O
is	VERB	O	O
in	ADP	O	O
line	NOUN	O	O
with	ADP	O	O
the	DET	O	O
growing	VERB	O	O
evidence	NOUN	O	O
on	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
develop	VERB	O	O
this	DET	O	O
skin	NOUN	O	B-Entity
lesion	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
could	VERB	O	O
be	VERB	O	O
conceivable	ADJ	O	O
that	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
genetic	ADJ	O	O
factor	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
drug	NOUN	O	O
response	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
for	ADP	O	O
a	DET	O	O
better	ADJ	O	O
clarification	NOUN	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
particular	ADJ	O	O
to	PART	O	O
differentiate	VERB	O	O
specific	ADJ	O	O
therapies	NOUN	O	O
for	ADP	O	O
different	ADJ	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
phenotypes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17351238)

A	DET	O	O
dramatic	ADJ	O	O
drop	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
following	VERB	O	O
prehospital	ADJ	O	O
GTN	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
male	NOUN	O	O
in	ADP	O	O
his	ADJ	O	O
sixties	NOUN	O	O
with	ADP	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
awoke	VERB	O	O
with	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
following	VERB	O	O
an	DET	O	O
afternoon	NOUN	O	O
sleep	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
observations	NOUN	O	O
were	VERB	O	O
within	ADP	O	O
normal	ADJ	O	O
limits	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
administered	VERB	O	O
oxygen	NOUN	O	I-Entity
via	ADP	O	O
a	DET	O	O
face	NOUN	O	O
mask	NOUN	O	O
and	CCONJ	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
(	PUNCT	O	O
GTN	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Several	ADJ	O	O
minutes	NOUN	O	O
after	ADP	O	O
the	DET	O	O
GTN	PROPN	O	I-Entity
the	DET	O	O
patient	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
sudden	ADJ	O	O
drop	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
was	VERB	O	O
rectified	VERB	O	O
by	ADP	O	O
atropine	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
fluid	ADJ	O	O
challenge	NOUN	O	O
.	PUNCT	O	O

Prehospital	ADJ	O	O
care	NOUN	O	O
providers	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
managing	VERB	O	O
any	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
syncopal	ADJ	O	B-Entity
episode	NOUN	O	I-Entity
that	ADJ	O	O
fails	VERB	O	O
to	PART	O	O
recover	VERB	O	O
within	ADP	O	O
a	DET	O	O
reasonable	ADJ	O	O
time	NOUN	O	O
frame	NOUN	O	O
should	VERB	O	O
consider	VERB	O	O
the	DET	O	O
Bezold	PROPN	O	O
-	PUNCT	O	O
Jarisch	PROPN	O	O
reflex	NOUN	O	O
as	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
and	CCONJ	O	O
manage	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
accordingly	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (17356399)

Acute	PROPN	O	B-Entity
encephalopathy	ADJ	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
after	ADP	O	O
multiagent	NOUN	O	O
chemotherapy	NOUN	O	O
including	VERB	O	O
PEG	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
asparaginase	NOUN	O	I-Entity
and	CCONJ	O	O
intrathecal	ADJ	O	O
cytarabine	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
7-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
with	ADP	O	O
an	DET	O	O
unusual	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
precursor	NOUN	O	O
B	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
ALL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
encephalopathy	NOUN	O	I-Entity
evidenced	VERB	O	O
by	ADP	O	O
behavioral	ADJ	O	O
changes	NOUN	O	O
,	PUNCT	O	O
aphasia	NOUN	O	I-Entity
,	PUNCT	O	O
incontinence	NOUN	O	I-Entity
,	PUNCT	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
right	ADV	O	O
-	PUNCT	O	O
sided	ADJ	O	O
weakness	NOUN	O	I-Entity
with	ADP	O	O
diffuse	NOUN	O	O
cerebral	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
on	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
angiography	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
cytarabine	NOUN	O	I-Entity
.	PUNCT	O	O

Vincristine	PROPN	O	I-Entity
,	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
polyethylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
asparaginase	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
administered	VERB	O	O
before	ADP	O	O
the	DET	O	O
episode	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17379047)

Comparison	NOUN	O	O
of	ADP	O	O
valsartan	NOUN	O	I-Entity
/	SYM	O	O
hydrochlorothiazide	NOUN	O	I-Entity
combination	NOUN	O	O
therapy	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
up	ADP	O	O
to	ADP	O	O
320/25	NUM	O	O
mg	NUM	O	O
versus	ADP	O	O
monotherapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	I-Entity
adults	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
third	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
attain	NOUN	O	O
adequate	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
multidrug	NOUN	O	O
regimens	NOUN	O	O
are	VERB	O	O
often	ADV	O	O
required	VERB	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
lifelong	ADJ	O	O
nature	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
need	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
hypertensive	ADJ	O	I-Entity
therapies	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
valsartan	NOUN	O	I-Entity
(	PUNCT	O	O
VAL	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
hydrochlorothiazide	NOUN	O	I-Entity
(	PUNCT	O	O
HCTZ)-monotherapy	PROPN	O	I-Entity
and	CCONJ	O	O
higher	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
combinations	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
sitting	VERB	O	O
diastolic	ADJ	O	O
BP	PROPN	O	O
[	PUNCT	O	O
MSDBP	PROPN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
>	NOUN	O	O
or	CCONJ	O	O
=	SYM	O	O
95	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
and	CCONJ	O	O
<	SYM	O	O
110	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
1	NUM	O	O
of	ADP	O	O
8	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
VAL	PROPN	O	I-Entity
160	NUM	O	O
or	CCONJ	O	O
320	NUM	O	O
mg	NUM	O	O
;	PUNCT	O	O
HCTZ	PROPN	O	I-Entity
12.5	NUM	O	O
or	CCONJ	O	O
25	NUM	O	O
mg	NUM	O	O
;	PUNCT	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
160/12.5	NUM	O	O
,	PUNCT	O	O
320/12.5	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
320/25	NUM	O	O
mg	NUM	O	O
;	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
320/12.5	NUM	O	O
and	CCONJ	O	O
320/25	NUM	O	O
mg	NUM	O	O
were	VERB	O	O
further	ADV	O	O
investigated	VERB	O	O
in	ADP	O	O
a	DET	O	O
54-week	NOUN	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
extension	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
active	ADJ	O	O
treatments	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significantly	ADV	O	O
reduced	VERB	O	O
MSSBP	PROPN	O	O
and	CCONJ	O	O
MSDBP	PROPN	O	O
during	ADP	O	O
the	DET	O	O
core	NOUN	O	O
8-week	NUM	O	O
study	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
each	DET	O	O
monotherapy	NOUN	O	O
significantly	ADV	O	O
contributing	VERB	O	O
to	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
VAL	PROPN	O	I-Entity
and	CCONJ	O	O
HCTZ	PROPN	O	I-Entity
,	PUNCT	O	O
P	NOUN	O	O

The	DET	O	O
mean	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
MSSBP	PROPN	O	O
/	SYM	O	O
MSDBP	PROPN	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
320/25	NUM	O	O
mg	NUM	O	O
was	VERB	O	O
24.7/16.6	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
5.9/7.0	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
MSSBP	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
320/25	NUM	O	O
mg	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
160/12.5	NUM	O	O
mg	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
hypokalemia	NOUN	O	I-Entity
was	VERB	O	O
lower	ADJ	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
combinations	NOUN	O	O
(	PUNCT	O	O
1.8%-6.1%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
with	ADP	O	O
HCTZ	PROPN	O	I-Entity
monotherapies	NOUN	O	O
(	PUNCT	O	O
7.1%-13.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
combinations	NOUN	O	O
were	VERB	O	O
maintained	VERB	O	O
during	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
(	PUNCT	O	O
797	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
combination	NOUN	O	O
therapies	NOUN	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significantly	ADV	O	O
greater	ADJ	O	O
BP	PROPN	O	O
reductions	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
either	DET	O	O
monotherapy	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
less	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
than	ADP	O	O
HCTZ	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (17384765)

Succimer	PROPN	O	I-Entity
chelation	NOUN	O	O
improves	VERB	O	O
learning	NOUN	O	O
,	PUNCT	O	O
attention	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
arousal	NOUN	O	O
regulation	NOUN	O	O
in	ADP	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
rats	NOUN	O	O
but	CCONJ	O	O
produces	VERB	O	O
lasting	VERB	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
lead	ADJ	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
is	VERB	O	O
growing	VERB	O	O
pressure	NOUN	O	O
for	ADP	O	O
clinicians	NOUN	O	O
to	PART	O	O
prescribe	VERB	O	O
chelation	NOUN	O	O
therapy	NOUN	O	O
at	ADP	O	O
only	ADV	O	O
slightly	ADV	O	O
elevated	VERB	O	O
blood	NOUN	O	O
lead	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
very	ADV	O	O
few	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
evaluated	VERB	O	O
whether	ADP	O	O
chelation	NOUN	O	O
improves	VERB	O	O
cognitive	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
Pb	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
children	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
whether	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
have	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
affect	VERB	O	O
brain	NOUN	O	O
development	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
answer	VERB	O	O
these	DET	O	O
questions	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
rodent	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
childhood	NOUN	O	O
Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
succimer	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
chelating	VERB	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Pb	PROPN	O	B-Entity
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O

Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
produced	VERB	O	O
lasting	VERB	O	O
impairments	NOUN	O	B-Entity
in	ADP	O	I-Entity
learning	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
attention	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
inhibitory	ADJ	O	I-Entity
control	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
arousal	NOUN	O	I-Entity
regulation	NOUN	O	I-Entity
,	PUNCT	O	O
paralleling	VERB	O	O
the	DET	O	O
areas	NOUN	O	O
of	ADP	O	O
dysfunction	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
Pb	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
children	NOUN	O	O
.	PUNCT	O	O

Succimer	ADJ	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Pb	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
rats	NOUN	O	O
significantly	ADV	O	O
improved	VERB	O	O
learning	NOUN	O	O
,	PUNCT	O	O
attention	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
arousal	NOUN	O	O
regulation	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
varied	VERB	O	O
as	ADP	O	O
a	DET	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
level	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
specific	ADJ	O	O
functional	ADJ	O	O
deficit	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
succimer	ADJ	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
not	ADV	O	O
previously	ADV	O	O
exposed	VERB	O	O
to	ADP	O	O
Pb	PROPN	O	I-Entity
produced	VERB	O	O
lasting	ADJ	O	O
and	CCONJ	O	O
pervasive	ADJ	O	O
cognitive	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
affective	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
comparable	ADJ	O	O
in	ADP	O	O
magnitude	NOUN	O	O
to	ADP	O	O
that	DET	O	O
produced	VERB	O	O
by	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
are	VERB	O	O
the	DET	O	O
first	ADJ	O	O
data	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
show	VERB	O	O
that	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
any	DET	O	O
chelating	VERB	O	O
agent	NOUN	O	O
can	VERB	O	O
alleviate	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
Pb	PROPN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
identify	VERB	O	O
a	DET	O	O
succimer	NOUN	O	I-Entity
treatment	NOUN	O	O
protocol	NOUN	O	O
that	ADJ	O	O
improves	VERB	O	O
cognitive	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
Pb	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
children	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
also	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
succimer	ADJ	O	I-Entity
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
strongly	ADV	O	O
discouraged	VERB	O	O
for	ADP	O	O
children	NOUN	O	O
who	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
have	VERB	O	O
elevated	VERB	O	O
tissue	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
Pb	PROPN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
heavy	ADJ	O	O
metals	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17445520)

Caffeine	NOUN	O	I-Entity
challenge	NOUN	O	O
test	NOUN	O	O
in	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
and	CCONJ	O	O
depression	NOUN	O	I-Entity
with	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
observe	VERB	O	O
if	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
with	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
(	PUNCT	O	O
MDP	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
Diagnostic	PROPN	O	O
and	CCONJ	O	O
Statistical	PROPN	O	O
Manual	PROPN	O	O
of	ADP	O	O
Mental	PROPN	O	B-Entity
Disorders	PROPN	O	I-Entity
,	PUNCT	O	O
Fourth	PROPN	O	O
Edition	PROPN	O	O
criteria	NOUN	O	O
)	PUNCT	O	O
respond	VERB	O	O
in	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
way	NOUN	O	O
to	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
by	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
caffeine	NOUN	O	I-Entity
challenge	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
randomly	ADV	O	O
selected	VERB	O	O
29	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
,	PUNCT	O	O
27	NUM	O	O
with	ADP	O	O
MDP	PROPN	O	I-Entity
,	PUNCT	O	O
25	NUM	O	O
with	ADP	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
without	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
(	PUNCT	O	O
MD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
28	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
experiment	NOUN	O	O
performed	VERB	O	O
in	ADP	O	O
2	NUM	O	O
occasions	NOUN	O	O
7	NUM	O	O
days	NOUN	O	O
apart	ADV	O	O
,	PUNCT	O	O
480	NUM	O	O
mg	CCONJ	O	O
caffeine	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
solution	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
a	DET	O	O
coffee	NOUN	O	O
form	NOUN	O	O
and	CCONJ	O	O
anxiety	NOUN	O	I-Entity
scales	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
each	DET	O	O
test	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
58.6%	NUM	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
,	PUNCT	O	O
44.4%	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
MDP	PROPN	O	I-Entity
,	PUNCT	O	O
12.0%	NUM	O	O

(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
MD	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
7.1%	NUM	O	O
(	PUNCT	O	O
n=	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
had	VERB	O	O
a	DET	O	O
panic	NOUN	O	B-Entity
attack	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
480-mg	NUM	O	O
caffeine	NOUN	O	I-Entity
challenge	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
chi(2)(3	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
16.22	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
and	CCONJ	O	O
MDP	PROPN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
caffeine	NOUN	O	I-Entity
than	ADP	O	O
were	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
MD	PROPN	O	I-Entity
and	CCONJ	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
panic	NOUN	O	B-Entity
attack	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
the	DET	O	O
caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
solution	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
MD	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
than	ADP	O	O
all	ADJ	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
2-way	NUM	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
by	ADP	O	O
time	NOUN	O	O
interaction	NOUN	O	O
with	ADP	O	O
Greenhouse	PROPN	O	O
-	PUNCT	O	O
Geisser	PROPN	O	O
correction	NOUN	O	O
:	PUNCT	O	O
F(3,762	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.85	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.026	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
there	ADV	O	O
is	VERB	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
panic	NOUN	O	B-Entity
attacks	NOUN	O	I-Entity
,	PUNCT	O	O
no	ADV	O	O
matter	ADV	O	O
if	ADP	O	O
associated	VERB	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
or	CCONJ	O	O
MDP	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hyperreactivity	NOUN	O	O
to	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
caffeine	NOUN	O	I-Entity
challenge	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17484470)

Mitral	PROPN	O	O
annuloplasty	NOUN	O	O
as	ADP	O	O
a	DET	O	O
ventricular	ADJ	O	O
restoration	NOUN	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
failing	VERB	O	B-Entity
left	VERB	O	I-Entity
ventricle	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Undersized	ADJ	O	O
mitral	ADJ	O	O
annuloplasty	NOUN	O	O
(	PUNCT	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
functional	ADJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
MR	PROPN	O	I-Entity
)	PUNCT	O	O
since	ADV	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
addressing	VERB	O	O
the	DET	O	O
MR	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
MAP	PROPN	O	O
may	VERB	O	O
also	ADV	O	O
reshape	VERB	O	O
the	DET	O	O
dilated	VERB	O	O
left	VERB	O	O
ventricular	NOUN	O	O
(	PUNCT	O	O
LV	PROPN	O	O
)	PUNCT	O	O
base	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
direct	ADJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
this	DET	O	O
possible	ADJ	O	O
reshaping	VERB	O	O
on	ADP	O	O
LV	PROPN	O	O
function	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
underlying	VERB	O	O
MR	PROPN	O	I-Entity
remain	VERB	O	O
incompletely	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
identify	VERB	O	O
these	DET	O	O
benefits	NOUN	O	O
in	ADP	O	O
a	DET	O	O
canine	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
volume	NOUN	O	O
loading	NOUN	O	O
after	ADP	O	O
weaning	VERB	O	O
from	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
;	PUNCT	O	O
an	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
MR	PROPN	O	I-Entity
was	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
acquired	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
MAP	PROPN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
The	DET	O	O
data	NOUN	O	O
acquired	VERB	O	O
suggest	VERB	O	O
that	ADP	O	O
isolated	VERB	O	O
MAP	PROPN	O	O
may	VERB	O	O
have	VERB	O	O
certain	ADJ	O	O
benefits	NOUN	O	O
on	ADP	O	O
LV	PROPN	O	O
dimension	NOUN	O	O
/	SYM	O	O
function	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
MR	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
further	ADJ	O	O
investigations	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17496739)

Piperacillin	PROPN	O	B-Entity
/	SYM	O	I-Entity
tazobactam	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
rapidly	ADV	O	O
reversed	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
flux	NOUN	O	O
hemodialysis	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
on	ADP	O	O
peritoneal	ADJ	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
popular	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
piperacillin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
dire	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
piperacillin	NOUN	O	I-Entity
still	ADV	O	O
goes	VERB	O	O
unrecognized	ADJ	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
a	DET	O	O
delay	NOUN	O	O
in	ADP	O	O
appropriate	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
57-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
receiving	VERB	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	NOUN	O	O
dialysis	NOUN	O	O
(	PUNCT	O	O
CAPD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
slurred	ADJ	O	O
speech	NOUN	O	O
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
bizarre	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	ADJ	O	I-Entity
seizure	NOUN	O	I-Entity
(	PUNCT	O	O
GTCS	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
5	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
piperacillin	NOUN	O	B-Entity
/	PUNCT	O	I-Entity
tazobactam	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
g/250	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
for	ADP	O	O
bronchiectasis	NOUN	O	I-Entity
with	ADP	O	O
secondary	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
laboratory	NOUN	O	O
data	NOUN	O	O
revealed	VERB	O	O
normal	ADJ	O	O
plasma	NOUN	O	O
electrolyte	NOUN	O	O
and	CCONJ	O	O
ammonia	NOUN	O	I-Entity
levels	NOUN	O	O
but	CCONJ	O	O
leukocytosis	NOUN	O	I-Entity
.	PUNCT	O	O

Neurologic	ADJ	O	O
examinations	NOUN	O	O
showed	VERB	O	O
dysarthria	NOUN	O	I-Entity
and	CCONJ	O	O
bilateral	ADJ	O	O
Babinski	PROPN	O	O
sign	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antiepileptic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
another	DET	O	O
GTCS	PROPN	O	I-Entity
episode	NOUN	O	O
recurred	VERB	O	O
after	ADP	O	O
the	DET	O	O
sixth	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
piperacillin	NOUN	O	B-Entity
/	SYM	O	I-Entity
tazobactam	NOUN	O	I-Entity
.	PUNCT	O	O

Brain	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
demonstrate	VERB	O	O
acute	ADJ	O	O
infarction	NOUN	O	I-Entity
and	CCONJ	O	O
organic	ADJ	O	B-Entity
brain	NOUN	O	I-Entity
lesions	NOUN	O	I-Entity
.	PUNCT	O	O

Piperacillin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
any	DET	O	O
uremic	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
unexplained	ADJ	O	O
neurological	ADJ	O	O
manifestations	NOUN	O	O
.	PUNCT	O	O

CAPD	NOUN	O	O
is	VERB	O	O
inefficient	ADJ	O	O
in	ADP	O	O
removing	VERB	O	O
piperacillin	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
hemodialysis	NOUN	O	O
can	VERB	O	O
rapidly	ADV	O	O
terminate	VERB	O	O
the	DET	O	O
piperacillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17543491)

Frequency	PROPN	O	O
of	ADP	O	O
transient	ADJ	O	O
ipsilateral	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
carotid	ADJ	O	O
endarterectomy	NOUN	O	O
under	ADP	O	O
local	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Temporary	ADJ	O	O
ipsilateral	ADJ	O	O
vocal	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
palsies	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
.	PUNCT	O	O

Such	ADJ	O	O
complications	NOUN	O	O
are	VERB	O	O
most	ADV	O	O
important	ADJ	O	O
in	ADP	O	O
situations	NOUN	O	O
where	ADV	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
contralateral	ADJ	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

Anesthesia	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
injecting	VERB	O	O
20	NUM	O	O
to	PART	O	O
40	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
(	PUNCT	O	O
ropivacaine	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	NOUN	O	O
(	PUNCT	O	O
prilocaine	NOUN	O	I-Entity
)	PUNCT	O	O
anesthetic	NOUN	O	O
.	PUNCT	O	O

Twelve	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
43%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
intraoperative	ADJ	O	O
ipsilateral	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
operating	VERB	O	O
time	NOUN	O	O
or	CCONJ	O	O
volume	NOUN	O	O
or	CCONJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
anesthetic	ADJ	O	O
administration	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
temporary	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
without	ADP	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Local	ADJ	O	O
anesthesia	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
temporary	ADJ	O	O
ipsilateral	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
in	ADP	O	O
almost	ADV	O	O
half	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
pre	ADV	O	O
-	PUNCT	O	O
existing	VERB	O	O
paralysis	NOUN	O	I-Entity
is	VERB	O	O
of	ADP	O	O
a	DET	O	O
relevant	ADJ	O	O
frequency	NOUN	O	O
(	PUNCT	O	O
up	ADP	O	O
to	ADP	O	O
3%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
preoperative	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
vocal	ADJ	O	O
cord	NOUN	O	O
function	NOUN	O	O
before	ADP	O	O
carotid	ADJ	O	O
endarterectomy	NOUN	O	O
under	ADP	O	O
local	ADJ	O	O
anesthesia	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
to	PART	O	O
avoid	VERB	O	O
intraoperative	ADJ	O	O
bilateral	ADJ	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
preoperative	ADJ	O	O
contralateral	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
surgery	NOUN	O	O
under	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17572393)

Neuroprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	I-Entity
upon	ADP	O	O
the	DET	O	O
offspring	NOUN	O	O
cerebellar	ADJ	O	O
cortex	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cortical	ADJ	O	B-Entity
dysplasia	NOUN	O	I-Entity
.	PUNCT	O	O

Cortical	ADJ	O	B-Entity
dysplasia	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
malformation	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
defects	NOUN	O	O
in	ADP	O	O
proliferation	NOUN	O	O
,	PUNCT	O	O
migration	NOUN	O	O
and	CCONJ	O	O
maturation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
alterations	NOUN	O	O
in	ADP	O	O
offspring	VERB	O	O
rat	NOUN	O	O
cerebellum	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
maternal	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
carmustine-[1,3-bis	PROPN	O	B-Entity
(	PUNCT	O	I-Entity
2-chloroethyl)-1-nitrosoure	NOUN	O	I-Entity
]	PUNCT	O	O
(	PUNCT	O	O
BCNU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
exogenous	ADJ	O	O
melatonin	NOUN	O	I-Entity
upon	ADP	O	O
cerebellar	ADJ	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cortical	ADJ	O	B-Entity
dysplasia	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
histological	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

Pregnant	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
five	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
intact	ADJ	O	O
-	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
saline	ADJ	O	O
-	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
melatonin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
,	PUNCT	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
and	CCONJ	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
plus	CCONJ	O	O
melatonin	NOUN	O	I-Entity
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
BCNU	PROPN	O	I-Entity
on	ADP	O	O
embryonic	ADJ	O	O
day	NOUN	O	O
15	NUM	O	O
and	CCONJ	O	O
melatonin	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
until	ADP	O	O
delivery	NOUN	O	O
.	PUNCT	O	O

Immuno	PROPN	O	O
/	SYM	O	O
histochemistry	NOUN	O	O
and	CCONJ	O	O
electron	NOUN	O	O
microscopy	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	PART	O	O
on	ADP	O	O
the	DET	O	O
offspring	NOUN	O	O
cerebellum	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
levels	NOUN	O	O
of	ADP	O	O
malondialdehyde	NOUN	O	I-Entity
and	CCONJ	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Histopathologically	ADV	O	O
,	PUNCT	O	O
typical	ADJ	O	O
findings	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
cerebella	NOUN	O	O
from	ADP	O	O
the	DET	O	O
control	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
findings	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
early	ADJ	O	O
embryonic	ADJ	O	O
development	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
cortical	ADJ	O	B-Entity
dysplasia	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
marked	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
TUNEL	PROPN	O	O
positive	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
nestin	ADJ	O	O
positive	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
decreased	ADJ	O	O
immunoreactivity	NOUN	O	O
to	ADP	O	O
glial	ADJ	O	O
fibrillary	ADJ	O	O
acidic	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
synaptophysin	NOUN	O	O
and	CCONJ	O	O
transforming	VERB	O	O
growth	NOUN	O	O
factor	NOUN	O	O
beta1	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
delayed	VERB	O	O
maturation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
melatonin	NOUN	O	I-Entity
significantly	ADV	O	O
reversed	VERB	O	O
these	DET	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Malondialdehyde	ADJ	O	I-Entity
level	NOUN	O	O
in	ADP	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
control	NOUN	O	O
groups	NOUN	O	O
and	CCONJ	O	O
melatonin	NOUN	O	I-Entity
decreased	VERB	O	O
malondialdehyde	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
BCNU	PROPN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
levels	NOUN	O	O
between	ADP	O	O
these	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
exposure	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
to	ADP	O	O
BCNU	PROPN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
leads	VERB	O	O
to	ADP	O	O
delayed	VERB	O	O
maturation	NOUN	O	O
of	ADP	O	O
offspring	NOUN	O	O
cerebellum	NOUN	O	O
and	CCONJ	O	O
melatonin	NOUN	O	I-Entity
protects	VERB	O	O
the	DET	O	O
cerebellum	NOUN	O	O
against	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
BCNU	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17828434)

Myo	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
inositol-1-phosphate	PROPN	O	I-Entity
(	PUNCT	O	O
MIP	PROPN	O	I-Entity
)	PUNCT	O	O

Lithium	NOUN	O	I-Entity
and	CCONJ	O	O
valproate	NOUN	O	I-Entity
are	VERB	O	O
the	DET	O	O
prototypic	ADJ	O	O
mood	NOUN	O	O
stabilizers	NOUN	O	O
and	CCONJ	O	O
have	VERB	O	O
diverse	ADJ	O	O
structures	NOUN	O	O
and	CCONJ	O	O
targets	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
drugs	NOUN	O	O
influence	VERB	O	O
inositol	NOUN	O	I-Entity
metabolism	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
inhibits	VERB	O	O
IMPase	PROPN	O	O
and	CCONJ	O	O
valproate	NOUN	O	I-Entity
inhibits	VERB	O	O
MIP	PROPN	O	I-Entity
synthase	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
MIP	PROPN	O	I-Entity
synthase	NOUN	O	O
inhibition	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
replicate	VERB	O	O
or	CCONJ	O	O
augment	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inositol	NOUN	O	I-Entity
sensitive	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
effects	NOUN	O	O
may	VERB	O	O
stem	VERB	O	O
from	ADP	O	O
the	DET	O	O
low	ADJ	O	O
contribution	NOUN	O	O
of	ADP	O	O
de	PROPN	O	O
-	PUNCT	O	O
novo	ADJ	O	O
synthesis	NOUN	O	O
to	ADP	O	O
cellular	ADJ	O	O
inositol	NOUN	O	I-Entity
supply	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
de	PROPN	O	O
-	PUNCT	O	O
novo	ADJ	O	O
synthesis	NOUN	O	O
by	ADP	O	O
lithium	NOUN	O	I-Entity
itself	PRON	O	O
.	PUNCT	O	O


-DOCSTART- (17879100)

Non	PROPN	O	O
-	PUNCT	O	O
steroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
with	ADP	O	O
granular	ADJ	O	O
tubular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
deposits	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	B-Entity
tubulo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
interstitial	ADJ	O	I-Entity
nephritis	NOUN	O	I-Entity
(	PUNCT	O	O
ATIN	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
insults	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
immune	ADJ	O	O
complex	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
tubulo	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
interstitial	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
drugs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
a	DET	O	O
far	ADV	O	O
more	ADV	O	O
frequent	ADJ	O	O
cause	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
entity	NOUN	O	O
,	PUNCT	O	O
ATIN	PROPN	O	I-Entity
remains	VERB	O	O
under	ADP	O	O
-	PUNCT	O	O
diagnosed	VERB	O	O
,	PUNCT	O	O
as	ADP	O	O
symptoms	NOUN	O	O
resolve	VERB	O	O
spontaneously	ADV	O	O
if	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
is	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
a	DET	O	O
14-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
aortic	ADJ	O	O
valve	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
put	VERB	O	O
on	ADP	O	O
aspirin	NOUN	O	I-Entity
following	VERB	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
took	VERB	O	O
ibuprofen	NOUN	O	I-Entity
for	ADP	O	O
fever	NOUN	O	I-Entity
for	ADP	O	O
nearly	ADV	O	O
a	DET	O	O
week	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
then	ADV	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
feeling	VERB	O	O
quite	ADV	O	O
ill	ADJ	O	O
and	CCONJ	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
(	PUNCT	O	O
BUN	PROPN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
of	ADP	O	O
of	ADP	O	O
147	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
of	ADP	O	O
15.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
of	ADP	O	O
8.7	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
l	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
kidney	NOUN	O	O
biopsy	NOUN	O	O
showed	VERB	O	O
inflammatory	ADJ	O	O
infiltrate	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
ATIN	PROPN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
needed	VERB	O	O
dialysis	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
treated	VERB	O	O
successfully	ADV	O	O
with	ADP	O	O
steroids	NOUN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

His	ADJ	O	O
renal	ADJ	O	O
recovery	NOUN	O	O
and	CCONJ	O	O
disappearance	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
took	VERB	O	O
a	DET	O	O
year	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
a	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
NSAIDs	PROPN	O	O
-	PUNCT	O	O
associated	VERB	O	O
ATIN	PROPN	O	I-Entity
,	PUNCT	O	O
showing	VERB	O	O
deposits	NOUN	O	O
of	ADP	O	O
granular	ADJ	O	O
immune	ADJ	O	O
complex	ADJ	O	O
present	ADJ	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
TBM	PROPN	O	O
and	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
glomeruli	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17879217)

Rifampicin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
segmental	NOUN	O	O
necrotizing	NOUN	O	O
glomerulonephritis	NOUN	O	I-Entity
in	ADP	O	O
staphylococcal	ADJ	O	B-Entity
endocarditis	NOUN	O	I-Entity
.	PUNCT	O	O

necrotising	VERB	O	O
glomerulonephritis	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
complication	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

Changing	VERB	O	O
epidemiology	NOUN	O	O
of	ADP	O	O
infections	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
infective	ADJ	O	B-Entity
endocarditis	NOUN	O	I-Entity
(	PUNCT	O	O
IE	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
led	VERB	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
for	ADP	O	O
Staphylococcal	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
Staphylococcal	PROPN	O	B-Entity
IE	PROPN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
a	DET	O	O
segmental	ADJ	O	O
necrotising	NOUN	O	O
glomerulonephritis	NOUN	O	I-Entity
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
rifampicin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
review	VERB	O	O
the	DET	O	O
literature	NOUN	O	O
regarding	VERB	O	O
this	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17954033)

Rate	NOUN	O	O
of	ADP	O	O
YMDD	PROPN	O	O
motif	NOUN	O	O
mutants	NOUN	O	O
in	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
Iranian	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
studies	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
YMDD	PROPN	O	O
motif	NOUN	O	O
mutants	NOUN	O	O
(	PUNCT	O	O
resistant	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
)	PUNCT	O	O
occur	VERB	O	O
as	ADP	O	O
natural	ADJ	O	O
genome	NOUN	O	O
variability	NOUN	O	O
in	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
we	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
YMDD	PROPN	O	O
motif	NOUN	O	O
mutants	NOUN	O	O
in	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
Iran	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
77	NUM	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
not	ADV	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
lamivudine	NOUN	O	I-Entity
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
tested	VERB	O	O
for	ADP	O	O
liver	NOUN	O	O
enzymes	NOUN	O	O
,	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HCV	PROPN	O	O
,	PUNCT	O	O
HBeAg	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBe	NOUN	O	O
.	PUNCT	O	O

HBeAg	PROPN	O	I-Entity
was	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
40%	NUM	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBe	NOUN	O	O
in	ADP	O	O
60%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

YMDD	PROPN	O	O
motif	NOUN	O	O
mutants	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
detected	VERB	O	O
in	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
enzyme	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
HBeAg	PROPN	O	I-Entity
or	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBe	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Although	ADP	O	O
the	DET	O	O
natural	ADJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
YMDD	PROPN	O	O
motif	NOUN	O	O
mutants	NOUN	O	O
in	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
these	DET	O	O
mutants	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
detected	VERB	O	O
in	ADP	O	O
Iranian	ADJ	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18025637)

Branch	PROPN	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
and	CCONJ	O	O
fluoxetine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
branch	NOUN	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	O
hypertension	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
an	DET	O	O
infrequent	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
that	ADP	O	O
ophthalmologists	NOUN	O	O
are	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
can	VERB	O	O
cause	VERB	O	O
hypertension	NOUN	O	I-Entity
because	ADP	O	O
this	DET	O	O
class	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
is	VERB	O	O
widely	ADV	O	O
prescribed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18165598)

The	DET	O	O
differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
and	CCONJ	O	O
lidocaine	NOUN	O	I-Entity
on	ADP	O	O
prostaglandin	NOUN	O	B-Entity
E2	PROPN	O	I-Entity
release	NOUN	O	O
,	PUNCT	O	O
cyclooxygenase	NOUN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
pain	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
blocking	VERB	O	O
nociceptive	ADJ	O	O
input	NOUN	O	O
from	ADP	O	O
surgical	ADJ	O	O
sites	NOUN	O	O
,	PUNCT	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
might	VERB	O	O
directly	ADV	O	O
modulate	VERB	O	O
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
the	DET	O	O
proinflammatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
on	ADP	O	O
local	ADJ	O	O
prostaglandin	NOUN	O	B-Entity
E2	NOUN	O	I-Entity
(	PUNCT	O	O
PGE2	PROPN	O	I-Entity
)	PUNCT	O	O
production	NOUN	O	O
and	CCONJ	O	O
cyclooxygenase	NOUN	O	O
(	PUNCT	O	O
COX	PROPN	O	O
)	PUNCT	O	O
gene	NOUN	O	O
expression	NOUN	O	O
that	ADJ	O	O
increases	VERB	O	O
postoperative	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
in	ADP	O	O
human	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Subjects	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
114	NUM	O	O
)	PUNCT	O	O
undergoing	VERB	O	O
extraction	NOUN	O	O
of	ADP	O	O
impacted	VERB	O	O
third	ADJ	O	O
molars	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
2%	NUM	O	O
lidocaine	NOUN	O	I-Entity
or	CCONJ	O	O
0.5%	NUM	O	O
bupivacaine	NOUN	O	I-Entity
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
either	CCONJ	O	O
rofecoxib	VERB	O	I-Entity
50	NUM	O	O
mg	NUM	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
orally	ADV	O	O
90	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
the	DET	O	O
following	VERB	O	O
48	NUM	O	O
h.	NOUN	O	O
Oral	ADJ	O	O
mucosal	NOUN	O	O
biopsies	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
48	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
extraction	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
microdialysis	NOUN	O	O
probe	NOUN	O	O
was	VERB	O	O
placed	VERB	O	O
at	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
site	NOUN	O	O
for	ADP	O	O
PGE2	PROPN	O	I-Entity
and	CCONJ	O	O
thromboxane	NOUN	O	B-Entity
B2	NOUN	O	I-Entity
(	PUNCT	O	O
TXB2	PROPN	O	I-Entity
)	PUNCT	O	O
measurements	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
bupivacaine	NOUN	O	I-Entity
/	SYM	O	O
rofecoxib	NOUN	O	I-Entity
group	NOUN	O	O
reported	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
other	ADJ	O	O
three	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
4	NUM	O	O
h.	NOUN	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
bupivacaine	NOUN	O	I-Entity
/	PUNCT	O	O
placebo	NOUN	O	O
group	NOUN	O	O
reported	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
pain	NOUN	O	I-Entity
at	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
PGE2	PROPN	O	I-Entity
levels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
4	NUM	O	O
h	PROPN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
the	DET	O	O
other	ADJ	O	O
three	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
bupivacaine	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
COX-2	PROPN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
at	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
lidocaine	NOUN	O	I-Entity
/	PUNCT	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Thromboxane	PROPN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
seen	VERB	O	O
were	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
COX-2	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
COX-1	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
bupivacaine	NOUN	O	I-Entity
stimulates	VERB	O	O
COX-2	ADJ	O	O
gene	NOUN	O	O
expression	NOUN	O	O
after	ADP	O	O
tissue	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
higher	ADJ	O	O
PGE2	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
effect	NOUN	O	O
dissipates	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18189308)

p75NTR	ADJ	O	O
expression	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
examined	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
tyrosine	NOUN	O	I-Entity
kinase	NOUN	O	O
receptors	NOUN	O	O
(	PUNCT	O	O
Trks	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
micturition	NOUN	O	O
reflexes	NOUN	O	O
with	ADP	O	O
urinary	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
studies	NOUN	O	O
examine	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
another	DET	O	O
receptor	NOUN	O	O
known	VERB	O	O
to	PART	O	O
bind	VERB	O	O
NGF	PROPN	O	O
,	PUNCT	O	O
p75(NTR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
after	ADP	O	O
various	ADJ	O	O
durations	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
inflammation	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYP	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
increased	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
p75(NTR)-immunoreactive	ADJ	O	O
(	PUNCT	O	O
-IR	PROPN	O	O
)	PUNCT	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lumbosacral	ADJ	O	O
dorsal	NOUN	O	O
root	NOUN	O	O
ganglia	NOUN	O	O
(	PUNCT	O	O
DRG	PROPN	O	O
)	PUNCT	O	O
also	ADV	O	O
increased	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
(	PUNCT	O	O
acute	ADJ	O	O
,	PUNCT	O	O
intermediate	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Quantitative	PROPN	O	O
,	PUNCT	O	O
real	ADJ	O	O
-	PUNCT	O	O
time	NOUN	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
also	ADV	O	O
demonstrated	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
p75(NTR	NOUN	O	O
)	PUNCT	O	O
mRNA	NOUN	O	O
in	ADP	O	O
DRG	PROPN	O	O
with	ADP	O	O
intermediate	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
bladder	NOUN	O	O
afferent	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
DRG	PROPN	O	O
,	PUNCT	O	O
p75(NTR)-IR	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
increased	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
studies	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
p75(NTR	PUNCT	O	O
)	PUNCT	O	O
expression	NOUN	O	O
in	ADP	O	O
micturition	NOUN	O	O
reflexes	NOUN	O	O
is	VERB	O	O
present	ADJ	O	O
constitutively	ADV	O	O
and	CCONJ	O	O
modified	VERB	O	O
by	ADP	O	O
bladder	NOUN	O	B-Entity
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18340638)

Azathioprine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
suicidal	ADJ	O	O
erythrocyte	NOUN	O	O
death	NOUN	O	O
.	PUNCT	O	O

Azathioprine	PROPN	O	I-Entity
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
immunosuppressive	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
azathioprine	NOUN	O	I-Entity
include	VERB	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
suppression	NOUN	O	O
.	PUNCT	O	O

Alternatively	ADV	O	O
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
could	VERB	O	O
result	VERB	O	O
from	ADP	O	O
accelerated	VERB	O	O
suicidal	ADJ	O	O
erythrocyte	NOUN	O	O
death	NOUN	O	O
or	CCONJ	O	O
eryptosis	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
exposure	NOUN	O	O
of	ADP	O	O
phosphatidylserine	NOUN	O	I-Entity
(	PUNCT	O	O
PS	PROPN	O	I-Entity
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
erythrocyte	NOUN	O	O
surface	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
cell	NOUN	O	O
shrinkage	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
present	ADJ	O	O
experiments	NOUN	O	O
explored	VERB	O	O
whether	ADP	O	O
azathioprine	NOUN	O	I-Entity
influences	VERB	O	O
eryptosis	NOUN	O	O
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
annexin	NOUN	O	O
V	NOUN	O	O
binding	VERB	O	O
,	PUNCT	O	O
erythrocytes	NOUN	O	O
from	ADP	O	O
patients	NOUN	O	O
indeed	ADV	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
PS	PROPN	O	I-Entity
exposure	NOUN	O	O
within	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
azathioprine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
second	ADJ	O	O
series	NOUN	O	O
,	PUNCT	O	O
cytosolic	ADJ	O	O
Ca2	PROPN	O	I-Entity
+	SYM	O	O
activity	NOUN	O	O
(	PUNCT	O	O
Fluo3	PROPN	O	I-Entity
fluorescence	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cell	NOUN	O	O
volume	NOUN	O	O
(	PUNCT	O	O
forward	ADV	O	O
scatter	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PS	PROPN	O	I-Entity
-	PUNCT	O	O
exposure	NOUN	O	O
(	PUNCT	O	O
annexin	NOUN	O	O
V	NOUN	O	O
binding	VERB	O	O
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
FACS	PROPN	O	O
analysis	NOUN	O	O
in	ADP	O	O
erythrocytes	NOUN	O	O
from	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Exposure	NOUN	O	O
to	ADP	O	O
azathioprine	NOUN	O	I-Entity
(	PUNCT	O	O
>	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
increased	VERB	O	O
cytosolic	ADJ	O	O
Ca2	PROPN	O	I-Entity
+	CCONJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
annexin	NOUN	O	O
V	NOUN	O	O
binding	VERB	O	O
and	CCONJ	O	O
decreased	VERB	O	O
forward	ADV	O	O
scatter	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
azathioprine	NOUN	O	I-Entity
on	ADP	O	O
both	DET	O	O
annexin	NOUN	O	O
V	NOUN	O	O
binding	VERB	O	O
and	CCONJ	O	O
forward	ADV	O	O
scatter	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
blunted	VERB	O	O
in	ADP	O	O
the	DET	O	O
nominal	ADJ	O	O
absence	NOUN	O	O
of	ADP	O	O
extracellular	ADJ	O	O
Ca2	PROPN	O	I-Entity
+	PROPN	O	O
.	PUNCT	O	O

Azathioprine	NOUN	O	I-Entity
triggers	VERB	O	O
suicidal	ADJ	O	O
erythrocyte	NOUN	O	O
death	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
presumably	ADV	O	O
contributing	VERB	O	O
to	ADP	O	O
azathioprine	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18399341)

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Spinal	ADJ	O	O
anaesthesia	NOUN	O	O
is	VERB	O	O
widely	ADV	O	O
employed	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
but	CCONJ	O	O
has	VERB	O	O
the	DET	O	O
main	ADJ	O	O
drawback	NOUN	O	O
of	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
spinal	ADJ	O	O
block	NOUN	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
position	NOUN	O	O
with	ADP	O	O
operative	ADJ	O	O
side	NOUN	O	O
down	PART	O	O
,	PUNCT	O	O
patients	NOUN	O	O
recived	VERB	O	O
10	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
2mls	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
0.5%	NUM	O	O
hyperbaric	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
through	ADP	O	O
a	DET	O	O
25-gauge	NUM	O	O
spinal	ADJ	O	O
needle	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
respiratory	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
oxygen	NOUN	O	I-Entity
saturation	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
over	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Three	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
8.1%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
unilateral	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
(	PUNCT	O	O
13.5%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
group	NOUN	O	O
developed	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
P=	PROPN	O	O
0.71	NUM	O	O
.	PUNCT	O	O

Four	NUM	O	O
(	PUNCT	O	O
10.8%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
(	PUNCT	O	O
2.7%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
unilateral	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
P=	PROPN	O	O
0.17	NUM	O	O
required	VERB	O	O
epinephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
respiratory	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
oxygen	NOUN	O	I-Entity
saturations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
block	NOUN	O	O
instituted	VERB	O	O
affected	VERB	O	O
neither	CCONJ	O	O
the	DET	O	O
respiratory	ADJ	O	O
rate	NOUN	O	O
nor	CCONJ	O	O
the	DET	O	O
arterial	ADJ	O	O
oxygen	NOUN	O	I-Entity
saturation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18422462)

Spectrum	PROPN	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
after	ADP	O	O
generic	ADJ	O	O
HAART	PROPN	O	O
in	ADP	O	O
southern	ADJ	O	O
Indian	ADJ	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
after	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
,	PUNCT	O	O
fixed	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
generic	ADJ	O	O
highly	ADV	O	O
active	ADJ	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HAART	PROPN	O	O
)	PUNCT	O	O
use	NOUN	O	O
among	ADP	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
individuals	NOUN	O	O
in	ADP	O	O
South	PROPN	O	O
India	PROPN	O	O
,	PUNCT	O	O
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
experiences	NOUN	O	O
of	ADP	O	O
3154	NUM	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
individuals	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
generic	ADJ	O	O
HAART	PROPN	O	O
between	ADP	O	O
February	PROPN	O	O
1996	NUM	O	O
and	CCONJ	O	O
December	PROPN	O	O
2006	NUM	O	O
at	ADP	O	O
a	DET	O	O
tertiary	ADJ	O	O
HIV	NOUN	O	O
care	NOUN	O	O
referral	ADJ	O	O
center	NOUN	O	O
in	ADP	O	O
South	PROPN	O	O
India	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
regimens	NOUN	O	O
were	VERB	O	O
3TC	NUM	O	I-Entity
+	SYM	O	O
d4	NOUN	O	B-Entity
T	NOUN	O	I-Entity
+	SYM	O	O
nevirapine	NOUN	O	I-Entity
(	PUNCT	O	O
NVP	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
54.8%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O

+	CCONJ	O	O
3TC	NUM	O	I-Entity
+	CCONJ	O	O
NVP	PROPN	O	I-Entity
(	PUNCT	O	O
14.5%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
3TC	NUM	O	I-Entity
+	CCONJ	O	O

d4	ADJ	O	B-Entity
T	NOUN	O	I-Entity
+	NOUN	O	O
efavirenz	NOUN	O	I-Entity
(	PUNCT	O	O
EFV	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
20.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
AZT	PROPN	O	I-Entity
+	SYM	O	O
3TC	NUM	O	I-Entity
+	CCONJ	O	O
EFV	PROPN	O	I-Entity
(	PUNCT	O	O
5.4%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
median	ADJ	O	O
CD4	PROPN	O	O
at	ADP	O	O
time	NOUN	O	O
of	ADP	O	O
event	NOUN	O	O
were	VERB	O	O
rash	NOUN	O	I-Entity
(	PUNCT	O	O
15.2%	NUM	O	O
;	PUNCT	O	O
CD4	PROPN	O	O
,	PUNCT	O	O
285	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
microL	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
(	PUNCT	O	O
9.0%	NUM	O	O
and	CCONJ	O	O
348	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
microL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinically	PROPN	O	O
significant	ADJ	O	O
anemia	NOUN	O	I-Entity
(	PUNCT	O	O
hemoglobin	NOUN	O	O

<	X	O	O
7	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
5.4%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
CD4	PROPN	O	O
,	PUNCT	O	O
165	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
microL	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hepatitis	NOUN	O	I-Entity
(	PUNCT	O	O
clinical	ADJ	O	O
jaundice	NOUN	O	I-Entity
with	ADP	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
>	SYM	O	O
5	NUM	O	O
times	NOUN	O	O
upper	ADJ	O	O
limits	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
)	PUNCT	O	O
in	ADP	O	O
3.5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
CD4	PROPN	O	O
,	PUNCT	O	O
260	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
microL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
experience	VERB	O	O
lactic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
men	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
experience	VERB	O	O
immune	ADJ	O	B-Entity
reconstitution	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
,	PUNCT	O	O
NVP	PROPN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
developing	VERB	O	O
rash	NOUN	O	I-Entity
and	CCONJ	O	O
d4	NOUN	O	B-Entity
T	NOUN	O	I-Entity
therapy	NOUN	O	O
with	ADP	O	O
developing	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Anemia	NOUN	O	I-Entity
and	CCONJ	O	O
hepatitis	NOUN	O	I-Entity
often	ADV	O	O
occur	VERB	O	O
within	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
initiating	VERB	O	O
generic	ADJ	O	O
HAART	PROPN	O	O
.	PUNCT	O	O

Frequent	NOUN	O	O
and	CCONJ	O	O
early	ADJ	O	O
monitoring	NOUN	O	O
for	ADP	O	O
these	DET	O	O
toxicities	NOUN	O	I-Entity
is	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
developing	VERB	O	O
countries	NOUN	O	O
where	ADV	O	O
generic	ADJ	O	O
HAART	PROPN	O	O
is	VERB	O	O
increasingly	ADV	O	O
available	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (18450790)

Thalidomide	PROPN	O	I-Entity
and	CCONJ	O	O
sensory	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
neurophysiological	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
studies	NOUN	O	O
confirmed	VERB	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
sensory	ADJ	O	B-Entity
axonal	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
different	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
's	PART	O	O
aims	NOUN	O	O
were	VERB	O	O
to	PART	O	O
measure	VERB	O	O
variations	NOUN	O	O
in	ADP	O	O
sural	ADJ	O	O
nerve	NOUN	O	O
sensory	ADJ	O	O
action	NOUN	O	O
potential	NOUN	O	O
(	PUNCT	O	O
SAP	PROPN	O	O
)	PUNCT	O	O
amplitude	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
refractory	ADJ	O	O
cutaneous	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematosus	NOUN	O	I-Entity
(	PUNCT	O	O
CLE	PROPN	O	I-Entity
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
thalidomide	NOUN	O	I-Entity
and	CCONJ	O	O
use	VERB	O	O
these	DET	O	O
findings	NOUN	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
recovery	NOUN	O	O
capacity	NOUN	O	O
of	ADP	O	O
sensory	ADJ	O	O
fibres	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Clinical	PROPN	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
data	NOUN	O	O
in	ADP	O	O
12	NUM	O	O
female	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
CLE	PROPN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
thalidomide	NOUN	O	I-Entity
and	CCONJ	O	O
up	ADV	O	O
to	ADP	O	O
47	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
were	VERB	O	O
analysed	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
paresthesias	NOUN	O	I-Entity
and	CCONJ	O	O
leg	NOUN	O	O
cramps	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
thalidomide	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
sural	ADJ	O	O
SAP	PROPN	O	O
amplitude	NOUN	O	O
recovered	VERB	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
sural	ADJ	O	O
nerve	NOUN	O	O
SAP	NOUN	O	O
amplitude	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
thalidomide	NOUN	O	I-Entity
cumulative	ADJ	O	O
dose	NOUN	O	O
was	VERB	O	O
21.4	NUM	O	O
g.	NOUN	O	O
The	DET	O	O
threshold	NOUN	O	O
neurotoxic	NOUN	O	I-Entity
dosage	NOUN	O	O
is	VERB	O	O
lower	ADJ	O	O
than	ADP	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
electrophysiological	ADJ	O	O
parameter	NOUN	O	O
provides	VERB	O	O
information	NOUN	O	O
about	ADP	O	O
subclinical	ADJ	O	O
neurotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
but	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
helpful	ADJ	O	O
in	ADP	O	O
predicting	VERB	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
sensory	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18801087)

Amiodarone	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
pulmonary	ADJ	O	B-Entity
mass	NOUN	O	I-Entity
and	CCONJ	O	O
unique	ADJ	O	O
membranous	ADJ	O	B-Entity
glomerulonephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O
Diagnostic	ADJ	O	O
pitfall	NOUN	O	O
and	CCONJ	O	O
new	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
arrhythmic	ADJ	O	I-Entity
drug	NOUN	O	O
for	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
various	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Reported	VERB	O	O
herein	ADV	O	O
is	VERB	O	O
an	DET	O	O
autopsy	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
lung	NOUN	O	B-Entity
mass	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
cm	NOUN	O	O
in	ADP	O	O
diameter	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
(	PUNCT	O	O
2.76	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
long	ADJ	O	O
time	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lung	NOUN	O	B-Entity
mass	NOUN	O	I-Entity
was	VERB	O	O
highly	ADV	O	O
suspected	VERB	O	O
to	PART	O	O
be	VERB	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
on	ADP	O	O
CT	PROPN	O	O
and	CCONJ	O	O
positron	NOUN	O	O
emission	NOUN	O	O
tomography	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
histologically	ADV	O	O
the	DET	O	O
lesion	NOUN	O	O
was	VERB	O	O
composed	VERB	O	O
of	ADP	O	O
lymphoplasmacytic	ADJ	O	O
infiltrates	NOUN	O	O
in	ADP	O	O
alveolar	ADJ	O	O
walls	NOUN	O	O
and	CCONJ	O	O
intra	ADJ	O	O
-	PUNCT	O	O
alveolar	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
foamy	ADJ	O	O
macrophages	NOUN	O	O
containing	VERB	O	O
characteristic	ADJ	O	O
myelinoid	ADJ	O	O
bodies	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
it	PRON	O	O
was	VERB	O	O
an	DET	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
lesion	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
lung	NOUN	O	O
tissue	NOUN	O	O
had	VERB	O	O
unevenly	ADV	O	O
distributed	VERB	O	O
hemosiderin	NOUN	O	I-Entity
deposition	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
abnormally	ADV	O	O
tortuous	ADJ	O	O
capillaries	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
mass	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
heavily	ADV	O	O
hemosiderotic	ADJ	O	I-Entity
lung	NOUN	O	O
portions	NOUN	O	O
outside	ADP	O	O
the	DET	O	O
mass	NOUN	O	O
.	PUNCT	O	O

Autoimmune	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
viral	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
malignant	ADJ	O	O
neoplasms	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
diseases	NOUN	O	O
with	ADP	O	O
a	DET	O	O
known	VERB	O	O
relationship	NOUN	O	O
to	ADP	O	O
membranous	ADJ	O	B-Entity
glomerulonephritis	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
found	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
highlights	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
differential	NOUN	O	O
diagnosis	NOUN	O	O
between	ADP	O	O
an	DET	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
pulmonary	ADJ	O	B-Entity
lesion	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
neoplasm	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
very	ADV	O	O
difficult	ADJ	O	O
radiologically	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
suggests	VERB	O	O
that	ADP	O	O
membranous	ADJ	O	B-Entity
glomerulonephritis	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
another	DET	O	O
possible	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18945509)

Risk	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
initial	ADJ	O	O
sulphonylurea	NOUN	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
matched	VERB	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
sought	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
CAD	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
with	ADP	O	O
different	ADJ	O	O
sulphonylureas	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetic	ADJ	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
cases	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
CAD	PROPN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
retrospectively	ADV	O	O
with	ADP	O	O
controls	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
20-year	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
CAD	PROPN	O	I-Entity
at	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
UKPDS	PROPN	O	O
risk	NOUN	O	O
engine	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
match	VERB	O	O
cases	NOUN	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
76	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
CAD	PROPN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
152	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hazard	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
CAD	PROPN	O	I-Entity
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
increased	VERB	O	O
by	ADP	O	O
2.4-fold	NUM	O	O
(	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
4.3	NUM	O	O
,	PUNCT	O	O
P=0.004	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
glibenclamide	NOUN	O	I-Entity
;	PUNCT	O	O
2-fold	NUM	O	O
(	PUNCT	O	O
0.9	NUM	O	O
-	SYM	O	O
4.6	NUM	O	O
,	PUNCT	O	O
P=0.099	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
glipizide	NOUN	O	I-Entity
;	PUNCT	O	O
2.9-fold	NUM	O	O
(	PUNCT	O	O
1.6	NUM	O	O
-	SYM	O	O
5.1	NUM	O	O
,	PUNCT	O	O
P=0.000	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
either	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
unchanged	ADJ	O	O
with	ADP	O	O
metformin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
hazard	NOUN	O	O
decreased	VERB	O	O
0.3-fold	NOUN	O	O
(	PUNCT	O	O
0.7	NUM	O	O
-	SYM	O	O
1.7	NUM	O	O
,	PUNCT	O	O
P=0.385	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
glimepiride	NOUN	O	I-Entity
,	PUNCT	O	O
0.4-fold	NUM	O	O
(	PUNCT	O	O
0.7	NUM	O	O
-	SYM	O	O
1.3	NUM	O	O
,	PUNCT	O	O
P=0.192	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
gliclazide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
0.4-fold	NUM	O	O
(	PUNCT	O	O
0.7	NUM	O	O
-	SYM	O	O
1.1	NUM	O	O
,	PUNCT	O	O
P=0.09	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
either	DET	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Initiating	VERB	O	O
treatment	NOUN	O	O
of	ADP	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
with	ADP	O	O
glibenclamide	NOUN	O	I-Entity
or	CCONJ	O	O
glipizide	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
CAD	PROPN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
to	PART	O	O
gliclazide	VERB	O	I-Entity
or	CCONJ	O	O
glimepiride	VERB	O	I-Entity
.	PUNCT	O	O

If	ADP	O	O
confirmed	VERB	O	O
,	PUNCT	O	O
this	DET	O	O
may	VERB	O	O
be	VERB	O	O
important	ADJ	O	O
because	ADP	O	O
most	ADJ	O	O
Indian	ADJ	O	O
patients	NOUN	O	O
receive	VERB	O	O
the	DET	O	O
cheaper	ADJ	O	O
older	ADJ	O	O
sulphonylureas	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
present	ADJ	O	O
guidelines	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
distinguish	VERB	O	O
between	ADP	O	O
individual	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18987260)

Reduced	ADJ	O	O
progression	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
losartan	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
antihypertensive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	B-Entity
II	NUM	O	I-Entity
type-1	NOUN	O	O
receptor	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
losartan	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
potential	ADJ	O	O
in	ADP	O	O
slowing	VERB	O	O
down	PART	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
progression	NOUN	O	O
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
SHR	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
adriamycin	ADJ	O	I-Entity
(	PUNCT	O	O
ADR	PROPN	O	I-Entity
)	PUNCT	O	O

nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Groups	NOUN	O	O
ADR(6	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
ADR+LOS(6	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
ADR(12	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ADR+LOS(12	PROPN	O	I-Entity
)	PUNCT	O	O
received	VERB	O	O
ADR	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
b.w	PROPN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
ADR+LOS(6	PROPN	O	I-Entity
)	PUNCT	O	O
received	VERB	O	O
losartan	NOUN	O	I-Entity

(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
b.w./day	NOUN	O	O
by	ADP	O	O
gavages	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
group	NOUN	O	O
ADR+LOS(12	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
second	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
ADR	PROPN	O	I-Entity
.	PUNCT	O	O

Short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
losartan	ADJ	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
besides	ADP	O	O
antihypertensive	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
improved	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
ameliorated	VERB	O	O
glomerulosclerosis	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
decreased	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Prolonged	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
losartan	NOUN	O	I-Entity
showed	VERB	O	O
further	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
reduced	ADJ	O	O
progression	NOUN	O	O
of	ADP	O	O
tubular	NOUN	O	O
atrophy	NOUN	O	I-Entity
and	CCONJ	O	O
interstitial	ADJ	O	B-Entity
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
thus	ADV	O	O
preventing	VERB	O	O
heavy	ADJ	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Losartan	PROPN	O	I-Entity
reduced	VERB	O	O
uraemia	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
urea	NOUN	O	I-Entity
clearance	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
ADR	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
examination	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
losartan	NOUN	O	I-Entity
could	VERB	O	O
prevent	VERB	O	O
tubular	ADJ	O	O
atrophy	NOUN	O	I-Entity
,	PUNCT	O	O
interstitial	ADJ	O	O
infiltration	NOUN	O	O
and	CCONJ	O	O
fibrosis	NOUN	O	I-Entity
in	ADP	O	O
ADR	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Losartan	PROPN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
focal	ADJ	O	B-Entity
segmental	ADJ	O	I-Entity
glomerulosclerosis	NOUN	O	I-Entity
to	PART	O	O
end	VERB	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (19020118)

The	DET	O	O
risks	NOUN	O	O
of	ADP	O	O
aprotinin	NOUN	O	O
and	CCONJ	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
one	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
1188	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
postoperative	ADJ	O	O
complications	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
aprotinin	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
unselected	ADJ	O	O
,	PUNCT	O	O
consecutive	ADJ	O	O
cohort	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
first	ADJ	O	O
5	NUM	O	O
mo	NOUN	O	O
,	PUNCT	O	O
596	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
aprotinin	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
A	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
next	ADJ	O	O
5	NUM	O	O
mo	NOUN	O	O
,	PUNCT	O	O
592	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
Group	PROPN	O	O
T	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postoperatively	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
Group	PROPN	O	O
T	PROPN	O	O
(	PUNCT	O	O
4.6%	NUM	O	O
vs	ADP	O	O
1.2%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O

Persistent	ADJ	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
(	PUNCT	O	O
7.9%	NUM	O	O
vs	ADP	O	O
2.3%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.020	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
9.7%	NUM	O	O
vs	ADP	O	O
1.7%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
T	PROPN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
valve	NOUN	O	O
surgery	NOUN	O	O
subgroup	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
among	ADP	O	O
primary	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
more	ADV	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
Group	PROPN	O	O
A	PROPN	O	O
(	PUNCT	O	O
5.8%	NUM	O	O
vs	ADP	O	O
2.0%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.027	NUM	O	O
;	PUNCT	O	O
22.5%	NUM	O	O
vs	ADP	O	O
15.2%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.036	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
aprotinin	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
in	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
risk	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
recommended	VERB	O	O
in	ADP	O	O
valve	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19108278)

The	DET	O	O
biological	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
the	DET	O	O
optical	ADJ	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
optical	ADJ	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
their	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	NOUN	O	O
and	CCONJ	O	O
antiarrhythmic	ADJ	O	O
activities.2	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
blocking	VERB	O	O
the	DET	O	O
positive	ADJ	O	O
inotropic	NOUN	O	O
and	CCONJ	O	O
chronotropic	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
isoprenaline	VERB	O	I-Entity
,	PUNCT	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O

-propranolol	PUNCT	O	I-Entity
had	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
one	NUM	O	O
hundredth	NOUN	O	O
the	DET	O	O
potency	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
-)-propranolol	PROPN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
dose	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-propranolol	PUNCT	O	I-Entity
which	ADJ	O	O
attenuated	VERB	O	O
the	DET	O	O
responses	NOUN	O	O
to	ADP	O	O
isoprenaline	VERB	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
prolongation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
PR	NOUN	O	O
interval	NOUN	O	O
of	ADP	O	O
the	DET	O	O
electrocardiogram.3	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
metabolic	NOUN	O	O
responses	VERB	O	O
to	ADP	O	O
isoprenaline	VERB	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
(	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
circulating	VERB	O	O
glucose	NOUN	O	I-Entity
,	PUNCT	O	O
lactate	NOUN	O	I-Entity
and	CCONJ	O	O
free	ADJ	O	O
fatty	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
all	DET	O	O
blocked	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
-)-propranolol	PROPN	O	I-Entity
.	PUNCT	O	O

-Propranolol	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
fatty	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
mobilization	NOUN	O	O
but	CCONJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
increments	NOUN	O	O
in	ADP	O	O
both	DET	O	O
lactate	NOUN	O	I-Entity
and	CCONJ	O	O
glucose.4	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
possessed	VERB	O	O
similar	ADJ	O	O
depressant	NOUN	O	O
potency	NOUN	O	O
on	ADP	O	O
isolated	ADJ	O	O
atrial	ADJ	O	O
muscle	NOUN	O	O
taken	VERB	O	O
from	ADP	O	O
guinea	NOUN	O	O
-	PUNCT	O	O
pigs.5	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
exhibited	VERB	O	O
similar	ADJ	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
potencies	NOUN	O	O
on	ADP	O	O
an	DET	O	O
isolated	ADJ	O	O
frog	NOUN	O	O
nerve	NOUN	O	O
preparation	NOUN	O	O
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
approximately	ADV	O	O
three	NUM	O	O
times	NOUN	O	O
that	DET	O	O
of	ADP	O	O
procaine	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
were	VERB	O	O
capable	ADJ	O	O
of	ADP	O	O
preventing	VERB	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
cats	NOUN	O	O
anaesthetized	VERB	O	O
with	ADP	O	O
halothane	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
mean	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
-)-propranolol	PROPN	O	I-Entity
was	VERB	O	O
0.09+/-0.02	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
whereas	ADP	O	O
that	DET	O	O
of	ADP	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-propranolol	NOUN	O	I-Entity
was	VERB	O	O
4.2+/-1.2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

-propranolol	CCONJ	O	I-Entity
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
prolongation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
PR	NOUN	O	O
interval	NOUN	O	O
of	ADP	O	O
the	DET	O	O
electrocardiogram	NOUN	O	O
.	PUNCT	O	O

Blockade	PROPN	O	O
of	ADP	O	O
arrhythmias	NOUN	O	I-Entity
with	ADP	O	O
both	DET	O	O
isomers	NOUN	O	O
was	VERB	O	O
surmountable	ADJ	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
adrenaline.7	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
capable	ADJ	O	O
of	ADP	O	O
reversing	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
ouabain	NOUN	O	I-Entity
in	ADP	O	O
anaesthetized	VERB	O	O
cats	NOUN	O	O
and	CCONJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
-)-propranolol	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
smaller	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-propranolol	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
species	NOUN	O	O
but	CCONJ	O	O
much	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
that	DET	O	O
required	VERB	O	O
to	PART	O	O
produce	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockade.8	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19139825)

Topotecan	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
radiotherapy	ADJ	O	O
in	ADP	O	O
unresectable	ADJ	O	O
glioblastoma	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
phase	NOUN	O	O
2	NUM	O	O
study	NOUN	O	O
.	PUNCT	O	O

Improving	VERB	O	O
glioblastoma	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
(	PUNCT	O	O
GBM	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
radio	NOUN	O	O
-	PUNCT	O	O
chemotherapy	NOUN	O	O
remains	VERB	O	O
a	DET	O	O
challenge	NOUN	O	O
.	PUNCT	O	O

Topotecan	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
attractive	ADJ	O	O
option	NOUN	O	O
as	ADP	O	O
it	PRON	O	O
exhibits	VERB	O	O
growth	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
glioma	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
brain	NOUN	O	O
penetration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
radiotherapy	ADJ	O	O
(	PUNCT	O	O
60	NUM	O	O
Gy/30	SYM	O	O
fractions/40	ADJ	O	O
days	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
topotecan	NOUN	O	I-Entity
(	PUNCT	O	O
0.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2)/day	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
-	SYM	O	O
5	NUM	O	O
on	ADP	O	O
weeks	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
50	NUM	O	O
adults	NOUN	O	O
with	ADP	O	O
histologically	ADV	O	O
proven	VERB	O	O
and	CCONJ	O	O
untreated	ADJ	O	O
GBM	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
hematological	ADJ	O	O
toxicities	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
grade	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
hematological	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mainly	ADV	O	O
lymphopenia	NOUN	O	I-Entity
and	CCONJ	O	O
neutropenia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Topotecan	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
radiotherapy	NOUN	O	O
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
response	NOUN	O	O
and	CCONJ	O	O
stabilization	NOUN	O	O
concerned	ADJ	O	O
one	NUM	O	O
-	PUNCT	O	O
third	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
study	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
show	VERB	O	O
increased	VERB	O	O
benefits	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
survival	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unresectable	ADJ	O	O
GBM	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19154241)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
hyperparathyroidism	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
reviews	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
parathyroid	ADJ	O	O
glands	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
pathogenesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
options	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patient	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
recurrent	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
to	PART	O	O
better	ADV	O	O
understand	VERB	O	O
the	DET	O	O
disease	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Primary	ADJ	O	B-Entity
hyperparathyroidism	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
potentially	ADV	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

PRACTICAL	PROPN	O	O
IMPLICATIONS	PROPN	O	O
:	PUNCT	O	O
As	ADV	O	O
much	ADV	O	O
as	ADP	O	O
15%	NUM	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
become	VERB	O	O
hypercalcemic	ADJ	O	I-Entity
.	PUNCT	O	O

By	ADP	O	O
routinely	ADV	O	O
monitoring	VERB	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
healthcare	NOUN	O	O
providers	NOUN	O	O
can	VERB	O	O
improve	VERB	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
of	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19178808)

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
compare	VERB	O	O
surgical	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
intraoperative	ADJ	O	O
bleeding	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
intraoperative	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
functional	ADJ	O	O
endoscopic	NOUN	O	O
sinus	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
FESS	PROPN	O	O
)	PUNCT	O	O
using	VERB	O	O
flexible	ADJ	O	O
reinforced	VERB	O	O
laryngeal	NOUN	O	O
mask	NOUN	O	O
airway	NOUN	O	O
(	PUNCT	O	O
FRLMA	PROPN	O	O
)	PUNCT	O	O
versus	ADP	O	O
endotracheal	ADJ	O	O
tube	NOUN	O	O
(	PUNCT	O	O
ETT	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
maintaining	VERB	O	O
controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
anesthesia	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	I-Entity
-	PUNCT	O	O
remifentanil	NOUN	O	I-Entity
total	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Sixty	NUM	O	O
normotensive	ADJ	O	O
American	ADJ	O	O
Society	PROPN	O	O
of	ADP	O	O
Anesthesiologists	PROPN	O	O
I	PROPN	O	O
-	PUNCT	O	O
II	PROPN	O	O
adult	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
FESS	PROPN	O	O
under	ADP	O	O
controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
anesthesia	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	I-Entity
-	PUNCT	O	O
remifentanil	NOUN	O	I-Entity
-	PUNCT	O	O
TIVA	PROPN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
group	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
FRLMA	PROPN	O	O
;	PUNCT	O	O
group	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
ETT	PROPN	O	O
.	PUNCT	O	O

Hemorrhage	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
visibility	NOUN	O	O
of	ADP	O	O
the	DET	O	O
operative	ADJ	O	O
field	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
according	VERB	O	O
to	ADP	O	O
a	DET	O	O
six	NUM	O	O
-	PUNCT	O	O
point	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
achieved	VERB	O	O
within	ADP	O	O
a	DET	O	O
shorter	ADJ	O	O
period	NOUN	O	O
using	VERB	O	O
laryngeal	NOUN	O	O
mask	NOUN	O	O
using	VERB	O	O
lower	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
remifentanil	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
total	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
remifentanil	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
airway	NOUN	O	O
management	NOUN	O	O
using	VERB	O	O
FRLMA	PROPN	O	O
during	ADP	O	O
controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
anesthesia	NOUN	O	O
provided	VERB	O	O
better	ADJ	O	O
surgical	ADJ	O	O
conditions	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
quality	NOUN	O	O
of	ADP	O	O
operative	ADJ	O	O
field	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
and	CCONJ	O	O
allowed	VERB	O	O
for	ADP	O	O
convenient	ADJ	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
with	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
remifentanil	NOUN	O	I-Entity
during	ADP	O	O
TIVA	PROPN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
FESS	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (19184102)

Nonalcoholic	ADJ	O	B-Entity
fatty	ADJ	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
during	ADP	O	O
valproate	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Valproic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
many	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
use	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
nonalcoholic	ADJ	O	B-Entity
fatty	ADJ	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
NAFLD	PROPN	O	I-Entity
)	PUNCT	O	O
arising	VERB	O	O
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
obesity	NOUN	O	I-Entity
during	ADP	O	O
VPA	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Laboratory	PROPN	O	O
data	NOUN	O	O
revealed	VERB	O	O
hyperinsulinemia	NOUN	O	I-Entity
with	ADP	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
patient	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
normalization	NOUN	O	O
of	ADP	O	O
metabolic	NOUN	O	O
and	CCONJ	O	O
endocrine	NOUN	O	O
parameters	NOUN	O	O
;	PUNCT	O	O
moreover	ADV	O	O
,	PUNCT	O	O
ultrasound	ADJ	O	O
measurements	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
complete	ADJ	O	O
normalization	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
obesity	NOUN	O	I-Entity
,	PUNCT	O	O
hyperinsulinemia	NOUN	O	I-Entity
,	PUNCT	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
VPA	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
all	DET	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
NAFLD	PROPN	O	I-Entity
;	PUNCT	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
is	VERB	O	O
reversible	ADJ	O	O
after	ADP	O	O
VPA	PROPN	O	I-Entity
withdrawal	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19263707)

Carbimazole	PROPN	O	I-Entity
induced	VERB	O	O
ANCA	PROPN	O	B-Entity
positive	ADJ	O	I-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

Anti	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
thyroid	ADJ	O	I-Entity
drugs	NOUN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
carbimazole	NOUN	O	I-Entity
and	CCONJ	O	O
propylthiouracil	NOUN	O	I-Entity
(	PUNCT	O	O
PTU	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	B-Entity
medications	NOUN	O	I-Entity
.	PUNCT	O	O

Antineutrophil	PROPN	O	B-Entity
cytoplasmic	ADJ	O	I-Entity
antibody	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
ANCA)--associated	VERB	O	I-Entity
vasculitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
antithyroidmedications	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
ANCA	PROPN	O	O
positive	ADJ	O	O
carbimazole	NOUN	O	I-Entity
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
episode	NOUN	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
vasculitic	ADJ	O	I-Entity
skin	NOUN	O	B-Entity
rash	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
large	ADJ	O	O
joint	ADJ	O	O
arthritis	NOUN	O	I-Entity
,	PUNCT	O	O
pyrexia	NOUN	O	I-Entity
and	CCONJ	O	O
parotiditis	NOUN	O	I-Entity
but	CCONJ	O	O
no	DET	O	O
renal	ADJ	O	O
or	CCONJ	O	O
pulmonary	ADJ	O	O
involvement	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
referred	VERB	O	O
to	ADP	O	O
us	PRON	O	O
for	ADP	O	O
neurological	ADJ	O	O
evaluation	NOUN	O	O
because	ADP	O	O
he	PRON	O	O
had	VERB	O	O
difficulty	NOUN	O	O
in	ADP	O	O
getting	VERB	O	O
up	PART	O	O
from	ADP	O	O
squatting	VERB	O	O
position	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
suspected	VERB	O	O
to	PART	O	O
have	VERB	O	O
myositis	NOUN	O	I-Entity
.	PUNCT	O	O

Carbimazole	PROPN	O	I-Entity
and	CCONJ	O	O
methimazole	NOUN	O	I-Entity
have	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
reported	VERB	O	O
ANCA	PROPN	O	O
positive	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
than	ADP	O	O
PUT	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
the	DET	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
ANCA	PROPN	O	O
positive	ADJ	O	O
carbimazole	NOUN	O	I-Entity
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
case	NOUN	O	O
reported	VERB	O	O
from	ADP	O	O
India	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (19293073)

Aspirin	PROPN	O	I-Entity
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
update	NOUN	O	O
of	ADP	O	O
the	DET	O	O
evidence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
U.S.	PROPN	O	O
Preventive	PROPN	O	O
Services	PROPN	O	O
Task	PROPN	O	O
Force	PROPN	O	O
.	PUNCT	O	O

Coronary	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
cerebrovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
are	VERB	O	O
leading	VERB	O	O
causes	NOUN	O	O
of	ADP	O	O
death	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
2002	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
U.S.	PROPN	O	O
Preventive	PROPN	O	O
Services	PROPN	O	O
Task	PROPN	O	O
Force	PROPN	O	O
(	PUNCT	O	O
USPSTF	PROPN	O	O
)	PUNCT	O	O
strongly	ADV	O	O
recommended	VERB	O	O
that	ADP	O	O
clinicians	NOUN	O	O
discuss	VERB	O	O
aspirin	NOUN	O	I-Entity
with	ADP	O	O
adults	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
coronary	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
benefits	NOUN	O	O
and	CCONJ	O	O
harms	NOUN	O	O
of	ADP	O	O
taking	VERB	O	O
aspirin	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
,	PUNCT	O	O
strokes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

STUDY	VERB	O	O
SELECTION	NOUN	O	O
:	PUNCT	O	O
English	PROPN	O	O
-	PUNCT	O	O
language	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trials	NOUN	O	O
(	PUNCT	O	O
RCTs	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
studies	NOUN	O	O
;	PUNCT	O	O
meta	ADJ	O	O
-	PUNCT	O	O
analyses	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
systematic	ADJ	O	O
reviews	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
versus	ADP	O	O
control	NOUN	O	O
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
CVD	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
selected	VERB	O	O
to	PART	O	O
answer	VERB	O	O
the	DET	O	O
following	ADJ	O	O
questions	NOUN	O	O
:	PUNCT	O	O
Does	VERB	O	O
aspirin	NOUN	O	I-Entity
decrease	NOUN	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
events	NOUN	O	O
,	PUNCT	O	O
strokes	NOUN	O	I-Entity
,	PUNCT	O	O
death	NOUN	O	O
from	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
events	NOUN	O	O
or	CCONJ	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
all	DET	O	O
-	PUNCT	O	O
cause	NOUN	O	O
mortality	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
without	ADP	O	O
known	VERB	O	O

CVD	PROPN	O	I-Entity
?	PUNCT	O	O

Does	VERB	O	O
aspirin	NOUN	O	I-Entity
increase	VERB	O	O
gastrointestinal	ADJ	O	B-Entity
bleeding	NOUN	O	I-Entity
or	CCONJ	O	O
hemorrhagic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
?	PUNCT	O	O

DATA	NOUN	O	O
SYNTHESIS	NOUN	O	O
:	PUNCT	O	O
New	ADJ	O	O
evidence	NOUN	O	O
from	ADP	O	O
1	NUM	O	O
good	ADJ	O	O
-	PUNCT	O	O
quality	NOUN	O	O
RCT	PROPN	O	O
,	PUNCT	O	O
1	NUM	O	O
good	ADJ	O	O
-	PUNCT	O	O
quality	NOUN	O	O
meta	NOUN	O	O
-	PUNCT	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
fair	ADJ	O	O
-	PUNCT	O	O
quality	NOUN	O	O
subanalyses	NOUN	O	O
of	ADP	O	O
RCTs	PROPN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
aspirin	NOUN	O	I-Entity
use	NOUN	O	O
reduces	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
CVD	PROPN	O	I-Entity
events	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
known	VERB	O	O
CVD	PROPN	O	I-Entity
.	PUNCT	O	O

Men	NOUN	O	O
in	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
experienced	VERB	O	O
fewer	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
and	CCONJ	O	O
women	NOUN	O	O
experienced	VERB	O	O
fewer	ADJ	O	O
ischemic	ADJ	O	O
strokes	NOUN	O	I-Entity
.	PUNCT	O	O

Aspirin	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
affect	VERB	O	O
CVD	PROPN	O	I-Entity
mortality	NOUN	O	O
or	CCONJ	O	O
all	DET	O	O
-	PUNCT	O	O
cause	NOUN	O	O
mortality	NOUN	O	O
in	ADP	O	O
either	DET	O	O
men	NOUN	O	O
or	CCONJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
for	ADP	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
major	ADJ	O	O
bleeding	NOUN	O	I-Entity
events	NOUN	O	O
,	PUNCT	O	O
primarily	ADV	O	O
gastrointestinal	ADJ	O	B-Entity
bleeding	NOUN	O	I-Entity
events	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
both	DET	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Men	NOUN	O	O
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
with	ADP	O	O
aspirin	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
new	ADJ	O	O
RCT	PROPN	O	O
and	CCONJ	O	O
meta	ADJ	O	O
-	PUNCT	O	O
analysis	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significantly	ADV	O	O
increased	VERB	O	O
.	PUNCT	O	O

New	ADJ	O	O
evidence	NOUN	O	O
on	ADP	O	O
aspirin	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
CVD	PROPN	O	I-Entity
is	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
RCTs	NOUN	O	O
varied	VERB	O	O
,	PUNCT	O	O
which	ADJ	O	O
prevented	VERB	O	O
the	DET	O	O
estimation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
appropriate	ADJ	O	O
dose	NOUN	O	O
for	ADP	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
.	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
strokes	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
.	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
use	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
serious	ADJ	O	O
bleeding	NOUN	O	I-Entity
events	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19338378)

Reducing	VERB	O	O
harm	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
anticoagulation	NOUN	O	O
:	PUNCT	O	O
practical	ADJ	O	O
considerations	NOUN	O	O
of	ADP	O	O
argatroban	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Argatroban	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
hepatically	ADV	O	O
metabolized	VERB	O	O
,	PUNCT	O	O
direct	ADJ	O	O
thrombin	NOUN	O	O
inhibitor	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
prophylaxis	NOUN	O	O
or	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
at	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
undergoing	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
PCI	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
review	NOUN	O	O
is	VERB	O	O
to	PART	O	O
summarize	VERB	O	O
practical	ADJ	O	O
considerations	NOUN	O	O
of	ADP	O	O
argatroban	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
HIT	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
US	PROPN	O	O
FDA	PROPN	O	O
-	PUNCT	O	O
recommended	VERB	O	O
argatroban	ADJ	O	I-Entity
dose	NOUN	O	O
in	ADP	O	O
HIT	PROPN	O	I-Entity
is	VERB	O	O
2	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
(	PUNCT	O	O
reduced	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
paediatric	ADJ	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
adjusted	VERB	O	O
to	PART	O	O
achieve	VERB	O	O
activated	VERB	O	O
partial	ADJ	O	O
thromboplastin	NOUN	O	O
times	NOUN	O	O
(	PUNCT	O	O
aPTTs	PROPN	O	O
)	PUNCT	O	O
1.5	NUM	O	O
-	SYM	O	O
3	NUM	O	O
times	NOUN	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
not	ADV	O	O
>	VERB	O	O
100	NUM	O	O
seconds	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Contemporary	ADJ	O	O
experiences	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
reduced	VERB	O	O
doses	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
needed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
conditions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
hepatic	ADJ	O	O
hypoperfusion	NOUN	O	O
,	PUNCT	O	O
e.g.	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
yet	CCONJ	O	O
are	VERB	O	O
unnecessary	ADJ	O	O
for	ADP	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
adult	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
race	NOUN	O	O
/	PUNCT	O	O
ethnicity	NOUN	O	O
or	CCONJ	O	O
obesity	NOUN	O	I-Entity
.	PUNCT	O	O

Argatroban	PROPN	O	I-Entity
0.5	NUM	O	O
-	SYM	O	O
1.2	NUM	O	O

For	ADP	O	O
PCI	PROPN	O	O
,	PUNCT	O	O
argatroban	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
hepatically	ADV	O	O
impaired	VERB	O	O
patients	NOUN	O	O
;	PUNCT	O	O
dose	NOUN	O	O
adjustment	NOUN	O	O
is	VERB	O	O
unnecessary	ADJ	O	O
for	ADP	O	O
adult	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
race	NOUN	O	O
/	PUNCT	O	O
ethnicity	NOUN	O	O
or	CCONJ	O	O
obesity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
lesser	ADJ	O	O
doses	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
adequate	ADJ	O	O
with	ADP	O	O
concurrent	ADJ	O	O
glycoprotein	NOUN	O	O
IIb	PROPN	O	O
/	SYM	O	O
IIIa	PROPN	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

Argatroban	PROPN	O	I-Entity
prolongs	VERB	O	O
the	DET	O	O
International	PROPN	O	O
Normalized	PROPN	O	O
Ratio	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
published	VERB	O	O
approaches	NOUN	O	O
for	ADP	O	O
monitoring	VERB	O	O
the	DET	O	O
argatroban	NOUN	O	I-Entity
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
warfarin	NOUN	O	I-Entity
transition	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
followed	VERB	O	O
.	PUNCT	O	O

Major	ADJ	O	O
bleeding	VERB	O	I-Entity
with	ADP	O	O
argatroban	NOUN	O	I-Entity
is	VERB	O	O
0	NUM	O	O
-	PUNCT	O	O
10%	NUM	O	O
in	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
interventional	ADJ	O	O
setting	NOUN	O	O
and	CCONJ	O	O
0	NUM	O	O
-	PUNCT	O	O
5.8%	NUM	O	O
periprocedurally	NOUN	O	O
.	PUNCT	O	O

Argatroban	PROPN	O	I-Entity
has	VERB	O	O
no	DET	O	O
specific	ADJ	O	O
antidote	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
if	ADP	O	O
excessive	ADJ	O	O
anticoagulation	NOUN	O	O
occurs	VERB	O	O
,	PUNCT	O	O
argatroban	ADJ	O	I-Entity
infusion	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
stopped	VERB	O	O
or	CCONJ	O	O
reduced	VERB	O	O
.	PUNCT	O	O

Improved	ADJ	O	O
familiarity	NOUN	O	O
of	ADP	O	O
healthcare	NOUN	O	O
professionals	NOUN	O	O
with	ADP	O	O
argatroban	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
HIT	PROPN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
in	ADP	O	O
special	ADJ	O	O
populations	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
PCI	PROPN	O	O
,	PUNCT	O	O
may	VERB	O	O
facilitate	VERB	O	O
reduction	NOUN	O	O
of	ADP	O	O
harm	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
HIT	PROPN	O	I-Entity
(	PUNCT	O	O
e.g.	ADV	O	O
fewer	ADJ	O	O
thromboses	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
its	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
e.g.	VERB	O	O
fewer	ADJ	O	O
argatroban	ADJ	O	I-Entity
medication	NOUN	O	O
errors	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (19392810)

Rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
brain	NOUN	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
heroin	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
male	NOUN	O	O
under	ADP	O	O
methadone	NOUN	O	I-Entity
maintenance	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
are	VERB	O	O
several	ADJ	O	O
complications	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
heroin	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
,	PUNCT	O	O
some	DET	O	O
of	ADP	O	O
which	ADJ	O	O
are	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
may	VERB	O	O
aggravate	VERB	O	O
this	DET	O	O
problem	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
33-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
heroin	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
had	VERB	O	O
used	VERB	O	O
heroin	NOUN	O	I-Entity
since	ADP	O	O
age	NOUN	O	O
20	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
had	VERB	O	O
used	VERB	O	O
150	NUM	O	O
mg	NUM	O	O
methadone	NOUN	O	I-Entity
daily	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
found	VERB	O	O
unconsciousness	ADJ	O	I-Entity
at	ADP	O	O
home	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
sent	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
ICU	PROPN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
rhabdomyolysis	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
transfer	NOUN	O	O
to	ADP	O	O
an	DET	O	O
internal	ADJ	O	O
ward	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
noted	VERB	O	O
aphasia	NOUN	O	I-Entity
and	CCONJ	O	O
weakness	NOUN	O	I-Entity
of	ADP	O	O
his	ADJ	O	O
left	ADJ	O	O
limbs	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
MRI	PROPN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
cerebral	ADJ	O	B-Entity
ischemic	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Those	DET	O	O
using	VERB	O	O
methadone	NOUN	O	I-Entity
and	CCONJ	O	O
heroin	NOUN	O	I-Entity
simultaneously	ADV	O	O
may	VERB	O	O
increase	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
under	ADP	O	O
methadone	NOUN	O	I-Entity
maintenance	NOUN	O	O
therapy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
warned	VERB	O	O
regarding	VERB	O	O
these	DET	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Hypotheses	NOUN	O	O
of	ADP	O	O
heroin	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
heroin	NOUN	O	I-Entity
abusers	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19419794)

Increased	VERB	O	O
vulnerability	NOUN	O	O
to	PART	O	O
6-hydroxydopamine	NUM	O	I-Entity
lesion	NOUN	O	O
and	CCONJ	O	O
reduced	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
lacking	VERB	O	O
CB1	PROPN	O	O
cannabinoid	ADJ	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Motor	PROPN	O	O
impairment	NOUN	O	O
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
neuronal	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
proenkephalin	NOUN	O	I-Entity
(	PUNCT	O	O
PENK	PROPN	O	I-Entity
)	PUNCT	O	O
gene	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
caudate	NOUN	O	O
-	PUNCT	O	O
putamen	NOUN	O	O
(	PUNCT	O	O
CPu	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
6-OHDA	NUM	O	I-Entity
-	PUNCT	O	O
lesioned	VERB	O	O
and	CCONJ	O	O
treated	VERB	O	O
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA+benserazide	PROPN	O	I-Entity
)	PUNCT	O	O

A	DET	O	O
lesion	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
6-OHDA	NUM	O	I-Entity
produced	VERB	O	O
more	ADV	O	O
severe	ADJ	O	O
motor	NOUN	O	O
deterioration	NOUN	O	O
in	ADP	O	O
CB1	PROPN	O	O
KO	PROPN	O	O
mice	NOUN	O	O
accompanied	VERB	O	O
by	ADP	O	O
more	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
DA	PROPN	O	I-Entity
neurons	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
PENK	PROPN	O	I-Entity
gene	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CPu	NOUN	O	O
.	PUNCT	O	O

CB1	PROPN	O	O
KO	PROPN	O	O
mice	NOUN	O	O
exhibited	VERB	O	O
higher	ADJ	O	O
MDA	PROPN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
iNOS	ADJ	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CPu	NOUN	O	O
and	CCONJ	O	O
Cg	PROPN	O	O
compared	VERB	O	O
to	ADP	O	O
WT	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA+benserazide	NOUN	O	I-Entity
(	PUNCT	O	O
12	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
less	ADV	O	O
severe	ADJ	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
CB1	PROPN	O	O
KO	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
WT	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
cannabinoid	ADJ	O	O
CB1	NOUN	O	O
receptors	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
impairment	NOUN	O	O
and	CCONJ	O	O
DA	PROPN	O	I-Entity
lesion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
reduced	VERB	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
CB1	PROPN	O	O
receptors	NOUN	O	O
offers	VERB	O	O
neuroprotection	NOUN	O	O
against	ADP	O	O
dopaminergic	ADJ	O	O
lesion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19447152)

Animal	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
mania	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ouabain	NOUN	O	I-Entity
:	PUNCT	O	O
Evidence	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
submitochondrial	ADJ	O	O
particles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
brain	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intracerebroventricular	NOUN	O	O
(	PUNCT	O	O
ICV	PROPN	O	O
)	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
Na(+)/K(+)-ATPase	PROPN	O	I-Entity
inhibitor	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
mimic	VERB	O	O
some	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Herein	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
effects	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
ICV	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
achieve	VERB	O	O
this	DET	O	O
aim	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
injection	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
and	CCONJ	O	O
7	NUM	O	O
days	NOUN	O	O
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
ICV	PROPN	O	O
administration	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
concentrations	NOUN	O	O
of	ADP	O	O
10(-2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
10(-3)M	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
locomotion	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
the	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
field	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
thiobarbituric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
reactive	ADJ	O	O
substances	NOUN	O	O
(	PUNCT	O	O
TBARSs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O

superoxide	NOUN	O	I-Entity
production	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
submitochondrial	ADJ	O	O
particles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prefrontal	ADJ	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
hippocampus	NOUN	O	O
,	PUNCT	O	O
striatum	NOUN	O	O
and	CCONJ	O	O
amygdala	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
ouabain	NOUN	O	I-Entity
at	ADP	O	O
10(-2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
10(-3)M	NUM	O	O
induced	VERB	O	O
hyperlocomotion	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
response	NOUN	O	O
remained	VERB	O	O
up	PART	O	O
to	PART	O	O
7	NUM	O	O
days	NOUN	O	O
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
ICV	PROPN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
observed	VERB	O	O
that	ADP	O	O
the	DET	O	O
persistent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
spontaneous	ADJ	O	O
locomotion	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
TBARS	PROPN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
superoxide	NOUN	O	I-Entity
generation	NOUN	O	O
in	ADP	O	O
submitochondrial	ADJ	O	O
particles	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prefrontal	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
striatum	NOUN	O	O
and	CCONJ	O	O
amygdala	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
ouabain	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
to	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19515070)

Intraoperative	ADJ	O	O
dialysis	NOUN	O	O
during	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
with	ADP	O	O
citrate	NOUN	O	I-Entity
dialysate	NOUN	O	O
.	PUNCT	O	O

Liver	PROPN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
acutely	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
fulminant	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
carries	VERB	O	O
high	ADJ	O	O
intraoperative	ADJ	O	O
and	CCONJ	O	O
immediate	ADJ	O	O
postoperative	ADJ	O	O
risks	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
are	VERB	O	O
increased	VERB	O	O
with	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
concomitant	ADJ	O	O
acute	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
AKI	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
intraoperative	ADJ	O	O
dialysis	NOUN	O	O
is	VERB	O	O
sometimes	ADV	O	O
required	VERB	O	O
to	PART	O	O
allow	VERB	O	O
the	DET	O	O
transplant	NOUN	O	O
to	PART	O	O
proceed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
derangements	NOUN	O	O
in	ADP	O	O
the	DET	O	O
procoagulant	NOUN	O	O
and	CCONJ	O	O
anticoagulant	NOUN	O	O
pathways	NOUN	O	O
during	ADP	O	O
fulminant	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
difficulties	NOUN	O	O
with	ADP	O	O
anticoagulation	NOUN	O	O
during	ADP	O	O
dialysis	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
continued	VERB	O	O
in	ADP	O	O
the	DET	O	O
operating	NOUN	O	O
room	NOUN	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
anticoagulation	NOUN	O	O
is	VERB	O	O
unsafe	ADJ	O	O
and	CCONJ	O	O
regional	ADJ	O	O
citrate	NOUN	O	I-Entity
anticoagulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
functional	ADJ	O	O
liver	NOUN	O	O
carries	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
citrate	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Citrate	PROPN	O	I-Entity
dialysate	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
dialysate	NOUN	O	O
with	ADP	O	O
citric	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
for	ADP	O	O
anticoagulation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
heparin	NOUN	O	I-Entity
or	CCONJ	O	O
regional	ADJ	O	O
citrate	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
with	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fulminant	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
associated	VERB	O	O
AKI	PROPN	O	I-Entity
who	NOUN	O	O
underwent	VERB	O	O
intraoperative	ADJ	O	O
dialytic	ADJ	O	O
support	NOUN	O	O
during	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
anticoagulated	VERB	O	O
with	ADP	O	O
citrate	NOUN	O	I-Entity
dialysate	NOUN	O	O
during	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
tolerated	VERB	O	O
the	DET	O	O
procedure	NOUN	O	O
well	ADV	O	O
without	ADP	O	O
any	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
citrate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
maintained	VERB	O	O
adequate	ADJ	O	O
anticoagulation	NOUN	O	O
for	ADP	O	O
patency	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dialysis	NOUN	O	O
circuit	NOUN	O	O
.	PUNCT	O	O

Citrate	PROPN	O	I-Entity
dialysate	NOUN	O	O
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
alternative	NOUN	O	O
for	ADP	O	O
intradialytic	ADJ	O	O
support	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
in	ADP	O	O
fulminant	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19531695)

Delirium	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
toxic	ADJ	O	O
flecainide	ADJ	O	I-Entity
plasma	NOUN	O	O
concentrations	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pharmacokinetic	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
with	ADP	O	O
paroxetine	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
flecainide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
delirium	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
pharmacokinetic	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
with	ADP	O	O
paroxetine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
69-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
female	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
confusion	NOUN	O	I-Entity
and	CCONJ	O	O
paranoia	NOUN	O	I-Entity
over	ADP	O	O
the	DET	O	O
past	ADJ	O	O
several	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
admission	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
taking	VERB	O	O
carvedilol	NOUN	O	I-Entity
12	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
warfarin	VERB	O	I-Entity
2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
levothyroxine	VERB	O	I-Entity
100	NUM	O	O
microg	NOUN	O	O

/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
pantoprazole	VERB	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
paroxetine	VERB	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
flecainide	ADV	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
.	PUNCT	O	O

Flecainide	PROPN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
started	VERB	O	O
2	NUM	O	O
weeks	NOUN	O	O
prior	ADV	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	ADJ	O	O
test	NOUN	O	O
findings	NOUN	O	O
on	ADP	O	O
admission	NOUN	O	O
were	VERB	O	O
notable	ADJ	O	O
only	ADV	O	O
for	ADP	O	O
a	DET	O	O
flecainide	ADJ	O	I-Entity
plasma	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
1360	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
reference	NOUN	O	O
range	VERB	O	O
200	NUM	O	O
-	SYM	O	O
1000	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
metabolic	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
between	ADP	O	O
flecainide	NOUN	O	I-Entity
and	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
for	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O

Paroxetine	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
flecainide	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
.	PUNCT	O	O

Her	ADJ	O	O
delirium	NOUN	O	I-Entity
resolved	VERB	O	O
3	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Flecainide	PROPN	O	I-Entity
and	CCONJ	O	O

pharmacologically	ADV	O	O
similar	ADJ	O	O
agents	NOUN	O	O
that	ADJ	O	O
interact	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	I-Entity
channels	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
delirium	NOUN	O	I-Entity
in	ADP	O	O
susceptible	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
MEDLINE	PROPN	O	O
search	NOUN	O	O
(	PUNCT	O	O
1966-January	ADJ	O	O
2009	NUM	O	O
)	PUNCT	O	O
revealed	VERB	O	O
one	NUM	O	O
in	ADP	O	O
vivo	NOUN	O	O
pharmacokinetic	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
flecainide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
CYP2D6	NOUN	O	O
substrate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
CYP2D6	PROPN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
3	NUM	O	O
case	NOUN	O	O
reports	NOUN	O	O
of	ADP	O	O
flecainide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
flecainide	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
probable	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
delirium	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
Horn	PROPN	O	O
Drug	NOUN	O	O
Interaction	PROPN	O	O
Probability	PROPN	O	O
Scale	PROPN	O	O
indicates	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
pharmacokinetic	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
between	ADP	O	O
flecainide	NOUN	O	I-Entity
and	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
.	PUNCT	O	O

Supratherapeutic	ADJ	O	O
flecainide	NOUN	O	I-Entity
plasma	NOUN	O	O
concentrations	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
toxicity	NOUN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
when	ADV	O	O
flecainide	NOUN	O	I-Entity
is	VERB	O	O
prescribed	VERB	O	O
with	ADP	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
potent	ADJ	O	O
CYP2D6	PROPN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
flecainide	ADJ	O	I-Entity
plasma	NOUN	O	O
concentrations	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
closely	ADV	O	O
with	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
CYP2D6	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19549709)

Efficacy	NOUN	O	O
of	ADP	O	O
everolimus	NOUN	O	I-Entity
(	PUNCT	O	O
RAD001	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
NSCLC	PROPN	O	I-Entity
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
alone	ADV	O	O
or	CCONJ	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
EGFR	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	PROPN	O	O
:	PUNCT	O	O
Treatment	NOUN	O	O
options	NOUN	O	O
are	VERB	O	O
scarce	ADJ	O	O
in	ADP	O	O
pretreated	VERB	O	O
advanced	ADJ	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RAD001	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
oral	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mammalian	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
rapamycin	NOUN	O	I-Entity
(	PUNCT	O	O
mTOR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
has	VERB	O	O
shown	VERB	O	O
phase	NOUN	O	O
I	PRON	O	O
efficacy	VERB	O	O
in	ADP	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Stage	VERB	O	O
IIIb	PROPN	O	O
or	CCONJ	O	O
IV	PROPN	O	O
NSCLC	PROPN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
two	NUM	O	O
or	CCONJ	O	O
fewer	ADJ	O	O
prior	ADJ	O	O
chemotherapy	NOUN	O	O
regimens	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
platinum	NOUN	O	I-Entity
based	VERB	O	O
(	PUNCT	O	O
stratum	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
receptor	NOUN	O	O
tyrosine	NOUN	O	I-Entity
kinase	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
stratum	ADV	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
received	VERB	O	O
RAD001	SYM	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
until	ADP	O	O
progression	NOUN	O	O
or	CCONJ	O	O
unacceptable	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Analyses	NOUN	O	O
of	ADP	O	O
markers	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
mTOR	PROPN	O	O
pathway	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	PART	O	O
on	ADP	O	O
archival	ADJ	O	O
tumor	NOUN	O	I-Entity
from	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
using	VERB	O	O
immunohistochemistry	NOUN	O	O
(	PUNCT	O	O
IHC	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
direct	ADJ	O	O
mutation	NOUN	O	O
sequencing	NOUN	O	O
.	PUNCT	O	O

Common	PROPN	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
grade	NOUN	O	O
3	NUM	O	O
events	NOUN	O	O
were	VERB	O	O
fatigue	NOUN	O	I-Entity
,	PUNCT	O	O
dyspnea	NOUN	O	I-Entity
,	PUNCT	O	O
stomatitis	NOUN	O	I-Entity
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Pneumonitis	PROPN	O	I-Entity
,	PUNCT	O	O
probably	ADV	O	O
or	CCONJ	O	O
possibly	ADV	O	O
related	VERB	O	O
,	PUNCT	O	O
mainly	ADV	O	O
grade	NOUN	O	O
1/2	NUM	O	O
,	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
25%	NUM	O	O
.	PUNCT	O	O

RAD001	SYM	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
showing	VERB	O	O
modest	ADJ	O	O
clinical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
pretreated	VERB	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
RAD001	PROPN	O	I-Entity
plus	CCONJ	O	O
standard	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
metastatic	NOUN	O	O

NSCLC	PROPN	O	I-Entity
continues	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19553912)

Posttransplant	ADJ	O	O
anemia	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
.	PUNCT	O	O

Posttransplant	ADJ	O	O
anemia	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
problem	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
hinder	VERB	O	O
patients	NOUN	O	O
'	PART	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
factors	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
identified	VERB	O	O
that	ADP	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
posttransplant	ADJ	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
of	ADP	O	O
which	ADJ	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
is	VERB	O	O
most	ADV	O	O
important	ADJ	O	O
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
mammalian	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
rapamycin	NOUN	O	I-Entity
inhibitor	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
as	ADP	O	O
playing	VERB	O	O
a	DET	O	O
special	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
posttransplant	ADJ	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
review	NOUN	O	O
considers	VERB	O	O
anemia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
its	ADJ	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
management	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19655282)

Coronary	ADJ	O	O
computerized	ADJ	O	O
tomography	NOUN	O	O
angiography	NOUN	O	O
for	ADP	O	O
rapid	ADJ	O	O
discharge	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Most	ADJ	O	O
patients	NOUN	O	O
presenting	VERB	O	O
to	ADP	O	O
emergency	NOUN	O	O
departments	NOUN	O	O
(	PUNCT	O	O
EDs	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
are	VERB	O	O
admitted	VERB	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
12	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
receive	VERB	O	O
a	DET	O	O
"	PUNCT	O	O
rule	NOUN	O	O
out	PART	O	O
acute	ADJ	O	B-Entity
coronary	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
"	PUNCT	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
often	ADV	O	O
with	ADP	O	O
noninvasive	ADJ	O	O
testing	NOUN	O	O
prior	ADV	O	O
to	PART	O	O
discharge	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
coronary	ADJ	O	O
computerized	NOUN	O	O
tomography	NOUN	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
CTA	PROPN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
identifying	VERB	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
low	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
who	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
safely	ADV	O	O
discharged	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
unclear	ADJ	O	O
whether	ADP	O	O
a	DET	O	O
coronary	ADJ	O	O
CTA	NOUN	O	O
strategy	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
efficacious	ADJ	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
coronary	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
may	VERB	O	O
account	VERB	O	O
for	ADP	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
whether	ADP	O	O
a	DET	O	O
negative	ADJ	O	O
coronary	ADJ	O	O
CTA	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
could	VERB	O	O
identify	VERB	O	O
a	DET	O	O
subset	NOUN	O	O
safe	ADJ	O	O
for	ADP	O	O
discharge	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
CTA	PROPN	O	O
for	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
ED	NOUN	O	O
with	ADP	O	O
cocaineassociated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
(	PUNCT	O	O
self	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
or	CCONJ	O	O
positive	ADJ	O	O
urine	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
coronary	ADJ	O	O
CTA	PROPN	O	O
(	PUNCT	O	O
maximal	ADJ	O	O
stenosis	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
discharged	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
30-day	ADJ	O	O
cardiovascular	ADJ	O	O
death	NOUN	O	O
or	CCONJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
59	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
>	X	O	O

During	ADP	O	O
the	DET	O	O
30-day	NUM	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
patients	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
a	DET	O	O
cardiovascular	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
0%	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
0	NUM	O	O
-	PUNCT	O	O
6.1%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
patient	NOUN	O	O
sustained	VERB	O	O
a	DET	O	O
nonfatal	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
0%	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
0	NUM	O	O
-	PUNCT	O	O
6.1%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myocardial	NOUN	O	B-Entity
ischemia	NOUN	O	I-Entity
can	VERB	O	O
result	VERB	O	O
from	ADP	O	O
coronary	ADJ	O	O
vasoconstriction	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
associated	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
ischemic	NOUN	O	I-Entity
ECG	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
TIMI	PROPN	O	O
risk	NOUN	O	O
score	NOUN	O	O


-DOCSTART- (19715529)

Late	ADJ	O	O
fulminant	ADJ	O	O
posterior	ADJ	O	B-Entity
reversible	ADJ	O	I-Entity
encephalopathy	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
.	PUNCT	O	O

Posterior	PROPN	O	B-Entity
leukoencephalopathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
calcineurin	NOUN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
severe	ADJ	O	O
complication	NOUN	O	O
that	ADJ	O	O
results	VERB	O	O
from	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
immunosuppressive	ADJ	O	O
agents	NOUN	O	O
(	PUNCT	O	O
primarily	ADV	O	O
those	DET	O	O
administered	VERB	O	O
after	ADP	O	O
a	DET	O	O
liver	NOUN	O	O
or	CCONJ	O	O
kidney	NOUN	O	O
transplant	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
46-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
a	DET	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
in	ADP	O	O
our	ADJ	O	O
center	NOUN	O	O
as	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
alcoholic	ADJ	O	B-Entity
cirrhosis	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
whom	NOUN	O	O
either	CCONJ	O	O
a	DET	O	O
fulminant	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
posterior	ADJ	O	B-Entity
leukoencephalopathy	NOUN	O	I-Entity
or	CCONJ	O	O
posterior	ADJ	O	B-Entity
reversible	ADJ	O	I-Entity
encephalopathy	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
developed	VERB	O	O
110	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
transplant	NOUN	O	O
.	PUNCT	O	O

Switching	VERB	O	O
the	DET	O	O
immunosuppressive	ADJ	O	O
regimen	NOUN	O	O
from	ADP	O	O
tacrolimus	NOUN	O	I-Entity
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
improve	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
situation	NOUN	O	O
.	PUNCT	O	O

Posterior	ADJ	O	B-Entity
reversible	ADJ	O	I-Entity
encephalopathy	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
is	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (19728177)

Prolonged	VERB	O	O
hypothermia	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
bridge	NOUN	O	O
to	ADP	O	O
recovery	NOUN	O	O
for	ADP	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
and	CCONJ	O	O
intracranial	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
review	VERB	O	O
evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
treatment	NOUN	O	O
options	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
complicating	VERB	O	O
fulminant	NOUN	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
FHF	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
discuss	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
applications	NOUN	O	O
of	ADP	O	O
hypothermia	NOUN	O	I-Entity
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Case	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
observations	NOUN	O	O
from	ADP	O	O
a	DET	O	O
medical	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
(	PUNCT	O	O
MICU	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
tertiary	ADJ	O	O
care	NOUN	O	O
facility	NOUN	O	O
in	ADP	O	O
a	DET	O	O
27-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
with	ADP	O	O
FHF	PROPN	O	I-Entity
from	ADP	O	O
acetaminophen	NOUN	O	I-Entity
and	CCONJ	O	O
resultant	ADJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
patient	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
MICU	PROPN	O	O
after	ADP	O	O
being	VERB	O	O
found	VERB	O	O
unresponsive	ADJ	O	O
with	ADP	O	O
presumed	VERB	O	O
toxicity	NOUN	O	I-Entity
from	ADP	O	O
acetaminophen	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
ingested	VERB	O	O
over	ADP	O	O
a	DET	O	O
2-day	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Initial	ADJ	O	O
evaluation	NOUN	O	O
confirmed	VERB	O	O
FHF	PROPN	O	I-Entity
from	ADP	O	O
acetaminophen	NOUN	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
hyperosmolar	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
hyperventilation	NOUN	O	I-Entity
,	PUNCT	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
chemical	ADJ	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
initiated	VERB	O	O
therapeutic	ADJ	O	O
hypothermia	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
continued	VERB	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
re	ADP	O	O
-	PUNCT	O	O
warming	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	O
had	VERB	O	O
resolution	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
and	CCONJ	O	O
intracranial	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
FHF	PROPN	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
from	ADP	O	O
acetaminophen	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
prolonged	ADJ	O	O
therapeutic	ADJ	O	O
hypothermia	NOUN	O	I-Entity
could	VERB	O	O
potentially	ADV	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
life	NOUN	O	O
saving	VERB	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
bridge	NOUN	O	O
to	ADP	O	O
hepatic	ADJ	O	O
and	CCONJ	O	O
neurological	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
hypothermia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
this	DET	O	O
condition	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19815465)

Binasal	ADJ	O	B-Entity
visual	ADJ	O	I-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
specific	ADJ	O	O
to	ADP	O	O
vigabatrin	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
visual	ADJ	O	B-Entity
defects	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
vigabatrin	NOUN	O	I-Entity
(	PUNCT	O	O
VGB	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
four	NUM	O	O
people	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
were	VERB	O	O
grouped	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
current	ADJ	O	O
,	PUNCT	O	O
previous	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
exposure	NOUN	O	O
to	ADP	O	O
VGB	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
visual	ADJ	O	O
field	NOUN	O	O
constriction	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
59%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
currently	ADV	O	O
taking	VERB	O	O
VGB	NOUN	O	I-Entity
,	PUNCT	O	O
43%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
previously	ADV	O	O
took	VERB	O	O
VGB	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
24%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
exposure	NOUN	O	O
to	ADP	O	O
VGB	PROPN	O	I-Entity
.	PUNCT	O	O

Assessment	PROPN	O	O
of	ADP	O	O
retinal	ADJ	O	O
function	NOUN	O	O
revealed	VERB	O	O
abnormal	ADJ	O	O
responses	NOUN	O	O
in	ADP	O	O
48%	NUM	O	O
of	ADP	O	O
current	ADJ	O	O
VGB	NOUN	O	I-Entity
users	NOUN	O	O
and	CCONJ	O	O
22%	NUM	O	O
of	ADP	O	O
prior	ADJ	O	O
VGB	PROPN	O	I-Entity
users	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
without	ADP	O	O
previous	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
VGB	PROPN	O	I-Entity
.	PUNCT	O	O

Bilateral	ADJ	O	B-Entity
visual	ADJ	O	I-Entity
field	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
are	VERB	O	O
common	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treated	VERB	O	O
epilepsy	NOUN	O	I-Entity
population	NOUN	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
drug	NOUN	O	O
history	NOUN	O	O
.	PUNCT	O	O

Assessment	NOUN	O	O
by	ADP	O	O
conventional	ADJ	O	O
static	ADJ	O	O
perimetry	NOUN	O	O
may	VERB	O	O
neither	DET	O	O
be	VERB	O	O
sufficiently	ADV	O	O
sensitive	ADJ	O	O
nor	CCONJ	O	O
specific	ADJ	O	O
to	PART	O	O
reliably	ADV	O	O
identify	VERB	O	O
retinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
VGB	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19841052)

Smoking	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
among	ADP	O	O
people	NOUN	O	O
who	NOUN	O	O
use	VERB	O	O
injection	NOUN	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Little	PROPN	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
that	DET	O	O
smoking	NOUN	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
has	VERB	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
increasing	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
sought	VERB	O	O
to	PART	O	O
examine	VERB	O	O
whether	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
illicit	ADJ	O	O
drug	NOUN	O	O
has	VERB	O	O
become	VERB	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
HIV	PROPN	O	B-Entity
seroconversion	NOUN	O	I-Entity
among	ADP	O	O
daily	ADJ	O	O
smokers	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
changed	VERB	O	O
over	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
used	VERB	O	O
Cox	PROPN	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
regression	NOUN	O	O
and	CCONJ	O	O
divided	VERB	O	O
the	DET	O	O
study	NOUN	O	O
into	ADP	O	O
3	NUM	O	O
periods	NOUN	O	O
:	PUNCT	O	O
May	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
1996-Nov	NUM	O	O
.	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
1999	NUM	O	O
(	PUNCT	O	O
period	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Dec.	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
1999-Nov	NUM	O	O
.	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
2002	NUM	O	O
(	PUNCT	O	O
period	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Dec.	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
2002-Dec	NUM	O	O
.	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
2005	NUM	O	O
(	PUNCT	O	O
period	NOUN	O	O
3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
137	NUM	O	O
acquired	VERB	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
during	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
participants	NOUN	O	O
who	NOUN	O	O
reported	VERB	O	O
daily	ADJ	O	O
smoking	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
increased	VERB	O	O
from	ADP	O	O
11.6%	NUM	O	O
in	ADP	O	O
period	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
39.7%	NUM	O	O
in	ADP	O	O
period	NOUN	O	O
3	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
adjusting	VERB	O	O
for	ADP	O	O
potential	ADJ	O	O
confounders	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
HIV	PROPN	O	B-Entity
seroconversion	NOUN	O	I-Entity
among	ADP	O	O
participants	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
daily	ADJ	O	O
smokers	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
increased	VERB	O	O
over	ADP	O	O
time	NOUN	O	O
(	PUNCT	O	O
period	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
HR	NOUN	O	O
]	PUNCT	O	O
1.03	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	PROPN	O	O
]	PUNCT	O	O
0.57	NUM	O	O
-	SYM	O	O
1.85	NUM	O	O
;	PUNCT	O	O
period	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
HR	NOUN	O	O
1.68	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O

INTERPRETATION	NOUN	O	O
:	PUNCT	O	O
Smoking	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
HIV	PROPN	O	B-Entity
seroconversion	NOUN	O	I-Entity
among	ADP	O	O
people	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
injection	NOUN	O	O
drug	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
finding	NOUN	O	O
points	VERB	O	O
to	ADP	O	O
the	DET	O	O
urgent	ADJ	O	O
need	NOUN	O	O
for	ADP	O	O
evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
public	ADJ	O	O
health	NOUN	O	O
initiatives	NOUN	O	O
targeted	VERB	O	O
at	ADP	O	O
people	NOUN	O	O
who	NOUN	O	O
smoke	VERB	O	O
crack	VERB	O	B-Entity
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19914299)

Fluoxetine	NOUN	O	I-Entity
improves	VERB	O	O
the	DET	O	O
memory	NOUN	O	B-Entity
deficits	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
agent	NOUN	O	O
5-fluorouracil	PROPN	O	I-Entity
.	PUNCT	O	O

Cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
systemic	ADJ	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
have	VERB	O	O
described	VERB	O	O
experiencing	VERB	O	O
deteriorations	NOUN	O	O
in	ADP	O	O
cognition	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
widely	ADV	O	O
used	VERB	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
5-fluorouracil	PROPN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
readily	ADV	O	O
crosses	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
and	CCONJ	O	O
so	ADV	O	O
could	VERB	O	O
have	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
brain	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
reports	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
hippocampal	ADJ	O	O
dependent	ADJ	O	O
neurogenesis	NOUN	O	O
and	CCONJ	O	O
cognition	NOUN	O	O
are	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
the	DET	O	O
SSRI	PROPN	O	I-Entity
antidepressant	NOUN	O	O
Fluoxetine	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
investigation	NOUN	O	O
the	DET	O	O
behavioural	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
(	PUNCT	O	O
two	NUM	O	O
week	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
three	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
Fluoxetine	PROPN	O	I-Entity
either	CCONJ	O	O
separately	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
were	VERB	O	O
tested	VERB	O	O
on	ADP	O	O
adult	NOUN	O	O
Lister	PROPN	O	O
hooded	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Behavioural	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
using	VERB	O	O
a	DET	O	O
context	NOUN	O	O
dependent	ADJ	O	O
conditioned	VERB	O	O
emotional	ADJ	O	O
response	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
CER	PROPN	O	O
)	PUNCT	O	O
which	ADJ	O	O
showed	VERB	O	O
that	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
had	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
freezing	VERB	O	O
time	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
treated	VERB	O	O
only	ADV	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
showed	VERB	O	O
significant	ADJ	O	O
deficits	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
carry	VERB	O	O
out	PART	O	O
the	DET	O	O
OLR	PROPN	O	O
task	NOUN	O	O
but	CCONJ	O	O
co	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
Fluoxetine	PROPN	O	I-Entity
improved	VERB	O	O
their	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

5-FU	NUM	O	I-Entity
chemotherapy	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
proliferating	VERB	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
sub	NOUN	O	O
granular	ADJ	O	O
zone	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
reduction	NOUN	O	O
was	VERB	O	O
eliminated	VERB	O	O
when	ADV	O	O
Fluoxetine	PROPN	O	I-Entity
was	VERB	O	O
co	X	O	O
administered	VERB	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
.	PUNCT	O	O

Fluoxetine	NOUN	O	I-Entity
on	ADP	O	O
its	ADJ	O	O
own	ADJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
proliferating	VERB	O	O
cell	NOUN	O	O
number	NOUN	O	O
or	CCONJ	O	O
behaviour	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
5-FU	PROPN	O	I-Entity
can	VERB	O	O
negatively	ADV	O	O
affect	VERB	O	O
both	DET	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
hippocampal	ADJ	O	O
dependent	ADJ	O	O
working	VERB	O	O
memory	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
these	DET	O	O
deficits	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
the	DET	O	O
simultaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antidepressant	NOUN	O	O
Fluoxetine	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19920070)

Liver	ADV	O	O
-	PUNCT	O	O
specific	ADJ	O	O
ablation	NOUN	O	O
of	ADP	O	O
integrin	NOUN	O	O
-	PUNCT	O	O
linked	VERB	O	O
kinase	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
enhanced	VERB	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
hepatomegaly	NOUN	O	I-Entity
after	ADP	O	O
phenobarbital	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigates	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
ILK	PROPN	O	O
in	ADP	O	O
liver	NOUN	O	O
enlargement	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
phenobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
PB	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

liver-/-	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
PB	PROPN	O	I-Entity
(	PUNCT	O	O
0.1%	NUM	O	O
in	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Livers	NOUN	O	O
were	VERB	O	O
harvested	VERB	O	O
on	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
days	NOUN	O	O
during	ADP	O	O
PB	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
slightly	ADV	O	O
increased	VERB	O	O
proliferating	VERB	O	O
cell	NOUN	O	O
nuclear	ADJ	O	O
antigen	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ILK	PROPN	O	O
/	SYM	O	O
liver-/-	ADJ	O	O
animals	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
WT	PROPN	O	O
after	ADP	O	O
PB	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

/	SYM	O	O
liver-/-	NOUN	O	O
mice	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
increased	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
key	ADJ	O	O
genes	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
hepatocyte	NOUN	O	O
proliferation	NOUN	O	O
at	ADP	O	O
different	ADJ	O	O
time	NOUN	O	O
points	NOUN	O	O
during	ADP	O	O
PB	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
ILK	PROPN	O	O
in	ADP	O	O
the	DET	O	O
hepatocytes	NOUN	O	O
imparts	VERB	O	O
prolonged	ADJ	O	O
proliferative	ADJ	O	O
response	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
to	PART	O	O
stimuli	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
liver	NOUN	O	O
regeneration	NOUN	O	O
but	CCONJ	O	O
also	ADV	O	O
to	ADP	O	O
xenobiotic	ADJ	O	O
chemical	NOUN	O	O
mitogens	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
PB	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19967075)

Decreased	VERB	O	O
Expression	NOUN	O	O
of	ADP	O	O
Na	PROPN	O	I-Entity
/	SYM	O	O
K	PROPN	O	I-Entity
-	PUNCT	O	O
ATPase	PROPN	O	O
,	PUNCT	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
NBC1	PROPN	O	O
,	PUNCT	O	O
AQP1	PROPN	O	O
and	CCONJ	O	O
OAT	PROPN	O	O
in	ADP	O	O
Gentamicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Nephropathy	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
aimed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
is	VERB	O	O
an	DET	O	O
altered	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
transporters	NOUN	O	O
in	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
male	NOUN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
200~250	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
subcutaneously	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
transporters	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
immunoblotting	VERB	O	O
and	CCONJ	O	O
immunohistochemistry	NOUN	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
exhibited	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
along	ADP	O	O
with	ADP	O	O
increased	VERB	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
fractional	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
increased	VERB	O	O
.	PUNCT	O	O

Immunoblotting	VERB	O	O
and	CCONJ	O	O
immunohistochemistry	NOUN	O	O
revealed	VERB	O	O
decreased	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
Na(+)/K(+)-ATPase	PROPN	O	I-Entity
,	PUNCT	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
NBC1	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
AQP1	PROPN	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
may	VERB	O	O
at	ADV	O	O
least	ADJ	O	O
in	ADP	O	O
part	NOUN	O	O
be	VERB	O	O
causally	ADV	O	O
related	VERB	O	O
with	ADP	O	O
a	DET	O	O
decreased	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
Na(+)/K(+)-ATPase	PROPN	O	I-Entity
,	PUNCT	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
NBC1	PROPN	O	O
,	PUNCT	O	O
AQP1	PROPN	O	O
and	CCONJ	O	O
OAT	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (20024739)

Longitudinal	ADJ	O	O
association	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
progression	NOUN	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
health	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
association	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
depression	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
HIV	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
progression	NOUN	O	O
among	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
had	VERB	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
medical	ADJ	O	O
record	NOUN	O	O
extraction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
venipuncture	NOUN	O	O
,	PUNCT	O	O
CD4+T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
counts	NOUN	O	O
determination	NOUN	O	O
,	PUNCT	O	O
measurement	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
symptoms	NOUN	O	O
(	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
self	NOUN	O	O
-	PUNCT	O	O
report	NOUN	O	O
Center	PROPN	O	O
for	ADP	O	O
Epidemiological	PROPN	O	O
Studies	PROPN	O	O
-	PUNCT	O	O
Depression	PROPN	O	I-Entity
Scale	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
assessment	NOUN	O	O
at	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
semiannually	ADV	O	O
until	ADP	O	O
March	PROPN	O	O
2000	NUM	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
level	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
CD4	PROPN	O	O
+	PUNCT	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
counts	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
participants	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ART	PROPN	O	O
)	PUNCT	O	O
use	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
alcohol	NOUN	O	I-Entity
and	CCONJ	O	O
CD4	PROPN	O	O
+	PUNCT	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
reach	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
between	ADP	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
depression	NOUN	O	I-Entity
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p<0.001	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Depression	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
negative	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
CD4	PROPN	O	O
+	CCONJ	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
counts	NOUN	O	O
over	ADP	O	O
time	NOUN	O	O
regardless	ADV	O	O
of	ADP	O	O
ART	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
has	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
depression	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
HIV	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
progression	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
have	VERB	O	O
implications	NOUN	O	O
for	ADP	O	O
the	DET	O	O
provision	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
interventions	NOUN	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
resources	NOUN	O	O
to	PART	O	O
improve	VERB	O	O
the	DET	O	O
health	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (20034406)

Chemokine	PROPN	O	O
CCL2	PROPN	O	O
and	CCONJ	O	O
its	ADJ	O	O
receptor	NOUN	O	O
CCR2	NOUN	O	O
are	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
following	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

Neuroinflammation	PROPN	O	I-Entity
occurs	VERB	O	O
after	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
epileptogenesis	NOUN	O	O
.	PUNCT	O	O

CCR2	NOUN	O	O
is	VERB	O	O
a	DET	O	O
chemokine	NOUN	O	O
receptor	NOUN	O	O
for	ADP	O	O
CCL2	PROPN	O	O
and	CCONJ	O	O
their	ADJ	O	O
interaction	NOUN	O	O
mediates	NOUN	O	O
monocyte	ADJ	O	O
infiltration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
neuroinflammatory	NOUN	O	I-Entity
cascade	NOUN	O	O
triggered	VERB	O	O
in	ADP	O	O
different	ADJ	O	O
brain	NOUN	O	O
pathologies	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
work	NOUN	O	O
CCR2	PROPN	O	O
and	CCONJ	O	O
CCL2	PROPN	O	O
expression	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
following	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
SE	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
SE	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

Control	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
instead	ADV	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
SE	PROPN	O	I-Entity
,	PUNCT	O	O
CCR2	PROPN	O	O
staining	VERB	O	O
in	ADP	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
glial	ADJ	O	O
cells	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
using	VERB	O	O
imunohistochemical	ADJ	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
CCR2	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
after	ADP	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
also	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
alterations	NOUN	O	O
to	ADP	O	O
the	DET	O	O
cell	NOUN	O	O
types	NOUN	O	O
expressing	VERB	O	O
CCR2	PROPN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
numbers	NOUN	O	O
of	ADP	O	O
neurons	NOUN	O	O
that	ADJ	O	O
expressed	VERB	O	O
CCR2	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
following	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

Microglial	ADJ	O	O
cells	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
closely	ADV	O	O
apposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
CCR2-labeled	PROPN	O	O
cells	NOUN	O	O
in	ADP	O	O
SE	PROPN	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
rats	NOUN	O	O
that	ADJ	O	O
experienced	VERB	O	O
SE	PROPN	O	I-Entity
exhibited	VERB	O	O
CCR2-labeling	VERB	O	O
in	ADP	O	O
populations	NOUN	O	O
of	ADP	O	O
hypertrophied	VERB	O	I-Entity
astrocytes	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
CA1	PROPN	O	O
and	CCONJ	O	O
dentate	ADJ	O	O
gyrus	NOUN	O	O
.	PUNCT	O	O

Examination	NOUN	O	O
of	ADP	O	O
CCL2	PROPN	O	O
expression	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
it	PRON	O	O
was	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
following	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
CCR2	PROPN	O	O
and	CCONJ	O	O
CCL2	PROPN	O	O
are	VERB	O	O
up	ADV	O	O
-	PUNCT	O	O
regulated	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
also	ADV	O	O
result	VERB	O	O
in	ADP	O	O
changes	NOUN	O	O
to	ADP	O	O
CCR2	VERB	O	O
receptor	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
astrocytes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
detrimental	ADJ	O	O
neuroplasticity	NOUN	O	O
and	CCONJ	O	O
neuroinflammatory	ADJ	O	I-Entity
changes	NOUN	O	O
that	ADJ	O	O
occur	VERB	O	O
following	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20046642)

Metallothionein	PROPN	O	I-Entity
induction	NOUN	O	O
reduces	VERB	O	O
caspase-3	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
TNFalpha	PROPN	O	O
levels	NOUN	O	O
with	ADP	O	O
preservation	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
intact	ADJ	O	O
hippocampal	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
carmustine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
induction	NOUN	O	O
of	ADP	O	O
metallothionein	NOUN	O	I-Entity
(	PUNCT	O	O
MT	PROPN	O	I-Entity
)	PUNCT	O	O
by	ADP	O	O
ZnSO(4	NUM	O	B-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
neuroprotection	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
documented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
MT	PROPN	O	I-Entity
induction	NOUN	O	O
on	ADP	O	O
carmustine	NOUN	O	I-Entity
(	PUNCT	O	O
BCNU)-induced	VERB	O	I-Entity
hippocampal	ADJ	O	O
cognitive	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
albino	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
15/group	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
injected	VERB	O	O
with	ADP	O	O
single	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
i.c.v	NOUN	O	O
)	PUNCT	O	O
followed	VERB	O	O
24	NUM	O	O
h	NOUN	O	O
later	ADV	O	O
by	ADP	O	O
BCNU	PROPN	O	I-Entity
solvent	ADJ	O	O
(	PUNCT	O	O
i.v	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
administered	VERB	O	O
ZnSO(4	PROPN	O	B-Entity
)	PUNCT	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
micromol/10	NUM	O	O
microl	NOUN	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
i.c.v	NOUN	O	O
,	PUNCT	O	O
once	ADV	O	O
)	PUNCT	O	O

then	ADV	O	O
BCNU	PROPN	O	I-Entity
solvent	ADJ	O	O
(	PUNCT	O	O
i.v	PUNCT	O	O
)	PUNCT	O	O
after	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
Third	PROPN	O	O
group	NOUN	O	O
received	VERB	O	O
BCNU	PROPN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.v	PROPN	O	O
,	PUNCT	O	O
once	ADV	O	O
)	PUNCT	O	O

Fourth	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ZnSO(4	PROPN	O	B-Entity
)	PUNCT	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
micromol/10	NUM	O	O
microl	NOUN	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
i.c.v	PUNCT	O	O
)	PUNCT	O	O
then	ADV	O	O
BCNU	PROPN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.v	PROPN	O	O
,	PUNCT	O	O
once	ADV	O	O
)	PUNCT	O	O
after	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
The	DET	O	O
obtained	VERB	O	O
data	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
BCNU	PROPN	O	I-Entity
administration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
short	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
term	NOUN	O	I-Entity
memory	NOUN	O	I-Entity
(	PUNCT	O	O
STM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
using	VERB	O	O
radial	ADJ	O	O
arm	NOUN	O	O
water	NOUN	O	O
maze	NOUN	O	O
,	PUNCT	O	O
accompanied	VERB	O	O
with	ADP	O	O
decreased	VERB	O	O
hippocampal	ADJ	O	O
glutathione	NOUN	O	I-Entity
reductase	NOUN	O	O
(	PUNCT	O	O
GR	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
glutathione	NOUN	O	I-Entity
(	PUNCT	O	O
GSH	PROPN	O	I-Entity
)	PUNCT	O	O
content	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
BCNU	PROPN	O	I-Entity
administration	NOUN	O	O
increased	VERB	O	O
serum	NOUN	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
TNFalpha	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hippocampal	ADJ	O	O
MT	PROPN	O	I-Entity
and	CCONJ	O	O
malondialdehyde	NOUN	O	I-Entity
(	PUNCT	O	O
MDA	PROPN	O	I-Entity
)	PUNCT	O	O
contents	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
caspase-3	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
histological	ADJ	O	O
alterations	NOUN	O	O
.	PUNCT	O	O

ZnSO(4	PUNCT	O	B-Entity
)	PUNCT	O	I-Entity
pretreatment	NOUN	O	O
counteracted	VERB	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
inhibition	NOUN	O	O
of	ADP	O	O
GR	PROPN	O	O
and	CCONJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
GSH	PROPN	O	I-Entity
and	CCONJ	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
MDA	PROPN	O	I-Entity
and	CCONJ	O	O
TNFalpha	PROPN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
caspase-3	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
histological	ADJ	O	O
features	NOUN	O	O
were	VERB	O	O
improved	VERB	O	O
in	ADP	O	O
hippocampus	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ZnSO(4	PROPN	O	B-Entity
)	PUNCT	O	I-Entity

+	CCONJ	O	O
BCNU	PROPN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
only	ADV	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
MT	PROPN	O	I-Entity
induction	NOUN	O	O
halts	NOUN	O	O
BCNU	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hippocampal	ADJ	O	O
toxicity	NOUN	O	I-Entity
as	ADP	O	O
it	PRON	O	O
prevented	VERB	O	O
GR	PROPN	O	O
inhibition	NOUN	O	O
and	CCONJ	O	O
GSH	PROPN	O	I-Entity
depletion	NOUN	O	O
and	CCONJ	O	O
counteracted	VERB	O	O
the	DET	O	O
increased	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
TNFalpha	PROPN	O	O
,	PUNCT	O	O
MDA	PROPN	O	I-Entity
and	CCONJ	O	O
caspase-3	ADJ	O	O
activity	NOUN	O	O
with	ADP	O	O
subsequent	ADJ	O	O
preservation	NOUN	O	O
of	ADP	O	O
cognition	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20129423)

Fatal	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
induced	VERB	O	O
fulminant	ADJ	O	B-Entity
eosinophilic	NOUN	O	I-Entity
(	PUNCT	O	O
hypersensitivity	NOUN	O	I-Entity
)	PUNCT	O	O

myocarditis	NOUN	O	I-Entity
:	PUNCT	O	O
emphasis	NOUN	O	O
on	ADP	O	O
anatomical	ADJ	O	O
and	CCONJ	O	O
histological	ADJ	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
genetics	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-Entity
hypersensitivity	NOUN	O	I-Entity
and	CCONJ	O	O
differential	ADJ	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
severe	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
haemopoietic	ADJ	O	O
system	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
frequently	ADV	O	O
fatal	ADJ	O	O
,	PUNCT	O	O
although	ADP	O	O
exceptionally	ADV	O	O
rare	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
is	VERB	O	O
necrotizing	VERB	O	O
eosinophilic	NOUN	O	O
(	PUNCT	O	O
hypersensitivity	NOUN	O	I-Entity
)	PUNCT	O	O

myocarditis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
hypersensitivity	ADJ	O	I-Entity
myocarditis	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	O
hypersensitivity	NOUN	O	I-Entity
myocarditis	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
suspected	VERB	O	O
clinically	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
diagnosis	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
post	NOUN	O	O
-	PUNCT	O	O
mortem	NOUN	O	O
.	PUNCT	O	O

Clinically	PROPN	O	O
,	PUNCT	O	O
death	NOUN	O	O
was	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
cardiogenic	ADJ	O	B-Entity
shock	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
induced	VERB	O	O
myocarditis	NOUN	O	I-Entity
reported	VERB	O	O
in	ADP	O	O
English	PROPN	O	O
literature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20169779)

Neuropsychiatric	ADJ	O	O
behaviors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MPTP	PROPN	O	I-Entity
marmoset	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Neuropsychiatric	ADJ	O	O
symptoms	NOUN	O	O
are	VERB	O	O
increasingly	ADV	O	O
recognised	VERB	O	O
as	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
problem	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
symptoms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
'	PUNCT	O	O
sensitisation	NOUN	O	O
'	PUNCT	O	O
following	VERB	O	O
repeated	VERB	O	O
levodopa	NOUN	O	I-Entity
treatment	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
direct	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
state	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
lesioned	VERB	O	O
marmoset	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
neuropsychiatric	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
in	ADP	O	O
PD	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
compare	VERB	O	O
the	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
and	CCONJ	O	O
neuropsychiatric	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
behaviors	NOUN	O	I-Entity
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
onset	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Marmosets	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	NUM	O	I-Entity
(	PUNCT	O	O
2.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

for	ADP	O	O
five	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
stable	ADJ	O	O
parkinsonism	NOUN	O	I-Entity
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
and	CCONJ	O	O
benserazide	NOUN	O	I-Entity
,	PUNCT	O	O
3.75	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O

Animals	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
parkinsonian	ADJ	O	B-Entity
disability	NOUN	O	I-Entity
,	PUNCT	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
on	ADP	O	O
-	PUNCT	O	O
time	NOUN	O	O
(	PUNCT	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
neuropsychiatric	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
behaviors	NOUN	O	I-Entity
on	ADP	O	O
Day	PROPN	O	O
0	NUM	O	O
(	PUNCT	O	O
prior	ADV	O	O
to	ADP	O	O
levodopa	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
Days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
13	NUM	O	O
,	PUNCT	O	O
27	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
of	ADP	O	O
treatment	NOUN	O	O
using	VERB	O	O
post	NOUN	O	O
hoc	X	O	O
DVD	NOUN	O	O
analysis	NOUN	O	O
by	ADP	O	O
a	DET	O	O
trained	VERB	O	O
rater	NOUN	O	O
,	PUNCT	O	O
blind	ADJ	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neuropsychiatric	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
behavior	NOUN	O	I-Entity
rating	VERB	O	O
scale	NOUN	O	O
demonstrated	VERB	O	O
high	ADJ	O	O
interrater	NOUN	O	O
reliability	NOUN	O	O
between	ADP	O	O
three	NUM	O	O
trained	VERB	O	O
raters	NOUN	O	O
of	ADP	O	O
differing	VERB	O	O
professional	ADJ	O	O
backgrounds	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
anticipated	VERB	O	O
,	PUNCT	O	O
animals	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
progressive	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
,	PUNCT	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
wearing	VERB	O	O
-	PUNCT	O	O
off	PART	O	O
,	PUNCT	O	O
that	DET	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuropsychiatric	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
behaviors	NOUN	O	I-Entity
were	VERB	O	O
present	ADJ	O	O
on	ADP	O	O
Day	PROPN	O	O
1	NUM	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
severity	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
neuropsychiatric	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
in	ADP	O	O
PD	PROPN	O	I-Entity
are	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
an	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
disease	NOUN	O	O
state	NOUN	O	O
than	ADP	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
sensitisation	NOUN	O	O
to	ADP	O	O
repeated	VERB	O	O
dopaminergic	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20192893)

Contrast	ADJ	O	B-Entity
medium	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
after	ADP	O	O
renal	ADJ	O	O
artery	NOUN	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
iodinated	ADJ	O	O
contrast	NOUN	O	B-Entity
medium	NOUN	O	I-Entity
(	PUNCT	O	O
CM	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
can	VERB	O	O
minimize	VERB	O	O
the	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
the	DET	O	O
interventional	ADJ	O	O
procedure	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
renal	ADJ	O	O
angioplasty	NOUN	O	O
(	PUNCT	O	O
PTRA	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
compare	VERB	O	O
the	DET	O	O
susceptibility	NOUN	O	O
to	PART	O	O
nephrotoxic	VERB	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
PTRA	PROPN	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
patients	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
PCI	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
PTRA	PROPN	O	O
(	PUNCT	O	O
PTRA	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
70+/-12	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
23	NUM	O	O
female	ADJ	O	O
,	PUNCT	O	O
basal	ADJ	O	O
creatinine	NOUN	O	I-Entity
1.46+/-0.79	NUM	O	O
,	PUNCT	O	O
range	VERB	O	O
0.7	NUM	O	O
-	SYM	O	O
4.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
successful	ADJ	O	O
PCI	PROPN	O	O
(	PUNCT	O	O
PCI	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
matched	VERB	O	O
for	ADP	O	O
basal	NOUN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
1.44+/-0.6	NUM	O	O
,	PUNCT	O	O
range	VERB	O	O
0.7	NUM	O	O
-	SYM	O	O
3.4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Postprocedural	ADJ	O	O
creatinine	NOUN	O	I-Entity
level	NOUN	O	O
decreased	VERB	O	O
nonsignificantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
PTRA	PROPN	O	O
group	NOUN	O	O
(	PUNCT	O	O
1.46+/-0.8	NUM	O	O
vs.	X	O	O
1.34+/-0.5	NUM	O	O
mg	X	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
after	ADP	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
after	ADP	O	O
-	PUNCT	O	O
before	ADV	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
PTRA	PROPN	O	O
and	CCONJ	O	O
PCI	PROPN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
-0.12+/-0.5	PUNCT	O	O
vs.	X	O	O
0.13+/-0.3	PUNCT	O	O
,	PUNCT	O	O
P=0.014	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
related	VERB	O	O
to	ADP	O	O
either	DET	O	O
a	DET	O	O
different	ADJ	O	O
clinical	ADJ	O	O
risk	NOUN	O	O
profile	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
administered	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
this	DET	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
patients	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
PTRA	PROPN	O	O
showed	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
CM	PROPN	O	I-Entity
administration	NOUN	O	O
than	ADP	O	O
PCI	PROPN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
PTRA	PROPN	O	O
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
barely	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
CM	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20408947)

Medical	ADJ	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	O
outcomes	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
transplanted	VERB	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Acetaminophen	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ALF	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
UK	PROPN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
pretransplant	ADJ	O	O
illness	NOUN	O	O
,	PUNCT	O	O
psychiatric	ADJ	O	O
co	NOUN	O	O
-	PUNCT	O	O
morbidity	NOUN	O	O
,	PUNCT	O	O
medical	ADJ	O	O
and	CCONJ	O	O
psychosocial	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
undergone	VERB	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
LT	PROPN	O	O
)	PUNCT	O	O
emergently	ADV	O	O
between	ADP	O	O
1999	NUM	O	O
-	SYM	O	O
2004	NUM	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
(	PUNCT	O	O
n=36	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
age-	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
emergent	ADJ	O	O
LT	PROPN	O	O
for	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
(	PUNCT	O	O
n=35	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
elective	ADJ	O	O
LT	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
CLD	PROPN	O	I-Entity
,	PUNCT	O	O
n=34	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Acetaminophen	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
undergoing	VERB	O	O
LT	PROPN	O	O
had	VERB	O	O
a	DET	O	O
greater	ADJ	O	O
severity	NOUN	O	O
of	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
LT	PROPN	O	O
illness	NOUN	O	O
reflected	VERB	O	O
by	ADP	O	O
higher	ADJ	O	O
Acute	PROPN	O	O
Physiology	PROPN	O	O
and	CCONJ	O	O
Chronic	PROPN	O	O
Health	PROPN	O	O
Evaluation	PROPN	O	O
II	PROPN	O	O

Twenty	NUM	O	O
(	PUNCT	O	O
56%	NUM	O	O
)	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
formal	ADJ	O	O
psychiatric	ADJ	O	O
diagnosis	NOUN	O	O
before	ADP	O	O
LT	PROPN	O	O
(	PUNCT	O	O
non	ADV	O	O
-	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF=0/35	PROPN	O	I-Entity
,	PUNCT	O	O
CLD=2/34	PROPN	O	I-Entity
;	PUNCT	O	O
P<0.01	PROPN	O	O
for	ADP	O	O
all	DET	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nine	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
previous	ADJ	O	O
suicide	NOUN	O	O
attempt	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
rejection	NOUN	O	O
(	PUNCT	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
graft	NOUN	O	O
failure	NOUN	O	O
or	CCONJ	O	O
survival	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
(	PUNCT	O	O
acetaminophen	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
1	NUM	O	O
year	NOUN	O	O
87%	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
years	NOUN	O	O
75%	NUM	O	O
;	PUNCT	O	O
non	ADV	O	O
-	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
88%	NUM	O	O
,	PUNCT	O	O
78%	NUM	O	O
;	PUNCT	O	O
CLD	PROPN	O	I-Entity
93%	NUM	O	O
,	PUNCT	O	O
82%	NUM	O	O
:	PUNCT	O	O
P>0.6	NOUN	O	O
log	NOUN	O	O
rank	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
reattempted	VERB	O	O
suicide	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
LT	PROPN	O	O
(	PUNCT	O	O
one	NUM	O	O
died	VERB	O	O
8	NUM	O	O
years	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
LT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Despite	ADP	O	O
a	DET	O	O
high	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
psychiatric	ADJ	O	O
disturbance	NOUN	O	O
,	PUNCT	O	O
outcomes	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
transplanted	VERB	O	O
emergently	ADV	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
were	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
those	DET	O	O
transplanted	VERB	O	O
for	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
and	CCONJ	O	O
electively	ADV	O	O
for	ADP	O	O
CLD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20447294)

Studies	NOUN	O	O
of	ADP	O	O
synergy	NOUN	O	O
between	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
novel	NOUN	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
CNSB002	PROPN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
determined	VERB	O	O
the	DET	O	O
antihyperalgesic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
CNSB002	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
with	ADP	O	O
antioxidant	ADJ	O	O
properties	NOUN	O	O
given	VERB	O	O
alone	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
combinations	NOUN	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Dose	VERB	O	O
response	NOUN	O	O
curves	NOUN	O	O
for	ADP	O	O
nonsedating	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
CNSB002	PROPN	O	I-Entity
given	VERB	O	O
intraperitoneally	ADV	O	O
alone	ADV	O	O
and	CCONJ	O	O
together	ADV	O	O
in	ADP	O	O
combinations	NOUN	O	O
were	VERB	O	O
constructed	VERB	O	O
for	ADP	O	O
antihyperalgesic	ADJ	O	O
effect	NOUN	O	O
using	VERB	O	O
paw	NOUN	O	O
withdrawal	NOUN	O	O
from	ADP	O	O
noxious	ADJ	O	O
heat	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
rat	NOUN	O	O
pain	NOUN	O	I-Entity
models	NOUN	O	O
:	PUNCT	O	O
carrageenan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
paw	NOUN	O	O
inflammation	NOUN	O	I-Entity
and	CCONJ	O	O
streptozotocin	NOUN	O	I-Entity
(	PUNCT	O	O
STZ)-induced	VERB	O	I-Entity
diabetic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
nonsedating	NOUN	O	O
doses	NOUN	O	O
were	VERB	O	O
:	PUNCT	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
3.2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
CNSB002	SYM	O	I-Entity
10.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
5.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
CNSB002	NOUN	O	I-Entity
with	ADP	O	O
morphine	NOUN	O	I-Entity
3.2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
doses	NOUN	O	O
calculated	VERB	O	O
to	PART	O	O
cause	VERB	O	O
50%	NUM	O	O
reversal	NOUN	O	O
of	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
(	PUNCT	O	O
ED50	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
7.54	NUM	O	O
(	PUNCT	O	O
1.81	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4.83	NUM	O	O
(	PUNCT	O	O
1.54	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
carrageenan	NOUN	O	I-Entity
model	NOUN	O	O
and	CCONJ	O	O
44.18	NUM	O	O
(	PUNCT	O	O
1.37	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
9.14	NUM	O	O
(	PUNCT	O	O
1.24	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuropathy	NOUN	O	I-Entity
model	NOUN	O	O
for	ADP	O	O
CNSB002	PROPN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
;	PUNCT	O	O
mean	VERB	O	O
,	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ED50	PROPN	O	O
values	NOUN	O	O
for	ADP	O	O
morphine	NOUN	O	I-Entity
when	ADV	O	O
given	VERB	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
CNSB002	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
the	DET	O	O
maximum	ADJ	O	O
nonsedating	NOUN	O	O
dose	NOUN	O	O
:	PUNCT	O	O
0.56	NUM	O	O
(	PUNCT	O	O
1.55	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
carrageenan	NOUN	O	I-Entity
model	NOUN	O	O
and	CCONJ	O	O
1.37	NUM	O	O
(	PUNCT	O	O
1.23	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
neuropathy	NOUN	O	I-Entity
model	NOUN	O	O
(	PUNCT	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
;	PUNCT	O	O
mean	VERB	O	O
,	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
antinociception	NOUN	O	O
after	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
3.2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
with	ADP	O	O
CNSB002	PROPN	O	I-Entity
from	ADP	O	O
28.0	NUM	O	O
and	CCONJ	O	O
31.7%	NUM	O	O
to	ADP	O	O
114.6	NUM	O	O
and	CCONJ	O	O
56.9%	NUM	O	O
reversal	NOUN	O	O
of	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
neuropathic	ADJ	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
;	PUNCT	O	O
one	NUM	O	O
-	PUNCT	O	O
way	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
-	PUNCT	O	O
significantly	ADV	O	O
greater	ADJ	O	O
than	ADP	O	O
either	DET	O	O
drug	NOUN	O	O
given	VERB	O	O
alone	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
antihyperalgesic	ADJ	O	O
effect	NOUN	O	O
achievable	ADJ	O	O
with	ADP	O	O
nonsedating	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
increased	VERB	O	O
significantly	ADV	O	O
when	ADV	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
CNSB002	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20495512)

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
practical	ADJ	O	O
review	NOUN	O	O
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
)	PUNCT	O	O
remains	VERB	O	O
under	ADP	O	O
-	PUNCT	O	O
recognized	VERB	O	O
despite	ADP	O	O
its	ADJ	O	O
potentially	ADV	O	O
devastating	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
begins	VERB	O	O
when	ADV	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
stimulates	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
platelet	NOUN	O	O
factor	NOUN	O	O
4	NUM	O	O
antibodies	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
in	ADP	O	O
turn	NOUN	O	O
triggers	VERB	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
procoagulant	NOUN	O	O
platelet	NOUN	O	O
particles	NOUN	O	O
.	PUNCT	O	O

Thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
that	ADJ	O	O
follow	VERB	O	O
comprise	VERB	O	O
the	DET	O	O
2	NUM	O	O
hallmark	NOUN	O	O
traits	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
former	ADJ	O	O
largely	ADV	O	O
responsible	ADJ	O	O
for	ADP	O	O
significant	ADJ	O	O
vascular	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
varies	VERB	O	O
among	ADP	O	O
several	ADJ	O	O
subgroups	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
greater	ADJ	O	O
incidence	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
medical	ADJ	O	O
populations	NOUN	O	O
.	PUNCT	O	O

HIT	PRON	O	I-Entity
must	VERB	O	O
be	VERB	O	O
acknowledged	VERB	O	O
for	ADP	O	O
its	ADJ	O	O
intense	ADJ	O	O
predilection	NOUN	O	O
for	ADP	O	O
thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
suspected	VERB	O	O
whenever	ADV	O	O
thrombosis	NOUN	O	I-Entity
occurs	VERB	O	O
after	ADP	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
mandates	VERB	O	O
an	DET	O	O
immediate	ADJ	O	O
cessation	NOUN	O	O
of	ADP	O	O
all	DET	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
institution	NOUN	O	O
of	ADP	O	O
an	DET	O	O
antithrombotic	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
most	ADV	O	O
commonly	ADV	O	O
using	VERB	O	O
a	DET	O	O
direct	ADJ	O	B-Entity
thrombin	NOUN	O	I-Entity
inhibitor	NOUN	O	I-Entity
.	PUNCT	O	O

Current	ADJ	O	O
"	PUNCT	O	O
diagnostic	ADJ	O	O
"	PUNCT	O	O
tests	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
primarily	ADV	O	O
include	VERB	O	O
functional	ADJ	O	O
and	CCONJ	O	O
antigenic	ADJ	O	O
assays	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
more	ADJ	O	O
of	ADP	O	O
a	DET	O	O
confirmatory	NOUN	O	O
than	ADP	O	O
diagnostic	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
.	PUNCT	O	O

Special	ADJ	O	O
attention	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
paid	VERB	O	O
to	ADP	O	O
cardiac	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
often	ADV	O	O
exposed	VERB	O	O
to	ADP	O	O
heparin	VERB	O	I-Entity
multiple	ADJ	O	O
times	NOUN	O	O
during	ADP	O	O
their	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Direct	ADJ	O	B-Entity
thrombin	NOUN	O	I-Entity
inhibitors	NOUN	O	I-Entity
are	VERB	O	O
appropriate	ADJ	O	O
,	PUNCT	O	O
evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
alternatives	NOUN	O	O
to	ADP	O	O
heparin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
need	VERB	O	O
to	PART	O	O
undergo	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
heparin	NOUN	O	I-Entity
remains	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
frequently	ADV	O	O
used	VERB	O	O
medications	NOUN	O	O
today	NOUN	O	O
with	ADP	O	O
potential	NOUN	O	O
for	ADP	O	O
HIT	PROPN	O	I-Entity
with	ADP	O	O
every	DET	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
close	ADJ	O	O
vigilance	NOUN	O	O
of	ADP	O	O
platelet	NOUN	O	O
counts	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
practiced	VERB	O	O
whenever	ADV	O	O
heparin	NOUN	O	I-Entity
is	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (20513036)

Abductor	PROPN	O	O
paralysis	NOUN	O	I-Entity
after	ADP	O	O
botox	NOUN	O	I-Entity
injection	NOUN	O	O
for	ADP	O	O
adductor	NOUN	O	B-Entity
spasmodic	NOUN	O	I-Entity
dysphonia	NOUN	O	I-Entity
.	PUNCT	O	O

Botulinum	PROPN	O	O
toxin	NOUN	O	O
(	PUNCT	O	O
Botox	PROPN	O	I-Entity

)	PUNCT	O	O
injections	NOUN	O	O
into	ADP	O	O
the	DET	O	O
thyroarytenoid	ADJ	O	O
muscles	NOUN	O	O
are	VERB	O	O
the	DET	O	O
current	ADJ	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
adductor	NOUN	O	B-Entity
spasmodic	NOUN	O	I-Entity
dysphonia	NOUN	O	I-Entity
(	PUNCT	O	O
ADSD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Reported	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
include	VERB	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
breathiness	NOUN	O	O
,	PUNCT	O	O
throat	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
difficulty	NOUN	O	O
with	ADP	O	O
swallowing	VERB	O	O
liquids	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
report	VERB	O	O
multiple	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
following	VERB	O	O
Botox	PROPN	O	I-Entity
injections	NOUN	O	O
for	ADP	O	O
ADSD	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
complication	NOUN	O	O
previously	ADV	O	O
unreported	ADJ	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
Botox	PROPN	O	I-Entity
injections	NOUN	O	O
for	ADP	O	O
spasmodic	NOUN	O	B-Entity
dysphonia	NOUN	O	I-Entity
between	ADP	O	O
January	PROPN	O	O
2000	NUM	O	O
and	CCONJ	O	O
October	PROPN	O	O
2009	NUM	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
ADSD	PROPN	O	I-Entity
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

For	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bilateral	ADJ	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
paralytic	ADJ	O	O
Botox	PROPN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
prior	ADJ	O	O
Botox	PROPN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
course	NOUN	O	O
following	VERB	O	O
paralysis	NOUN	O	I-Entity
were	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

From	ADP	O	O
a	DET	O	O
database	NOUN	O	O
of	ADP	O	O
452	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
Botox	PROPN	O	I-Entity
,	PUNCT	O	O
352	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
ADSD	PROPN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
352	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
eight	NUM	O	O
patients	NOUN	O	O
suffered	VERB	O	O
bilateral	ADJ	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
suffered	VERB	O	O
this	DET	O	O
complication	NOUN	O	O
twice	ADV	O	O
.	PUNCT	O	O

Most	ADJ	O	O
patients	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
treatments	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
and	CCONJ	O	O
continued	VERB	O	O
receiving	VERB	O	O
after	ADP	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
after	ADP	O	O
Botox	PROPN	O	I-Entity
injection	NOUN	O	O
for	ADP	O	O
ADSD	PROPN	O	I-Entity
was	VERB	O	O
0.34%	NUM	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
abductor	NOUN	O	O
paralysis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
Botox	PROPN	O	I-Entity
injections	NOUN	O	O
for	ADP	O	O
ADSD	PROPN	O	I-Entity
,	PUNCT	O	O
causing	VERB	O	O
difficulty	NOUN	O	O
with	ADP	O	O
breathing	VERB	O	O
upon	ADP	O	O
exertion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
likely	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
paralysis	NOUN	O	I-Entity
is	VERB	O	O
diffusion	NOUN	O	O
of	ADP	O	O
Botox	PROPN	O	I-Entity
around	ADP	O	O
the	DET	O	O
muscular	ADJ	O	O
process	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arytenoid	NOUN	O	O
to	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
cricoarytenoid	ADJ	O	O
muscles	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
paralysis	NOUN	O	I-Entity
is	VERB	O	O
temporary	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
watchful	ADJ	O	O
waiting	NOUN	O	O
with	ADP	O	O
restriction	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
is	VERB	O	O
the	DET	O	O
recommended	VERB	O	O
management	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20566328)

Mitochondrial	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
contributes	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
:	PUNCT	O	O
Prevention	PROPN	O	O
by	ADP	O	O
the	DET	O	O
targeted	VERB	O	O
antioxidant	NOUN	O	O
MitoQ.	PROPN	O	I-Entity

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
mitochondrial	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
ROS	PROPN	O	O
production	NOUN	O	O
in	ADP	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
altered	VERB	O	O
mitochondrial	ADJ	O	O
function	NOUN	O	O
that	ADP	O	O
in	ADP	O	O
turn	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Seven	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
administration	NOUN	O	O
to	ADP	O	O
rats	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
an	DET	O	O
increased	VERB	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
detected	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	O
fibers	NOUN	O	O
,	PUNCT	O	O
specifically	ADV	O	O
through	ADP	O	O
complex	ADJ	O	O
I	PRON	O	O
and	CCONJ	O	O
complex	ADJ	O	O
III	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
parallel	ADJ	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
ATP	PROPN	O	I-Entity
synthesis	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
subsarcolemmal	ADJ	O	O
mitochondria	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
uncoupling	VERB	O	O
effect	NOUN	O	O
on	ADP	O	O
oxidative	ADJ	O	O
phosphorylation	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
detectable	ADJ	O	O
after	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
these	DET	O	O
mitochondrial	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
were	VERB	O	O
a	DET	O	O
late	ADJ	O	O
rather	ADV	O	O
than	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
event	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathological	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

MitoQ	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
mitochondrial	NOUN	O	O
-	PUNCT	O	O
targeted	VERB	O	O
antioxidant	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
completely	ADV	O	O
prevent	VERB	O	O
these	DET	O	O
mitochondrial	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
characterized	VERB	O	O
here	ADV	O	O
by	ADP	O	O
a	DET	O	O
diastolic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
studied	VERB	O	O
with	ADP	O	O
a	DET	O	O
conductance	NOUN	O	O
catheter	NOUN	O	O
to	PART	O	O
obtain	VERB	O	O
pressure	NOUN	O	O
-	PUNCT	O	O
volume	NOUN	O	O
data	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
extend	VERB	O	O
previous	ADJ	O	O
studies	NOUN	O	O
and	CCONJ	O	O
demonstrate	VERB	O	O
that	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
mitochondrial	ADJ	O	B-Entity
defect	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20589632)

Trimethoprim	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
oncology	NOUN	O	O
patient	NOUN	O	O
presenting	VERB	O	O
as	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
hemolytic	ADJ	O	O
transfusion	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
10-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
leukemia	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
chemotherapy	NOUN	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
red	ADJ	O	O
cell	NOUN	O	O
transfusion	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
developed	VERB	O	O
hemoglobinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
because	ADP	O	O
of	ADP	O	O
positive	ADJ	O	O
direct	ADJ	O	O
antiglobulin	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
negative	ADJ	O	O
eluate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
microspherocytes	NOUN	O	O
on	ADP	O	O
smear	NOUN	O	O
pre-	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
transfusion	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
studies	NOUN	O	O
using	VERB	O	O
the	DET	O	O
indirect	ADJ	O	O
antiglobulin	NOUN	O	O
test	NOUN	O	O
were	VERB	O	O
strongly	ADV	O	O
positive	ADJ	O	O
with	ADP	O	O
trimethoprim	NOUN	O	I-Entity
and	CCONJ	O	O
trimethoprim	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
sulfamethoxazole	NOUN	O	I-Entity
but	CCONJ	O	O
negative	ADJ	O	O
with	ADP	O	O
sulfamethoxazole	NOUN	O	I-Entity
.	PUNCT	O	O

Other	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
worse	ADJ	O	O
-	PUNCT	O	O
than	ADP	O	O
-	PUNCT	O	O
expected	VERB	O	O
anemia	NOUN	O	I-Entity
after	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
hemolysis	NOUN	O	I-Entity
during	ADP	O	O
transfusion	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
always	ADV	O	O
a	DET	O	O
transfusion	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20682692)

Blockade	PROPN	O	O
of	ADP	O	O
endothelial	ADJ	O	O
-	PUNCT	O	O
mesenchymal	ADJ	O	O
transition	NOUN	O	O
by	ADP	O	O
a	DET	O	O
Smad3	ADJ	O	O
inhibitor	NOUN	O	O
delays	VERB	O	O
the	DET	O	O
early	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
early	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	B-Entity
1	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
and	CCONJ	O	O
normoalbuminuria	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
retard	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
other	ADJ	O	O
mechanism(s	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
previously	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
endothelial	ADJ	O	O
-	PUNCT	O	O
mesenchymal	ADJ	O	O
-	PUNCT	O	O
transition	NOUN	O	O
(	PUNCT	O	O
EndoMT	PROPN	O	O
)	PUNCT	O	O
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
early	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
independently	ADV	O	O
of	ADP	O	O
microalbuminuria	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
streptozotocin	NOUN	O	I-Entity
(	PUNCT	O	O
STZ)-induced	VERB	O	I-Entity
diabetes	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
blocking	VERB	O	O
EndoMT	PROPN	O	O
reduces	VERB	O	O
the	DET	O	O
early	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Blocking	VERB	O	O
studies	NOUN	O	O
using	VERB	O	O
receptor	NOUN	O	O
for	ADP	O	O
AGE	PROPN	O	O
siRNA	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
specific	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
Smad3	PROPN	O	O
(	PUNCT	O	O
SIS3	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
MMECs	PROPN	O	O
and	CCONJ	O	O
in	ADP	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
Tie2-Cre;Loxp	PROPN	O	O
-	PUNCT	O	O
EGFP	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

/	SYM	O	O
Western	ADJ	O	O
blotting	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
Smad3	PROPN	O	O
was	VERB	O	O
activated	VERB	O	O
by	ADP	O	O
AGEs	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
SIS3	PROPN	O	O
in	ADP	O	O
MMECs	PROPN	O	O
and	CCONJ	O	O
in	ADP	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Confocal	ADJ	O	O
microscopy	NOUN	O	O
and	CCONJ	O	O
real	ADJ	O	O
-	PUNCT	O	O
time	NOUN	O	O
PCR	PROPN	O	O
further	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
SIS3	PROPN	O	O
abrogated	VERB	O	O
EndoMT	PROPN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
renal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
retarded	ADJ	O	O
progression	NOUN	O	O
of	ADP	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

EndoMT	PROPN	O	O
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
pathway	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
early	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Blockade	PROPN	O	O
of	ADP	O	O
EndoMT	PROPN	O	O
by	ADP	O	O
SIS3	PROPN	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
new	ADJ	O	O
strategy	NOUN	O	O
to	PART	O	O
retard	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
diabetes	NOUN	O	B-Entity
complications	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20828385)

Cytostatic	ADJ	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
angiogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
temsirolimus	NOUN	O	I-Entity
in	ADP	O	O
refractory	ADJ	O	O
mantle	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

Mantle	PROPN	O	B-Entity
cell	NOUN	O	I-Entity
lymphoma	NOUN	O	I-Entity
(	PUNCT	O	O
MCL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
and	CCONJ	O	O
aggressive	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
B	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
non	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
's	PART	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
38%	NUM	O	O
remission	NOUN	O	O
rate	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
recently	ADV	O	O
reported	VERB	O	O
in	ADP	O	O
refractory	ADJ	O	O
MCL	PROPN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
temsirolimus	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
mTOR	ADJ	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
had	VERB	O	O
the	DET	O	O
opportunity	NOUN	O	O
to	PART	O	O
study	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
refractory	ADJ	O	O
MCL	PROPN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
tumor	NOUN	O	I-Entity
regression	NOUN	O	O
two	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
temsirolimus	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
progression	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
survival	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
case	NOUN	O	O
,	PUNCT	O	O
lymph	ADJ	O	O
node	NOUN	O	O
biopsies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
temsirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
biopsies	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
temsirolimus	NOUN	O	I-Entity
inhibited	VERB	O	O
tumor	NOUN	O	I-Entity
cell	NOUN	O	O
proliferation	NOUN	O	O
through	ADP	O	O
cell	NOUN	O	O
cycle	NOUN	O	O
arrest	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
any	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
apoptotic	ADJ	O	O
tumor	NOUN	O	I-Entity
cells	NOUN	O	O
.	PUNCT	O	O

Apart	ADV	O	O
from	ADP	O	O
this	DET	O	O
cytostatic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
temsirolimus	NOUN	O	I-Entity
had	VERB	O	O
an	DET	O	O
antiangiogenic	ADJ	O	O
effect	NOUN	O	O
with	ADP	O	O
decrease	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
microvessel	NOUN	O	O
density	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
VEGF	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
numerous	ADJ	O	O
patchy	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
-	PUNCT	O	O
limited	VERB	O	O
fibrotic	ADJ	O	O
areas	NOUN	O	O
,	PUNCT	O	O
compatible	ADJ	O	O
with	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
necrotic	ADJ	O	I-Entity
tissue	NOUN	O	O
repair	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
after	ADP	O	O
6-month	ADJ	O	O
temsirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
temsirolimus	NOUN	O	I-Entity
reduced	VERB	O	O
tumor	NOUN	O	I-Entity
burden	NOUN	O	O
through	ADP	O	O
associated	VERB	O	O
cytostatic	ADJ	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
angiogenic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
dual	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
temsirolimus	NOUN	O	I-Entity
on	ADP	O	O
tumor	NOUN	O	I-Entity
tissue	NOUN	O	O
could	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
recently	ADV	O	O
reported	VERB	O	O
efficiency	NOUN	O	O
in	ADP	O	O
refractory	ADJ	O	O
MCL	PROPN	O	I-Entity
resistant	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20859899)

Syncope	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
during	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combined	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
the	DET	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
spironolactone	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
76	NUM	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
grafting	NOUN	O	O
and	CCONJ	O	O
prior	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
transferred	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
room	NOUN	O	O
with	ADP	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
consciousness	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
marked	VERB	O	O
bradycardia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
was	VERB	O	O
high	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
normal	ADJ	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
was	VERB	O	O
restored	VERB	O	O
after	ADP	O	O
correction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
was	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
several	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
spiranolactone	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
aldosterone	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
intake	NOUN	O	O
of	ADP	O	O
ramipril	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
ACE	PROPN	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
alert	ADJ	O	O
to	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
using	VERB	O	O
ACE	PROPN	O	O
/	SYM	O	O
ARB	PROPN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
potassium	NOUN	O	I-Entity
sparing	VERB	O	O
agents	NOUN	O	O
and	CCONJ	O	O
who	NOUN	O	O
have	VERB	O	O
mild	ADJ	O	O
renal	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20927253)

Diffuse	ADP	O	O
skeletal	ADJ	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
alendronate	NOUN	O	I-Entity
.	PUNCT	O	O

Osteoporosis	PROPN	O	I-Entity
is	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
bone	NOUN	O	O
resorption	NOUN	O	O
in	ADP	O	O
excess	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
formation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bisphosphonates	NOUN	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
used	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
bone	NOUN	O	O
resorption	NOUN	O	O
.	PUNCT	O	O

Alendronate	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
biphosphonate	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
for	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
osteoporosis	NOUN	O	I-Entity
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

Musculoskeletal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
presented	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
out	ADV	O	O
-	PUNCT	O	O
patient	ADJ	O	O
clinic	NOUN	O	O
with	ADP	O	O
diffuse	NOUN	O	O
skeletal	ADJ	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
three	NUM	O	O
consecutive	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
alendronate	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
osteoporosis	NOUN	O	I-Entity
can	VERB	O	O
report	VERB	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bisphosphonate	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
pain	NOUN	O	I-Entity
should	VERB	O	O
also	ADV	O	O
be	VERB	O	O
considered	VERB	O	O
before	ADP	O	O
ascribing	VERB	O	O
this	DET	O	O
complaint	NOUN	O	O
to	ADP	O	O
osteoporosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20959502)

Cerebrospinal	ADJ	O	O
fluid	ADJ	O	O
penetration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
daptomycin	NOUN	O	I-Entity
in	ADP	O	O
suspected	VERB	O	O
Staphylococcus	PROPN	O	O
aureus	ADP	O	O
meningitis	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
methicillin	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
Staphylococcus	PROPN	O	O
aureus	NOUN	O	O
(	PUNCT	O	O
MSSA	PROPN	O	O
)	PUNCT	O	O
bacteremia	NOUN	O	I-Entity
with	ADP	O	O
suspected	VERB	O	O
MSSA	PROPN	O	O
meningitis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
daptomycin	NOUN	O	I-Entity
assessed	VERB	O	O
with	ADP	O	O
concurrent	ADJ	O	O
serum	NOUN	O	O
and	CCONJ	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
CSF	PROPN	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
with	ADP	O	O
generalized	ADJ	O	O
weakness	NOUN	O	I-Entity
and	CCONJ	O	O
presumed	ADJ	O	O
health	NOUN	O	O
-	PUNCT	O	O
care	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
pneumonia	NOUN	O	I-Entity
shown	VERB	O	O
on	ADP	O	O
chest	NOUN	O	O
radiograph	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
empirically	ADV	O	O
initiated	VERB	O	O
with	ADP	O	O
vancomycin	NOUN	O	I-Entity
,	PUNCT	O	O
levofloxacin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
piperacillin	ADJ	O	I-Entity
/	SYM	O	O
tazobactam	NOUN	O	I-Entity
.	PUNCT	O	O

Blood	NOUN	O	O
cultures	NOUN	O	O
revealed	VERB	O	O
S.	PROPN	O	O
aureus	NOUN	O	O
susceptible	ADJ	O	O
to	ADP	O	O
oxacillin	NOUN	O	I-Entity
.	PUNCT	O	O

Empiric	ADJ	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
narrowed	VERB	O	O
to	ADP	O	O
nafcillin	NOUN	O	I-Entity
on	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
8	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
1.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
from	ADP	O	O
1.2	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
the	DET	O	O
previous	ADJ	O	O
day	NOUN	O	O
and	CCONJ	O	O
0.8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
on	ADP	O	O
admission	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
Glasgow	PROPN	O	O
Coma	PROPN	O	O
Score	PROPN	O	O
was	VERB	O	O
3	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
normal	ADJ	O	O
findings	NOUN	O	O
shown	VERB	O	O
on	ADP	O	O
computed	VERB	O	O
tomography	NOUN	O	O
scan	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
72	NUM	O	O
hours	NOUN	O	O
following	VERB	O	O
an	DET	O	O
episode	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
on	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
experienced	VERB	O	O
relapsing	VERB	O	O
MSSA	PROPN	O	O
bacteremia	NOUN	O	I-Entity
on	ADP	O	O
day	NOUN	O	O
9	NUM	O	O
,	PUNCT	O	O
increasing	VERB	O	O
the	DET	O	O
suspicion	NOUN	O	O
for	ADP	O	O
a	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Nafcillin	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
daptomycin	NOUN	O	I-Entity
9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
daily	ADV	O	O
was	VERB	O	O
initiated	VERB	O	O
for	ADP	O	O
suspected	VERB	O	O
meningitis	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
continued	VERB	O	O
until	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
death	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
16	NUM	O	O
.	PUNCT	O	O

Daptomycin	PROPN	O	I-Entity
serum	NOUN	O	O
and	CCONJ	O	O
CSF	PROPN	O	O
trough	NOUN	O	O
concentrations	NOUN	O	O
were	VERB	O	O
11.21	NUM	O	O
ug	INTJ	O	O
/	SYM	O	O
mL	PROPN	O	O
and	CCONJ	O	O
0.52	NUM	O	O

Creatine	PROPN	O	I-Entity
kinase	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
prior	ADV	O	O
to	ADP	O	O
daptomycin	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
reassessed	VERB	O	O
.	PUNCT	O	O

Daptomycin	PROPN	O	I-Entity
was	VERB	O	O
initiated	VERB	O	O
in	ADP	O	O
our	ADJ	O	O
patient	ADJ	O	O
secondary	ADJ	O	O
to	ADP	O	O
possible	ADJ	O	O
nafcillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
relapsing	VERB	O	O
bacteremia	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
daptomycin	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
alternative	NOUN	O	O
option	NOUN	O	O
for	ADP	O	O
MSSA	PROPN	O	O
bacteremia	NOUN	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
a	DET	O	O
CNS	PROPN	O	O
source	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
failed	VERB	O	O
or	CCONJ	O	O
can	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
standard	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
confirmed	VERB	O	O
meningitis	NOUN	O	I-Entity
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (21195121)

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
in	ADP	O	O
convulsions	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
lindane	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Lindane	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
organochloride	NOUN	O	O
pesticide	NOUN	O	O
and	CCONJ	O	O
scabicide	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
evokes	VERB	O	O
convulsions	NOUN	O	I-Entity
mainly	ADV	O	O
trough	ADP	O	O
the	DET	O	O
blockage	NOUN	O	O
of	ADP	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
gaseous	ADJ	O	O
neurotransmitter	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
contradictor	VERB	O	O
role	NOUN	O	O
in	ADP	O	O
epileptogenesis	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
opposite	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
,	PUNCT	O	O
precursor	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
syntheses	NOUN	O	O
(	PUNCT	O	O
NOS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
(	PUNCT	O	O
NOS	PROPN	O	O
inhibitor	NOUN	O	O
)	PUNCT	O	O
observed	VERB	O	O
in	ADP	O	O
different	ADJ	O	O
epilepsy	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
NO	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
EEG	PROPN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epilepsy	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
albino	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
(	PUNCT	O	O
600	NUM	O	O
,	PUNCT	O	O
800	NUM	O	O
and	CCONJ	O	O
1000	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O

in	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
convulsion	NOUN	O	I-Entity
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
and	CCONJ	O	O
shortened	VERB	O	O
latency	ADJ	O	O
time	NOUN	O	O
to	PART	O	O
first	ADJ	O	O
convulsion	NOUN	O	I-Entity
elicited	VERB	O	O
by	ADP	O	O
lower	ADJ	O	O
lindane	NOUN	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	NOUN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
,	PUNCT	O	O
700	NUM	O	O
and	CCONJ	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

decreased	VERB	O	O
convulsion	NOUN	O	I-Entity
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
and	CCONJ	O	O
prolonged	ADJ	O	O
latency	NOUN	O	O
time	NOUN	O	O
to	PART	O	O
convulsion	NOUN	O	I-Entity
following	VERB	O	O
injection	NOUN	O	O
with	ADP	O	O
a	DET	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
(	PUNCT	O	O
8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

EEG	NOUN	O	O
analyses	NOUN	O	O
showed	VERB	O	O
increase	NOUN	O	O
of	ADP	O	O
number	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
ictal	ADJ	O	O
periods	NOUN	O	O
in	ADP	O	O
EEG	PROPN	O	O
of	ADP	O	O
rats	NOUN	O	O
receiving	VERB	O	O
l	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
prior	ADV	O	O
to	ADP	O	O
lindane	NOUN	O	I-Entity
and	CCONJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
this	DET	O	O
number	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
conclusion	NOUN	O	O
that	ADP	O	O
NO	DET	O	I-Entity
plays	VERB	O	O
a	DET	O	O
role	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
convulsant	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (24055495)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
treatment	NOUN	O	O
prevents	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
treated	VERB	O	O
intracerebroventricularly	ADV	O	O
with	ADP	O	O
streptozotocin	NOUN	O	I-Entity
.	PUNCT	O	O

Basic	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
research	NOUN	O	O
has	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
dementia	NOUN	O	I-Entity
of	ADP	O	O
sporadic	ADJ	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
sAD	PROPN	O	O
)	PUNCT	O	O
type	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
dysfunction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
IR	PROPN	O	O
)	PUNCT	O	O
system	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
decreased	VERB	O	O
glucose	NOUN	O	I-Entity
transport	NOUN	O	O
via	ADP	O	O
glucose	NOUN	O	I-Entity
transporter	NOUN	O	O
GLUT4	PROPN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
glucose	NOUN	O	I-Entity
metabolism	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
alternative	ADJ	O	O
source	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
is	VERB	O	O
d	PUNCT	O	B-Entity
-	PUNCT	O	I-Entity
galactose	NOUN	O	I-Entity
(	PUNCT	O	O
the	DET	O	O
C-4-epimer	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
glucose	NOUN	O	I-Entity
)	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
transported	VERB	O	O
into	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
by	ADP	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
GLUT3	PROPN	O	O
transporter	NOUN	O	O
where	ADV	O	O
it	PRON	O	O
might	VERB	O	O
be	VERB	O	O
metabolized	VERB	O	O
to	ADP	O	O
glucose	NOUN	O	I-Entity
via	ADP	O	O
the	DET	O	O
Leloir	PROPN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

Exclusively	ADV	O	O
parenteral	ADJ	O	O
daily	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
galactose	NOUN	O	I-Entity
induce	VERB	O	O
memory	NOUN	O	B-Entity
deterioration	NOUN	O	I-Entity
in	ADP	O	O
rodents	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
used	VERB	O	O
to	PART	O	O
generate	VERB	O	O
animal	NOUN	O	O
aging	VERB	O	O
model	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	O
functions	NOUN	O	O
have	VERB	O	O
never	ADV	O	O
been	VERB	O	O
tested	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
daily	ADJ	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
in	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
(	PUNCT	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
)	PUNCT	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
sAD	PROPN	O	O
,	PUNCT	O	O
tested	VERB	O	O
by	ADP	O	O
Morris	PROPN	O	O
Water	PROPN	O	O
Maze	PROPN	O	O
and	CCONJ	O	O
Passive	PROPN	O	O
Avoidance	PROPN	O	O
test	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
treatment	NOUN	O	O
initiated	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
successfully	ADV	O	O
prevented	VERB	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
.	PUNCT	O	O

Beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
was	VERB	O	O
independent	ADJ	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
age	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
galactose	NOUN	O	I-Entity
dose	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
100	NUM	O	O
to	ADP	O	O
300	NUM	O	O
mg	NUM	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
oral	ADJ	O	O
galactose	NOUN	O	I-Entity
administration	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
galactose	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
galactose	ADJ	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
was	VERB	O	O
several	ADJ	O	O
times	NOUN	O	O
lower	ADJ	O	O
after	ADP	O	O
oral	ADJ	O	O
than	ADP	O	O
after	ADP	O	O
parenteral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
galactose	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

Oral	PROPN	O	O
galactose	VERB	O	I-Entity
exposure	NOUN	O	O
might	VERB	O	O
have	VERB	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
ability	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
be	VERB	O	O
worth	ADJ	O	O
investigating	VERB	O	O
for	ADP	O	O
improvement	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
glucose	NOUN	O	B-Entity
hypometabolism	NOUN	O	I-Entity
in	ADP	O	O
AD	NOUN	O	I-Entity
.	PUNCT	O	O


